FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Durham, EL
   Balog, C
   Howie, RN
   Boyce, MA
   Arand, JR
   Warren, G
   LaRue, AC
   Cray, JJ
AF Durham, E. L.
   Balog, C.
   Howie, R. N.
   Boyce, M. A.
   Arand, J. R.
   Warren, G.
   LaRue, A. C.
   Cray, J. J., Jr.
TI Effects of nicotine exposure on murine mandibular development
SO PLOS ONE
LA English
DT Article
ID SPHENO-OCCIPITAL SYNCHONDROSIS; MATERNAL SMOKING; CONSUMPTION; TOBACCO;
   GROWTH
AB Nicotine is known to affect cell proliferation and differentiation, two processes vital to proper development of the mandible. The mandible, the lower jaw in mammals and fish, plays a crucial role in craniofacial development. Malformation of the jaw can precipitate a plethora of complications including disrupting development of the upper jaw, the palate, and or impeding airway function. The purpose of this study was to test the hypothesis that in utero nicotine exposure alters the development of the murine mandible in a dose dependent manner. To test this hypothesis, wild type C57BL6 mice were used to produce in utero nicotine exposed litters by adding nicotine to the drinking water of pregnant dams at concentrations of 0 mu g/ml (control), 50 mu g/ml (low), 100 mu g/ml (medium), 200 mu g/ml (high) throughout pregnancy to birth of litters mimicking clinically relevant nicotine exposures. Resultant pups revealed no significant differences in body weight however, cephalometric investigation revealed several dimensions affected by nicotine exposure including mandibular ramus height, mandibular body height, and molar length. Histological investigation of molars revealed an increase in proliferation and a decrease in apoptosis with nicotine exposure. These results demonstrate the direct effects of nicotine on the developing mandible outside the context of tobacco use, indicating that nicotine use including tobacco alternatives, cessation methods, and electronic nicotine delivering products may disrupt normal growth and development of the craniofacial complex.
C1 [Durham, E. L.; Balog, C.; Howie, R. N.] Med Univ South Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA.
   [Boyce, M. A.; Arand, J. R.; Cray, J. J., Jr.] Ohio State Univ, Coll Med, Dept Biomed Educ & Anat, Columbus, OH 43210 USA.
   [Warren, G.] Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
   [Warren, G.] Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.
   [LaRue, A. C.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
   [LaRue, A. C.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Cray, JJ (reprint author), Ohio State Univ, Coll Med, Dept Biomed Educ & Anat, Columbus, OH 43210 USA.
EM james.cray@osumc.edu
FU National Institutes of Health (NIH) National Institute of Dental and
   Craniofacial Research [F31DE026684, R03DE026192, 5T32DE017551]; Plastic
   Surgery Education Foundation; South Carolina Clinical and Translational
   Research Institute [NIH/NCATS NIH/NCATS UL1TR000062]; NIH National
   Institute of General Medicine [P30GM103331]
FX This study was supported by research grants from the National Institutes
   of Health (NIH) National Institute of Dental and Craniofacial Research
   [F31DE026684 to ELD; R03DE026192 to JJC Jr.; 5T32DE017551]; the Plastic
   Surgery Education Foundation Pilot Award to JJC Jr., the NIH National
   Institute of General Medicine [P30GM103331], and the South Carolina
   Clinical and Translational Research Institute (NIH/NCATS NIH/NCATS
   UL1TR000062). This study utilized the expertise, resources, and
   facilities of the MUSC Center for Oral Health Research (COHR). The
   authors declare no conflicts of interest.
CR BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67
   Berrettini WH, 2005, AM J PSYCHIAT, V162, P1441, DOI 10.1176/appi.ajp.162.8.1441
   Carmichael SL, 2008, BIRTH DEFECTS RES A, V82, P78, DOI 10.1002/bdra.20426
   Chistyakov V, 2010, EUR J PHARMACOL, V640, P87, DOI 10.1016/j.ejphar.2010.04.044
   Chowdhury IG, 2000, ANAT RECORD, V258, P397
   Durham E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40796-z
   Durham E, 2017, CALCIFIED TISSUE INT, V101, P300, DOI 10.1007/s00223-017-0278-z
   Giovino GA, 2012, LANCET, V380, P668, DOI 10.1016/S0140-6736(12)61085-X
   Grewal J, 2008, BIRTH DEFECTS RES A, V82, P519, DOI 10.1002/bdra.20461
   Hackshaw A, 2011, HUM REPROD UPDATE, V17, P589, DOI 10.1093/humupd/dmr022
   Heikkinen T, 1997, EARLY HUM DEV, V47, P327, DOI 10.1016/S0378-3782(96)01792-6
   Holloway AC, 2014, AM J PHYSIOL-ENDOC M, V306, pE443, DOI 10.1152/ajpendo.00478.2013
   Howie RN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167805
   Hurst R, 2013, PHARMACOL THERAPEUT, V137, P22, DOI 10.1016/j.pharmthera.2012.08.012
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim S, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121236
   Klingenberg CP, 2004, GENETICS, V166, P1909, DOI 10.1534/genetics.166.4.1909
   L Benowitz N, CLIN PHARMACOL THER, V44, P23, DOI [10.1038/clpt.1988.107, DOI 10.1038/CLPT.1988.107]
   Licht AS, 2012, AM J PUBLIC HEALTH, V102, P1868, DOI [10.2105/AJPH.2012.300717, 10.2105/AJPH.2012.301002]
   Locker AR, 2016, BRAIN RES BULL, V123, P13, DOI 10.1016/j.brainresbull.2015.09.009
   McGrath J, 2012, PLAST RECONSTR SURG, V130, p681E, DOI 10.1097/PRS.0b013e318267d4c0
   Pirttiniemi P, 2009, EUR J ORTHODONT, V31, P1, DOI 10.1093/ejo/cjn117
   Ramaesh T, 2003, J ANAT, V203, P213, DOI 10.1046/j.1469-7580.2003.00210.x
   Renda A, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-89
   Schaal C, 2014, MOL CANCER RES, V12, P14, DOI 10.1158/1541-7786.MCR-13-0541
   SCHMITERLOW CG, 1962, NATURE, V194, P298, DOI 10.1038/194298b0
   Schoenborn CA, 2014, NCHS DATA BRIEF, V2015, P1
   Tahiri Y, 2014, J ORAL MAXIL SURG, V72, P1173, DOI 10.1016/j.joms.2013.11.015
   Thun MJ, 2013, NEW ENGL J MED, V368, P351, DOI 10.1056/NEJMsa1211127
   Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801
   Xu X, 2014, SCI REP-UK, V4, DOI 10.1038/srep03864
   Yousef Saad A., POSTNATAL EFFECTS NI
   Zhou S, 2014, CURR PROB PEDIATR AD, V44, P219, DOI 10.1016/j.cppeds.2014.03.007
NR 33
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2019
VL 14
IS 6
AR e0218376
DI 10.1371/journal.pone.0218376
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IC8NN
UT WOS:000471238300095
PM 31194840
OA DOAJ Gold
DA 2019-07-07
ER

PT J
AU Ferreira, GS
   Veening-Griffioen, DH
   Boon, WPC
   Moors, EHM
   Gispen-de Wied, CC
   Schellekens, H
   van Meer, PJK
AF Ferreira, Guilherme S.
   Veening-Griffioen, Desiree H.
   Boon, Wouter P. C.
   Moors, Ellen H. M.
   Gispen-de Wied, Christine C.
   Schellekens, Huub
   van Meer, Peter J. K.
TI A standardised framework to identify optimal animal models for efficacy
   assessment in drug development
SO PLOS ONE
LA English
DT Article
ID DUCHENNE MUSCULAR-DYSTROPHY; TRANSLATIONAL RESEARCH; CLINICAL
   DEVELOPMENT; VALIDITY
AB Introduction
   Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients-or even put them at risk-and is a potential contributor to costly and unnecessary attrition in drug development.
   Objectives
   To develop a tool to assess, validate and compare the clinical translatability of animal models used for the preliminary assessment of efficacy.
   Design and results
   We performed a scoping review to identify the key aspects used to validate animal models. Eight domains (Epidemiology, Symptomatology and Natural History-SNH, Genetic, Biochemistry, Aetiology, Histology, Pharmacology and Endpoints) were identified. We drafted questions to evaluate the different facets of human disease simulation. We designed the Framework to Identify Models of Disease (FIMD) to include standardised instructions, a weighting and scoring system to compare models as well as factors to help interpret model similarity and evidence uncertainty. We also added a reporting quality and risk of bias assessment of drug intervention studies in the Pharmacological Validation domain. A web-based survey was conducted with experts from different stakeholders to gather input on the framework. We conducted a pilot study of the validation in two models for Type 2 Diabetes (T2D)-the ZDF rat and db/db mouse. Finally, we present a full validation and comparison of two animal models for Duchenne Muscular Dystrophy (DMD): the mdx mouse and GRMD dog. We show that there are significant differences between the mdx mouse and the GRMD dog, the latter mimicking the human epidemiological, SNH, and histological aspects to a greater extent than the mouse despite the overall lack of published data.
   Conclusions
   FIMD facilitates drug development by serving as the basis to select the most relevant model that can provide meaningful data and is more likely to generate translatable results to progress drug candidates to the clinic.
C1 [Ferreira, Guilherme S.; Veening-Griffioen, Desiree H.; Schellekens, Huub; van Meer, Peter J. K.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands.
   [Boon, Wouter P. C.; Moors, Ellen H. M.] Univ Utrecht, Copernicus Inst Sustainable Dev, Innovat Studies, Utrecht, Netherlands.
   [Gispen-de Wied, Christine C.; van Meer, Peter J. K.] Med Evaluat Board, Utrecht, Netherlands.
RP Ferreira, GS (reprint author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands.
EM gsantferr@gmail.com
OI Veening-Griffioen, Desiree/0000-0001-5331-2698; Ferreira, Guilherme
   S./0000-0001-5606-6525
FU Dutch Ministry of Economic Affairs and Climate (EZC); Dutch Ministry of
   Health, Welfare and Sport (VWS); Medicines Evaluation Board (CBG)
FX This project was supported by the Dutch Ministry of Economic Affairs and
   Climate (EZC), the Dutch Ministry of Health, Welfare and Sport (VWS),
   and the Medicines Evaluation Board (CBG). No grant number or
   identification is available. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
   https://www.rijksoverheid.nl/ministeries/ministerie-van-economische-zake
   n-en-klimaat.https://www.rijksoverheid.nl/ministeries/ministerie-van-vol
   ksgezondheid-welzijn-en-sport.https://www.cbg-meb.nl/.
CR Arrowsmith J, 2013, NAT REV DRUG DISCOV, V12, P568, DOI 10.1038/nrd4090
   Arrowsmith J, 2011, NAT REV DRUG DISCOV, V10, P1, DOI 10.1038/nrd3375
   Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1197/aemj.10.6.684
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Denayer T, 2014, NEW HORIZ TRANSL MED, V2, P5, DOI 10.1016/j.nhtm.2014.08.001
   Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081
   Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x
   EQIPD, EUROPEAN QUALITY IN
   Godlee F., 2018, BMJ-BRIT MED J, V360, P1
   Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731
   Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Hwang TJ, 2016, JAMA INTERN MED, V176, P1826, DOI 10.1001/jamainternmed.2016.6008
   ICH, 2017, REV S5 GUID DET TOX, P1
   Jansen SJ, 2014, EUR J CLIN INVEST, V44, P892, DOI 10.1111/eci.12299
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kimmelman J, 2012, NAT BIOTECHNOL, V30, P488, DOI 10.1038/nbt.2261
   Kooijman M, 2013, REGUL TOXICOL PHARM, V67, P221, DOI 10.1016/j.yrtph.2013.07.014
   Kooijman M, 2017, TECHNOL FORECAST SOC, V118, P70, DOI 10.1016/j.techfore.2017.02.003
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Langhof H, 2018, BRIT J PHARMACOL, V175, P4229, DOI 10.1111/bph.14485
   McGonigle P, 2014, BIOCHEM PHARMACOL, V87, P162, DOI 10.1016/j.bcp.2013.08.006
   McGreevy JW, 2015, DIS MODEL MECH, V8, P195, DOI 10.1242/dmm.018424
   MCKINNEY WT, 1969, ARCH GEN PSYCHIAT, V21, P240
   OECD, 2005, GUID DOC VAL INT ACC, V34, P1
   Pasquarelli N, 2017, BEHAV BRAIN RES, V333, P35, DOI 10.1016/j.bbr.2017.06.018
   Peers IS, 2014, NAT REV DRUG DISCOV, V13, DOI 10.1038/nrd4090-c1
   Perel P, 2007, BMJ-BRIT MED J, V334, P197, DOI 10.1136/bmj.39048.407928.BE
   Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   Reinig AM, 2017, PHARMACOTHERAPY, V37, P492, DOI 10.1002/phar.1909
   Sams-Dodd F, 2006, DRUG DISCOV TODAY, V11, P355, DOI 10.1016/j.drudis.2006.02.005
   Schulz JB, 2016, J NEUROCHEM, V139, P253, DOI 10.1111/jnc.13844
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   Smith Adam D., 2017, 2017 Conference on Lasers and Electro-Optics Europe & European Quantum Electronics Conference (CLEO/Europe-EQEC), DOI 10.1109/CLEOE-EQEC.2017.8086745
   Top Institute Pharma, PRED VAL AN TEST RES
   US Congress, 1938, FED FOOD DRUG COSM A
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   van Meer PJK, 2013, NAT BIOTECHNOL, V31, P882, DOI 10.1038/nbt.2709
   van Meer PJK, 2015, DRUG DISCOV TODAY, V20, P483, DOI 10.1016/j.drudis.2014.11.009
   van Meer PJK, 2012, REGUL TOXICOL PHARM, V64, P345, DOI 10.1016/j.yrtph.2012.09.002
   Varga OE, 2010, ATLA-ALTERN LAB ANIM, V38, P245, DOI 10.1177/026119291003800309
   Wei Dang, 2016, J Evid Based Med, V9, P98, DOI 10.1111/jebm.12198
   Wieschowski S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2004879
   WILLNER P, 1984, PSYCHOPHARMACOLOGY, V83, P1, DOI 10.1007/BF00427414
   Yu XR, 2015, AM J TRANSL RES, V7, P1314
NR 46
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2019
VL 14
IS 6
AR e0218014
DI 10.1371/journal.pone.0218014
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IC8NN
UT WOS:000471238300038
PM 31194784
OA DOAJ Gold
DA 2019-07-07
ER

PT J
AU Fergusson, DA
   Avey, MT
   Barron, CC
   Bocock, M
   Biefer, KE
   Boet, S
   Bourque, SL
   Conic, I
   Chen, K
   Dong, YY
   Fox, GM
   George, RB
   Goldenberg, NM
   Gragasin, FS
   Harsha, P
   Hong, PJ
   James, TE
   Larrigan, SM
   MacNeil, JL
   Manuel, CA
   Maximos, S
   Mazer, D
   Mittal, R
   McGinn, R
   Nguyen, LH
   Patel, A
   Richebe, P
   Saha, TK
   Steinberg, BE
   Sampson, SD
   Stewart, DJ
   Syed, S
   Vella, K
   Wesch, NL
   Lalu, MM
   Bautista, M
   Boyle, D
   Bryson, G
   Butler, H
   Denault, A
   Deschamps, A
   Grocott, HP
   Hall, R
   Karkouti, K
   Kent, BA
   McDonald, H
   de Medicis, E
   Paul, J
   Ralley, F
   Sampson, SD
   Tran, DTT
AF Fergusson, Dean A.
   Avey, Marc T.
   Barron, Carly C.
   Bocock, Mathew
   Biefer, Kristen E.
   Boet, Sylvain
   Bourque, Stephane L.
   Conic, Isidora
   Chen, Kai
   Dong, Yuan Yi.
   Fox, Grace M.
   George, Ronald B.
   Goldenberg, Neil M.
   Gragasin, Ferrante S.
   Harsha, Prathiba
   Hong, Patrick J.
   James, Tyler E.
   Larrigan, Sarah M.
   MacNeil, Jenna L.
   Manuel, Courtney A.
   Maximos, Sarah
   Mazer, David
   Mittal, Rohan
   McGinn, Ryan
   Nguyen, Long H.
   Patel, Abhilasha
   Richebe, Philippe
   Saha, Tarit K.
   Steinberg, Benjamin E.
   Sampson, Sonja D.
   Stewart, Duncan J.
   Syed, Summer
   Vella, Kimberly
   Wesch, Neil L.
   Lalu, Manoj M.
   Bautista, Michael
   Boyle, David
   Bryson, Gregory
   Butler, Heather
   Denault, Andre
   Deschamps, Alain
   Grocott, Hilary P.
   Hall, Richard
   Karkouti, Keyvan
   Kent, Blaine A.
   McDonald, Heather
   de Medicis, Etienne
   Paul, James
   Ralley, Fiona
   Sampson, Sonia D.
   Tran, Diem T. T.
CA Canadian Perioperative Anesthesia
TI Reporting preclinical anesthesia study (REPEAT): Evaluating the quality
   of reporting in the preclinical anesthesiology literature
SO PLOS ONE
LA English
DT Article
ID DESIGN AFFECTS OUTCOMES; ANIMAL RESEARCH; TRANSPARENCY; METAANALYSIS;
   STATEMENT; MEDICINE; THERAPY; STROKE; IMPACT
AB Poor reporting quality may contribute to irreproducibility of results and failed 'bench-to-bed-side' translation. Consequently, guidelines have been developed to improve the complete and transparent reporting of in vivo preclinical studies. To examine the impact of such guidelines on core methodological and analytical reporting items in the preclinical anesthesiology literature, we sampled a cohort of studies. Preclinical in vivo studies published in Anesthesiology, Anesthesia & Analgesia, Anaesthesia, and the British Journal of Anaesthesia (2008-2009, 2014-2016) were identified. Data was extracted independently and in duplicate. Reporting completeness was assessed using the National Institutes of Health Principles and Guidelines for Reporting Preclinical Research. Risk ratios were used for comparative analyses. Of 7615 screened articles, 604 met our inclusion criteria and included experiments reporting on 52 490 animals. The most common topic of investigation was pain and analgesia (30%), rodents were most frequently used (77%), and studies were most commonly conducted in the United States (36%). Use of preclinical reporting guidelines was listed in 10% of applicable articles. A minority of studies fully reported on replicates (0.3%), randomization (10%), blinding (12%), sample-size estimation (3%), and inclusion/exclusion criteria (5%). Statistics were well reported (81%). Comparative analysis demonstrated few differences in reporting rigor between journals, including those that endorsed reporting guidelines. Principal items of study design were infrequently reported, with few differences between journals. Methods to improve implementation and adherence to community-based reporting guidelines may be necessary to increase transparent and consistent reporting in the preclinical anesthesiology literature.
C1 [Fergusson, Dean A.; Avey, Marc T.; Boet, Sylvain; Conic, Isidora; Fox, Grace M.; Larrigan, Sarah M.; MacNeil, Jenna L.; Wesch, Neil L.; Lalu, Manoj M.] Ottawa Hosp Res Inst, Blueprint Translat Res Grp, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Fergusson, Dean A.; Avey, Marc T.; Bocock, Mathew; Dong, Yuan Yi.; Hong, Patrick J.; Larrigan, Sarah M.; McGinn, Ryan; Nguyen, Long H.; Patel, Abhilasha; Lalu, Manoj M.] Univ Ottawa, Fac Med, Ottawa, ON, Canada.
   [Barron, Carly C.; Harsha, Prathiba; Syed, Summer] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.
   [Barron, Carly C.; James, Tyler E.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Biefer, Kristen E.; Bourque, Stephane L.; Gragasin, Ferrante S.; Mittal, Rohan] Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada.
   [Boet, Sylvain; Larrigan, Sarah M.; Lalu, Manoj M.] Ottawa Hosp, Dept Anesthesiol & Pain Med, Ottawa, ON, Canada.
   [Boet, Sylvain] Univ Ottawa, Dept Innovat Med Educ, Ottawa, ON, Canada.
   [Chen, Kai; Saha, Tarit K.] Queens Univ, Dept Anesthesiol & Perioperat Med, Kingston, ON, Canada.
   [George, Ronald B.; Vella, Kimberly] Dalhousie Univ, Dept Anesthesia Pain Management & Perioperat Med, Halifax, NS, Canada.
   [Goldenberg, Neil M.; Mazer, David; Steinberg, Benjamin E.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada.
   [Manuel, Courtney A.; Sampson, Sonja D.] Mem Univ, Discipline Anesthesia, St John, NF, Canada.
   [Maximos, Sarah; Richebe, Philippe] Univ Montreal, Dept Anesthesiol, Montreal, PQ, Canada.
   [Stewart, Duncan J.; Lalu, Manoj M.] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada.
   [Stewart, Duncan J.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.
RP Lalu, MM (reprint author), Ottawa Hosp Res Inst, Blueprint Translat Res Grp, Clin Epidemiol Program, Ottawa, ON, Canada.; Lalu, MM (reprint author), Univ Ottawa, Fac Med, Ottawa, ON, Canada.; Lalu, MM (reprint author), Ottawa Hosp, Dept Anesthesiol & Pain Med, Ottawa, ON, Canada.; Lalu, MM (reprint author), Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada.
EM manojlalu@gmail.com
OI George, Ronald/0000-0002-1848-036X
CR Andrews NA, 2016, PAIN, V157, P901, DOI 10.1097/j.pain.0000000000000458
   Avey MT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166733
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1197/aemj.10.6.684
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Clark JD, 2016, ANESTHESIOLOGY, V125, P846, DOI 10.1097/ALN.0000000000001340
   COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408
   Collins FS, 2014, NATURE, V505, P612, DOI 10.1038/505612a
   Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5
   Cressey D, 2015, NATURE, V520, P271, DOI 10.1038/520271a
   Davidson A, 2011, ANESTHESIOLOGY, V115, P909, DOI 10.1097/ALN.0b013e3182337a5e
   Eisenach JC, 2016, ANESTHESIOLOGY, V124, P763, DOI 10.1097/ALN.0000000000001044
   Freedman LP, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002165
   Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731
   Hair K, 2018, BIORXIV, DOI [10.1101/370874, DOI 10.1101/370874]
   Idris AH, 1996, CIRCULATION, V94, P2324, DOI 10.1161/01.CIR.94.9.2324
   Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821
   Jarvis MF, 2016, TRENDS PHARMACOL SCI, V37, P290, DOI 10.1016/j.tips.2015.12.001
   Khangura S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-10
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Kimmelman J, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001863
   Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470
   Lalu M, 2015, REPORTING PRECLINICA
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Lee MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177499
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Macleod MR, 2017, BIORXIV, DOI DOI 10.1101/187245
   Matthews RAJ, 2008, J ROY SOC MED, V101, P95, DOI 10.1258/jrsm.2007.070164
   MILLER JN, 1989, STAT MED, V8, P455, DOI 10.1002/sim.4780080409
   Minnerup J, 2010, J CEREBR BLOOD F MET, V30, P1619, DOI 10.1038/jcbfm.2010.74
   National Institues of Health, 2014, PRINC GUID REP PRECL
   Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514
   Pussegoda K, 2017, SYST REV, V6, DOI 10.1186/s13643-017-0527-2
   Ramirez FD, 2017, CIRC RES, V120, P1916, DOI 10.1161/CIRCRESAHA.117.310628
   SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4
   Sandve GK, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003285
   Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009
   Sena ES, 2014, J CEREBR BLOOD F MET, V34, P737, DOI 10.1038/jcbfm.2014.28
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647
   Turner L, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-60
   YEZIERSKI RP, 2018, PAIN, V19, P571, DOI DOI 10.1016/J.JPAIN.2017.12.261
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 23
PY 2019
VL 14
IS 5
AR e0215221
DI 10.1371/journal.pone.0215221
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HZ3VE
UT WOS:000468775700006
PM 31120888
OA DOAJ Gold
DA 2019-07-07
ER

PT J
AU Allchin, RL
   Kelly, ME
   Mamand, S
   Doran, AG
   Keane, T
   Ahearne, MJ
   Wagner, SD
AF Allchin, Rebecca L.
   Kelly, Michael E.
   Mamand, Sami
   Doran, Anthony G.
   Keane, Thomas
   Ahearne, Matthew J.
   Wagner, Simon D.
TI Structural and diffusion weighted MRI demonstrates responses to
   ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma
SO PLOS ONE
LA English
DT Article
ID TYROSINE KINASE; MUTATIONS; ITK; RECEPTOR; TUMORS; ACTIVATION;
   REGULATORS; MIGRATION; APOPTOSIS; BIOMARKER
AB Recent analyses of the genetics of peripheral T-cell lymphoma (PTCL) have shown that a large proportion of cases are derived from normal follicular helper (Tfh) T-cells. The sanroque mouse strain bears a mutation that increases Tfh cell number and heterozygous animals (Roquin(san/+)) develop lymphomas similar to human Tfh lymphoma. Here we demonstrate the usefulness of Roquin(san/+) animals as a pre-clinical model of Tfh lymphoma. Long latency of development and incomplete penetrance in this strain suggests the lymphomas are genetically diverse. We carried out preliminary genetic characterisation by whole exome sequencing and detected tumor specific mutations in Hsp90ab1, Ccnb3 and RhoA. Interleukin-2-inducible kinase (ITK) is expressed in Tfh lymphoma and is a potential therapeutic agent. A preclinical study of ibrutinib, a small molecule inhibitor of mouse and human ITK, in established lymphoma was carried out and showed lymphoma regression in 8/12 (67%) mice. Using T2-weighted MRI to assess lymph node volume and diffusion weighted MRI scanning as a measure of function, we showed that treatment increased mean apparent diffusion coefficient (ADC) suggesting cell death, and that change in ADC following treatment correlated with change in lymphoma volume. We suggest that heterozygous sanroque mice are a useful model of Tfh cell derived lymphomas in an immunocompetent animal.
C1 [Allchin, Rebecca L.; Mamand, Sami; Ahearne, Matthew J.; Wagner, Simon D.] Univ Leicester, Leicester Canc Res Ctr, Leicester, Leics, England.
   [Allchin, Rebecca L.; Mamand, Sami; Ahearne, Matthew J.; Wagner, Simon D.] Univ Leicester, Ernest & Helen Scott Haematol Res Inst, Leicester, Leics, England.
   [Kelly, Michael E.] Univ Leicester, Core Biotechnol Serv, Leicester, Leics, England.
   [Doran, Anthony G.; Keane, Thomas] European Bioinformat Inst, Cambridge, England.
RP Wagner, SD (reprint author), Univ Leicester, Leicester Canc Res Ctr, Leicester, Leics, England.; Wagner, SD (reprint author), Univ Leicester, Ernest & Helen Scott Haematol Res Inst, Leicester, Leics, England.
EM sw227@le.ac.uk
OI Wagner, Simon/0000-0002-8914-0370
FU Janssen; Ernest and Helen Scott Haematology Research Institute;
   Government of Iraq
FX The work was in part supported by a grant from Janssen who also provided
   Ibrutinib. RLA was supported by a clinical research fellowship from the
   Ernest and Helen Scott Haematology Research Institute and SM was
   supported by a PhD studentship from the Government of Iraq. The funders
   had no role in study design, data collection and analysis, decision to
   publish or preparation of the manuscript.
CR Agostinelli C, 2014, AM J SURG PATHOL, V38, P1349, DOI 10.1097/PAS.0000000000000309
   Ahearne MJ, 2014, BRIT J HAEMATOL, V166, P326, DOI 10.1111/bjh.12941
   Attygalle A, 2002, BLOOD, V99, P627, DOI 10.1182/blood.V99.2.627
   Ayers GD, 2010, J ULTRAS MED, V29, P891, DOI 10.7863/jum.2010.29.6.891
   Blomberg KEM, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-233
   Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055
   Brindle KM, 2002, ADV ENZYME REGUL, V42, P101, DOI 10.1016/S0065-2571(01)00025-5
   Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637
   Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748
   Cornish N, 2018, BRIT J HAEMATOL, V180, P176, DOI 10.1111/bjh.14959
   Cortes JR, 2018, CANCER CELL, V33, P259, DOI 10.1016/j.ccell.2018.01.001
   de Leval L, 2007, BLOOD, V109, P4952, DOI 10.1182/blood-2006-10-055145
   de Leval L, 2015, HAEMATOLOGICA, V100, pE361, DOI 10.3324/haematol.2015.126300
   Doran AG, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1024-y
   Dubovsky JA, 2013, BLOOD, V122, P2539, DOI 10.1182/blood-2013-06-507947
   Ellyard JI, 2012, BLOOD, V120, P812, DOI 10.1182/blood-2011-07-365130
   Fischer AM, 2004, J BIOL CHEM, V279, P29816, DOI 10.1074/jbc.M312848200
   Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6
   Gibson S, 1996, J IMMUNOL, V156, P2716
   Gomez-Rodriguez J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10857
   Gomez-Rodriguez J, 2014, J EXP MED, V211, P529, DOI 10.1084/jem.20131459
   Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900
   Huang WS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15871
   Jensen Mette Munk, 2008, BMC Med Imaging, V8, P16, DOI 10.1186/1471-2342-8-16
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kumar A, 2018, BLOOD ADV, V2, P871, DOI 10.1182/bloodadvances.2017011916
   Lemonnier F, 2012, BLOOD, V120, P1466, DOI 10.1182/blood-2012-02-408542
   Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9
   Lin C, 2012, CANCER IMAGING, V12, P403, DOI 10.1102/1470-7330.2012.9048
   Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886
   Mamand S, 2018, SCI REP, P1, DOI [10.1038/s41598-017-17765-5, DOI 10.1038/S41598-017-17765-5]
   Montelius M, 2012, BMC MED IMAGING, V12, DOI 10.1186/1471-2342-12-12
   Muto H, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.83
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Ng SY, 2018, NATURE COMMUNICATION, P1, DOI [10.1038/s41467-017-02088-w, DOI 10.1038/S41467-017-02088-W]
   Nguyen TB, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2016.122
   Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509
   Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873
   Papaevangelou E, 2015, BRIT J CANCER, V112, P1471, DOI 10.1038/bjc.2015.134
   Patterson DM, 2008, NAT CLIN PRACT ONCOL, V5, P220, DOI 10.1038/ncponc1073
   Pechloff K, 2010, J EXP MED, V207, P1031, DOI 10.1084/jem.20092042
   Piccaluga PP, 2007, J CLIN INVEST, V117, P823, DOI 10.1172/JCI26833
   Puaux Anne-Laure, 2011, Int J Mol Imaging, V2011, P321538, DOI 10.1155/2011/321538
   Punwani S, 2010, CANCER BIOMARK, V7, P249, DOI 10.3233/CBM-2010-0197
   Raman V, 2007, NMR BIOMED, V20, P186, DOI 10.1002/nbm.1136
   Rodriguez-Justo M, 2009, MODERN PATHOL, V22, P753, DOI 10.1038/modpathol.2009.12
   Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872
   Schwartzberg PL, 2005, NAT REV IMMUNOL, V5, P284, DOI 10.1038/nri1591
   SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194
   Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569
   Takesono A, 2004, CURR BIOL, V14, P917, DOI 10.1016/j.cub.2004.04.011
   Thoeny HC, 2005, NEOPLASIA, V7, P779, DOI 10.1593/neo.04748
   Toledano-Massiah S, 2015, RADIOGRAPHICS, V35, P747, DOI 10.1148/rg.2015140145
   Trotman-Lucas M, 2017, DIS MODEL MECH, V10, P931, DOI 10.1242/dmm.029108
   Vallois D, 2016, BLOOD, V128, P1490, DOI 10.1182/blood-2016-02-698977
   Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555
   Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558
   Wang C, 2015, BLOOD, V126, P1741, DOI 10.1182/blood-2015-05-644591
   Wang HS, 2010, J MAGN RESON IMAGING, V32, P409, DOI 10.1002/jmri.22247
NR 59
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2019
VL 14
IS 4
AR e0215765
DI 10.1371/journal.pone.0215765
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HU4DH
UT WOS:000465223900037
PM 31013298
OA DOAJ Gold
DA 2019-07-07
ER

PT J
AU Solevag, AL
   Luong, D
   Lee, TF
   O'Reilly, M
   Cheung, PY
   Schmolzer, GM
AF Solevag, Anne Lee
   Luong, Deandra
   Lee, Tze-Fun
   O'Reilly, Megan
   Cheung, Po-Yin
   Schmolzer, Georg M.
TI Non-perfusing cardiac rhythms in asphyxiated newborn piglets
SO PLOS ONE
LA English
DT Article
ID PULSELESS ELECTRICAL-ACTIVITY; 2015 INTERNATIONAL CONSENSUS;
   CARDIOVASCULAR CARE SCIENCE; HEART-RATE; CARDIOPULMONARY-RESUSCITATION;
   ARREST REGISTRY; SURVIVAL; MANAGEMENT; TERM; EPIDEMIOLOGY
AB Aim
   We recently demonstrated that asphyxiated piglets commonly had bradycardia displayed on electrocardiography (ECG) while no carotid blood flow (CBF) or audible heart sounds could be detected. Such pulseless electrical activity (PEA) in newborn infants has not previously been thoroughly described. The aim of this study was to further investigate the occurrence of non-perfusing cardiac rhythms in asphyxiated piglets and the potential implications for the success of cardiopulmonary resuscitation (CPR) and short-term survival.
   Methods
   Neonatal piglets (1-4 days, 1.7-2.4kg) had their right common carotid artery exposed and enclosed with a real-time ultrasonic flow probe. Heart rate (HR) was continuously measured and recorded using ECG. This allowed simultaneous monitoring of HR via ECG and CBF. The piglets were asphyxiated until cardiac arrest, defined as no CBF and no audible beat upon precordial auscultation. CPR was performed until return of spontaneous circulation (ROSC, defined as a HR >= 100 bpm). ECG traces were retrospectively assessed.
   Results
   Nine out of 21 piglets (43%) had QRS-complexes on their ECG while no CBF and no audible heart sounds could be detected. Five (56%) of the piglets with PEA and 12/12 (100%) piglets with asystole at cardiac arrest obtained ROSC (p = 0.02). Thirty-three per cent of the piglets with PEA versus 58% with asystole survived to 4 hours post-ROSC (p = 0.39).
   Conclusion
   Cardiac arrest in the presence of a non-perfusing cardiac rhythm on ECG is common in asphyxiated piglets. Clinical arrest in the presence of a non-perfusing cardiac rhythm on ECG may reduce the success of CPR.
C1 [Solevag, Anne Lee] Akershus Univ Hosp, Dept Paediat & Adolescent Med, Lorenskog, Norway.
   [Luong, Deandra; Lee, Tze-Fun; O'Reilly, Megan; Cheung, Po-Yin; Schmolzer, Georg M.] Royal Alexandra Hosp, Neonatal Res Unit, Ctr Studies Asphyxia & Resuscitat, Edmonton, AB, Canada.
   [Luong, Deandra] Univ Alberta, Fac Sci, Edmonton, AB, Canada.
   [Lee, Tze-Fun; O'Reilly, Megan; Cheung, Po-Yin; Schmolzer, Georg M.] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB, Canada.
RP Solevag, AL (reprint author), Akershus Univ Hosp, Dept Paediat & Adolescent Med, Lorenskog, Norway.
EM a.l.solevag@medisin.uio.no
FU Heart and Stroke Foundation/University of Alberta Professorship of
   Neonatal Resuscitation; National New Investigator of the Heart and
   Stroke Foundation Canada; Alberta New Investigator of the Heart and
   Stroke Foundation Alberta; Stollery Children's Hospital Foundation
FX GMS is a recipient of the Heart and Stroke Foundation/University of
   Alberta Professorship of Neonatal Resuscitation, a National New
   Investigator of the Heart and Stroke Foundation Canada and an Alberta
   New Investigator of the Heart and Stroke Foundation Alberta. This
   research has also been facilitated by the Women and Children's Health
   Research Institute through the generous support of the Stollery
   Children's Hospital Foundation. The funder had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abrams HC, 2013, RESUSCITATION, V84, P1093, DOI 10.1016/j.resuscitation.2013.03.030
   Babaeizadeh S, 2014, J ELECTROCARDIOL, V47, P798, DOI 10.1016/j.jelectrocard.2014.07.021
   Brooks SC, 2010, RESUSCITATION, V81, P175, DOI 10.1016/j.resuscitation.2009.10.021
   de Caen AR, 2015, CIRCULATION, V132, pS177, DOI 10.1161/CIR.0000000000000275
   Dyson A, 2017, ARCH DIS CHILD-FETAL, V102, pF116, DOI 10.1136/archdischild-2016-310669
   EISENBERG M, 1983, ANN EMERG MED, V12, P672, DOI 10.1016/S0196-0644(83)80413-2
   Engdahl J, 2001, RESUSCITATION, V51, P17, DOI 10.1016/S0300-9572(01)00377-X
   Gaertner VD, 2017, ARCH DIS CHILD-FETAL, V102, pF370, DOI 10.1136/archdischild-2016-312316
   Hauck M, 2015, AM J EMERG MED, V33, P891, DOI 10.1016/j.ajem.2015.03.050
   Hostler David, 2003, Prehosp Emerg Care, V7, P286, DOI 10.1080/10903120390936969
   Kamarainen A, 2007, RESUSCITATION, V75, P235, DOI 10.1016/j.resuscitation.2007.04.011
   Katheria A, 2012, PEDIATRICS, V130, pE1177, DOI 10.1542/peds.2012-0784
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kuisma M, 1997, ANN EMERG MED, V30, P69, DOI 10.1016/S0196-0644(97)70114-8
   Larabee TM, 2008, RESUSCITATION, V78, P196, DOI 10.1016/j.resuscitation.2008.03.011
   LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2
   Lemke RP, 2011, USE NEW DOPPLER UMBI, P83
   Littmann L, 2014, MED PRIN PRACT, V23, P1, DOI 10.1159/000354195
   Luong Deandra, 2019, Arch Dis Child Fetal Neonatal Ed, DOI 10.1136/archdischild-2018-316087
   Luong DH, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00366
   McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1
   Mehta C, 2012, AM J EMERG MED, V30, P236, DOI 10.1016/j.ajem.2010.08.017
   MOGAYZEL C, 1995, ANN EMERG MED, V25, P484, DOI 10.1016/S0196-0644(95)70263-6
   Myerburg RJ, 2013, CIRCULATION, V128, P2532, DOI 10.1161/CIRCULATIONAHA.113.004490
   Patel S, 2019, ARCH DIS CHILD-FETAL, V104, pF215, DOI 10.1136/archdischild-2018-314907
   Perlman JM, 2015, CIRCULATION, V132, pS204, DOI 10.1161/CIR.0000000000000276
   Phillipos E, 2016, NEONATOLOGY, V109, P130, DOI 10.1159/000441940
   Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025
   Sillers L, 2019, NEONATOLOGY, V115, P95, DOI 10.1159/000493357
   Sobotka KS, 2015, ARCH DIS CHILD-FETAL, V100, pF337, DOI 10.1136/archdischild-2014-307319
   Solevag AL, 2010, NEONATOLOGY, V98, P64, DOI 10.1159/000275560
   Solevag AL, 2016, RESUSCITATION, V106, P7, DOI 10.1016/j.resuscitation.2016.06.014
   Thomas AJ, 2013, RESUSCITATION, V84, P1261, DOI 10.1016/j.resuscitation.2013.02.016
   van Vonderen JJ, 2015, J PEDIATR-US, V166, P49, DOI 10.1016/j.jpeds.2014.09.015
   Vayrynen T, 2008, RESUSCITATION, V76, P207, DOI 10.1016/j.resuscitation.2007.07.023
   Wyckoff MH, 2015, CIRCULATION, V132, pS543, DOI 10.1161/CIR.0000000000000267
   Young KD, 2004, PEDIATRICS, V114, P157, DOI 10.1542/peds.114.1.157
NR 37
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2019
VL 14
IS 4
AR e0214506
DI 10.1371/journal.pone.0214506
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HR7EH
UT WOS:000463314500037
PM 30947278
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Gomez-Gil, V
   Rodriguez, M
   Nisa, FGM
   Perez-Kohler, B
   Pascual, G
AF Gomez-Gil, Veronica
   Rodriguez, Marta
   Garcia-Moreno Nisa, Francisca
   Perez-Kohler, Barbara
   Pascual, Gemma
TI Evaluation of synthetic reticular hybrid meshes designed for
   intraperitoneal abdominal wall repair: Preclinical and in vitro behavior
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; VENTRAL HERNIA REPAIR; POLYPROPYLENE MESH;
   POLYVINYLIDENE FLUORIDE; ADHESION FORMATION; INCISIONAL HERNIA;
   COMPOSITE MESH; LIGHTWEIGHT MESH; TIMESH; IMPLANTATION
AB Introduction
   Reticular hybrid meshes represent an alternative material for intraperitoneal repair of abdominal hernias. These consist of a reticular mesh coated or interwoven/knitted with inert materials. This study assesses the performance of two reticular polypropylene-containing hybrid meshes, TiMESH (coated with titanium) and DynaMesh (interwoven with polyvinylidene fluoride), in vitro, as well as their efficiency in adhesion prevention and tissue incorporation in an intraperitoneal model.
   Methods
   The mesothelialization capacity of TiMESH and DynaMesh was evaluated in vitro and compared to that of Surgipro (reticular bare polypropylene) and Preclude (laminar expanded polytetrafluoroethylene). Mesh fragments were placed on the intact parietal peritoneum of New Zealand white rabbits (n = 24), and laparoscopy performed 7 days post-surgery. Fourteen days post-implantation, adhesions were evaluated and host tissue incorporation, macrophage response, collagen expression (immunohistochemistry/RT-PCR) and neoperitoneum formation assessed. Adhesions and omental tissue were also examined.
   Results
   Mesh pores in reticular meshes were devoid of cells in the in vitro study. TiMESH, DynaMesh and Surgipro showed similar adhesion rates at 7/14 days and optimal tissue integration, with significant differences in comparison to Preclude. The greatest presence of macrophages was observed for TiMESH and was significant versus that for Preclude. Hybrid meshes revealed significantly higher collagen 1 mRNA expression in implants, with no differences in the levels of collagen 3. Omental samples from animals with a reticular mesh showed significantly greater collagen 1 mRNA levels.
   Conclusions
   The reticular structure of a mesh limits the formation of a continuous mesothelial monolayer in vitro, regardless of its composition. The presence of titanium as a coating or polyvinylidene fluoride interwoven with polypropylene in a reticular structure did not prevent adhesions. The hybrid meshes showed proper integration and an increase in the mRNA Col 1 levels in the implant area compared to Surgipro or Preclude.
C1 [Gomez-Gil, Veronica; Rodriguez, Marta; Garcia-Moreno Nisa, Francisca; Perez-Kohler, Barbara] Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Surg Med & Social Sci, Madrid, Spain.
   [Gomez-Gil, Veronica; Rodriguez, Marta; Garcia-Moreno Nisa, Francisca; Perez-Kohler, Barbara; Pascual, Gemma] Networking Biomed Res Ctr Bioengn Biomat & Nanome, Madrid, Spain.
   [Rodriguez, Marta; Garcia-Moreno Nisa, Francisca; Perez-Kohler, Barbara; Pascual, Gemma] Ramon y Cajal Hlth Res Inst IRYCIS, Madrid, Spain.
   [Pascual, Gemma] Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Med & Med Specialties, Madrid, Spain.
RP Gomez-Gil, V (reprint author), Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Surg Med & Social Sci, Madrid, Spain.; Gomez-Gil, V (reprint author), Networking Biomed Res Ctr Bioengn Biomat & Nanome, Madrid, Spain.
EM veronica.gomezg@uah.es
RI ; PASCUAL, GEMMA/M-6564-2016
OI Gomez-Gil, Veronica/0000-0002-6642-5912; PASCUAL,
   GEMMA/0000-0002-1623-4384; garcia-moreno nisa,
   francisca/0000-0002-2194-4647
FU Spanish Ministry of Economy and Competitiveness [SAF2014-55022-P,
   SAF2017-89481-P]
FX The study was supported by Grants "SAF2014-55022-P" and "
   SAF2017-89481-P" from the Spanish Ministry of Economy and
   Competitiveness. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amid PK, 2000, BRIT J SURG, V87, P1436
   AMID PK, 1994, J BIOMED MATER RES, V28, P373, DOI 10.1002/jbm.820280312
   [Anonymous], 2015, CURR PROB SURG, V52, P271, DOI 10.1067/j.cpsurg.2015.05.001
   Baptista ML, 2000, J AM COLL SURGEONS, V190, P271, DOI 10.1016/S1072-7515(99)00277-X
   Bellon J M, 2005, Hernia, V9, P338, DOI 10.1007/s10029-005-0012-z
   Bellon JM, 2003, J MATER SCI-MATER M, V14, P359, DOI 10.1023/A:1022936016618
   Bellon JM, 2002, AM J SURG, V184, P154, DOI 10.1016/S0002-9610(02)00907-8
   Bellon JM, 2002, J BIOMED MATER RES, V63, P182, DOI 10.1002/jbm.10123
   Bellon JM, 1997, J BIOMED MATER RES, V38, P197
   Bellon JM, 2012, SURG ENDOSC, V26, P27, DOI 10.1007/s00464-011-1823-x
   Berger D, 2009, HERNIA, V13, P167, DOI 10.1007/s10029-008-0435-4
   Bilsel Y, 2012, INT J SURG, V10, P317, DOI 10.1016/j.ijsu.2012.05.002
   Burger JWA, 2006, SURG ENDOSC, V20, P1320, DOI 10.1007/s00464-005-0706-4
   Chuback JA, 2000, SURGERY, V127, P475, DOI 10.1067/msy.2000.104122
   Conze J, 2005, BRIT J SURG, V92, P1488, DOI 10.1002/bjs.5208
   Conze J, 2008, J BIOMED MATER RES B, V87B, P321, DOI 10.1002/jbm.b.31106
   D'Amore L, 2017, HERNIA, V21, P115, DOI 10.1007/s10029-016-1541-3
   Delibegovic S, 2016, ACTA CHIR BELG, V116, P293, DOI 10.1080/00015458.2016.1179513
   DIZEREGA GS, 2000, PERITONEAL SURG, P3
   Fortelny RH, 2010, BRIT J SURG, V97, P1140, DOI 10.1002/bjs.7082
   Gaertner WB, 2010, HERNIA, V14, P375, DOI 10.1007/s10029-010-0659-y
   Gomez-Gil V, 2010, SURGERY, V147, P378, DOI 10.1016/j.surg.2009.10.011
   Gomez-Gil V, 2009, WOUND REPAIR REGEN, V17, P51, DOI 10.1111/j.1524-475X.2008.00441.x
   Jamry A, 2013, ARCH MED SCI, V9, P487, DOI 10.5114/aoms.2013.35345
   Junge K, 2007, LANGENBECK ARCH SURG, V392, P465, DOI 10.1007/s00423-006-0138-1
   Junge K, 2009, SURG ENDOSC, V23, P327, DOI 10.1007/s00464-008-9923-y
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klinge U, 2002, BIOMATERIALS, V23, P3487, DOI 10.1016/S0142-9612(02)00070-4
   Kockerling F, 2014, HERNIA, V18, P445, DOI 10.1007/s10029-013-1187-3
   Kockerling F, 2018, ANN SURG, V268, P1097, DOI 10.1097/SLA.0000000000002326
   Mary C, 1998, ASAIO J, V44, P199, DOI 10.1097/00002480-199805000-00015
   Moreno-Egea A, 2013, SURG ENDOSC, V27, P231, DOI 10.1007/s00464-012-2425-y
   Moussi A, 2012, HERNIA, V16, P215, DOI 10.1007/s10029-010-0734-4
   Ott V, 2005, Hernia, V9, P103, DOI 10.1007/s10029-004-0271-0
   Pascual G, 2008, SURGERY, V144, P427, DOI 10.1016/j.surg.2008.04.005
   Rutkow IM, 2003, SURG CLIN N AM, V83, P1045, DOI 10.1016/S0039-6109(03)00132-4
   Savioz D, 1997, EUR J SURG, V163, P631
   Scheidbach H, 2004, EUR SURG RES, V36, P313, DOI 10.1159/000079917
   Schreinemacher MHF, 2009, BRIT J SURG, V96, P305, DOI 10.1002/bjs.6446
   Schug-Pass C, 2006, SURG ENDOSC, V20, P402, DOI 10.1007/s00464-004-8277-3
   Schug-Pass C, 2008, SURG ENDOSC, V22, P2433, DOI 10.1007/s00464-008-9876-1
   Tandon A, 2016, ANN ROY COLL SURG, V98, P568, DOI 10.1308/rcsann.2016.0292
   Vrijland WW, 2000, BRIT J SURG, V87, P348, DOI 10.1046/j.1365-2168.2000.01364.x
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2019
VL 14
IS 2
AR e0213005
DI 10.1371/journal.pone.0213005
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HM9LQ
UT WOS:000459806400106
PM 30811503
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Babacic, H
   Mehta, A
   Merkel, O
   Schoser, B
AF Babacic, Haris
   Mehta, Aditi
   Merkel, Olivia
   Schoser, Benedikt
TI CRISPR-cas gene-editing as plausible treatment of neuromuscular and
   nucleotide-repeat-expansion diseases: A systematic review
SO PLOS ONE
LA English
DT Review
ID CONTROL CELL-LINE; RESTORES DYSTROPHIN EXPRESSION; PLURIPOTENT
   STEM-CELLS; MUSCULAR-DYSTROPHY; IN-VIVO; MOUSE MODEL; HOMOLOGOUS
   RECOMBINATION; HUNTINGTONS-DISEASE; PRECISE CORRECTION; GENOME
AB Introduction
   The system of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (cas) is a new technology that allows easier manipulation of the genome. Its potential to edit genes opened a new door in treatment development for incurable neurological monogenic diseases (NMGDs). The aim of this systematic review was to summarise the findings on the current development of CRISPR-cas for therapeutic purposes in the most frequent NMGDs and provide critical assessment.
   Methods and data acquisition
   We searched the MEDLINE and EMBASE databases, looking for original studies on the use of CRISPR-cas to edit pathogenic variants in models of the most frequent NMGDs, until end of 2017. We included all the studies that met the following criteria: 1. Peer-reviewed study report with explicitly described experimental designs; 2. In vitro, ex vivo, or in vivo study using human or other animal biological systems (including cells, tissues, organs, organisms); 3. focusing on CRISPR as the gene-editing method of choice; and 5. featured at least one NMGD.
   Results
   We obtained 404 papers from MEDLINE and 513 from EMBASE. After removing the duplicates, we screened 490 papers by title and abstract and assessed them for eligibility. After reading 50 full-text papers, we finally selected 42 for the review.
   Discussion
   Here we give a systematic summary on the preclinical development of CRISPR-cas for therapeutic purposes in NMGDs. Furthermore, we address the clinical interpretability of the findings, giving a comprehensive overview of the current state of the art. Duchenne's muscular dystrophy (DMD) paves the way forward, with 26 out of 42 studies reporting different strategies on DMD gene editing in different models of the disease. Most of the strategies aimed for permanent exon skipping by deletion with CRISPR-cas. Successful silencing of the mHTT gene with CRISPR-cas led to successful reversal of the neurotoxic effects in the striatum of mouse models of Huntington's disease. Many other strategies have been explored, including epigenetic regulation of gene expression, in cellular and animal models of: myotonic dystrophy, Fraxile X syndrome, ataxias, and other less frequent dystrophies.
   Still, before even considering the clinical application of CRISPR-cas, three major bottlenecks need to be addressed: efficacy, safety, and delivery of the systems. This requires a collaborative approach in the research community, while having ethical considerations in mind.
C1 [Babacic, Haris; Schoser, Benedikt] Ludwig Maximilians Univ Munchen, Friedrich Baur Inst, Dept Neurol, Munich, Germany.
   [Mehta, Aditi; Merkel, Olivia] Ludwig Maximilians Univ Munchen, Fac Pharm, Munich, Germany.
RP Babacic, H; Schoser, B (reprint author), Ludwig Maximilians Univ Munchen, Friedrich Baur Inst, Dept Neurol, Munich, Germany.
EM haris.babacic@gmail.com; benedikt.schoser@med.uni-muenchen.de
RI Merkel, Olivia M/A-9772-2010
OI Merkel, Olivia M/0000-0002-4151-3916
CR Aartsma-Rus A, 2006, MUSCLE NERVE, V34, P135, DOI 10.1002/mus.20586
   Amoasii L, 2017, SCI TRANSL MED, V9, DOI [10.1126/scitransimed.aan8081, DOI 10.1126/SCITRANSIMED.AAN8081]
   Ball P, 2017, DESIGNER BABIES ETHI
   Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140
   Bates GP, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.5
   Batra R, 2017, CELL, V170, P899, DOI 10.1016/j.cell.2017.07.010
   Bengtsson NE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14454
   Benston S, 2017, J MED ETHICS, V43, P819, DOI 10.1136/medethics-2016-103666
   Blat Y, 2015, J BIOMOL SCREEN, V20, P1189, DOI 10.1177/1087057115586535
   Burk Katrin, 2017, Cerebellum Ataxias, V4, P4, DOI 10.1186/s40673-017-0062-x
   Chau A, 2015, DEV DYNAM, V244, P377, DOI 10.1002/dvdy.24240
   Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993
   CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968
   Chu ML, 2018, NEUROTHERAPEUTICS, DOI 10.1007/s13311.018-0648-x
   Collins PJ, 2017, PHARM RES, DOI 10.1016/j.phrs.2017.09.008
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cribbs Adam P., 2017, Yale Journal of Biology and Medicine, V90, P625
   DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411
   de Die-Smulders CEM, 1998, BRAIN, V121, P1557, DOI 10.1093/brain/121.8.1557
   Deenen JCW, 2014, NEUROLOGY, V83, P1056, DOI 10.1212/WNL.0000000000000797
   DeMichele G, 1996, NEUROLOGY, V47, P1260, DOI 10.1212/WNL.47.5.1260
   Duchene B, 2018, METHODS MOL BIOL, V1687, P267, DOI 10.1007/978-1-4939-7374-3_19
   Durbeej M, 2015, CURR TOP MEMBR, V76, P31, DOI 10.1016/bs.ctm.2015.05.002
   E JM, 2000, STRUCT FUNCT DYSTR G
   Echigoya Y, 2014, NUCLEIC ACID THER, V24, P57, DOI 10.1089/nat.2013.0451
   Ehrhardt A, 2002, BLOOD, V99, P3923, DOI 10.1182/blood.V99.11.3923
   Ehrke-Schulz E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17180-w
   Ehrke-Schulz E, 2016, MOL THER, V24, pS44
   El Refaey M, 2017, CIRC RES, V121, P923, DOI 10.1161/CIRCRESAHA.117.310996
   Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R20021200
   Fardaei M, 2002, HUM MOL GENET, V11, P805, DOI 10.1093/hmg/11.7.805
   Fardaei M, 2001, NUCLEIC ACIDS RES, V29, P2766, DOI 10.1093/nar/29.13.2766
   Garneau JE, 2010, NATURE, V468, P67, DOI 10.1038/nature09523
   Gasiunas G, 2012, P NATL ACAD SCI USA, V109, pE2579, DOI 10.1073/pnas.1208507109
   Govert F, 2013, CURR OPIN NEUROL, V26, P420, DOI 10.1097/WCO.0b013e3283632d90
   Hagerman RJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.65
   Hale CR, 2009, CELL, V139, P945, DOI 10.1016/j.cell.2009.07.040
   Harper PS, 2001, MYOTONIC DYSTROPHY
   Himeda CL, 2016, MOL THER, V24, P527, DOI 10.1038/mt.2015.200
   Ho TH, 2005, J CELL SCI, V118, P2923, DOI 10.1242/jcs.02404
   Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300
   HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4
   HOFFMAN EP, 1987, NATURE, V330, P754, DOI 10.1038/330754a0
   Iyombe-Engembe JP, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2015.58
   Jackson MF, 2013, FEBS J, V280, P827, DOI 10.1111/febs.12072
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kemaladewi DU, 2017, NAT MED, V23, P984, DOI 10.1038/nm.4367
   Kennedy EM, 2015, VIROLOGY, V479, P213, DOI 10.1016/j.virol.2015.02.024
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2
   Kolli N, 2017, INT J MOL SCI, V18, DOI [10.3390/brns18040754, DOI 10.3390/BRNS18040754]
   Kyrychenko V, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95918
   Lattanzi A, 2017, MOL THER-NUCL ACIDS, V7, P11, DOI 10.1016/j.omtn.2017.02.004
   Lee K, 2017, NAT BIOMED ENG, V1, P889, DOI 10.1038/s41551-017-0137-2
   Lemmers RJLF, 2010, SCIENCE, V329, P1650, DOI 10.1126/science.1189044
   Li HL, 2015, STEM CELL REP, V4, P143, DOI 10.1016/j.stemcr.2014.10.013
   Liao HK, 2017, CELL, V171, P1495, DOI 10.1016/j.cell.2017.10.025
   Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125
   Liu C, 2017, J CONTROL RELEASE, V266, P17, DOI 10.1016/j.jconrel.2017.09.012
   Long CZ, 2016, SCIENCE, V351, P400, DOI 10.1126/science.aad5725
   Long CZ, 2014, SCIENCE, V345, P1184, DOI 10.1126/science.1254445
   Lu QL, 2011, MOL THER, V19, P9, DOI 10.1038/mt.2010.219
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   Maggio I, 2016, SCI REP-UK, V6, DOI 10.1038/srep37051
   Maggio I, 2016, NUCLEIC ACIDS RES, V44, P1449, DOI 10.1093/nar/gkv1540
   MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244
   Marthaler AG, 2016, STEM CELL RES, V16, P202, DOI 10.1016/j.scr.2015.12.048
   Marthaler AG, 2016, STEM CELL RES, V16, P180, DOI 10.1016/j.scr.2015.12.028
   Marthaler AG, 2016, STEM CELL RES, V16, P162, DOI 10.1016/j.scr.2015.12.031
   Martin F, 2016, INT J MOL SCI, V17, DOI [10.3390/Os-17091507, DOI 10.3390/IJMS-17091507]
   Mast TC, 2010, VACCINE, V28, P950, DOI 10.1016/j.vaccine.2009.10.145
   Mathieu J, 2012, NEUROMUSCULAR DISORD, V22, P974, DOI 10.1016/j.nmd.2012.05.017
   Maxmen A, 2015, THE GENESIS ENGINE
   Mehta A, 2014, COLD SPRING HARBOR P, V6, DOI [10.1101/cshperspecta016428, DOI 10.1101/CSHPERSPECTA016428]
   Meola G, 2015, BBA-MOL BASIS DIS, V1852, P594, DOI 10.1016/j.bbadis.2014.05.019
   Mila M, 2018, CLIN GENET, V93, P197, DOI 10.1111/cge.13075
   Moat SJ, 2013, EUR J HUM GENET, V21, P1049, DOI 10.1038/ejhg.2012.301
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mojica FJM, 2005, J MOL EVOL, V60, P174, DOI 10.1007/s00239-004-0046-3
   Monteys AM, 2017, MOL THER, V25, P12, DOI 10.1016/j.ymthe.2016.11.010
   Morris Evan D., 2017, Yale Journal of Biology and Medicine, V90, P661
   Mou HW, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1237-8
   Mulvihill JJ, 2017, BRIT MED BULL, V122, P17, DOI 10.1093/bmb/ldx002
   Muthuswamy S, 2015, NEUROLOGIST, V20, P51, DOI 10.1097/NRL.0000000000000054
   Nakamura A, 2017, J HUM GENET, V62, P871, DOI 10.1038/jhg.2017.57
   Nelson CE, 2016, SCIENCE, V351, P403, DOI 10.1126/science.aad5143
   Nigro V, 2015, BBA-MOL BASIS DIS, V1852, P585, DOI 10.1016/j.bbadis.2014.07.023
   Nigro Vincenzo, 2014, Acta Myol, V33, P1
   Ouellet DL, 2017, GENE THER, V24, P265, DOI 10.1038/gt.2016.89
   Ousterout DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7244
   Park CY, 2015, CELL REP, V13, P234, DOI 10.1016/j.celrep.2015.08.084
   Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565
   Pavlath GK, 2003, CELL CYCLE, V2, P420, DOI 10.4161/cc.2.5.497
   Perrin A, 2017, MOL THER-NUCL ACIDS, V6, P68, DOI 10.1016/j.omtn.2016.11.004
   Pinto BS, 2017, MOL CELL, V68, P479, DOI 10.1016/j.molcel.2017.09.033
   Pourcel C, 2005, MICROBIOL-SGM, V151, P653, DOI 10.1099/mic.0.27437-0
   ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096
   ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064
   RUDIN N, 1989, GENETICS, V122, P519
   Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661
   Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771
   Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209
   Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842
   Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180
   Shin JW, 2016, HUM MOL GENET, V25, P4566, DOI 10.1093/hmg/ddw286
   Smith C, 2014, CELL STEM CELL, V15, P13, DOI 10.1016/j.stem.2014.06.011
   Tabebordbar M, 2016, SCIENCE, V351, P407, DOI 10.1126/science.aad5177
   Turan S, 2016, MOL THER, V24, P685, DOI 10.1038/mt.2016.40
   Turner C, 2010, J NEUROL NEUROSUR PS, V81, P358, DOI 10.1136/jnnp.2008.158261
   Ul Ain Q, 2015, J CONTROL RELEASE, V205, P120, DOI 10.1016/j.jconrel.2014.12.036
   van Agtmaal EL, 2017, MOL THER, V25, P24, DOI 10.1016/j.ymthe.2016.10.014
   Veres A, 2014, CELL STEM CELL, V15, P27, DOI 10.1016/j.stem.2014.04.020
   Vestergaard G, 2014, RNA BIOL, V11, P156, DOI 10.4161/rna.27990
   Wang HF, 2016, ANNU REV BIOCHEM, V85, P227, DOI 10.1146/annurev-biochem-060815-014607
   Wang JZ, 2017, BRAIN DEV-JPN, V39, P547, DOI 10.1016/j.braindev.2017.03.024
   Wild EJ, 2017, LANCET NEUROL, V16, P837, DOI 10.1016/S1474-4422(17)30280-6
   Wojtal D, 2016, AM J HUM GENET, V98, P90, DOI 10.1016/j.ajhg.2015.11.012
   Wright DA, 2014, BIOCHEM J, V462, P15, DOI 10.1042/BJ20140295
   Xie N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165499
   Xu L, 2016, MOL THER, V24, P564, DOI 10.1038/mt.2015.192
   Xu XH, 2017, STEM CELL REP, V8, P619, DOI 10.1016/j.stemcr.2017.01.022
   Yang S, 2017, J CLIN INVEST, V127, P2719, DOI 10.1172/JCI92087
   Yiu EM, 2015, J PAEDIATR CHILD H, V51, P759, DOI 10.1111/jpc.12868
   Young CS, 2016, CELL STEM CELL, V18, P533, DOI 10.1016/j.stem.2016.01.021
   Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038
   Zhang H, 2016, BRIT J HAEMATOL, V175, P208, DOI 10.1111/bjh.14297
   Zhang Y, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602814
   Zhu P, 2017, MOL THER-NUCL ACIDS, V7, P31, DOI 10.1016/j.omtn.2017.02.007
NR 130
TC 0
Z9 0
U1 8
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2019
VL 14
IS 2
AR e0212198
DI 10.1371/journal.pone.0212198
PG 32
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HM8DR
UT WOS:000459709100046
PM 30794581
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lopez, MY
   Pardon, MC
   Baiker, K
   Prior, M
   Ding, YC
   Agostini, A
   Bai, L
   Auer, DP
   Faas, HM
AF Lopez, Maria Yanez
   Pardon, Marie-Christine
   Baiker, Kerstin
   Prior, Malcolm
   Ding Yuchun
   Agostini, Alessandra
   Bai, Li
   Auer, Dorothee P.
   Faas, Henryk M.
TI Myoinositol CEST signal in animals with increased Iba-1 levels in
   response to an inflammatory challenge-Preliminary findings
SO PLOS ONE
LA English
DT Article
ID SATURATION-TRANSFER CEST; MAGNETIC-RESONANCE-SPECTROSCOPY; IN-VIVO;
   ALZHEIMERS-DISEASE; MOUSE MODEL; RAT-BRAIN; EXCHANGE; NEUROINFLAMMATION;
   ACTIVATION; AGENTS
AB Neuroinflammation plays an important role in the pathogenesis of a range of brain disorders. Non-invasive imaging of neuroinflammation is critical to help improve our understanding of the underlying disease mechanisms, monitor therapies and guide drug development. Generally, MRI lacks specificity to molecular imaging biomarkers, but molecular MR imaging based on chemical exchange saturation transfer (CEST) can potentially detect changes of myoinositol, a putative glial marker that may index neuroinflammation. In this pilot study we aimed to investigate, through validation with immunohistochemistry and in vivo magnetic resonance spectroscopy (MRS), whether CEST imaging can reflect the microglial response to a mild inflammatory challenge with lipopolysaccharide (LPS), in the APPSwe/PS1 mouse model of Alzheimer's disease and wild type controls. The response to the immune challenge was variable and did not align with genotype. Animals with a strong response to LPS (Iba1+, n = 6) showed an increase in CEST contrast compared with those who did not (Iba1-, n = 6). Changes of myoinositol levels after LPS were not significant. We discuss the difficulties of this mild inflammatory model, the role of myoinositol as a glial biomarker, and the technical challenges of CEST imaging at 0.6ppm.
C1 [Lopez, Maria Yanez; Auer, Dorothee P.; Faas, Henryk M.] Univ Nottingham, Sch Med, Sir Peter Mansfield Imaging Ctr, Nottingham, England.
   [Pardon, Marie-Christine; Agostini, Alessandra] Univ Nottingham, Sch Life Sci, Nottingham, England.
   [Baiker, Kerstin] Univ Nottingham, Sch Vet Sci, Nottingham, England.
   [Prior, Malcolm] Univ Nottingham, Med Imaging Unit, Nottingham, England.
   [Ding Yuchun; Bai, Li] Univ Nottingham, Sch Comp Sci, Nottingham, England.
RP Faas, HM (reprint author), Univ Nottingham, Sch Med, Sir Peter Mansfield Imaging Ctr, Nottingham, England.
EM henryk.faas@nottingham.ac.uk
OI Yanez Lopez, Maria/0000-0001-5187-2501; Pardon,
   Marie-Christine/0000-0003-4737-9479
FU UNICAS - a University of Nottingham initiative [UNICAS-A2B177]; Medical
   Research Council [CiC2014029]
FX We acknowledge support from UNICAS - a University of Nottingham
   initiative to fund interdisciplinary equipment based research
   (UNICAS-A2B177), as well as a Medical Research Council Confidence in
   Concept award (CiC2014029).; We acknowledge support on interpretation of
   histology from Diana Cash and Camilla Simmons, BRAIN Centre, Department
   of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience,
   King's College London.
CR Adamczak JM, 2010, NEUROIMAGE, V51, P704, DOI 10.1016/j.neuroimage.2010.02.083
   Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901
   [Anonymous], 2013, R LANG ENV STAT COMP
   Bagga P, 2016, J NEUROCHEM, V139, P432, DOI 10.1111/jnc.13771
   Banks WA, 2010, BRAIN BEHAV IMMUN, V24, P102, DOI 10.1016/j.bbi.2009.09.001
   Bitsch A, 1999, AM J NEURORADIOL, V20, P1619
   BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347
   Cai KJ, 2015, NMR BIOMED, V28, P1, DOI 10.1002/nbm.3216
   Carrillo-de Sauvage MA, 2015, J CEREBR BLOOD F MET, V35, P917, DOI 10.1038/jcbfm.2015.48
   Chan KWY, 2016, NMR BIOMED, V29, P806, DOI 10.1002/nbm.3526
   Chang LD, 2013, J NEUROIMMUNE PHARM, V8, P576, DOI 10.1007/s11481-013-9460-x
   Clark DJ, 2016, MAGN RESON MED, V76, P826, DOI 10.1002/mrm.25987
   Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005
   Datta G, 2017, MULT SCLER J, V23, P1469, DOI 10.1177/1352458516681504
   DiCarlo G, 2001, NEUROBIOL AGING, V22, P1007, DOI 10.1016/S0197-4580(01)00292-5
   Ding YC, 2017, IEEE ACM T COMPUT BI, V14, P1366, DOI 10.1109/TCBB.2016.2591520
   Garwood M, 2001, J MAGN RESON, V153, P155, DOI 10.1006/jmre.2001.2340
   Go M, 2016, BIOCHEM BIOPH RES CO, V479, P331, DOI 10.1016/j.bbrc.2016.09.073
   GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613
   Haris M, 2013, NMR BIOMED, V26, P386, DOI 10.1002/nbm.2875
   Haris M, 2011, NEUROIMAGE, V54, P2079, DOI [10.1016/j.neuroimage.2010.10.017, 10.1016/ineuroimage.2010.10.017]
   Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5
   HENKELMAN RM, 1993, MAGNET RESON MED, V29, P759, DOI 10.1002/mrm.1910290607
   HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602
   Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15
   Herber DL, 2004, EXP NEUROL, V190, P245, DOI 10.1016/j.expneurol.2004.07.007
   Huang W, 1999, AM J PSYCHIAT, V156, P1879
   Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019
   Jin T, 2014, NMR BIOMED, V27, P1313, DOI 10.1002/nbm.3191
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim M, 2009, MAGN RESON MED, V61, P1441, DOI 10.1002/mrm.21873
   Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000
   Kozlowski C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031814
   Kreisel T, 2014, MOL PSYCHIATR, V19, P699, DOI 10.1038/mp.2013.155
   Lee DH, 2017, MAGN RESON MED, V77, P855, DOI 10.1002/mrm.26131
   Lee JS, 2016, CONTRAST MEDIA MOL I, V11, P4, DOI 10.1002/cmmi.1652
   Liu GS, 2013, MAGN RESON MED, V70, P1690, DOI 10.1002/mrm.24955
   Liu Z, 2015, BRAIN, V138, P1239, DOI 10.1093/brain/awv065
   Marjanska M, 2014, NEUROSCIENCE, V259, P94, DOI 10.1016/j.neuroscience.2013.11.052
   McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631
   Melah KE, 2016, J ALZHEIMERS DIS, V50, P873, DOI 10.3233/JAD-150897
   Michaud JP, 2013, P NATL ACAD SCI USA, V110, P1941, DOI 10.1073/pnas.1215165110
   Murray ME, 2014, J NEUROSCI, V34, P16247, DOI 10.1523/JNEUROSCI.2027-14.2014
   Pardon MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19880
   Pepin J, 2016, NEUROIMAGE, V139, P53, DOI 10.1016/j.neuroimage.2016.06.023
   PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Roalf DR, 2017, MOL PSYCHIATR, V22, P1298, DOI 10.1038/mp.2016.258
   Robinson KM, 2010, MOL IMAGING BIOL, V12, P240, DOI 10.1007/s11307-009-0272-6
   Schneider P, 2012, BRAIN BEHAV IMMUN, V26, P277, DOI 10.1016/j.bbi.2011.09.011
   Sled JG, 2001, MAGNET RESON MED, V46, P923
   Song XL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7719
   Stefaniak J, 2016, J NEUROL NEUROSUR PS, V87, P21, DOI 10.1136/jnnp-2015-311336
   Sulzer D, 2017, NATURE, V546, P656, DOI 10.1038/nature22815
   Suridjan I, 2014, NEUROIMAGE, V84, P868, DOI 10.1016/j.neuroimage.2013.09.021
   Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G
   Tu TW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19094-z
   Turkheimer FE, 2015, BIOCHEM SOC T, V43, P586, DOI 10.1042/BST20150058
   Ward KM, 2000, J MAGN RESON, V143, P79, DOI 10.1006/jmre.1999.1956
   Wells JA, 2015, NEUROIMAGE, V111, P369, DOI 10.1016/j.neuroimage.2015.02.023
   Woessner DE, 2005, MAGN RESON MED, V53, P790, DOI 10.1002/mrm.20408
   Zahr NM, 2014, BRAIN PATHOL, V24, P654, DOI 10.1111/bpa.12197
   Zhang XY, 2017, MAGN RESON MED, V78, P881, DOI 10.1002/mrm.26802
   Zhang XY, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3716
   Zhong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140238
NR 65
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2019
VL 14
IS 2
AR e0212002
DI 10.1371/journal.pone.0212002
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HM2WC
UT WOS:000459330800016
PM 30789943
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Foster, AD
AF Foster, Adam D.
TI The impact of bipedal mechanical loading history on longitudinal long
   bone growth
SO PLOS ONE
LA English
DT Article
ID RAT; PLATE; COMPRESSION; LOCOMOTION; MODULATION; WALKING; YOUNG
AB Longitudinal bone growth is accomplished through a process where proliferating chondrocytes produce cartilage in the growth plate, which ultimately ossifies. Environmental influences, like mechanical loading, can moderate the growth of this cartilage, which can alter bone length. However, little is known about how specific behaviors like bipedalism, which is characterized by a shift in body mass (mechanical load), to the lower limbs, may impact bone growth. This study uses an experimental approach to induce bipedal behaviors in a rodent model (Rattus norvegicus) over a 12-week period using a treadmill-mounted harness system to test how rat hindlimbs respond to the following loading conditions: 1) fully loaded bipedal walking, 2) partially loaded bipedal walking, 3) standing, 4) quadrupedal walking, and 5) no exercise control. These experimental conditions test whether mechanical loading from 1) locomotor or postural behaviors, and 2) a change in the magnitude of load can moderate longitudinal bone growth in the femur and tibia, relative to controls. The results demonstrate that fully loaded bipedal walking and bipedal standing groups showed significant differences in the percentage change in length for the tibia and femur. When comparing the change from baseline, which control for body mass, all bipedal groups showed significant differences in tibia length compared to control groups. However, there were no absolute differences in bone length, which suggests that mechanical loads from bipedal behaviors may instead be moderating changes in growth velocity. Implications for the relationship between bipedal behaviors and longitudinal bone growth are discussed.
C1 [Foster, Adam D.] Campbell Univ, Dept Anat, Sch Osteopath Med, Buies Creek, NC 27506 USA.
RP Foster, AD (reprint author), Campbell Univ, Dept Anat, Sch Osteopath Med, Buies Creek, NC 27506 USA.
EM afoster@campbell.edu
OI Foster, Adam/0000-0002-1265-8171
FU National Science Foundation [BCS 1153863]; Force & Motion Foundation;
   School of Anthropology at the University of Arizona
FX I would like to thank the National Science Foundation (BCS 1153863;
   https://www.nsf.gov/), the Force & Motion Foundation
   http://www.forceandmotion.org/), and the School of Anthropology at the
   University of Arizona (https://anthropology.arizona.edu/) for funding
   this study. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ALEXANDER RM, 1983, J ZOOL, V201, P135
   Bailey AS, 2001, SPINE, V26, P308
   BOURRIN S, 1994, J APPL PHYSIOL, V76, P1999
   Colton HS, 1929, J EXP ZOOL, V53, P1, DOI 10.1002/jez.1400530102
   Cowgill LW, 2010, AM J PHYS ANTHROPOL, V143, P52, DOI 10.1002/ajpa.21289
   Currey J. D., 2002, BONES STRUCTURE MECH
   Geiger M, 2014, J EVOLUTION BIOL, V27, P98, DOI 10.1111/jeb.12279
   Giszter SF, 2008, EXP BRAIN RES, V190, P53, DOI 10.1007/s00221-008-1451-4
   Goff WC, 1957, J BONE JT SURG, V39, P616
   Hammond AS, 2010, ANAT REC, V293, P658, DOI 10.1002/ar.21136
   Horton JA, 2008, ANAT REC, V291, P283, DOI 10.1002/ar.20650
   Ireland A, 2017, J BONE MINER RES, V32, P1209, DOI 10.1002/jbmr.3099
   Kelly PM, 2008, J CHILD ORTHOP, V2, P407, DOI 10.1007/s11832-008-0119-8
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lenth RV, 2016, J STAT SOFTW, V69, P1, DOI 10.18637/jss.v069.i01
   LI KC, 1991, J APPL PHYSIOL, V70, P554
   MOSS ML, 1961, AM J PHYS ANTHROPOL, V19, P301, DOI 10.1002/ajpa.1330190311
   Niehoff A, 2004, BONE, V35, P899, DOI 10.1016/j.bone.2004.06.006
   Pratt LW, 1943, B JOHNS HOPKINS HOSP, V72, P265
   R Core Team, 2017, R LANG ENV STAT COMP
   Raichlen DA, 2015, J HUM EVOL, V81, P1, DOI 10.1016/j.jhevol.2015.01.003
   RIESENFE.A, 1966, ACTA ANAT, V65, P449
   RIESENFELD A, 1972, AM J PHYS ANTHROPOL, V36, P229, DOI 10.1002/ajpa.1330360211
   Robling AG, 2001, BONE, V29, P105, DOI 10.1016/S8756-3282(01)00488-4
   Rolian C, 2008, EVOL DEV, V10, P15, DOI 10.1111/j.1525-142X.2008.00211.x
   Russo Gabrielle A, 2018, Anat Rec (Hoboken), DOI 10.1002/ar.24003
   SIMON MR, 1982, ACTA ANAT, V114, P321
   Stokes IAF, 2006, J ORTHOP RES, V24, P1327, DOI 10.1002/jor.20189
   Stokes IAF, 2007, BONE, V41, P197, DOI 10.1016/j.bone.2007.04.180
   Ueki M, 2008, ANN BIOMED ENG, V36, P793, DOI 10.1007/s10439-008-9462-7
   UMEMURA Y, 1995, INT J SPORTS MED, V16, P364, DOI 10.1055/s-2007-973021
   Vickers A J, 2001, BMC Med Res Methodol, V1, P6, DOI 10.1186/1471-2288-1-6
   Villemure I, 2009, J BIOMECH, V42, P1793, DOI 10.1016/j.jbiomech.2009.05.021
   Wada N, 2008, BRAIN RES, V1243, P70, DOI 10.1016/j.brainres.2008.09.034
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wickham H, 2007, J STAT SOFTW, V21, P1
   Zhang P, 2012, J BONE MINER METAB, V30, P31, DOI 10.1007/s00774-011-0292-6
   Zhang P, 2010, J BONE MINER METAB, V28, P268, DOI 10.1007/s00774-009-0135-x
   Zhang P, 2008, BONE, V43, pS42, DOI 10.1016/j.bone.2008.08.015
NR 40
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 7
PY 2019
VL 14
IS 2
AR e0211692
DI 10.1371/journal.pone.0211692
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HK5RX
UT WOS:000458026000045
PM 30730948
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hehrlein, C
   Schorch, B
   Kress, N
   Arab, A
   von zur Muhlen, C
   Bode, C
   Epting, T
   Haberstroh, J
   Mey, L
   Schwarzbach, H
   Kinscherf, R
   Stachniss, V
   Schiestel, S
   Kovacs, A
   Fischer, H
   Nennig, E
AF Hehrlein, Christoph
   Schorch, Bjoern
   Kress, Nadia
   Arab, Amina
   von zur Muehlen, Constantin
   Bode, Christoph
   Epting, Thomas
   Haberstroh, Joerg
   Mey, Lilly
   Schwarzbach, Hans
   Kinscherf, Ralf
   Stachniss, Vitus
   Schiestel, Stefanie
   Kovacs, Adalbert
   Fischer, Harald
   Nennig, Ernst
TI Zn-alloy provides a novel platform for mechanically stable bioresorbable
   vascular stents
SO PLOS ONE
LA English
DT Article
ID MAGNESIUM ALLOYS; BIODEGRADABLE METALS; ARTERY; CELLS; CYTOTOXICITY;
   MULTICENTER; SCAFFOLDS; RESPONSES; BEHAVIOR; LESIONS
AB Metallic Zn alloys have recently gained interest as potential candidates for developing platforms of bioresorbable vascular stents (BVS). Previous studies revealed that Mg alloys used for BVS can degrade too early, whereas PLLA materials may fail to provide effective scaffolding properties. Here we report on results of a new bioresorbable, metallic stent made from a Zn-Ag alloy studied in a porcine animal model of thrombosis and restenosis. While the tensile strength (MPa) of Zn-3Ag was higher than that of PLLA and resembled Mg's (WE43), fracture elongation (%) of Zn-3Ag was much greater (18-fold) than the PLLA's or Mg alloy's (WE43). Zn-3Ag exposed to HAoSMC culture medium for 30 days revealed degradation elements consisting of Zn, O, N, C, P, and Na at a 6 nm surface depth. Platelet adhesion rates and blood biocompatibility did not differ between Zn-3Ag, PLLA, Mg (WE43), and non-resorbable Nitinol (NiTi) stent materials. Balloon-expandable Zn-3Ag alloy BVS implanted into iliofemoral arteries of 15 juvenile domestic pigs were easily visible fluoroscopically at implantation, and their bioresorption was readily detectable via X-ray over time. Histologically, arteries with Zn-3Ag BVS were completely endothelialized, covered with neointima, and were patent at 1, 3, and 6 months follow-up with no signs of stent thrombosis. Zn-3Ag alloy appears to be a promising material platform for the fabrication of a new generation of bioresorbable vascular stents.
C1 [Hehrlein, Christoph; Schorch, Bjoern; Kress, Nadia; Arab, Amina; von zur Muehlen, Constantin; Bode, Christoph] Univ Freiburg, Fac Med, Heart Ctr, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Epting, Thomas] Univ Freiburg, Fac Med, Med Ctr, Dept Lab Med, Freiburg, Germany.
   [Haberstroh, Joerg] Univ Freiburg, Fac Med, Med Ctr, Div Expt Surg,Ctr Expt Models & Transgen Serv, Freiburg, Germany.
   [Mey, Lilly; Schwarzbach, Hans; Kinscherf, Ralf] Philipps Univ Marburg, Dept Med Cell Biol, Inst Anat & Cell Biol, Marburg, Germany.
   [Stachniss, Vitus] Univ Marburg, Sch Dent, Dept Operat Dent & Endodont, Marburg, Germany.
   [Stachniss, Vitus] Univ Med Ctr Giessen & Marburg, Marburg, Germany.
   [Schiestel, Stefanie; Kovacs, Adalbert] Limedion GmbH, Mannheim, Germany.
   [Fischer, Harald; Nennig, Ernst] Optimed GmbH, Ettlingen, Germany.
RP Hehrlein, C (reprint author), Univ Freiburg, Fac Med, Heart Ctr, Dept Cardiol & Angiol 1, Freiburg, Germany.
EM christoph.hehrlein@universitaets-herzzentrum.de
OI Schorch, Bjorn/0000-0001-8311-0210
FU BMBF research foundation, Germany [13GW0035B]; Optimed GmbH; Limedion
   GmbH
FX All authors received financial support from the BMBF research
   foundation, Germany (13GW0035B). The funder had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript. Optimed GmbH and Limedion GmbH provided support in the form
   of research materials and salaries for authors (Optimed GmbH: E. N. and
   H. F., Limedion GmbH: S. S. and A. K.], but did not have any additional
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript. The specific roles of these
   authors are articulated in the 'author contributions' section."
CR Bornapour M, 2013, ACTA BIOMATER, V9, P5319, DOI 10.1016/j.actbio.2012.07.045
   Bowen PK, 2016, ADV HEALTHC MATER, V5, P1121, DOI 10.1002/adhm.201501019
   Campos CM, 2014, CATHETER CARDIO INTE, V84, P46, DOI 10.1002/ccd.25541
   Di Mario Carlo, 2004, J Interv Cardiol, V17, P391, DOI 10.1111/j.1540-8183.2004.04081.x
   Feyerabend F, 2010, ACTA BIOMATER, V6, P1834, DOI 10.1016/j.actbio.2009.09.024
   Fukada T, 2011, J BIOL INORG CHEM, V16, P1123, DOI 10.1007/s00775-011-0797-4
   Gong HB, 2015, J BIOMED MATER RES B, V103, P1632, DOI 10.1002/jbm.b.33341
   Haude M, 2016, LANCET, V387, P31, DOI 10.1016/S0140-6736(15)00447-X
   Hehrlein C, 1996, CIRCULATION, V93, P641
   Hehrlein C., 1999, INT J CARDIOVASC INT, V2, P21
   Heublein B, 2003, HEART, V89, P651, DOI 10.1136/heart.89.6.651
   Kfoury G, 2013, FRONT CHEM, V1, DOI 10.3389/fchem.2013.00032
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   King SB, 2000, CIRCULATION, V102, P81
   Konstantinos K, 2016, J MECH BEHAV BIOMED, V40, P240
   Ma J, 2016, SCI REP-UK, V6, DOI 10.1038/srep26661
   Ma J, 2015, ACS BIOMATER SCI ENG, V1, P1174, DOI 10.1021/acsbiomaterials.5b00319
   Mani G, 2007, BIOMATERIALS, V28, P1689, DOI 10.1016/j.biomaterials.2006.11.042
   Moravej M, 2011, INT J MOL SCI, V12, P4250, DOI 10.3390/ijms12074250
   MURPHY JG, 1992, CIRCULATION, V86, P1596, DOI 10.1161/01.CIR.86.5.1596
   Niu JL, 2016, MAT SCI ENG C-MATER, V69, P407, DOI 10.1016/j.msec.2016.06.082
   Persaud-Sharma Dharam, 2013, J Biomim Biomater Tissue Eng, V17, P25, DOI 10.4028/www.scientific.net/JBBTE.17.25
   Saper RB, 2009, AM FAM PHYSICIAN, V79, P768
   Serruys PW, 2016, LANCET, V388, P2479, DOI 10.1016/S0140-6736(16)32050-5
   Shearier ER, 2016, ACS BIOMATER SCI ENG, V2, P634, DOI 10.1021/acsbiomaterials.6b00035
   Sikora-Jasinska M, 2017, MAT SCI ENG C-MATER, V77, P1170, DOI 10.1016/j.msec.2017.04.023
   Tan LP, 2006, J BIOMED MATER RES B, V79B, P102, DOI 10.1002/jbm.30518
   Tenekecioglu E, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0207-5
   Wan P, 2013, MAT SCI ENG C-MATER, V33, P2885, DOI 10.1016/j.msec.2013.03.017
   Werner M, 2014, JACC-CARDIOVASC INTE, V7, P305, DOI 10.1016/j.jcin.2013.09.009
   Wu ZX, 2015, NATURE, V526, P62, DOI 10.1038/nature15364
   Yang HT, 2018, ACTA BIOMATER, V71, P200, DOI 10.1016/j.actbio.2018.03.007
   Yang HT, 2017, BIOMATERIALS, V145, P92, DOI 10.1016/j.biomaterials.2017.08.022
   Zhang SX, 2010, ACTA BIOMATER, V6, P626, DOI 10.1016/j.actbio.2009.06.028
   Zhu DH, 2017, ACS APPL MATER INTER, V9, P27453, DOI 10.1021/acsami.7b06654
NR 35
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 2
PY 2019
VL 14
IS 1
AR e0209111
DI 10.1371/journal.pone.0209111
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HG1BB
UT WOS:000454683200038
PM 30601854
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bayliss, M
   Trotman-Lucas, M
   Janus, J
   Kelly, ME
   Gibson, CL
AF Bayliss, Michaela
   Trotman-Lucas, Melissa
   Janus, Justyna
   Kelly, Michael E.
   Gibson, Claire L.
TI Pre-stroke surgery is not beneficial to normotensive rats undergoing
   sixty minutes of transient focal cerebral ischemia
SO PLOS ONE
LA English
DT Article
ID ARTERY OCCLUSION; ANIMAL-MODELS; TEMPORAL EVOLUTION; INJURY; WISTAR;
   EDEMA; TRANSLATION; SENSITIVITY; INFARCTION; PLATFORM
AB Experimental stroke in rodents, via middle cerebral artery occlusion (MCAO), can be associated with a negative impact on wellbeing and mortality. In hypertensive rodents, pre-stroke craniotomy increased survival and decreased body weight loss post-MCAO. Here we determined the effect, in normotensive Sprague-Dawley rats following 60 minutes MCAO, with or without pre-surgical craniotomy, on post-stroke outcomes in terms of weight loss, neurological deficit, lesion volume and functional outcomes. There was no effect of pre-stroke craniotomy on indicators of wellbeing including survival rate (P = 0.32), body weight loss (P = 0.42) and neurological deficit (P = 0.75). We also assessed common outcome measures following experimental stroke and found no effect of pre-stroke craniotomy on lesion volume as measured by T2-weighted MRI (P = 0.846), or functional performance up to 28 days post-MCAO (staircase test, P = 0.32; adhesive sticker test, P = 0.49; cylinder test, P = 0.38). Thus, pre-stroke craniotomy did not improve animal welfare in terms of body weight loss and neurological deficit. However, it is important, given that a number of drug delivery studies utilise the craniotomy procedure, to note that there was no effect on lesion volume or functional outcome following experimental stroke.
C1 [Bayliss, Michaela; Trotman-Lucas, Melissa; Gibson, Claire L.] Univ Leicester, Dept Neurosci Psychol & Behav, Leicester, Leics, England.
   [Janus, Justyna; Kelly, Michael E.] Univ Leicester, Preclin Imaging Facil, Core Biotechnol Serv, Leicester, Leics, England.
RP Gibson, CL (reprint author), Univ Leicester, Dept Neurosci Psychol & Behav, Leicester, Leics, England.
EM claire.gibson@nottingham.ac.uk
OI trotman-lucas, melissa/0000-0002-7735-7476; Gibson,
   Claire/0000-0002-3358-7341; Bayliss, Michaela/0000-0003-2375-6890
FU National Centre for the Replacement, Refinement and Reduction of Animals
   in Research (NC3Rs) [NC/M001768/1]
FX This work was supported by the National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NC3Rs; NC/M001768/1 to
   CG and MK).
CR Arora S, 2005, STROKE, V36, P1232, DOI 10.1161/01.STR.0000165902.18021.5b
   Aspey BS, 2000, NEUROPATH APPL NEURO, V26, P232, DOI 10.1046/j.1365-2990.2000.00221.x
   Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290
   Carswell HVO, 1999, HYPERTENSION, V33, P681, DOI 10.1161/01.HYP.33.2.681
   COYLE P, 1983, STROKE, V14, P605, DOI 10.1161/01.STR.14.4.605
   Dirnagl U, 2014, STROKE, V45, P1510, DOI 10.1161/STROKEAHA.113.004075
   Dogan A, 1998, NEUROL RES, V20, P265
   du Sert NP, 2017, J CEREBR BLOOD F MET, V37, P3488, DOI 10.1177/0271678X17709185
   DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Fluri F, 2015, DRUG DES DEV THER, V9, P3445, DOI 10.2147/DDDT.S56071
   GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636
   GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613
   Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012
   Hoehn M, 2001, J MAGN RESON IMAGING, V14, P491, DOI 10.1002/jmri.1213
   Howells DW, 2010, J CEREBR BLOOD F MET, V30, P1412, DOI 10.1038/jcbfm.2010.66
   Jiang Q, 1997, J NEUROL SCI, V145, P15, DOI 10.1016/S0022-510X(96)00286-9
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kreuter J., ADV DRUG DELIV REV, V23, P65
   Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/nmeth.1455, 10.1038/NMETH.1455]
   Latour LL, 2004, ANN NEUROL, V56, P468, DOI 10.1002/ana.20199
   Li FH, 2000, NEUROLOGY, V54, P689, DOI 10.1212/WNL.54.3.689
   Li L, 2009, NEUROSCIENCE, V164, P497, DOI 10.1016/j.neuroscience.2009.08.011
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Macrae IM, 2011, BRIT J PHARMACOL, V164, P1062, DOI 10.1111/j.1476-5381.2011.01398.x
   MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5
   Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965
   O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741
   O'Collins VE, 2013, ANIMAL MODELS FOR THE STUDY OF HUMAN DISEASE, P531, DOI 10.1016/B978-0-12-415894-8.00023-3
   Ord ENJ, 2012, J NEUROSCI METH, V211, P305, DOI 10.1016/j.jneumeth.2012.09.001
   Rhim T, 2013, PHARM RES-DORDR, V30, P2429, DOI 10.1007/s11095-012-0959-2
   ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017
   Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sutherland BA, 2012, INT J STROKE, V7, P407, DOI 10.1111/j.1747-4949.2012.00770.x
   Trotman-Lucas M, 2017, DIS MODEL MECH, V10, P931, DOI 10.1242/dmm.029108
   Walberer M, 2006, LAB ANIM-UK, V40, P1, DOI 10.1258/002367706775404426
   Warach S, 2004, STROKE, V35, P2659, DOI 10.1161/01.STR.0000144051.32131.09
   Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 28
PY 2018
VL 13
IS 12
AR e0209370
DI 10.1371/journal.pone.0209370
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HG0GV
UT WOS:000454621900023
PM 30592760
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yanala, UR
   Johanning, JM
   Pipinos, II
   High, RR
   Larsen, G
   Velander, WH
   Carlson, MA
AF Yanala, Ujwal R.
   Johanning, Jason M.
   Pipinos, Iraklis I.
   High, Robin R.
   Larsen, Gustavo
   Velander, William H.
   Carlson, Mark A.
TI Fluid administration rate for uncontrolled intraabdominal hemorrhage in
   swine
SO PLOS ONE
LA English
DT Article
ID HYPOTENSIVE RESUSCITATION; LACTATED RINGERS; TRAUMA PATIENTS;
   ANIMAL-MODEL; BLOOD-LOSS; COAGULOPATHIC SWINE; HYPERTONIC SALINE;
   IMPROVES SURVIVAL; CLOSED-ABDOMEN; SHOCK
AB Background
   We hypothesized that slow crystalloid resuscitation would result in less blood loss and a smaller hemoglobin decrease compared to a rapid resuscitation during uncontrolled hemorrhage.
   Methods
   Anesthetized, splenectomized domestic swine underwent hepatic lobar hemitransection. Lactated Ringers was given at 150 or 20 mL/min IV (rapid vs. slow, respectively, N = 12 per group; limit of 100 mL/kg). Primary endpoints were blood loss and serum hemoglobin; secondary endpoints included survival, vital signs, coagulation parameters, and blood gases.
   Results
   The slow group had a less blood loss (1.6 vs. 2.7 L, respectively) and a higher final hemoglobin concentration (6.0 vs. 3.4 g/dL).
   Conclusions
   Using a fixed volume of crystalloid resuscitation in this porcine model of uncontrolled intraabdominal hemorrhage, a slow IV infusion rate produced less blood loss and a smaller hemoglobin decrease compared to rapid infusion.
C1 [Yanala, Ujwal R.; Johanning, Jason M.; Pipinos, Iraklis I.; Carlson, Mark A.] Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68588 USA.
   [Yanala, Ujwal R.; Johanning, Jason M.; Pipinos, Iraklis I.; Carlson, Mark A.] VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE 68105 USA.
   [High, Robin R.] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE USA.
   [Larsen, Gustavo; Velander, William H.] Univ Nebraska, Coll Engn, Dept Chem & Biomol Engn, Lincoln, NE USA.
   [Carlson, Mark A.] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68588 USA.
RP Carlson, MA (reprint author), Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68588 USA.; Carlson, MA (reprint author), VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE 68105 USA.; Carlson, MA (reprint author), Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68588 USA.
EM macarlso@unmc.edu
OI Carlson, Mark/0000-0002-8113-9199
FU United States Army [W81XWH-11-1-0836]
FX This work was supported by a grant from the United States Army
   (W81XWH-11-1-0836).
CR Aksu U, 2012, RESUSCITATION, V83, P767, DOI 10.1016/j.resuscitation.2011.11.022
   American Veterinary Medical Association, 2013, AVMA GUIDELINES EUTH
   [Anonymous], 2011, GUIDE CARE USE LAB A
   Bebarta VS, 2013, J TRAUMA ACUTE CARE, V75, P920, DOI 10.1097/TA.0b013e3182a539b8
   BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701
   BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1
   Blackbourne LH, 2010, J TRAUMA, V69, pS1, DOI 10.1097/TA.0b013e3181e4206f
   Boysen SR, 2016, SHOCK, V46, P439, DOI 10.1097/SHK.0000000000000608
   Butler FK, 2013, J SPEC OPER MED, V14, P13
   Cannon JW, 2018, NEW ENGL J MED, V378, P370, DOI 10.1056/NEJMra1705649
   Cannon WB, 1918, J AMER MED ASSOC, V70, P618
   Carlson MA, 2014, J SURG RES, V187, P334, DOI 10.1016/j.jss.2013.09.039
   Cho SD, 2009, SHOCK, V31, P87, DOI 10.1097/SHK.0b013e3181777ffb
   Committee on Tactical Combat Casualty Care, 2018, ICCC GUID MED PERS 1
   Delgado AV, 2008, J TRAUMA, V64, P75, DOI 10.1097/TA.0b013e31815b843c
   Duggan M, 2013, J TRAUMA ACUTE CARE, V74, P1462, DOI 10.1097/TA.0b013e31828da937
   Duggan MJ, 2014, J SURG RES, V187, P536, DOI 10.1016/j.jss.2013.12.005
   Duggan MJ, 2013, J SURG RES, V182, P101, DOI 10.1016/j.jss.2012.07.048
   Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b
   Grottke O, 2011, J SURG RES, V171, P234, DOI 10.1016/j.jss.2010.02.002
   Hildebrand F, 2013, SHOCK, V40, P247, DOI 10.1097/SHK.0b013e3182a3cd74
   Holcomb JB, 1999, J TRAUMA, V46, P49, DOI 10.1097/00005373-199901000-00009
   Kellum JA, 2006, CHEST, V130, P962, DOI 10.1378/chest.130.4.962
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kiraly LN, 2006, J TRAUMA, V61, P57, DOI 10.1097/01.ta.0000220373.29743.69
   KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003
   Langan NR, 2014, JAMA SURG, V149, P904, DOI 10.1001/jamasurg.2014.940
   Moore HB, 2018, LANCET, V392, P283, DOI 10.1016/S0140-6736(18)31553-8
   Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea
   Neter J., 1990, APPL LINEAR STAT MOD
   Pusateri AE, 2003, J TRAUMA, V55, P518, DOI 10.1097/01.TA.0000075336.92129.27
   Riha GM, 2011, J TRAUMA, V71, P1755, DOI 10.1097/TA.0b013e3182367b1c
   Schreiber MA, 2002, J TRAUMA, V53, P252, DOI 10.1097/01.TA.0000022087.35916.9F
   Schreiber MA, 2015, J TRAUMA ACUTE CARE, V78, P687, DOI 10.1097/TA.0000000000000600
   Sena MJ, 2013, J SURG RES, V183, P704, DOI 10.1016/j.jss.2013.02.039
   Shrestha B, 2015, J TRAUMA ACUTE CARE, V78, P336, DOI 10.1097/TA.0000000000000514
   Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P998, DOI 10.1097/TA.0000000000000193
   Soller B, 2015, SHOCK, V44, P90, DOI 10.1097/SHK.0000000000000307
   Sondeen JL, 2003, J TRAUMA, V54, pS110, DOI 10.1097/01.TA.0000047220.81795.3D
   Sperry JL, 2018, NEW ENGL J MED, V379, P315, DOI 10.1056/NEJMoa1802345
   Swindle MM, 2016, SWINE LAB SURG ANEST
   Via D, 2001, J TRAUMA, V50, P1076, DOI 10.1097/00005373-200106000-00016
   Woolley T, 2018, J TRAUMA ACUTE CARE, V84, pS3, DOI 10.1097/TA.0000000000001856
   Yanala UR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108293
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 29
PY 2018
VL 13
IS 11
AR e0207708
DI 10.1371/journal.pone.0207708
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HC4HL
UT WOS:000451763800044
PM 30496239
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Pascual, G
   Mesa-Ciller, C
   Rodriguez, M
   Perez-Kohler, B
   Gomez-Gil, V
   Fernandez-Gutierrez, M
   San Roman, J
   Bellon, JM
AF Pascual, Gemma
   Mesa-Ciller, Claudia
   Rodriguez, Marta
   Perez-Kohler, Barbara
   Gomez-Gil, Veronica
   Fernandez-Gutierrez, Mar
   San Roman, Julio
   Bellon, Juan M.
TI Pre-clinical assay of the tissue integration and mechanical adhesion of
   several types of cyanoacrylate adhesives in the fixation of lightweight
   polypropylene meshes for abdominal hernia repair
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; N-BUTYL CYANOACRYLATE; LONG-TERM; VENTRAL
   HERNIA; INGUINAL HERNIORRHAPHY; LICHTENSTEIN TECHNIQUE;
   EXPERIMENTAL-MODEL; WALL DEFECTS; CHRONIC PAIN; FIBRIN GLUE
AB Introduction
   Lightweight (LW) polypropylene (PP) meshes better adapt to host tissue, causing less fibrosis and inflammatory responses than high-density meshes. Mesh fixation using tissue adhesives (TA) that replace conventional sutures may improve the process of hernia repair and tissue trauma. This preclinical study compares the behavior of different cyanoacrylate-based adhesives in the fixation of LW-PP meshes for hernia repair.
   Methods
   Partial abdominal wall defects were repaired using LW-PP Optilene meshes in New Zealand rabbits. The following groups were established according to the mesh fixation method: Suture (control), Glubran 2 (n-butyl), Ifabond (n-hexyl), SafetySeal (n-butyl) and Evobond (n-octyl). At 14, 90 and 180 days after surgery, the recovered implants were examined to assess the host tissue integration, the macrophage response and the biomechanical strength.
   Results
   All the groups showed optimal host tissue incorporation regardless of the fixation procedure. Significantly increased levels of collagen 1 and collagen 3 gene expression (p<0.001) were observed at 14 days compared to the medium- and long-term durations, where the Suture and Glubran groups showed the highest expression of collagen 1. All the adhesives increased the macrophage reaction (p<0.001) compared to sutures at all implant times. Maximal macrophage response was observed in the short-term Glubran group (p<0.01) compared to the rest of the groups. Although SafetySeal and Evobond did not reach the biomechanical resistance of sutures at 14 days, all the adhesives did reach this level in the medium- to long-term periods, providing significantly higher resistance (p<0.05).
   Conclusions
   All the cyanoacrylates, despite inducing a significantly increased macrophage response versus sutures, showed optimal host tissue integration and long-term mechanical behavior; thus, they might be good choices for LW-PP mesh hernia repairs.
C1 [Pascual, Gemma] Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Med & Med Specialties, Madrid, Spain.
   [Pascual, Gemma; Rodriguez, Marta; Perez-Kohler, Barbara; Gomez-Gil, Veronica; Fernandez-Gutierrez, Mar; San Roman, Julio; Bellon, Juan M.] Networking Biomed Res Ctr Bioengn Biomat & Nanome, Ramon y Cajal Hlth Res Inst IRYCIS, Madrid, Spain.
   [Mesa-Ciller, Claudia; Rodriguez, Marta; Perez-Kohler, Barbara; Gomez-Gil, Veronica; Bellon, Juan M.] Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Surg Med & Social Sci, Madrid, Spain.
   [Fernandez-Gutierrez, Mar; San Roman, Julio] Networking Biomed Res Ctr Bioengn Biomat & Nanome, Polymer Sci & Technol Inst, ICTP, Polymer Biomat Grp,CSIC, Madrid, Spain.
RP Pascual, G (reprint author), Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Med & Med Specialties, Madrid, Spain.; Pascual, G (reprint author), Networking Biomed Res Ctr Bioengn Biomat & Nanome, Ramon y Cajal Hlth Res Inst IRYCIS, Madrid, Spain.
EM gemma.pascual@uah.es
RI ; PASCUAL, GEMMA/M-6564-2016
OI Gomez-Gil, Veronica/0000-0002-6642-5912; PASCUAL,
   GEMMA/0000-0002-1623-4384
FU Spanish Ministry of Economy and Competitiveness [SAF2014-55022-P,
   SAF2017-89481-P]
FX The study was supported by Grant "SAF2014-55022-P" and "SAF2017-89481-P"
   from the Spanish Ministry of Economy and Competitiveness.
CR Agresta F, 2010, HERNIA, V14, P471, DOI 10.1007/s10029-010-0677-9
   Bellon JM, 2009, J BIOMED MATER RES B, V89B, P448, DOI 10.1002/jbm.b.31234
   Bellon JM, 2017, J SURG RES, V208, P68, DOI 10.1016/j.jss.2016.09.021
   Bjurstrom MF, 2014, J PAIN RES, V7, P277, DOI 10.2147/JPR.S47005
   Bona S, 2018, UPDATES SURG, V70, P77, DOI 10.1007/s13304-017-0483-3
   Campanelli G, 2012, ANN SURG, V255, P650, DOI 10.1097/SLA.0b013e31824b32bf
   Chen DC, 2014, WORLD J SURG, V38, P2571, DOI 10.1007/s00268-014-2626-8
   Chowbey PK, 2010, SURG ENDOSC, V24, P3073, DOI 10.1007/s00464-010-1092-0
   Cobb WS, 2006, J SURG RES, V136, P1, DOI 10.1016/j.jss.2006.05.022
   Cobb William S, 2005, Surg Innov, V12, P63, DOI 10.1177/155335060501200109
   Colvin HS, 2013, WORLD J SURG, V37, P2282, DOI 10.1007/s00268-013-2140-4
   Conze J, 1999, BIOCOMPATIBILITY BIO
   de Goede B, 2013, BRIT J SURG, V100, P735, DOI 10.1002/bjs.9072
   Dilege E, 2010, J INVEST SURG, V23, P262, DOI 10.3109/08941939.2010.481008
   Fernandez-Gutierrez M, 2016, MACROMOL BIOSCI, V16, P1803, DOI 10.1002/mabi.201600246
   Greca F H, 2001, Hernia, V5, P59
   Hernandez B, 2011, J MECH BEHAV BIOMED, V4, P392, DOI 10.1016/j.jmbbm.2010.11.012
   Hernandez-Gascon B, 2013, ANN BIOMED ENG, V41, P433, DOI 10.1007/s10439-012-0672-7
   Hernandez-Gascon B, 2012, J MECH BEHAV BIOMED, V5, P257, DOI 10.1016/j.jmbbm.2011.09.005
   Hernandez-Gascon B, 2011, ACTA BIOMATER, V7, P3905, DOI 10.1016/j.actbio.2011.06.033
   Junge K, 2001, Hernia, V5, P113
   Khaleal F, 2011, ANZ J SURG, V81, P154, DOI 10.1111/j.1445-2197.2010.05438.x
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim-Fuchs C, 2012, HERNIA, V16, P21, DOI 10.1007/s10029-011-0856-3
   Klinge U, 2007, WORLD J SURG, V31, P867, DOI 10.1007/s00268-006-0670-8
   Klinge U, 2002, J BIOMED MATER RES, V63, P129, DOI 10.1002/jbm.10119
   Kukleta JF, 2012, HERNIA, V16, P153, DOI 10.1007/s10029-011-0887-9
   Leggat PA, 2007, ANZ J SURG, V77, P209, DOI 10.1111/j.1445-2197.2007.04020.x
   Li JS, 2015, SURG LAPARO ENDO PER, V25, P238, DOI 10.1097/SLE.0000000000000144
   Montanaro L, 2001, BIOMATERIALS, V22, P59, DOI 10.1016/S0142-9612(00)00163-0
   Moreno-Egea A, 2014, SURG INNOV, V21, P590, DOI 10.1177/1553350613517944
   Negro P, 2011, HERNIA, V15, P7, DOI 10.1007/s10029-010-0706-8
   O'Dwyer PJ, 2005, BRIT J SURG, V92, P166, DOI 10.1002/bjs.4833
   Paajanen H, 2011, BRIT J SURG, V98, P1245, DOI 10.1002/bjs.7598
   Pascual G, 2008, SURGERY, V144, P427, DOI 10.1016/j.surg.2008.04.005
   Pascual G, 2017, J SURG RES, V220, P30, DOI 10.1016/j.jss.2017.06.074
   Pascual G, 2017, J MATER SCI-MATER M, V28, DOI 10.1007/s10856-017-5869-8
   Pascual G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157920
   Pascual G, 2012, SURGERY, V152, P886, DOI 10.1016/j.surg.2012.03.009
   Ronka K, 2015, ANN SURG, V262, P714, DOI 10.1097/SLA.0000000000001458
   Sanders Lindsey, 2014, Critical Reviews in Biomedical Engineering, V42, P271, DOI 10.1615/CritRevBiomedEng.2014011676
   Scognamiglio F, 2016, J BIOMED MATER RES B, V104, P626, DOI 10.1002/jbm.b.33409
   Shen YM, 2012, SURGERY, V151, P550, DOI 10.1016/j.surg.2011.09.031
   Simon-Allue R, 2016, HERNIA, V20, P839, DOI 10.1007/s10029-016-1525-3
   Stefano O, 2010, JSLS-J SOC LAPAROEND, V14, P240, DOI [10.4293/108680810X12785289144359, 10.4293/108680810X12785289141359]
   Weyhe D, 2006, WORLD J SURG, V30, P1586, DOI 10.1007/s00268-005-0601-0
NR 46
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 2
PY 2018
VL 13
IS 11
AR e0206515
DI 10.1371/journal.pone.0206515
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GZ3MD
UT WOS:000449289800036
PM 30388135
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Won, SJ
   Minnella, AM
   Wu, L
   Eun, CH
   Rome, E
   Herson, PS
   Shaw, AE
   Bamburg, JR
   Swanson, RA
AF Won, Seok Joon
   Minnella, Angela M.
   Wu, Long
   Eun, Claire H.
   Rome, Eric
   Herson, Paco S.
   Shaw, Alisa E.
   Bamburg, James R.
   Swanson, Raymond A.
TI Cofilin-actin rod formation in neuronal processes after brain ischemia
SO PLOS ONE
LA English
DT Article
ID CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST; ADF/COFILIN; ATP;
   OCCLUSION; DYNAMICS; PROTEIN; MODELS
AB Functional impairment after brain ischemia results in part from loss of neuronal spines and dendrites, independent of neuronal death. Cofilin-actin rods are covalently linked aggregates of cofilin-1 and actin that form in neuronal processes (neurites) under conditions of ATP depletion and oxidative stress, and which cause neurite degeneration if not disassembled. ATP depletion and oxidative stress occur with differing severity, duration, and time course in different ischemic conditions. Here we evaluated four mouse models of brain ischemia to define the conditions that drive formation of cofilin-actin rods. Three of the models provide early reperfusion: transient middle cerebral artery occlusion (MCAo), transient bilateral common carotid artery occlusion (CCAo), and cardiac arrest/cardiopulmonary resuscitation (CA/CPR). Early reperfusion restores ATP generating capacity, but also induces oxidative stress. The fourth model, photothrombotic cortical infarction, does not provide reperfusion. Cofilin-actin rods were formed in each of these models, but with differing patterns. Where acute reperfusion occurred, rod formation was maximal within 4 hours after reperfusion. Where infarction occurred, rods continued to form for at least 24 hours after ischemic onset, and extended into the adjacent non-ischemic tissue. Interventions that limit cofilin-actin rod formation may help to preserve integrity of neuronal processes in permanent ischemia.
C1 [Won, Seok Joon; Minnella, Angela M.; Wu, Long; Eun, Claire H.; Rome, Eric; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
   [Won, Seok Joon; Minnella, Angela M.; Wu, Long; Eun, Claire H.; Rome, Eric; Swanson, Raymond A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
   [Herson, Paco S.] Univ Colorado, Neuronal Injury Program, Dept Anesthesiol, Anschutz Med Campus, Aurora, CO USA.
   [Herson, Paco S.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO USA.
   [Shaw, Alisa E.; Bamburg, James R.] Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.
RP Won, SJ (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Won, SJ (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM Seokjoon.won@va.gov
OI Cai, Wesley L/0000-0002-3871-5509
FU National Institutes of Health [R01AG049668, R01NS081149]
FX This research was supported by the National Institutes of Health
   (R01AG049668, JRB; R01NS081149, RAS). The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919
   Alhadidi Q, 2016, TRANSL STROKE RES, V7, P33, DOI 10.1007/s12975-015-0438-2
   Bamburg JR, 2010, CURR ALZHEIMER RES, V7, P241, DOI 10.2174/156720510791050902
   Bamburg JR, 2016, CYTOSKELETON, V73, P477, DOI 10.1002/cm.21282
   Bernstein BW, 2006, AM J PHYSIOL-CELL PH, V291, pC828, DOI 10.1152/ajpcell.00066.2006
   Bernstein BW, 2012, J NEUROSCI, V32, P6670, DOI 10.1523/JNEUROSCI.6020-11.2012
   Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001
   Bernstein BW, 2003, J NEUROSCI, V23, P1
   Brown CE, 2008, STROKE, V39, P1286, DOI 10.1161/STROKEAHA.107.498238
   Cichon J, 2012, J BIOL CHEM, V287, P3919, DOI 10.1074/jbc.M111.301911
   Engl E, 2015, J PHYSIOL-LONDON, V593, P3417, DOI 10.1113/jphysiol.2014.282517
   Flynn KC, 2009, DEV NEUROBIOL, V69, P761, DOI 10.1002/dneu.20734
   Garvalov BK, 2007, J NEUROSCI, V27, P13117, DOI 10.1523/JNEUROSCI.3322-07.2007
   Gulati T, 2015, J NEUROSCI, V35, P8653, DOI 10.1523/JNEUROSCI.5007-14.2015
   Huang TY, 2008, DEV CELL, V15, P691, DOI 10.1016/j.devcel.2008.09.017
   Kanellos G, 2016, J CELL SCI, V129, P3211, DOI 10.1242/jcs.187849
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JS, 2009, MOL BIOL CELL, V20, P2650, DOI 10.1091/mbc.E09-02-0131
   Kofler J, 2004, J NEUROSCI METH, V136, P33, DOI 10.1016/j.jneumeth.2003.12.024
   LIU T, 2017, SCI REP, P1
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Madineni A, 2016, MOL NEUROBIOL, V53, P867, DOI 10.1007/s12035-014-9056-3
   Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8
   MELDRUM BS, 1987, MED BIOL, V65, P153
   Mi JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059430
   Minamide LS, 2010, J BIOL CHEM, V285, P5450, DOI 10.1074/jbc.M109.063768
   Minamide LS, 2000, NAT CELL BIOL, V2, P628
   Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002
   Neumann JT, 2013, CURR DRUG TARGETS, V14, P20
   Quillinan N, 2017, J CEREBR BLOOD F MET, V37, P3053, DOI 10.1177/0271678X16683691
   Shaw AE, 2017, PHARMACOL THERAPEUT, V175, P17, DOI 10.1016/j.pharmthera.2017.02.031
   Sheth SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129735
   Shi YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10523
   Shu Liang, 2018, J Cereb Blood Flow Metab, p271678X18785567, DOI 10.1177/0271678X18785567
   SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x
   Traystman RJ, 2003, ILAR J, V44, P85, DOI 10.1093/ilar.44.2.85
   Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060
   WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513
   Whiteman IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020878
   Whiteman IT, 2009, J NEUROSCI, V29, P12994, DOI 10.1523/JNEUROSCI.3531-09.2009
   Won SJ, 2015, J NEUROSCI, V35, P7143, DOI 10.1523/JNEUROSCI.4826-14.2015
   Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005
NR 42
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2018
VL 13
IS 10
AR e0198709
DI 10.1371/journal.pone.0198709
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GX0VS
UT WOS:000447430800002
PM 30325927
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Mamach, M
   Kessler, M
   Bankstahl, JP
   Wilke, F
   Geworski, L
   Bengel, FM
   Kurt, S
   Berding, G
AF Mamach, Martin
   Kessler, Mariella
   Bankstahl, Jens P.
   Wilke, Florian
   Geworski, Lilli
   Bengel, Frank M.
   Kurt, Simone
   Berding, Georg
TI Visualization of the auditory pathway in rats with F-18-FDG PET
   activation studies based on different auditory stimuli and reference
   conditions including cochlea ablation
SO PLOS ONE
LA English
DT Article
ID BRAIN; NOISE; IMPLANTATION
AB Activation studies with positron emission tomography (PET) in auditory implant users explained some of the mechanisms underlying the variability of achieved speech comprehension. Since future developments of auditory implants will include studies in rodents, we aimed to inversely translate functional PET imaging to rats. In normal hearing rats, activity in auditory and non-auditory regions was studied using F-18-fluorodeoxyglucose (F-18-FDG) PET with 3 different acoustic conditions: sound attenuated laboratory background, continuous white noise and rippled noise. Additionally, bilateral cochlea ablated animals were scanned. 3D image data were transferred into a stereotaxic standard space and evaluated using volume of interest (VOI) analyses and statistical parametric mapping (SPM). In normal hearing rats alongside the auditory pathway consistent activations of the nucleus cochlearis (NC), olivary complex (OC) and inferior colliculus (IC) were seen comparing stimuli with background. In this respect, no increased activation could be detected in the auditory cortex (AC), which even showed deactivation with white noise stimulation. Nevertheless, higher activity in the AC in normal hearing rats was observed for all 3 auditory conditions against the cochlea ablated status. Vice versa, in ablated status activity in the olfactory nucleus (ON) was higher compared to all auditory conditions in normal hearing rats. Our results indicate that activations can be demonstrated in normal hearing animals based on F-18-FDG PET in nuclei along the central auditory pathway with different types of noise stimuli. However, in the AC missing activation with respect to the background advises the need for more rigorous background noise attenuation for non-invasive reference conditions. Finally, our data suggest cross-modal activation of the olfactory system following cochlea ablation-underlining, that F-18-FDG PET appears to be well suited to study plasticity in rat models for cochlear implantation.
C1 [Mamach, Martin; Wilke, Florian; Geworski, Lilli] Hannover Med Sch, Dept Med Phys & Radiat Protect, Hannover, Germany.
   [Mamach, Martin; Kessler, Mariella; Kurt, Simone; Berding, Georg] Hannover Med Sch, Cluster Excellence Hearing4all, Hannover, Germany.
   [Kessler, Mariella; Bankstahl, Jens P.; Bengel, Frank M.; Berding, Georg] Hannover Med Sch, Dept Nucl Med, Hannover, Germany.
   [Kurt, Simone] Hannover Med Sch, Dept Otolaryngol, Hannover, Germany.
   [Kurt, Simone] Saarland Univ, CIPMM, Dept Biophys, Homburg, Germany.
RP Mamach, M (reprint author), Hannover Med Sch, Dept Med Phys & Radiat Protect, Hannover, Germany.; Mamach, M (reprint author), Hannover Med Sch, Cluster Excellence Hearing4all, Hannover, Germany.
EM mamach.martin@mh-hannover.de
OI Kurt, Simone/0000-0002-1820-2597; Mamach, Martin/0000-0002-3461-2668
FU public "Deutsche Forschungsgemeinschaft" (DFG) [EXC 1077]
FX This research was executed within the Cluster of Excellence EXC 1077
   "Hearing for all: Models, technology and solutions for diagnostics,
   restoration and support of hearing", funded by the public "Deutsche
   Forschungsgemeinschaft" (DFG). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbott SD, 1999, NEUROSCIENCE, V93, P1375, DOI 10.1016/S0306-4522(99)00300-0
   Ahn SH, 2004, HEARING RES, V196, P33, DOI 10.1016/j.heares.2004.05.012
   Arno P, 2001, NEUROIMAGE, V13, P632, DOI 10.1006/nimg.2000.0731
   Berding G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128743
   Blamey PJ, 2015, EAR HEARING, V36, P408, DOI 10.1097/AUD.0000000000000150
   Chonde DB, 2013, INVEST RADIOL, V48, P302, DOI 10.1097/RLI.0b013e3182839fbc
   CLARK WW, 1991, J ACOUST SOC AM, V90, P155, DOI 10.1121/1.401309
   Constantinescu CC, 2009, PHYS MED BIOL, V54, P2885, DOI 10.1088/0031-9155/54/9/020
   Dedeurwaerdere S, 2009, EUR J NUCL MED MOL I, V36, P958, DOI 10.1007/s00259-009-1066-4
   Deutscher A, 2006, NEUROREPORT, V17, P853, DOI 10.1097/01.wnr.0000221837.20255.62
   Giraud AL, 2001, AUDIOL NEURO-OTOL, V6, P381, DOI 10.1159/000046847
   Hsu WC, 2009, ACTA OTO-LARYNGOL, V129, P423, DOI 10.1080/00016480802593497
   Jang DP, 2012, NEUROREPORT, V23, P228, DOI 10.1097/WNR.0b013e32835022c7
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Knoop BO, 2002, PHYS MED BIOL, V47, P1237, DOI 10.1088/0031-9155/47/8/302
   Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009
   Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8
   Laudanski J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050539
   Lazard DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048739
   Lu W, 2005, HEARING RES, V205, P115, DOI 10.1016/j.heares.2005.03.010
   Mamach M, 2018, EJNMMI RES, V8, DOI 10.1186/s13550-018-0362-z
   Merabet LB, 2010, NAT REV NEUROSCI, V11, P44, DOI 10.1038/nrn2758
   Niparko JK, 2010, JAMA-J AM MED ASSOC, V303, P1498, DOI 10.1001/jama.2010.451
   Parellada E, 2008, NUCL MED COMMUN, V29, P894, DOI 10.1097/MNM.0b013e328302cd10
   Paul AK, 2009, NEUROIMAGE, V44, P312, DOI 10.1016/j.neuroimage.2008.09.024
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix
   Pietrini P, 2000, J NUCL MED, V41, P575
   Rao DB, 2000, HEARING RES, V150, P206, DOI 10.1016/S0378-5955(00)00202-1
   Rausch I, 2015, EJNMMI PHYS, V2, DOI 10.1186/s40658-015-0132-1
   Ruytjens L, 2006, ACTA OTO-LARYNGOL, V126, P1236, DOI 10.1080/00016480600801373
   Schiffer WK, 2006, J NEUROSCI METH, V155, P272, DOI 10.1016/j.jneumeth.2006.01.027
   Schwarz AJ, 2006, NEUROIMAGE, V32, P538, DOI 10.1016/j.neuroimage.2006.04.214
   Smith JJ, 2009, NEURAL PLAST, DOI 10.1155/2009/754014
   Soto-Montenegro M, 2009, MOL IMAGING BIOL, V11, P94, DOI 10.1007/s11307-008-0179-7
   Wehr M, 2005, NEURON, V47, P437, DOI 10.1016/j.neuron.2005.06.009
   Willmore BDB, 2009, CURR BIOL, V19, pR1123, DOI 10.1016/j.cub.2009.11.003
   Wilson BS, 2008, HEARING RES, V242, P3, DOI 10.1016/j.heares.2008.06.005
   Zhou Y, 2017, BIOCHEM BIOPH RES CO, V486, P833, DOI 10.1016/j.bbrc.2017.03.140
   Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547
NR 39
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2018
VL 13
IS 10
AR e0205044
DI 10.1371/journal.pone.0205044
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GV3QJ
UT WOS:000446010200036
PM 30278068
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Cruz-Benedetti, IC
   Bublot, I
   Ribas, T
   Fourel, I
   Vogl, C
   Dubois, C
   Milani, M
   Ida, KK
   Portier, K
AF Cruz-Benedetti, Inga-Catalina
   Bublot, Isabelle
   Ribas, Thibault
   Fourel, Isabelle
   Vogl, Claus
   Dubois, Claire
   Milani, Mathilde
   Ida, Keila Kazue
   Portier, Karine
TI Pharmacokinetics of intramuscular alfaxalone and its echocardiographic,
   cardiopulmonary and sedative effects in healthy dogs
SO PLOS ONE
LA English
DT Article
ID BEAGLE DOGS; BUTORPHANOL; INDUCTION; ANESTHESIA; ACEPROMAZINE;
   MEDETOMIDINE; COMBINATION; ALPHAXALONE; MEDICATION; ROUTE
AB The pharmacokinetics and the effects of a single intramuscular (IM) dose of alfaxalone on sedation and cardiopulmonary and echocardiographic variables was studied in dogs. Twelve healthy adult Beagles (3 females, 9 males) were used in this prospective controlled cross-over trial. Echocardiography was performed with and without 4 mg kg(-1) alfaxalone IM with a week wash-out interval. Sedation (19-point scale; 0 = no sedation), cardiopulmonary parameters, blood gas analysis and plasma concentration of alfaxalone were assessed every 5 minutes following the injection (T0). The influence of the alfaxalone plasma concentration and time on physiological variables was tested using a linear model whereas echocardiographic measurements were compared between conscious and alfaxalone-administered dogs using paired t-tests. Compared to baseline, alfaxalone administration was followed by an increase in heart rate (HR) from T5 to T30 and a decrease in mean arterial pressure (MAP) at T10, T25 and T30, in stroke volume (SV; 15 +/- 5 to 11 +/- 3 ml; P<0.0001), and end-diastolic volume (EDV; 24.7 +/- 5.7 to 19.4 +/- 4.9 ml). Cardiac output (CO) and blood gas analysis did not change significantly throughout. Mean plasma half-life was 29 +/- 8 minutes, volume of distribution was 1.94 +/- 0.63 L kg(-1), and plasma clearance was 47.7 +/- 14.1 ml kg(-1) minute(-1). Moderate to deep sedation was observed from T5 to T35. Ten dogs showed paddling, trembling, nystagmus and strong reaction to sound during the procedure. Although there were no significant changes in CO and oxygenation, the impact of HR, MAP, SV, EDV alterations requires further investigations in dogs with cardiac disease.
C1 [Cruz-Benedetti, Inga-Catalina; Dubois, Claire; Ida, Keila Kazue; Portier, Karine] Univ Lyon, VetAgro Sup, GREAT, Marcy Ietoile, France.
   [Bublot, Isabelle; Milani, Mathilde] Univ Lyon, Unit Cardiol, VetAgro Sup, Marcy Ietoile, France.
   [Ribas, Thibault] Azurvet, Hippodrome, Cagnes Sur Mer, France.
   [Fourel, Isabelle] Univ Lyon, RS2GP, USC1233, INRA,VetAgro Sup, Marcy Ietoile, France.
   [Vogl, Claus] Vetmeduni, Sect Mol Biol, Dept Anim Husb & Genet, Vienna, Austria.
   [Ida, Keila Kazue] Univ Sao Paulo, Med Sch, Lab Med Invest Anaesthesiol 8, Sao Paulo, Brazil.
   [Portier, Karine] Univ Claude Bernard Lyon 1, Univ Lyon, INSERM,INSA Lyon, INRA,CarMeN Lab, Bron, France.
   [Cruz-Benedetti, Inga-Catalina] Vet Med Univ Wien, Dept Anaesthesiol & Perioperat Intens Care Med, Vienna, Austria.
   [Bublot, Isabelle] Clin Vet Cerisioz, Cardiol, St Priest, France.
   [Milani, Mathilde] Clin Vet Calvisson, Cardiol, Calvisson, France.
   [Ida, Keila Kazue] Univ Liege, Dept Compan Anim & Horses Clin, Anesthesiol & Vet Reanimat, Liege, Belgium.
RP Portier, K (reprint author), Univ Lyon, VetAgro Sup, GREAT, Marcy Ietoile, France.; Portier, K (reprint author), Univ Claude Bernard Lyon 1, Univ Lyon, INSERM,INSA Lyon, INRA,CarMeN Lab, Bron, France.
EM karine.portier@vetagro-sup.fr
OI Ida, Keila/0000-0003-2200-4355; FOUREL, Isabelle/0000-0001-5470-612X
FU Dechra; Jurox; biochemistry department of Vetagro-Sup
FX We would like to thank Dr. Mehdi Midoun and SCIL for lending us the
   echocardiograph and Dechra and Jurox for providing us with alfaxalone
   and for their financial support. We would like to thank Dr. Benoit
   Rannou from the biochemistry department of Vetagro-Sup for sponsoring
   the pre-operative blood work and Mr. Guillaume Noel from the Institut
   Claude Bourgelat for providing the dogs for our study. A very heartfelt
   thank you goes to the rest of the Anaesthesia Team of Vetagro-Sup.
CR Amengual M, 2013, VET ANAESTH ANALG, V40, P115, DOI 10.1111/j.1467-2995.2012.00747.x
   Boon JA, 2011, VET ECHOCARDIOGRAPHY, P118
   BREWSTER ME, 1989, J PARENT SCI TECHN, V43, P262
   Chiu KW, 2016, J VET PHARMACOL THER, V39, P525, DOI 10.1111/jvp.12312
   Clutton RE, 2007, BSAVA MANUAL CANINE, P200
   Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727
   Ferchichi S, 2013, VET ANAESTH ANALG, V40, P655, DOI 10.1111/vaa.12085
   Ferre PJ, 2006, VET ANAESTH ANALG, V33, P229, DOI 10.1111/j.1467-2995.2005.00264.x
   Gurney M, 2009, J SMALL ANIM PRACT, V50, P474, DOI 10.1111/j.1748-5827.2009.00786.x
   Jin JF, 2015, PATIENT PREFER ADHER, V9, P923, DOI 10.2147/PPA.S87271
   Kellum HB, 2007, J VET INTERN MED, V21, P1258, DOI 10.1892/07-006.1
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim YeWon, 2015, Korean Journal of Veterinary Research, V55, P221, DOI 10.14405/kjvr.2015.55.4.221
   Lee J, 2015, J VET MED SCI, V77, P1677, DOI 10.1292/jvms.15-0065
   Maney JK, 2013, VET ANAESTH ANALG, V40, P237, DOI 10.1111/vaa.12006
   Rodriguez JM, 2012, VET ANAESTH ANALG, V39, P357, DOI 10.1111/j.1467-2995.2011.00695.x
   Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x
   Pasloske K, 2009, J VET PHARMACOL THER, V32, P510, DOI 10.1111/j.1365-2885.2009.01070.x
   Psatha E, 2011, VET ANAESTH ANALG, V38, P24, DOI 10.1111/j.1467-2995.2010.00577.x
   Ribas T, 2015, J FELINE MED SURG, V17, P530, DOI 10.1177/1098612X14551187
   Rishniw M, 2000, J VET INTERN MED, V14, P429, DOI 10.1892/0891-6640(2000)014<0429:EOFEMO>2.3.CO;2
   Robinson R, 2016, BSAVA MANUAL CANINE, P283
   Seo JI, 2015, VET ANAESTH ANALG, V42, P304, DOI 10.1111/vaa.12223
   Smith LJ, 2001, J AM VET MED ASSOC, V218, P1101, DOI 10.2460/javma.2001.218.1101
   Tamura J, 2016, J VET MED SCI, V78, P929, DOI 10.1292/jvms.15-0159
   Tamura J, 2015, J VET MED SCI, V77, P289, DOI 10.1292/jvms.14-0368
   THOMAS WP, 1993, J VET INTERN MED, V7, P247, DOI 10.1111/j.1939-1676.1993.tb01015.x
   Visser SAG, 2000, J CHROMATOGR B, V745, P357, DOI 10.1016/S0378-4347(00)00296-6
NR 28
TC 0
Z9 0
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2018
VL 13
IS 9
AR e0204553
DI 10.1371/journal.pone.0204553
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GV3MI
UT WOS:000445998100050
PM 30248146
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sanches, IC
   Buzin, M
   Conti, FF
   Dias, DD
   dos Santos, CP
   Sirvente, R
   Salemi, VMC
   Llesuy, S
   Irigoyen, MC
   De Angelis, K
AF Sanches, Iris Callado
   Buzin, Morgana
   Conti, Filipe Fernandes
   Dias, Danielle da Silva
   dos Santos, Camila Paixao
   Sirvente, Raquel
   Cury Salemi, Vera Maria
   Llesuy, Susana
   Irigoyen, Maria-Claudia
   De Angelis, Katia
TI Combined aerobic and resistance exercise training attenuates cardiac
   dysfunctions in a model of diabetes and menopause
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; ENDOTHELIAL DYSFUNCTION;
   BAROREFLEX SENSITIVITY; AUTONOMIC DYSFUNCTION; RISK; 17-BETA-ESTRADIOL;
   CARDIOMYOPATHY; HYPERGLYCEMIA; GLUTATHIONE
AB The study aimed at evaluating the effects of combined aerobic and resistance exercise training on cardiac morphometry and function, oxidative stress and inflammatory parameters in diabetic ovariectomized rats. For this, female Wistar rats (10 weeks-old) were divided into 4 groups (n = 8): euglycemic (E), diabetic (streptozotocin, 50 mg/kg, iv) (D), diabetic ovariectomized (DO) and trained diabetic ovariectomized (TDO). The combined exercise training was performed on a treadmill and in a ladder adapted to rats (8 weeks, at 40 +/- 60% of maximal capacity). The left ventricle (LV) morphometry and function were evaluated by echocardiography. Oxidative stress and inflammatory markers were measured on ventricles tissue. The sedentary diabetic animals (D and DO) showed impaired systolic and diastolic functions, as well as increased cardiac overload, evaluated by myocardial performance index (MPI-D: 0.32 +/- 0.05; DO: 0.39 +/- 0.13 vs. E: 0.25 +/- 0.07), in relation to E group. Systolic and MPI dysfunctions were exacerbated in DO when compared to D group. The DO group presented higher protein oxidation and TNF-alpha/IL-10 ratio than D groups. Glutathione redox ratio (GSH/GSSG) and IL-10 were decreased in both D and DO groups when compared to E group. Exercise training improved exercise capacity, systolic and diastolic functions and MPI (0.18 +/- 0.11). The TDO group showed reduced protein oxidation and TNF-alpha/IL-10 ratio and increased GSH/GSSG and IL-10 in relation to the DO group. These results showed that combined exercise training was able to attenuate the cardiac dysfunctions, probably by reducing inflammation and oxidative stress in an experimental model of diabetes and menopause.
C1 [Sanches, Iris Callado] Sao Judas Tadeu Univ USJT, Human Movement Lab, Sao Paulo, Brazil.
   [Buzin, Morgana; Conti, Filipe Fernandes; Dias, Danielle da Silva; dos Santos, Camila Paixao; Llesuy, Susana; De Angelis, Katia] Univ Nove Julho UNINOVE, Lab Translat Physiol, Sao Paulo, Brazil.
   [Sirvente, Raquel; Cury Salemi, Vera Maria; Irigoyen, Maria-Claudia] Univ Sao Paulo, Heart Inst InCor, Sch Med, Hypertens Unit, Sao Paulo, Brazil.
   [Llesuy, Susana] Univ Buenos Aires, Fac Farm & Bioquim, Buenos Aires, DF, Argentina.
   [De Angelis, Katia] Fed Univ Sao Paulo UNIFESP, Dept Physiol, Sao Paulo, Brazil.
RP De Angelis, K (reprint author), Univ Nove Julho UNINOVE, Lab Translat Physiol, Sao Paulo, Brazil.; De Angelis, K (reprint author), Fed Univ Sao Paulo UNIFESP, Dept Physiol, Sao Paulo, Brazil.
EM prof.kangelis@yahoo.com.br
OI Sanches, Iris Callado/0000-0001-6195-4340
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES-PROSUP, CAPES-PVE, CAPES DFAIT) [8881.062178/2014-01]; Sao Paulo
   Research Foundation (FAPESP) [2012/20141-5]; CNPq [563961/2010-4,
   479766/2011-8]; CNPq-BPQ fellowships
FX This study was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES-PROSUP, CAPES-PVE: 8881.062178/2014-01; CAPES
   DFAIT), Sao Paulo Research Foundation (FAPESP: 2012/20141-5); and CNPq
   (563961/2010-4, 479766/2011-8). K.D.A. and M.C.I. are the recipients of
   CNPq-BPQ fellowships.
CR Acar E, 2011, ANATOL J CARDIOL, V11, P732, DOI 10.5152/akd.2011.196
   AEBI H, 1984, METHOD ENZYMOL, V105, P121
   ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548
   Battiprolu Pavan K, 2010, Drug Discov Today Dis Mech, V7, pe135, DOI 10.1016/j.ddmec.2010.08.001
   BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405
   CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396
   Cai L, 2001, Cardiovasc Toxicol, V1, P181, DOI 10.1385/CT:1:3:181
   Call JA, 2015, CIRC-HEART FAIL, V8, P188, DOI 10.1161/CIRCHEARTFAILURE.114.001540
   DallAgo P, 1997, BRAZ J MED BIOL RES, V30, P119, DOI 10.1590/S0100-879X1997000100018
   De Angelis K, 2002, BRAZ J MED BIOL RES, V35, P1091, DOI 10.1590/S0100-879X2002000900010
   De Angelis K, 2009, AUTON NEUROSCI-BASIC, V145, P3, DOI 10.1016/j.autneu.2008.10.013
   Dhingra R, 2007, AM J MED, V120, P1054, DOI 10.1016/j.amjmed.2007.08.037
   FLOHE L, 1984, METHOD ENZYMOL, V105, P114
   Flues K, 2010, MATURITAS, V65, P267, DOI 10.1016/j.maturitas.2009.11.007
   Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Goff DC, 2007, AM J CARDIOL, V99, p4I, DOI 10.1016/j.amjcard.2007.03.002
   Guha M, 2000, J BIOL CHEM, V275, P17728, DOI 10.1074/jbc.275.23.17728
   Hernandez I, 2000, AM J PHYSIOL-REG I, V279, pR1599
   Hsueh WA, 2003, AM J CARDIOL, V92, p10J, DOI 10.1016/S0002-9149(03)00611-8
   Irigoyen MC, 2005, HYPERTENSION, V46, P998, DOI 10.1161/01.HYP.0000176238.90688.6b
   Jorge L, 2012, EXP DIABETES RES, DOI 10.1155/2012/108680
   KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447
   Kaseta JR, 1999, J CLIN ENDOCR METAB, V84, P1835, DOI 10.1210/jc.84.6.1835
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JS, 2014, BIOL SPORT, V31, P73, DOI 10.5604/20831862.1093775
   Latour MG, 2001, J APPL PHYSIOL, V90, P235
   Leuzzi C, 2012, G ITAL CARDIOL, V13, P401, DOI 10.1714/1073.11757
   LITWIN SE, 1990, J CLIN INVEST, V86, P481, DOI 10.1172/JCI114734
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAEDA CY, 1995, HYPERTENSION, V26, P1100, DOI 10.1161/01.HYP.26.6.1100
   MAEDA CY, 1995, BRAZ J MED BIOL RES, V28, P497
   Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058
   MATUTE ML, 1973, ENDOCRINOLOGY, V92, P762, DOI 10.1210/endo-92-3-762
   Mosca Lori, 2007, Circulation, V115, P1481, DOI 10.1161/CIRCULATIONAHA.107.181546
   Pinkney JH, 1997, DIABETES, V46, pS9, DOI 10.2337/diab.46.2.S9
   Quinteiro H, 2015, MENOPAUSE, V22, P534, DOI [10.1097/GME.0000000000000344, 10.1097/gme.0000000000000344]
   Renna NF, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/513251
   REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357
   Rossi R, 2002, PATHOPHYSIOL HAEMO T, V32, P325, DOI 10.1159/000073591
   Rouyer O, 2007, EXP PHYSIOL, V92, P1047, DOI 10.1113/expphysiol.2007.038851
   RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4
   Samsioe G, 1998, MATURITAS, V30, P11, DOI 10.1016/S0378-5122(98)00054-1
   Sanches IC, 2014, INT J SPORTS MED, V35, P323, DOI 10.1055/s-0033-1351254
   Sans S, 1997, EUR HEART J, V18, P1231
   SATO Y, 1979, BIOCHEM MED METAB B, V21, P104, DOI 10.1016/0006-2944(79)90061-9
   Schaan BD, 2004, BRAZ J MED BIOL RES, V37, P1895, DOI 10.1590/S0100-879X2004001200016
   Shiguemoto GE, 2012, SCAND J MED SCI SPOR, V22, P607, DOI 10.1111/j.1600-0838.2010.01284.x
   Souza SBC, 2007, HYPERTENSION, V50, P786, DOI 10.1161/HYPERTENSIONAHA.107.095000
   Sowers MR, 1995, EPIDEMIOL REV, V17, P287, DOI 10.1093/oxfordjournals.epirev.a036194
   Strasser B, 2010, SPORTS MED, V40, P397, DOI 10.2165/11531380-000000000-00000
   VANNINEN E, 1992, AM J CARDIOL, V70, P371, DOI 10.1016/0002-9149(92)90622-6
   Wichi R, 2007, CARDIOVASC DIABETOL, V6, DOI 10.1186/1475-2840-6-14
NR 53
TC 0
Z9 0
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 7
PY 2018
VL 13
IS 9
AR e0202731
DI 10.1371/journal.pone.0202731
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GT0BU
UT WOS:000444093600031
PM 30192778
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Dzhonova, D
   Olariu, R
   Leckenby, J
   Dhayani, A
   Vemula, PK
   Prost, JC
   Banz, Y
   Taddeo, A
   Rieben, R
AF Dzhonova, Dzhuliya
   Olariu, Radu
   Leckenby, Jonathan
   Dhayani, Ashish
   Vemula, Praveen Kumar
   Prost, Jean-Christophe
   Banz, Yara
   Taddeo, Adriano
   Rieben, Robert
TI Local release of tacrolimus from hydrogel-based drug delivery system is
   controlled by inflammatory enzymes in vivo and can be monitored
   non-invasively using in vivo imaging
SO PLOS ONE
LA English
DT Article
ID REJECTION
AB Background
   Local drug delivery systems that adjust the release of immunosuppressive drug in response to the nature and intensity of inflammation represent a promising approach to reduce systemic immunosuppression and its side effects in allotransplantation. Here we aimed to demonstrate that release of tacrolimus from triglycerol monostearate hydrogel is inflammationdependent in vivo. We further report that by loading the hydrogel with a near-infrared dye, it is possible to monitor drug release non-invasively in an in vivo model of vascularized composite allotransplantation.
   Materials and methods
   Inflammation was induced by local challenge with lipopolysaccharides in naive rats 7 days after injection of tacrolimus-loaded hydrogel in the hind limb. Tacrolimus levels in blood and tissues were measured at selected time points. A near-infrared dye was encapsulated in the hydrogel together with tacrolimus in order to monitor hydrogel deposits and drug release in vitro and in vivo in a model of vascularized composite allotransplantation.
   Results
   Injection of lipopolysaccharides led to increased blood and skin tacrolimus levels (p = 0.0076, day 7 vs. day 12 in blood, and p = 0.0007 in treated limbs, 48 h after injection compared to controls). Moreover, lipopolysaccharides-injected animals had higher tacrolimus levels in treated limbs compared to contralateral limbs (p = 0.0003 for skin and p = 0.0053 for muscle). Imaging of hydrogel deposits and tacrolimus release was achieved by encapsu-lating near-infrared dye in the hydrogel for 160 days. The correlation of tacrolimus and near infrared dye release from hydrogel was R-2 = 0.6297 and R-2 = 0.5619 in blood and grafts of transplanted animals respectively and R-2 = 0.6066 in vitro.
   Conclusions
   Here we demonstrate the inflammation-responsiveness of a tacrolimus-loaded hydrogel in vivo. Moreover, we show that encapsulating a near-infrared dye in the hydrogel provides a reliable correlation of tacrolimus and dye release from the hydrogel, and an accessible noninvasive method for monitoring drug release from hydrogel deposits.
C1 [Dzhonova, Dzhuliya; Taddeo, Adriano; Rieben, Robert] Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland.
   [Dzhonova, Dzhuliya] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland.
   [Olariu, Radu; Leckenby, Jonathan; Taddeo, Adriano] Bern Univ Hosp, Inselspital, Dept Plast & Hand Surg, Bern, Switzerland.
   [Dhayani, Ashish; Vemula, Praveen Kumar] Inst Stem Cell Biol & Regenerat Med, Bangalore, Karnataka, India.
   [Dhayani, Ashish] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur, Tamil Nadu, India.
   [Prost, Jean-Christophe] Univ Hosp, Univ Inst Clin Chem, Ctr Lab Med, Bern, Switzerland.
   [Banz, Yara] Univ Bern, Inst Pathol, Bern, Switzerland.
RP Taddeo, A; Rieben, R (reprint author), Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland.; Taddeo, A (reprint author), Bern Univ Hosp, Inselspital, Dept Plast & Hand Surg, Bern, Switzerland.
EM adriano.taddeo@dbmr.unibe.ch; robert.rieben@dbmr.unibe.ch
RI ; Rieben, Robert/D-7044-2017
OI Olariu, Radu/0000-0002-0204-4432; Rieben, Robert/0000-0003-4179-8891;
   Taddeo, Adriano/0000-0003-3281-1548; Dzhonova,
   Dzhuliya/0000-0001-5196-5417
FU Indo-Swiss Joint Research Program of the Swiss National Science
   Foundation (SNF) [156773]; Department of Science and Technology, Govt.
   of India [INT/SWISS/SNSFP-51/2015]; University Grant Commission
FX This work was supported by Indo-Swiss Joint Research Program of the
   Swiss National Science Foundation (SNF, grant 156773) and the Department
   of Science and Technology, Govt. of India (grant
   INT/SWISS/SNSFP-51/2015) to R.R. and P.V. respectively. A.D. thanks the
   University Grant Commission for the senior research fellowship.
CR Asai D, 2012, BIOMATERIALS, V33, P5451, DOI 10.1016/j.biomaterials.2012.03.083
   Bloch S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2070148
   Capron A, 2012, TRANSPL INT, V25, P41, DOI 10.1111/j.1432-2277.2011.01365.x
   Dzhonova DV, 2018, TRANSPLANTATION, P1
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gajanayake T, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008778
   Gharb BB, 2013, TRANSPLANTATION, V95, P1197, DOI 10.1097/TP.0b013e31828bca61
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Mieog JSD, 2011, ANN SURG ONCOL, V18, P2483, DOI 10.1245/s10434-011-1566-x
   Olariu R, 2017, J SURG RES, V218, P49, DOI 10.1016/j.jss.2017.05.046
   Petrou P, 2018, CULT HEALTH SEX, V20, P640, DOI 10.1080/13691058.2017.1368710
   Petruzzo P, 2017, CURRENT TRANSPLANTAT, P1
   Selvam S, 2011, BIOMATERIALS, V32, P7785, DOI 10.1016/j.biomaterials.2011.07.020
   Solari MG, 2009, PLAST RECONSTR SURG, V123, p17S, DOI 10.1097/PRS.0b013e318191bcbd
   Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55
   Taddeo A, 2018, CURRENT OPINION ORGA, V1
   Unadkat JV, 2017, PLAST RECONSTR SURG, V139, p403E, DOI 10.1097/PRS.0000000000002951
   Wang T, 2010, AM J TRANSPLANT, V10, P1524, DOI 10.1111/j.1600-6143.2010.03066.x
NR 18
TC 1
Z9 1
U1 4
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 30
PY 2018
VL 13
IS 8
AR e0203409
DI 10.1371/journal.pone.0203409
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GS2NZ
UT WOS:000443388900123
PM 30161258
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wang, ZY
   Yang, XM
   Zhang, WG
   Zhang, PX
   Jiang, BG
AF Wang, Zhiyong
   Yang, Xiaomei
   Zhang, Weiguang
   Zhang, Peixun
   Jiang, Baoguo
TI Tanshinone IIA attenuates nerve structural and functional damage induced
   by nerve crush injury in rats
SO PLOS ONE
LA English
DT Article
ID GROWTH; RECOVERY; MICE
AB After peripheral nerve crush injury, the fibers of distal nerve segments gradually disintegrate, and axons regrow from the proximal nerve segment, eventually reaching the target organ. However, the axon regeneration is generally not sufficient for the recovery of neurological function, so drug therapy is necessary. In the current study, we explored the effect of Tanshinone IIA in nerve regeneration in a sciatic nerve crush injury model using Sprague Dawley rats. The rats were administered 45 mg/kg of Tanshinone IIA once daily. Motor behavior and tibialis anterior muscle mass were assessed, and histological analysis of the sciatic nerve and lumbar spinal cord were conducted. The results showed that the administration of Tanshinone IIA improved nerve growth and motor function, and resulted in a marked decrease of neuronal death. The findings of this exploratory study suggest that Tan-shinone IIA alleviates injury and boosts regeneration after nerve crush injury in a rat model of sciatic nerve injury.
C1 [Wang, Zhiyong; Yang, Xiaomei; Zhang, Weiguang] Peking Univ, Sch Basic Med Sci, Dept Anat & Histoembryol, Beijing, Peoples R China.
   [Zhang, Peixun; Jiang, Baoguo] Peking Univ, Peoples Hosp, Dept Trauma & Orthoped, Beijing, Peoples R China.
RP Zhang, PX (reprint author), Peking Univ, Peoples Hosp, Dept Trauma & Orthoped, Beijing, Peoples R China.
EM zhangpeixun@126.com
FU Chinese National Key Basic Research 973 Program [2014CB542201]; Beijing
   Science and Technology New Star Cross Subject; National Natural Science
   Foundation of China [31571235, 31771322, 51373023, 21171019, 31671248,
   31640045, 31571236, 81171146, 31471144, 30971526, 31100860, 31040043,
   31371210, 81372044, 81401007]; Natural Science Foundation of Beijing
   Municipality [7162098]; Fostering Young Scholars of Peking University
   Health Science Center [BMU2017PY013]; Chinese National General Program
   of National Natural Science Fund [31571235, 31771322]; Beijing City
   Science & Technology New Star Cross Project [201819]
FX This research was continuously funded by Chinese National Key Basic
   Research 973 Program (2014CB542201); Beijing Science and Technology New
   Star Cross Subject (2018); National Natural Science Foundation of China
   (31571235, 31771322, 51373023, 21171019, 31671248, 31640045, 31571236,
   81171146, 31471144, 30971526, 31100860, 31040043, 31371210, 81372044,
   81401007); Natural Science Foundation of Beijing Municipality (7162098);
   Fostering Young Scholars of Peking University Health Science Center
   (BMU2017PY013), Chinese National General Program of National Natural
   Science Fund (31571235, 31771322) and Beijing City Science & Technology
   New Star Cross Project (201819).
CR Chen MM, 2017, J NUTR BIOCHEM, V46, P57, DOI 10.1016/j.jnutbio.2017.04.006
   Chen YL, 2012, BIOL PHARM BULL, V35, P164, DOI 10.1248/bpb.35.164
   Cui Q, 2009, CURR NEUROVASC RES, V6, P117, DOI 10.2174/156720209788185641
   DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353
   Dong KN, 2009, PHYTOTHER RES, V23, P608, DOI 10.1002/ptr.2615
   Gu M, 2004, J CHROMATOGR A, V1041, P239, DOI 10.1016/j.chroma.2004.04.030
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Li M, 2017, NEUROSCI LETT, V659, P18, DOI 10.1016/j.neulet.2017.08.059
   Lin R, 2006, J ETHNOPHARMACOL, V108, P217, DOI 10.1016/j.jep.2006.05.004
   Pang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092216
   RUTISHAUSER U, 1985, J NEUROSCI RES, V13, P123, DOI 10.1002/jnr.490130109
   Shen JL, 2011, EVID-BASED COMPL ALT, DOI 10.1155/2011/378907
   Valencia A, 2001, J NEUROSCI RES, V64, P284, DOI 10.1002/jnr.1077.abs
   Wang YX, 2013, NEUROCHEM RES, V38, P538, DOI 10.1007/s11064-012-0946-3
   Wang ZY, 2018, CNS NEUROSCI THER, V24, P483, DOI 10.1111/cns.12820
   Yu CS, 2009, NEUROIMAGE, V47, P451, DOI 10.1016/j.neuroimage.2009.04.066
NR 16
TC 3
Z9 3
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2018
VL 13
IS 8
AR e0202532
DI 10.1371/journal.pone.0202532
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GR6TZ
UT WOS:000442800100080
PM 30138344
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Rhyasen, GW
   Yao, Y
   Zhang, JW
   Dulak, A
   Castriotta, L
   Jacques, K
   Zhao, W
   Gharandaghi, F
   Hattersley, MM
   Lyne, PD
   Clark, E
   Zinda, M
   Fawell, SE
   Mills, GB
   Che, HW
AF Rhyasen, Garrett W.
   Yao, Yi
   Zhang, Jingwen
   Dulak, Austin
   Castriotta, Lillian
   Jacques, Kelly
   Zhao, Wei
   Gharandaghi, Farzin
   Hattersley, Maureen M.
   Lyne, Paul D.
   Clark, Edwin
   Zinda, Michael
   Fawell, Stephen E.
   Mills, Gordon B.
   Che, Huawei
TI BRD4 amplification facilitates an oncogenic gene expression program in
   high-grade serous ovarian cancer and confers sensitivity to BET
   inhibitors
SO PLOS ONE
LA English
DT Article
ID BROMODOMAIN PROTEIN BRD4; P-TEFB; DRUG-SENSITIVITY; CARCINOMA; CELLS;
   REVEALS; MUTATIONS; CHROMATIN; RECURRENT; BINDING
AB BRD4 is a transcriptional co-activator functioning to recruit regulatory complexes to acety-lated chromatin. A subset of High-grade Serous Ovarian Cancer (HGSOC) patients are typified by focal, recurrent BRD4 gene amplifications. Despite previously described cancer dependencies, it is unclear whether BRD4 amplification events are oncogenic in HGSOC. We find that physiologically relevant levels of expression of BRD4 isoforms in non-transformed ovarian cells result in cellular transformation. Transcriptional profiling of BRD4-transformed ovarian cells, and BRD4-amplified HGSOC patient samples revealed shared expression patterns, including enriched MYC, and E2F1 gene signatures. Furthermore, we demonstrate that a novel BET inhibitor, AZD5153, is highly active in BRD4-amplified patient derived xenografts and uncover Neuregulin-1 as a novel BRD4 effector. Experiments involving Neuregulin-1 inhibition and exogenous addition, demonstrate Neuregulin-1 as necessary and sufficient for BRD4-mediated transformation. This study demonstrates the oncogenic potential of BRD4 amplification in cancer and establishes BRD4-amplified HGSOC as a potential patient population that could benefit from BET inhibitors.
C1 [Rhyasen, Garrett W.; Yao, Yi; Zhang, Jingwen; Dulak, Austin; Castriotta, Lillian; Jacques, Kelly; Gharandaghi, Farzin; Hattersley, Maureen M.; Lyne, Paul D.; Clark, Edwin; Zinda, Michael; Fawell, Stephen E.; Che, Huawei] AstraZeneca, IMED Biotech Unit, Biosci, Oncol, Boston, MA USA.
   [Zhao, Wei; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
RP Che, HW (reprint author), AstraZeneca, IMED Biotech Unit, Biosci, Oncol, Boston, MA USA.
EM raymond.chen@astrazeneca.com
FU AstraZeneca Pharmaceuticals; NCI [P50CA083639]
FX The study is funded mainly by AstraZeneca Pharmaceuticals LP and also
   partially by grant P50CA083639 from NCI: https://www. cancer.gov/ (GBM).
   AstraZeneca provided support in the form of salaries for authors G.W.R.,
   Y.Y., A. D., L.C, K.J., J.Z., F.G., M.H., P.L., E.C., M.Z., S.F., and
   H.C, but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of these authors are articulated in the
   `author contributions' section.
CR Alsarraj J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080746
   Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974
   Dhanasekaran SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6893
   Duygu UaL, 2015, MOL CLIN ONCOLOGY, V3, P1291, DOI [10.3892/mco.2015.622, DOI 10.3892/MCO.2015.622]
   Fernandez-Cuesta L, 2014, CANCER DISCOV, V4, P415, DOI 10.1158/2159-8290.CD-13-0633
   Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Gorringe KL, 2007, CLIN CANCER RES, V13, P4731, DOI 10.1158/1078-0432.CCR-07-0502
   Goundiam O, 2015, INT J CANCER, V137, P1890, DOI 10.1002/ijc.29568
   Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997
   Itzen F, 2014, NUCLEIC ACIDS RES, V42, P7577, DOI 10.1093/nar/gku449
   Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392
   Miller DS, 2009, J CLIN ONCOL, V27, P2686, DOI 10.1200/JCO.2008.19.2963
   Moriniere J, 2009, NATURE, V461, P664, DOI 10.1038/nature08397
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002
   Rhyasen GW, 2016, MOL CANCER THER, V15, P2563, DOI 10.1158/1535-7163.MCT-16-0141
   Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Stewart HJS, 2013, CANCER MED-US, V2, P826, DOI 10.1002/cam4.146
   Sung CO, 2014, GYNECOL ONCOL, V132, P343, DOI 10.1016/j.ygyno.2013.11.036
   Therapeutics T., DOSE ESCALATION COHO
   Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433
   Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029
   Zhang YQ, 2017, CANCER CELL, V31, P820, DOI 10.1016/j.ccell.2017.04.013
   Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179
NR 39
TC 2
Z9 3
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2018
VL 13
IS 7
AR e0200826
DI 10.1371/journal.pone.0200826
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GN8PM
UT WOS:000439429200018
PM 30036377
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Fang, H
   Cui, YB
   Wang, Z
   Wang, S
AF Fang, Hao
   Cui, Yibin
   Wang, Zhuang
   Wang, Se
TI Toxicological assessment of multi-walled carbon nanotubes combined with
   nonylphenol in male mice
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; SINGLE-WALL; BISPHENOL-A; DNA-DAMAGE; PULMONARY
   TOXICITY; GRAPHITIC CARBON; MEAT FLAVOR; CELL-CYCLE; IN-VITRO; KAPPA-B
AB Carbon nanotubes have attracted increasing attention attributable to their widespread application. To evaluate the joint toxicity of multi-walled carbon nanotubes (MWCNTs) and nonylphenol (NP), we investigated the toxicological effects of NP, pristine MWCNTs, and MWCNTs combined with NP in male mice. After exposing male mice by gavage for 5 days, intracellular superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, as well as malondialdehyde (MDA) and glutathione (GSH) levels in tissues were determined to evaluate in vivo oxidative stress. In addition, genotoxicity was assessed by examining DNA damage in mouse liver and sperm via the comet assay, and transmission electron microscopy (TEM) was used for direct visual observations of mitochondrial damage in the liver. Results from the oxidative damage and DNA damage experiments indicate that after adsorbing NP, MWCNTs at a high dose induce oxidative lesions in the liver and cause DNA damage in mouse sperm; these data offer new insights regarding the toxicological assessment of MWCNTs.
C1 [Fang, Hao; Wang, Zhuang; Wang, Se] Nanjing Univ Informat Sci & Technol, Collaborat Innovat Ctr Atmospher Environm & Equip, Sch Environm Sci & Engn, Nanjing, Jiangsu, Peoples R China.
   [Cui, Yibin] Minist Environm Protect, Nanjing Inst Environm Sci, Nanjing, Jiangsu, Peoples R China.
RP Cui, YB (reprint author), Minist Environm Protect, Nanjing Inst Environm Sci, Nanjing, Jiangsu, Peoples R China.
EM cyb@nies.org
FU Startup Foundation for Introducing Talent of Nanjing University of
   Information Science and Technology [2014r020]; Natural Science
   Foundation of Jiangsu Province [BK20170948]; Natural Science Foundation
   of Jiangsu Higher Education Institutions of China [17KJB610007];
   Top-notch Academic Programs Project of Jiangsu Higher Education
   Institutions [PPZY2015C222]; National Natural Science Foundation of
   China, China [31572623]
FX This project was supported by Startup Foundation for Introducing Talent
   of Nanjing University of Information Science and Technology (2014r020 to
   HF), The Natural Science Foundation of Jiangsu Province (BK20170948 to
   HF), The Natural Science Foundation of Jiangsu Higher Education
   Institutions of China (17KJB610007 to HF), Top-notch Academic Programs
   Project of Jiangsu Higher Education Institutions (PPZY2015C222 to HF)
   and National Natural Science Foundation of China (31572623 to YC),
   China. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; This
   project was supported by Startup Foundation for Introducing Talent
   (2014r020) of Nanjing University of Information Science and Technology,
   The Natural Science Foundation of Jiangsu Province (BK20170948), The
   Natural Science Foundation of Jiangsu Higher Education Institutions of
   China (17KJB610007), Top-notch Academic Programs Project of Jiangsu
   Higher Education Institutions (PPZY2015C222) and National Natural
   Science Foundation of China (31572623), China.
CR Aly HAA, 2012, TOXICOL APPL PHARM, V261, P134, DOI 10.1016/j.taap.2012.02.015
   Aydogan M, 2008, TOXICOLOGY, V249, P35, DOI 10.1016/j.tox.2008.04.002
   Bai YH, 2010, NAT NANOTECHNOL, V5, P683, DOI [10.1038/NNANO.2010.153, 10.1038/nnano.2010.153]
   Brown DM, 2007, CARBON, V45, P1743, DOI 10.1016/j.carbon.2007.05.011
   Chitra KC, 2002, ARCH TOXICOL, V76, P545, DOI 10.1007/s00204-002-0372-4
   Clark KA, 2012, J TOXICOL ENV HEAL A, V75, P25, DOI 10.1080/15287394.2011.589105
   Colerangle JB, 1996, ENDOCRINE, V4, P115, DOI 10.1007/BF02782756
   COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6
   DAVID NA, 1972, ANNU REV PHARMACOLOG, V12, P353, DOI 10.1146/annurev.pa.12.040172.002033
   Deng X, 2007, CARBON, V45, P1419, DOI 10.1016/j.carbon.2007.03.035
   El-Dakdoky MH, 2007, B ENVIRON CONTAM TOX, V79, P188, DOI 10.1007/s00128-007-9158-y
   Ghosh M, 2011, J HAZARD MATER, V197, P327, DOI 10.1016/j.jhazmat.2011.09.090
   Gong Y, 2006, REPROD TOXICOL, V22, P623, DOI 10.1016/j.reprotox.2006.04.019
   Gundersen JL, 2001, J CHROMATOGR A, V914, P161, DOI 10.1016/S0021-9673(00)01235-8
   Horiuchi K, 2005, ARCH HISTOL CYTOL, V68, P51, DOI 10.1679/aohc.68.51
   Hu CW, 2013, ENVIRON SCI-PROC IMP, V15, P2125, DOI 10.1039/c3em00376k
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   Johnston HJ, 2010, NANOTOXICOLOGY, V4, P207, DOI 10.3109/17435390903569639
   Kelly SA, 1998, ENVIRON HEALTH PERSP, V106, P375, DOI 10.2307/3434064
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kisin ER, 2007, J TOXICOL ENV HEAL A, V70, P2071, DOI 10.1080/15287390701601251
   Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x
   Kyselova Vendula, 2003, Reprod Biol Endocrinol, V1, P30, DOI 10.1186/1477-7827-1-30
   Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243
   Lee PC, 1998, ENDOCRINE, V9, P105, DOI 10.1385/ENDO:9:1:105
   Lee S, 2009, ENVIRON TOXICOL PHAR, V27, P90, DOI 10.1016/j.etap.2008.08.009
   Li XN, 2014, J COLLOID INTERF SCI, V415, P159, DOI 10.1016/j.jcis.2013.10.021
   Li Z, 2007, ENVIRON HEALTH PERSP, V115, P377, DOI 10.1289/ehp.9688
   Li ZY, 2013, ENVIRON MONIT ASSESS, V185, P5221, DOI 10.1007/s10661-012-2938-9
   Liang GY, 2010, J TOXICOL ENV HEAL A, V73, P463, DOI 10.1080/15287390903523378
   Manna SK, 2005, NANO LETT, V5, P1676, DOI 10.1021/nl0507966
   Matsumoto M, 2012, J TOXICOL SCI, V37, P463
   Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008
   Negishi T, 2004, ENVIRON HEALTH PERSP, V112, P1159, DOI 10.1289/ehp.6961
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Pan B, 2008, ENVIRON SCI TECHNOL, V42, P9005, DOI 10.1021/es801777n
   Pan B, 2008, ENVIRON SCI TECHNOL, V42, P5480, DOI 10.1021/es8001184
   Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111
   RAMARATHNAM N, 1993, J AGR FOOD CHEM, V41, P939, DOI 10.1021/jf00030a020
   RAMARATHNAM N, 1993, J AGR FOOD CHEM, V41, P933, DOI 10.1021/jf00030a019
   Reddy ARN, 2011, REGUL TOXICOL PHARM, V59, P251, DOI 10.1016/j.yrtph.2010.10.007
   Roy D, 1998, FRONT BIOSCI-LANDMRK, V3, P913
   Sanchis J, 2016, ENVIRON SCI TECHNOL, V50, P961, DOI 10.1021/acs.est.5b03966
   Shvedova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL552, DOI 10.1152/ajplung.90287.2008
   Shvedova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL698, DOI 10.1152/ajplung.00084.2005
   Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/15287390390231566
   Shvedova AA, 2012, TOXICOL APPL PHARM, V261, P121, DOI 10.1016/j.taap.2012.03.023
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Singh R, 2006, P NATL ACAD SCI USA, V103, P3357, DOI 10.1073/pnas.0509009103
   Soares A, 2008, ENVIRON INT, V34, P1033, DOI 10.1016/j.envint.2008.01.004
   SUN Y, 1988, CLIN CHEM, V34, P497
   Vazquez-Duhalt R., 2005, APPL ECOL ENV RES, V4, P1
   Wang JX, 2006, BIOCHEM PHARMACOL, V71, P872, DOI 10.1016/j.bcp.2005.12.001
   Wang WW, 2014, INT J MOL SCI, V15, P15981, DOI 10.3390/ijms150915981
   Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228
   Watanabe H, 2004, J MOL ENDOCRINOL, V33, P243, DOI 10.1677/jme.0.0330243
   Xu C, 2016, ONCOTARGET, V7, P39270, DOI 10.18632/oncotarget.9689
   Yang H, 2009, J APPL TOXICOL, V29, P69, DOI 10.1002/jat.1385
   Yang K, 2009, ENVIRON POLLUT, V157, P1095, DOI 10.1016/j.envpol.2008.11.007
   Ye SF, 2009, BIOCHEM BIOPH RES CO, V379, P643, DOI 10.1016/j.bbrc.2008.12.137
NR 61
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 20
PY 2018
VL 13
IS 7
AR e0200238
DI 10.1371/journal.pone.0200238
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GN8GG
UT WOS:000439396900005
PM 30028835
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Grandhi, R
   Peitz, GW
   Foley, LM
   Bonfield, CM
   Fellows-Mayle, W
   Hitchens, TK
   Mooney, MP
AF Grandhi, Ramesh
   Peitz, Geoffrey W.
   Foley, Lesley M.
   Bonfield, Christopher M.
   Fellows-Mayle, Wendy
   Hitchens, T. Kevin
   Mooney, Mark P.
TI The influence of suturectomy on age-related changes in cerebral blood
   flow in rabbits with familial bicoronal suture craniosynostosis: A
   quantitative analysis
SO PLOS ONE
LA English
DT Article
ID SPIN-LABELED MRI; INTRACRANIAL-PRESSURE; SINGLE-SUTURE; CRANIOFACIAL
   GROWTH; COMPLEX CRANIOSYNOSTOSIS; CHILDREN; SYNOSTOSIS; PERFUSION;
   BRAIN; VOLUME
AB Background
   Coronal suture synostosis is a condition which can have deleterious physical and cognitive sequelae in humans if not corrected. A well-established animal model has previously demonstrated disruptions in intracranial pressure and developmental abnormalities in rabbits with congenital craniosynostosis compared to wild type rabbits.
   Objective
   The current study aimed to measure the cerebral blood flow (CBF) in developing rabbits with craniosynostosis who underwent suturectomy compared to those with no intervention and compared to wild type rabbits.
   Methods
   Rabbits with early onset coronal suture synostosis were assigned to have suturectomy at 10 days of age (EOCS-SU, n = 15) or no intervention (EOCS, n = 18). A subset of each group was randomly selected for measurement at 10 days of age, 25 days of age, and 42 days of age. Wild type rabbits (WT, n = 18) were also randomly assigned to measurement at each time point as controls. Cerebral blood flow at the bilateral hemispheres, cortices, thalami, and superficial cortices was measured in each group using arterial spin-labeling MRI.
   Results
   At 25 days of age, CBF at the superficial cortex was significantly higher in EOCS rabbits (192.6 +/- 10.1 mL/100 mg/min on the left and 195 +/- 9.5 mL/100 mg/min on the right) compared to WT rabbits (99.2 +/- 29.1 mL/100 mg/min on the left and 96.2 +/- 21.4 mL/100 mg/min on the right), but there was no significant difference in CBF between EOCS-SU (97.6 +/- 11.3 mL/100 mg/min on the left and 99 +/- 7.4 mL/100 mg/min on the right) and WT rabbits. By 42 days of age the CBF in EOCS rabbits was not significantly different than that of WT rabbits.
   Conclusion
   Suturectomy eliminated the abnormally increased CBF at the superficial cortex seen in EOCS rabbits at 25 days of age. This finding contributes to the evidence that suturectomy limits abnormalities of ICP and CBF associated with craniosynostosis.
C1 [Grandhi, Ramesh; Peitz, Geoffrey W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA.
   [Foley, Lesley M.; Hitchens, T. Kevin] Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA.
   [Foley, Lesley M.; Hitchens, T. Kevin] Univ Pittsburgh, High Field Anim Imaging Ctr, Pittsburgh, PA USA.
   [Bonfield, Christopher M.] Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN USA.
   [Fellows-Mayle, Wendy] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
   [Mooney, Mark P.] Univ Pittsburgh, Dept Oral Biol, Pittsburgh, PA USA.
   [Mooney, Mark P.] Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA 15260 USA.
   [Mooney, Mark P.] Univ Pittsburgh, Deparment Plast Surg, Pittsburgh, PA USA.
   [Mooney, Mark P.] Univ Pittsburgh, Deparment Orthodont, Pittsburgh, PA USA.
   [Mooney, Mark P.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA.
RP Grandhi, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA.
EM grandhi@uthscsa.edu
FU Walter L. Copeland Fund of The Pittsburgh Foundation; Posvar Hall Animal
   Care Facility, Department of Anthropology, University of Pittsburgh
FX This work was funded by Walter L. Copeland Fund of The Pittsburgh
   Foundation (URL: pittsburghfoundation.org) and the Posvar Hall Animal
   Care Facility, Department of Anthropology, University of Pittsburgh
   (URL: www.anthropology.pitt.edu) to RG. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Otibi M, 2007, J NEUROSURG, V107, P508, DOI 10.3171/PED-07/12/508
   Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002
   AUER LM, 1987, ACTA NEUROCHIR, V84, P124, DOI 10.1007/BF01418837
   Beiner JM, 1997, COMP BIOCHEM PHYS A, V116, P245, DOI 10.1016/S0300-9629(96)00206-X
   Bondar RL, 1995, CAN AERONAUTICS SPAC, V45, P3
   Bonfield CM, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.2.FOCUS14849
   CohenJr MM, 2000, CRANIOSYNOSTOSIS DIA, P95
   Cooper GM, 1999, CLEFT PALATE-CRAN J, V36, P314, DOI 10.1597/1545-1569(1999)036<0314:BGRICR>2.3.CO;2
   Cooper GM, 2006, PLAST RECONSTR SURG, V117, P1886, DOI 10.1097/01.prs.0000218845.70591.7e
   David LR, 1996, J CRANIOFAC SURG, V7, P177, DOI 10.1097/00001665-199605000-00003
   David LR, 1999, J CRANIOFAC SURG, V10, P38, DOI 10.1097/00001665-199901000-00008
   DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106
   Enlow DH, 1990, HDB FACIAL GROWTH
   Fellows-Mayle WK, 2004, PLAST RECONSTR SURG, V113, P557, DOI 10.1097/01.PRS.0000101056.33534.F0
   Fellows-Mayle WK, 2000, CLEFT PALATE-CRAN J, V37, P370, DOI 10.1597/1545-1569(2000)037<0370:ARCIIP>2.3.CO;2
   Foley L, 2009, CHILD NERV SYST, V25, P861, DOI 10.1007/s00381-009-0812-z
   Foley LM, 2005, MAGN RESON MED, V54, P798, DOI 10.1002/mrm.20621
   GAULT DT, 1992, PLAST RECONSTR SURG, V90, P377, DOI 10.1097/00006534-199209000-00003
   Gilbert J, 2016, CLEFT PALATE-CRAN J, V53, P210, DOI 10.1597/14-298
   Gosain AK, 1996, PLAST RECONSTR SURG, V97, P292, DOI 10.1097/00006534-199602000-00004
   HAREL S, 1972, BIOL NEONATE, V21, P381
   Hayward R, 2016, J NEUROSURG-PEDIATR, V18, P242, DOI 10.3171/2015.6.PEDS15144
   Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B
   HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9
   Kapp-Simon KA, 2005, CLEFT PALATE-CRAN J, V42, P377, DOI 10.1597/04-044.1
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Littleton-Kearney MT, 2000, AM J PHYSIOL-HEART C, V279, pH1208
   Mathijssen I, 2017, J NEUROSURG-PEDIATR, V20, P498, DOI 10.3171/2017.3.PEDS17118
   Miller J D, 1972, Prog Brain Res, V35, P411
   Mitchell RL, 2003, CLEFT PALATE-CRAN J, V40, P486, DOI 10.1597/1545-1569(2003)040<0486:ENBICR>2.0.CO;2
   Mooney MP, 2012, 9TH EUROPEAN CRANIOFACIAL CONGRESS, P9
   Mooney MP, 2007, J CRANIOFAC SURG, V18, P336, DOI 10.1097/scs.0b013e3180336047
   Mooney MP, 2004, EXPERT OPIN BIOL TH, V4, P279, DOI 10.1517/eobt.4.3.279.27332
   Mooney MP, 1998, CHILD NERV SYST, V14, P247, DOI 10.1007/s003810050220
   Mooney MP, 1999, J CRANIOFAC SURG, V10, P104, DOI 10.1097/00001665-199903000-00003
   MOONEY MP, 1994, CLEFT PALATE-CRAN J, V31, P8, DOI 10.1597/1545-1569(1994)031<0008:DOASOR>2.3.CO;2
   Mooney MP, 1996, CLEFT PALATE-CRAN J, V33, P369, DOI 10.1597/1545-1569(1996)033<0369:CSPASP>2.3.CO;2
   Mooney MP, 2002, UNDERSTANDING CRANIO, P209
   Mursch K, 1999, CHILD NERV SYST, V15, P110, DOI 10.1007/s003810050344
   NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83
   Panchal J, 2001, PLAST RECONSTR SURG, V108, P1492, DOI 10.1097/00006534-200111000-00007
   Pennings FA, 2004, STROKE, V35, P1284, DOI 10.1161/01.STR.0000126039.91400.cb
   Putz D A, 2002, Orthod Craniofac Res, V5, P90, DOI 10.1034/j.1600-0544.2002.01178.x
   Renier D, 2000, CHILD NERV SYST, V16, P645, DOI 10.1007/s003810000320
   Roatta S, 2000, EXP PHYSIOL, V85, P431, DOI 10.1111/j.1469-445X.2000.02038.x
   Rollins N, 2000, PEDIATR NEUROSURG, V32, P308, DOI 10.1159/000028959
   SAINTEROSE C, 1984, J NEUROSURG, V60, P727, DOI 10.3171/jns.1984.60.4.0727
   SATOH M, 1990, Kaku Igaku, V27, P1411
   SEN A, 1995, J NUCL MED, V36, P394
   Shek JW, 1986, ATLAS RABBIT BRAIN S
   Slater BJ, 2008, PLAST RECONSTR SURG, V121, p170E, DOI 10.1097/01.prs.0000304441.99483.97
   Tamburrini G, 2005, CHILD NERV SYST, V21, P913, DOI 10.1007/s00381-004-1117-x
   TUOR UI, 1991, PEDIATR RES, V29, P517, DOI 10.1203/00006450-199105010-00020
   Zhang F, 2003, NEURORADIOLOGY, V45, P773, DOI 10.1007/s00234-003-1001-5
   ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310
   ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323
NR 56
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 1
PY 2018
VL 13
IS 6
AR e0197296
DI 10.1371/journal.pone.0197296
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GH8ES
UT WOS:000433900800017
PM 29856748
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Leung, V
   Rousseau-Blass, F
   Beauchamp, G
   Pang, DSJ
AF Leung, Vivian
   Rousseau-Blass, Frederik
   Beauchamp, Guy
   Pang, Daniel S. J.
TI ARRIVE has not ARRIVEd: Support for the ARRIVE (Animal Research:
   Reporting of in vivo Experiments) guidelines does not improve the
   reporting quality of papers in animal welfare, analgesia or anesthesia
SO PLOS ONE
LA English
DT Article
ID PUBLICATION
AB Poor research reporting is a major contributing factor to low study reproducibility, financial and animal waste. The ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines were developed to improve reporting quality and many journals support these guidelines. The influence of this support is unknown. We hypothesized that papers published in journals supporting the ARRIVE guidelines would show improved reporting compared with those in non-supporting journals. In a retrospective, observational cohort study, papers from 5 ARRIVE supporting (SUPP) and 2 non-supporting (nonSUPP) journals, published before (2009) and 5 years after (2015) the ARRIVE guidelines, were selected. Adherence to the ARRIVE checklist of 20 items was independently evaluated by two reviewers and items assessed as fully, partially or not reported. Mean percentages of items reported were compared between journal types and years with an unequal variance t-test. Individual items and sub-items were compared with a chi-square test. From an initial cohort of 956, 236 papers were included: 120 from 2009 (SUPP; n = 52, nonSUPP; n = 68), 116 from 2015 (SUPP; n = 61, nonSUPP; n = 55). The percentage of fully reported items was similar between journal types in 2009 (SUPP: 55.3 +/- 11.5% [SD]; nonSUPP: 51.8 +/- 9.0%; p = 0.07, 95% CI of mean difference -0.3-7.3%) and 2015 (SUPP: 60.5 +/- 11.2%; nonSUPP; 60.2 +/- 10.0%; p = 0.89, 95%)/CI -3.6-4.2%). The small increase in fully reported items between years was similar for both journal types (p = 0.09, 95% CI -0.5-4.3%). No paper fully reported 100% of items on the ARRIVE checklist and measures associated with bias were poorly reported. These results suggest that journal support for the ARRIVE guidelines has not resulted in a meaningful improvement in reporting quality, contributing to ongoing waste in animal research.
C1 [Leung, Vivian; Rousseau-Blass, Frederik; Beauchamp, Guy; Pang, Daniel S. J.] Univ Montreal, Fac Vet Med, St Hyacinthe, PQ, Canada.
RP Pang, DSJ (reprint author), Univ Montreal, Fac Vet Med, St Hyacinthe, PQ, Canada.
EM daniel.pang@umontreal.ca
FU Natural Sciences and Engineering Research Council of Canada
   [424022-2013]; Fondation J.-Louis Levesque
FX Natural Sciences and Engineering Research Council of Canada Discovery
   Grant awarded to DSJP (ID: 424022-2013)
   http://www.nserc-crsng.gc.ca/index_eng.asp Fondation J.-Louis Levesque
   operating grant awarded to DSJP. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2013, NATURE, V496, P398, DOI 10.1038/496398a
   [Anonymous], ARRIVE ANIMAL RES RE
   Avey MT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166733
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Baker D, 2012, J NEUROIMMUNOL, V242, P78, DOI 10.1016/j.jneuroim.2011.11.003
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Cressey D, 2016, NATURE, DOI [10.1038/nature.2016.19274, DOI 10.1038/NATURE.2016.19274]
   Delgado-Ruiz RA, 2015, CLIN ORAL IMPLAN RES, V26, P915, DOI 10.1111/clr.12406
   Di Girolamo N, 2017, VET REC, V181, DOI 10.1136/vr.104035
   Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128
   Freedman LP, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002165
   Han S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183591
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Leung V, 2017, ARRIVE GUIDELINES ST, DOI [10.7910/DVN/8IGTN3, DOI 10.7910/DVN/8IGTN3]
   Liu YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154657
   Ludolph AC, 2010, AMYOTROPH LATERAL SC, V11, P38, DOI 10.3109/17482960903545334
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Macleod MR, 2017187245 BIORXIV
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P3189, DOI 10.1111/bph.12955
   Russell W, 1959, PRINCIPLES HUMANE EX
   Schwarz F, 2012, J CLIN PERIODONTOL, V39, P63, DOI 10.1111/j.1600-051X.2011.01838.x
   Shineman DW, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt90
   Stevens A, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3804
   Ting KH, 2015, INT J RHEUM DIS, V18, P488, DOI 10.1111/1756-185X.12699
   Turner L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000030.pub2
   Vesterinen HM, 2010, MULT SCLER J, V16, P1044, DOI 10.1177/1352458510379612
   Vogt L, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000598
NR 31
TC 8
Z9 8
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 24
PY 2018
VL 13
IS 5
AR e0197882
DI 10.1371/journal.pone.0197882
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GH0HY
UT WOS:000433084300089
PM 29795636
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Cristea, IA
   Ioannidis, JPA
AF Cristea, Ioana Alina
   Ioannidis, John P. A.
TI P values in display items are ubiquitous and almost invariably
   significant: A survey of top science journals
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE SIGNIFICANCE; METAANALYSIS; ASSOCIATION; THRESHOLDS;
   CONFIDENCE; REDEFINE; FALSE
AB P values represent a widely used, but pervasively misunderstood and fiercely contested method of scientific inference. Display items, such as figures and tables, often containing the main results, are an important source of P values. We conducted a survey comparing the overall use of P values and the occurrence of significant P values in display items of a sample of articles in the three top multidisciplinary journals (Nature, Science, PNAS) in 2017 and, respectively, in 1997. We also examined the reporting of multiplicity corrections and its potential influence on the proportion of statistically significant P values. Our findings demonstrated substantial and growing reliance on P values in display items, with increases of 2.5 to 14.5 times in 2017 compared to 1997. The overwhelming majority of P values (94%, 95% confidence interval [CI] 92% to 96%) were statistically significant. Methods to adjust for multiplicity were almost non-existent in 1997, but reported in many articles relying on P values in 2017 (Nature 68%, Science 48%, PNAS 38%). In their absence, almost all reported P values were statistically significant (98%, 95% CI 96% to 99%). Conversely, when any multiplicity corrections were described, 88% (95% CI 82% to 93%) of reported P values were statistically significant. Use of Bayesian methods was scant (2.5%) and rarely (0.7%) articles relied exclusively on Bayesian statistics. Overall, wider appreciation of the need for multiplicity corrections is a welcome evolution, but the rapid growth of reliance on Pvalues and implausibly high rates of reported statistical significance are worrisome.
C1 [Cristea, Ioana Alina; Ioannidis, John P. A.] Stanford Univ, Metares Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA.
   [Cristea, Ioana Alina] Babes Bolyai Univ, Dept Clin Psychol & Psychotherapy, Cluj Napoca, Romania.
   [Ioannidis, John P. A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
   [Ioannidis, John P. A.] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
   [Ioannidis, John P. A.] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [Ioannidis, John P. A.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
RP Ioannidis, JPA (reprint author), Stanford Univ, Metares Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA.; Ioannidis, JPA (reprint author), Stanford Univ, Dept Med, Stanford, CA 94305 USA.; Ioannidis, JPA (reprint author), Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA.; Ioannidis, JPA (reprint author), Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.; Ioannidis, JPA (reprint author), Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
EM jioannid@stanford.edu
FU Laura and John Arnold Foundation
FX METRICS is funded by the Laura and John Arnold Foundation. The work of
   J.P.A.I. is supported by an unrestricted gift from Sue and Bob ODonnell.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amrhein V, 2018, NAT HUM BEHAV, V2, P4, DOI 10.1038/s41562-017-0224-0
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Benjamin DJ, 2018, NAT HUM BEHAV, V2, P6, DOI 10.1038/s41562-017-0189-z
   Chavalarias D, 2016, JAMA-J AM MED ASSOC, V315, P1141, DOI 10.1001/jama.2016.1952
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Coblentz KE, 2017, ECOLOGY, V98, P1535, DOI 10.1002/ecy.1802
   Conneely KN, 2010, GENET EPIDEMIOL, V34, P739, DOI 10.1002/gepi.20538
   de Winter JCF, 2015, PEERJ, V3, DOI 10.7717/peerj.733
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dienes Z, 2017, PSYCHONOMIC B REV, DOI [10.3758/s13423-017-1266-z10.3758/s13423-017-1266-z, DOI 10.3758/S13423-017-1266-Z10.3758/S13423-017-1266-Z]
   Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297
   Eklund A, 2017, NEUROIMAGE, V155, P354, DOI 10.1016/j.neuroimage.2017.04.069
   Fanelli D, 2012, SCIENTOMETRICS, V90, P891, DOI 10.1007/s11192-011-0494-7
   Gao XY, 2011, GENET EPIDEMIOL, V35, P154, DOI 10.1002/gepi.20563
   Gelman A, 2018, PERS SOC PSYCHOL B, V44, P16, DOI 10.1177/0146167217729162
   Gelman A, 2013, EPIDEMIOLOGY, V24, P69, DOI 10.1097/EDE.0b013e31827886f7
   Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008
   Goodman S, 2008, SEMIN HEMATOL, V45, P135, DOI 10.1053/j.seminhematol.2008.04.003
   Greenland S, 2006, INT J EPIDEMIOL, V35, P765, DOI 10.1093/ije.dyi312
   Greenland S, 2016, EUR J EPIDEMIOL, V31, P337, DOI 10.1007/s10654-016-0149-3
   Han B, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000456
   Hazlewood GS, 2018, J CLIN EPIDEMIOL, V93, P56, DOI 10.1016/j.jclinepi.2017.10.003
   Head ML, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002106
   Hoggart CJ, 2008, GENET EPIDEMIOL, V32, P179, DOI 10.1002/gepi.20292
   Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P1429, DOI 10.1001/jama.2018.1536
   Ioannidis JPA, 2014, BIOSTATISTICS, V15, P28, DOI 10.1093/biostatistics/kxt036
   Jager LR, 2014, BIOSTATISTICS, V15, P1, DOI 10.1093/biostatistics/kxt007
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lakens D, 2018, NAT HUM BEHAV, V2, P168, DOI 10.1038/s41562-018-0311-x
   Masicampo EJ, 2012, Q J EXP PSYCHOL, V65, P2271, DOI 10.1080/17470218.2012.711335
   McShane B., 2017, ABANDON STAT SIGNIFI
   Monsarrat P, 2017, GIGASCIENCE, V7, DOI 10.1093/gigascience/gix121
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Perneger TV, 2017, J CLIN EPIDEMIOL, V87, P70, DOI 10.1016/j.jclinepi.2017.04.003
   Schonbrodt FD, 2018, PSYCHON B REV, V25, P128, DOI 10.3758/s13423-017-1230-y
   Senn SJ, 2017, P VALUE WARS
   Simmons JP, 2011, PSYCHOL SCI, V22, P1359, DOI 10.1177/0956797611417632
   Simonsohn U, 2014, J EXP PSYCHOL GEN, V143, P534, DOI 10.1037/a0033242
   Stacey AW, 2012, INVEST OPHTH VIS SCI, V53, P1830, DOI 10.1167/iovs.11-8730
   Stang A, 2017, EUR J EPIDEMIOL, V32, P21, DOI 10.1007/s10654-016-0211-1
   Stang A, 2011, J CLIN EPIDEMIOL, V64, P1047, DOI 10.1016/j.jclinepi.2011.03.004
   Stang A, 2010, EUR J EPIDEMIOL, V25, P225, DOI 10.1007/s10654-010-9440-x
   StataCorp, 2017, STAT STAT SOFTW REL, V15
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Streiner DL, 2015, AM J CLIN NUTR, V102, P721, DOI 10.3945/ajcn.115.113548
   Szucs D, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00390
   Trafimow D, 2015, BASIC APPL SOC PSYCH, V37, P197, DOI 10.1080/01973533.2015.1064290
   van Ravenzwaaij D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173184
   Vsevolozhskaya OA, 2015, ENVIRON ECOL STAT, V22, P45, DOI 10.1007/s10651-014-0282-7
   Wagenmakers EJ, 2018, PSYCHON B REV, V25, P35, DOI [10.3758/s13423-017-1343-3, 10.3758/s13423-017-1323-7]
   Walenkamp Monique M J, 2013, BMC Res Notes, V6, P374, DOI 10.1186/1756-0500-6-374
   Wang TT, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4030-x
   Wason JMS, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-364
   Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108
   Xu CJ, 2014, GENET EPIDEMIOL, V38, P281, DOI 10.1002/gepi.21797
   Zhang X, 2012, GENETICS, V190, P1511, DOI 10.1534/genetics.111.137737
NR 57
TC 4
Z9 4
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2018
VL 13
IS 5
AR e0197440
DI 10.1371/journal.pone.0197440
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GF7AA
UT WOS:000432118800051
PM 29763472
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Carneiro, CFD
   Moulin, TC
   Macleod, MR
   Amaral, OB
AF Carneiro, Clarissa F. D.
   Moulin, Thiago C.
   Macleod, Malcolm R.
   Amaral, Olavo B.
TI Effect size and statistical power in the rodent fear conditioning
   literature - A systematic review
SO PLOS ONE
LA English
DT Review
ID CONFIDENCE-INTERVALS; ANIMAL-MODELS; P-VALUES; BIAS; METAANALYSIS;
   GUIDE; SEX
AB Proposals to increase research reproducibility frequently call for focusing on effect sizes instead of p values, as well as for increasing the statistical power of experiments. However, it is unclear to what extent these two concepts are indeed taken into account in basic biomedical science. To study this in a real-case scenario, we performed a systematic review of effect sizes and statistical power in studies on learning of rodent fear conditioning, a widely used behavioral task to evaluate memory. Our search criteria yielded 410 experiments comparing control and treated groups in 122 articles. Interventions had a mean effect size of 29.5%, and amnesia caused by memory-impairing interventions was nearly always partial. Mean statistical power to detect the average effect size observed in well-powered experiments with significant differences (37.2%) was 65%, and was lower among studies with non-significant results. Only one article reported a sample size calculation, and our estimated sample size to achieve 80% power considering typical effect sizes and variances (15 animals per group) was reached in only 12.2% of experiments. Actual effect sizes correlated with effect size inferences made by readers on the basis of textual descriptions of results only when findings were non-significant, and neither effect size nor power correlated with study quality indicators, number of citations or impact factor of the publishing journal. In summary, effect sizes and statistical power have a wide distribution in the rodent fear conditioning literature, but do not seem to have a large influence on how results are described or cited. Failure to take these concepts into consideration might limit attempts to improve reproducibility in this field of science.
C1 [Carneiro, Clarissa F. D.; Moulin, Thiago C.; Amaral, Olavo B.] Univ Fed Rio de Janeiro, Inst Med Biochem Leopoldo de Meis, Rio De Janeiro, Brazil.
   [Macleod, Malcolm R.] Univ Edinburgh, Div Clin Neurosci, Edinburgh, Midlothian, Scotland.
RP Amaral, OB (reprint author), Univ Fed Rio de Janeiro, Inst Med Biochem Leopoldo de Meis, Rio De Janeiro, Brazil.
EM olavo@bioqmed.ufrj.br
RI Amaral, Olavo/B-2874-2009; Moulin, Thiago C/I-4070-2013
OI Amaral, Olavo/0000-0002-4299-8978; Moulin, Thiago C/0000-0001-7811-5383
FU FAPERJ [E-26/111.277/2014, E-26/201.544/2014]; RCUK NC3Rs grant
   [NC/L000970/1]; CNPq; FAPERJ
FX This work is supported by FAPERJ grants E-26/111.277/2014 and
   E-26/201.544/2014 to O.B. A., by RCUK NC3Rs grant NC/L000970/1 to M.R.
   M., by CNPq scholarships to T.C.M. and C.F.D.C, and by a FAPERJ
   supplementary scholarship to C. F.D.C. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Altman N, 2016, NAT METHODS, V14, P3, DOI [10.1038/nmeth.4120, DOI 10.1038/NMETH.4120]
   Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a
   COHEN J, 1962, J ABNORM PSYCHOL, V65, P145, DOI 10.1037/h0045186
   Cohen J, 1977, STAT POWER ANAL BEHA
   Colquhoun D, 2014, ROY SOC OPEN SCI, V1, DOI 10.1098/rsos.140216
   Currie GL, 2013, PAIN, V154, P917, DOI 10.1016/j.pain.2013.02.033
   de Winter JCF, 2015, PEERJ, V3, DOI 10.7717/peerj.733
   GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008
   Goodman SN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5027
   Greenland S, 2016, EUR J EPIDEMIOL, V31, P337, DOI 10.1007/s10654-016-0149-3
   Halsey LG, 2015, NAT METHODS, V12, P179, DOI 10.1038/nmeth.3288
   Higginson AD, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000995
   Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7
   Ioannidis JPA, 2007, CLIN TRIALS, V4, P245, DOI 10.1177/1740774507079441
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Kuhberger A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105825
   Lazebnik Y, 2002, CANCER CELL, V2, P179, DOI 10.1016/S1535-6108(02)00133-2
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897
   Mogil JS, 2005, PAIN, V117, P1, DOI 10.1016/j.pain.2005.06.020
   Mohammad F, 2016, NEUROSCI BIOBEHAV R, V68, P504, DOI 10.1016/j.neubiorev.2016.04.011
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moulin TC, 2016, EVID BASED PRECLIN M, V3, P24
   Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x
   Norberg MM, 2008, BIOL PSYCHIAT, V63, P1118, DOI 10.1016/j.biopsych.2008.01.012
   Nord CL, 2017, J NEUROSCI, V37, P8051, DOI 10.1523/JNEUROSCI.3592-16.2017
   Nuzzo R, 2014, NATURE, V506, P150, DOI 10.1038/506150a
   Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   Ridley J, 2007, J EVOLUTION BIOL, V20, P1082, DOI 10.1111/j.1420-9101.2006.0291.x
   Rooke EDM, 2011, PARKINSONISM RELAT D, V17, P313, DOI 10.1016/j.parkreldis.2011.02.010
   Sanes JR, 1999, NAT NEUROSCI, V2, P597, DOI 10.1038/10154
   Scott S, 2008, AMYOTROPH LATERAL SC, V9, P4, DOI 10.1080/17482960701856300
   SEDLMEIER P, 1989, PSYCHOL BULL, V105, P309, DOI 10.1037/0033-2909.105.2.309
   Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009
   Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988
   Smaldino PE, 2016, ROY SOC OPEN SCI, V3, DOI 10.1098/rsos.160384
   Szucs D, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000797
   Trafimow D, 2015, BASIC APPL SOC PSYCH, V37, P197, DOI 10.1080/01973533.2015.1064290
   Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010
   Vesterinen HM, 2010, MULT SCLER J, V16, P1044, DOI 10.1177/1352458510379612
   Wagenmakers EJ, 2007, PSYCHON B REV, V14, P779, DOI 10.3758/BF03194105
   Wald C, 2010, SCIENCE, V327, P1571, DOI 10.1126/science.327.5973.1571
   Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108
   Wizemann TM, 2012, SEX SPECIFIC REPORTI
NR 51
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 26
PY 2018
VL 13
IS 4
AR e0196258
DI 10.1371/journal.pone.0196258
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GE1WN
UT WOS:000431007600054
PM 29698451
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Su, YB
   Li, TH
   Huang, CC
   Tsai, HC
   Huang, SF
   Hsieh, YC
   Yang, YY
   Huang, YH
   Hou, MC
   Lin, HC
AF Su, Yen-Bo
   Li, Tzu-Hao
   Huang, Chia-Chang
   Tsai, Hung-Cheng
   Huang, Shiang-Fen
   Hsieh, Yun-Cheng
   Yang, Ying-Ying
   Huang, Yi-Hsiang
   Hou, Ming-Chih
   Lin, Han-Chieh
TI Chronic calcitriol supplementation improves the inflammatory profiles of
   circulating monocytes and the associated intestinal/adipose tissue
   alteration in a diet-induced steatohepatitis rat model
SO PLOS ONE
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; FATTY LIVER-DISEASE; VITAMIN-D DEFICIENCY;
   NF-KAPPA-B; NONALCOHOLIC STEATOHEPATITIS; TNF-ALPHA; D-RECEPTOR; BARRIER
   DYSFUNCTION; BOWEL DISEASES; ADIPOSE-TISSUE
AB Vitamin D deficiency and up-regulated TNF alpha-related signals are reported to be involved in abnormalities including intestinal hyper-permeability, bacterial translocation, systemic/portal endotoxemia, intestinal/adipose tissue/hepatic inflammation, and hepatic steatosis in nonalcoholic steatohepatitis (NASH). This study aims to explore the molecular mechanisms and effects of chronic calcitriol [1,25-(OH)(2)D-3, hormonal form of vitamin D] on gut-adipose tissue-liver axis abnormalities using a high-fat diet (HFD)-fed rat model of NASH. In HFD-fed obese rats on a 10-week calcitriol (0.3 pg/kg/TIW) or vehicle treatment (NASH-vit. D and NASH-V rats) reigme, various in vivo and in vitro experiments were undertaken. Through anti-INF alpha-TNFR1-NF kappa B signaling effects, chronic calcitriol treatment significantly restored plasma calcitriol levels and significantly improved vitamin D receptor (VDR) expression in monocytes and the small intestine of NASH-vit. D rats. Significantly, plasma and portal endotoxin/INF alpha levels, bacterial translocation to mesenteric lymph nodes, plasma DX4000-FITC, fecal albumin-assessed intestinal hyper-permeability, over-expression of TNF alpha-related immune profiles in monocytes, inflammation of intestinal/mesenteric adipose tissue (MAT)/liver and hepatic steatosis were improved by chronic calcitriol treatment of NASH rats. Additionally, in vitro experiments with acute calcitriol co-incubation reversed NASH-V rat monocyte supernatant/TNF alpha-induced monolayer barrier dysfunction in caco-2 cells, cytokine release from MAT-derived adipocytes, and triglyceride synthesis by lean-V rat hepatocytes. Using in vivo and in vitro experiments, our study reported calcitriol signaling in the gut as well as in adipose tissue. Meanwhile, our study suggests that restoration of systemic and intestinal vitamin D deficiency using by chronic vitamin D treatment effectively reduces TNF alpha-mediated immunological abnormalities associated with the gut-adipose tissue-liver axis and hepatic steatosis in NASH rats.
C1 [Su, Yen-Bo; Huang, Chia-Chang; Tsai, Hung-Cheng; Yang, Ying-Ying] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.
   [Su, Yen-Bo; Li, Tzu-Hao; Huang, Chia-Chang; Tsai, Hung-Cheng; Huang, Shiang-Fen; Hsieh, Yun-Cheng; Yang, Ying-Ying; Huang, Yi-Hsiang; Hou, Ming-Chih; Lin, Han-Chieh] Natl Yang Ming Univ, Sch Med, Dept Med, Taipei, Taiwan.
   [Li, Tzu-Hao] Taipei Vet Gen Hosp, Div Allergy & Immunol, Taipei, Taiwan.
   [Li, Tzu-Hao; Huang, Chia-Chang; Yang, Ying-Ying] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei, Taiwan.
   [Li, Tzu-Hao] Taichung Vet Gen Hosp, Chia Yi Branch, Chiayi, Taiwan.
   [Huang, Shiang-Fen] Taipei Vet Gen Hosp, Div Infect, Taipei, Taiwan.
   [Hsieh, Yun-Cheng; Yang, Ying-Ying; Huang, Yi-Hsiang; Hou, Ming-Chih; Lin, Han-Chieh] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan.
   [Yang, Ying-Ying] Taipei Vet Gen Hosp, Div Gen Med, Taipei, Taiwan.
RP Yang, YY (reprint author), Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.; Yang, YY; Lin, HC (reprint author), Natl Yang Ming Univ, Sch Med, Dept Med, Taipei, Taiwan.; Yang, YY (reprint author), Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei, Taiwan.; Yang, YY; Lin, HC (reprint author), Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan.; Yang, YY (reprint author), Taipei Vet Gen Hosp, Div Gen Med, Taipei, Taiwan.
EM yangyy@vghtpe.gov.tw; hclin@vghtpe.gov.tw
OI Huang, Shiang-Fen/0000-0002-6685-8259
FU National Science Council [NSC-102-2314-B-010-036-MY3]; Taipei Veterans
   General Hospital;  [V106EA-007];  [VGHUST105-GI-2-2]
FX We especially thank Yun-Ru Wang, Fan-Yi Jhan, Che-Jui Chang and Yen-Ling
   Lin for their excellent technical supports. This work was entirely
   supported by research grants NSC-102-2314-B-010-036-MY3 and from the
   National Science Council, and V106EA-007, VGHUST105-GI-2-2 and by the
   Taipei Veterans General Hospital.
CR Amar J, 2011, EMBO MOL MED, V3, P559, DOI 10.1002/emmm.201100159
   Blair SA, 2006, LAB INVEST, V86, P191, DOI 10.1038/labinvest.3700373
   Brandl K, 2015, EXPERT REV GASTROENT, V9, P1069, DOI 10.1586/17474124.2015.1057122
   Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006
   Cantorna MT, 2010, P NUTR SOC, V69, P286, DOI 10.1017/S0029665110001722
   Chang E, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040338
   Chen YZ, 2014, INFLAMM BOWEL DIS, V20, P1910, DOI 10.1097/MIB.0000000000000158
   Cohen ML, 2001, KIDNEY INT, V59, P69, DOI 10.1046/j.1523-1755.2001.00467.x
   Crespo J, 2001, HEPATOLOGY, V34, P1158, DOI 10.1053/jhep.2001.29628
   Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001
   Ding C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061707
   Drori A, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0688-4
   Duarte MS, 2012, J METABOLIC SYND, V1, P4, DOI [10.4172/2167-0943.1000112, DOI 10.4172/2167-0943.1000112]
   FEINGOLD KR, 1987, J CLIN INVEST, V80, P184, DOI 10.1172/JCI113046
   Feng YJ, 2013, J PHYSIOL-LONDON, V591, P3709, DOI 10.1113/jphysiol.2013.253518
   Froicu M, 2003, MOL ENDOCRINOL, V17, P2386, DOI 10.1210/me.2003-0281
   Gabele E, 2011, J HEPATOL, V55, P1391, DOI 10.1016/j.jhep.2011.02.035
   Gao D, 2013, INT J OBESITY, V37, P357, DOI 10.1038/ijo.2012.53
   Garcia-Alvarez M, 2016, AIDS, V30, P1069, DOI 10.1097/QAD.0000000000001007
   Giulietti A, 2007, DIABETES RES CLIN PR, V77, P47, DOI 10.1016/j.diabres.2006.10.007
   Gonzalez-Quintela A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054600
   GRUNFELD C, 1991, METABOLISM, V40, P894, DOI 10.1016/0026-0495(91)90062-2
   Han H, 2015, NUTR METAB CARDIOVAS, V25, P556, DOI 10.1016/j.numecd.2015.02.011
   Jiang TT, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030126
   Jiang WW, 2015, SCI REP-UK, V5, DOI 10.1038/srep08096
   Kang EJ, 2015, INT J MOL MED, V36, P1151, DOI 10.3892/ijmm.2015.2300
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007
   Lam YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034233
   Leppkes M, 2014, INT IMMUNOL, V26, P509, DOI 10.1093/intimm/dxu051
   Li H, 2008, METABOLISM, V57, P1704, DOI 10.1016/j.metabol.2008.07.029
   Li YC, 2015, J STEROID BIOCHEM, V148, P179, DOI 10.1016/j.jsbmb.2015.01.011
   Liu H, 2011, CYTOKINE, V56, P581, DOI 10.1016/j.cyto.2011.08.023
   Liu LN, 2016, EXP THER MED, V11, P2284, DOI 10.3892/etm.2016.3242
   Liu XJ, 2015, ENDOCRINOLOGY, V156, P2103, DOI 10.1210/en.2014-2037
   Ma TY, 2004, AM J PHYSIOL-GASTR L, V286, pG367, DOI 10.1152/ajpgi.00173.2003
   Manna P, 2017, ARCH BIOCHEM BIOPHYS, V615, P22, DOI 10.1016/j.abb.2017.01.002
   Miele L, 2009, HEPATOLOGY, V49, P1877, DOI 10.1002/hep.22848
   MULLER K, 1992, CYTOKINE, V4, P506, DOI 10.1016/1043-4666(92)90012-G
   Nakano T, 2011, J HEPATOL, V55, P415, DOI 10.1016/j.jhep.2010.11.028
   Nelson JE, 2016, AM J GASTROENTEROL, V111, P852, DOI 10.1038/ajg.2016.51
   Peterson CA, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-10
   Poniachik J, 2006, CYTOKINE, V33, P252, DOI 10.1016/j.cyto.2006.02.006
   Roth CL, 2012, HEPATOLOGY, V55, P1103, DOI 10.1002/hep.24737
   SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561
   Su LP, 2013, GASTROENTEROLOGY, V145, P407, DOI 10.1053/j.gastro.2013.04.011
   Targher G, 2007, NUTR METAB CARDIOVAS, V17, P517, DOI 10.1016/j.numecd.2006.04.002
   Tomita K, 2006, GUT, V55, P415, DOI 10.1136/gut.2005.071118
   Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194
   Unno N, 1996, AM J PHYSIOL-GASTR L, V270, pG1010
   van der Bruggen T, 1999, INFECT IMMUN, V67, P3824
   Vida M, 2015, DIS MODEL MECH, V8, P721, DOI 10.1242/dmm.019166
   Wang JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086117
   Wigg AJ, 2001, GUT, V48, P206, DOI 10.1136/gut.48.2.206
   Zhao HW, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-57
NR 55
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2018
VL 13
IS 4
AR e0194867
DI 10.1371/journal.pone.0194867
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GD7AK
UT WOS:000430660600008
PM 29684027
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ogawa, K
   Aoki, M
   Kadono, S
   Odani, A
AF Ogawa, Kazuma
   Aoki, Miho
   Kadono, Sumi
   Odani, Akira
TI Complexes of myo-inositol-hexakisphosphate (InsP6) with zinc or
   lanthanum to enhance excretion of radioactive strontium from the body
SO PLOS ONE
LA English
DT Article
ID PHYTIC ACID; BONE METASTASES; RADIOCESIUM; CHERNOBYL; CALCIUM
AB Sr-90, which was released into the atmosphere and the ocean following the Chernobyl and Fukushima Daiichi nuclear power plant disasters, is an important nuclear fission element. Compounds that inhibit the absorption of Sr-90 into the bloodstream and enhance its elimination can be beneficial in decreasing the absorbed radiation dose in people exposed to Sr-90. Recently, we prepared complexes of myo-inositol-hexakisphosphate (InsP6) with zinc or lanthanum as decorporation agents. These complexes, called Zn-InsP6 and La-InsP6 respectively, are insoluble in water and can potentially chelate additional metal cations. Hypothesizing that these complexes can assist the excretion of Sr-90 from the body, we evaluated them using Sr-85 instead of Sr-90. In in vitro binding experiments, Zn-InsP6 showed higher strontium adsorption capacity than La-InsP6. We then performed in vivo biodistribution experiments of Zn-InsP6 in mice after oral administration of (SrCl2)-Sr-85. Mice treated with Zn-InsP6 showed significantly lower bone accumulation of radioactivity than mice in a non treatment control group. Zn-InsP6 adsorbed radiostrontium in the gastrointestinal tract, inhibited this ion's absorption into the bloodstream, and enhanced its excretion in the feces. Therefore, Zn-InsP6 appears to be a promising Sr-90 "decorporation" agent.
C1 [Ogawa, Kazuma] Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa, Japan.
   [Aoki, Miho; Kadono, Sumi; Odani, Akira] Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan.
RP Ogawa, K (reprint author), Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa, Japan.
EM kogawa@p.kanazawa-u.ac.jp
RI Ogawa, Kazuma/D-8406-2015
OI Ogawa, Kazuma/0000-0002-1691-7302
CR BARNES DWH, 1970, INT J RADIAT BIOL RE, V18, P531, DOI 10.1080/09553007014551461
   Brumfiel G, 2011, NATURE, V474, P135, DOI 10.1038/474135a
   Davis J, 2000, J NUCL MED, V41, P183
   DUNGWORTH DL, 1969, BLOOD-J HEMATOL, V34, P610
   Evangeliou N, 2014, ENVIRON INT, V64, P17, DOI 10.1016/j.envint.2013.11.020
   GRAF E, 1990, FREE RADICAL BIO MED, V8, P61, DOI 10.1016/0891-5849(90)90146-A
   GRAF E, 1983, J AM OIL CHEM SOC, V60, P1861, DOI 10.1007/BF02901539
   Haratake M, 2012, CHEM PHARM BULL, V60, P1258, DOI 10.1248/cpb.c12-00430
   HARRISON JE, 1966, CAN MED ASSOC J, V94, P1092
   Kanai Y, 2012, J ENVIRON RADIOACTIV, V111, P33, DOI 10.1016/j.jenvrad.2011.10.011
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Liepe K, 2003, J NUCL MED, V44, P953
   Ogawa K, 2012, CURR MED CHEM, V19, P3290, DOI 10.2174/092986712801215865
   Ogawa K, 2017, CHEM PHARM BULL, V65, P261, DOI 10.1248/cpb.c16-00792
   Ogawa K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148080
   Ogawa K, 2009, NUCL MED BIOL, V36, P129, DOI 10.1016/j.nucmedbio.2008.11.007
   SIMPSON CJ, 1990, BRIT J NUTR, V64, P225, DOI 10.1079/BJN19900024
   Stabin MG, 2005, J NUCL MED, V46, P1023
   SUTTON A, 1967, NATURE, V216, P1005, DOI 10.1038/2161005a0
   Szkudelski T, 2005, J ANIM PHYSIOL AN N, V89, P397, DOI 10.1111/j.1439-0396.2005.00532.x
   Yablokov AV, 2009, ANN NY ACAD SCI, V1181, P5, DOI [10.1111/j.1749-6632.2009.04821.x, 10.1111/j.1749-6632.2009.04820.x]
NR 21
TC 0
Z9 0
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 3
PY 2018
VL 13
IS 4
AR e0195067
DI 10.1371/journal.pone.0195067
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GB5DC
UT WOS:000429081600028
PM 29614122
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Meadows, KRT
   Steinberg, MW
   Clemons, B
   Stokes, ME
   Opiteck, GJ
   Peach, R
   Scott, FL
AF Meadows, Kristen R. Taylor
   Steinberg, Marcos W.
   Clemons, Bryan
   Stokes, Matthew E.
   Opiteck, Gregory J.
   Peach, Robert
   Scott, Fiona L.
TI Ozanimod (RPC1063), a selective S1P(R1) and S1P(R5) modulator, reduces
   chronic inflammation and alleviates kidney pathology in murine systemic
   lupus erythematosus
SO PLOS ONE
LA English
DT Article
ID SPHINGOSINE 1-PHOSPHATE RECEPTOR; LYMPHOID ORGANS; FTY720; S1P(1);
   PATHOGENESIS; FINGOLIMOD; INFECTION; NEPHRITIS; EFFICACY; UPDATE
AB Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PRi) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis. Ozanimod and its active metabolite, RP-101075, exhibit a similar specificity profile at the S1P receptor family in vitro and pharmacodynamic profile in vivo. The NZBWF1 mouse model was used in therapeutic dosing mode to assess the potential benefit of ozanimod and RP-101075 in an established animal model of systemic lupus erythematosus. Compared with vehicle-treated animals, ozanimod and RP-101075 reduced proteinuria over the duration of the study and serum blood urea nitrogen at termination. Additionally, ozanimod and RP-101075 reduced kidney disease in a dose-dependent manner, as measured by histological assessment of mesangial expansion, endo- and exo-capillary proliferation, interstitial infiltrates and fibrosis, glomerular deposits, and tubular atrophy. Further exploration into gene expression changes in the kidney demonstrate that RP-101075 also significantly reduced expression of fibrotic and immune-related genes in the kidneys. Of note, RP-101075 lowered the number of plasmacytoid dendritic cells, a major source of interferon alpha in lupus patients, and reduced all B and T cell subsets in the spleen. Given the efficacy demonstrated by ozanimod and its metabolite RP-101075 in the NZBWF1 preclinical animal model, ozanimod may warrant clinical evaluation as a potential treatment for systemic lupus erythematosus.
C1 [Meadows, Kristen R. Taylor; Steinberg, Marcos W.; Clemons, Bryan; Opiteck, Gregory J.; Peach, Robert; Scott, Fiona L.] Receptos, San Diego, CA 92121 USA.
   [Stokes, Matthew E.] Celgene Corp, Seattle, WA USA.
RP Meadows, KRT (reprint author), Receptos, San Diego, CA 92121 USA.
EM krtaylor@celgene.com
FU Celgene Corporation
FX Celgene Corporation (http://www.celgene.com/) funded this study. The
   funder provided support in the form of salaries and research materials
   for authors KRTM, MWS, BC, MES, GJO, RP and FLS. KRTM, MWS, BC, MES,
   GJO, RP and FLS had additional roles in the study design, data
   collection and analysis, decision to publish or preparation of the
   manuscript. The specific roles of these authors are articulated in the
   "author contributions" section.
CR Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200
   Alperovich G, 2007, LUPUS, V16, P18, DOI 10.1177/0961203306073136
   Ando S, 2010, BIOCHEM BIOPH RES CO, V394, P804, DOI 10.1016/j.bbrc.2010.03.078
   Aoki M, 2016, MEDIAT INFLAMM, V2016, DOI DOI 10.1155/2016/8606878
   Brinkmann V, 2009, BRIT J PHARMACOL, V158, P1173, DOI 10.1111/j.1476-5381.2009.00451.x
   Chang A, 2011, J IMMUNOL, V186, P1849, DOI 10.4049/jimmunol.1001983
   Clark EA, 2005, ANN RHEUM DIS, V64, P77, DOI 10.1136/ard.2005.042507
   Cohen JA, 2016, LANCET NEUROL, V15, P373, DOI 10.1016/S1474-4422(16)00018-1
   Corsiero E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00430
   Gong Q, 2005, J IMMUNOL, V174, P817, DOI 10.4049/jimmunol.174.2.817
   Gonzalez-Cabrera Pedro J, 2014, F1000Prime Rep, V6, P109, DOI 10.12703/P6-109
   HURD ER, 1975, ARTHRITIS RHEUM, V18, P67, DOI 10.1002/art.1780180113
   Kappos L, 2016, JAMA NEUROL, V73, P1089, DOI 10.1001/jamaneurol.2016.1451
   Khatri BO, 2016, THER ADV NEUROL DISO, V9, P130, DOI 10.1177/1756285616628766
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim SS, 2012, THER ADV CHRONIC DIS, V3, P11, DOI 10.1177/2040622311424806
   Lech M, 2013, J AM SOC NEPHROL, V24, P1357, DOI 10.1681/ASN.2013010026
   Marro BS, 2017, P NATL ACAD SCI USA, V114, P3708, DOI 10.1073/pnas.1700878114
   Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284
   Mehling M, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000028
   Moulton VR, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3251
   Neyt K, 2012, TRENDS IMMUNOL, V33, P297, DOI 10.1016/j.it.2012.04.006
   Noor S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-77
   Okazaki H, 2002, J RHEUMATOL, V29, P707
   Oldstone MBA, 2013, VIROLOGY, V435, P92, DOI 10.1016/j.virol.2012.09.039
   Oon S, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.26
   Perry D, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/271694
   Pham THM, 2008, IMMUNITY, V28, P122, DOI 10.1016/j.immuni.2007.11.017
   Sandborn WJ, 2016, NEW ENGL J MED, V374, P1754, DOI 10.1056/NEJMoa1513248
   SCHRIEBER L, 1986, RHEUMATOL INT, V6, P215, DOI 10.1007/BF00541370
   Schurer SC, 2008, ACS CHEM BIOL, V3, P486, DOI 10.1021/cb800051m
   Scott FL, 2016, BRIT J PHARMACOL, V173, P1778, DOI 10.1111/bph.13476
   Sistigu A, 2011, SEMIN IMMUNOPATHOL, V33, P369, DOI 10.1007/s00281-011-0245-0
   Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939
   Teijaro JR, 2016, P NATL ACAD SCI USA, V113, P1351, DOI 10.1073/pnas.1525356113
   Tobon GJ, 2013, AUTOIMMUN DIS, DOI 10.1155/2013/827254
NR 36
TC 1
Z9 1
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2018
VL 13
IS 4
AR e0193236
DI 10.1371/journal.pone.0193236
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GB3VV
UT WOS:000428988800002
PM 29608575
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Pound, P
   Nicol, CJ
AF Pound, Pandora
   Nicol, Christine J.
TI Retrospective harm benefit analysis of pre-clinical animal research for
   six treatment interventions
SO PLOS ONE
LA English
DT Article
ID FELASA WORKING GROUP; TRANSPARENCY
AB Background
   The harm benefit analysis (HBA) is the cornerstone of animal research regulation and is considered to be a key ethical safeguard for animals. The HBA involves weighing the anticipated benefits of animal research against its predicted harms to animals but there are doubts about how objective and accountable this process is.
   Objectives
   i. To explore the harms to animals involved in pre-clinical animal studies and to assess these against the benefits for humans accruing from these studies; ii. To test the feasibility of conducting this type of retrospective HBA.
   Methods
   Data on harms were systematically extracted from a sample of pre-clinical animal studies whose clinical relevance had already been investigated by comparing systematic reviews of the animal studies with systematic reviews of human studies for the same interventions (antifibrinolytics for haemorrhage, bisphosphonates for osteoporosis, corticosteroids for brain injury, Tirilazad for stroke, antenatal corticosteroids for neonatal respiratory distress and thrombolytics for stroke). Clinical relevance was also explored in terms of current clinical practice. Harms were categorised for severity using an expert panel. The quality of the research and its impact were considered. Bateson's Cube was used to conduct the HBA.
   Results
   The most common assessment of animal harms by the expert panel was 'severe'. Reported use of analgesia was rare and some animals (including most neonates) endured significant procedures with no, or only light, anaesthesia reported. Some animals suffered iatrogenic harms. Many were kept alive for long periods post-experimentally but only 1% of studies reported post-operative care. A third of studies reported that some animals died prior to endpoints. All the studies were of poor quality. Having weighed the actual harms to animals against the actual clinical benefits accruing from these studies, and taking into account the quality of the research and its impact, less than 7% of the studies were permissible according to Bateson's Cube: only the moderate bisphosphonate studies appeared to minimise harms to animals whilst being associated with benefit for humans.
   Conclusions
   This is the first time the accountability of the HBA has been systematically explored across a range of pre-clinical animal studies. The regulatory systems in place when these studies were conducted failed to safeguard animals from severe suffering or to ensure that only beneficial, scientifically rigorous research was conducted. Our findings indicate a pressing need to: i. review regulations, particularly those that permit animals to suffer severe harms; ii. reform the processes of prospectively assessing pre-clinical animal studies to make them fit for purpose; and iii. systematically evaluate the benefits of pre-clinical animal research to permit a more realistic assessment of its likely future benefits.
C1 [Pound, Pandora] Univ Bristol, Populat Hlth Sci, Canynge Hall, Bristol, Avon, England.
   [Nicol, Christine J.] Univ Bristol, Sch Vet Sci, Langford House, Langford, England.
RP Pound, P (reprint author), Univ Bristol, Populat Hlth Sci, Canynge Hall, Bristol, Avon, England.
EM pandora.pound@bristol.ac.uk
RI Nicol, Christine J/B-4841-2011
OI Nicol, Christine J/0000-0001-6734-2177; Pound,
   Pandora/0000-0001-6885-6401
CR Alderson P, 2005, CORTICOSTEROIDS ACUT
   Andrews NA, 2016, PAIN, V157, P901, DOI 10.1097/j.pain.0000000000000458
   [Anonymous], 2012, ALT TREAT AC ISCH ST
   [Anonymous], 2009, GUIDELINES ASSIGNING
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   BATESON P, 1986, NEW SCI, V109, P30
   Bateson P., 2017, COMMUNICATION
   Bronstad A, 2016, LAB ANIM-UK, V50, P1, DOI 10.1177/0023677216642398
   Brown N., 2003, SCI TECHNOLOGY STUDI
   Brown SGA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5215
   Carbone L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155001
   Cohen D., 2018, BMJ-BRIT MED J, P360
   Comroe JH, 1978, BIOMEDICAL SCI PUBLI, P15
   Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5
   Cressey D, 2015, NATURE, V523
   Davies G, 2017, REV HARM BENEFIT ANA
   Davies GF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158791
   De Cock Buning T., 1994, Animal Welfare, V3, P107
   DeGrazia D, 2015, CAMB Q HEALTHC ETHIC, V24, P420, DOI 10.1017/S0963180115000080
   European Commission, 2013, CAR AN AIM BETT SCI
   European Commission, 2012, CAR AN AIM BETT SCI
   European Union. European Union Directive, 2010, OFFICIAL J EUROPEAN, P276
   Franco NH, 2012, ATLA-ALTERN LAB ANIM, V40, P271, DOI 10.1177/026119291204000506
   Franco NH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047723
   Grant J, 2000, BRIT MED J, V320, P1107, DOI 10.1136/bmj.320.7242.1107
   Greek R, 2011, J PHILOS SCI LAW, V11, P1
   Griffin G, 2014, REV SCI TECH OIE, V33, P265, DOI 10.20506/rst.33.1.2283
   Grimm H, 2015, ALTERN LAB ANIM, V43, P22
   Gruber Franz P, 2004, ALTEX, V21 Suppl 1, P3
   Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731
   Hawkes Nigel, 2015, BMJ, V351, ph5453, DOI 10.1136/bmj.h5453
   Henderson VC, 2015, ELIFE, V4, DOI 10.7554/eLife.08351
   Henderson VC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001489
   Hirst JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098856
   Holman C, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002331
   Home Office, NONT SUMM GRANT 2015
   Hooijmans CR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001482
   Hooijmans C. R, 2010, GOLD STANDARD PUBLIC
   Ioannidis JPA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004631
   Ipsos Mori, 2016, PUBLIC ATTITUDES ANI
   Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Laber K, 2016, LAB ANIM-UK, V50, P21, DOI 10.1177/0023677216642397
   Lenzer J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3830
   Macleod M., 2018, BMJ-BRIT MED J, P360
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Martic-Kehl MI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137235
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P2671, DOI 10.1111/bph.12954
   Mellor DJ, 2015, ANIM WELFARE, V24, P241, DOI 10.7120/09627286.24.3.241
   National Institute for Health and Clinical Excellence, 2008, AL ET RIS RAL STRONT
   NC3Rs, 2017, RESP US AN BIOSC RES
   Percie du Sert N, 2017, J CEREBRAL BLOOD FLO
   Perel P, 2006, TESTING TREATMENT AN
   Perel P, 2007, BMJ-BRIT MED J, V334, P197, DOI 10.1136/bmj.39048.407928.BE
   Pollock N, 2010, SOC STUD SCI, V40, P525, DOI 10.1177/0306312710362275
   PORTER DG, 1992, NATURE, V356, P101, DOI 10.1038/356101a0
   Pound P, 2014, BMJ-BRIT MED J, P348
   Pound P, 2016, ATLA-ALTERN LAB ANIM, V44, P167, DOI 10.1177/026119291604400210
   Rands SA, 2011, J AM ASSOC LAB ANIM, V50, P901
   RCP. National Clinical Guideline for Stroke, 2016, NAT CLIN GUID STROK
   Reichlin TS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165999
   REINES BP, 1991, J MED PHILOS, V16, P183, DOI 10.1093/jmp/16.2.183
   Richardson CA, 2005, ANESTHESIA ANALGESIA, V1, P3
   Ritskes-Hoitinga M, 2018, IMPROVING CONDUCT RE
   Roberts D BJ, 2017, COCHRANE DB SYST REV, P3
   Sandercock PAG, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0767-5
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   Stafleu FR, 1999, LAB ANIM, V33, P295, DOI 10.1258/002367799780578255
   Tirilazad International Steering Committee, 2001, COCHRANE DB SYST REV, P4
   Tsilidis KK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001609
   Vogt L, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000598
   Walport M., 2016, COMMUNICATION
   Wooding S, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-47
NR 74
TC 4
Z9 4
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2018
VL 13
IS 3
AR e0193758
DI 10.1371/journal.pone.0193758
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GA8PV
UT WOS:000428603100030
PM 29590200
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kim, HK
   Kim, HJ
   Kim, JH
   Kim, TH
   Lee, SH
AF Kim, Ha Kyun
   Kim, Hyun Jung
   Kim, Jae Hyung
   Kim, Tae Hoon
   Lee, Sang Hag
TI Asymmetric expression level of clock genes in left vs. right nasal
   mucosa in humans with and without allergies and in rats: Circadian
   characteristics and possible contribution to nasal cycle
SO PLOS ONE
LA English
DT Article
ID RHYTHMIC EXPRESSION; MOLECULAR CLOCK; RHINITIS; TIME; INNERVATION;
   PACEMAKER; PROTEINS; GENETICS; SKIN
AB Numerous peripheral tissues possess self-sustaining daily biologic rhythms that are regulated at the molecular level by clock genes such as PER1, PER2, CLOCK, and BMAL1. Physiological function of nasal mucosa exhibits rhythmic variability to a day-night environmental cycle. Nevertheless, little is known of the expression and distribution pattern of clock genes in nasal mucosa. The present study investigates the expression level and distribution pattern of PER1, PER2, CLOCK, and BMAL1 genes in nasal mucosa of healthy controls, allergic rhinitis patients, and normal rats. In human and rat nasal mucosa, the levels of these genes are asymmetrically expressed in nasal mucosa derived from right and left cavities in normal controls, allergic patients, and rat. In human nasal mucosa, the expression levels of these genes were higher in the decongested side than the congested mucosa. In rat nasal mucosa, these clock genes are expressed in a rhythmic circadian manner under the regular light/dark cycles. The expression levels of MUC5AC, a key mucin genes produced in superficial epithelium, are higher in decongested side than that congested side in human nasal mucosa. In rat nasal mucosa, MUC5AC levels showed a circadian rhythm which was associated with different expression levels in nasal mucosa derived from the right and left nasal cavities. Taken together with these results, the present study shows that the clock genes such as PER1, PER2, CLOCK, and BMAL1 are present in human and rat nasal mucosa, and suggest that these clock genes may control the pathophysiological function of nasal mucosa as circadian oscillators and affect the maintenance of the nasal cycle.
C1 [Kim, Ha Kyun; Kim, Hyun Jung; Kim, Jae Hyung; Kim, Tae Hoon; Lee, Sang Hag] Korea Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea.
RP Lee, SH (reprint author), Korea Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea.
EM sanghag@kumc.or.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea [2016R1D1A1A02936927]; Korea University grant, Korea [Q1524681]
FX This work was supported by The Basic Science Research Program through
   the National Research Foundation of Korea (2016R1D1A1A02936927). This
   research was also supported by a Korea University grant, Korea
   (Q1524681). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; This
   work was supported by The Basic Science Research Program through the
   National Research Foundation of Korea (2016R1D1A1A02936927). This
   research was also supported by a Korea University grant, Korea
   (Q1524681).
CR Ando N, 2015, ALLERGY, V70, P319, DOI 10.1111/all.12552
   Anea CB, 2009, CIRCULATION, V119, P1510, DOI 10.1161/CIRCULATIONAHA.108.827477
   Arbour P, 1975, Can J Otolaryngol, V4, P333
   Balsalobre A, 2002, CELL TISSUE RES, V309, P193, DOI 10.1007/s00441-002-0585-0
   BAMFORD OS, 1982, PFLUG ARCH EUR J PHY, V394, P139, DOI 10.1007/BF00582915
   Bando H, 2007, J NEUROSCI, V27, P4359, DOI 10.1523/JNEUROSCI.4131-06.2007
   BENDE M, 1989, ACTA OTO-LARYNGOL, V107, P262, DOI 10.3109/00016488909127507
   Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1
   BOJSENMOLLER F, 1971, J ANAT, V110, P25
   Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053
   CAMPBELL W M, 1981, Rhinology (Utrecht), V19, P127
   Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500
   Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8
   Eccles R, 1996, EUR RESPIR J, V9, P371, DOI 10.1183/09031936.96.09020371
   ECCLES R, 1978, ACTA OTO-LARYNGOL, V85, P431, DOI 10.3109/00016487809121472
   ECCLES R, 1981, ACTA OTO-LARYNGOL, V91, P127, DOI 10.3109/00016488109138490
   ECCLES R, 1983, EUR J RESPIR DIS, V64, P150
   Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043
   GILBERT AN, 1987, ACTA OTO-LARYNGOL, V104, P180, DOI 10.3109/00016488709109065
   Gomez-Santos C, 2009, OBESITY, V17, P1481, DOI 10.1038/oby.2009.164
   Greiff L, 1996, ACTA OTO-LARYNGOL, V116, P85, DOI 10.3109/00016489609137719
   Hayasaka N, 2007, ENDOCRINOLOGY, V148, P3316, DOI 10.1210/en.2007-0010
   Heetderks DR, 1927, AM J MED SCI, V174, P231, DOI 10.1097/00000441-192708000-00008
   Hiragaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106819
   Honma A, 2015, ENDOCRINOLOGY, V156, P4302, DOI 10.1210/en.2015-1490
   Johansson AS, 2016, SCHIZOPHR RES, V174, P17, DOI 10.1016/j.schres.2016.04.029
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kizaki T, 2015, CRIT REV IMMUNOL, V35, P261, DOI 10.1615/CritRevImmunol.2015014925
   KLAASEN ABM, 1988, ORL J OTO-RHINO-LARY, V50, P32, DOI 10.1159/000275967
   Kouri VP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054049
   KURITA N, 1988, ACTA OTO-LARYNGOL, V106, P448, DOI 10.3109/00016488809122269
   Leibetseder V, 2009, CHRONOBIOL INT, V26, P621, DOI 10.1080/07420520902924939
   Lillie HI, 1923, J IOWA MED SOC, V13, P403
   LITTLEJOHN MC, 1992, LARYNGOSCOPE, V102, P117
   MALM L, 1977, ACTA OTO-LARYNGOL, V83, P20, DOI 10.3109/00016487709128805
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128
   Mullol J, 1985, J APPL PHYSIOL, V73, P2069
   NAGAI M, 1983, ARCH OTO-RHINO-LARYN, V238, P115, DOI 10.1007/BF00454302
   Nakamura Y, 2014, J IMMUNOL RES, DOI 10.1155/2014/474217
   Nakamura Y, 2011, J ALLERGY CLIN IMMUN, V127, P1038, DOI 10.1016/j.jaci.2011.02.006
   Nakaya M, 2002, ANN OTO RHINOL LARYN, V111, P593, DOI 10.1177/000348940211100705
   Paschos GK, 2010, CIRC RES, V106, P833, DOI 10.1161/CIRCRESAHA.109.211706
   PASSALI D, 1988, ACTA OTO-LARYNGOL, V106, P281, DOI 10.3109/00016488809106437
   REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5
   RIECHELMANN H, 1994, EUR ARCH OTO-RHINO-L, V251, P210, DOI 10.1007/BF00628425
   Roithymann R, 2005, EFFECTS POSTURE CHAN, V71, P478
   Rosbash M, 2007, COLD SPRING HARB SYM, V72, P75, DOI 10.1101/sqb.2007.72.062
   Rudic RD, 2009, CIRCULATION, V120, P1714, DOI 10.1161/CIRCULATIONAHA.109.853002
   Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039
   Sandu C, 2015, CELL MOL LIFE SCI, V72, P2237, DOI 10.1007/s00018-014-1809-7
   Saroha D, 2003, CLIN OTOLARYNGOL, V28, P142, DOI 10.1046/j.1365-2273.2003.00679.x
   Sen H, 1901, LANCET, V2, P564
   Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013
   Siepka SM, 2007, COLD SPRING HARB SYM, V72, P251, DOI 10.1101/sqb.2007.72.052
   SMOLENSKY MH, 1995, J ALLERGY CLIN IMMUN, V95, P1084, DOI 10.1016/S0091-6749(95)70212-1
   Smolensky MH, 2007, ADV DRUG DELIVER REV, V59, P852, DOI 10.1016/j.addr.2007.08.016
   Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490
   STOKSTED P, 1953, Acta Otolaryngol Suppl, V109, P159
   Sundar IK, 2015, SCI REP-UK, V5, DOI 10.1038/srep09927
   Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430
   Takita E, 2013, BRIT J DERMATOL, V168, P39, DOI 10.1111/j.1365-2133.2012.11176.x
   Watanabe M, 2012, BIOCHEM BIOPH RES CO, V425, P902, DOI 10.1016/j.bbrc.2012.08.008
   Xie ZW, 2015, J CLIN INVEST, V125, P324, DOI 10.1172/JCI76881
   Yagita K, 2000, GENE DEV, V14, P1353
   Yao HW, 2015, AM J RESP CELL MOL, V53, P782, DOI 10.1165/rcmb.2014-0474OC
   Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101
   Zanello SB, 2000, J INVEST DERMATOL, V115, P757, DOI 10.1046/j.1523-1747.2000.00121.x
   Zhang YJ, 2009, J PHARMACEUT BIOMED, V50, P823, DOI 10.1016/j.jpba.2009.06.043
   Zuber AM, 2009, P NATL ACAD SCI USA, V106, P16523, DOI 10.1073/pnas.0904890106
   Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4
NR 71
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 13
PY 2018
VL 13
IS 3
AR e0194018
DI 10.1371/journal.pone.0194018
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ0JA
UT WOS:000427253500018
PM 29534090
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Schmidt, KE
   Kuepper, JM
   Schumak, B
   Alferink, J
   Hofmann, A
   Howland, SW
   Renia, L
   Limmer, A
   Specht, S
   Hoerauf, A
AF Schmidt, Kim E.
   Kuepper, Janina M.
   Schumak, Beatrix
   Alferink, Judith
   Hofmann, Andrea
   Howland, Shanshan W.
   Renia, Laurent
   Limmer, Andreas
   Specht, Sabine
   Hoerauf, Achim
TI Doxycycline inhibits experimental cerebral malaria by reducing
   inflammatory immune reactions and tissue-degrading mediators
SO PLOS ONE
LA English
DT Article
ID T-CELLS; DENDRITIC CELLS; MATRIX METALLOPROTEINASES; PLASMODIUM
   INFECTION; GRANZYME-B; PATHOGENESIS; EXPRESSION; BRAIN; ADHESION; MICE
AB Malaria ranks among the most important infectious diseases worldwide and affects mostly people living in tropical countries. Mechanisms involved in disease progression are still not fully understood and specific treatments that might interfere with cerebral malaria (CM) are limited. Here we show that administration of doxycycline (DOX) prevented experimental CM (ECM) in Plasmodium berghei ANKA (PbA)-infected C57BL/6 wildtype (WT) mice in an IL-10-independent manner. DOX-treated mice showed an intact blood-brain barrier (BBB) and attenuated brain inflammation. Importantly, if WT mice were infected with a 20-fold increased parasite load, they could be still protected from ECM if they received DOX from day 4 +/- 6 post infection, despite similar parasitemia compared to control-infected mice that did not receive DOX and developed ECM. Infiltration of T cells and cytotoxic responses were reduced in brains of DOX-treated mice. Analysis of brain tissue by RNA-array revealed reduced expression of chemokines and tumour necrosis factor (TNF) in brains of DOX-treated mice. Furthermore, DOX-administration resulted in brains of the mice in reduced expression of matrix metalloproteinase 2 (MMP2) and granzyme B, which are both factors associated with ECM pathology. Systemic interferon gamma production was reduced and activated peripheral T cells accumulated in the spleen in DOX-treated mice. Our results suggest that DOX targeted inflammatory processes in the central nervous system (CNS) and prevented ECM by impaired brain access of effector T cells in addition to its anti-parasitic effect, thereby expanding the understanding of molecular events that underlie DOX-mediated therapeutic interventions.
C1 [Schmidt, Kim E.; Kuepper, Janina M.; Schumak, Beatrix; Hofmann, Andrea; Specht, Sabine; Hoerauf, Achim] Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany.
   [Alferink, Judith] Univ Hosp Muenster, Dept Psychiat & Psychotherapy, Munster, Germany.
   [Howland, Shanshan W.; Renia, Laurent] ASTAR, Singapore Immunol Network, Singapore, Singapore.
   [Limmer, Andreas] Univ Hosp Essen, Clin Anaesthesiol & Intens Care, Essen, Germany.
   [Limmer, Andreas] Univ Hosp Bonn, Inst Mol Med, Bonn, Germany.
   [Limmer, Andreas] Univ Hosp Bonn, Inst Expt Immunol, Bonn, Germany.
RP Schumak, B (reprint author), Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany.
EM bschumak@uni-bonn.de
RI ; Howland, Shanshan/I-2245-2014
OI Kuehlwein, Janina M./0000-0003-3648-2649; Howland,
   Shanshan/0000-0003-4794-1564
FU intramural funding (BONFOR program) of the Medical Faculty of the
   Friedrich-Wilhelms University Bonn; German Centre for Infection Research
   (Deutsches Zentrum fuer Infektionsforschung, DZIF); Singapore's Agency
   for Science, Technology and Research (A*STAR)
FX This work was financially supported by intramural funding (BONFOR
   program) of the Medical Faculty of the Friedrich-Wilhelms University
   Bonn to SS, BS and JK (www.ukb.unibonn.de/bonfor/) and also by the
   German Centre for Infection Research (Deutsches Zentrum fuer
   Infektionsforschung, DZIF, www.dzif.de). Part of this work was supported
   by an intramural grant from Singapore's Agency for Science, Technology
   and Research (A*STAR). BS and AH are members of the Bonn Excellence
   Cluster "Immunosensation" EXC1023.
CR Amante FH, 2007, AM J PATHOL, V171, P548, DOI 10.2353/ajpath.2007.061033
   Angulo I, 2002, CLIN DIAGN LAB IMMUN, V9, P1145, DOI 10.1128/CDLI9.6.1145-1152.2002
   [Anonymous], 2016, WORLD MAL REP 2016
   [Anonymous], 2010, GUID TREATM MAL
   Batty KT, 2007, ANTIMICROB AGENTS CH, V51, P4477, DOI 10.1128/AAC.00529-07
   Bauer PR, 2002, MICROCIRCULATION, V9, P463, DOI 10.1038/sj.mn.7899159
   Belnoue E, 2003, BLOOD, V101, P4253, DOI 10.1182/blood-2002-05-1493
   Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133
   Castro JEZ, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/370872
   Chang WL, 2003, INFECT IMMUN, V71, P1911, DOI 10.1128/IAI.71.4.1911-1918.2003
   Costa GD, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/3694714
   Crawford A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002098
   Curtsinger JM, 2005, J IMMUNOL, V175, P4392, DOI 10.4049/jimmunol.175.7.4392
   D'Orlando O, 2013, EUR J IMMUNOL, V43, P194, DOI 10.1002/eji.201142343
   Dahl EL, 2006, ANTIMICROB AGENTS CH, V50, P3124, DOI 10.1128/AAC.00394-06
   de Souza JB, 2010, PARASITOLOGY, V137, P755, DOI 10.1017/S0031182009991715
   Draper MP, 2013, ANTIMICROB AGENTS CH
   Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128
   Enose-Akahata Y, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-16
   Geurts N, 2012, PHARMACOL THERAPEUT, V133, P257, DOI 10.1016/j.pharmthera.2011.11.008
   Gu Y, 2010, FEMS IMMUNOL MED MIC, V58, P218, DOI 10.1111/j.1574-695X.2009.00625.x
   Guermonprez P, 2013, NAT MED, V19, P730, DOI 10.1038/nm.3197
   Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717
   Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955
   Hirako IC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13277
   Howland SW, 2013, EMBO MOL MED, V5, P984, DOI 10.1002/emmm.201202273
   Howland SW, 2015, SEMIN IMMUNOPATHOL
   Huang XQ, 2014, INT IMMUNOPHARMACOL, V22, P266, DOI 10.1016/j.intimp.2014.07.001
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kossodo S, 1997, IMMUNOLOGY, V91, P536, DOI 10.1046/j.1365-2567.1997.00290.x
   Krakauer T, 2003, ANTIMICROB AGENTS CH, V47, P3630, DOI 10.1128/AAC.47.11.3630-3633.2003
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P
   Li X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074108
   Lindeman JHN, 2009, CIRCULATION, V119, P2209, DOI 10.1161/CIRCULATIONAHA.108.806505
   Lundie RJ, 2008, P NATL ACAD SCI USA, V105, P14509, DOI 10.1073/pnas.0806727105
   Mairuae N, 2011, NEUROSCI LETT, V500, P36, DOI 10.1016/j.neulet.2011.06.001
   McQuillan JA, 2011, INT J PARASITOL, V41, P155, DOI 10.1016/j.ijpara.2010.08.003
   Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669
   Miranda AS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-388
   Miu J, 2008, J IMMUNOL, V180, P1217, DOI 10.4049/jimmunol.180.2.1217
   Nie CQ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000369
   Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221
   Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851
   Piva L, 2012, J IMMUNOL, V189, P1128, DOI 10.4049/jimmunol.1201171
   Potter S, 2006, INT J PARASITOL, V36, P485, DOI 10.1016/j.ijpara.2005.12.005
   Prall AK, 2002, J VASC SURG, V35, P923, DOI 10.1067/mva.2002.123757
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   Ramos TN, 2013, J BIOL CHEM, V288, P10962, DOI 10.1074/jbc.C113.457028
   Randall LM, 2010, EXP PARASITOL, V126, P326, DOI 10.1016/j.exppara.2010.04.016
   Renia L, 2006, INT J PARASITOL, V36, P547, DOI 10.1016/j.ijpara.2006.02.007
   Riley EM, 2010, TRENDS PARASITOL, V26, P277, DOI 10.1016/j.pt.2010.03.002
   Sarto BY, 2004, ANN TROP MED PARASIT, V98, P297, DOI 10.1179/000349804225003271
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Shaw TN, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005210
   SMITH JR, 1994, INFLAMMATION, V18, P193, DOI 10.1007/BF01534560
   Stevenson MM, 2006, PARASITE IMMUNOL, V28, P5, DOI 10.1111/j.1365-3024.2006.00772.x
   Takata F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-106
   Tan KR, 2011, AM J TROP MED HYG, V84, P517, DOI 10.4269/ajtmh.2011.10-0285
   Tauber S C, 2008, Curr Mol Pharmacol, V1, P68
   Van den Steen PE, 2006, LAB INVEST, V86, P873, DOI 10.1038/labinvest.3700454
   van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002
   Wang JX, 2008, BRIT J PHARMACOL, V153, P1303, DOI 10.1038/bjp.2008.11
   Wang ZH, 2012, J MOL NEUROSCI, V47, P89, DOI 10.1007/s12031-011-9689-x
   White NJ, 2010, TRENDS PARASITOL, V26, P11, DOI 10.1016/j.pt.2009.10.007
   Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602
   World Health Organization, 2015, GUID TREATM MAL
   Yang YN, 2012, OPHTHALMIC RES, V48, P165, DOI 10.1159/000338819
   Yang Z, 2012, CURR MED CHEM, V19, P4541, DOI 10.2174/092986712803251575
NR 68
TC 2
Z9 2
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 13
PY 2018
VL 13
IS 2
AR e0192717
DI 10.1371/journal.pone.0192717
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FW1TV
UT WOS:000425083400047
PM 29438386
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wagner, N
   Dieteren, S
   Franz, N
   Kohler, K
   Mors, K
   Nicin, L
   Schmidt, J
   Perl, M
   Marzi, I
   Relja, B
AF Wagner, Nils
   Dieteren, Scott
   Franz, Niklas
   Koehler, Kernt
   Moers, Katharina
   Nicin, Luka
   Schmidt, Julia
   Perl, Mario
   Marzi, Ingo
   Relja, Borna
TI Ethyl pyruvate ameliorates hepatic injury following blunt chest trauma
   and hemorrhagic shock by reducing local inflammation, NF-kappaB
   activation and HMGB1 release
SO PLOS ONE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; SODIUM PYRUVATE; LIVER-INJURY; BASE
   DEFICIT; SYSTEMIC INFLAMMATION; OXIDATIVE STRESS; TERMINAL KINASE;
   IN-VITRO; RESUSCITATION; RESPONSES
AB Background
   The treatment of patients with multiple trauma including blunt chest/thoracic trauma (TxT) and hemorrhagic shock (H) is still challenging. Numerous studies show detrimental consequences of TxT and HS resulting in strong inflammatory changes, organ injury and mortality. Additionally, the reperfusion (R) phase plays a key role in triggering inflammation and worsening outcome. Ethyl pyruvate (EP), a stable lipophilic ester, has anti-inflammatory properties. Here, the influence of EP on the inflammatory reaction and liver injury in a double hit model of TxT and H/R in rats was explored.
   Methods
   Female Lewis rats were subjected to TxT followed by hemorrhage/H (60 min, 35 +/- 3mm Hg) and resuscitation/R (TxT+H/R). Reperfusion was performed by either Ringer's lactated solution (RL) alone or RL supplemented with EP (50 mg/kg). Sham animals underwent all surgical procedures without TxT+H/R. After 2h, blood and liver tissue were collected for analyses, and survival was assessed after 24h.
   Results
   Resuscitation with EP significantly improved haemoglobin levels and base excess recovery compared with controls after TxT+H/R, respectively (p<0.05). TxT+H/R-induced significant increase in alanine aminotransferase levels and liver injury were attenuated by EP compared with controls (p<0.05). Local inflammation as shown by increased gene expression of IL-6 and ICAM-1, enhanced ICAM-1 and HMGB1 protein expression and infiltration of the liver with neutrophils were also significantly attenuated by EP compared with controls after TxT+H/R (p<0.05). EP significantly reduced TxT+H/R-induced p65 activation in liver tissue. Survival rates improved by EP from 50% to 70% after TxT+H/R.
   Conclusions
   These data support the concept that the pronounced local pro-inflammatory response in the liver after blunt chest trauma and hemorrhagic shock is associated with NF-kappa B. In particular, the beneficial anti-inflammatory effects of ethyl pyruvate seem to be regulated by the HMGB1/NF-kappa B axis in the liver, thereby, restraining inflammatory responses and liver injury after double hit trauma in the rat.
C1 [Wagner, Nils; Dieteren, Scott; Franz, Niklas; Moers, Katharina; Nicin, Luka; Schmidt, Julia; Marzi, Ingo; Relja, Borna] Goethe Univ, Univ Hosp Frankfurt, Dept Trauma Surg, Frankfurt, Germany.
   [Koehler, Kernt] Justus Liebig Univ Giessen, Inst Vet Pathol, Giessen, Germany.
   [Perl, Mario] BG Trauma Ctr Murnau, Murnau, Germany.
RP Relja, B (reprint author), Goethe Univ, Univ Hosp Frankfurt, Dept Trauma Surg, Frankfurt, Germany.
EM info@bornarelja.com
RI Relja, Borna/B-6642-2016
OI Relja, Borna/0000-0002-5625-8823
FU DFG [RE 3304/5-1, PE 908/3-1]
FX This work was supported by DFG RE 3304/5-1 and PE 908/3-1. We thank
   Katrin Jurida, Kerstin Kontradowitz and Alexander Schaible for
   outstanding technical assistance. Grant support: The work was supported
   by grants from the DFG RE 3304/5-1 and PE 908/3-1.
CR Abt R, 2009, EUR J TRAUMA EMERG S, V35, P429, DOI 10.1007/s00068-009-8245-7
   Bennett-Guerrero E, 2009, J CARDIOTHOR VASC AN, V23, P324, DOI 10.1053/j.jvca.2008.08.005
   Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2
   DAVIS JW, 1988, J TRAUMA, V28, P1464, DOI 10.1097/00005373-198810000-00010
   Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001
   Dong WH, 2010, SHOCK, V34, P205, DOI 10.1097/SHK.0b013e3181cc0c63
   Esmer E, 2016, PREHOSPITAL ASSESSME
   Fang R, 2016, ACTA NEUROCHIR, V158, P1069, DOI 10.1007/s00701-016-2795-3
   Fink MP, 2008, CURR OPIN ANESTHESIO, V21, P160, DOI 10.1097/ACO.0b013e3282f63c2e
   Han YS, 2005, J PHARMACOL EXP THER, V312, P1097, DOI 10.1124/jpet.104.079707
   Hauser B, 2005, CRIT CARE MED, V33, P2034, DOI 10.1097/01.CCM.0000178177.03979.CE
   Hietbrink F, 2006, World J Emerg Surg, V1, P15, DOI 10.1186/1749-7922-1-15
   Horst K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154788
   Huber-Lang M, 2016, SEMIN IMMUNOL, V28, P278, DOI 10.1016/j.smim.2016.04.005
   Kao KK, 2010, BIOCHEM PHARMACOL, V80, P151, DOI 10.1016/j.bcp.2010.03.007
   Kao RLC, 2014, J INFLAMM-LOND, V11, DOI 10.1186/s12950-014-0030-7
   Karmaniolou II, 2013, J ANESTH, V27, P447, DOI 10.1007/s00540-012-1543-y
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lehnert M, 2008, SHOCK, V30, P159, DOI 10.1097/SHK.0b013e31815dd623
   Levy RM, 2007, AM J PHYSIOL-REG I, V293, pR1538, DOI 10.1152/ajpregu.00272.2007
   Liang Y, 2004, CELL MOL IMMUNOL, V1, P343
   Liener UC, 2003, SHOCK, V20, P511, DOI 10.1097/01.shk.0000095057.62263.fb
   Luan ZG, 2012, PANCREAS, V41, P729, DOI 10.1097/MPA.0b013e31823cd3ef
   Maier M, 2009, EUR J TRAUMA EMERG S, V35, P463, DOI 10.1007/s00068-009-9123-z
   Mongan PD, 1999, AM J PHYSIOL-HEART C, V277, pH2253
   Mulier KE, 2005, SHOCK, V23, P248, DOI 10.1097/01.shk.0000153353.58341.ff
   Mutschler M, 2013, CRIT CARE, V17, DOI 10.1186/cc12555
   Partrick D A, 1996, New Horiz, V4, P194
   Pierce A, 2014, CURR OPIN ANESTHESIO, V27, P246, DOI 10.1097/ACO.0000000000000047
   Polito F, 2016, INT J IMMUNOPATH PH, V29, P504, DOI 10.1177/0394632016656187
   Pulathan Z, 2014, BIOMED RES INT, DOI 10.1155/2014/857109
   Relja B, 2016, INT J MOL MED, V37, P517, DOI 10.3892/ijmm.2015.2431
   Relja B, 2012, OXID MED CELL LONGEV, DOI 10.1155/2012/983427
   Relja B, 2012, BRIT J PHARMACOL, V165, P1188, DOI 10.1111/j.1476-5381.2011.01595.x
   Relja B, 2012, EUR J NUTR, V51, P311, DOI 10.1007/s00394-011-0216-1
   Relja B, 2009, SHOCK, V32, P509, DOI 10.1097/SHK.0b013e3181a2530d
   Rixen D, 2005, CRIT CARE, V9, P441, DOI 10.1186/cc3526
   Rixen D, 2001, SHOCK, V15, P83, DOI 10.1097/00024382-200115020-00001
   Sakran JV, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-64
   SALAHUDEEN AK, 1991, J CLIN INVEST, V88, P1886, DOI 10.1172/JCI115511
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Seitz DH, 2008, SHOCK, V30, P537, DOI 10.1097/SHK.0b013e31816a394b
   Sharma P, 2010, SHOCK, V33, P532, DOI 10.1097/SHK.0b013e3181cc02b3
   Shen M., 2013, MEDIAT INFLAMM, V2013, DOI DOI 10.1155/2013/461536
   Shen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087977
   Sileri P, 2001, TRANSPLANTATION, V72, P27, DOI 10.1097/00007890-200107150-00008
   Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003
   Slovin PN, 2001, RESUSCITATION, V50, P109, DOI 10.1016/S0300-9572(01)00325-2
   Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tsung A, 2005, TRANSPLANTATION, V79, P196, DOI 10.1097/01.TP.0000151681.07474.2E
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   Worlein JM, 2011, AM J PRIMATOL, V73, P98
   Wutzler S, 2013, CHIRURG, V84, P753, DOI 10.1007/s00104-013-2477-0
   Yang RK, 2003, J LAB CLIN MED, V142, P322, DOI 10.1016/S0022-2143(03)00138-0
   Yang RK, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0144-1
   Yang RK, 2009, J SURG RES, V153, P302, DOI 10.1016/j.jss.2008.04.004
   Yu YF, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2607-5
   Zeng JY, 2007, ANESTHESIOLOGY, V107, P630, DOI 10.1097/01.anes.0000281898.01966.1e
   Zhang M, 2017, CLIN RES HEPATOLOGY
NR 60
TC 3
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 8
PY 2018
VL 13
IS 2
AR e0192171
DI 10.1371/journal.pone.0192171
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FV4BG
UT WOS:000424517900045
PM 29420582
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Buren, C
   Logters, T
   Oezel, L
   Rommelfanger, G
   Scholz, AO
   Windolf, J
   Windolf, CD
AF Bueren, Carina
   Loegters, Tim
   Oezel, Lisa
   Rommelfanger, Golnessa
   Scholz, Armin Olaf
   Windolf, Joachim
   Windolf, Ceylan Daniela
TI Effect of hyperbaric oxygen therapy (HBO) on implant-associated osteitis
   in a femur fracture model in mice
SO PLOS ONE
LA English
DT Article
ID EXPERIMENTAL STAPHYLOCOCCAL OSTEOMYELITIS; IMMUNE EVASION; AUREUS;
   DIAGNOSIS; BIOFILM
AB Hyperbaric oxygen therapy (HBO) is applied very successfully in treatment of various diseases such as chronic wounds. It has been already suggested as adjunctive treatment option for osteitis by immune- and fracture modulating effects. This study evaluates the importance of HBO in an early implant-associated localized osteitis caused by Staphylococcus aureus (SA) compared to the standard therapy. In a standardized murine model the left femur of 120 BALB/c mice were osteotomized and fixed by a titanium locking plate. Osteitis has been induced with a defined amount of SA into the fracture gap. Debridement and lavages were progressed on day 7, 14, 28 and 56 to determine the local bacterial growth and the immune reaction. Hyperbaric oxygen (2 ATA, 90%) was applied for 90 minutes on day 7 to 21 for those mice allocated to HBO therapy. To evaluate the effect of HBO therapy the following groups were analyzed: Two sham-groups (12 mice / group) with and without HBO therapy, two osteotomy groups (24 mice / group) with plate osteosynthesis of the femur with and without HBO therapy, and two osteotomy SA infection groups (24 mice / group) with and without HBO therapy. Fracture healing was also quantified on day 7, 14, 28 and 56 by a.p. x-ray and bone healing markers from blood samples. Progression of infection was assessed by estimation of colony-forming units (CFU) and immune response was analyzed by determination of polymorphonuclear neutrophils (PMN), Interleukin (IL) - 6, and the circulating free DNA (cfDNA) in lavage samples. Osteitis induced significantly higher IL-6, cfDNA- and PMN-levels in the lavage samples (on day 7 and 14, each p < 0.05). HBO-therapy did not have a significant influence on the CFU and immune response compared to the standard therapy (each p > 0.05). At the same time HBO-therapy was associated with a delayed bone healing assessed by x-ray radiography and a higher rate of non-union until day 28. In conclusion, osteitis led to significantly higher bacterial count and infection parameters. HBO-therapy neither had a beneficial influence on local infection nor on immune response or fracture healing compared to the standard therapy in an osteitis mouse model.
C1 [Bueren, Carina; Loegters, Tim; Oezel, Lisa; Rommelfanger, Golnessa; Scholz, Armin Olaf; Windolf, Joachim; Windolf, Ceylan Daniela] Heinrich Heine Univ, Med Fac, Dept Trauma & Hand Surg, Dusseldorf Moorenstr 5, Dusseldorf, Germany.
   [Loegters, Tim] St Antonius Hosp Cologne, Dept Trauma Hand & Orthoped Surg, Schillerstr 23, Cologne, Germany.
RP Buren, C (reprint author), Heinrich Heine Univ, Med Fac, Dept Trauma & Hand Surg, Dusseldorf Moorenstr 5, Dusseldorf, Germany.
EM carina.bueren@med.uni-duesseldorf.de
FU AO Foundation [S-15-123L]
FX Project no. S-15-123L was supported by the AO Foundation to TL. The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abdulrazak A, 2005, J DIABETES COMPLICAT, V19, P138, DOI 10.1016/j.jdiacomp.2004.06.001
   Benito D, 2014, FOODBORNE PATHOG DIS, V11, P354, DOI 10.1089/fpd.2013.1689
   Birt MC, 2017, J ORTHOP, V14, P45, DOI 10.1016/j.jor.2016.10.004
   Frommelt L, 2004, ORTHOPADE, V33, P822, DOI 10.1007/s00132-004-0677-5
   Garzoni C, 2011, EMBO MOL MED, V3, P115, DOI 10.1002/emmm.201100123
   Gotz F, 2002, MOL MICROBIOL, V43, P1367, DOI 10.1046/j.1365-2958.2002.02827.x
   HAMBLEN DL, 1968, J BONE JOINT SURG AM, VA 50, P1129, DOI 10.2106/00004623-196850060-00004
   Hatzenbuehler J, 2011, AM FAM PHYSICIAN, V84, P1027
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jacqueline C, 2014, J ANTIMICROB CHEMOTH, V69, P37, DOI 10.1093/jac/dku254
   Jorgensen NP, 2017, MICROORGANISMS, V5, DOI 10.3390/microorganisms5020021
   Kawada S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072603
   Kendall AC, 2013, WOUND REPAIR REGEN, V21, P860, DOI 10.1111/wrr.12108
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lipsky B, 2010, AM COLL PHYS MED 7, VXVI, P1
   Liu CI, 2008, SCIENCE, V319, P1391, DOI 10.1126/science.1153018
   Ma YB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047255
   MADER JT, 1978, J INFECT DIS, V138, P312, DOI 10.1093/infdis/138.3.312
   MADER JT, 1980, J INFECT DIS, V142, P915, DOI 10.1093/infdis/142.6.915
   Margraf S, 2008, SHOCK, V30, P352, DOI 10.1097/SHK.0b013e31816a6bb1
   Mendel V, 2004, UNDERSEA HYPERBAR M, V31, P407
   Mendel V, 1999, UNDERSEA HYPERBAR M, V26, P169
   Meng W, 2012, CRIT CARE, V16, DOI 10.1186/cc11442
   Schierholz JM, 2001, J HOSP INFECT, V49, P87, DOI 10.1053/jhin.2001.1052
   Schmidt HGK, 2011, Z ORTHOP UNFALLCHIR, V149, P449, DOI 10.1055/s-0030-1270970
   Shandley S, 2012, J ORTHOP RES, V30, P203, DOI 10.1002/jor.21522
   Takao K, 2015, P NATL ACAD SCI USA, V112, P1167, DOI 10.1073/pnas.1401965111
   Tiemann AH, 2012, UNFALLCHIRURG, V115, P480, DOI 10.1007/s00113-012-2187-y
   Tiemann AH, 2011, PATHOLOGE, V32, P200, DOI 10.1007/s00292-011-1417-3
   Wagner C, 2003, SHOCK, V20, P503, DOI 10.1097/01.shk.0000093542.78705.e3
   Walter G, 2012, DTSCH ARZTEBL INT, V109, P257, DOI [10.3238/arztebl.2012.0257, 10.3238/arztebl.012.0257]
   Windolf CD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115940
   Windolf CD, 2013, J ORTHOP RES, V31, P2013, DOI 10.1002/jor.22446
   Zhang QX, 2008, J INVEST DERMATOL, V128, P2102, DOI 10.1038/jid.2008.53
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2018
VL 13
IS 1
AR e0191594
DI 10.1371/journal.pone.0191594
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FU0AV
UT WOS:000423514700019
PM 29377928
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hooijmans, CR
   de Vries, RBM
   Ritskes-Hoitinga, M
   Rovers, MM
   Leeflang, MM
   IntHout, J
   Wever, KE
   Hooft, L
   de Beer, H
   Kuijpers, T
   Macleod, MR
   Sena, ES
   ter Riet, G
   Morgan, RL
   Thayer, KA
   Rooney, AA
   Guyatt, GH
   Schunemann, HJ
   Langendam, MW
AF Hooijmans, Carlijn R.
   de Vries, Rob B. M.
   Ritskes-Hoitinga, Merel
   Rovers, Maroeska M.
   Leeflang, Mariska M.
   IntHout, Joanna
   Wever, Kimberley E.
   Hooft, Lotty
   de Beer, Hans
   Kuijpers, Ton
   Macleod, Malcolm R.
   Sena, Emily S.
   ter Riet, Gerben
   Morgan, Rebecca L.
   Thayer, Kristina A.
   Rooney, Andrew A.
   Guyatt, Gordon H.
   Schunemann, Holger J.
   Langendam, Miranda W.
CA GRADE Working Grp
TI Facilitating healthcare decisions by assessing the certainty in the
   evidence from preclinical animal studies
SO PLOS ONE
LA English
DT Article
ID SYSTEMATIC REVIEWS; SEARCH FILTER; FINDINGS TABLES; GRADE; QUALITY;
   BIAS; RECOMMENDATIONS; METAANALYSES; STRENGTH; IMPROVE
AB Laboratory animal studies are used in a wide range of human health related research areas, such as basic biomedical research, drug research, experimental surgery and environmental health. The results of these studies can be used to inform decisions regarding clinical research in humans, for example the decision to proceed to clinical trials. If the research question relates to potential harms with no expectation of benefit (e.g., toxicology), studies in experimental animals may provide the only relevant or controlled data and directly inform clinical management decisions.
   Systematic reviews and meta-analyses are important tools to provide robust and informative evidence summaries of these animal studies. Rating how certain we are about the evidence could provide important information about the translational probability of findings in experimental animal studies to clinical practice and probably improve it. Evidence summaries and certainty in the evidence ratings could also be used (1) to support selection of interventions with best therapeutic potential to be tested in clinical trials, (2) to justify a regulatory decision limiting human exposure (to drug or toxin), or to (3) support decisions on the utility of further animal experiments. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach is the most widely used framework to rate the certainty in the evidence and strength of health care recommendations. Here we present how the GRADE approach could be used to rate the certainty in the evidence of preclinical animal studies in the context of therapeutic interventions. We also discuss the methodological challenges that we identified, and for which further work is needed. Examples are defining the importance of consistency within and across animal species and using GRADE's indirectness domain as a tool to predict translation from animal models to humans.
C1 [Hooijmans, Carlijn R.; de Vries, Rob B. M.; Ritskes-Hoitinga, Merel; Rovers, Maroeska M.; IntHout, Joanna; Wever, Kimberley E.] Radboud Univ Nijmegen, Dept Hlth Evidence, Systemat Review Ctr Lab Anim Experimentat SYRCLE, Med Ctr, Nijmegen, Netherlands.
   [Leeflang, Mariska M.; Langendam, Miranda W.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands.
   [Hooft, Lotty] Univ Med Ctr, Cochrane Netherlands, Utrecht, Netherlands.
   [de Beer, Hans] Guide2Guidance, Utrecht, Netherlands.
   [Kuijpers, Ton] Dutch Coll Gen Practitioners, Utrecht, Netherlands.
   [Macleod, Malcolm R.; Sena, Emily S.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.
   [ter Riet, Gerben] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, Amsterdam, Netherlands.
   [Morgan, Rebecca L.; Guyatt, Gordon H.; Schunemann, Holger J.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Morgan, Rebecca L.; Guyatt, Gordon H.; Schunemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Thayer, Kristina A.; Rooney, Andrew A.] NIEHS, Div Natl Toxicol Program, NIH, Dept Hlth & Human Serv, Washington, DC USA.
RP Langendam, MW (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands.
EM m.w.langendam@amc.uva.nl
RI Rovers, Maroeska M/F-2969-2014; IntHout, Joanna/A-1863-2016; Wever,
   Kimberley/D-9705-2016; Hooijmans, C.R./L-4390-2015
OI Rovers, Maroeska M/0000-0002-3095-170X; IntHout,
   Joanna/0000-0002-6127-0747; Wever, Kimberley/0000-0003-3635-3660;
   Hooijmans, C.R./0000-0001-6435-5714
FU National Centre for the Replacement, Refinement and Reduction of Animals
   in Research [NC/L000970/1]
CR Administration UFaD, DRUG DEV REV DEF
   Alonso-Coello P, BMJ IN PRESS
   Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Birnbaum LS, 2013, ENVIRON HEALTH PERSP, V121, pA108, DOI 10.1289/ehp.1306711
   de Vries RBM, 2015, EVIDENCE BASED PRECL, V2, DOI DOI 10.1002/EBM2.7
   de Vries RBM, 2014, LAB ANIM-UK, V48, P88, DOI 10.1177/0023677213494374
   de Vries RBM, 2011, LAB ANIM-UK, V45, P268, DOI 10.1258/la.2011.011056
   Festing Michael F W, 2002, ILAR J, V43, P244
   Guyatt G, 2013, J CLIN EPIDEMIOL, V66, P151, DOI 10.1016/j.jclinepi.2012.01.006
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012
   Henderson VC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001489
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Hooijmans CR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001482
   Hooijmans CR, 2009, NEUROBIOL DIS, V33, P482, DOI 10.1016/j.nbd.2008.12.002
   Hooijmans CR, 2014, ILAR J, V55, P418, DOI 10.1093/ilar/ilu042
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Hooijmans CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048811
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   Jansen SJ, 2014, EUR J CLIN INVEST, V44, P892, DOI 10.1111/eci.12299
   Johnson CD, 2005, GUT, V54, P1, DOI 10.1136/gut.200A.057026
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Korevaar DA, 2011, LAB ANIM-UK, V45, P225, DOI 10.1258/la.2011.010121
   Krauth D, 2013, ENVIRON HEALTH PERSP, V121, P985, DOI 10.1289/ehp.1206389
   Langendam M, 2016, J CLIN EPIDEMIOL, V74, P19, DOI 10.1016/j.jclinepi.2015.12.008
   Leenaars M, 2012, LAB ANIM-UK, V46, P24, DOI 10.1258/la.2011.011087
   Morgan RL, 2016, ENV INT
   NTP, 2015, HDB COND LIT BAS HLT
   NTP (National Toxicology Program), OHAT RISK BIAS T
   Rooney AA, 2014, ENV HLTH PERSPECTIVE
   Santesso N, 2016, J CLIN EPIDEMIOLOGY
   Schuenemann HJ, 2016, J CLIN EPID IN PRESS
   Schunemann HJ, 2003, CAN MED ASSOC J, V169, P677
   Schunemann HJ, 2011, COCHRANE HDB SYSTEMA
   Schunemann Holger J, 2012, Proc Am Thorac Soc, V9, P282, DOI 10.1513/pats.201208-064ST
   Schunemann HJ, 2012, Z EVIDENZ FORTBILD Q, V106, P153, DOI 10.1016/j.zefq.2012.04.001
   Sena ES, 2014, J CEREBR BLOOD F MET, V34, P737, DOI 10.1038/jcbfm.2014.28
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   ter Riet G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043404
   van Luijk J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089981
   Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010
   Wever KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142021
   Woodruff TJ, 2014, ENVIRON HEALTH PERSP, V122, P1007, DOI 10.1289/ehp.1307175
NR 56
TC 10
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 11
PY 2018
VL 13
IS 1
AR e0187271
DI 10.1371/journal.pone.0187271
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FS7BJ
UT WOS:000419952400003
PM 29324741
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Jung, H
   Jung, SM
   Rim, YA
   Park, N
   Nam, Y
   Lee, J
   Park, SH
   Ju, JH
AF Jung, Hyerin
   Jung, Seung Min
   Rim, Yeri Alice
   Park, Narae
   Nam, Yoojun
   Lee, Jennifer
   Park, Sung-Hwan
   Ju, Ji Hyeon
TI Arthritic role of Porphyromonas gingivalis in collagen-induced arthritis
   mice
SO PLOS ONE
LA English
DT Article
ID IMPROVING BIOSCIENCE RESEARCH; RHEUMATOID-ARTHRITIS; PEPTIDYLARGININE
   DEIMINASE; CITRULLINATED PROTEINS; ARRIVE GUIDELINES; BACTERIAL
   ADHESION; TUMOR-MARKERS; FIBRONECTIN; ASSOCIATION; ANTIBODIES
AB Epidemiological studies show an association between rheumatoid arthritis (RA) and periodontal disease. Porphyromonas gingivalis (P. gingivalis) is a well-known pathogen in periodontitis. This study investigated the pathogenic effects of P. gingivalis on autoimmune arthritis in vivo. Collagen-induced arthritis (CIA) mice were intraperitoneally injected with W83 and 2561 strains of P. gingivalis. Infection with P. gingivalis exacerbated arthritis score in CIA mice. Synovial inflammation and bone destruction in CIA mice infected with P. gingivalis were more severe than in uninfected CIA mice. Both W83 and 2561 strains were more pro-arthritic after arthritis symptom was fully activated. Interestingly, only W83 strain was arthritogenic before autoimmune reaction initiated. Citrullination was detected in synovial tissue of CIA mice and CIA mice inoculated with P. gingivalis, but not in normal control mice. The citrullinated area was greater in P. gingivalis-infected CIA mice than in non-infected CIA mice. This study showed that P. gingivalis exacerbated disease in a mouse model of autoimmune arthritis and increased the expression of citrullinated antigens in the synovium. The arthritogenic effects of P. gingivalis were at least in part, dependent upon the bacterial strain with or without fimbriae expression, route and time of infection. P. gingivalis-mediated citrullination may explain the possible link between periodontal disease and RA.
C1 [Jung, Hyerin; Rim, Yeri Alice; Park, Narae; Nam, Yoojun; Lee, Jennifer; Ju, Ji Hyeon] Catholic Univ Korea, Coll Med, Catholic iPSC Res Ctr, Seoul, South Korea.
   [Jung, Hyerin; Rim, Yeri Alice; Park, Narae; Nam, Yoojun; Lee, Jennifer; Park, Sung-Hwan; Ju, Ji Hyeon] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Rheumatol,Dept Internal Med, Seoul, South Korea.
   [Jung, Seung Min] Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea.
RP Ju, JH (reprint author), Catholic Univ Korea, Coll Med, Catholic iPSC Res Ctr, Seoul, South Korea.; Ju, JH (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Rheumatol,Dept Internal Med, Seoul, South Korea.
EM juji@catholic.ac.kr
OI Ju, Ji Hyeon/0000-0002-1381-5466
FU Korea Healthcare Technology R&D project, Ministry for Health, Welfare &
   Family Affairs, Republic of Korea [HI14C3417]; Advanced Production
   Technology Development Program, Ministry for Food, Agriculture, Forestry
   and Fisheries [312037-05]
FX This work was supported by a grant from the Korea Healthcare Technology
   R&D project, Ministry for Health, Welfare & Family Affairs, Republic of
   Korea (HI14C3417), and by a grant from the Advanced Production
   Technology Development Program, Ministry for Food, Agriculture, Forestry
   and Fisheries (312037-05).
CR Abdullah SN, 2013, ANAEROBE, V23, P102, DOI 10.1016/j.anaerobe.2013.07.001
   Arajo VMA, 2015, MEDIAT INFLAMM, DOI 10.1155/2015/259074
   Berne C, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MB-0018-2015
   Bingham CO, 2013, CURR OPIN RHEUMATOL, V25, P345, DOI 10.1097/BOR.0b013e32835fb8ec
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Chang X, 2005, RHEUMATOLOGY, V44, P1374, DOI 10.1093/rheumatology/kei023
   Chang XT, 2009, RHEUMATOL INT, V29, P1411, DOI 10.1007/s00296-009-0870-2
   Chang XT, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-40
   Cooper E. H., 1994, International Journal of Biological Markers, V9, P205
   de Aquino SG, 2014, J IMMUNOL, V192, P4103, DOI 10.4049/jimmunol.1301970
   Detert J, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3106
   Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795
   Dunne WM, 2002, CLIN MICROBIOL REV, V15, P155, DOI 10.1128/CMR.15.2.155-166.2002
   Ebina K, 2009, BIOCHEM BIOPH RES CO, V378, P186, DOI 10.1016/j.bbrc.2008.11.005
   Eriksson B, 2000, DIGESTION, V62, P33, DOI 10.1159/000051853
   Foulquier C, 2007, ARTHRITIS RHEUM-US, V56, P3541, DOI 10.1002/art.22983
   Fox DA, 2015, J IMMUNOL, V195, P5, DOI 10.4049/jimmunol.1501021
   Geng J, 2011, ADV EXP MED BIOL, V715, P315, DOI 10.1007/978-94-007-0940-9_20
   Ghosh A, 2008, INFECT IMMUN, V76, P5514, DOI 10.1128/IAI.00625-08
   Harre U, J CLIN INVESTIGATION, V122, P1791
   Huckel M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1869
   Imboden JB, 2009, ANNU REV PATHOL-MECH, V4, P417, DOI 10.1146/annurev.pathol.4.110807.092254
   Jansen LMA, 2003, J RHEUMATOL, V30, P1691
   Kesavalu L, 2007, INFECT IMMUN, V75, P1704, DOI 10.1128/IAI.00733-06
   Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010
   Kilkenny C, 2012, VET CLIN PATH, V41, P27, DOI 10.1111/j.1939-165X.2012.00418.x
   Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim Y, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.24
   Kinloch A, 2008, ARTHRITIS RHEUM, V58
   Koziel J, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0408-9
   LEDERMANN JA, 1994, EUR J CANCER, V30A, P574, DOI 10.1016/0959-8049(94)90519-3
   Li L, 2008, J AM CHEM SOC, V130, P1918, DOI 10.1021/ja0760877
   Ling S, 2013, ARTHRITIS RHEUM-US, V65, P618, DOI 10.1002/art.37814
   Lundberg K, 2008, ARTHRITIS RHEUM, V58, P3009, DOI 10.1002/art.23936
   Mangat P, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3000
   Marchesan JT, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4376
   Maresz KJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003627
   McGraw WT, 1999, INFECT IMMUN, V67, P3248
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Mikuls TR, 2014, ARTHRITIS RHEUMATOL, V66, P1090, DOI 10.1002/art.38348
   Moscarello MA, 2007, NEUROCHEM RES, V32, P251, DOI 10.1007/s11064-006-9144-5
   Nachat R, 2005, J INVEST DERMATOL, V124, P384, DOI 10.1111/j.0022-202X.2004.23568.x
   NIEDERMAN R, 1990, ARCH ORAL BIOL, V35, pS205, DOI 10.1016/0003-9969(90)90159-8
   NIKLINSKI J, 1995, EUR J CANCER PREV, V4, P129, DOI 10.1097/00008469-199504000-00002
   Okada M, 2013, J PERIODONTOL, V84, pE74, DOI 10.1902/jop.2013.130079
   Park N, 2017, SCI REP-UK, V7, DOI 10.1038/srep39593
   Persson G Rutger, 2012, J ORAL MICROBIOLOGY, V4
   Pischon N, 2008, J PERIODONTOL, V79, P979, DOI [10.1902/jop.2008.070501, 10.1902/jop.2008.070501 ]
   Rim YA, 2014, SCI REP-UK, V4, DOI 10.1038/srep06935
   Rivera MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057178
   Sanchez-Pernaute O, 2013, ANN RHEUM DIS, V72, P1400, DOI 10.1136/annrheumdis-2012-201906
   Sandal I, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1143-6
   Sato K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07196-7
   Sharma A, 1996, APPL ENVIRON MICROB, V62, P3933
   Szodoray P, 2010, AUTOIMMUN REV, V9, P140, DOI 10.1016/j.autrev.2009.04.006
   Totaro MC, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4243
   van Oss CJ, 2003, J MOL RECOGNIT, V16, P177, DOI 10.1002/jmr.618
   Velsko IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097811
   Voskuyl AE, 1998, CLIN EXP RHEUMATOL, V16, P429
   Vossenaar ER, 2003, ARTHRITIS RHEUM-US, V48, P2489, DOI 10.1002/art.11229
   Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357
   Vossenaar ER, 2004, ANN RHEUM DIS, V63, P373, DOI 10.1136/ard.2003.012211
   Wegner N, 2010, ARTHRITIS RHEUM-US, V62, P2662, DOI 10.1002/art.27552
   Wegner N, 2010, IMMUNOL REV, V233, P34, DOI 10.1111/j.0105-2896.2009.00850.x
   Wruck CJ, 2011, ANN RHEUM DIS, V70, P844, DOI 10.1136/ard.2010.132720
   Yamada R, 2005, FRONT BIOSCI, V10, P54, DOI 10.2741/1506
   Yu JJ, 2008, INFECT IMMUN, V76, P4206, DOI 10.1128/IAI.01209-07
NR 68
TC 4
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2017
VL 12
IS 11
AR e0188698
DI 10.1371/journal.pone.0188698
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FO4UI
UT WOS:000416841900103
PM 29190705
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lopez, G
   Braggio, D
   Zewdu, A
   Casadei, L
   Batte, K
   Bid, HK
   Koller, D
   Yu, P
   Iwenofu, OH
   Strohecker, A
   Choy, E
   Lev, D
   Pollock, R
AF Lopez, Gonzalo
   Braggio, Danielle
   Zewdu, Abeba
   Casadei, Lucia
   Batte, Kara
   Bid, Hemant Kumar
   Koller, David
   Yu, Peter
   Iwenofu, Obiajulu Hans
   Strohecker, Anne
   Choy, Edwin
   Lev, Dina
   Pollock, Raphael
TI Mocetinostat combined with gemcitabine for the treatment of
   leiomyosarcoma: Preclinical correlates
SO PLOS ONE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; ACTIVITY IN-VITRO; PANCREATIC-CANCER;
   HDAC INHIBITOR; TRICHOSTATIN-A; CELL-GROWTH; CHEMOTHERAPY; RESISTANT;
   MGCD0103; VORINOSTAT
AB Leiomyosarcoma (LMS) is a malignant soft tissue sarcoma (STS) with a dismal prognosis following metastatic disease. Chemotherapeutic intervention has demonstrated to have modest clinical efficacy with no curative potential in LMS patients. Previously, we demonstrated pan-HDAC inhibition to have a superior effect in various complex karyotypic sarcomas. In this study, our goal is to evaluate the therapeutic efficacy of mocetinostat alone and in combination with gemcitabine in LMS. Human leiomyosarcoma (LMS) cell lines were used for in vitro and in vivo studies. Compounds tested included the class I HDAC inhibitor, mocetinostat, and nucleoside analog, gemcitabine. MTS and clonogenic assays were used to evaluate the effect of mocetinostat on LMS cell growth. Cleaved caspase 3/7 analysis was used to determine the effects of mocetinostat on apoptosis. Compusyn software was used to determine in vitro synergy studies for the combination of mocetinostat plus gemcitabine. A LMS xenograft model in SCID mice was used to test the impact of mocetinostat alone, gemcitabine alone and the combination of mocetinostat plus gemcitabine. Mocetinostat abrogated LMS cell growth and clonogenic potential, and enhanced apoptosis in LMS cell lines. The combination of mocetinostat plus gemcitabine exhibited a synergistic effect in LMS cells in vitro. Similarly, mocetinostat combined with gemcitabine resulted in superior anti-LMS effects in vivo. Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells. LMS are aggressive, metastatic tumors with poor prognosis where effective therapeutic interventions are wanting. Our studies demonstrate the potential utility of mocetinostat combined with gemcitabine for the treatment of LMS.
C1 [Lopez, Gonzalo; Braggio, Danielle; Zewdu, Abeba; Casadei, Lucia; Batte, Kara; Koller, David; Yu, Peter; Strohecker, Anne] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Bid, Hemant Kumar] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.
   [Iwenofu, Obiajulu Hans] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
   [Choy, Edwin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.
   [Lev, Dina] Sheba Med Ctr, Surg B, Tel Aviv, Israel.
   [Pollock, Raphael] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA.
RP Pollock, R (reprint author), Ohio State Univ, Dept Surg, Columbus, OH 43210 USA.
EM raphael.pollock@osumc.edu
FU NIH SARC SPORE grant [U54CA168512]; National Leiomyosarcoma Foundation
   grant [GRT00041181/60052311]
FX This work was supported by NIH SARC SPORE grant (U54CA168512), funding
   recipient RP; and National Leiomyosarcoma Foundation grant
   (GRT00041181/60052311), funding recipient GL. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ammerpohl O, 2007, BRIT J CANCER, V96, P73, DOI 10.1038/sj.bjc.6603511
   Ansari D, 2014, ANTICANCER RES, V34, P5269
   Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155
   Boumber Y, 2011, EXPERT OPIN INV DRUG, V20, P823, DOI 10.1517/13543784.2011.577737
   Buggy JJ, 2006, MOL CANCER THER, V5, P1309, DOI 10.1158/1535-7163.MCT-05-0442
   Candelaria M, 2010, MED ONCOL, V27, P1133, DOI 10.1007/s12032-009-9349-y
   Candelaria M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029181
   Cen Y, 2011, CURR MED CHEM, V18, P1919, DOI 10.2174/092986711795590084
   Chatterjee S, 2016, GYNECOL ONCOL, V141, P51
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Donadelli M, 2007, BBA-MOL CELL RES, V1773, P1095, DOI 10.1016/j.bbamcr.2007.05.002
   Dovzhanskiy DI, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-226
   Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   HEINEMANN V, 1988, CANCER RES, V48, P4024
   Henderson SE, 2016, NEOPLASIA, V18, P765, DOI 10.1016/j.neo.2016.10.003
   Hensley ML, 2008, GYNECOL ONCOL, V109, P329, DOI 10.1016/j.ygyno.2008.03.0
   Hensley ML, 2002, J CLIN ONCOL, V20, P2824, DOI 10.1200/JCO.2002.11.050
   Hosokawa M, 2015, ONCOL LETT, V10, P761, DOI 10.3892/ol.2015.3253
   Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0
   Iwahashi S, 2011, INT J CLIN ONCOL, V16, P671, DOI 10.1007/s10147-011-0246-y
   Iwahashi S, 2011, ONCOL REP, V26, P1057, DOI 10.3892/or.2011.1407
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klein JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079502
   Lee HS, 2017, SCI REP-UK, V7, DOI 10.1038/srep41615
   Lee L, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S7262
   Look KY, 2004, GYNECOL ONCOL, V92, P644, DOI 10.1016/j.ygyno.2003.11.023
   Lopez G, 2011, CANCER RES, V71, P185, DOI 10.1158/0008-5472.CAN-10-2799
   Lopez G, 2009, CLIN CANCER RES, V15, P3472, DOI 10.1158/1078-0432.CCR-08-2714
   Merimsky O, 1998, EUR J CANCER, V34, P1296
   Pastor-Anglada M, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00013
   Piacentini P, 2006, VIRCHOWS ARCH, V448, P797, DOI 10.1007/s00428-006-0173-x
   Rundall BK, 2005, SURGERY, V138, P360, DOI 10.1016/j.surg.2005.06.016
   Sakamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145985
   Sampson ER, 2011, J ORTHOP RES, V29, P623, DOI 10.1002/jor.21274
   Samulitis BK, 2015, CANCER BIOL THER, V16, P43, DOI 10.4161/15384047.2014.986967
   Schniewind Bodo, 2006, J Carcinog, V5, P25, DOI 10.1186/1477-3163-5-25
   Seddon B, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569-015-0029-8
   Shang MJ, 2015, TUMOR BIOL, V36, P9015, DOI 10.1007/s13277-015-3537-5
   Siu LL, 2008, J CLIN ONCOL, V26, P1940, DOI 10.1200/JCO.2007.14.5730
   Sung V, 2011, CANCER SCI, V102, P1201, DOI 10.1111/j.1349-7006.2011.01921.x
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wang R, 2001, GENE CHROMOSOME CANC, V31, P54, DOI 10.1002/gcc.1118
   Wang ZJ, 2016, CANCER MED-US, V5, P3437, DOI 10.1002/cam4.956
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Xue K, 2016, J CANCER RES CLIN, V142, P379, DOI 10.1007/s00432-015-2026-y
NR 47
TC 0
Z9 1
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 29
PY 2017
VL 12
IS 11
AR e0188859
DI 10.1371/journal.pone.088859
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FO0ZL
UT WOS:000416484900067
PM 29186204
OA DOAJ Gold
DA 2019-07-07
ER

PT J
AU Wang, NN
   Guo, J
   Liu, FD
   Wang, MX
   Li, CT
   Jia, LH
   Zhai, LL
   Wei, W
   Bai, YL
AF Wang, Nannan
   Guo, Jie
   Liu, Fuding
   Wang, Mingxia
   Li, Chuntao
   Jia, Lihong
   Zhai, Lingling
   Wei, Wei
   Bai, Yinglong
TI Depot-specific inflammation with decreased expression of ATM2 in white
   adipose tissues induced by high-margarine/lard intake
SO PLOS ONE
LA English
DT Article
ID TRANS-FATTY-ACIDS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; DIET-INDUCED
   OBESE; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; METABOLIC DISEASE;
   CARDIOVASCULAR RISK; IMMUNE-SYSTEM; MEDIATED INFLAMMATION; FUNCTIONAL
   GENOMICS
AB A high-fat diet has been recognized as an important risk factor of obesity, with variable impacts of different fatty acid compositions on the physiological process. To understand the effects of a high-margarine/lard diet, which is a major source of trans fatty acids (TFAs)/saturated fatty acids (SFAs), elaidic acid as a biomarker of margarine intake was used to screen affected adipokines on mature human adipocytes in vitro. Weaned male Wistar rats were fed a high-fat diet enriched with margarine/lard to generate obesity-prone (OP) and obesity-resistant (OR) models, which were then used to explore the inflammatory responses of depot-specific white adipose tissue. Adiposity, glucose and lipid metabolism parameters and macrophage cell markers were also compared in vivo. In the subcutaneous depot, a high-margarine diet induced elevated IL-6, MCP-1 and XCL1 expression levels in both MOP and M-OR groups. High-lard diet-fed rats displayed higher protein expression levels of MCP-1 and XCL1 compared with the control group. In the epididymal depot, significantly elevated IL-6 production was observed in M-OP rats, and high-lard diet-fed rats displayed elevated IL-6 and decreased XCL1 expression. In the retroperitoneal depot, a high-margarine diet caused higher IL-6 and MCP-1 expression levels, a high-lard diet caused elevated IL-6 expression in L-OP/L-OR rats, and elevated XCL1 expression was observed only in LOP rats. In general, CD206 mRNA levels were notably down-regulated by high-fat diet feeding in the above-mentioned depots. CD11c mRNA levels were slightly upregulated in the subcutaneous depot of OP rats fed a high-margarine/lard diet. In the epidydimal depot, higher expression levels of F4/80 and CD206 mRNA were observed only in high-margarine diet-fed OP rats. These results suggest that depot-specific inflammation with decreased expression of adipose tissue anti-inflammatory M2-type (ATM2) macrophages could be induced by high-margarine/lard intake.
C1 [Wang, Nannan; Guo, Jie; Liu, Fuding; Wang, Mingxia; Jia, Lihong; Zhai, Lingling; Wei, Wei; Bai, Yinglong] China Med Univ, Sch Publ Hlth, Dept Child & Adolescent Hlth, Shenyang, Liaoning, Peoples R China.
   [Guo, Jie] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R China.
   [Liu, Fuding] Huangshi Cent Hosp, Dept Publ Hlth, Edong Healthcare Grp, Huangshi, Hubei, Peoples R China.
   [Li, Chuntao] China Med Univ, Informat Ctr, Hosp 1, Shenyang, Liaoning, Peoples R China.
RP Bai, YL (reprint author), China Med Univ, Sch Publ Hlth, Dept Child & Adolescent Hlth, Shenyang, Liaoning, Peoples R China.
EM ylbai@cmu.edu.cn
FU National Natural Science Foundation Committee of China [81373018,
   81172691]
FX The present study was supported by grants from the National Natural
   Science Foundation Committee of China (No 81373018 and 81172691).
CR Albersen M, 2013, SEX MED-UK, V1, P3, DOI 10.1002/sm2.1
   Austin GL, 2011, AM J CLIN NUTR, V93, P836, DOI 10.3945/ajcn.110.000141
   Bai Y, 2015, OBES REV, V16, P127, DOI 10.1111/obr.12242
   BELZUNG F, 1993, AM J PHYSIOL, V264, pR1111
   Bendsen NT, 2011, EUR J CLIN NUTR, V65, P773, DOI 10.1038/ejcn.2011.34
   Benoit B, 2013, NUTR RES, V33, P952, DOI 10.1016/j.nutres.2013.07.017
   Blogowski W, 2012, J BIOL REG HOMEOS AG, V26, P607
   Booth A, 2016, HORM MOL BIOL CLIN I, V26, P25, DOI 10.1515/hmbci-2015-0073
   Bost F, 2005, BIOCHIMIE, V87, P51, DOI 10.1016/j.biochi.2004.10.018
   Bueno AA, 2010, EUR J NUTR, V49, P235, DOI 10.1007/s00394-009-0069-z
   Buettner R, 2006, J MOL ENDOCRINOL, V36, P485, DOI 10.1677/jme.1.01909
   Buettner R, 2007, OBESITY, V15, P798, DOI 10.1038/oby.2007.608
   Cao HM, 2014, J ENDOCRINOL, V220, pT47, DOI 10.1530/JOE-13-0339
   Casas-Agustench P, 2009, CLIN NUTR, V28, P39, DOI 10.1016/j.clnu.2008.10.008
   Chacon MR, 2007, OBESITY, V15, P664, DOI 10.1038/oby.2007.578
   Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071
   Chu Y, 2010, ENDOCRINOLOGY, V151, P5669, DOI 10.1210/en.2010-0772
   Comstock IA, 2017, FERTIL STERIL, V107, P740, DOI [10.1016/j.fertnstert.2016.11.009, 10.1016/.fertnstert.2016.11.009]
   Dawczynski C, 2016, EXPERT REV CARDIOVAS, V14, P1001, DOI 10.1080/14779072.2016.1199956
   Ellander A, 2015, EUR J LIPID SCI TECH, V117, P1370, DOI 10.1002/ejlt.201400513
   Estadella D, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/137579
   Fenton JI, 2009, DIABETES OBES METAB, V11, P343, DOI 10.1111/j.1463-1326.2008.00974.x
   Fox JC, 2015, ACS CHEM BIOL, V10, P2580, DOI 10.1021/acschembio.5b00542
   Fu CP, 2012, CLIN CHIM ACTA, V413, P1647, DOI 10.1016/j.cca.2012.05.008
   Gao MM, 2013, PHARM RES-DORDR, V30, P2940, DOI 10.1007/s11095-013-1125-1
   Gayet-Boyer C, 2014, BRIT J NUTR, V112, P1914, DOI 10.1017/S0007114514002578
   Ghosh Sagar, 2013, Front Biosci (Elite Ed), V5, P461
   Giancarlo B, 1996, EUR J IMMUNOL, V26, P3238, DOI 10.1002/eji.1830261260
   Ginter E, 2016, BRATISL MED J, V117, P251, DOI 10.4149/BLL_2016_048
   Gomez-Hernandez A, 2013, CLIN INVEST ARTERIOS, V25, P27, DOI 10.1016/j.arteri.2012.11.003
   Harris HR, 2017, CANCER RES, V77, P1179, DOI 10.1158/0008-5472.CAN-16-2273
   Heilbronn LK, 2008, CURR PHARM DESIGN, V14, P1225, DOI 10.2174/138161208784246153
   Hodge AM, 2004, CANCER CAUSE CONTROL, V15, P11, DOI 10.1023/B:CACO.0000016568.25127.10
   Hooper L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011737
   Huang H, 2001, BIOCHEM BIOPH RES CO, V281, P378, DOI 10.1006/bbrc.2001.4363
   Hutcheson J, 2015, CYTOKINE, V75, P272, DOI 10.1016/j.cyto.2015.04.004
   Ibrahim MM, 2010, OBES REV, V11, P11, DOI 10.1111/j.1467-789X.2009.00623.x
   Jakobsen MU, 2009, AM J CLIN NUTR, V89, P1425, DOI 10.3945/ajcn.2008.27124
   Jen KLC, 2003, EXP BIOL MED, V228, P843, DOI 10.1177/15353702-0322807-10
   Jung C, 2009, PEDIATR DIABETES, V10, P329, DOI 10.1111/j.1399-5448.2008.00486.x
   Kalaitzidis RG, 2011, INT UROL NEPHROL, V43, P771, DOI 10.1007/s11255-011-9974-1
   Kang YE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154003
   KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732
   KENNEDY J, 1995, J IMMUNOL, V155, P203
   Khorramdelazad H, 2016, J NEUROIMMUNOL, V290, P70, DOI 10.1016/j.jneuroim.2015.11.021
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim D, 2014, DIABETOLOGIA, V57, P1456, DOI 10.1007/s00125-014-3237-5
   Kremmyda LS, 2011, BIOMED PAP, V155, P195, DOI 10.5507/bp.2011.052
   Lamacchia O, 2011, NEPHROL DIAL TRANSPL, V26, P892, DOI 10.1093/ndt/gfq522
   Lei Y, 2012, MICROBES INFECT, V14, P262, DOI 10.1016/j.micinf.2011.10.003
   Levin BE, 1999, AM J PHYSIOL-REG I, V276, pR382
   Li SY, 2008, OBESITY, V16, P811, DOI 10.1038/oby.2007.116
   Lichtenstein A H, 2000, J Cardiopulm Rehabil, V20, P143, DOI 10.1097/00008483-200005000-00001
   Lionetti L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092753
   Liu AD, 2015, BIOMED ENVIRON SCI, V28, P477, DOI 10.3967/bes2015.069
   Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132
   Luo MY, 2016, OBESITY, V24, P1244, DOI 10.1002/oby.21463
   Lytle LA, 2002, PUBLIC HEALTH NUTR, V5, P319, DOI [10.1079/PHN2002255, 10.1079/PHN2001255]
   MacLean PS, 2004, AM J PHYSIOL-REG I, V287, pR1306, DOI 10.1152/ajpregu.00463.2004
   Mansour SG, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0490-0
   Mayneris-Perxachs J, 2010, FOOD CHEM, V123, P296, DOI 10.1016/j.foodchem.2010.04.035
   Mertens E, 2017, NUTRIENTS, V9, DOI 10.3390/nu9010075
   Micha R, 2010, AM J CLIN NUTR, V91, P883, DOI 10.3945/ajcn.2009.28877
   Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035
   Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200
   Odegaard JI, 2013, IMMUNITY, V38, P644, DOI 10.1016/j.immuni.2013.04.001
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Ordway D, 2007, J LEUKOCYTE BIOL, V82, P1221, DOI 10.1189/jlb.0607426
   Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921
   Pande G, 2012, J FOOD SCI, V77, pC1203, DOI 10.1111/j.1750-3841.2012.02935.x
   Panee J, 2012, CYTOKINE, V60, P1, DOI 10.1016/j.cyto.2012.06.018
   de Heredia FP, 2012, P NUTR SOC, V71, P332, DOI 10.1017/S0029665112000092
   Perusse L, 2000, AM J CLIN NUTR, V72, p1285S, DOI 10.1093/ajcn/72.5.1285s
   Proenca ARG, 2014, BRAZ J MED BIOL RES, V47, P192, DOI 10.1590/1414-431X20132911
   Rehm CD, 2016, JAMA-J AM MED ASSOC, V315, P2542, DOI 10.1001/jama.2016.7491
   Rokholm B, 2010, OBES REV, V11, P835, DOI 10.1111/j.1467-789X.2010.00810.x
   Rokling-Andersen MH, 2009, BRIT J NUTR, V102, P995, DOI 10.1017/S0007114509353210
   Rumsaeng V, 1997, J IMMUNOL, V158, P1353
   Saadatian-Elahi M, 2009, AM J CLIN NUTR, V89, P331, DOI 10.3945/ajcn.2008.26834
   Sackmann-Sala L, 2012, OBESITY, V20, P101, DOI 10.1038/oby.2011.235
   Schipper HS, 2012, TRENDS ENDOCRIN MET, V23, P407, DOI 10.1016/j.tem.2012.05.011
   Sheng XL, 2007, WORLD J GASTROENTERO, V13, P5944, DOI 10.3748/wjg.v13.i44.5944
   Sindhu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133494
   Skeaff CM, 2006, BRIT J NUTR, V96, P377, DOI 10.1079/BJN20061737
   Skopkova M, 2007, OBESITY, V15, P2396, DOI 10.1038/oby.2007.285
   Stender S, 2006, NEW ENGL J MED, V354, P1650, DOI 10.1056/NEJMc052959
   Suburu Janel, 2013, Food Biosci, V4, P1
   Tang Wenjing, 2013, Wei Sheng Yan Jiu, V42, P571
   Tardy AL, 2011, NUTR RES REV, V24, P111, DOI 10.1017/S0954422411000011
   Tschop M, 2001, EXP CLIN ENDOCR DIAB, V109, P307, DOI 10.1055/s-2001-17297
   van den Berg SAA, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-24
   VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171
   Vaughan RA, 2015, LIPIDS, V50, P1115, DOI 10.1007/s11745-015-4072-2
   Wang QY, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000914
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Wensveen FM, 2015, EUR J IMMUNOL, V45, P2446, DOI 10.1002/eji.201545502
   Xu L, 2015, BIOMOLECULES, V5, P1563, DOI 10.3390/biom5031563
   Xu ZG, 2005, CIRCULATION, V111, P1962, DOI 10.1161/01.CIR.0000161831.07637.63
   Yamada M, 2010, J EPIDEMIOL, V20, P119, DOI 10.2188/jea.JE20090080
   YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O
   Zeyda M, 2007, IMMUNOL LETT, V112, P61, DOI 10.1016/j.imlet.2007.07.003
   Zong G, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5796
NR 104
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 15
PY 2017
VL 12
IS 11
AR e0188007
DI 10.1371/journal.pone.0188007
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FM7MC
UT WOS:000415260400043
PM 29141038
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Schimunek, L
   Serve, R
   Teuben, MPJ
   Stormann, P
   Auner, B
   Woschek, M
   Pfeifer, R
   Horst, K
   Simon, TP
   Kalbitz, M
   Sturm, R
   Pape, HC
   Hildebrand, F
   Marzi, I
   Relja, B
AF Schimunek, Lukas
   Serve, Rafael
   Teuben, Michel P. J.
   Stoermann, Philipp
   Auner, Birgit
   Woschek, Mathias
   Pfeifer, Roman
   Horst, Klemens
   Simon, Tim-P.
   Kalbitz, Miriam
   Sturm, Ramona
   Pape, Hans-C.
   Hildebrand, Frank
   Marzi, Ingo
   Relja, Borna
TI Early decreased TLR2 expression on monocytes is associated with their
   reduced phagocytic activity and impaired maturation in a porcine
   polytrauma model
SO PLOS ONE
LA English
DT Article
ID TOLL-LIKE RECEPTOR; STAPHYLOCOCCUS-AUREUS; STREPTOCOCCUS-SUIS; ZOONOTIC
   AGENT; DR EXPRESSION; SEVERE INJURY; CLASS-I; TRAUMA; CARE; SEPSIS
AB In their post-traumatic course, trauma patients suffering from multiple injuries have a high risk for immune dysregulation, which may contribute to post-injury complications and late mortality. Monocytes as specific effector cells of the innate immunity play a crucial role in inflammation. Using their Pattern Recognition Receptors (PRRs), notably Toll-Like Receptors (TLR), the monocytes recognize pathogens and/or pathogen-associated molecular patterns (PAMPs) and organize their clearance. TLR2 is the major receptor for particles of gram-positive bacteria, and initiates their phagocytosis. Here, we investigated the phagocytizing capability of monocytes in a long-term porcine severe trauma model (polytrauma, PT) with regard to their TLR2 expression. Polytrauma consisted of femur fracture, unilateral lung contusion, liver laceration, hemorrhagic shock with subsequent resuscitation and surgical fracture fixation. After induction of PT, peripheral blood was withdrawn before (-1 h) and directly after trauma (0 h), as well as 3.5 h, 5.5 h, 24 h and 72 h later. CD14(+) monocytes were identified and the expression levels of H(S) LA-DR and TLR2 were investigated by flow cytometry. Additionally, the phagocytizing activity of monocytes by applying S. aureus particles labelled with pHrodo fluorescent reagent was also assessed by flow cytometry. Furthermore, blood samples from 10 healthy pigs were exposed to a TLR2-neutralizing antibody and subsequently to S. aureus particles. Using flow cytometry, phagocytizing activity was determined. P below 0.05 was considered significant. The number of CD14(+) monocytes of all circulating leukocytes remained constant during the observational time period, while the percentage of CD14(+) H(S) LA-DR+ monocytes significantly decreased directly, 3.5 h and 5.5 h after trauma. The percentage of TLR2(+) expressing cells out of all monocytes significantly decreased directly, 3.5 h and 5.5 h after trauma. The percentage of phagocytizing monocytes decreased immediately and remained lower during the first 3.5 h after trauma, but increased after 24 h. Antagonizing TLR2 significantly decreased the phagocytizing activity of monocytes. Both, decreased percentage of activated as well as TLR2 expressing monocytes persisted as long as the reduced phagocytosis was observed. Moreover, neutralizing TLR2 led to a reduced capability of phagocytosis as well. Therefore, we assume that reduced TLR2 expression may be responsible for the decreased phagocytizing capacity of circulating monocytes in the early post-traumatic phase.
C1 [Schimunek, Lukas; Serve, Rafael; Stoermann, Philipp; Auner, Birgit; Woschek, Mathias; Sturm, Ramona; Marzi, Ingo; Relja, Borna] Goethe Univ, Univ Hosp Frankfurt, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany.
   [Teuben, Michel P. J.; Pfeifer, Roman; Pape, Hans-C.] Univ Zurich, Univ Hosp Zurich, Dept Orthopaed Trauma Surg, Zurich, Switzerland.
   [Horst, Klemens; Hildebrand, Frank] Rhein Westfal TH Aachen, Dept Orthopaed Trauma, Aachen, Germany.
   [Simon, Tim-P.] Rhein Westfal TH Aachen, Dept Intens Care & Intermediate Care, Aachen, Germany.
   [Kalbitz, Miriam] Univ Ulm, Dept Orthoped Trauma Hand Plast & Reconstruct Sur, Ulm, Germany.
RP Relja, B (reprint author), Goethe Univ, Univ Hosp Frankfurt, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany.
EM info@bornarelja.com
RI Relja, Borna/B-6642-2016
OI Relja, Borna/0000-0002-5625-8823
FU Arbeitsgemeinschaft fur Osteosynthesefragen (AO) Foundation [5-14-14P]
FX Project no. 5-14-14P was supported by the Arbeitsgemeinschaft fur
   Osteosynthesefragen (AO) Foundation.
CR Adib-Conquy M, 2003, AM J RESP CRIT CARE, V168, P158, DOI 10.1164/rccm.200209.1077OC
   AYALA A, 1992, CYTOKINE, V4, P66, DOI 10.1016/1043-4666(92)90039-T
   Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004
   Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010
   Bossaert L, 2010, RESUSCITATION, V81, pE175, DOI 10.1016/j.resuscitation.2010.09.001
   BROOKS CF, 1988, IMMUNOLOGY, V63, P303
   Castillo JS, 2012, REV PANAM SALUD PUBL, V32, P343, DOI 10.1590/S1020-49892012001100004
   Chamorro S, 2004, IMMUNOBIOLOGY, V209, P57, DOI 10.1016/j.imbio.2004.02.002
   Dominguez-Punaro MD, 2010, INFECT IMMUN, V78, P5074, DOI 10.1128/IAI.00698-10
   Fairbairn L, 2013, J IMMUNOL, V190, P6389, DOI 10.4049/jimmunol.1300365
   Fairbairn L, 2011, J LEUKOCYTE BIOL, V89, P855, DOI 10.1189/jlb.1110607
   Freeman SA, 2014, IMMUNOL REV, V262, P193, DOI 10.1111/imr.12212
   Hanzelmann D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12304
   Heftrig D, 2017, MEDIAT INFLAMM, DOI 10.1155/2017/2608349
   HERSHMAN MJ, 1990, BRIT J SURG, V77, P204, DOI 10.1002/bjs.1800770225
   Hornef MW, 2008, CURR OPIN INFECT DIS, V21, P304, DOI 10.1097/QCO.0b013e3282f88ba3
   Horst K, 2016, SCI REP-UK, V6, DOI 10.1038/srep39659
   Humphreys H, 2012, SURG-J R COLL SURG E, V10, P357, DOI 10.1016/j.surge.2012.05.003
   Islam MN, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.13
   Keel M, 1996, J TRAUMA, V41, P430, DOI 10.1097/00005373-199609000-00008
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kollef MH, 2005, CHEST, V128, P3854, DOI 10.1378/chest.128.6.3854
   Kumar H, 2009, BIOCHEM BIOPH RES CO, V388, P621, DOI 10.1016/j.bbrc.2009.08.062
   Lendemans S, 2007, J TRAUMA, V63, P740, DOI 10.1097/01.ta.0000240451.42238.d1
   Liu CH, 2009, VET MICROBIOL, V136, P266, DOI 10.1016/j.vetmic.2008.11.016
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806
   McGettrick AF, 2010, CURR OPIN IMMUNOL, V22, P20, DOI 10.1016/j.coi.2009.12.002
   McHoney M, 2006, PEDIATR SURG INT, V22, P330, DOI 10.1007/s00383-006-1657-0
   Monneret G, 2006, INTENS CARE MED, V32, P1175, DOI 10.1007/s00134-006-0204-8
   Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084
   Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F
   PASSLICK B, 1989, BLOOD, V74, P2527
   Perez-Barcena J, 2010, ANN SURG, V251, P521, DOI 10.1097/SLA.0b013e3181cc8f84
   Raymond CR, 2005, VET IMMUNOL IMMUNOP, V107, P235, DOI 10.1016/j.vetimm.2005.05.008
   Relja B, 2015, J MOL MED, V93, P1391, DOI 10.1007/s00109-015-1320-0
   Reuven EM, 2014, BBA-BIOMEMBRANES, V1838, P1586, DOI 10.1016/j.bbamem.2014.01.020
   Rouget C, 2016, MINERVA ANESTESIOL
   Seshadri A, 2017, CRIT CARE MED, V45, P1523, DOI 10.1097/CCM.0000000000002577
   Shah P, 2013, J BIOL CHEM, V288, P12345, DOI 10.1074/jbc.M113.449983
   Sirijatuphat Rujipas, 2014, Journal of the Medical Association of Thailand, V97, pS20
   Sturm R, 2017, IMMUNOBIOLOGY, V222, P301, DOI 10.1016/j.imbio.2016.09.010
   Subcommittee A, 2013, J TRAUMA ACUTE CARE, V74, P1363
   Tsujimoto H, 2006, CLIN IMMUNOL, V119, P180, DOI 10.1016/j.clim.2006.01.004
   Turner JD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002817
   Vester H, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0180-y
   Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3
   Worlein JM, 2011, AM J PRIMATOL, V73, P98
   Wutzler S, 2013, CHIRURG, V84, P753, DOI 10.1007/s00104-013-2477-0
   Zhang NZ, 2011, J VIROL, V85, P11709, DOI 10.1128/JVI.05040-11
   Zheng H, 2011, J NEUROIMMUNOL, V234, P71, DOI 10.1016/j.jneuroim.2011.02.005
   Ziegler-Heitbrock L, 2014, CELL IMMUNOL, V289, P135, DOI 10.1016/j.cellimm.2014.03.019
   ZIEGLERHEITBROCK HWL, 1994, SCAND J IMMUNOL, V40, P509, DOI 10.1111/j.1365-3083.1994.tb03497.x
NR 52
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 10
PY 2017
VL 12
IS 11
AR e0187404
DI 10.1371/journal.pone.0187404
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FM2XM
UT WOS:000414866000013
PM 29125848
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Petzoldt, M
   Trepte, CJ
   Ridder, J
   Maisch, S
   Klapsing, P
   Kersten, JF
   Richter, HP
   Kubitz, JC
   Reuter, DA
   Goepfert, MS
AF Petzoldt, Martin
   Trepte, Constantin J.
   Ridder, Jan
   Maisch, Stefan
   Klapsing, Philipp
   Kersten, Jan F.
   Richter, Hans Peter
   Kubitz, Jens C.
   Reuter, Daniel A.
   Goepfert, Matthias S.
TI Reliability of transcardiopulmonary thermodilution cardiac output
   measurement in experimental aortic valve insufficiency
SO PLOS ONE
LA English
DT Article
ID PULSE CONTOUR ANALYSIS; TRANSPULMONARY THERMODILUTION; PULMONARY-ARTERY;
   REGURGITATION; AGREEMENT; MONITORS; THERAPY; SURGERY; ABILITY; DEVICE
AB Background
   Monitoring cardiac output (CO) is important to optimize hemodynamic function in critically ill patients. The prevalence of aortic valve insufficiency (AI) is rising in the aging population. However, reliability of CO monitoring techniques in AI is unknown. The aim of this study was to investigate the impact of AI on accuracy, precision, and trending ability of transcardiopulmonary thermodilution-derived COTCPTD in comparison with pulmonary artery catheter thermodilution COPAC.
   Methods
   Sixteen anesthetized domestic pigs were subjected to serial simultaneous measurements of COPAC and COTCPTD. In a novel experimental model, AI was induced by retraction of an expanded Dormia basket in the aortic valve annulus. The Dormia basket was delivered via a Judkins catheter guided by substernal epicardial echocardiography. High (HPC), moderate (MPC) and low cardiac preload conditions (LPC) were induced by fluid unloading (20 ml kg(-1) blood withdrawal) and loading (subsequent retransfusion of the shed blood and additional infusion of 20 ml kg(-1) hydroxyethyl starch). Within each preload condition CO was measured before and after the onset of AI. For statistical analysis, we used a mixed model analysis of variance, Bland-Altman analysis, the percentage error and concordance analysis.
   Results
   Experimental AI had a mean regurgitant volume of 33.6 +/- 12.0 ml and regurgitant fraction of 42.9 +/- 12.6%. The percentage error between COTCPTD and COPAC during competent valve function and after induction of substantial AI was: HPC 17.7% vs. 20.0%, MPC 20.5% vs. 26.1%, LPC 26.5% vs. 28.1% (pooled data: 22.5% vs. 24.1%). The ability to trend CO-changes induced by fluid loading and unloading did not differ between baseline and AI (concordance rate 95.8% during both conditions).
   Conclusion
   Despite substantial AI, transcardiopulmonary thermodilution reliably measured CO under various cardiac preload conditions with a good ability to trend CO changes in a porcine model. COTCPTD and COPAC were interchangeable in substantial AI.
C1 [Petzoldt, Martin; Trepte, Constantin J.; Ridder, Jan; Maisch, Stefan; Klapsing, Philipp; Richter, Hans Peter; Kubitz, Jens C.; Reuter, Daniel A.; Goepfert, Matthias S.] Univ Med Ctr Hamburg Eppendorf, Dept Anesthesiol, Ctr Anesthesiol & Intens Care Med, Hamburg, Germany.
   [Kersten, Jan F.] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany.
RP Petzoldt, M (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Anesthesiol, Ctr Anesthesiol & Intens Care Med, Hamburg, Germany.
EM m.petzoldt@uke.de
OI Reuter, Daniel/0000-0003-2080-5597; Petzoldt, Martin/0000-0001-5295-2925
CR Ardehali A, 1996, CARDIOLOGY, V87, P276, DOI 10.1159/000177104
   Aya HD, 2013, BRIT J ANAESTH, V110, P510, DOI 10.1093/bja/aet020
   Balik M, 2002, INTENS CARE MED, V28, P1117, DOI 10.1007/s00134-002-1352-0
   Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422
   BOCK JC, 1989, J CRIT CARE, V4, P106, DOI 10.1016/0883-9441(89)90125-1
   Breukers Rose-Marieke B G E, 2009, Interact Cardiovasc Thorac Surg, V9, P4, DOI 10.1510/icvts.2009.204545
   CIGARROA RG, 1989, AM J MED, V86, P417, DOI 10.1016/0002-9343(89)90339-2
   Critchley LAH, 1999, J CLIN MONITOR COMP, V15, P85, DOI 10.1023/A:1009982611386
   Critchley LA, 2011, J CARDIOTHOR VASC AN, V25, P536, DOI 10.1053/j.jvca.2011.01.003
   Critchley LA, 2010, ANESTH ANALG, V111, P1180, DOI 10.1213/ANE.0b013e3181f08a5b
   Funcke S, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0148-2
   Furukawa Hiroshi, 2013, Kyobu Geka, V66, P775
   Goepfert MS, 2013, ANESTHESIOLOGY, V119, P824, DOI 10.1097/ALN.0b013e31829bd770
   HILLIS LD, 1986, AM J CARDIOL, V57, P1201, DOI 10.1016/0002-9149(86)90704-6
   Hoiseth LO, 2015, J CLIN MONIT COMPUT, V29, P435, DOI 10.1007/s10877-015-9666-y
   Huter L, 2007, J CARDIOTHOR VASC AN, V21, P659, DOI 10.1053/j.jvca.2007.01.005
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lorsomradee S, 2007, J CARDIOTHOR VASC AN, V21, P636, DOI 10.1053/j.jvca.2007.02.003
   Magalhaes MA, 2014, CARDIOVASC REVASCULA, V15, P156, DOI 10.1016/j.carrev.2014.02.006
   Maisch S, 2011, CRIT CARE MED, V39, P2173, DOI 10.1097/CCM.0b013e3182227e65
   Naruse H, 2017, CIRCULATION, V136
   Pearse RM, 2014, JAMA-J AM MED ASSOC, V311, P2181, DOI 10.1001/jama.2014.5305
   Petzoldt M, 2015, J CLIN MONIT COMPUT, V29, P429, DOI 10.1007/s10877-015-9688-5
   Petzoldt M, 2015, J CLIN MONIT COMPUT, V29, P323, DOI 10.1007/s10877-014-9630-2
   Petzoldt M, 2013, INTENS CARE MED, V39, P601, DOI 10.1007/s00134-012-2786-7
   R_ Core_ Team, R A LANGUAGE AND ENV
   RENNER LE, 1993, CRIT CARE MED, V21, P586, DOI 10.1097/00003246-199304000-00021
   Reuter DA, 2010, ANESTH ANALG, V110, P799, DOI 10.1213/ANE.0b013e3181cc885a
   Sakka SG, 2007, BRIT J ANAESTH, V99, P337, DOI 10.1093/bja/aem177
   Saugel B, 2015, ANESTH ANALG, V121, P514, DOI 10.1213/ANE.0000000000000725
   SPRING DA, 1970, J APPL PHYSIOL, V29, P538
   Staier K, 2012, EUR J ANAESTH, V29, P431, DOI 10.1097/EJA.0b013e3283542222
   Stugaard M, 2015, EUR HEART J-CARD IMG, V16, P723, DOI 10.1093/ehjci/jev035
   Vahanian A, 2012, EUR J CARDIO-THORAC, V42, pS1, DOI 10.1093/ejcts/ezs455
   Wiggers CJ, 1930, J CLIN INVEST, V9, P215, DOI 10.1172/JCI100300
   Zong GJ, 2013, J SURG RES, V185, P940, DOI 10.1016/j.jss.2013.06.059
NR 36
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 19
PY 2017
VL 12
IS 10
AR e0186481
DI 10.1371/journal.pone.0186481
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FK0UN
UT WOS:000413195900071
PM 29049339
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Woitke, F
   Ceanga, M
   Rudolph, M
   Niv, F
   Witte, OW
   Redecker, C
   Kunze, A
   Keiner, S
AF Woitke, Florus
   Ceanga, Mihai
   Rudolph, Max
   Niv, Fanny
   Witte, Otto W.
   Redecker, Christoph
   Kunze, Albrecht
   Keiner, Silke
TI Adult hippocampal neurogenesis poststroke: More new granule cells but
   aberrant morphology and impaired spatial memory
SO PLOS ONE
LA English
DT Article
ID COGNITIVE DECLINE; DENTATE GYRUS; PATTERN SEPARATION; STATUS
   EPILEPTICUS; NEURONS; STROKE; PERSPECTIVES; CONTRIBUTES; INFARCTS
AB Stroke significantly stimulates neurogenesis in the adult dentate gyrus, though the functional role of this postlesional response is mostly unclear. Recent findings suggest that newborn neurons generated in the context of stroke may fail to correctly integrate into pre-existing networks. We hypothesized that increased neurogenesis in the dentate gyrus following stroke is associated with aberrant neurogenesis and impairment of hippocampus-dependent memory. To address these questions we used the middle cerebral artery occlusion model (MCAO) in mice. Animals were housed either under standard conditions or with free access to running wheels. Newborn granule cells were labelled with the thymidine analoque EdU and retroviral vectors. To assess memory performance, we employed a modified version of the Morris water maze (MWM) allowing differentiation between hippocampus dependent and independent learning strategies. Newborn neurons were morphologically analyzed using confocal microscopy and Neurolucida system at 7 weeks. We found that neurogenesis was significantly increased following MCAO. Animals with MCAO needed more time to localize the platform and employed less hippocampus-dependent search strategies in MWM versus controls. Confocal studies revealed an aberrant cell morphology with basal dendrites and an ectopic location (e. g. hilus) of new granule cells born in the ischemic brain. Running increased the number of new neurons but also enhanced aberrant neurogenesis. Running, did not improve the general performance in the MWM but slightly promoted the application of precise spatial search strategies. In conclusion, ischemic insults cause hippocampal-dependent memory deficits which are associated with aberrant neurogenesis in the dentate gyrus indicating ischemia-induced maladaptive plasticity in the hippocampus.
C1 [Woitke, Florus; Ceanga, Mihai; Rudolph, Max; Niv, Fanny; Witte, Otto W.; Redecker, Christoph; Kunze, Albrecht; Keiner, Silke] Jena Univ Hosp, Hans Berger Dept Neurol, Klinikum 1, Jena, Germany.
RP Kunze, A (reprint author), Jena Univ Hosp, Hans Berger Dept Neurol, Klinikum 1, Jena, Germany.
EM albrecht.kunze@med.uni-jena.de
RI Witte, Otto/P-4127-2018
OI Witte, Otto/0000-0003-2101-4105
FU BMBF program [01GN0977]; Interdisciplinary Center for Clinical Research
   (IZKF) Jena
FX Financial support was received from the BMBF program "Cell-based,
   regenerative therapies," 01GN0977; and the Interdisciplinary Center for
   Clinical Research (IZKF) Jena.
CR Austin JE, 2004, J COMP NEUROL, V476, P205, DOI 10.1002/cne.20182
   Blum S, 2012, NEUROLOGY, V78, P38, DOI 10.1212/WNL.0b013e31823ed0cc
   Brainin M, 2015, EUR J NEUROL, V22, P229, DOI 10.1111/ene.12626
   Cho KO, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7606
   Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215
   Dupret D, 2007, PLOS BIOL, V5, P1683, DOI 10.1371/journal.pbio.0050214
   Garthe A, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00063
   Garthe A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005464
   Geibig CS, 2012, NEUROBIOL DIS, V46, P431, DOI 10.1016/j.nbd.2012.02.007
   Jessberger S, 2015, COLD SPRING HARB PER
   Jessberger S, 2007, J NEUROSCI, V27, P9400, DOI 10.1523/JNEUROSCI.2002-07.2007
   Kempermann G, 2012, NAT REV NEUROSCI, V13, P727, DOI 10.1038/nrn3319
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kunze A, 2009, P NATL ACAD SCI USA, V106, P11336, DOI 10.1073/pnas.0813160106
   Myers CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068208
   Niv F, 2012, STROKE, V43, P2468, DOI 10.1161/STROKEAHA.112.660977
   Parent JM, 1997, J NEUROSCI, V17, P3727
   Patel LS, 2004, J NEUROSCI, V24, P9005, DOI 10.1523/JNEUROSCI.2943-04.2004
   Prins ND, 2005, BRAIN, V128, P2034, DOI 10.1093/brain/awh553
   Rangel LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4181
   Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817
   Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000
   Scharfman H, 2007, DEV NEUROSCI-BASEL, V29, P14, DOI 10.1159/000096208
   Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003
   Shapiro LA, 2008, EPILEPSIA, V49, P13, DOI 10.1111/j.1528-1167.2008.01633.x
   Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066
   Yu TS, 2016, NEUROSCIENTIST, V22, P61, DOI 10.1177/1073858414563616
NR 27
TC 7
Z9 7
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2017
VL 12
IS 9
AR e0183463
DI 10.1371/journal.pone.0183463
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FH0VR
UT WOS:000410859200011
PM 28910298
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Han, S
   Olonisakin, TF
   Pribis, JP
   Zupetic, J
   Yoon, JH
   Holleran, KM
   Jeong, K
   Shaikh, N
   Rubio, DM
   Lee, JS
AF Han, SeungHye
   Olonisakin, Tolani F.
   Pribis, John P.
   Zupetic, Jill
   Yoon, Joo Heung
   Holleran, Kyle M.
   Jeong, Kwonho
   Shaikh, Nader
   Rubio, Doris M.
   Lee, Janet S.
TI A checklist is associated with increased quality of reporting
   preclinical biomedical research: A systematic review
SO PLOS ONE
LA English
DT Review
ID SURGICAL SAFETY CHECKLIST; RANDOMIZED CONTROLLED-TRIALS; CONSORT
   CHECKLIST; REPRODUCIBILITY; TRANSLATION; STANDARDS; TARGETS; IMPROVE;
   POLICY
AB Irreproducibility of preclinical biomedical research has gained recent attention. It is suggested that requiring authors to complete a checklist at the time of manuscript submission would improve the quality and transparency of scientific reporting, and ultimately enhance reproducibility. Whether a checklist enhances quality and transparency in reporting preclinical animal studies, however, has not been empirically studied. Here we searched two highly cited life science journals, one that requires a checklist at submission (Nature) and one that does not (Cell), to identify in vivo animal studies. After screening 943 articles, a total of 80 articles were identified in 2013 (pre-checklist) and 2015 (post-checklist), and included for the detailed evaluation of reporting methodological and analytical information. We compared the quality of reporting preclinical animal studies between the two journals, accounting for differences between journals and changes over time in reporting. We find that reporting of randomization, blinding, and sample-size estimation significantly improved when comparing Nature to Cell from 2013 to 2015, likely due to implementation of a checklist. Specifically, improvement in reporting of the three methodological information was at least three times greater when a mandatory checklist was implemented than when it was not. Reporting the sex of animals and the number of independent experiments performed also improved from 2013 to 2015, likely from factors not related to a checklist. Our study demonstrates that completing a checklist at manuscript submission is associated with improved reporting of key methodological information in preclinical animal studies.
C1 [Han, SeungHye; Olonisakin, Tolani F.; Zupetic, Jill; Yoon, Joo Heung; Lee, Janet S.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA.
   [Pribis, John P.] Baylor Coll Med, Integrat Mol & Biomed Sci Grad Program, Houston, TX 77030 USA.
   [Holleran, Kyle M.; Jeong, Kwonho; Rubio, Doris M.] Univ Pittsburgh, Ctr Res Hlth Care Data Ctr, Pittsburgh, PA USA.
   [Shaikh, Nader] Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA.
   [Shaikh, Nader; Rubio, Doris M.; Lee, Janet S.] Univ Pittsburgh, Inst Clin Res Educ, Pittsburgh, PA USA.
   [Rubio, Doris M.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
   [Lee, Janet S.] Univ Pittsburgh, Pittsburgh Heart Lung Blood & Vasc Med Inst, Pittsburgh, PA USA.
   [Han, SeungHye] Northwestern Univ, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA.
RP Han, S (reprint author), Northwestern Univ, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA.
EM shan.workmd@gmail.com
OI Han, SeungHye/0000-0001-5625-6337
FU National Institutes of Health [UL1TR001857, HL086884, Al119042];
   American Heart Association [15P0ST25700096]; Breathe Pennsylvania Lung
   Health Research Grant; Howard Hughes Medical Institute Research
FX The project described was supported by the National Institutes of Health
   through Grant Numbers UL1TR001857 (University of Pittsburgh CTSI),
   HL086884 (JSL), Al119042 (JSL), American Heart Association Award
   15P0ST25700096 (SH), Breathe Pennsylvania Lung Health Research Grant
   (SH), and Howard Hughes Medical Institute Research Fellow Award (TFO).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2013, NATURE, V496, P398, DOI 10.1038/496398a
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Baker M, 2016, NATURE, V533, P452, DOI 10.1038/533452a
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Benger JR, 2002, BRIT MED J, V324, P780, DOI 10.1136/bmj.324.7340.780
   Bergs J, 2014, BRIT J SURG, V101, P150, DOI 10.1002/bjs.9381
   Bohmer AB, 2012, ACTA ANAESTH SCAND, V56, P332, DOI 10.1111/j.1399-6576.2011.02590.x
   Casadevall A, 2010, INFECT IMMUN, V78, P4972, DOI 10.1128/IAI.00908-10
   Chen JJ, 2010, CANCER CONTROL, V17, P58, DOI 10.1177/107327481001700108
   Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5
   Cousens S, 2011, J EPIDEMIOL COMMUN H, V65, P576, DOI 10.1136/jech.2008.082610
   Cramond F, 2016, SCIENTOMETRICS, V108, P315, DOI 10.1007/s11192-016-1964-8
   Devereaux PJ, 2002, CONTROL CLIN TRIALS, V23, P380, DOI 10.1016/S0197-2456(02)00214-3
   Drummond C., 2009, P EV METH MACH LEARN
   Festing Michael F W, 2002, ILAR J, V43, P244
   Florez-Vargas O, 2016, ELIFE, V5, DOI 10.7554/eLife.13615
   Goodman SN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5027
   Group OLoEW, 2011, OCEBM LEV EV
   Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731
   Harris AD, 2004, CLIN INFECT DIS, V38, P1586, DOI 10.1086/420936
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Kane RL, 2007, J CLIN EPIDEMIOL, V60, P241, DOI 10.1016/j.jclinepi.2006.06.016
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   McNutt M, 2014, SCIENCE, V343, P231, DOI 10.1126/science.1250475
   Mobley A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063221
   Morris R, 2012, NATURE, V491, P192, DOI 10.1038/491192c
   Peng RD, 2009, BIOSTATISTICS, V10, P405, DOI 10.1093/biostatistics/kxp014
   Plint AC, 2006, MED J AUSTRALIA, V185, P263
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   Ramirez FD, 2017, CIRC RES, V120, P1916, DOI 10.1161/CIRCRESAHA.117.310628
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Turner L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000030.pub2
   *US PREV SERV TASK, 1996, GUID CLIN PREV SERV
   Weiser TG, 2010, INT J QUAL HEALTH C, V22, P365, DOI 10.1093/intqhc/mzq039
NR 35
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2017
VL 12
IS 9
AR e183591
DI 10.1371/journal.pone.0183591
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FG8GZ
UT WOS:000410669200014
PM 28902887
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Saldias, MP
   Fernandez, C
   Morgan, A
   Diaz, C
   Morales, D
   Jana, F
   Gomez, A
   Silva, A
   Briceno, F
   Oyarzun, A
   Maldonado, F
   Cerda, O
   Smith, PC
   Caceres, M
AF Paz Saldias, Maria
   Fernandez, Christian
   Morgan, Alejandra
   Diaz, Catalina
   Morales, Diego
   Jana, Fabian
   Gomez, Alvaro
   Silva, Alonso
   Briceno, Fernanda
   Oyarzun, Alejandro
   Maldonado, Felipe
   Cerda, Oscar
   Smith, Patricio C.
   Caceres, Monica
TI Aged blood factors decrease cellular responses associated with delayed
   gingival wound repair
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTORS; DNA-DAMAGE; DONOR AGE; SENESCENCE; ALPHA; CELLS; BETA;
   SERUM; VEGF
AB Aging is a gradual biological process characterized by a decrease in cell and organism functions. Gingival wound healing is one of the impaired processes found in old rats. Here, we studied the in vivo wound healing process using a gingival repair rat model and an in vitro model using human gingival fibroblast for cellular responses associated to wound healing. To do that, we evaluated cell proliferation of both epithelial and connective tissue cells in gingival wounds and found decreased of Ki67 nuclear staining in old rats when compared to their young counterparts. We next evaluated cellular responses of primary gingival fibroblast obtained from young subjects in the presence human blood serum of individuals of different ages. Eighteen to sixty five years old masculine donors were classified into 3 groups: "young" from 18 to 22 years old, "middle-aged" from 30 to 48 years old and "aged" over 50 years old. Cell proliferation, measured through immunofluorescence for Ki67 and flow cytometry for DNA content, was decreased when middle-aged and aged serum was added to gingival fibroblast compared to young serum. Myofibroblastic differentiation, measured through alpha-smooth muscle actin (alpha-SMA), was stimulated with young but not middle-aged or aged serum both the protein levels and incorporation of alpha-SMA into actin stress fibers. High levels of PDGF, VEGF, IL-6R were detected in blood serum from young subjects when compared to middle-aged and aged donors. In addition, the pro-inflammatory cytokines MCP-1 and TNF were increased in the serum of aged donors. In old rat wound there is an increased of staining for TNF compared to young wound. Moreover, healthy gingiva (non injury) shows less staining compared to a wound site, suggesting a role in wound healing. Moreover, serum from middle-aged and aged donors was able to stimulate cellular senescence in young cells as determined by the expression of senescence associated beta-galactosidase and histone H2A.X phosphorylated at Ser139. Moreover, we detected an increased frequency of gamma-H2A. X-positive cells in aged rat gingival tissues. The present study suggests that serum factors present in middle-aged and aged individuals may be responsible, at least in part, for the altered responses observed during wound healing in aging.
C1 [Paz Saldias, Maria; Fernandez, Christian; Morgan, Alejandra; Diaz, Catalina; Morales, Diego; Gomez, Alvaro; Silva, Alonso; Briceno, Fernanda; Cerda, Oscar; Caceres, Monica] Univ Chile, Inst Biomed Sci, Program Mol & Cell Biol, Fac Med, Santiago, Chile.
   [Jana, Fabian] Univ Aysen, Coyhaique, Chile.
   [Oyarzun, Alejandro] Univ Finis Terrae, Fac Dent, Santiago, Chile.
   [Maldonado, Felipe] Univ Chile, Hosp Clin, Dept Anesthesia, Fac Med, Santiago, Chile.
   [Cerda, Oscar; Caceres, Monica] Millennium Nucleus Ion Channels Associated Dis Mi, Santiago, Chile.
   [Smith, Patricio C.] Pontificia Univ Catolica Chile, Sch Dent, Fac Med, Santiago, Chile.
RP Caceres, M (reprint author), Univ Chile, Inst Biomed Sci, Program Mol & Cell Biol, Fac Med, Santiago, Chile.; Caceres, M (reprint author), Millennium Nucleus Ion Channels Associated Dis Mi, Santiago, Chile.
EM monicacaceres@med.uchile.cl
RI Smith, Patricio C/I-5897-2014; Cerda, Oscar/N-5134-2019; Jana,
   Fabian/D-9364-2017
OI Smith, Patricio C/0000-0001-7314-621X; Cerda, Oscar/0000-0003-2873-5722;
   Jana, Fabian/0000-0001-7786-4569; Maldonado, Felipe/0000-0002-2633-4717
FU National Fund for Science and Technology (Fondecyt) Grant [11140064];
   Universidad de Chile [UINICIA 44051]; Fondecyt Grant [1160518]
FX This work was supported by National Fund for Science and Technology
   (Fondecyt) Grant 11140064 (MC), UINICIA 44051 Grant from Universidad de
   Chile (MC) and Fondecyt Grant 1160518 (OC).; The present study was
   funded by a grant from the National Fund for Science and Technology
   (Fondecyt) Grant 11140064 (MC), Grant from Universidad de Chile UINICIA
   44051 (MC) and Fondecyt Grant 1160518 (OC). The authors have stated
   explicitly that there are no conflicts of interest in connection with
   this article.
CR Arancibia R, 2013, J PERIODONTOL, V84, P683, DOI 10.1902/jop.2012.120225
   Baht GS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8131
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x
   Bayer ML, 2012, MECH AGEING DEV, V133, P246, DOI 10.1016/j.mad.2012.02.002
   Belsky DW, 2015, P NATL ACAD SCI USA, V112, pE4104, DOI 10.1073/pnas.1506264112
   Bryan BA, 2010, FASEB J, V24, P3186, DOI 10.1096/fj.09-145102
   Caceres M, 2014, J DENT RES, V93, P691, DOI 10.1177/0022034514533126
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Cook DN, 1996, J LEUKOCYTE BIOL, V59, P61
   Czarkowska-Paczek B, 2006, J PHYSIOL PHARMACOL, V57, P189
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Di Paolo NC, 2016, NAT IMMUNOL, V17, P906, DOI 10.1038/ni.3503
   Fontana L, 2014, NATURE, V511, P405, DOI 10.1038/511405a
   Goldberg MT, 2007, J INVEST DERMATOL, V127, P2645, DOI 10.1038/sj.jid.5700890
   Hakkinen L, 2000, PERIODONTOL 2000, V24, P127, DOI 10.1034/j.1600-0757.2000.2240107.x
   Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112
   Hubackova S, 2016, ONCOGENE, V35, P1236, DOI 10.1038/onc.2015.162
   Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Liu RK, 2006, AM J PATHOL, V168, P757, DOI 10.2353/ajpath.2006.050907
   Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Rozman P, 2007, ACTA DERMATOVEN ALP, V16, P156
   Smith PC, 2006, J DENT RES, V85, P150, DOI 10.1177/154405910608500207
   Takaishi K, 2000, J BIOCHEM-TOKYO, V127, P511, DOI 10.1093/oxfordjournals.jbchem.a022634
   Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569
   Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x
   Weibrich G, 2002, J CRANIO MAXILL SURG, V30, P97, DOI 10.1054/jems.2002.0285
   Zhang CY, 2015, J CELL BIOL, V209, P289, DOI 10.1083/jcb.201409032
   Zhang FQ, 2015, J BIOL CHEM, V290, P8232, DOI 10.1074/jbc.M114.623074
   Zhou F, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-78
NR 33
TC 1
Z9 1
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2017
VL 12
IS 9
AR e0184189
DI 10.1371/journal.pone.0184189
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FG6AR
UT WOS:000410449500016
PM 28898261
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Cruz-Baquero, A
   Jaramillo, LMC
   Gutierrez-Meza, M
   Jarillo-Luna, RA
   Campos-Rodriguez, R
   Rivera-Aguilar, V
   Miliar-Garcia, A
   Pacheco-Yepez, J
AF Cruz-Baquero, Andrea
   Cardenas Jaramillo, Luz Maria
   Gutierrez-Meza, Manuel
   Adriana Jarillo-Luna, Rosa
   Campos-Rodriguez, Rafael
   Rivera-Aguilar, Victor
   Miliar-Garcia, Angel
   Pacheco-Yepez, Judith
TI Different behavior of myeloperoxidase in two rodent amoebic liver
   abscess models
SO PLOS ONE
LA English
DT Article
ID HUMAN RECOMBINANT MYELOPEROXIDASE; PORE-FORMING PEPTIDE; EARLY
   HOST-DEFENSE; ENTAMOEBA-HISTOLYTICA; NEUTROPHIL MYELOPEROXIDASE;
   GENE-EXPRESSION; MACROPHAGE ACTIVATION; PULMONARY INFECTIONS;
   CANDIDA-ALBICANS; MICE DEFICIENT
AB The protozoan Entamoeba histolytica is the etiological agent of amoebiasis, which can spread to the liver and form amoebic liver abscesses. Histological studies conducted with resistant and susceptible models of amoebic liver abscesses (ALAs) have established that neutrophils are the first cells to contact invasive amoebae at the lesion site. Myeloperoxidase is the most abundant enzyme secreted by neutrophils. It uses hydrogen peroxide secreted by the same cells to oxidize chloride ions and produce hypochlorous acid, which is the most efficient microbicidal system of neutrophils. In a previous report, our group demonstrated that myeloperoxidase presents amoebicidal activity in vitro. The aim of the current contribution was to analyze in vivo the role of myeloperoxidase in a susceptible (hamsters) and resistant (Balb/c mice) animal models of ALAs. In liver samples of hamsters and mice inoculated intraportally with Entamoeba histolytica trophozoites, the number of neutrophils in ALAs was determined by enzymatic activity. The presence of myeloperoxidase was observed by staining, and its expression and activity were quantified in situ. A significant difference existed between the two animal models in the number of neutrophils and the expression and activity of myeloperoxidase, which may explain the distinct evolution of amoebic liver abscesses. Hamsters and mice were treated with an MPO inhibitor (4-aminobenzoic acid hydrazide). Hamsters treated with ABAH showed no significant differences in the percentage of lesions or in the percentage of amoebae damaged compared with the untreated hamsters. ABAH treated mice versus untreated mice showed larger abscesses and a decreased percentage of damaged amoebae in these lesion at all stages of evolution. Further studies are needed to elucidate the host and amoebic mechanisms involved in the adequate or inadequate activation and modulation of myeloperoxidase.
C1 [Cruz-Baquero, Andrea; Gutierrez-Meza, Manuel; Adriana Jarillo-Luna, Rosa; Campos-Rodriguez, Rafael; Miliar-Garcia, Angel; Pacheco-Yepez, Judith] Inst Politecn Nacl, Escuela Super Med, Secc Estudios Posgrad & Invest, Mexico City, DF, Mexico.
   [Cardenas Jaramillo, Luz Maria; Gutierrez-Meza, Manuel; Adriana Jarillo-Luna, Rosa] Inst Politecn Nacl, Escuela Super Med, Coordinac Ciencias Morfol, Mexico City, DF, Mexico.
   [Rivera-Aguilar, Victor] UNAM, FES Iztacala, UBIPRO, Dept Microbiol, Tlalnepantla, Estado De Mexic, Mexico.
RP Pacheco-Yepez, J (reprint author), Inst Politecn Nacl, Escuela Super Med, Secc Estudios Posgrad & Invest, Mexico City, DF, Mexico.
EM payejuca@prodigy.net.mx
FU CONACyT [181566]; SIP-IPN [20141119, 20150945]; COFAA-IPN
FX This work was supported by grants from CONACyT (181566), SIP-IPN
   (20141119, 20150945) and COFAA-IPN. Judith Pacheco-Yepez, Rosa Adriana
   Jarillo-Luna and Rafael Campos-Rodriguez are fellows of COFAA and
   EDIIPN. The funders had no role in study design, data analysis or
   manuscript preparation.
CR Ackers JP, 2006, CURR OPIN MICROBIOL, V9, P367, DOI 10.1016/j.mib.2006.06.014
   Acuna-Soto R, 2000, AM J GASTROENTEROL, V95, P1277, DOI 10.1016/S0002-9270(99)00584-5
   Ankri S, 1999, MOL MICROBIOL, V33, P327, DOI 10.1046/j.1365-2958.1999.01476.x
   Aratani Y, 2002, MED MYCOL, V40, P557, DOI 10.1080/714031156
   Aratani Y, 2002, J INFECT DIS, V185, P1833, DOI 10.1086/340635
   Aratani Y, 1999, INFECT IMMUN, V67, P1828
   Aratani Y, 2000, J INFECT DIS, V182, P1276, DOI 10.1086/315843
   Aratani Y, 2006, J MED MICROBIOL, V55, P1291, DOI 10.1099/jmm.0.46620-0
   Babior BM, 2003, P NATL ACAD SCI USA, V100, P3031, DOI 10.1073/pnas.0530251100
   Begum S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01394
   Borregaard N, 1997, BLOOD, V89, P3503
   Brandt H, 1970, Hum Pathol, V1, P351
   Bugatti S, 2011, CURR RHEUMATOL REP, V13, P440, DOI 10.1007/s11926-011-0201-y
   BUYS J, 1984, IMMUNOLOGY, V51, P601
   Caro TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091415
   Chapman ALP, 2013, J BIOL CHEM, V288, P6465, DOI 10.1074/jbc.M112.418970
   CLARK RA, 1982, J IMMUNOL, V129, P2725
   Costa CAX, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-23
   CRAMER E, 1985, BLOOD, V65, P423
   DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X
   ELHAG A, 1986, J IMMUNOL, V136, P3420
   FERRANTE A, 1987, INFECT IMMUN, V55, P1047
   Forghani R, 2012, RADIOLOGY, V263, P451, DOI 10.1148/radiol.12111593
   Foster CB, 1998, J CLIN INVEST, V102, P2146, DOI 10.1172/JCI5084
   Furtmuller PG, 2001, FEBS LETT, V503, P147, DOI 10.1016/S0014-5793(01)02725-9
   Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298
   Gelderman MP, 1998, MEDIAT INFLAMM, V7, P381, DOI 10.1080/09629359890758
   Green PS, 2004, J NEUROCHEM, V90, P724, DOI 10.1111/j.1471-4159.2004.02527.x
   Hampton MB, 1998, BLOOD, V92, P3007
   Hansson M, 2006, ARCH BIOCHEM BIOPHYS, V445, P214, DOI 10.1016/j.abb.2005.08.009
   Hasegawa T, 2005, AM J PHYSIOL-GASTR L, V289, pG760, DOI 10.1152/ajpgi.00141.2005
   Helk E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003096
   Hirche TO, 2005, J IMMUNOL, V174, P1557, DOI 10.4049/jimmunol.174.3.1557
   JACQUET A, 1991, ARCH BIOCHEM BIOPHYS, V291, P132, DOI 10.1016/0003-9861(91)90115-Y
   Jarillo-Luna RA, 2002, EXP PARASITOL, V101, P40, DOI 10.1016/S0014-4894(02)00021-8
   Jeitner TM, 2005, J NEUROCHEM, V92, P302, DOI 10.1111/j.1471-4159.2004.02868.x
   JONG EC, 1981, J IMMUNOL, V126, P468
   Kettle AJ, 2004, AM J RESP CRIT CARE, V170, P1317, DOI 10.1164/rccm.200311-15160C
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klebanoff SJ, 2013, J LEUKOCYTE BIOL, V93, P185, DOI 10.1189/jlb.0712349
   Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Klebanoff SJ, 1978, NEUTROPHIL FUNCTION
   Klinke A, 2011, BLOOD, V117, P1350, DOI 10.1182/blood-2010-05-284513
   Kumar AP, 2005, BIOCHEM BIOPH RES CO, V331, P442, DOI 10.1016/j.bbrc.2005.03.204
   Kumar V, 2010, INT IMMUNOPHARMACOL, V10, P1325, DOI 10.1016/j.intimp.2010.08.012
   Kutter D, 2000, ACTA HAEMATOL-BASEL, V104, P10, DOI 10.1159/000041062
   Lau D, 2005, P NATL ACAD SCI USA, V102, P431, DOI 10.1073/pnas.0405193102
   LEFKOWITZ DL, 1992, P SOC EXP BIOL MED, V199, P204
   LEIPPE M, 1994, P NATL ACAD SCI USA, V91, P2602, DOI 10.1073/pnas.91.7.2602
   LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659
   LI E, 1995, INFECT IMMUN, V63, P4150
   Lidell ME, 2006, P NATL ACAD SCI USA, V103, P9298, DOI 10.1073/pnas.0600623103
   Little MA, 2005, BLOOD, V106, P2050, DOI 10.1182/blood-2005-03-0921
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lotter H, 2006, INFECT IMMUN, V74, P118, DOI 10.1128/IAI.74.1.118-124.2006
   Malle E, 2007, BRIT J PHARMACOL, V152, P838, DOI 10.1038/sj.bjp.0707358
   MIYASAKI KT, 1987, INFECT IMMUN, V55, P1029
   MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x
   Yapura VM, 2013, ACTA BIOQUIM CLIN L, V47, P53
   Mortimer L, 2010, EXP PARASITOL, V126, P366, DOI 10.1016/j.exppara.2010.03.005
   Nikpoor B, 2001, AM HEART J, V142, P336, DOI 10.1067/mhj.2001.116769
   O'Connell AE, 2011, INFECT IMMUN, V79, P2770, DOI 10.1128/IAI.00931-10
   Olivos-Garcia A, 2004, EXP MOL PATHOL, V77, P66, DOI 10.1016/j.yexmp.2003.09.003
   Olivos-Garcia A, 2009, INFECT GENET EVOL, V9, P1033, DOI 10.1016/j.meegid.2009.04.005
   Pacheco-Yepez J, 2011, PARASITE IMMUNOL, V33, P56, DOI 10.1111/j.1365-3024.2010.01252.x
   Petri WA, 2002, CURR OPIN MICROBIOL, V5, P443, DOI 10.1016/S1369-5274(02)00335-1
   Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412
   Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X
   Prokopowicz Z, 2012, ARCH IMMUNOL THER EX, V60, P43, DOI 10.1007/s00005-011-0156-8
   Ralston KS, 2011, TRENDS PARASITOL, V27, P253, DOI 10.1016/j.pt.2011.02.006
   Ramos E, 2007, EXP PARASITOL, V116, P257, DOI 10.1016/j.exppara.2007.01.011
   Ramsaransing G, 2003, J NEUROL NEUROSUR PS, V74, P953, DOI 10.1136/jnnp.74.7.953
   Reynolds WF, 1997, BLOOD, V90, P2730
   Rutgers A, 2003, BRIT J HAEMATOL, V123, P536, DOI 10.1046/j.1365-2141.2003.04602.x
   Santi-Rocca J, 2009, CLIN MICROBIOL REV, V22, P65, DOI 10.1128/CMR.00029-08
   Savill J, 1997, J LEUKOCYTE BIOL, V61, P375
   Segelmark M, 1997, CLIN EXP IMMUNOL, V108, P167, DOI 10.1046/j.1365-2249.1997.d01-992.x
   Seydel KB, 1997, INFECT IMMUN, V65, P3951
   Takeuchi K, 2012, INFLAMM RES, V61, P197, DOI 10.1007/s00011-011-0401-y
   Talarowska M, 2015, ADV MED SCI-POLAND, V60, P1, DOI 10.1016/j.advms.2014.06.001
   Tsutsumi V, 2006, ARCH MED RES, V37, P210, DOI 10.1016/j.arcmed.2005.09.011
   TSUTSUMI V, 1984, AM J PATHOL, V117, P81
   Velazquez C, 1998, PARASITE IMMUNOL, V20, P255, DOI 10.1046/j.1365-3024.1998.00128.x
NR 84
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2017
VL 12
IS 8
AR e0182480
DI 10.1371/journal.pone.0182480
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD2WT
UT WOS:000407396200054
PM 28796788
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Thurk, F
   Boehme, S
   Mudrak, D
   Kampusch, S
   Wielandner, A
   Prosch, H
   Braun, C
   Toemboel, FPR
   Hofmanninger, J
   Kaniusas, E
AF Thuerk, Florian
   Boehme, Stefan
   Mudrak, Daniel
   Kampusch, Stefan
   Wielandner, Alice
   Prosch, Helmut
   Braun, Christina
   Toemboel, Frederic P. R.
   Hofmanninger, Johannes
   Kaniusas, Eugenijus
TI Effects of individualized electrical impedance tomography and image
   reconstruction settings upon the assessment of regional ventilation
   distribution: Comparison to 4-dimensional computed tomography in a
   porcine model
SO PLOS ONE
LA English
DT Article
ID EIT RECONSTRUCTION; LUNG INJURY; TISSUE
AB Electrical impedance tomography (EIT) is a promising imaging technique for bedside monitoring of lung function. It is easily applicable, cheap and requires no ionizing radiation, but clinical interpretation of EIT-images is still not standardized. One of the reasons for this is the ill-posed nature of EIT, allowing a range of possible images to be produced-rather than a single explicit solution. Thus, to further advance the EIT technology for clinical application, thorough examinations of EIT-image reconstruction settings-i.e., mathematical parameters and addition of a priori (e.g., anatomical) information-is essential. In the present work, regional ventilation distribution profiles derived from different EIT finite-element reconstruction models and settings (for GREIT and Gauss Newton) were compared to regional aeration profiles assessed by the gold-standard of 4-dimensional computed tomography (4DCT) by calculating the root mean squared error (RMSE). Specifically, non-individualized reconstruction models (based on circular and averaged thoracic contours) and individualized reconstruction models (based on true thoracic contours) were compared. Our results suggest that GREIT with noise figure of 0.15 and non-uniform background works best for the assessment of regional ventilation distribution by EIT, as verified versus 4DCT. Furthermore, the RMSE of anteroposterior ventilation profiles decreased from 2.53 +/- 0.62% to 1.67 +/- 0.49% while correlation increased from 0.77 to 0.89 after embedding anatomical information into the reconstruction models. In conclusion, the present work reveals that anatomically enhanced EIT-image reconstruction is superior to non-individualized reconstruction models, but further investigations in humans, so as to standardize reconstruction settings, is warranted.
C1 [Thuerk, Florian; Mudrak, Daniel; Kampusch, Stefan; Kaniusas, Eugenijus] TU Wien, Inst Electrodynam Microwave & Circuit Engn, Vienna, Austria.
   [Boehme, Stefan; Toemboel, Frederic P. R.] Med Univ Vienna, Dept Anesthesia Pain Management & Gen Intens Care, Vienna, Austria.
   [Wielandner, Alice; Prosch, Helmut; Hofmanninger, Johannes] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria.
   [Braun, Christina] Univ Vet Med Vienna, Anesthesiol & Perioperat Intens Care Med, Vienna, Austria.
RP Thurk, F (reprint author), TU Wien, Inst Electrodynam Microwave & Circuit Engn, Vienna, Austria.; Boehme, S (reprint author), Med Univ Vienna, Dept Anesthesia Pain Management & Gen Intens Care, Vienna, Austria.
EM florian.thuerk@tuwien.ac.at; stefan.boehme@meduniwien.ac.at
FU Vienna Science and Technology Fund [LS 14-069]
FX This study has been funded by the Vienna Science and Technology Fund
   (WWTF;http://www.wwtf.at/index.php?lang-EN) through project LS 14-069.
   The funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adler A, 2006, PHYSIOL MEAS, V27, pS25, DOI 10.1088/0967-3334/27/5/S03
   Adler A, 2009, PHYSIOL MEAS, V30, pS35, DOI 10.1088/0967-3334/30/6/S03
   Alsaggar M, 2015, ADV GENET, V89, P1, DOI 10.1016/bs.adgen.2014.10.001
   Bahrani N, 2012, P 25 IEEE CAN C EL C, P1
   Becher T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152267
   Cressoni M, 2008, CRIT CARE MED, V36, P669, DOI 10.1097/01.CCM.0000300276.12074.E1
   Cressoni M, 2013, CRIT CARE, V17, DOI 10.1186/cc12738
   Dellamonica J, 2011, INTENS CARE MED, V37, P1595, DOI 10.1007/s00134-011-2333-y
   Elke G, 2013, PHYSIOL MEAS, V34, P1303, DOI 10.1088/0967-3334/34/10/1303
   Gagnon H, 2015, PHYSIOL MEAS, V36, P1093, DOI 10.1088/0967-3334/36/6/1093
   Gomez-Laberge C, 2012, IEEE T MED IMAGING, V31, P834, DOI 10.1109/TMI.2012.2183641
   Graham BM, 2006, PHYSIOL MEAS, V27, pS65, DOI 10.1088/0967-3334/27/5/S06
   Grychtol B, 2011, 12 INT C EL IMP TOM, P2
   Grychtol B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103045
   Grychtol B, 2014, PHYSIOL MEAS, V35, P1035, DOI 10.1088/0967-3334/35/6/1035
   Grychtol B, 2013, PHYSIOL MEAS, V34, P579, DOI 10.1088/0967-3334/34/6/579
   Grychtol B, 2012, IEEE T MED IMAGING, V31, P1754, DOI 10.1109/TMI.2012.2200904
   Grychtol B, 2009, PHYSIOL MEAS, V30, pS137, DOI 10.1088/0967-3334/30/6/S09
   Hinz J, 2003, CHEST, V124, P314, DOI 10.1378/chest.124.1.314
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Leonhardt S, 2012, INTENS CARE MED, V38, P1917, DOI 10.1007/s00134-012-2684-z
   Lionheart WRB, 2004, PHYSIOL MEAS, V25, P125, DOI 10.1088/0967-3334/25/1/021
   Muders T, 2012, CRIT CARE MED, V40, P903, DOI 10.1097/CCM.0b013e318236f452
   NOPP P, 1993, PHYS MED BIOL, V38, P699, DOI 10.1088/0031-9155/38/6/005
   Putensen C, 2009, ANN INTERN MED, V151, P566, DOI 10.7326/0003-4819-151-8-200910200-00011
   Richard JC, 2009, CRIT CARE, V13, DOI 10.1186/cc7900
   Sbarbaro D, 2015, INVERSE PROBL, V31, DOI 10.1088/0266-5611/31/4/045004
   Schoberl J., 1997, Computing and Visualization in Science, V1, P41, DOI 10.1007/s007910050004
   Silva OLuppi, 2016, CONTROL ENG PRACT, P1
   Thurk Florian, 2016, Current Directions in Biomedical Engineering, V2, P511, DOI 10.1515/cdbme-2016-0113
   Ukere A, 2016, BRIT J ANAESTH, V117, P228, DOI 10.1093/bja/aew188
   Vercauteren T., 2007, LNCS, V10, P319, DOI DOI 10.1016/J.NEUR0IMAGE.2008.10.040
   Waldmann AD, 2015, INT C EL IMP TOM 201, V27, P2012
   WOO EJ, 1994, MED BIOL ENG COMPUT, V32, P530, DOI 10.1007/BF02515311
   Wrigge H, 2008, CRIT CARE MED, V36, P903, DOI 10.1097/CCM.0B013E3181652EDD
   Zhao ZQ, 2009, INTENS CARE MED, V35, P1900, DOI 10.1007/s00134-009-1589-y
NR 36
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2017
VL 12
IS 8
AR e0182215
DI 10.1371/journal.pone.0182215
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FC3VC
UT WOS:000406766500050
PM 28763474
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bennion, DM
   Isenberg, JD
   Harmel, AT
   DeMars, K
   Dang, AN
   Jones, CH
   Pignataro, ME
   Graham, JT
   Steckelings, UM
   Alexander, JC
   Febo, M
   Krause, EG
   de Kloet, AD
   Candelario-Jalil, E
   Sumners, C
AF Bennion, Douglas M.
   Isenberg, Jacob D.
   Harmel, Allison T.
   DeMars, Kelly
   Dang, Alex N.
   Jones, Chad H.
   Pignataro, Megan E.
   Graham, Justin T.
   Steckelings, U. Muscha
   Alexander, Jon C.
   Febo, Marcelo
   Krause, Eric G.
   de Kloet, Annette D.
   Candelario-Jalil, Eduardo
   Sumners, Colin
TI Post-stroke angiotensin II type 2 receptor activation provides long-term
   neuro-protection in aged rats
SO PLOS ONE
LA English
DT Article
ID CEREBRAL-ARTERY OCCLUSION; ISCHEMIC-STROKE; CAUSES NEUROPROTECTION;
   COMPOUND 21; BRAIN; STIMULATION; CEREBROPROTECTION; SYSTEM; MODEL; MICE
AB Activation of the angiotensin II type 2 receptor (AT2R) by administration of Compound 21 (C21), a selective AT2R agonist, induces neuroprotection in models of ischemic stroke in young adult animals. The mechanisms of this neuroprotective action are varied, and may include direct and indirect effects of AT2R activation. Our objectives were to assess the long-term protective effects of post-stroke C21 treatments in a clinically-relevant model of stroke in aged rats and to characterize the cellular localization of AT2Rs in the mouse brain of transgenic reporter mice following stroke. Intraperitoneal injections of C21 (0.03mg/kg) after ischemic stroke induced by transient monofilament middle cerebral artery occlusion resulted in protective effects that were sustained for up to at least 3-weeks post-stroke. These included improved neurological function across multiple assessments and a significant reduction in infarct volume as assessed by magnetic resonance imaging. We also found AT2R expression to be on neurons, not astrocytes or microglia, in normal female and male mouse brains. Stroke did not induce altered cellular localization of AT2R when assessed at 7 and 14 days post-stroke. These findings demonstrate that the neuroprotection previously characterized only during earlier time points using stroke models in young animals is sustained long-term in aged rats, implying even greater clinical relevance for the study of AT2R agonists for the acute treatment of ischemic stroke in human disease. Further, it appears that this sustained neuroprotection is likely due to a mix of both direct and indirect effects stemming from selective activation of AT2Rs on neurons or other cells besides astrocytes and microglia.
EM csumners@ufl.edu
RI Candelario-Jalil, Eduardo/I-1139-2019
OI Candelario-Jalil, Eduardo/0000-0003-3631-1989; Krause,
   Eric/0000-0002-2718-3113; Steckelings, Ulrike
   Muscha/0000-0002-5430-4275; Sumners, Colin/0000-0002-9689-2255; de
   Kloet, Annette/0000-0002-7213-6957
FU American Heart Association [12PRE11940010]; National Heart Lung and
   Blood Institute [2T32HL083810-06A1]; McKnight Brain Institute at the
   University of Florida
FX Support for this study was provided by the American Heart Association
   (12PRE11940010, CS), National Heart Lung and Blood Institute
   (2T32HL083810-06A1, DMB), and the McKnight Brain Institute at the
   University of Florida (DMB). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript
CR Alhusban A, 2015, J HYPERTENS, V33, P170, DOI 10.1097/HJH.0000000000000364
   Bennion DM, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-014-0512-2
   Bosnyak S, 2011, CLIN SCI, V121, P297, DOI 10.1042/CS20110036
   Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125
   de Kloet AD, 2014, BRAIN STRUCT FUNCT
   Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128
   Fouda AY, 2016, CLIN SCI, V130, P221, DOI 10.1042/CS20150350
   Hawkins KE, 2013, J NEUROCHEM
   Joseph JP, 2014, NEUROPHARMACOLOGY, V81, P134, DOI 10.1016/j.neuropharm.2014.01.044
   Kagiyama T, 2003, REGUL PEPTIDES, V110, P241, DOI 10.1016/S0167-0115(02)00223-9
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lee Seyoung, 2012, Exp Transl Stroke Med, V4, P16, DOI 10.1186/2040-7378-4-16
   Li J, 2005, FASEB J, V19, P617, DOI 10.1096/fj.04-2960fje
   Makino I, 1996, NEUROPEPTIDES, V30, P596, DOI 10.1016/S0143-4179(96)90043-8
   Mateos L, 2016, BIOCHIM BIOPHYS ACTA
   McCarthy CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095762
   McCarthy CA, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0440-1
   McCarthy CA, 2012, HYPERTENSION, V60, P1531, DOI 10.1161/HYPERTENSIONAHA.112.199646
   McCarthy CA, 2009, STROKE, V40, P1482, DOI 10.1161/STROKEAHA.108.531509
   Mecca AP, 2011, EXP PHYSIOL, V96, P1084, DOI 10.1113/expphysiol.2011.058578
   Mecca AP, 2009, EXP PHYSIOL, V94, P937, DOI 10.1113/expphysiol.2009.047936
   Min LJ, 2014, AM J HYPERTENS, V27, P1036, DOI 10.1093/ajh/hpu015
   Miyamoto N, 2008, NEUROSCI RES, V61, P249, DOI 10.1016/j.neures.2008.03.003
   Regenhardt RW, 2013, NEUROPHARMACOLOGY, V71, P154, DOI 10.1016/j.neuropharm.2013.03.025
   Schwengel K, 2016, J MOL MED BERL
   Villela D, 2015, CLIN SCI, V128, P227, DOI 10.1042/CS20130515
NR 26
TC 6
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 3
PY 2017
VL 12
IS 7
AR e0180738
DI 10.1371/journal.pone.0180738
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA2JX
UT WOS:000405268500084
PM 28671997
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bengtson, S
   Knudsen, KB
   Kyjovska, ZO
   Berthing, T
   Skaug, V
   Levin, M
   Koponen, IK
   Shivayogimath, A
   Booth, TJ
   Alonso, B
   Pesquera, A
   Zurutuza, A
   Thomsen, BL
   Troelsen, JT
   Jacobsen, NR
   Vogel, U
AF Bengtson, Stefan
   Knudsen, Kristina B.
   Kyjovska, Zdenka O.
   Berthing, Trine
   Skaug, Vidar
   Levin, Marcus
   Koponen, Ismo K.
   Shivayogimath, Abhay
   Booth, Timothy J.
   Alonso, Beatriz
   Pesquera, Amaia
   Zurutuza, Amaia
   Thomsen, Birthe L.
   Troelsen, Jesper T.
   Jacobsen, Nicklas R.
   Vogel, Ulla
TI Differences in inflammation and acute phase response but similar
   genotoxicity in mice following pulmonary exposure to graphene oxide and
   reduced graphene oxide
SO PLOS ONE
LA English
DT Article
ID WALLED CARBON NANOTUBES; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE;
   MOUSE LUNG; MECHANICAL-PROPERTIES; DIOXIDE PARTICLES; NANOPARTICLES;
   INSTILLATION; INHALATION; TOXICITY
AB We investigated toxicity of 2-3 layered >1 mu m sized graphene oxide (GO) and reduced graphene oxide (rGO) in mice following single intratracheal exposure with respect to pulmonary inflammation, acute phase response (biomarker for risk of cardiovascular disease) and genotoxicity. In addition, we assessed exposure levels of particulate matter emitted during production of graphene in a clean room and in a normal industrial environment using chemical vapour deposition. Toxicity was evaluated at day 1, 3, 28 and 90 days (18, 54 and 162 mu g/mouse), except for GO exposed mice at day 28 and 90 where only the lowest dose was evaluated. GO induced a strong acute inflammatory response together with a pulmonary (Serum-Amyloid A, Saa3) and hepatic (Saa1) acute phase response. rGO induced less acute, but a constant and prolonged inflammation up to day 90. Lung histopathology showed particle agglomerates at day 90 without signs of fibrosis. In addition, DNA damage in BAL cells was observed across time points and doses for both GO and rGO. In conclusion, pulmonary exposure to GO and rGO induced inflammation, acute phase response and genotoxicity but no fibrosis.
C1 [Bengtson, Stefan; Knudsen, Kristina B.; Kyjovska, Zdenka O.; Berthing, Trine; Levin, Marcus; Koponen, Ismo K.; Thomsen, Birthe L.; Jacobsen, Nicklas R.; Vogel, Ulla] Natl Res Ctr Working Environm, Copenhagen O, Denmark.
   [Bengtson, Stefan; Troelsen, Jesper T.] Roskilde Univ, Dept Sci & Environm, Roskilde, Denmark.
   [Skaug, Vidar] Natl Inst Occupat Hlth, Oslo, Norway.
   [Shivayogimath, Abhay; Booth, Timothy J.; Vogel, Ulla] Tech Univ Denmark, Dept Micro & Nanotechnol, Lyngby, Denmark.
   [Alonso, Beatriz; Pesquera, Amaia; Zurutuza, Amaia] Graphenea SA, R&D Dept, San Sebastian, Spain.
RP Vogel, U (reprint author), Natl Res Ctr Working Environm, Copenhagen O, Denmark.; Vogel, U (reprint author), Tech Univ Denmark, Dept Micro & Nanotechnol, Lyngby, Denmark.
EM ubv@nrcwe.dk
RI Troelsen, Jesper Thorvald T/B-6264-2013; Vogel, Ulla/I-5048-2012
OI Troelsen, Jesper Thorvald T/0000-0002-4177-3267; bram knudsen,
   kristina/0000-0001-9362-2893; Berthing, Trine/0000-0003-0723-9869;
   Vogel, Ulla/0000-0001-6807-1524; Bengtson, Stefan/0000-0001-6174-2161
FU European Union Seventh Framework Programme [FP7-604000]
FX The work leading to these results has received funding from the European
   Union Seventh Framework Programme (FP7/2007-2013) under grant agreement
   no FP7-604000. The funder provided support in the form of salaries for
   authors [BA, AP, AZ], but did not have any additional role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Asbach C, 2014, MEASUREMENT MONITORI
   Bengtson S, 2016, ENVIRON MOL MUTAGEN, V57, P469, DOI 10.1002/em.22017
   Bianco A, 2013, CARBON, V65, P1, DOI 10.1016/j.carbon.2013.08.038
   Bourdon JA, 2012, TOXICOL SCI, V127, P474, DOI 10.1093/toxsci/kfs119
   Bourdon JA, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-5
   Bussy C, 2013, ACCOUNTS CHEM RES, V46, P692, DOI 10.1021/ar300199e
   Christophersen DV, 2016, TOXICOLOGY, V371, P29, DOI 10.1016/j.tox.2016.10.003
   Dong L, 2009, J ASTHMA, V46, P229, DOI 10.1080/02770900802610050
   Dong Z, 2011, MOL MED, V17, P1357, DOI 10.2119/molmed.2011.00186
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Driscoll KE, 2000, TOXICOL SCI, V55, P24, DOI 10.1093/toxsci/55.1.24
   Duch MC, 2011, NANO LETT, V11, P5201, DOI 10.1021/nl202515a
   Halappanavar S, 2011, ENVIRON MOL MUTAGEN, V52, P425, DOI 10.1002/em.20639
   Heitbrink WA, 2015, J OCCUP ENVIRON HYG, V12, P16, DOI 10.1080/15459624.2014.930559
   Husain M, 2013, TOXICOL APPL PHARM, V269, P250, DOI 10.1016/j.taap.2013.03.018
   Jackson P, 2015, ENVIRON MOL MUTAGEN, V56, P183, DOI 10.1002/em.21922
   Jackson P, 2013, MUTAGENESIS, V28, P699, DOI 10.1093/mutage/get049
   Jackson P, 2011, BASIC CLIN PHARMACOL, V108, P202, DOI 10.1111/j.1742-7843.2010.00644.x
   Jacobsen NR, 2008, MUTAT RES-FUND MOL M, V641, P54, DOI 10.1016/j.mrfmmm.2008.03.001
   Jacobsen NR, 2008, ENVIRON MOL MUTAGEN, V49, P476, DOI 10.1002/em.20406
   Jacobsen NR, 2007, ENVIRON MOL MUTAGEN, V48, P451, DOI 10.1002/em.20300
   Jacobsen NR, 2011, ENVIRON MOL MUTAGEN, V52, P331, DOI 10.1002/em.20629
   Jacobsen NR, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-2
   Jayjock MA, 2011, J OCCUP ENVIRON HYG, V8, pD114, DOI 10.1080/15459624.2011.624387
   Johnson BD, 2004, CIRCULATION, V109, P726, DOI 10.1161/01.CIR.0000115516.54550.B1
   Kaminski H, 2015, AEROSOL AIR QUAL RES, V15, P129, DOI 10.4209/aaqr.2014.03.0065
   Kaptoge S, 2012, NEW ENGL J MED, V367, P1310, DOI 10.1056/NEJMoa1107477
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JK, 2015, NANOTOXICOLOGY, V10, P1, DOI DOI 10.1108/0IR-01-2015-0022
   Koivisto AJ, 2014, INT J ENV RES PUB HE, V11, P5382, DOI 10.3390/ijerph110505382
   Kyjovska ZO, 2015, MUTAGENESIS, V30, P499, DOI 10.1093/mutage/gev009
   Kyjovska ZO, 2015, ENVIRON MOL MUTAGEN, V56, P41, DOI 10.1002/em.21888
   Li B, 2013, NPG ASIA MATER, V5, DOI 10.1038/am.2013.7
   Lindhorst E, 1997, BBA-PROTEIN STRUCT M, V1339, P143, DOI 10.1016/S0167-4838(96)00227-0
   Liu JH, 2015, TOXICOL RES-UK, V4, P83, DOI 10.1039/c4tx00044g
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma-Hock L, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-23
   Mao L, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0120-1
   Mikkelsen L, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-32
   Moller P, 2016, CRIT REV TOXICOL, V46, P437, DOI 10.3109/10408444.2016.1149451
   Morimoto Y, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-4
   Novoselov KS, 2012, NATURE, V490, P192, DOI 10.1038/nature11458
   Paci JT, 2007, J PHYS CHEM C, V111, P18099, DOI 10.1021/jp075799g
   Park EJ, 2014, ARCH TOXICOL, V89
   Park S, 2009, NAT NANOTECHNOL, V4, P217, DOI [10.1038/nnano.2009.58, 10.1038/NNANO.2009.58]
   Poulsen SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174167
   Poulsen SS, 2015, TOXICOL APPL PHARM, V284, P16, DOI 10.1016/j.taap.2014.12.011
   Poulsen SS, 2015, TOXICOL APPL PHARM, V283, P210, DOI 10.1016/j.taap.2015.01.011
   Poulsen SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080452
   Poulsen SS, 2016, NANOTOXICOLOGY, P1
   Ren WC, 2014, NAT NANOTECHNOL, V9, P726, DOI 10.1038/nnano.2014.229
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Saber AT, 2014, WIRES NANOMED NANOBI, V6, P517, DOI 10.1002/wnan.1279
   Saber AT, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0148-2
   Saber AT, 2012, NANOTOXICOLOGY, V6, P453, DOI 10.3109/17435390.2011.587900
   Saber AT, 2012, NANOTOXICOLOGY, V6, P776, DOI 10.3109/17435390.2011.620745
   Saber AT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069020
   Saber AT, 2005, ARCH TOXICOL, V79, P177, DOI 10.1007/s00204-004-0613-9
   Saber AT, 2012, PART FIBRE TOXICOL, V9, P1
   Schinwald A, 2014, NANOTOXICOLOGY, V8, P824, DOI 10.3109/17435390.2013.831502
   Schinwald A, 2012, ACS NANO, V6, P736, DOI 10.1021/nn204229f
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Fonseca AS, 2015, ANN OCCUP HYG, V59, P586, DOI 10.1093/annhyg/meu110
   Su WC, 2016, J OCCUP ENVIRON HYG, V13, P48, DOI 10.1080/15459624.2015.1076162
   Suk JW, 2010, ACS NANO, V4, P6557, DOI 10.1021/nn101781v
   Sydlik SA, 2015, ACS NANO, V9, P3866, DOI 10.1021/acsnano.5b01290
   Taubes G, 2002, SCIENCE, V296, P242, DOI 10.1126/science.296.5566.242
   The National Institutes for Occupational Safety and Health, 2013, NAT I OCC SAF HLTH C, V65, P2013
   Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600
   Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x
   UK Intellectual Property Office Informatics Team, 2015, 0RAPH WORLDW PAT LAN
   Wallin H, 2016, MUTAGENESIS
   Warheit DB, 2003, EXP LUNG RES, V29, P593, DOI 10.1080/01902140390240104
   Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228
   Westberg H, 2016, INT ARCH OCC ENV HEA, V89, P813, DOI 10.1007/s00420-016-1119-5
   Wick P, 2014, ANGEW CHEM INT EDIT, V53, P7714, DOI 10.1002/anie.201403335
   Xu M, 2016, ACS NANO, V10, P3267, DOI [10.1021/acsnano.6b00539, 10.1021/acsnano.5b00539]
   Zhang WD, 2015, TOXICOL LETT, V237, P61, DOI 10.1016/j.toxlet.2015.05.021
   Zhang Y, 2013, ACCOUNTS CHEM RES, V46, P2329, DOI 10.1021/ar300203n
   Zurutuza A, 2014, NAT NANOTECHNOL, V9, P730, DOI 10.1038/nnano.2014.225
NR 80
TC 12
Z9 12
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 1
PY 2017
VL 12
IS 6
AR e0178355
DI 10.1371/journal.pone.0178355
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EW6HZ
UT WOS:000402611800040
PM 28570647
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hirose, T
   Tanaka, Y
   Tanaka, A
   Sakai, H
   Sasaki, Y
   Shinohara, N
   Ohdan, H
AF Hirose, Takayuki
   Tanaka, Yuka
   Tanaka, Asuka
   Sakai, Hiroshi
   Sasaki, Yu
   Shinohara, Nobuo
   Ohdan, Hideki
TI PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice
SO PLOS ONE
LA English
DT Article
ID REGULATORY B-CELLS; DONOR-SPECIFIC TRANSFUSION; TRANSPLANTATION
   TOLERANCE; ANTIGEN PRESENTATION; ALLOGRAFT-REJECTION;
   AUTOIMMUNE-DISEASE; B10 CELLS; RESPONSES; BLOCKADE; DIFFERENTIATION
AB B cells constitute a complex system of antigen-presenting cells (APCs) and exist as distinct subsets that differ in their lineage affiliation, surface molecule expression, and biological function, thus potentially regulating the immune response. In this study, we investigated the immune-regulatory roles of murine B cell subsets as regulatory APCs targeting alloreactive T cells. Either splenic B cells, peritoneal cavity (PerC) B cells, or non-B cells from Balb/c mice were intravenously injected into B6 mice. Serum levels of anti-Balb/c antibodies in the recipients of PerC B cells were significantly lower than those in the recipients of splenic B cells and PerC non-B cells, as determined over a 4-week period after the injection. Mixed-lymphocyte reaction (MLR) assays using splenocytes from the B6 mice at 2 weeks after the injection revealed the significantly reduced anti-Balb/c T cell-responses in the recipients of PerC B cells, as compared to those in the recipients of splenic B cells or untreated control mice. Since PerC B cells contained MHC class II+ CD80(+) CD86(+) PD-L1(+) PD-L2(+\) cells among the CD5(+) B-1a cell subset, PerC B cells from Balb/c mice were pre-incubated with anti-PD-L1/PD-L2 mAbs prior to injection. This treatment abrogated their immune-regulatory effects on anti-Balb/c T cells in the MLR assays. In addition, the inoculation with Balb/c PerC B cells significantly prolonged the survival of subsequently grafted Balb/c hearts in B6 mouse recipients, whereas that with SPL B cells did not. These findings indicate that the PerC B cells, including PD-L1/PD-L2 B-1a cells, may suppress T cells responding to allostimulation, and thus may be optimal for donor lymphocyte injection.
C1 [Hirose, Takayuki; Tanaka, Yuka; Tanaka, Asuka; Sakai, Hiroshi; Sasaki, Yu; Ohdan, Hideki] Hiroshima Univ, Inst Biomed & Hlth Sci, Appl Life Sci, Dept Gastroenterol & Transplant Surg, Hiroshima, Japan.
   [Hirose, Takayuki; Shinohara, Nobuo] Hokkaido Univ, Grad Sch Med, Dept Renal & Genitourinary Surg, Sapporo, Hokkaido, Japan.
RP Ohdan, H (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Appl Life Sci, Dept Gastroenterol & Transplant Surg, Hiroshima, Japan.
EM hohdan@hiroshima-u.ac.jp
RI Ohdan, Hideki/G-4719-2019; Tanaka, Yuka/G-9580-2019
OI Ohdan, Hideki/0000-0002-9066-1288; 
FU Ministry of Education, Culture, Sports, Science and Technology
   [15H02555]
FX We thank Dr. Jinlian Piao for expert technical assistance. This work was
   carried out in part at the Analysis Center of Life Science, Hiroshima
   University. This work was carried out in part at the Research Facilities
   for Laboratory Animal Science, Natural Science Center for Basic Research
   and Development (N-BARD), Hiroshima University. This work was supported
   by a Grant-in-Aid for Scientific Research (A) from the Ministry of
   Education, Culture, Sports, Science and Technology (15H02555).; This
   work was carried out in part at the Research Facilities for Laboratory
   Animal Science, Natural Science Center for Basic Research and
   Development (N-BARD), Hiroshima University. This work was supported by a
   Grant-in-Aid for Scientific Research (A) from the Ministry of Education,
   Culture, Sports, Science and Technology (15H02555). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Barnett LG, 2014, J IMMUNOL, V192, P3607, DOI 10.4049/jimmunol.1301284
   BRENNAN DC, 1995, AM J KIDNEY DIS, V26, P701, DOI 10.1016/0272-6386(95)90432-8
   Chai JG, 2015, EUR J IMMUNOL, V45, P2017, DOI 10.1002/eji.201545455
   Chesneau M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00497
   Choi YS, 2008, J EXP MED, V205, P3053, DOI 10.1084/jem.20080979
   DiLillo DJ, 2010, ANN NY ACAD SCI, V1183, P38, DOI 10.1111/j.1749-6632.2009.05137.x
   Ding Q, 2011, CLIN INVESTIGATOR, V121, P3645, DOI DOI 10.1172/JCI46274
   Du JF, 2009, TRANSPL P, V41, P1840, DOI [10.1016/j.transproceed.2009.01.106, DOI 10.1016/J.TRANSPROCEED.2009.01.106]
   Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868
   Gao JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077761
   Ghosn EEB, 2008, P NATL ACAD SCI USA, V105, P5195, DOI 10.1073/pnas.0712350105
   Hastings WD, 2006, EUR J IMMUNOL, V36, P1114, DOI 10.1002/eji.200535142
   Kalampokis I, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3907
   KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320
   Khan AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6997
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klinker MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070131
   Knight AM, 2015, EUR J IMMUNOL, V45, P1600, DOI 10.1002/eji.201545684
   KRAAL G, 1992, INT REV CYTOL, V132, P31, DOI 10.1016/S0074-7696(08)62453-5
   Lal G, 2015, TRANSPLANTATION, V99, P1817, DOI 10.1097/TP.0000000000000718
   Marti HP, 2006, TRANSPLANT INT, V19, P19, DOI 10.1111/j.1432-2277.2005.00233.x
   Molnarfi N, 2013, J EXP MED, V210, P2921, DOI 10.1084/jem.20130699
   Montecino-Rodriguez E, 2006, NAT IMMUNOL, V7, P293, DOI 10.1038/ni1301
   Montecino-Rodriguez E, 2012, IMMUNITY, V36, P13, DOI 10.1016/j.immuni.2011.11.017
   Muzzio DO, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00006
   Noorchashm H, 2006, J IMMUNOL, V177, P7715, DOI 10.4049/jimmunol.177.11.7715
   Ohdan H, 1999, J CLIN INVEST, V104, P281, DOI 10.1172/JCI6656
   Ohdan Zhou, 2005, TRANSPL P, V37, P1808
   Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935
   Onoe T, 2005, J IMMUNOL, V175, P139, DOI 10.4049/jimmunol.175.1.139
   Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005
   Rosser EC, 2014, MOL IMMUNOL, V62, P296, DOI 10.1016/j.molimm.2014.01.014
   Rozali EN, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/656340
   Sandner SE, 2005, AM J TRANSPLANT, V5, P31, DOI 10.1111/j.1600-6143.2004.00640.x
   Tanaka Y, 2004, IMMUNOL INVEST, V33, P309, DOI 10.1081/IMM-120038079
   Tazawa H, 2013, BLOOD, V122, P2582, DOI 10.1182/blood-2012-02-407452
   WANG H., 2015, EURASIP J WIREL COMM, V2015, P1, DOI DOI 10.1016/J.TPLANTS.2015.04.003
   Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554
   Wu DL, 1996, VET IMMUNOL IMMUNOP, V55, P63, DOI 10.1016/S0165-2427(96)05631-0
   Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017
   Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501
   Young KJ, 2002, BLOOD, V100, P3408, DOI 10.1182/blood-2002-01-0235
   Zhong XM, 2007, EUR J IMMUNOL, V37, P2405, DOI 10.1002/eji.200737461
NR 43
TC 6
Z9 6
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 1
PY 2017
VL 12
IS 6
AR e0178765
DI 10.1371/journal.pone.0178765
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EW6HZ
UT WOS:000402611800119
PM 28570665
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Choy, KW
   Lau, YS
   Murugan, D
   Mustafa, MR
AF Choy, Ker Woon
   Lau, Yeh Siang
   Murugan, Dharmani
   Mustafa, Mohd Rais
TI Chronic treatment with paeonol improves endothelial function in mice
   through inhibition of endoplasmic reticulum stress-mediated oxidative
   stress
SO PLOS ONE
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; BLOOD-PRESSURE; INDUCED APOPTOSIS; CARDIAC
   DAMAGE; NITRIC-OXIDE; MUSCLE-CELLS; ER STRESS; DYSFUNCTION;
   HYPERTENSION; ACTIVATION
AB Endoplasmic reticulum (ER) stress leads to endothelial dysfunction which is commonly associated in the pathogenesis of several cardiovascular diseases. We explored the vascular protective effects of chronic treatment with paeonol (2'-hydroxy-4'-methoxyacetophenone), the major compound from the root bark of Paeonia suffruticosa on ER stress-induced endothelial dysfunction in mice. Male C57BL/6J mice were injected intraperitoneally with ER stress inducer, tunicamycin (1 mg/kg/week) for 2 weeks to induce ER stress. The animals were co-administered with or without paeonol (20 mg/kg/oral gavage), reactive oxygen species (ROS) scavenger, tempol (20 mg/kg/day) or ER stress inhibitor, tauroursodeoxycholic acid (TUDCA, 150 mg/kg/day) respectively. Blood pressure and body weight were monitored weekly and at the end of treatment, the aorta was isolated for isometric force measurement. Protein associated with ER stress (GRP78, ATF6 and p-elF2 alpha) and oxidative stress (NOX2 and nitrotyrosine) were evaluated using Western blotting. Nitric oxide (NO) bioavailability were determined using total nitrate/nitrite assay and western blotting (phosphorylation of eNOS protein). ROS production was assessed by en face dihydroethidium staining and lucigenin-enhanced chemiluminescence assay, respectively. Our results revealed that mice treated with tunicamycin showed an increased blood pressure, reduction in body weight and impairment of endothelium-dependent relaxations (EDRs) of aorta, which were ameliorated by co-treatment with either paeonol, TUDCA and tempol. Furthermore, paeonol reduced the ROS level in the mouse aorta and improved NO bioavailability in tunicamycin treated mice. These beneficial effects of paeonol observed were comparable to those produced by TUDCA and tempol, suggesting that the actions of paeonol may involve inhibition of ER stress-mediated oxidative stress pathway. Taken together, the present results suggest that chronic treatment with paeonol preserved endothelial function and normalized blood pressure in mice induced by tunicamycin in vivo through the inhibition of ER stress-associated ROS.
C1 [Choy, Ker Woon; Lau, Yeh Siang; Murugan, Dharmani; Mustafa, Mohd Rais] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur, Malaysia.
RP Mustafa, MR (reprint author), Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur, Malaysia.
EM rais@um.edu.my
RI Lahuddin, Haslinda/S-1588-2017; Mustafa, Mohamed/B-1647-2009; Lau, Yeh
   Siang/D-2136-2016; MURUGAN, DHARMANI DEVI/B-8436-2010
OI Mustafa, Mohamed/0000-0002-7864-5189; Lau, Yeh
   Siang/0000-0002-1770-3058; Ker Woon, Choy/0000-0002-8432-9035
FU postgraduate research fund (PPP) [PG254-2015B]; Fundamental Research
   Grant Scheme (FRGS) [FP021-2016, FRGS/1/2016/SKK10/UM/01/1]
FX This study was funded by postgraduate research fund (PPP): Project
   number PG254-2015B and Fundamental Research Grant Scheme (FRGS): Project
   code FP021-2016 (Reference code: FRGS/1/2016/SKK10/UM/01/1).
CR Al-Magableh MR, 2015, HYPERTENS RES, V38, P13, DOI 10.1038/hr.2014.125
   Baradaran A, 2014, J RES MED SCI, V19, P358
   Bhandary B, 2013, INT J MOL SCI, V14, P434, DOI 10.3390/ijms14010434
   Brozovic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076397
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Choi SK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31925
   Choy KW, 2016, BIOCHEM PHARMACOL, V116, P51, DOI 10.1016/j.bcp.2016.07.013
   Demirtas L, 2016, INDIAN J MED RES, V144, P515, DOI 10.4103/0971-5916.200887
   Ding Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154375
   Dornas WC, 2017, SCI REP-UK, V7, DOI 10.1038/srep46051
   Fan LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062627
   Forstermann U, 2017, CIRC RES, V120, P713, DOI 10.1161/CIRCRESAHA.116.309326
   Fu Pin-Kuei, 2012, Evid Based Complement Alternat Med, V2012, P837513, DOI 10.1155/2012/837513
   Galan M, 2014, BBA-MOL CELL RES, V1843, P1063, DOI 10.1016/j.bbamcr.2014.02.009
   Galan M, 2012, HYPERTENSION, V60, P71, DOI 10.1161/HYPERTENSIONAHA.112.192500
   Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7
   Harrison DG, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00128
   Higashi Y, 2014, TRENDS CARDIOVAS MED, V24, P165, DOI 10.1016/j.tcm.2013.12.001
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hsieh CL, 2006, J ETHNOPHARMACOL, V106, P208, DOI 10.1016/j.jep.2005.12.027
   Huang PL, 2009, TRENDS ENDOCRIN MET, V20, P295, DOI 10.1016/j.tem.2009.03.005
   Isodono K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009746
   Kalinowski L, 2004, ACTA BIOCHIM POL, V51, P459
   Kassan M, 2011, J DIABETES METABOLIS, P2
   Kassan M, 2012, ARTERIOSCL THROM VAS, V32, P1652, DOI 10.1161/ATVBAHA.112.249318
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Laurindo FRM, 2014, ANTIOXID REDOX SIGN, V20, P2755, DOI 10.1089/ars.2013.5605
   Lee H, 2013, ECAM, V2013
   Li G, 2010, J CELL BIOL, V191, P1113, DOI 10.1083/jcb.201006121
   Li HK, 2009, PLANTA MED, V75, P7, DOI 10.1055/s-0028-1088332
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048872
   Li HG, 2014, ATHEROSCLEROSIS, V237, P208, DOI 10.1016/j.atherosclerosis.2014.09.001
   Li JF, 2003, NEUROSCI LETT, V350, P173, DOI 10.1016/S0304-3940(03)00881-4
   Liang B, 2013, ARTERIOSCL THROM VAS, V33, P595, DOI 10.1161/ATVBAHA.112.300606
   Lin C, 2015, INT J MOL SCI, V16, P8844, DOI 10.3390/ijms16048844
   Liu JP, 2013, J MED FOOD, V16, P577, DOI 10.1089/jmf.2012.2654
   Ma LN, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00298
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Mihalj M, 2016, KIDNEY BLOOD PRESS R, V41, P721, DOI 10.1159/000450562
   Minamino T, 2010, CIRC RES, V107, P1071, DOI 10.1161/CIRCRESAHA.110.227819
   Minamino T, 2010, J MOL CELL CARDIOL, V48, P1105, DOI 10.1016/j.yjmcc.2009.10.026
   Montezano AC, 2012, ANN MED, V44, pS2, DOI 10.3109/07853890.2011.653393
   Murugan D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145413
   Paravicini TM, 2006, CARDIOVASC RES, V71, P247, DOI 10.1016/j.cardiores.2006.05.001
   Rafieian-Kopaei Mahmoud, 2013, J Nephropathol, V2, P152, DOI 10.12860/JNP.2013.26
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Santos CXC, 2014, ANTIOXID REDOX SIGN, V20, P121, DOI 10.1089/ars.2013.5262
   Santos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI [10.1089/ars.2009.2625, 10.1089/ARS.2009.2625]
   Scull CM, 2011, ARTERIOSCL THROM VAS, V31, P2792, DOI 10.1161/ATVBAHA.111.224881
   Shi XJ, 2016, MOL MED REP, V14, P2397, DOI 10.3892/mmr.2016.5573
   Spitler KM, 2013, AM J PHYSIOL-HEART C, V305, pH344, DOI 10.1152/ajpheart.00952.2012
   Tabet F, 2004, J CARDIOVASC PHARM, V44, P200, DOI 10.1097/00005344-200408000-00009
   Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F
   Touyz RM, 2004, HYPERTENSION, V44, P248, DOI 10.1161/01.HYP.0000138070.47616.9d
   Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131
   Xu J, 2009, HYPERTENSION, V54, P625, DOI 10.1161/HYPERTENSIONAHA.109.133736
   Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327
   Zhang JY, 2013, CHIN J INTEGR MED, V19, P510, DOI 10.1007/s11655-013-1505-8
   Zhang L H, 1996, Zhongguo Zhong Xi Yi Jie He Za Zhi, V16, P187
   Zhang YM, 2011, FREE RADICAL BIO MED, V51, P2172, DOI 10.1016/j.freeradbiomed.2011.09.005
   Zhu Y-P, 1998, PHARM APPL
   Zuo L, 2015, ACTA PHYSIOL, V214, P329, DOI 10.1111/apha.12515
   Zuo Li, 2013, [Frontiers in Biology, ], V8, P305
NR 64
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2017
VL 12
IS 5
AR e0178365
DI 10.1371/journal.pone.0178365
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EW6GY
UT WOS:000402608700054
PM 28562691
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Collins, A
   Ross, J
   Lang, SH
AF Collins, Anne
   Ross, Janine
   Lang, Shona H.
TI A systematic review of the asymmetric inheritance of cellular organelles
   in eukaryotes: A critique of basic science validity and imprecision
SO PLOS ONE
LA English
DT Review
ID SARA ENDOSOMES; STEM-CELL; SPINDLE ORIENTATION; NOTCH TRAFFICKING;
   DAUGHTER CELLS; CENTROSOME; DIVISION; MITOCHONDRIA; SEGREGATION;
   CLEAVAGE
AB We performed a systematic review to identify all original publications describing the asymmetric inheritance of cellular organelles in normal animal eukaryotic cells and to critique the validity and imprecision of the evidence. Searches were performed in Embase, MEDLINE and Pubmed up to November 2015. Screening of titles, abstracts and full papers was performed by two independent reviewers. Data extraction and validity were performed by one reviewer and checked by a second reviewer. Study quality was assessed using the SYRCLE risk of bias tool, for animal studies and by developing validity tools for the experimental model, organelle markers and imprecision. A narrative data synthesis was performed. We identified 31 studies (34 publications) of the asymmetric inheritance of organelles after mitotic or meiotic division. Studies for the asymmetric inheritance of centrosomes (n = 9); endosomes (n = 6), P granules (n = 4), the midbody (n = 3), mitochondria (n = 3), proteosomes (n = 2), spectrosomes (n = 2), cilia (n = 2) and endoplasmic reticulum (n = 2) were identified. Asymmetry was defined and quantified by variable methods. Assessment of the statistical reliability of the results indicated only two studies (7%) were judged to have low concern, the majority of studies (77`)/o) were 'unclear' and five (16`)/o) were judged to have 'high concerns'; the main reasons were low technical repeats (<10). Assessment of model validity indicated that the majority of studies (61`)/o) were judged to be valid, ten studies (32`)/o) were unclear and two studies (7%) were judged to have 'high concerns'; both described 'stem cells' without providing experimental evidence to confirm this (pluripotency and self-renewal). Assessment of marker validity indicated that no studies had low concern, most studies were unclear (96.5%), indicating there were insufficient details to judge if the markers were appropriate. One study had high concern for marker validity due to the contradictory results of two markers for the same organelle. For most studies the validity and imprecision of results could not be confirmed. In particular, data were limited due to a lack of reporting of interassay variability, sample size calculations, controls and functional validation of organelle markers. An evaluation of 16 systematic reviews containing cell assays found that only 50% reported adherence to PRISMA or ARRIVE reporting guidelines and 38% reported a formal risk of bias assessment. 44% of the reviews did not consider how relevant or valid the models were to the research question. 75% reviews did not consider how valid the markers were. 69% of reviews did not consider the impact of the statistical reliability of the results. Future systematic reviews in basic or preclinical research should ensure the rigorous reporting of the statistical reliability of the results in addition to the validity of the methods. Increased awareness of the importance of reporting guidelines and validation tools is needed for the scientific community.
C1 [Collins, Anne] Univ York, Dept Biol, Heslington, England.
   [Ross, Janine; Lang, Shona H.] Independent, York, N Yorkshire, England.
RP Lang, SH (reprint author), Independent, York, N Yorkshire, England.
EM shlang@hotmail.co.uk
RI Lang, Shona Helen/M-8397-2019
OI Lang, Shona Helen/0000-0002-4883-8393
FU Dutch Cancer Society Alpe d'HuZes/KWF program [UL2014-7058]
FX AC is supported by a grant received from the Dutch Cancer Society Alpe
   d'HuZes/KWF program (UL2014-7058). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anderson CT, 2009, CURR BIOL, V19, P1498, DOI 10.1016/j.cub.2009.07.034
   Basham SE, 1999, DEV BIOL, V215, P253, DOI 10.1006/dbio.1999.9447
   Batista Napotnik T, 2016, FDS, V110, P1
   Beckmann J, 2007, BLOOD, V109, P5494, DOI 10.1182/blood-2006-11-055921
   Birnie R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-r83
   Bouter Lex M, 2016, Res Integr Peer Rev, V1, P17, DOI 10.1186/s41073-016-0024-5
   Boyd L, 1996, DEVELOPMENT, V122, P3075
   Bus P, 2012, CELL ONCOL, V35, P149, DOI 10.1007/s13402-012-0076-6
   Pavan LMC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130476
   Chang JT, 2011, IMMUNITY, V34, P492, DOI 10.1016/j.immuni.2011.03.017
   Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726
   Conduit PT, 2010, CURR BIOL, V20, P2187, DOI 10.1016/j.cub.2010.11.055
   Coumailleau F, 2009, NATURE, V458, P1051, DOI 10.1038/nature07854
   Dalton CM, 2013, J CELL SCI, V126, P2955, DOI 10.1242/jcs.128744
   de Cuevas M, 1998, DEVELOPMENT, V125, P2781
   de Vries RBM, 2014, ILAR J, V55, P427, DOI 10.1093/ilar/ilu043
   Deng W, 1997, DEV BIOL, V189, P79, DOI 10.1006/dbio.1997.8669
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Emery G, 2005, CELL, V122, P763, DOI 10.1016/j.cell.2005.08.017
   Gallo CM, 2010, SCIENCE, V330, P1685, DOI 10.1126/science.1193697
   Goss JW, 2008, J CELL BIOL, V181, P1047, DOI 10.1083/jcb.200712137
   Grecchi S, 2014, EUROPEAN J HISTOCHEM, P58
   Gudbergsson JM, 2016, CYTOTECHNOLOGY, V68, P579, DOI 10.1007/s10616-015-9913-6
   Harkin DG, 2015, STEM CELLS, V33, P785, DOI 10.1002/stem.1895
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   HOLY J, 1991, J CELL SCI, V98, P423
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Hynes K, 2016, SEMIN ARTHRITIS RHEU, V46, P1, DOI 10.1016/j.semarthrit.2016.02.008
   Januschke J, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1245
   Katajisto P, 2015, SCIENCE, V348, P340, DOI 10.1126/science.1260384
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Korobelnik JF, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0035-x
   Korpershoek JV, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117690131
   Kressmann S, 2015, NAT CELL BIOL, V17, P333, DOI 10.1038/ncb3119
   Kuo TC, 2011, NAT CELL BIOL, V13, P1214, DOI 10.1038/ncb2332
   Lang S, 2014, RARE DISEASES ORJAM, P1
   Lang SH, 2009, J PATHOL, V217, P299, DOI 10.1002/path.2478
   Lang SH, 2010, STEM CELLS DEV, V19, P537, DOI 10.1089/scd.2009.0291
   Leadley RM, SYSTEMATIC REV PREVA
   LIN HF, 1995, DEV GENET, V16, P6, DOI 10.1002/dvg.1020160104
   Loubery S, 2014, CURR BIOL, V24, P2142, DOI 10.1016/j.cub.2014.07.054
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Montagne C, 2014, DEVELOPMENT, V141, P2014, DOI 10.1242/dev.104240
   Moylan EC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012047
   Ogrodnik M, 2014, P NATL ACAD SCI USA, V111, P8049, DOI 10.1073/pnas.1324035111
   Ouzzani M, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0384-4
   Pang KM, 2004, DEV BIOL, V265, P127, DOI 10.1016/j.ydbio.2003.09.024
   Petticrew M, 2001, BMJ-BRIT MED J, V322, P98, DOI 10.1136/bmj.322.7278.98
   Piotrowska-Nitsche K, 2012, CILIA, V1, P1
   Rahman NA, 2016, BRAIN RES, V1642, P532, DOI 10.1016/j.brainres.2016.04.024
   Ramamoorthi M, 2015, STEM CELLS INT, DOI 10.1155/2015/378368
   Rebollo E, 2007, DEV CELL, V12, P467, DOI 10.1016/j.devcel.2007.01.021
   Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222
   Rivolta MN, 2002, DEV BRAIN RES, V133, P49, DOI 10.1016/S0165-3806(01)00321-2
   Rose LS, 1998, DEVELOPMENT, V125, P1337
   Rusan NM, 2007, J CELL BIOL, V177, P13, DOI 10.1083/jcb.200612140
   Salzmann V, 2014, MOL BIOL CELL, V25, P267, DOI 10.1091/mbc.E13-09-0541
   Shanbhag S, 2016, TISSUE ENG PART B-RE, P23
   Shimizu T, 1996, ROUX ARCH DEV BIOL, V205, P290, DOI 10.1007/BF00365807
   Smyth JT, 2015, OPEN BIOL, P5
   Sterne JAC, 2016, NONRANDOMIZED STUDIE
   Tamura M, 2001, EXP CELL RES, V269, P130, DOI 10.1006/excr.2001.5305
   Vogt L, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000598
   Wang XQ, 2009, NATURE, V461, P947, DOI 10.1038/nature08435
   Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Xiao Z, 2011, AM J NEPHROL, V33, P558, DOI 10.1159/000328584
   Yamashita YM, 2007, SCIENCE, V315, P518, DOI 10.1126/science.1134910
NR 68
TC 2
Z9 2
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2017
VL 12
IS 5
AR e0178645
DI 10.1371/journal.pone.0178645
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EW6GY
UT WOS:000402608700080
PM 28562636
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Jun, HY
   Kim, TH
   Choi, JW
   Lee, YH
   Lee, KK
   Yoon, KH
AF Jun, Hong Young
   Kim, Tae-Hoon
   Choi, Jin Woo
   Lee, Young Hwan
   Lee, Kang Kyoo
   Yoon, Kwon-Ha
TI Evaluation of connectivity map-discovered celastrol as a
   radiosensitizing agent in a murine lung carcinoma model: Feasibility
   study of diffusion-weighted magnetic resonance imaging
SO PLOS ONE
LA English
DT Article
ID TUMOR RESPONSE; CANCER; MRI; RADIATION; CHEMOTHERAPY; THERAPY;
   CHEMORADIOTHERAPY; INHIBITION; MECHANISMS; MOLECULES
AB This study was designed to identify potential radiosensitizing (RS) agents for combined radio-and chemotherapy in a murine model of human lung carcinoma, and to evaluate the in vivo effect of the RS agents using diffusion-weighted magnetic resonance imaging (DWMRI). Radioresistance-associated genes in A549 and H460 cells were isolated on the basis of their gene expression profiles. Celastrol was selected as a candidate RS by using connectivity mapping, and its efficacy in lung cancer radiotherapy was tested. Mice inoculated with A549 carcinoma cells were treated with single ionizing radiation (SIR), single celastrol (SC), or celastrol-combined ionizing radiation (CCIR). Changes in radiosensitization over time were assessed using DW-MRI before and at 3, 6, and 12 days after therapy initiation. The tumors were stained with hematoxylin and eosin at 6 and 12 days after therapy. The percentage change in the apparent diffusion coefficient (ADC) value in the CCIR group was significantly higher than that in the SC and SIR group on the 12 th day (Mann-Whitney U-test, p = 0.05; Kruskal-Wallis test, p < 0.05). A significant correlation (Spearman's rho correlation coefficient of 0.713, p = 0.001) was observed between the mean percentage tumor necrotic area and the mean ADC values after therapy initiation. These results suggest that the novel radiosensitizing agent celastrol has therapeutic effects when combined with ionizing radiation (IR), thereby maximizing the therapeutic effect of radiation in non-small cell lung carcinoma. In addition, DW-MRI is a useful noninvasive tool to monitor the effects of RS agents by assessing cellularity changes and sequential therapeutic responses.
C1 [Jun, Hong Young; Kim, Tae-Hoon; Yoon, Kwon-Ha] Wonkwang Univ Hosp, Imaging Sci Res Ctr, Iksan, South Korea.
   [Choi, Jin Woo] Kyung Hee Univ, Coll Pharm, Lab Pharmacogenet, Seoul, South Korea.
   [Lee, Young Hwan; Yoon, Kwon-Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan, South Korea.
   [Lee, Kang Kyoo] Wonkwang Univ, Sch Med, Dept Radiat Oncol, Iksan, South Korea.
RP Yoon, KH (reprint author), Wonkwang Univ Hosp, Imaging Sci Res Ctr, Iksan, South Korea.; Yoon, KH (reprint author), Wonkwang Univ, Sch Med, Dept Radiol, Iksan, South Korea.
EM khy1646@wku.ac.kr
FU National Research Foundation of Korea; Korean government (MSIP)
   [NRF-2016M3A9A7918501]; Ministry of Health and Welfare, Republic of
   Korea [HI16C0062, HI12C0110]
FX This work was supported by the National Research Foundation of Korea and
   the Korean government (MSIP), NRF-2016M3A9A7918501 (Professor Kwon-Ha
   Yoon); the Ministry of Health and Welfare, Republic of Korea, HI16C0062
   (Professor Kwon-Ha Yoon); and the Ministry of Health and Welfare,
   Republic of Korea, HI12C0110, (Professor Kwon-Ha Yoon).
CR Charles-Edwards Elizabeth M, 2006, Cancer Imaging, V6, P135, DOI 10.1102/1470-7330.2006.0021
   Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003
   Hassane DC, 2010, BLOOD, V116, P5983, DOI 10.1182/blood-2010-04-278044
   Heijmen L, 2012, CRIT REV ONCOL HEMAT, V83, P194, DOI 10.1016/j.critrevonc.2011.12.008
   Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005
   Im Chang-Nim, 2013, Genomics & Informatics, V11, P245, DOI 10.5808/GI.2013.11.4.245
   Jiang QW, 2015, ONCOTARGET, V6, P32790, DOI 10.18632/oncotarget.5411
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koh DM, 2007, AM J ROENTGENOL, V188, P1622, DOI 10.2214/AJR.06.1403
   Kumaraswamy S, 2008, CANCER RES, V68, P3819, DOI 10.1158/0008-5472.CAN-08-0016
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076
   Lee JH, 2011, INT J MOL MED, V27, P441, DOI 10.3892/ijmm.2011.601
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Liu Y, 2015, INT J GYNECOL CANCER, V25, P1073, DOI 10.1097/IGC.0000000000000472
   Matsuoka Y, 2014, EUR UROL, V65, P186, DOI 10.1016/j.eururo.2012.10.010
   Morris ZS, 2014, J CLIN ONCOL, V32, P2886, DOI 10.1200/JCO.2014.55.1366
   Morse DL, 2007, NMR BIOMED, V20, P602, DOI 10.1002/nbm.1127
   Pang XF, 2010, CANCER RES, V70, P1951, DOI 10.1158/0008-5472.CAN-09-3201
   Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053
   Provencio M, 2014, TRANSL LUNG CANCER R, V3, P89, DOI 10.3978/j.issn.2218-6751.2014.03.06
   Seo HR, 2011, CHEM-BIOL INTERACT, V193, P34, DOI 10.1016/j.cbi.2011.04.009
   Setty AR, 2005, SEMIN ARTHRITIS RHEU, V34, P773, DOI 10.1016/j.semarthrit.2005.01.011
   Sharma U, 2009, NMR BIOMED, V22, P104, DOI 10.1002/nbm.1245
   Shi HS, 2012, INT J NANOMED, V7, P2601, DOI 10.2147/IJN.S31439
   Sinkus R, 2012, EUR J CANCER, V48, P425, DOI 10.1016/j.ejca.2011.11.034
   Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305
   Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122
   Sugahara T, 1999, JMRI-J MAGN RESON IM, V9, P53, DOI 10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2
   Tian JQ, 2012, CLIN CANCER RES, V18, P3366, DOI 10.1158/1078-0432.CCR-11-3179
   Vandecaveye V, 2012, INT J RADIAT ONCOL, V82, P1098, DOI 10.1016/j.ijrobp.2011.02.044
   Vogel-Claussen J, 2007, CANCER BIOL THER, V6, P1469
   Vokes EE, 2007, J CLIN ONCOL, V25, P1698, DOI 10.1200/JCO.2006.07.3569
   Wang BS, 2014, TUMOR BIOL, V35, P81, DOI 10.1007/s13277-013-1009-3
   Wang Y, 2011, RADIOGRAPHICS, V31, pE13, DOI 10.1148/rg.313105174
   Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006
   Zhang T, 2009, J BIOL CHEM, V284, P35381, DOI 10.1074/jbc.M109.051532
   Zoberi I, 2002, CANCER LETT, V175, P165, DOI 10.1016/S0304-3835(01)00719-4
NR 39
TC 2
Z9 2
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 23
PY 2017
VL 12
IS 5
AR e0178204
DI 10.1371/journal.pone.0178204
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EV8UE
UT WOS:000402058800047
PM 28542649
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Rosa, DF
   Sarandy, MM
   Novaes, RD
   da Matta, SLP
   Goncalves, RV
AF Rosa, Daiane Figueiredo
   Sarandy, Mariaurea Matias
   Novaes, Romulo Dias
   Pinto da Matta, Sergio Luis
   Goncalves, Reggiani Vilela
TI Effect of a high-fat diet and alcohol on cutaneous repair: A systematic
   review of murine experimental models
SO PLOS ONE
LA English
DT Review
ID ACUTE ETHANOL EXPOSURE; INFLAMMATORY RESPONSE; EXTRACELLULAR-MATRIX;
   FIBROBLAST FUNCTION; OXIDATIVE STRESS; WOUND REPAIR; TISSUE;
   ANGIOGENESIS; RAT; ASSOCIATION
AB Background and purpose
   Chronic alcohol intake associated with an inappropriate diet can cause lesions in multiple organs and tissues and complicate the tissue repair process. In a systematic review, we analyzed the relevance of alcohol and high fat consumption to cutaneous and repair, compared the main methodologies used and the most important parameters tested. Preclinical investigations with murine models were assessed to analyze whether the current evidence support clinical trials.
   Methods
   The studies were selected from MEDLINE/PubMed and Scopus databases, according to Fig 1. All 15 identified articles had their data extracted. The reporting bias was investigated according to the ARRIVE (Animal Research: Reporting of in Vivo Experiments) strategy.
   Results
   In general, animals offered a high-fat diet and alcohol showed decreased cutaneous wound closure, delayed skin contraction, chronic inflammation and incomplete re-epithelialization.
   Conclusion
   In further studies, standardized experimental design is needed to establish comparable study groups and advance the overall knowledge background, facilitating data translatability from animal models to human clinical conditions.
C1 [Rosa, Daiane Figueiredo; Sarandy, Mariaurea Matias; Pinto da Matta, Sergio Luis] Univ Fed Vicosa, Dept Gen Biol, Vicosa, MG, Brazil.
   [Novaes, Romulo Dias] Univ Fed Alfenas, Dept Cell Tissue & Dev Biol, Alfenas, MG, Brazil.
   [Goncalves, Reggiani Vilela] Univ Fed Vicosa, Dept Anim Biol, Vicosa, MG, Brazil.
RP Goncalves, RV (reprint author), Univ Fed Vicosa, Dept Anim Biol, Vicosa, MG, Brazil.
EM reggiani.goncalves@ufv.br
RI Novaes, Romulo/F-1210-2015; Goncalves, Reggiani/J-1550-2016
OI Novaes, Romulo/0000-0002-3186-5328; Goncalves,
   Reggiani/0000-0002-5831-3590
FU Fundagao de Amparo a Pesquisa do estado de Minas Gerais (Fapemig)
FX The authors received funding of the Fundagao de Amparo a Pesquisa do
   estado de Minas Gerais (Fapemig).
CR Aghdam SY, 2012, BIOCHEM BIOPH RES CO, V421, P197, DOI 10.1016/j.bbrc.2012.03.134
   Altman DG, 2010, J ANTIMICROB CHEMOTH, V65, P1, DOI 10.1093/jac/dkp410
   Amar MB, 2014, J R SOC INTERFACE, V11, P1
   Blum KS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094713
   Bogl LH, 2013, NUTR METAB CARDIOVAS, V23, P1071, DOI 10.1016/j.numecd.2012.11.007
   Campbell L, 2010, J EXP MED, V207, P1825, DOI 10.1084/jem.20100500
   Chang WJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008540
   Choudhry MA, 2000, ALCOHOL, V21, P239, DOI 10.1016/S0741-8329(00)00093-8
   Das SK, 2010, OXID MED CELL LONGEV, V3, P414, DOI 10.4161/oxim.3.6.14417
   Ding J, 2015, ADV WOUND CARE, V4, P673, DOI 10.1089/wound.2014.0550
   do Nascimento AP, 2011, BRIT J NUTR, V106, P603, DOI [10.1017/80007114511000468, 10.1017/S0007114511000468]
   Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701
   Emmerson E, 2013, MOL CELL ENDOCRINOL, V375, P149, DOI 10.1016/j.mce.2013.05.015
   Faunce DE, 2003, ALCOHOL CLIN EXP RES, V27, P1199, DOI 10.1097/01.ALC.0000075833.92139.35
   Fitzgerald DJ, 2007, ALCOHOL CLIN EXP RES, V31, P317, DOI 10.1111/j.1530-0277.2006.00307.x
   Flegg JA, 2015, FRONT PHYSIOL, V6, P1
   Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   Gallardo CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041161
   Gantwerker EA, 2011, FACIAL PLAST SURG CL, V19, P441, DOI 10.1016/j.fsc.2011.06.009
   GENTILELLO LM, 1993, J TRAUMA, V34, P669, DOI 10.1097/00005373-199305000-00009
   Gupta M, 2015, J DIABETES, V7, P573, DOI 10.1111/1753-0407.12223
   Halici M, 2010, EKLEM HAST CERRAHISI, V21, P172
   Hiebert PR, 2013, CELL DEATH DIFFER, V20, P1404, DOI 10.1038/cdd.2013.96
   Holcomb VB, 2009, VIVO, V23, P15
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Jakobsdottir G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080476
   Jung MK, 2011, ALCOHOL CLIN EXP RES, V35, P392, DOI 10.1111/j.1530-0277.2010.01356.x
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Leite SN, 2015, LASER MED SCI, V30, P1481, DOI 10.1007/s10103-015-1745-2
   Masuda R, 2009, WOUND REPAIR REGEN, V17, P127, DOI 10.1111/j.1524-475X.2008.00450.x
   McCutcheon JE, 2009, EUR J NEUROSCI, V29, P997, DOI 10.1111/j.1460-9568.2009.06648.x
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Moraes JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005045
   Nascimento AP, 2006, BRIT J NUTR, V96, P1069, DOI 10.1017/BJN20061955
   Nassar D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037084
   Olczyk P, 2014, BIOMED RES INT, V2014, P8, DOI DOI 10.1155/2014/747584
   Otranto M, 2013, WOUND REPAIR REGEN, V21, P464, DOI 10.1111/wrr.12042
   Panigrahy D, 2013, P NATL ACAD SCI USA, V110, P13528, DOI 10.1073/pnas.1311565110
   Pence BD, 2012, MED SCI SPORT EXER, V44, P1846, DOI 10.1249/MSS.0b013e31825a5971
   Potz BA, 2016, J SURG RES, V203, P154, DOI 10.1016/j.jss.2016.03.009
   Radek KA, 2005, AM J PHYSIOL-HEART C, V289, pH1084, DOI 10.1152/ajpheart.00080.2005
   Radek KA, 2009, J LEUKOCYTE BIOL, V86, P1125, DOI 10.1189/jlb.0209103
   Ram M, 2015, EUR J PHARMACOL, V764, P9, DOI 10.1016/j.ejphar.2015.06.029
   Randi AM, 2017, J THROMB HAEMOST, V15, P13, DOI 10.1111/jth.13551
   Ranzer MJ, 2011, ALCOHOL CLIN EXP RES, V35, P83, DOI 10.1111/j.1530-0277.2010.01324.x
   Renaud HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088584
   Sampey BP, 2011, OBESITY, V19, P1109, DOI 10.1038/oby.2011.18
   Seitz O, 2010, EXP DIABETES RES, DOI 10.1155/2010/476969
   Silva MLS, 2016, ACTA TROP, V154, P133, DOI 10.1016/j.actatropica.2015.11.010
   Slavkovsky R, 2011, WOUND REPAIR REGEN, V19, P515, DOI 10.1111/j.1524-475X.2011.00703.x
   Stephens P, 1996, INT J ORAL MAX SURG, V25, P161, DOI 10.1016/S0901-5027(96)80065-8
   Su YJ, 2015, ADV WOUND CARE, V4, P631, DOI 10.1089/wound.2014.0559
   Szabo G, 2009, ALCOHOL CLIN EXP RES, V33, P220, DOI 10.1111/j.1530-0277.2008.00842.x
   Tang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092082
   Tepole AB, 2013, PEDIATR RES, V73, P553, DOI 10.1038/pr.2013.3
   Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x
   Tracy LE, 2016, ADV WOUND CARE, V5, P119, DOI 10.1089/wound.2014.0561
   Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823
   WANG H., 2015, EURASIP J WIREL COMM, V2015, P1, DOI DOI 10.1016/J.TPLANTS.2015.04.003
   Wang JH, 2014, INTERNATIONAL CONFERENCE ON MECHANISM SCIENCE AND CONTROL ENGINEERING (MSCE 2014), P1
   Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407
   Yonehiro L, 2013, WOUNDS, V25, P340
NR 62
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2017
VL 12
IS 5
AR e0176240
DI 10.1371/journal.pone.0176240
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EU8UP
UT WOS:000401314300010
PM 28493875
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kiss, T
   Szabo, A
   Oszlanczi, G
   Lukacs, A
   Timar, Z
   Tiszlavicz, L
   Csupor, D
AF Kiss, Tivadar
   Szabo, Andrea
   Oszlanczi, Gabor
   Lukacs, Anita
   Timar, Zoltan
   Tiszlavicz, Laszlo
   Csupor, Dezso
TI Repeated-dose toxicity of common ragweed on rats
SO PLOS ONE
LA English
DT Article
ID AMBROSIA-ARTEMISIIFOLIA L.; SPECIES-MEDIATED APOPTOSIS; SESQUITERPENE
   LACTONES; INULA-HELENIUM; IN-VITRO; NRF2-MEDIATED INDUCTION;
   CHEMICAL-COMPOSITION; DETOXIFYING ENZYMES; TRYPANOSOMA-CRUZI;
   PSILOSTACHYIN-C
AB Ambrosia artemisiifolia L. is an invasive species with highly allergenic pollens. Ragweed originates from North America, but it also occurs and is spreading in Europe, causing seasonal allergic rhinitis for millions of people. Recently, the herb of A. artemisiifolia has gained popularity as medicinal plant and food. The effects of its long-term intake are unknown; there are no toxicological data to support the safe use of this plant. The aim of our study was to assess the repeated dose toxicity of A. artemisiifolia on animals. Ragweed puree was administered in low dose (500 mg/kg b. w.) and high dose (1000 mg/kg b. w.) to male Wistar rats according to 407 OECD Guidelines for the Testing of Chemicals. Clinical symptoms, various blood chemical parameters, body weight and organ weights of the rats were measured. Reduced liver function enzymes (AST, ALT), reduced triglyceride level in the low dose and increased carbamide level in the high dose group were observed. The weight of the liver relative to body weight was significantly reduced in both groups, while the brain weight relative to body weight was significantly elevated in both groups. According to our results, the repeated use of ragweed resulted in toxic effects in rats and these results question the safety of long-term human consumption of common ragweed.
C1 [Kiss, Tivadar; Csupor, Dezso] Univ Szeged, Fac Pharm, Dept Pharmacognosy, Szeged, Hungary.
   [Kiss, Tivadar; Szabo, Andrea; Lukacs, Anita; Csupor, Dezso] Univ Szeged, Interdisciplinary Ctr Nat Prod, Szeged, Hungary.
   [Szabo, Andrea; Oszlanczi, Gabor; Lukacs, Anita] Univ Szeged, Fac Med, Dept Publ Hlth, Szeged, Hungary.
   [Timar, Zoltan] SOLVO Biotechnol, Szeged, Hungary.
   [Tiszlavicz, Laszlo] Univ Szeged, Fac Med, Dept Pathol, Szeged, Hungary.
RP Csupor, D (reprint author), Univ Szeged, Fac Pharm, Dept Pharmacognosy, Szeged, Hungary.; Csupor, D (reprint author), Univ Szeged, Interdisciplinary Ctr Nat Prod, Szeged, Hungary.
EM csupor.dezso@pharm.u-szeged.hu
RI Csupor, Dezso/B-2952-2009; Kiss, Tivadar/L-3233-2013
OI Csupor, Dezso/0000-0002-4088-3333; Kiss, Tivadar/0000-0003-3538-377X;
   Timar, Zoltan/0000-0003-0316-9947
FU European Union and the State of Hungary; European Social Fund [TAMOP
   4.2.4A/2-11-1-2012-0001]; Janos Bolyai Research Scholarship of the
   Hungarian Academy of Sciences; National Research, Development and
   Innovation Office [115796]; SOLVO Biotechnology; 
   [GINOP-2.3.2-15-2016-00012]
FX This research was supported by the European Union and the State of
   Hungary, co-financed by the European Social Fund in the framework of
   TAMOP 4.2.4A/2-11-1-2012-0001 'National Excellence Program'. This paper
   was supported by the Janos Bolyai Research Scholarship of the Hungarian
   Academy of Sciences, the National Research, Development and Innovation
   Office (115796) and the project GINOP-2.3.2-15-2016-00012 (New ways in
   the natural product-based drug discovery system metabolomic approaches
   to discover biologically active terpenoids of herbal and microbial
   origin). The funder SOLVO Biotechnology provided support in the form of
   salaries for author ZT. The specific roles of the author are articulated
   in the 'author contributions' section. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; This research was supported by the
   European Union and the State of Hungary, co-financed by the European
   Social Fund in the framework of TAMOP 4.2.4.A/2-11-1-2012-0001 'National
   Excellence Program'. This paper was supported by the Janos Bolyai
   Research Scholarship of the Hungarian Academy of Sciences, the National
   Research, Development and Innovation Office (115796) and the project
   GINOP-2.3.2-15-2016-00012 (New ways in the natural product-based drug
   discovery-system metabolomic approaches to discover biologically active
   terpenoids of herbal and microbial origin). The funder SOLVO
   Biotechnology provided support in the form of salaries for author ZT,
   but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of the author are articulated in the
   'author contributions' section. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdel-Aziz M, 1991, ALEX J PHARM SCI, V5, P98
   Abdelgaleil SAM, 2011, AFR J MICROBIOL RES, V5, P3385
   AbouZid S, 2007, NAT PROD COMMUN, V2, P177
   Amorim MHR, 2013, CRIT REV TOXICOL, V43, P559, DOI 10.3109/10408444.2013.813905
   Aponte JC, 2010, PLANTA MED, V76, P705, DOI 10.1055/s-0029-1240681
   ARNASON JT, 1985, J NAT PROD, V48, P581, DOI 10.1021/np50040a010
   Atawodi S. E., 2013, INT J BIOCH REREV, V3, P119
   Bashir MEH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053337
   BIANCHI E, 1968, AUST J CHEM, V21, P1109, DOI 10.1071/CH9681109
   Blanco JG, 1997, FEBS LETT, V409, P396, DOI 10.1016/S0014-5793(97)00560-7
   BLOSZYK E, 1992, COLLECT CZECH CHEM C, V57, P1092, DOI 10.1135/cccc19921092
   Cai H, 2014, PHYTOTHER RES, V28, P1679, DOI 10.1002/ptr.5182
   Cantrell CL, 1999, PLANTA MED, V65, P351, DOI 10.1055/s-1999-14001
   [ Chen Jinjun], 2010, [, Carcinogenesis, Teratogenesis and Mutagenesis], V22, P440
   Chiltoskey M. U., 1975, CHEROKEE PLANTS THEI
   Corbett A, 2012, LAB ANIM-UK, V46, P318, DOI 10.1258/la.2012.012018
   Cotugno R, 2012, CELL PROLIFERAT, V45, P53, DOI 10.1111/j.1365-2184.2011.00796.x
   Csubak M., 2012, PARAMEDICA, V8
   Csupor-Loffler B, 2009, PHYTOTHER RES, V23, P672, DOI 10.1002/ptr.2697
   CUNZE S, 2013, ISRN ECOL, DOI DOI 10.1155/2013/610126
   da Silva CF, 2013, ANTIMICROB AGENTS CH, V57, P5307, DOI 10.1128/AAC.00595-13
   David JP, 1999, PHARM BIOL, V37, P165, DOI 10.1076/phbi.37.2.165.6077
   de Oliveira RB, 2011, J ETHNOPHARMACOL, V133, P434, DOI 10.1016/j.jep.2010.10.019
   Di WH, 2014, ONCOL REP, V32, P1585, DOI 10.3892/or.2014.3368
   Ding J, 1995, P 8 INT S BIOL CONTR, P193
   Ding WB, 2015, MOLECULES, V20, P4450, DOI 10.3390/molecules20034450
   Dirsch VM, 2001, PLANTA MED, V67, P557, DOI 10.1055/s-2001-16478
   Duan HuiPing, 2000, Acta Agriculturae Shanghai, V16, P73
   El Kelish A, 2014, BMC PLANT BIOL, V14, DOI 10.1186/1471-2229-14-176
   Elufioye TO, 2009, J ETHNOPHARMACOL, V122, P410, DOI 10.1016/j.jep.2008.12.007
   Essl F, 2015, J ECOL, V103, P1069, DOI 10.1111/1365-2745.12424
   Foster S, 2000, FIELD GUIDE MED PLAN
   Gattone VH, 2004, ANAT REC PART A, V277A, P384, DOI 10.1002/ar.a.20022
   Gerber E, 2011, WEED RES, V51, P559, DOI 10.1111/j.1365-3180.2011.00879.x
   Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752
   Gilmore MR., 1913, COLLECTIONS NEBRASKA, V17, P358
   Gowda S, 2009, PAN AFR MED J, V3, P1
   Green D., RAGWEED
   He Q, 2014, J CHEM-NY, DOI 10.1155/2014/738796
   Herrick JW, 1977, IROQUOIS MED NOTANY
   HERZ W, 1961, J ORG CHEM, V26, P5011, DOI 10.1021/jo01070a056
   Heyl FW, 1917, J AM CHEM SOC, V39, P1470, DOI 10.1021/ja02252a022
   ISSG, 2010, AMBR ART HERB
   KELSEY RG, 1973, PHYTOCHEMISTRY, V12, P1345, DOI 10.1016/0031-9422(73)80562-X
   Khan M, 2012, INT J BIOL SCI, V8, P533, DOI 10.7150/ijbs.3753
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026
   Kiss T, 2012, GYOGYSZERESZET, V56, P560
   Konishi T, 2002, BIOL PHARM BULL, V25, P1370, DOI 10.1248/bpb.25.1370
   Kumar A, 2016, PHYTOCHEM LETT, V18, P117, DOI 10.1016/j.phytol.2016.09.004
   Lake IR, 2016, ENV HLTH PERSPECT
   Lastra AL, 2004, J ETHNOPHARMACOL, V95, P221, DOI 10.1016/j.jep.2004.07.020
   Lawrence NJ, 2001, BIOORG MED CHEM LETT, V11, P429, DOI 10.1016/S0960-894X(00)00686-7
   Leach MC, 2010, LAB ANIM-UK, V44, P54, DOI 10.1258/la.2009.009029
   Li M, 2013, HEBEI YIKE DAXUE XUE, V34, P869
   Li M, 2013, TIANRAN CHANWU YANJI, V25, P529
   [ Li Ming], 2013, [, Natural Product R & D], V25, P555
   Li Y, 2006, J NAT PROD, V69, P616, DOI 10.1021/np050480d
   Li Y., 2010, ZHONG CAO YAO, V41, P1336
   Li Y, 2012, Z NATURFORSCH C, V67, P375
   Li Yong, 2010, Zhongguo Yaolixue Tongbao, V26, P112
   Li ZL, 2016, ARCH PHARM RES, V39, P1441, DOI 10.1007/s12272-016-0815-8
   Liu CH, 2001, CHINESE SCI BULL, V46, P498, DOI 10.1007/BF03187267
   Mahesh A, 2010, ACTA BIOL HUNG, V61, P175, DOI 10.1556/ABiol.61.2010.2.6
   Martino R, 2015, TOXICOL IN VITRO, V29, P1529, DOI 10.1016/j.tiv.2015.06.011
   Milosavljevic S, 1999, J SERB CHEM SOC, V64, P397
   Moller H, 2002, CONTACT DERMATITIS, V47, P157, DOI 10.1034/j.1600-0536.2002.470306.x
   NARASIMHAN TR, 1985, PLANTA MED, V51, P194, DOI 10.1055/s-2007-969454
   Nirogi R, 2014, INT J PHARM SCI RES, V5, P1525, DOI 10.13040/IJPSR.0975-8232.5(4).1525-32
   Noori A, 2014, AVICENNA J PHYTOMEDI, V4, P371
   OECD (Organisation for Economic Co-operation and Development), 2008, OECD GUID TEST CHEM
   Ognjenovic J, 2013, VET IMMUNOL IMMUNOP, V155, P38, DOI 10.1016/j.vetimm.2013.06.005
   Parkhomenko A. Y., 2006, PHARM CHEM J, V40, P627
   Parkhomenko AY, 2005, PHARM CHEM J, V39, P149, DOI DOI 10.1007/S11094-005-0106-Z
   PAYNE WW, 1966, BRITTONIA, V18, P28, DOI 10.2307/2805107
   Piao Y, 2013, J TOXICOL PATHOL, V26, P29, DOI 10.1293/tox.26.29
   PICMAN AK, 1982, CONTACT DERMATITIS, V8, P294, DOI 10.1111/j.1600-0536.1982.tb04234.x
   PORTER TH, 1969, PHYTOCHEMISTRY, V8, P793, DOI 10.1016/S0031-9422(00)85858-6
   Ramesh C, 2004, ARKIVOC, V2003, P126
   Rasul A, 2013, ARCH PHARM RES, V36, P1262, DOI 10.1007/s12272-013-0217-0
   RASZEJA W, 1977, PLANTA MED, V32, P319, DOI 10.1055/s-0028-1097606
   RODRIGUEZ E, 1976, EXPERIENTIA, V32, P236, DOI 10.1007/BF01937785
   Romero JB., 1954, BOT LORE CALIFORNIA, P13
   Rugutt JK, 1997, J AGR FOOD CHEM, V45, P4845, DOI 10.1021/jf970420g
   Schomburg C, 2013, EUR J MED CHEM, V63, P313, DOI 10.1016/j.ejmech.2013.02.018
   Seo JY, 2009, J MED FOOD, V12, P1038, DOI 10.1089/jmf.2009.0072
   Seo JY, 2008, PHYTOTHER RES, V22, P1500, DOI 10.1002/ptr.2521
   Solujic S, 2008, J SERB CHEM SOC, V73, P1039, DOI 10.2298/JSC0811039S
   Speck FG, 1941, PRIMITIVE MAN, V14, P49, DOI [10.2307/3316460, DOI 10.2307/3316460]
   STEFANOVIC M, 1987, PHYTOCHEMISTRY, V26, P850, DOI 10.1016/S0031-9422(00)84804-9
   Stefanovic M, 1972, GLAS HEM DRUG BEOGRA, V37, P463
   Stojanovic-Radic Z, 2012, EUR J CLIN MICROBIOL, V31, P1015, DOI 10.1007/s10096-011-1400-1
   Sturgeon CM, 2005, PLANTA MED, V71, P938, DOI 10.1055/s-2005-873109
   Sulsen VP, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002494
   Sulsen VP, 2011, LAT AM J PHARM, V30, P202
   Sulsen VP, 2011, INT J ANTIMICROB AG, V37, P536, DOI 10.1016/j.ijantimicag.2011.02.003
   Sulsen V, 2011, EVID-BASED COMPL ALT, V2011, P1
   Sulsen V, 2010, MOLECULES, V15, P545, DOI 10.3390/molecules15010545
   Sulsen VP, 2008, ANTIMICROB AGENTS CH, V52, P2415, DOI 10.1128/AAC.01630-07
   Sulsen VP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150526
   Szigetvari C, 2004, ZONNOVENYEK BIOL INV, P337
   Taglialatela-Scafati O, 2012, EUR J ORG CHEM, P5162, DOI 10.1002/ejoc.201200650
   Tantaquidgeon G., 1942, STUDY DELAWARE INDIA
   Tantaquidgeon Gladys, 1972, FOLK MED DELAWARE RE
   TORRANCE SJ, 1975, J PHARM SCI, V64, P887, DOI 10.1002/jps.2600640542
   Venables L, 2016, S AFR J BOT, V103, P216, DOI 10.1016/j.sajb.2015.08.016
   VILLAGOMEZ R, 2014, J BIOMEDICAL SCI ENG, V7, P833, DOI DOI 10.4236/JBISE.2014.710083
   Villagomez R, 2013, ANTICANCER RES, V33, P3799
   Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279, DOI 10.1016/S1081-1206(10)62009-1
   Weng ZY, 2016, ONCOL REP, V35, P833, DOI 10.3892/or.2015.4461
   Wopfner N, 2009, MOL IMMUNOL, V46, P2090, DOI 10.1016/j.molimm.2009.02.005
   Wu MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076000
   Zhao F, 2016, PLANT CELL ENVIRON, V39, P147, DOI 10.1111/pce.12601
NR 113
TC 0
Z9 0
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 4
PY 2017
VL 12
IS 5
AR e0176818
DI 10.1371/journal.pone.0176818
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET9SP
UT WOS:000400648500077
PM 28472131
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Dariolli, R
   Naghetini, MV
   Marques, EF
   Takimura, CK
   Jensen, LS
   Kiers, B
   Tsutsui, JM
   Mathias, W
   Neto, PAL
   Krieger, JE
AF Dariolli, Rafael
   Naghetini, Marcus V.
   Marques, Euclydes F.
   Takimura, Celso K.
   Jensen, Leonardo S.
   Kiers, Bianca
   Tsutsui, Jeane M.
   Mathias, Wilson, Jr.
   Lemos Neto, Pedro A.
   Krieger, Jose E.
TI Allogeneic pASC transplantation in humanized pigs attenuates cardiac
   remodeling post-myocardial infarction
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY;
   LEFT-VENTRICULAR FUNCTION; HEART-DISEASE; CELLULAR CARDIOMYOPLASTY;
   BLOOD-FLOW; IN-VITRO; PROLIFERATION; THERAPY; ANGIOGENESIS
AB Cell therapy repair strategies using adult mesenchymal stromal cells have shown promising evidence to prevent cardiac deterioration in rodents even in the absence of robust differentiation of the cells into cardiomyocytes. We tested whether increasing doses of porcine adipose- tissue derived mesenchymal stem cells (pASCs) increase cardiac tissue perfusion in pigs post-myocardial infarction (MI) receiving angiotensin-converting-enzyme inhibitor (ACE inhibitors) and Beta-blockers similarly to patients. Female pigs were subjected to MI induction by sponge permanent occlusion of left circumflex coronary artery (LCx) generating approximately 10% of injured LV area with minimum hemodynamic impact. We assessed tissue perfusion by real time myocardial perfusion echocardiography (RTMPE) using commercial microbubbles before and following pASCs treatment. Four weeks after the occlusion of the left circumflex artery, we transplanted placebo or pASCs (1, 2 and 4x10 6 cells/Kg BW) into the myocardium. The highest dose of pASCs increased myocardial vessel number and blood flow in the border (56% and 3.7-fold, respectively) and in the remote area (54% and 3.9-fold, respectively) while the non-perfused scar area decreased (up to 38%). We also found an increase of immature collagen fibers, although the increase in total tissue collagen and types I and III was similar in all groups. Our results provide evidence that pASCsinduced stimulation of tissue perfusion and accumulation of immature collagen fibers attenuates adverse remodeling post-MI beyond the normal beneficial effects associated with ACE inhibition and beta-blockade.
C1 [Dariolli, Rafael; Naghetini, Marcus V.; Marques, Euclydes F.; Takimura, Celso K.; Jensen, Leonardo S.; Kiers, Bianca; Tsutsui, Jeane M.; Mathias, Wilson, Jr.; Lemos Neto, Pedro A.; Krieger, Jose E.] Univ Sao Paulo, Med Sch, Heart Inst InCor, Sao Paulo, Brazil.
RP Krieger, JE (reprint author), Univ Sao Paulo, Med Sch, Heart Inst InCor, Sao Paulo, Brazil.
EM krieger@incor.usp.br
RI Lemos, Pedro A./G-5758-2013; Mathias Jr., Wilson/A-4772-2008; Tsutsui,
   Jeane/C-6051-2013
OI Lemos, Pedro A./0000-0002-6782-750X; Dariolli,
   Rafael/0000-0003-0957-1259; Krieger, Jose/0000-0001-5464-1792
FU Fundacao Zerbini; Sao Paulo Research Foundation [FAPESP 13/17368-0];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   [404733-2012-3]; CAPES PROBITEC [23038-4156-2012-80]; Ministerio da
   Saude do Brasil; FAPESP
FX This work was supported by grants to J. E.K. from Fundacao Zerbini; Sao
   Paulo Research Foundation [FAPESP 13/17368-0]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico [404733-2012-3]; CAPES PROBITEC
   [23038-4156-2012-80] and Ministerio da Saude do Brasil
   [MS-DECIT-PROADI_SUS - H. Samaritano]. R.D. was a recipient of a
   post-doctoral fellowship from FAPESP.
CR Abdelmoneim SS, 2011, DIABETES VASC DIS RE, V8, P254, DOI 10.1177/1479164111419973
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X
   Bin JP, 2003, J AM SOC ECHOCARDIOG, V16, P871, DOI 10.1067/S0894-7317(03)00423-1
   Butler D, 2011, NATURE, V477, P260, DOI 10.1038/477260a
   Brescane RC, 2009, REV ESP CARDIOL, V62, P235
   Chen DH, 2005, CURR BIOL, V15, P179, DOI 10.1016/j.cub.2005.01.004
   Chen PP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103587
   Chen YH, 2014, SCI CHINA LIFE SCI, V57, P195, DOI 10.1007/s11427-013-4605-y
   Clarke S a, 2016, J MOL CELL IN PRESS
   Costanzo MR, 2010, J HEART LUNG TRANSPL, V29, P914, DOI 10.1016/j.healun.2010.05.034
   Dai B, 2011, J AM COLL CARDIOL, V58, P2118, DOI 10.1016/j.jacc.2011.06.062
   Dai WD, 2005, J AM COLL CARDIOL, V46, P714, DOI 10.1016/j.jacc.2005.04.056
   Danoviz ME, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012077
   Dariolli R, 2014, PHYSL REP, V2, P1
   Dariolli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067939
   Dobrucki LW, 2010, J MOL CELL CARDIOL, V48, P1071, DOI 10.1016/j.yjmcc.2009.10.008
   dos Santos L, 2010, INT J CARDIOL, V145, P34, DOI 10.1016/j.ijcard.2009.06.008
   Ebelt H, 2007, STEM CELLS, V25, P236, DOI 10.1634/stemcells.2006-0374
   Eding JEC, 2015, CIRC RES, V116, P80, DOI 10.1161/CIRCRESAHA.116.304872
   Funakoshi S, 2016, SCI REP-UK, V6, DOI 10.1038/srep19111
   Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad
   Hatzistergos KE, 2010, CIRC RES, V107, P913, DOI 10.1161/CIRCRESAHA.110.222703
   HEYNDRICKX GR, 1978, AM J PHYSIOL, V234, pH653
   Karantalis V, 2015, J AM COLL CARDIOL, V66, P1990, DOI 10.1016/j.jacc.2015.08.879
   Katayama Y, 2010, ANN THORAC CARDIOVAS, V16, P174
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Landa N, 2008, CIRCULATION, V117, P1388, DOI 10.1161/CIRCULATIONAHA.107.727420
   Langen M, 2010, MEAT SCI, V86, P821, DOI 10.1016/j.meatsci.2010.07.003
   Leor J, 2009, J AM COLL CARDIOL, V54, P1014, DOI 10.1016/j.jacc.2009.06.010
   Li DY, 2013, CLIN CARDIOL, V36, P468, DOI 10.1002/clc.22142
   Malliaras K, 2012, CIRCULATION
   McIntosh KR, 2009, TISSUE ENG PT A, V15, P2677, DOI [10.1089/ten.tea.2008.0566, 10.1089/ten.TEA.2008.0566]
   Modonesi E, 2010, CURR CARDIOL REV, V6, P24, DOI 10.2174/157340310790231653
   Moran AE, 2014, CIRCULATION, V129, P1483, DOI 10.1161/CIRCULATIONAHA.113.004042
   Mummery CL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000558
   Nakamuta JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006005
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Pathan F, 2015, PROG CARDIOVASC DIS, V57, P632, DOI 10.1016/j.pcad.2015.03.005
   Poh KK, 2007, INT J CARDIOL, V117, P360, DOI 10.1016/j.ijcard.2006.04.092
   Poncelet AJ, 2010, EUR J CARDIO-THORAC, V38, P781, DOI 10.1016/j.ejcts.2010.03.035
   Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x
   Quevedo HC, 2009, P NATL ACAD SCI USA, V106, P14022, DOI 10.1073/pnas.0903201106
   Regieli JJ, 2009, INT J CARDIOL, V132, P257, DOI 10.1016/j.ijcard.2007.11.100
   REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786
   Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998
   Ruiz-Villalba A, 2015, J AM COLL CARDIOL, V65, P2057, DOI 10.1016/j.jacc.2015.03.520
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Senior R, 2013, J AM COLL CARDIOL, V62, P1353, DOI 10.1016/j.jacc.2013.04.082
   Stewart S, 2005, J HEART LUNG TRANSPL, V24, P1710, DOI 10.1016/j.healun.2005.03.019
   Tao ZX, 2011, P NATL ACAD SCI USA, V108, P2064, DOI 10.1073/pnas.1018925108
   Verma A, 2008, JACC-CARDIOVASC IMAG, V1, P582, DOI 10.1016/j.jcmg.2008.05.012
   Wei K, 1998, CIRCULATION, V97, P473
   WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44
   WHITTAKER P, 1994, BASIC RES CARDIOL, V89, P397, DOI 10.1007/BF00788278
   Wollert KC, 2005, CIRC RES, V96, P151, DOI 10.1161/01.RES.0000155333.69009.63
   Xiong Q, 2013, CIRCULATION, V127, P997, DOI 10.1161/CIRCULATIONAHA.112.000641
NR 57
TC 3
Z9 3
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2017
VL 12
IS 4
AR e0176412
DI 10.1371/journal.pone.0176412
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET6EL
UT WOS:000400383600076
PM 28448588
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Doodnaught, GM
   Monteiro, BP
   Benito, J
   Edge, D
   Beaudry, F
   Pelligand, L
   Steagall, P
AF Doodnaught, Graeme M.
   Monteiro, Beatriz P.
   Benito, Javier
   Edge, Daniel
   Beaudry, Francis
   Pelligand, Ludovic
   Steagall, Paulo
TI Pharmacokinetic and pharmacodynamic modelling after subcutaneous,
   intravenous and buccal administration of a high-concentration
   formulation of buprenorphine in conscious cats
SO PLOS ONE
LA English
DT Article
ID THERMAL THRESHOLD; SAMPLING SITE; MORPHINE; ANTINOCICEPTION;
   DEXMEDETOMIDINE; BUTORPHANOL; COMBINATION; ABSORPTION; PROFILES
AB Background
   The aim of this study was to describe the joint pharmacokinetic-pharmacodynamic model and evaluate thermal antinociception of a high-concentration formulation of buprenorphine (Simbadol (TM)) in cats.
   Methods
   Six healthy cats (4.9 +/- 0.7 kg) were included in a prospective, randomized, blinded, crossover study. Simbadol (TM) (1.8 mg mL(-1)) was administered by the subcutaneous (SC; 0.24 mg kg(-1)), intravenous (IV; 0.12 mg kg(-1)) or buccal (OTM; 0.12 mg kg(-1)) route of administration and thermal thresholds (TT) were compared with a saline group (SAL). Thermal threshold testing and blood sampling were performed at predetermined time points up to 72 hours including a placebo group. Plasma buprenorphine and norbuprenorphine concentrations were measured using liquid chromatography mass spectrometry. A bespoke bicompartmental pharmacokinetic model simultaneously fitted data from two analytes/ three routes of administration. Temporal changes in TT were analyzed using one-way ANOVA followed by Dunnett's test and treatment comparisons using two-way ANOVA with Bonferroni's correction (P < 0.05).
   Results
   Thermal thresholds were significantly increased after SC, IV and OTM from 1-24 hours (except 2 hours), 0.5-8 hours (except 6 hours), and 1-8 hours (except 6 hours), respectively, when compared with baseline. Thermal thresholds were significantly increased after SC (1- 30 hours), IV (1-8 hours) and OTM (1-12 hours) when compared with SAL, but not different among buprenorphine- treated cats. The absolute buprenorphine clearance was 0.98 L Kg(-1) hour(-1), volume of distribution at steady state was 7.9 L kg(-1) and the elimination-half-life was 12.3 hours. Bioavailability for SC and OTM was 94% and 24%, respectively. Subcutaneous absorption was biphasic. An initial peak (0.08 hours) was followed by a slow (half-life 11.2 hours) and progressive (peak acceleration at 2.8 hours) uptake.
   Conclusion
   The SC administration of Simbadol T was characterized by prolonged absorption half-life and sustained plasma concentrations yielding long-lasting antinociception (>= 24 hours) when compared with the IV and OTM routes.
C1 [Doodnaught, Graeme M.; Benito, Javier; Steagall, Paulo] Univ Montreal, Fac Med Vet, Dept Sci Clin, St Hyacinthe, PQ, Canada.
   [Monteiro, Beatriz P.; Beaudry, Francis; Steagall, Paulo] Univ Montreal, Fac Med Vet, Dept Biomed Vet, Grp Rech Pharmacol Anim Quebec GREPAQ, St Hyacinthe, PQ, Canada.
   [Edge, Daniel] Zoetis Inc, Florham Pk, NJ USA.
   [Pelligand, Ludovic] Royal Vet Coll, Dept Clin Sci & Serv, N Mymms, Herts, England.
RP Steagall, P (reprint author), Univ Montreal, Fac Med Vet, Dept Sci Clin, St Hyacinthe, PQ, Canada.; Steagall, P (reprint author), Univ Montreal, Fac Med Vet, Dept Biomed Vet, Grp Rech Pharmacol Anim Quebec GREPAQ, St Hyacinthe, PQ, Canada.
EM psteagall@gmail.com
RI Beaudry, Francis/A-9462-2012
OI Beaudry, Francis/0000-0001-5403-7333; Monteiro Steagall,
   Beatriz/0000-0002-5722-5687
FU Zoetis; Vanier Canada Graduate Scholarship
FX This study was funded by Zoetis; principal investigator Dr. Paulo
   Steagall. Zoetis reviewed the proposal, approved the study design,
   authorized data and manuscript publication. Dr. Daniel Edge is an
   employee of Zoetis who has participated in the conceptualization,
   funding acquisition, development of methodology and preparation of
   manuscript. Dr. Beatriz Monteiro is a recipient of the Vanier Canada
   Graduate Scholarship.
CR Center for Drug Evaluation and Research (CDER) Center of Veterinary Medicine (CVM), 2013, GUID IND BIOAN METH
   Dixon MJ, 2002, RES VET SCI, V72, P205, DOI 10.1053/rvsc.2001.0543
   Ellis SLH, 2013, J FELINE MED SURG, V15, P219, DOI 10.1177/1098612X13477537
   Gabrielsson J, 2006, PHARMACOKINETIC PHAR, P11
   Gaudreault F, 2012, J PHARMACOKINET PHAR, V39, P635, DOI 10.1007/s10928-012-9275-z
   Hedges AR, 2014, J VET PHARMACOL THER, V37, P252, DOI 10.1111/jvp.12084
   Hedges AR, 2014, J VET PHARMACOL THER, V37, P145, DOI 10.1111/jvp.12075
   Johnson JA, 2007, AM J VET RES, V68, P699, DOI 10.2460/ajvr.68.7.699
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Messenger KM, 2011, VET ANAESTH ANALG, V38, P374, DOI 10.1111/j.1467-2995.2011.00613.x
   Niedfeldt RL, 2006, VET ANAESTH ANALG, V33, P381, DOI 10.1111/j.1467-2995.2005.00275.x
   Pelligand L, 2016, CPT-PHARMACOMET SYST, V5, P625, DOI 10.1002/psp4.12141
   Robertson SA, 2005, J VET PHARMACOL THER, V28, P453, DOI 10.1111/j.1365-2885.2005.00677.x
   Robertson SA, 2003, VET REC, V153, P462, DOI 10.1136/vr.153.15.462
   Sadiq MW, 2013, J PHARM SCI-US, V102, P3320, DOI 10.1002/jps.23492
   SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358
   Slingsby LS, 2008, J VET PHARMACOL THER, V31, P135, DOI 10.1111/j.1365-2885.2007.00931.x
   Slingsby LS, 2012, VET J, V192, P523, DOI 10.1016/j.tvjl.2011.09.008
   Slingsby LS, 2010, VET ANAESTH ANALG, V37, P162, DOI 10.1111/j.1467-2995.2009.00519.x
   Steagall PVM, 2006, J VET PHARMACOL THER, V29, P531, DOI 10.1111/j.1365-2885.2006.00800.x
   Steagall PVM, 2014, J VET INTERN MED, V28, P762, DOI 10.1111/jvim.12346
   Steagall PVM, 2013, VET ANAESTH ANALG, V40, P83, DOI 10.1111/j.1467-2995.2012.00779.x
   Taylor PM, 2001, J VET PHARMACOL THER, V24, P391, DOI 10.1046/j.1365-2885.2001.368goblin.x
   Taylor PM, 2016, J FELINE MED SURG, V18, P290, DOI 10.1177/1098612X15581206
   Toutain PL, 2004, J VET PHARMACOL THER, V27, P415, DOI 10.1111/j.1365-2885.2004.00605.x
   Yassen A, 2007, J PHARMACOL EXP THER, V321, P598, DOI 10.1124/jpet.106.115972
   Zhou HH, 2003, J CLIN PHARMACOL, V43, P211, DOI 10.1177/0091270002250613
NR 27
TC 5
Z9 5
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 26
PY 2017
VL 12
IS 4
AR e0176443
DI 10.1371/journal.pone.0176443
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET5FI
UT WOS:000400309200062
PM 28445495
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Monteiro, BP
   Klinck, MP
   Moreau, M
   Guillot, M
   Steagall, PVM
   Pelletier, JP
   Martel-Pelletier, J
   Gauvin, D
   del Castillo, JRE
   Troncy, E
AF Monteiro, Beatriz P.
   Klinck, Mary P.
   Moreau, Maxim
   Guillot, Martin
   Steagall, Paulo V. M.
   Pelletier, Jean-Pierre
   Martel-Pelletier, Johanne
   Gauvin, Dominique
   del Castillo, Jerome R. E.
   Troncy, Eric
TI Analgesic efficacy of tramadol in cats with naturally occurring
   osteoarthritis
SO PLOS ONE
LA English
DT Article
ID DEGENERATIVE JOINT DISEASE; FELINE OSTEOARTHRITIS; PAIN; MELOXICAM;
   MECHANISM; DIAGNOSIS; SAFETY; BRAIN; DRUGS; DOGS
AB Objectives
   This study aimed to (1) compare outcome assessments in normal and osteoarthritic cats and (2) evaluate the analgesic efficacy of tramadol in feline osteoarthritis (OA), in a prospective, randomised, blinded, placebo-controlled, crossover design.
   Methods
   Twenty cats were included after clinical examination, blood work and full body radiographs were performed. In Phase 1, outcome assessments aimed to differentiate normal (n = 5; i. e. exempt of any radiographic and clinical sign of OA) from OA (n = 15) cats. In Phase 2, OA cats were treated twice daily with a placebo (PG: cornstarch 15 mg) or tramadol (TG: 3 mg/kg) orally for 19 days, with a 3-month washout period between treatments. Evaluations were performed in normal and OA cats at baseline and consisted of: 1) peak vertical force (PVF) after staircase exercise; 2) telemetered night-time motor activity (NMA); and 3) response to mechanical temporal summation (RMTS). After treatment, PVF, NMA and RMTS evaluations were repeated in OA cats. Data were analysed with mixed model methods with an alpha-threshold of 5%.
   Results
   Phase 1: 1) PVF (% of body weight; mean +/- SD) was higher in normal (59 +/- 10.5) than in OA cats (50.6 +/- 5.7) (p = 0.005); 2) NMA (no unit) was not different between groups; 3) RMTS (number of stimuli; median (range)) was higher in normal [29.5 (23.5 +/- 30)] than in OA cats [14 (8.5 +/- 28)] (p < 0.0001). Phase 2: PVF, NMA and RMTS presented a treatment effect (p = 0.024, p = 0.008 and p = 0.018, respectively). No clinically important adverse-effects were observed.
   Conclusion
   Outcome assessments such as kinetics (PVF) and evaluation of central sensitisation (RMTS) are discriminant of OA status. Mobility measured by NMA was not discriminant of OA status, however it increased in OA cats with tramadol treatment. Nociceptive hypersensitivity quantified by RMTS was evident in OA cats and was responsive to tramadol treatment.
C1 [Monteiro, Beatriz P.; Klinck, Mary P.; Moreau, Maxim; Guillot, Martin; Gauvin, Dominique; del Castillo, Jerome R. E.; Troncy, Eric] Univ Montreal, Fac Med Vet, GREPAQ Anim Pharmacol Res Grp Quebec, St Hyacinthe, PQ, Canada.
   [Klinck, Mary P.; Moreau, Maxim; Guillot, Martin; Pelletier, Jean-Pierre; Martel-Pelletier, Johanne; Troncy, Eric] Univ Montreal Hosp Ctr, Res Ctr, Osteoarthrit Res Unit, Montreal, PQ, Canada.
   [Steagall, Paulo V. M.] Univ Montreal, Fac Med Vet, Dept Clin Sci, St Hyacinthe, PQ, Canada.
RP Troncy, E (reprint author), Univ Montreal, Fac Med Vet, GREPAQ Anim Pharmacol Res Grp Quebec, St Hyacinthe, PQ, Canada.; Troncy, E (reprint author), Univ Montreal Hosp Ctr, Res Ctr, Osteoarthrit Res Unit, Montreal, PQ, Canada.
EM eric.troncy@umontreal.ca
RI Troncy, Eric/J-6650-2013; del Castillo, Jerome/J-6976-2013
OI Troncy, Eric/0000-0003-0209-5261; Monteiro Steagall,
   Beatriz/0000-0002-5722-5687; del Castillo, Jerome/0000-0001-5046-7926
FU Morris Animal Foundation Grant [D09FE-803A]; TOP-CAT: Tracking
   Osteoarthritis Pain in the CAT; Natural Sciences and Engineering
   Research Council (NSERC) of Canada [RDCPJ 491953-2016, RDCPJ
   418399-2011]; New Opportunities Fund grant [9483]; Foundation for
   Innovation; Elanco Animal Health, a division of Eli Lilly and company;
   Vanier Canada Graduate Scholarship; Alexander Graham Bell NSERC Canada
   Graduate Scholarship [D10-901]; Fonds de recherche du Quebec-Sante;
   Canadian Institutes of Health Research MENTOR Strategic Training
   Initiative in Health Research Program; Alexander Graham Bell NSERC
   Canada Graduate Scholarship for Doctorate research;  [441651-2013]
FX This study was funded (Pr. Eric Troncy) in part by a Morris Animal
   Foundation Grant (#D09FE-803A), "TOP-CAT: Tracking Osteoarthritis Pain
   in the CAT", by a Discovery grant (#441651-2013 supporting salaries) and
   a Collaborative Research and Development grant (#RDCPJ 418399-2011,
   #RDCPJ 491953-2016 supporting operations and salaries in partnership
   with ArthroLab Inc.) from the Natural Sciences and Engineering Research
   Council (NSERC) of Canada, as well as by an ongoing New Opportunities
   Fund grant (#9483) and a Leader Opportunity Fund grant (#24601),
   supporting pain/function equipment, from the Canada Foundation for
   Innovation. Funding for the clinical trial study was provided by a grant
   from Elanco Animal Health, a division of Eli Lilly and company. The
   funders had no role in study design, data collection, and analysis,
   decision to publish, or preparation of the manuscript. Dr. Beatriz
   Monteiro is the recipient of a Vanier Canada Graduate Scholarship. Dr.
   Mary Klinck was the recipient of an Alexander Graham Bell NSERC Canada
   Graduate Scholarship for Master's research, of a Zoetis Morris Animal
   Foundation (#D10-901) Doctoral Fellowship. Dr. Maxim Moreau received a
   Doctoral Scholarship from the Fonds de recherche du Quebec-Sante, and a
   Doctoral Scholarship from the Canadian Institutes of Health Research
   MENTOR Strategic Training Initiative in Health Research Program. Dr.
   Martin Guillot was the recipient of an Alexander Graham Bell NSERC
   Canada Graduate Scholarship for Doctorate research, and a Doctoral
   Scholarship from the Canadian Institutes of Health Research MENTOR
   Strategic Training Initiative in Health Research Program.
CR Andriacchi TP, 2004, ANN BIOMED ENG, V32, P447, DOI 10.1023/B:ABME.0000017541.82498.37
   Benito J, 2013, J VET INTERN MED, V27, P474, DOI 10.1111/jvim.12077
   Bianchi M, 1998, BRAIN RES, V797, P163, DOI 10.1016/S0006-8993(98)00388-6
   Clarke SP, 2006, J SMALL ANIM PRACT, V47, P439, DOI 10.1111/j.1748-5827.2006.00143.x
   Desmeules JA, 1996, BRIT J CLIN PHARMACO, V41, P7, DOI 10.1111/j.1365-2125.1996.tb00152.x
   Farnworth MJ, 2015, VET ANAESTH ANALG, V42, P638, DOI 10.1111/vaa.12245
   Fox S, 2010, MULTIMODAL MANAGEMEN
   Frink MC, 1996, ARZNEIMITTEL-FORSCH, V46, P1029
   Gowan RA, 2011, J FELINE MED SURG, V13, P752, DOI 10.1016/j.jfms.2011.06.008
   Guillot M, 2013, VET J, V196, P360, DOI 10.1016/j.tvjl.2013.01.009
   Guillot M, 2015, VET J, V204, P299, DOI 10.1016/j.tvjl.2015.03.023
   Guillot M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097347
   Guillot M, 2012, VET SURG, V41, P328, DOI 10.1111/j.1532-950X.2012.00976.x
   Gunew MN, 2008, J FELINE MED SURG, V10, P235, DOI 10.1016/j.jfms.2007.10.007
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klinck MP, 2012, CAN VET J, V53, P1181
   Klinck MP, 2017, APPL ANIM B IN PRESS
   KuKanich B, 2004, J VET PHARMACOL THER, V27, P239, DOI 10.1111/j.1365-2885.2004.00578.x
   KuKanich B, 2013, VET CLIN N AM-SMALL, V43, P1109, DOI 10.1016/j.cvsm.2013.04.007
   Lascelles BDX, 2010, J VET INTERN MED, V24, P487, DOI 10.1111/j.1939-1676.2010.0495.x
   Lascelles BDX, 2007, J VET INTERN MED, V21, P410, DOI 10.1892/0891-6640(2007)21[410:EOCOMA]2.0.CO;2
   Minami K, 2015, N-S ARCH PHARMACOL, V388, P999, DOI 10.1007/s00210-015-1167-5
   Monteiro BP, 2016, VET ANAESTH ANALG
   Moreau M, 2014, CAN VET J, V70, P287
   Moreau M, 2013, RES VET SCI, V95, P219, DOI 10.1016/j.rvsc.2013.01.020
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Pypendop BH, 2008, J VET PHARMACOL THER, V31, P52, DOI 10.1111/j.1365-2885.2007.00921.x
   Pypendop BH, 2009, AM J VET RES, V70, P1465, DOI 10.2460/ajvr.70.12.1465
   RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275
   Schaefert R, 2015, SCHMERZ, V29, P47, DOI 10.1007/s00482-014-1451-1
   Schnabl E, 2015, VET J, V206, P83, DOI 10.1016/j.tvjl.2015.05.017
   Slingerland LI, 2011, VET J, V187, P304, DOI [10.1016/j.tvjl.2009.12.014, 10.1016/j.tvl.2009.12.014]
   Steagall PVM, 2008, J FELINE MED SURG, V10, P24, DOI 10.1016/j.jfms.2007.06.009
   Vranken Jan H., 2012, Central Nervous System Agents in Medicinal Chemistry, V12, P304
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 36
TC 6
Z9 6
U1 3
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2017
VL 12
IS 4
AR e0175565
DI 10.1371/journal.pone.0175565
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET0LZ
UT WOS:000399955200080
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ma, B
   Xu, JK
   Wu, WJ
   Liu, HY
   Kou, CK
   Liu, N
   Zhao, LL
AF Ma, Bin
   Xu, Jia-ke
   Wu, Wen-jing
   Liu, Hong-yan
   Kou, Cheng-kun
   Liu, Na
   Zhao, Lulu
TI Survey of basic medical researchers on the awareness of animal
   experimental designs and reporting standards in China
SO PLOS ONE
LA English
DT Article
ID ARRIVE GUIDELINES; CONTROLLED TRIALS; QUALITY; PHARMACOKINETICS; BIAS;
   RAT
AB Objective
   To investigate the awareness and use of the Systematic Review Center for Laboratory Animal Experimentation's (SYRCLE) risk-of-bias tool, the Animal Research: Reporting of In Vivo Experiments (ARRIVE) reporting guidelines, and Gold Standard Publication Checklist (GSPC) in China in basic medical researchers of animal experimental studies.
   Methods
   A national questionnaire-based survey targeting basic medical researchers was carried in China to investigate the basic information and awareness of SYRCLE's risk of bias tool, ARRIVE guidelines, GSPC, and animal experimental bias risk control factors. The EpiData3.1 software was used for data entry, and Microsoft Excel 2013 was used for statistical analysis in this study. The number of cases (n) and percentage (%) of classified information were statistically described, and the comparison between groups (i.e., current students vs. research staff) was performed using chi-square test.
   Results
   A total of 298 questionnaires were distributed, and 272 responses were received, which included 266 valid questionnaires (from 118 current students and 148 research staff). Among the 266 survey participants, only 15.8% was aware of the SYRCLE's risk of bias tool, with significant difference between the two groups (P = 0.003), and the awareness rates of ARRIVE guidelines and GSPC were only 9.4% and 9.0%, respectively; 58.6% survey participants believed that the reports of animal experimental studies in Chinese literature were inadequate, with significant difference between the two groups (P = 0.004). In addition, only approximately 1/3 of the survey participants had read systematic reviews and meta-analysis reports of animal experimental studies; only 16/266 (6.0%) had carried out/participated in and 11/266 (4.1%) had published systematic reviews/meta-analysis of animal experimental studies.
   Conclusions
   The awareness and use rates of SYRCLE's risk-of-bias tool, the ARRIVE guidelines, and the GSPC were low among Chinese basic medical researchers. Therefore, specific measures are necessary to promote and popularize these standards and specifications and to introduce these standards into guidelines of Chinese domestic journals as soon as possible to raise awareness and increase use rates of researchers and journal editors, thereby improving the quality of animal experimental methods and reports.
C1 [Ma, Bin; Xu, Jia-ke; Wu, Wen-jing; Liu, Hong-yan; Kou, Cheng-kun; Liu, Na; Zhao, Lulu] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Peoples R China.
   [Ma, Bin] Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China.
   [Xu, Jia-ke; Zhao, Lulu] Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China.
RP Ma, B (reprint author), Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Peoples R China.; Ma, B (reprint author), Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China.
EM kitty_mab@163.com
FU National Natural Science Foundation of China [81303147]; Fundamental
   Research Funds for the Central Universities [lzujblry-201667]
FX The Project is Supported by National Natural Science Foundation of China
   (Grant No. 81303147) and the Fundamental Research Funds for the Central
   Universities(Number: lzujblry-201667). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [ Bai Xi], 2016, [, Chinese Journal of Evidence-Based Medicine], V16, P1020
   Bebarta V, 2003, ACAD EMERG MED, V10, P1410
   Beynen ACG, 2001, PRINCIPLES LAB ANIMA
   BRUGUEROLLE B, 1983, EUR J DRUG METAB PH, V8, P233, DOI 10.1007/BF03188753
   BRUGUEROLLE B, 1983, THERAPIE, V38, P223
   [ Chen Kuangyang], 2014, [, Chinese Journal of Evidence-Based Medicine], V14, P1281
   CLOUGH G, 1982, BIOL REV, V57, P487, DOI 10.1111/j.1469-185X.1982.tb00705.x
   Clough G, 1984, STANDARDS LAB ANIMAL, P7
   DONNELLY H, 1993, LAB ANIM, V27, P385, DOI 10.1258/002367793780745598
   Fang Ze-ping, 2015, CHIN J EVID BASED ME, P797
   Hess KR, 2011, CANCER RES, V71, P625, DOI 10.1158/0008-5472.CAN-10-3296
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Hooijmans C, 2011, LAB ANIM-UK, V45, P61, DOI 10.1258/la.2010.010130
   Hooijmans CR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001482
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Johnston NA, 2010, HDB LAB ANIMAL SCI, P343
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Liu YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154657
   MARRINO P, 1987, BIOCHIM BIOPHYS ACTA, V920, P277, DOI 10.1016/0005-2760(87)90105-6
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Perel P, 2007, BMJ-BRIT MED J, V334, P197, DOI 10.1136/bmj.39048.407928.BE
   Sandercock P, 2002, LANCET, V360, P586, DOI 10.1016/S0140-6736(02)09812-4
   SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009
   VANDERSCHUREN LJMJ, 1995, PHYSIOL BEHAV, V58, P119, DOI 10.1016/0031-9384(94)00385-I
   Yali L, 2011, CHINESE J EVIDENCE B, V6, P233
NR 28
TC 1
Z9 3
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2017
VL 12
IS 4
AR e0174530
DI 10.1371/journal.pone.0174530
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ES2JD
UT WOS:000399353500052
PM 28380050
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sun, MY
   Taylor, A
   Zorumski, CF
   Mennerick, S
AF Sun, Min-Yu
   Taylor, Amanda
   Zorumski, Charles F.
   Mennerick, Steven
TI 24S-hydroxycholesterol and 25-hydroxycholesterol differentially impact
   hippocampal neuronal survival following oxygen-glucose deprivation
SO PLOS ONE
LA English
DT Article
ID D-ASPARTATE RECEPTORS; CHOLESTEROL 24-HYDROXYLASE; BRAIN; OXYSTEROLS;
   24(S)-HYDROXYCHOLESTEROL; METABOLISM; NECROPTOSIS; TURNOVER; PROTEINS;
   KNOCKOUT
AB N-methyl-D-aspartate receptors (NMDARs), a major subtype of glutamate receptor mediating excitatory transmission throughout the CNS, participate in ischemia-induced neuronal death. Unfortunately, undesired side effects have limited the strategy of inhibiting/blocking NMDARs as therapy. Targeting endogenous positive allosteric modulators of NMDAR function may offer a strategy with fewer downsides. Here, we explored whether 24S-hydroxycholesterol (24S-HC), an endogenous positive NMDAR modulator characterized recently by our group, participates in NMDAR-mediated excitotoxicity following oxygen-glucose deprivation (OGD) in primary neuron cultures. 24S-HC is the major brain cholesterol metabolite produced exclusively in neurons near sites of glutamate transmission. By selectively potentiating NMDAR current, 24S-HC may participate in NMDAR-mediated excitotoxicity following energy failure, thus impacting recovery after stroke. In support of this hypothesis, our findings indicate that exogenous application of 24S-HC exacerbates NMDAR-dependent excitotoxicity in primary neuron culture following OGD, an ischemic-like challenge. Similarly, enhancement of endogenous 24S-HC synthesis reduced survival rate. On the other hand, reducing endogenous 24S-HC synthesis alleviated OGD-induced cell death. We found that 25-HC, another oxysterol that antagonizes 24S-HC potentiation, partially rescued OGD-mediated cell death in the presence or absence of exogenous 24S-HC application, and 25HC exhibited NMDAR-dependent/24S-HC-dependent neuroprotection, as well as NMDARindependent neuroprotection in rat tissue but not mouse tissue. Our findings suggest that both endogenous and exogenous 24S-HC exacerbate OGD-induced damage via NMDAR activation, while 25-HC exhibits species dependent neuroprotection through both NMDAR-dependent and independent mechanisms.
C1 [Sun, Min-Yu; Taylor, Amanda; Zorumski, Charles F.; Mennerick, Steven] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
   [Zorumski, Charles F.; Mennerick, Steven] Washington Univ, Sch Med, Dept Neurosci, St Louis, MO 63110 USA.
   [Zorumski, Charles F.; Mennerick, Steven] Washington Univ, Sch Med, Taylor Family Inst Innovat Psychiat Res, St Louis, MO 63110 USA.
RP Mennerick, S (reprint author), Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.; Mennerick, S (reprint author), Washington Univ, Sch Med, Dept Neurosci, St Louis, MO 63110 USA.; Mennerick, S (reprint author), Washington Univ, Sch Med, Taylor Family Inst Innovat Psychiat Res, St Louis, MO 63110 USA.
EM menneris@wustl.edu
RI Mennerick, Steven/O-2806-2017
OI Mennerick, Steven/0000-0003-0868-0664
FU Bantly Foundation; National Institutes of Health [AA017413, MH077791,
   MH078823, MH101874, MH104506]; Washington University in St. Louis
   McDonnell Center for Cellular and Molecular Neurobiology postdoctoral
   fellowship
FX This work was supported by the Bantly Foundation and by National
   Institutes of Health (https://www.nih.gov/) grants AA017413, MH077791,
   MH078823, MH101874, and MH104506 (S.M.), and by Washington University in
   St. Louis McDonnell Center for Cellular and Molecular Neurobiology
   postdoctoral fellowship (M-Y. S.). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200
   Bjorkhem I, 2013, NEUROSCI LETT, V555, P102, DOI 10.1016/j.neulet.2013.09.003
   Burgett AWG, 2011, NAT CHEM BIOL, V7, P639, DOI 10.1038/nchembio.625
   Charman M, 2014, J BIOL CHEM, V289, P15705, DOI 10.1074/jbc.M114.571216
   Chisari M, 2010, TRENDS NEUROSCI, V33, P299, DOI 10.1016/j.tins.2010.03.005
   Emnett CM, 2013, MOL PHARMACOL, V84, P935, DOI 10.1124/mol.113.089334
   GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784
   Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911
   Hughes TM, 2013, J ALZHEIMERS DIS, V33, P891, DOI 10.3233/JAD-2012-121585
   KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Leoni V, 2014, BIOCHEM BIOPH RES CO, V446, P697, DOI 10.1016/j.bbrc.2014.01.188
   Linsenbardt AJ, 2014, NEUROPHARMACOLOGY, V85, P232, DOI 10.1016/j.neuropharm.2014.05.027
   Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Meljon A, 2014, BIOCHEM BIOPH RES CO, V446, P768, DOI 10.1016/j.bbrc.2014.01.153
   Meljon A, 2012, J LIPID RES, V53, P2469, DOI 10.1194/jlr.D028233
   Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002
   Paul SM, 2013, J NEUROSCI, V33, P17290, DOI 10.1523/JNEUROSCI.2619-13.2013
   Porter FD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001417
   ROTHMAN SM, 1987, NEUROSCIENCE, V21, P673, DOI 10.1016/0306-4522(87)90028-5
   Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859
   SMITH LL, 1972, J NEUROCHEM, V19, P899, DOI 10.1111/j.1471-4159.1972.tb01406.x
   Sodero AO, 2012, EMBO J, V31, P1764, DOI 10.1038/emboj.2012.31
   Sodero AO, 2011, J NEUROCHEM, V116, P747, DOI 10.1111/j.1471-4159.2010.07079.x
   Soderoa AO, 2011, NEUROBIOL AGING, V32, P1043, DOI 10.1016/j.neurobiolaging.2010.06.001
   Suchanek M, 2007, BIOCHEM J, V405, P473, DOI 10.1042/BJ20070176
   Sun M.Y., 2015, NEUROSCIENTIST
   Sun MY, 2015, J NEUROPHYSIOL
   Weilinger NL, 2013, ACTA PHARMACOL SIN, V34, P39, DOI 10.1038/aps.2012.95
   Yamanaka K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.524
   Yamanaka K, 2011, J BIOL CHEM, V286, P24666, DOI 10.1074/jbc.M111.236273
   Zar JH, 1999, BIOSTATISTICAL ANAL
NR 33
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 27
PY 2017
VL 12
IS 3
AR e0174416
DI 10.1371/journal.pone.0174416
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ER9VD
UT WOS:000399174300044
PM 28346482
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Schroeder, DC
   Guschlbauer, M
   Maul, AC
   Cremer, DA
   Becker, I
   Bethencourt, DD
   Paal, P
   Padosch, SA
   Wetsch, WA
   Annecke, T
   Boettiger, BW
   Sterner-Kock, A
   Herff, H
AF Schroeder, Daniel C.
   Guschlbauer, Maria
   Maul, Alexandra C.
   Cremer, Daniel A.
   Becker, Ingrid
   Bethencourt, David de la Puente
   Paal, Peter
   Padosch, Stephan A.
   Wetsch, Wolfgang A.
   Annecke, Thorsten
   Boettiger, Bernd W.
   Sterner-Kock, Anja
   Herff, Holger
TI Oesophageal heat exchangers with a diameter of 11mm or 14.7mm are
   equally effective and safe for targeted temperature management
SO PLOS ONE
LA English
DT Article
ID THERAPEUTIC HYPOTHERMIA; INTRACRANIAL HYPERTENSION; TRANSFER DEVICE;
   RESUSCITATION; ASSOCIATION; PREVENTION; GUIDELINES; INDUCTION
AB Background
   Targeted temperature management (TTM) is widely used in critical care settings for conditions including hepatic encephalopathy, hypoxic ischemic encephalopathy, meningitis, myocardial infarction, paediatric cardiac arrest, spinal cord injury, traumatic brain injury, ischemic stroke and sepsis. Furthermore, TTM is a key treatment for patients after out-of-hospital cardiac-arrest (OHCA). However, the optimal cooling method, which is quick, safe and cost-effective still remains controversial. Since the oesophagus is adjacent to heart and aorta, fast heat-convection to the central blood-stream could be achieved with a minimally invasive oesophageal heat exchanger (OHE). To date, the optimal diameter of an OHE is still unknown. While larger diameters may cause thermal-or pressure-related tissue damage after long-term exposure to the oesophageal wall, smaller diameter (e.g., gastric tubes, up to 11mm) may not provide effective cooling rates. Thus, the objective of the study was to compare OHE-diameters of 11mm (OHE11) and 14.7mm (OHE14.7) and their effects on tissue and cooling capability.
   Methods
   Pigs were randomized to OHE11 (N = 8) or OHE14.7 (N = 8). After cooling, pigs were maintained at 33 degrees C for 1 hour. After 10h rewarming, oesophagi were analyzed by means of histopathology. The oesophagus of four animals from a separate study that underwent exactly the identical preparation and cooling protocol described above but received a maintenance period of 24h were used as histopathological controls.
   Results
   Mean cooling rates were 2.8 +/- 0.4 degrees C degrees C/h (OHE11) and 3.0 +/- 0.3 degrees C degrees C/h (OHE14.7; p = 0.20). Occasional mild acute inflammatory transepithelial infiltrates were found in the cranial segment of the oesophagus in all groups including controls. Deviations from target temperature were 0.1 +/- 0.4 degrees C (OHE11) and 0 +/- 0.1 degrees C (OHE14.7; p = 0.91). Rewarming rates were 0.19 +/- 0.07 degrees C degrees C/h (OHE11) and 0.20 +/- 0.05 degrees C degrees C/h (OHE14.7; p = 0.75).
   Conclusions
   OHE with diameters of 11 mm and 14.7 mm achieve effective cooling rates for TTM and did not cause any relevant oesophageal tissue damage. Both OHE demonstrated acceptable deviations from target temperature and allowed for an intended rewarming rate (0.25 degrees C/h).
C1 [Schroeder, Daniel C.; Cremer, Daniel A.; Bethencourt, David de la Puente; Padosch, Stephan A.; Wetsch, Wolfgang A.; Annecke, Thorsten; Boettiger, Bernd W.; Herff, Holger] Univ Hosp Cologne, Dept Anaesthesiol & Intens Care Med, Kerpener Str 62, Cologne, Germany.
   [Guschlbauer, Maria; Maul, Alexandra C.; Sterner-Kock, Anja] Univ Hosp Cologne, Dept Expt Med, Cologne, Germany.
   [Becker, Ingrid] Univ Hosp Cologne, Inst Med Stat Informat & Epidemiol, Kerpener Str 62, Cologne, Germany.
   [Paal, Peter] Queen Mary Univ London, Barts Heart Ctr, St Bartholomews Hosp, Barts Hlth NHS Trust, London, England.
   [Paal, Peter] Barmherzige Bruder Salzburg Hosp, Dept Anaesthesiol & Crit Care Med, Kajetanerpl 2, Salzburg, Austria.
RP Schroeder, DC (reprint author), Univ Hosp Cologne, Dept Anaesthesiol & Intens Care Med, Kerpener Str 62, Cologne, Germany.
EM Daniel.Schroeder@uk-koeln.de
OI Schroeder, Daniel/0000-0002-0104-5986; Guschlbauer,
   Maria/0000-0002-5401-4542
FU "The Central Innovation Program for Small and Medium-sized enterprises",
   German Federal Ministry for Economic affairs and Energy [KF2429611AK3]
FX This work was supported by "The Central Innovation Program for Small and
   Medium-sized enterprises", German Federal Ministry for Economic affairs
   and Energy (KF2429611AK3) (HH). Equipment was provided by Hirtz & Co.
   KG, Cologne, Germany.
CR BUGGY D, 1994, BRIT J ANAESTH, V72, P393, DOI 10.1093/bja/72.4.393
   Desai TK, 2005, GASTROINTEST ENDOSC, V61, P795, DOI 10.1016/S0016-5107(05)00313-5
   Gotberg M, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-7
   Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559
   He Xiaoming, 2003, Crit Rev Biomed Eng, V31, P355, DOI 10.1615/CritRevBiomedEng.v31.i56.10
   HENRIQUES FC, 1947, AM J PATHOL, V23, P531
   Hoedemaekers CW, 2007, CRIT CARE, V11, DOI 10.1186/cc6104
   HUDACK STEPHEN, 1932, JOUR EXP MED, V55, P431, DOI 10.1084/jem.55.3.431
   Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101
   KOKATE JY, 1995, ARCH PHYS MED REHAB, V76, P666, DOI 10.1016/S0003-9993(95)80637-7
   KULKARNI P, 1993, BRIT J ANAESTH, V70, P216, DOI 10.1093/bja/70.2.216
   Kulstad E, 2013, RESUSCITATION, V84, P1619, DOI 10.1016/j.resuscitation.2013.06.019
   Kulstad EB, 2012, WORLD J EMERG MED, V3, P118, DOI [10.5847/wjem.j.issn.1920-8642.2012.02.007, 10.5847/wjem.j.1920-8642.2012.02.007]
   Lefrant JY, 2003, INTENS CARE MED, V29, P414, DOI 10.1007/s00134-002-1619-5
   Lequerica JL, 2009, INT J HYPERTHER, V25, P150, DOI 10.1080/02656730802537626
   LI DJ, 1987, INT J HYPERTHER, V3, P143, DOI 10.3109/02656738709140382
   Long J, 2002, GASTROINTESTINAL LIV, P551
   Markota A, 2016, J EMERGENCY MED
   Markota A, 2016, AM J EMERG MED, V34, P741, DOI 10.1016/j.ajem.2016.01.028
   Markota A, 2015, RESUSCITATION, V89, pE1, DOI 10.1016/j.resuscitation.2015.01.032
   McMaster PD, 1934, J EXP MED, V60, P479, DOI 10.1084/jem.60.4.479
   Naiman M, 2016, EXPERT REV MED DEVIC, V13, P423, DOI 10.1080/17434440.2016.1174573
   Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018
   Pehbock D, 2014, ANAESTHESIST
   Piercy M, 2009, J CARDIOTHOR VASC AN, V23, P62, DOI 10.1053/j.jvca.2008.09.014
   Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5
   Popugaev KA, 2014, J NEUROL SURG REP, V75, pE224, DOI 10.1055/s-0034-1387188
   Ran ZG, 2015, J VIROL, V89, P4818, DOI 10.1128/JVI.00059-15
   Rasmussen YH, 1998, ACTA ANAESTH SCAND, V42, P348
   Saito T, 2013, J VASC SURG, V57, P173, DOI 10.1016/j.jvs.2012.05.101
   Sause A, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-52
   Schortgen F, 2012, AM J RESP CRIT CARE, V185, P1088, DOI 10.1164/rccm.201110-1820OC
   Sessler DI, 2008, ANESTHESIOLOGY, V109, P318, DOI 10.1097/ALN.0b013e31817f6d76
   Sessler DI, 2013, ANESTHESIOLOGY, V118, P181, DOI 10.1097/ALN.0b013e3182784df3
   SESSLER DI, 1988, ANESTHESIOLOGY, V68, P836, DOI 10.1097/00000542-198806000-00002
   Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929
   Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub4
   Tobey NA, 1999, AM J PHYSIOL-GASTR L, V276, pG1322
NR 40
TC 5
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2017
VL 12
IS 3
AR e0173229
DI 10.1371/journal.pone.0173229
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN6DM
UT WOS:000396094700016
PM 28291783
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Rewell, SSJ
   Churilov, L
   Sidon, TK
   Aleksoska, E
   Cox, SF
   Macleod, MR
   Howells, DW
AF Rewell, Sarah S. J.
   Churilov, Leonid
   Sidon, T. Kate
   Aleksoska, Elena
   Cox, Susan F.
   Macleod, Malcolm R.
   Howells, David W.
TI Evolution of ischemic damage and behavioural deficit over 6 months after
   MCAo in the rat: Selecting the optimal outcomes and statistical power
   for multi-centre preclinical trials
SO PLOS ONE
LA English
DT Article
ID MIDDLE CEREBRAL-ARTERY; ADHESIVE REMOVAL TEST; MODIFIED RANKIN SCALE;
   EXPERIMENTAL STROKE; FOCAL ISCHEMIA; FUNCTIONAL RECOVERY;
   SOCIAL-INTERACTION; NEURONAL DAMAGE; EDEMA FORMATION; BRAIN-DAMAGE
AB Key disparities between the timing and methods of assessment in animal stroke studies and clinical trial may be part of the reason for the failure to translate promising findings. This study investigates the development of ischemic damage after thread occlusion MCAo in the rat, using histological and behavioural outcomes. Using the adhesive removal test we investigate the longevity of behavioural deficit after ischemic stroke in rats, and examine the practicality of using such measures as the primary outcome for future studies. Ischemic stroke was induced in 132 Spontaneously Hypertensive Rats which were assessed for behavioural and histological deficits at 1, 3, 7, 14, 21, 28 days, 12 and 24 weeks (n> 11 per timepoint). The basic behavioural score confirmed induction of stroke, with deficits specific to stroke animals. Within 7 days, these deficits resolved in 50% of animals. The adhesive removal test revealed contralateral neglect for up to 6 months following stroke. Sample size calculations to facilitate the use of this test as the primary experimental outcome resulted in cohort sizes much larger than are the norm for experimental studies. Histological damage progressed from a necrotic infarct to a hypercellular area that cleared to leave a fluid filled cavity. Whilst absolute volume of damage changed over time, when corrected for changes in hemispheric volume, an equivalent area of damage was lost at all timepoints. Using behavioural measures at chronic timepoints presents significant challenges to the basic science community in terms of the large number of animals required and the practicalities associated with this. Multicentre preclinical randomised controlled trials as advocated by the MultiPART consortium may be the only practical way to deal with this issue.
C1 [Rewell, Sarah S. J.; Churilov, Leonid; Sidon, T. Kate; Aleksoska, Elena; Cox, Susan F.; Howells, David W.] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic, Australia.
   [Macleod, Malcolm R.] Univ Edinburgh, Dept Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland.
   [Howells, David W.] Univ Tasmania, Sch Med, Fac Hlth, Hobart, Tas, Australia.
RP Howells, DW (reprint author), Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic, Australia.; Howells, DW (reprint author), Univ Tasmania, Sch Med, Fac Hlth, Hobart, Tas, Australia.
EM david.howells@utas.edu.au
RI Macleod, Malcolm Robert/B-2052-2010
OI Macleod, Malcolm Robert/0000-0001-9187-9839; Howells,
   David/0000-0002-2512-7724; Rewell, Sarah/0000-0002-4754-6524
FU National Health & Medical Research Council [GNT1013612]; NHMRC-EU
   collaborative grant; Victorian State Government; National Centre for the
   Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
   [NC/L000970/1]
FX This work was supported by the National Health & Medical Research
   Council (https://www.nhmrc.gov.au/)) [GNT1013612] (DWH) and an NHMRC-EU
   collaborative grant (DWH, MRM). The Florey gratefully acknowledges the
   operational infrastructure support of the Victorian State Government.
   The Victorian Cancer Biobank is supported by the Victorian State
   Government. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alaverdashvili M, 2015, J NEUROSCI METH, V247, P58, DOI 10.1016/j.jneumeth.2015.03.029
   Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022
   Aspey BS, 1998, NEUROPATH APPL NEURO, V24, P487
   Balkaya M, 2013, J CEREBR BLOOD F MET, V33, P330, DOI 10.1038/jcbfm.2012.185
   Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6
   BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472
   Bouet V, 2012, A MASTER KEY TO ASSE
   Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006
   Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125
   BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88
   Bronnum-Hansen H, 2001, STROKE, V32, P2131, DOI 10.1161/hs0901.094253
   CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K
   Churilov L, 2014, INT J STROKE, V9, P999, DOI 10.1111/ijs.12364
   CLARK RK, 1994, BRAIN RES BULL, V35, P387, DOI 10.1016/0361-9230(94)90119-8
   CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T
   Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6
   Craft TKS, 2005, STROKE, V36, P2006, DOI 10.1161/01.STR.0000177538.17687.54
   DERESKI MO, 1993, ACTA NEUROPATHOL, V85, P327
   Dirnagl U, 2006, J CEREBR BLOOD F MET, V26, P1465, DOI 10.1038/sj.jcbfm.9600298
   Dirnagl U, 2013, STROKE, V44, P1754, DOI 10.1161/STROKEAHA.113.000734
   Dirnagl U, 2012, J CEREBR BLOOD F MET, V32, P933, DOI 10.1038/jcbfm.2012.51
   Dittmar M, 2003, STROKE, V34, P2252, DOI 10.1161/01.STR.0000083625.54851.9A
   Doeppner TR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00338
   Dogan A, 1998, NEUROL RES, V20, P265
   FARBER JL, 1981, AM J PATHOL, V102, P271
   Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752
   Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128
   Freret T, 2006, EUR J NEUROSCI, V23, P1757, DOI 10.1111/j.1460-9568.2006.04699.x
   Freret T, 2008, J CEREBR BLOOD F MET, V28, P786, DOI 10.1038/sj.jcbfm.9600575
   Freret T, 2006, BEHAV NEUROSCI, V120, P1285, DOI 10.1037/0735-7044.120.6.1285
   Freret T, 2009, BEHAV NEUROSCI, V123, P224, DOI 10.1037/a0014157
   GARCIA JH, 1994, AM J PATHOL, V144, P188
   GARCIA JH, 1993, AM J PATHOL, V142, P623
   Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503
   Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51
   Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x
   Graham SM, 2004, COMPARATIVE MED, V54, P486
   Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096
   Harada H, 2005, BRAIN RES PROTOC, V14, P165, DOI 10.1016/j.brainresprot.2004.12.007
   Henninger N, 2006, STROKE, V37, P1283, DOI 10.1161/01.STR.0000217223.72193.98
   Howells DW, 2014, NAT REV NEUROL, V10, P37, DOI 10.1038/nrneurol.2013.232
   Ishibashi S, 2003, STROKE, V34, P1501, DOI 10.1161/01.STR.0000074034.32371.13
   Justicia C, 2008, STROKE, V39, P1541, DOI 10.1161/STROKEAHA.107.503565
   Karelina K, 2011, STROKE, V42, P3606, DOI 10.1161/STROKEAHA.111.628008
   Karelina K, 2009, EXP NEUROL, V220, P276, DOI 10.1016/j.expneurol.2009.08.022
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kleikers PWM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13428
   KUGE Y, 1995, STROKE, V26, P1655, DOI 10.1161/01.STR.26.9.1655
   Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2
   Lees KR, 2012, STROKE, V43, P1163, DOI 10.1161/STROKEAHA.111.641423
   Lehrmann E, 1997, J COMP NEUROL, V386, P461
   Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807
   Li HL, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-58
   Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7
   Lindner MD, 2003, J NEUROSCI, V23, P10913
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Lourbopoulos A, 2016, J CEREB BLOOD FLOW M
   Macleod M, 2010, NEUROMETHODS, V47, P7, DOI 10.1007/978-1-60761-750-1_2
   Mammen E F, 2000, Clin Lab Sci, V13, P239
   MATSUMOTO N, 1973, Stroke, V4, P20
   Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C
   Mergenthaler P, 2012, DIS MODEL MECH, V5, P718, DOI 10.1242/dmm.010033
   Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0
   Modo M, 2003, NEUROREPORT, V14, P39, DOI 10.1097/01.wnr.0000053066.88427.c2
   Modo Michel, 2009, J Exp Stroke Transl Med, V2, P52
   Mracsko E, 2014, BRAIN BEHAV IMMUN, V41, P200, DOI 10.1016/j.bbi.2014.05.015
   NEDERGAARD M, 1987, ACTA NEUROPATHOL, V73, P267, DOI 10.1007/BF00686621
   Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965
   O'Collins VE, 2013, ANIMAL MODELS FOR THE STUDY OF HUMAN DISEASE, P531, DOI 10.1016/B978-0-12-415894-8.00023-3
   Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7
   Philip M, 2009, STROKE, V40, P577, DOI 10.1161/STROKEAHA.108.524330
   Porritt MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041090
   Rosell A, 2013, TRANSL STROKE RES, V4, P297, DOI 10.1007/s12975-012-0234-1
   Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13
   SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X
   Schellinger PD, 2012, INT J STROKE, V7, P227, DOI 10.1111/j.1747-4949.2012.00773.x
   Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218
   Sicard Kenneth M, 2009, Exp Transl Stroke Med, V1, P7, DOI 10.1186/2040-7378-1-7
   Soleman S, 2010, EXP NEUROL, V222, P13, DOI 10.1016/j.expneurol.2009.11.007
   Spratt NJ, 2006, J NEUROSCI METH, V155, P285, DOI 10.1016/j.jneumeth.2006.01.020
   Stuller KA, 2012, EXP NEUROL, V233, P33, DOI 10.1016/j.expneurol.2011.01.016
   Sun LY, 2009, NEUROPATHOLOGY, V29, P45, DOI 10.1111/j.1440-1789.2008.00939.x
   Tennant KA, 2009, J NEUROSCI METH, V181, P18, DOI 10.1016/j.jneumeth.2009.04.009
   Trueman RC, 2016, J CEREB BLOOD FLOW M
   Turner RJ, 2011, TRANSL STROKE RES, V2, P138, DOI 10.1007/s12975-011-0067-3
   Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012
   Venna VR, 2011, STROKE, V42, P3329, DOI 10.1161/STROKEAHA.111.632570
   Venna VR, 2012, ACTA NEUROPATHOL, V124, P425, DOI 10.1007/s00401-012-0990-8
   Virley D, 2000, J CEREB BLOOD FLOW M, V20, P536
   Wang MM, 2013, TRANSL STROKE RES, V4, P3, DOI 10.1007/s12975-012-0219-0
   Whishaw IQ, 1998, BEHAV BRAIN RES, V96, P79, DOI 10.1016/S0166-4328(97)00200-3
   Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126
   Zhang L, 2000, J NEUROL SCI, V174, P141, DOI 10.1016/S0022-510X(00)00268-9
   Zhang L, 2011, STROKE, V42, P1437, DOI 10.1161/STROKEAHA.110.593129
NR 94
TC 11
Z9 11
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2017
VL 12
IS 2
AR e0171688
DI 10.1371/journal.pone.0171688
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EK9GJ
UT WOS:000394231800090
PM 28182727
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Thomas, A
   Detilleux, J
   Flecknell, P
   Sandersen, C
AF Thomas, Aurelie
   Detilleux, Johann
   Flecknell, Paul
   Sandersen, Charlotte
TI Impact of Stroke Therapy Academic Industry Roundtable (STAIR) Guidelines
   on Peri-Anesthesia Care for Rat Models of Stroke: A Meta-Analysis
   Comparing the Years 2005 and 2015
SO PLOS ONE
LA English
DT Article
ID MIDDLE CEREBRAL-ARTERY; BLOOD-FLOW; METHODOLOGICAL QUALITY; CHLORAL
   HYDRATE; ISCHEMIC-STROKE; ANIMAL RESEARCH; HALOTHANE; OCCLUSION;
   ISOFLURANE; RECOMMENDATIONS
AB Numerous studies using rats in stroke models have failed to translate into successful clinical trials in humans. The Stroke Therapy Academic Industry Roundtable (STAIR) has produced guidelines on the rodent stroke model for preclinical trials in order to promote the successful translation of animal to human studies. These guidelines also underline the importance of anaesthetic and monitoring techniques. The aim of this literature review is to document whether anaesthesia protocols (i.e., choice of agents, mode of ventilation, physiological support and monitoring) have been amended since the publication of the STAIR guidelines in 2009. A number of articles describing the use of a stroke model in adult rats from the years 2005 and 2015 were randomly selected from the PubMed database and analysed for the following parameters: country where the study was performed, strain of rats used, technique of stroke induction, anaesthetic agent for induction and maintenance, mode of intubation and ventilation, monitoring techniques, control of body temperature, vascular accesses, and administration of intravenous fluids and analgesics. For each parameter (stroke, induction, maintenance, monitoring), exact chi-square tests were used to determine whether or not proportions were significantly different across year and p values were corrected for multiple comparisons. An exact p-test was used for each parameter to compare the frequency distribution of each value followed by a Bonferroni test. The level of significant set at < 0.05. Results show that there were very few differences in the anaesthetic and monitoring techniques used between 2005 and 2015. In 2015, significantly more studies were performed in China and significantly fewer studies used isoflurane and nitrous oxide. The most striking finding is that the vast majority of all the studies from both 2005 and 2015 did not report the use of ventilation; measurement of blood gases, end-tidal carbon dioxide concentration, or blood pressure; or administration of intravenous fluids or analgesics. The review of articles published in 2015 showed that the STAIR guidelines appear to have had no effect on the anaesthetic and monitoring techniques in rats undergoing experimental stroke induction, despite the publication of said guidelines in 2009.
C1 [Thomas, Aurelie; Detilleux, Johann; Sandersen, Charlotte] Univ Liege, Fac Vet Med, Liege, Belgium.
   [Flecknell, Paul] Univ Newcastle, Comparat Biol Ctr, Newcastle, NSW, Australia.
RP Sandersen, C (reprint author), Univ Liege, Fac Vet Med, Liege, Belgium.
EM Charlotte.sandersen@ulg.ac.be
OI Flecknell, Paul/0000-0002-1075-1129
CR Adamson Joy, 2004, J Stroke Cerebrovasc Dis, V13, P171, DOI 10.1016/j.jstrokecerebrovasdis.2004.06.003
   Albers GW, 2001, STROKE, V32, P1598
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Bara M, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0026-8
   BAUGHMAN VL, 1988, ANESTHESIOLOGY, V69, P192, DOI 10.1097/00000542-198808000-00007
   Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616
   Bleilevens C, 2013, EXP BRAIN RES, V224, P155, DOI 10.1007/s00221-012-3296-0
   BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083
   Browning JL, 1997, MOL CHEM NEUROPATHOL, V31, P29, DOI 10.1007/BF02815158
   Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458
   Carbone L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155001
   Cattell JM, 1906, STAT STUDY AM MEN SC
   CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138
   Cheong SH, 2010, LAB ANIM-UK, V44, P278, DOI 10.1258/la.2010.009118
   Chileuitt L, 1996, SURG NEUROL, V46, P229, DOI 10.1016/0090-3019(95)00453-X
   Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009
   Davis DA, 1997, CAN MED ASSOC J, V157, P408
   DRUMMOND JC, 1986, ANESTHESIOLOGY, V65, P462, DOI 10.1097/00000542-198611000-00002
   Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015
   Eisen JA, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001757
   Endres M, 2008, CEREBROVASC DIS, V25, P268, DOI 10.1159/000118039
   Erb HN, 2010, PREV VET MED, V97, P165, DOI 10.1016/j.prevetmed.2010.09.011
   Ergorul C, 2013, CURR OPIN PHARMACOL, V13, P108, DOI 10.1016/j.coph.2012.08.005
   Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27
   Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53
   Fisher M, 2007, STROKE, V38, P245, DOI 10.1161/01.STR.0000255951.37434.aa
   Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128
   Florian B, 2008, NEUROSCI LETT, V438, P180, DOI 10.1016/j.neulet.2008.04.020
   Fluri F, 2015, DRUG DES DEV THER, V9, P3445, DOI 10.2147/DDDT.S56071
   FOURCADE HE, 1971, ANESTHESIOLOGY, V35, P26, DOI 10.1097/00000542-197107000-00008
   Greek R, 2013, INT J MED SCI, V10, P206, DOI 10.7150/ijms.5529
   Grol R, 2001, MED CARE, V39, pII46
   GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630
   Grundy D, 2015, EXP PHYSIOL, V100, P755, DOI 10.1113/EP085299
   HOFFMAN WE, 1993, ANESTH ANALG, V76, P279
   Jilka RL, 2016, J BONE MINER RES, V31, P1317, DOI 10.1002/jbmr.2881
   Joffe AR, 2015, J AM ASS LAB ANIMAL, V16, P1
   Kahle MP, 2012, STROKE RES TREATMENT, V1, P1
   Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58
   Kawaguchi Masahiko, 2005, J Anesth, V19, P150, DOI 10.1007/s00540-005-0305-5
   KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274
   Kitano H, 2007, J CEREBR BLOOD F MET, V27, P1108, DOI 10.1038/sj.jcbfm.9600410
   KNILL RL, 1982, ANESTHESIOLOGY, V57, P151
   Laletin VS, 2015, BIOCHEM MOSC-SUPPL S, V9, P1, DOI 10.1134/S1990750815010059
   Lapchak P. A., 2012, J NEUROL NEUROPHYSIO, V3, pe111, DOI DOI 10.4172/2155-9562.1000E111
   Leenaars M, 2012, LAB ANIM-UK, V46, P24, DOI 10.1258/la.2011.011087
   Liu Shimin, 2009, J Exp Stroke Transl Med, V2, P2
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   MacCallum CJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000413
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Macleod MR, 2014, LANCET, V383, P101, DOI 10.1016/S0140-6736(13)62329-6
   Marion DW, 2004, CRIT CARE MED S, V32
   Martins AR, 2015, ANIMALS, V5, P315, DOI 10.3390/ani5020315
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P2427, DOI 10.1111/bph.12956
   Minnerup J, 2010, J CEREBR BLOOD F MET, V30, P1619, DOI 10.1038/jcbfm.2010.74
   Nellgard B, 2000, ANESTHESIOLOGY, V93, P431, DOI 10.1097/00000542-200008000-00022
   O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741
   Osborne NJ, 2009, AM J BIOETHICS, V9, P55, DOI 10.1080/15265160903318343
   Pelosi P, 1998, ANESTH ANALG, V87, P654, DOI 10.1097/00000539-199809000-00031
   Rehder K, 1986, HDB PHYSL 3, P737
   Saver JL, 2009, STROKE, V40, P2594, DOI 10.1161/STROKEAHA.109.552554
   SHIMOJYO S, 1968, NEUROLOGY, V18, P127, DOI 10.1212/WNL.18.2.127
   SIESJO BK, 1993, PROG BRAIN RES, V96, P23
   SILVERMAN J, 1993, LAB ANIM SCI, V43, P210
   Steckler T, 2015, EUR NEUROPSYCHOPHARM, V25, P1803, DOI 10.1016/j.euroneuro.2015.05.011
   Strom JO, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-41
   Su CS, 2012, EUR J ANAESTH, V29, P515, DOI 10.1097/EJA.0b013e328357ce5b
   Theodorsson A, 2005, BRAIN RES PROTOC, V14, P181, DOI 10.1016/j.brainresprot.2005.01.002
   Turner RJ, 2011, TRANSL STROKE RES, V2, P138, DOI 10.1007/s12975-011-0067-3
   Uematsu M, 2009, NEUROREPORT, V20, P219, DOI 10.1097/WNR.0b013e328302ee46
   Van Noorden R, 2010, NATURE, V463, P12, DOI 10.1038/463012a
   WARNER DS, 1991, J CEREBR BLOOD F MET, V11, P794, DOI 10.1038/jcbfm.1991.137
   WARNER DS, 1995, ANESTHESIOLOGY, V82, P1237, DOI 10.1097/00000542-199505000-00019
   WARNER DS, 1993, ANESTHESIOLOGY, V79, P985, DOI 10.1097/00000542-199311000-00017
   World Health Organization, 2012, TOP 10 CAUS DEATH
   Worrall A, 2011, INT REV PSYCHIATR, V23, P336, DOI 10.3109/09540261.2011.606542
   YAMORI Y, 1976, STROKE, V7, P46, DOI 10.1161/01.STR.7.1.46
   Zausinger S, 2002, BRAIN RES PROTOC, V9, P112, DOI 10.1016/S1385-299X(02)00138-1
NR 80
TC 7
Z9 7
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2017
VL 12
IS 1
AR e0170243
DI 10.1371/journal.pone.0170243
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN7FK
UT WOS:000396167300049
PM 28122007
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhou, RP
   Lin, SJ
   Wan, WB
   Zuo, HL
   Yao, FF
   Ruan, HB
   Xu, J
   Song, W
   Zhou, YC
   Wen, SY
   Dai, JH
   Zhu, ML
   Luo, J
AF Zhou, Rong Ping
   Lin, Si Jian
   Wan, Wen Bing
   Zuo, Hui Ling
   Yao, Fen Fen
   Ruan, Hui Bing
   Xu, Jin
   Song, Wei
   Zhou, Yi Cheng
   Wen, Shi Yao
   Dai, Jiang Hua
   Zhu, Mei Lan
   Luo, Jun
TI Chlorogenic Acid Prevents Osteoporosis by Shp2/PI3K/Akt Pathway in
   Ovariectomized Rats
SO PLOS ONE
LA English
DT Article
ID EUCOMMIA-ULMOIDES OLIV.; OVX-INDUCED OSTEOPOROSIS; BONE LOSS;
   ANTIOXIDANT ACTIVITY; POSTMENOPAUSAL OSTEOPOROSIS; PHENOLIC-COMPOUNDS;
   TISSUE METABOLISM; OXIDATIVE STRESS; CONTROLLED TRIAL; ESTROGEN
AB Cortex Eucommiae is used worldwide in traditional medicine, various constituents of Cortex Eucommiae, such as chlorogenic acid (CGA), has been reported to exert anti-osteoporosis activity in China, but the mechanism about their contribution to the overall activity is limited. The aims of this study were to determine whether chlorogenic acid can prevent estrogen deficiency-induced osteoporosis and to analyze the mechanism of CGA bioactivity. The effect of CGA on estrogen deficiency-induced osteoporosis was performed in vivo. Sixty female Sprague-Dawley rats were divided randomly among a sham-operated group and five ovariectomy (OVX) plus treatment subgroups: saline vehicle, 17 alpha-ethinylestradiol (E2), or CGA at 9, 27, or 45 mg/kg/d. The rats' femoral metaphyses were evaluated by microcomputed tomography (mu CT). The mechanism of CGA bioactivity was investigated in vitro. Bone mesenchymal stem cells (BMSCs) were treated with CGA, with or without phosphoinositide 3-kinase (PI3K) inhibitor LY294002. BMSCs proliferation and osteoblast differentiation were assessed with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and alkaline phosphatase, with or without Shp2 interfering RNA (RNAi). The results display that CGA at 27 and 45 mg/kg/day inhibited the decrease of bone mineral density (BMD) that induced by OVX in femur (p<0.01), significantly promoted the levels of bone turnover markers, and prevented bone volume fraction (BV/TV), connectivity density (CoonD), trabecular number (Tb. N), trabecular thickness (Tb. Th) (all p<0.01) to decrease and prevented the trabecular separation (Tb. Sp), structure model index (SMI)(both p<0.01) to increase. CGA at 1 or 10 mu M enhanced BMSC proliferation in a dose-dependent manner. CGA at 0.1 to 10 mu M increased phosphorylated Akt (p-Akt) and cyclin D1. These effects were reversed by LY294002. CGA at 1 or 10 mu M increased BMSC differentiation to osteoblasts (p<0.01), Shp2 RNAi suppressed CGA-induced osteoblast differentiation by decreasing Shp2, p-Akt, and cyclin D1. This study found that CGA improved the BMD and trabecular micro-architecture for the OVX-induced osteoporosis. Therefore, CGA might be an effective alternative treatment for postmenopausal osteoporosis. CGA promoted proliferation of osteoblast precursors and osteoblastic differentiation of BMSCs via the Shp2/PI3K/ Akt/cyclin D1 pathway.
C1 [Zhou, Rong Ping; Wan, Wen Bing; Ruan, Hui Bing; Xu, Jin; Song, Wei; Zhou, Yi Cheng; Wen, Shi Yao] NanChang Univ, Affiliated Hosp 2, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.
   [Zhou, Rong Ping; Lin, Si Jian; Dai, Jiang Hua; Zhu, Mei Lan; Luo, Jun] Regenerat & Rehabil Engn Res Inst Bone & Nerve Ji, Nanchang, Jiangxi, Peoples R China.
   [Zhou, Rong Ping; Wan, Wen Bing; Ruan, Hui Bing; Xu, Jin; Song, Wei; Zhou, Yi Cheng; Wen, Shi Yao; Luo, Jun] NanChuang Univ, Orthopaed Res Inst Jiangxi, Nanchang, Jiangxi, Peoples R China.
   [Lin, Si Jian; Zuo, Hui Ling; Yao, Fen Fen; Dai, Jiang Hua; Zhu, Mei Lan; Luo, Jun] NanChang Univ, Affiliated Hosp 2, Rehabil Dept, Nanchang, Jiangxi, Peoples R China.
RP Zhou, RP (reprint author), NanChang Univ, Affiliated Hosp 2, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.; Zhou, RP; Luo, J (reprint author), Regenerat & Rehabil Engn Res Inst Bone & Nerve Ji, Nanchang, Jiangxi, Peoples R China.; Zhou, RP; Luo, J (reprint author), NanChuang Univ, Orthopaed Res Inst Jiangxi, Nanchang, Jiangxi, Peoples R China.; Luo, J (reprint author), NanChang Univ, Affiliated Hosp 2, Rehabil Dept, Nanchang, Jiangxi, Peoples R China.
EM rong8618241@126.com; Luojun1786@163.com
FU National Natural Science Foundation of China [81160508, 81260401,
   81460342]; Natural Science Foundation of Jiangxi Province [GZY0170]
FX This work was supported by National Natural Science Foundation of China
   (No: 81160508, 81260401, 81460342) and the Natural Science Foundation of
   Jiangxi Province (No: GZY0170).
CR Allen AJ, 2002, J CLIN PSYCHIAT, V63, P44
   Andia DC, 2008, HISTOL HISTOPATHOL, V23, P1177, DOI 10.14670/HH-23.1177
   Arjmandi BH, 1998, AM J CLIN NUTR, V68, p1364S, DOI 10.1093/ajcn/68.6.1364S
   AVIOLI LV, 1965, J CLIN ENDOCR METAB, V25, P912, DOI 10.1210/jcem-25-7-912
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   BREZINSKI A, 1999, EUR J OBSTET GYN R B, V85, P47
   Bunin DI, 2013, RADIAT RES, V179, P171, DOI 10.1667/RR3115.1
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI 10.1359/JBMR.061113
   Castelo-Branco C, 2013, GYNECOL ENDOCRINOL, V29, P735, DOI 10.3109/09513590.2013.801441
   Chang KL, 2013, NUTRITION, V29, P250, DOI 10.1016/j.nut.2012.03.009
   Cheng XG, 2007, J CLIN DENSITOM, V10, P276, DOI 10.1016/j.jocd.2007.05.004
   Dang ZC, 2002, J BONE MINER RES, V17, P394, DOI 10.1359/jbmr.2002.17.3.394
   Eklund PC, 2005, ORG BIOMOL CHEM, V3, P3336, DOI 10.1039/b506739a
   FERRETTI JL, 1990, BONE MINER, V11, P111, DOI 10.1016/0169-6009(90)90020-G
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010-2552
   Geng WX, 2013, BIOCHEM BIOPH RES CO, V434, P280, DOI 10.1016/j.bbrc.2013.02.116
   Hassan HA, 2013, CYTOTECHNOLOGY, V65, P609, DOI 10.1007/s10616-012-9514-6
   Ho SC, 2007, MENOPAUSE, V14, P905, DOI 10.1097/gme.0b013e318032b2d3
   Horcajada-Molteni MN, 2000, J BONE MINER RES, V15, P2251, DOI 10.1359/jbmr.2000.15.11.2251
   Hsieh CL, 2000, LIFE SCI, V66, P1387, DOI 10.1016/S0024-3205(00)00450-1
   Huber Florian, 2003, Clin Lab, V49, P203
   Hunyadi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050619
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Iolascon G, 2013, CLIN CASES MINER BON, V10, P47, DOI 10.11138/ccmbm/2013.10.1.047
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Alonso-Castro AJ, 2015, J ETHNOPHARMACOL, V175, P335, DOI 10.1016/j.jep.2015.09.029
   Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I
   Kamiyama M, 2015, J AGR FOOD CHEM, V63, P1996, DOI 10.1021/jf5060563
   Khajuria DK, 2014, J ORTHOP SCI, V19, P646, DOI 10.1007/s00776-014-0557-8
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim MK, 2002, CLIN ENDOCRINOL, V56, P321, DOI 10.1046/j.1365-2265.2002.01470.x
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Lee MK, 2007, BIOL PHARM BULL, V30, P814, DOI 10.1248/bpb.30.814
   Lee MK, 2005, J MED FOOD, V8, P86, DOI 10.1089/jmf.2005.8.86
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1
   Luo JY, 2009, J ENZYM INHIB MED CH, V24, P1280, DOI 10.3109/14756360902829741
   Mattsson C, 2007, CURR MED CHEM, V14, P2918, DOI 10.2174/092986707782359972
   Medical Advisory Secretariat, 2006, Ont Health Technol Assess Ser, V6, P1
   MEYERSABELLEK W, 1988, J CHROMATOGR-BIOMED, V429, P419, DOI 10.1016/S0378-4347(00)83881-5
   Omsland TK, 2014, OSTEOPOROSIS INT, V25, P2493, DOI 10.1007/s00198-014-2781-7
   Rachidi Mouna, 2008, Journal de la Societe de Biologie, V202, P265, DOI 10.1051/jbio:2008035
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rakshit S, 2010, BIOCHEM PHARMACOL, V80, P1662, DOI 10.1016/j.bcp.2010.08.013
   Rendina E, 2012, J NUTR BIOCHEM, V23, P60, DOI 10.1016/j.jnutbio.2010.10.010
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Ro SC, 2007, MENOPAUSE, V14, P489, DOI 10.1097/gme.0b013e31802v4f4f
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321
   Rufus P, 2013, CURR DRUG TARGETS, V14, P1689, DOI 10.2174/1389450114666131220160357
   Seidlova-Wuttke D, 2008, BONE, V43, P849, DOI 10.1016/j.bone.2008.07.237
   Sontakke A, 2002, CLIN CHIM ACTA, V318, P145, DOI 10.1016/S0009-8981(01)00766-5
   Tchernof A, 1998, OBES RES, V6, P246, DOI 10.1002/j.1550-8528.1998.tb00344.x
   Teixeira S, 2005, FREE RADICAL BIO MED, V39, P1099, DOI 10.1016/j.freeadbiomed.2005.05.028
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   WRONSKI TJ, 1989, ENDOCRINOLOGY, V125, P810, DOI 10.1210/endo-125-2-810
   Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699
   Xu ZS, 2010, J AGR FOOD CHEM, V58, P7289, DOI 10.1021/jf100304t
   Yang C., 2014, J BOT, V2014, P9, DOI [10.1155/2014/181727, DOI 10.1155/2014/181727]
   Yin J, 2006, PHYTOMEDICINE, V13, P37, DOI 10.1016/j.phymed.2004.06.017
   Zhang G, 2006, BONE, V38, P818, DOI 10.1016/j.bone.2005.11.019
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhao Q, 2013, CALCIFIED TISSUE INT, V93, P172, DOI 10.1007/s00223-013-9739-1
   Zheng J, 2012, INDIAN J EXP BIOL, V50, P875
   Zhu HM, 2012, MOLECULES, V17, P8001, DOI 10.3390/molecules17078001
   Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446
NR 66
TC 6
Z9 6
U1 0
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2016
VL 11
IS 12
AR e0166751
DI 10.1371/journal.pone.0166751
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EG7KQ
UT WOS:000391226900007
PM 28033335
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Howie, RN
   Durham, EL
   Black, L
   Bennfors, G
   Parsons, TE
   Elsalanty, ME
   Yu, JC
   Weinberg, SM
   Cray, JJ
AF Howie, R. Nicole
   Durham, Emily L.
   Black, Laurel
   Bennfors, Grace
   Parsons, Trish E.
   Elsalanty, Mohammed E.
   Yu, Jack C.
   Weinberg, Seth M.
   Cray, James J., Jr.
TI Effects of In Utero Thyroxine Exposure on Murine Cranial Suture Growth
SO PLOS ONE
LA English
DT Article
ID CELL-CYCLE PROGRESSION; THYROID-HORMONE; SKELETAL DEVELOPMENT;
   BETA-CATENIN; BONE-GROWTH; STEM-CELLS; C-JUN; CRANIOSYNOSTOSIS; MICE;
   DIFFERENTIATION
AB Large scale surveillance studies, case studies, as well as cohort studies have identified the influence of thyroid hormones on calvarial growth and development. Surveillance data suggests maternal thyroid disorders (hyperthyroidism, hypothyroidism with pharmacological replacement, and Maternal Graves Disease) are linked to as much as a 2.5 fold increased risk for craniosynostosis. Craniosynostosis is the premature fusion of one or more calvarial growth sites (sutures) prior to the completion of brain expansion. Thyroid hormones maintain proper bone mineral densities by interacting with growth hormone and aiding in the regulation of insulin like growth factors (IGFs). Disruption of this hormonal control of bone physiology may lead to altered bone dynamics thereby increasing the risk for craniosynostosis. In order to elucidate the effect of exogenous thyroxine exposure on cranial suture growth and morphology, wild type C57BL6 mouse litters were exposed to thyroxine in utero (control = no treatment; low similar to 167 ng per day; high similar to 667 ng per day). Thyroxine exposed mice demonstrated craniofacial dysmorphology (brachycranic). High dose exposed mice showed diminished area of the coronal and widening of the sagittal sutures indicative of premature fusion and compensatory growth. Presence of thyroid receptors was confirmed for the murine cranial suture and markers of proliferation and osteogenesis were increased in sutures from exposed mice. Increased Htra1 and Igf1 gene expression were found in sutures from high dose exposed individuals. Pathways related to the HTRA1/IGF axis, specifically Akt and Wnt, demonstrated evidence of increased activity. Overall our data suggest that maternal exogenous thyroxine exposure can drive calvarial growth alterations and altered suture morphology.
C1 [Howie, R. Nicole; Durham, Emily L.; Black, Laurel; Bennfors, Grace; Cray, James J., Jr.] Med Univ South Carolina, Dept Oral Hlth Sci, Charleston, SC USA.
   [Parsons, Trish E.; Weinberg, Seth M.] Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, Ctr Craniofacial & Dent Genet, Pittsburgh, PA USA.
   [Elsalanty, Mohammed E.] Augusta Univ, Dept Oral Biol, Augusta, GA USA.
   [Elsalanty, Mohammed E.] Augusta Univ, Dept Cellular Biol & Anat, Augusta, GA USA.
   [Elsalanty, Mohammed E.] Augusta Univ, Dept Orthoped Surg, Augusta, GA USA.
   [Elsalanty, Mohammed E.] Augusta Univ, Dept Oral & Maxillofacial Surg, Augusta, GA USA.
   [Elsalanty, Mohammed E.; Yu, Jack C.] Augusta Univ, Inst Regenerat & Reparat Med, Augusta, GA USA.
   [Yu, Jack C.] Augusta Univ, Div Plast Surg, Dept Surg, Augusta, GA USA.
RP Cray, JJ (reprint author), Med Univ South Carolina, Dept Oral Hlth Sci, Charleston, SC USA.
EM crayj@musc.edu
OI Weinberg, Seth/0000-0001-9467-4556
FU National Institute of Dental and Craniofacial Research [R03DE023350A];
   Cleft Palate Foundation Cleft/Craniofacial Anomalies Grant Award;
   National Institutes of Health National Institute of Dental and
   Craniofacial Research [5T32DE017551]; National Institutes of Health
   National Institute of General Medicine [P30GM103331]
FX This study utilized the facilities and resources of the MUSC Center for
   Oral Health Research (COHR). This work was funded in part by the
   National Institute of Dental and Craniofacial Research [R03DE023350A to
   JJC], and the Cleft Palate Foundation Cleft/Craniofacial Anomalies Grant
   Award to JJC. Micro-Computed Tomography scans were made possible by the
   National Institute on Aging (NIA) 1P01AG036675 (ME). ELD and RNH are
   funded through a training grant from the National Institutes of Health
   National Institute of Dental and Craniofacial Research [5T32DE017551].
   The MUSC Center for Oral Health Research (COHR), is partially supported
   by the National Institutes of Health National Institute of General
   Medicine [P30GM103331].
CR Akita S, 1996, PLAST RECONSTR SURG, V97, P1, DOI 10.1097/00006534-199601000-00001
   AKITA S, 1994, THYROID, V4, P99, DOI 10.1089/thy.1994.4.99
   Ardalan M, 2012, PEDIATR NEUROSURG, V48, P152, DOI 10.1159/000346261
   ARNAUD E, 1995, J NEUROSURG, V83, P476, DOI 10.3171/jns.1995.83.3.0476
   Bassett JHD, 2016, ENDOCR REV, V37, P135, DOI 10.1210/er.2015-1106
   Bassett JH, 2016, ENDOCR REV
   Borgatti P, 2000, FEBS LETT, V477, P27, DOI 10.1016/S0014-5793(00)01758-0
   Browne ML, 2011, BIRTH DEFECTS RES A, V91, P93, DOI 10.1002/bdra.20752
   Bu YH, 2010, J ENDOCRINOL, V206, P271, DOI 10.1677/JOE-10-0064
   BURR W, 1986, CLIN OBSTET GYNAECOL, V13, P277
   Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093
   Capelo LP, 2008, BONE, V43, P921, DOI 10.1016/j.bone.2008.06.020
   Capuco AV, 1999, P SOC EXP BIOL MED, V221, P345, DOI 10.1046/j.1525-1373.1999.d01-91.x
   Carmichael S, 2015, AM J MED GENETICS A
   Carmichael SL, 2010, BIRTH DEFECTS RES A, V88, P1032, DOI 10.1002/bdra.20717
   CHADDUCK WM, 1992, NEUROSURGERY, V30, P867, DOI 10.1227/00006123-199206000-00008
   Cray JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069067
   Darnerud PO, 1996, TOXICOLOGY, V106, P105, DOI 10.1016/0300-483X(95)03169-G
   DULHUNTY AF, 1986, J MUSCLE RES CELL M, V7, P225, DOI 10.1007/BF01753555
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Gauthier K, 2014, ENDOCRINOLOGY, V155, P3206, DOI 10.1210/en.2014-1597
   Glanz S, 2016, STEM CELLS DEV, V25, P687, DOI 10.1089/scd.2015.0368
   Glinoer D, 1998, THYROID, V8, P859, DOI 10.1089/thy.1998.8.859
   Hashmi SS, 2012, BIRTH DEFECTS RES A, V94, P1004, DOI 10.1002/bdra.23077
   Heuze Yann, 2014, Curr Genet Med Rep, V2, P135
   Jin SW, 2016, J KOREAN NEUROSURG S, V59, P192, DOI 10.3340/jkns.2016.59.3.192
   JOHNSTON MC, 1995, CRIT REV ORAL BIOL M, V6, P368, DOI 10.1177/10454411950060040601
   JURILOFF DM, 1985, TERATOLOGY, V31, P319, DOI 10.1002/tera.1420310302
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim HY, 2013, BONE RES, V1, DOI 10.4248/BR201302004
   Krause K, 2015, EUR THYROID J, V4, P59, DOI 10.1159/000437304
   Krude H, 1997, EXP CLIN ENDOCR DIAB, V105, P6, DOI 10.1055/s-0029-1211924
   LAMB JC, 1986, TOXICOL APPL PHARM, V84, P115, DOI 10.1016/0041-008X(86)90420-5
   LAMBERG BA, 1986, CLIN ENDOCRINOL, V25, P259, DOI 10.1111/j.1365-2265.1986.tb01690.x
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Maruyama T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10526
   McNab T, 2005, CLIN INVEST MED, V28, P127
   McNabb FMA, 1992, THYROID HORMONES, Vxv
   Miller MT, 2000, CRANIOSYNOSTOSIS DIA, P184
   Murphy E, 2004, CLIN ENDOCRINOL, V61, P285, DOI 10.1111/j.1365-2265.2004.02053.x
   O'Shea PJ, 2003, MOL ENDOCRINOL, V17, P1410, DOI 10.1210/me.2002-0296
   Oppenheimer JH, 1983, MOL BASIS THYROID HO, Vxv
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1073>3.0.CO;2-F
   Parsons TE, 2014, ANAT REC, V297, P826, DOI 10.1002/ar.22899
   PENFOLD JL, 1975, J PEDIATR-US, V86, P360, DOI 10.1016/S0022-3476(75)80963-2
   PIRINEN S, 1995, ACTA ODONTOL SCAND, V53, P179, DOI 10.3109/00016359509005969
   Proff P, 2006, J CRANIO MAXILL SURG, V34, P96, DOI 10.1016/S1010-5182(06)60021-8
   Radetti G, 2002, Minerva Pediatr, V54, P383
   Rasmussen SA, 2008, AM J MED GENET A, V146A, P149, DOI 10.1002/ajmg.a.32106
   Rasmussen SA, 2007, OBSTET GYNECOL, V110, P369, DOI 10.1097/01.AOG.0000270157.88896.76
   Reefhuis J, 2011, HUM REPROD, V26, P451, DOI 10.1093/humrep/deq313
   Richardson S, 2011, BIRTH DEFECTS RES A, V91, P623, DOI 10.1002/bdra.20823
   Robubi A, 2014, BONE JOINT RES, V3, P236, DOI 10.1302/2046-3758.37.2000231
   Rybchyn MS, 2011, J BIOL CHEM, V286, P23771, DOI 10.1074/jbc.M111.251116
   Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607
   Stevens DA, 2003, MOL ENDOCRINOL, V17, P1751, DOI 10.1210/me.2003-0137
   THORDARSON G, 1992, BIOL REPROD, V47, P676, DOI 10.1095/biolreprod47.4.676
   Twigg SRF, 2015, HUM MOL GENET, V24, pR50, DOI 10.1093/hmg/ddv228
   Twigg SRF, 2015, AM J HUM GENET, V97, P359, DOI 10.1016/j.ajhg.2015.07.006
   Ulici V, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-40
   Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801
   Vecchione L, 2010, ANAT REC, V293, P32, DOI 10.1002/ar.21024
   Wang L, 2010, J BONE MINER RES, V25, P1138, DOI 10.1002/jbmr.5
   Williams GR, 2013, EUR THYROID J, V2, P3, DOI 10.1159/000345548
   Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188
   Wojcicka A, 2013, BBA-GEN SUBJECTS, V1830, P3979, DOI 10.1016/j.bbagen.2012.05.005
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
   Zimmerman D, 1999, THYROID, V9, P727, DOI 10.1089/thy.1999.9.727
NR 69
TC 6
Z9 6
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 13
PY 2016
VL 11
IS 12
AR e0167805
DI 10.1371/journal.pone.0167805
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI8JY
UT WOS:000392753900016
PM 27959899
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Grove, E
   Eckardt, S
   McLaughlin, KJ
AF Grove, Erin
   Eckardt, Sigrid
   McLaughlin, K. John
TI High-Speed Mouse Backcrossing Through the Female Germ Line
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; SUPEROVULATION; MICE; STRAINS; PERTURBATIONS;
   METHYLATION; STRATEGIES; MODEL; DNA
AB Transferring mouse mutations into specific mouse strain backgrounds can be critical for appropriate analysis of phenotypic effects of targeted genomic alterations and quantitative trait loci. Speed congenic breeding strategies incorporating marker-assisted selection of progeny with the highest percentage target background as breeders for the next generation can produce congenic strains within approximately 5 generations. When mating selected donor males to target strain females, this may require more than 1 year, with each generation lasting 10 to 11 weeks including 3 weeks of gestation and 7 to 8 weeks until the males reach sexual maturity. Because ovulation can be induced in female mice as early as 3 weeks of age, superovulation-aided backcrossing of marker-selected females could accelerate the production of congenic animals by approximately 4 weeks per generation, reducing time and cost. Using this approach, we transferred a transgenic strain of undefined genetic background to >99% C57BL/6J within 10 months, with most generations lasting 7 weeks. This involved less than 60 mice in total, with 9 to 18 animals per generation. Our data demonstrate that high-speed backcrossing through the female germline is feasible and practical with small mouse numbers.
C1 [Grove, Erin; Eckardt, Sigrid; McLaughlin, K. John] Nationwide Childrens Hosp, Res Inst, Ctr Mol & Human Genet, Columbus, OH 43205 USA.
RP McLaughlin, KJ (reprint author), Nationwide Childrens Hosp, Res Inst, Ctr Mol & Human Genet, Columbus, OH 43205 USA.
EM John.McLaughlin@nationwidechildrens.org
FU Research Institute at Nationwide Children's Hospital
FX This study was funded by The Research Institute at Nationwide Children's
   Hospital, and there was no additional external funding received for this
   study.
CR Ackert-Bicknell CL, 2016, J BONE MINER RES, V31, P270, DOI 10.1002/jbmr.2772
   Almind K, 2003, DIABETES, V52, P1535, DOI 10.2337/diabetes.52.6.1535
   Armstrong NJ, 2006, MAMM GENOME, V17, P273, DOI 10.1007/s00335-005-0123-y
   Behringer R, 1998, NAT GENET, V18, P108, DOI 10.1038/ng0298-108
   Behringer R, 2014, MANIPULATING THE MOU
   de Waal E, 2015, HUM MOL GENET, V24, P6975, DOI 10.1093/hmg/ddv400
   Denomme MM, 2011, FERTIL STERIL, V96, P734, DOI 10.1016/j.fertnstert.2011.06.055
   Fortier AL, 2014, MOL CELL ENDOCRINOL, V388, P51, DOI 10.1016/j.mce.2014.03.003
   Gao Z, 2014, J ASSIST REPROD GEN, V31, P1243, DOI 10.1007/s10815-014-0295-z
   Huffman SR, 2015, MOL REPROD DEV, V82, P207, DOI 10.1002/mrd.22463
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Landa V, 2010, METHODS MOL BIOL, V597, P267, DOI 10.1007/978-1-60327-389-3_18
   Linder CC, 2006, ILAR J, V47, P132, DOI 10.1093/ilar.47.2.132
   Luo C, 2011, J AM ASSOC LAB ANIM, V50, P471
   Lusis AJ, 2007, ARTERIOSCL THROM VAS, V27, P2100, DOI 10.1161/ATVBAHA.107.147918
   Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280
   Market-Velker BA, 2010, BIOL REPROD, V83, P938, DOI 10.1095/biolreprod.110.085480
   Market-Velker BA, 2010, HUM MOL GENET, V19, P36, DOI 10.1093/hmg/ddp465
   Ogonuki N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004943
   Rivera J, 2008, IMMUNITY, V28, P1, DOI 10.1016/j.immuni.2007.12.008
   Singh P, 2015, GENETICS, V199, P1, DOI 10.1534/genetics.114.169771
   Takeo T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128330
   Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09
   Vanden Berghe T, 2015, IMMUNITY, V43, P200, DOI 10.1016/j.immuni.2015.06.011
   Wei ZT, 2014, J ASSIST REPROD GEN, V31, P555, DOI 10.1007/s10815-014-0191-6
   Yoshiki A, 2006, ILAR J, V47, P94, DOI 10.1093/ilar.47.2.94
NR 26
TC 3
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2016
VL 11
IS 12
AR e0166822
DI 10.1371/journal.pone.0166822
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE4NG
UT WOS:000389578800007
PM 27926922
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Reichlin, TS
   Vogt, L
   Wurbel, H
AF Reichlin, Thomas S.
   Vogt, Lucile
   Wurbel, Hanno
TI The Researchers' View of Scientific Rigor-Survey on the Conduct and
   Reporting of In Vivo Research
SO PLOS ONE
LA English
DT Article
ID RESEARCH-AND-DEVELOPMENT; ANIMAL-MODELS; ENVIRONMENTAL STANDARDIZATION;
   PRECLINICAL RESEARCH; BIOMEDICAL-RESEARCH; EXPERIMENTAL-DESIGN;
   REPRODUCIBILITY; STROKE; METAANALYSIS; BIAS
AB Reproducibility in animal research is alarmingly low, and a lack of scientific rigor has been proposed as a major cause. Systematic reviews found low reporting rates of measures against risks of bias (e.g., randomization, blinding), and a correlation between low reporting rates and overstated treatment effects. Reporting rates of measures against bias are thus used as a proxy measure for scientific rigor, and reporting guidelines (e.g., ARRIVE) have become a major weapon in the fight against risks of bias in animal research. Surprisingly, animal scientists have never been asked about their use of measures against risks of bias and how they report these in publications. Whether poor reporting reflects poor use of such measures, and whether reporting guidelines may effectively reduce risks of bias has therefore remained elusive. To address these questions, we asked in vivo researchers about their use and reporting of measures against risks of bias and examined how self-reports relate to reporting rates obtained through systematic reviews. An online survey was sent out to all registered in vivo researchers in Switzerland (N = 1891) and was complemented by personal interviews with five representative in vivo researchers to facilitate interpretation of the survey results. Return rate was 28% (N = 530), of which 302 participants (16%) returned fully completed questionnaires that were used for further analysis. According to the researchers' self-report, they use measures against risks of bias to a much greater extent than suggested by reporting rates obtained through systematic reviews. However, the researchers' self-reports are likely biased to some extent. Thus, although they claimed to be reporting measures against risks of bias at much lower rates than they claimed to be using these measures, the self-reported reporting rates were considerably higher than reporting rates found by systematic reviews. Furthermore, participants performed rather poorly when asked to choose effective over ineffective measures against six different biases. Our results further indicate that knowledge of the ARRIVE guidelines had a positive effect on scientific rigor. However, the ARRIVE guidelines were known by less than half of the participants (43.7%); and among those whose latest paper was published in a journal that had endorsed the ARRIVE guidelines, more than half (51%) had never heard of these guidelines. Our results suggest that whereas reporting rates may underestimate the true use of measures against risks of bias, self-reports may overestimate it. To a large extent, this discrepancy can be explained by the researchers' ignorance and lack of knowledge of risks of bias and measures to prevent them. Our analysis thus adds significant new evidence to the assessment of research integrity in animal research. Our findings further question the confidence that the authorities have in scientific rigor, which is taken for granted in the harm-benefit analyses on which approval of animal experiments is based. Furthermore, they suggest that better education on scientific integrity and good research practice is needed. However, they also question reliance on reporting rates as indicators of scientific rigor and highlight a need for more reliable predictors.
C1 [Reichlin, Thomas S.; Vogt, Lucile; Wurbel, Hanno] Univ Bern, Vetsuisse Fac, Vet Publ Hlth Inst, Div Anim Welf, Bern, Switzerland.
RP Wurbel, H (reprint author), Univ Bern, Vetsuisse Fac, Vet Publ Hlth Inst, Div Anim Welf, Bern, Switzerland.
EM hanno.wuerbel@vetsuisse.unibe.ch
RI Wuerbel, Hanno/D-6281-2012
OI Wuerbel, Hanno/0000-0002-2934-3010
FU Swiss Federal Food Safety and Veterinary Office (FSVO) [2.13.01]
FX This study was funded by the Swiss Federal Food Safety and Veterinary
   Office (FSVO, www.blv.admin.ch/, Grant No. 2.13.01). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aho K, 2014, ECOLOGY, V95, P631, DOI 10.1890/13-1452.1
   [Anonymous], 2012, NAT BIOTECHNOL, V30, P806, DOI 10.1038/nbt.2335
   Bailoo JD, 2014, ILAR J, V55, P383, DOI 10.1093/ilar/ilu037
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Barton K., 2014, MUMIN MULTIMODEL INF
   Begley CG, 2015, CIRC RES, V116, P116, DOI 10.1161/CIRCRESAHA.114.303819
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Bello S, 2014, J CLIN EPIDEMIOL, V67, P973, DOI 10.1016/j.jclinepi.2014.04.008
   Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Collins FS, 2014, NATURE, V505, P612, DOI 10.1038/505612a
   Cressey D., 2016, NATURE NEWS
   Currie GL, 2013, PAIN, V154, P917, DOI 10.1016/j.pain.2013.02.033
   Editor, 2013, NATURE, V496, P198
   Ehrlinger J, 2003, J PERS SOC PSYCHOL, V84, P5, DOI 10.1037/0022-3514.84.1.5
   Fanelli D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010271
   Fang FC, 2012, P NATL ACAD SCI USA, V110, P1136
   Festing MFW, 2013, ALTERN LAB ANIM ATLA, V41, P19
   Frantzias J, 2011, ANN NEUROL, V69, P389, DOI 10.1002/ana.22243
   Freedman LP, 2015, CLIN PHARMACOL THER, V97, P16, DOI 10.1002/cpt.9
   Freedman LP, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002165
   Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X
   Henderson VC, 2015, ELIFE, V4, DOI 10.7554/eLife.08351
   Henderson VC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001489
   Hirst JA, 2014, PLOS ONE, V9, DOI [10.1161/01.STR.0000125719.25853.20, DOI 10.1161/01.STR.0000125719.25853.20]
   Howells DW, 2014, NAT REV NEUROL, V10, P37, DOI 10.1038/nrneurol.2013.232
   Howells DW, 2012, INT J STROKE, V7, P371, DOI 10.1111/j.1747-4949.2012.00805.x
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470
   Kontinen V, 2015, SCAND J PAIN, V7, P38, DOI 10.1016/j.sjpain.2015.01.004
   Kontinen VK, 2013, SCAND J PAIN, V4, P57, DOI 10.1016/j.sjpain.2013.02.004
   Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Macleod M, 2011, NATURE, V477, P511, DOI 10.1038/477511a
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Macleod MR, 2004, STROKE, V35, P1203, DOI 10.1161/01.STR.0000125719.25853.20
   McCann SK, 2014, STROKE, V45, P3055, DOI 10.1161/STROKEAHA.114.006304
   McNutt M., 2014, NATURE, V515, P7
   McNutt M, 2014, SCIENCE, V343, P231, DOI 10.1126/science.1250475
   Minnerup J, 2016, STROKE, V47, P267, DOI 10.1161/STROKEAHA.115.011695
   Mullane K, 2015, BIOCHEM PHARMACOL, V97, P225, DOI 10.1016/j.bcp.2015.06.023
   Nuzzo R, 2014, NATURE, V506, P150, DOI 10.1038/506150a
   O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741
   Pound P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3387
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   R Core Team, 2014, R LANG ENV STAT COMP, DOI [10.1161/STROKEAHA.115.011695, DOI 10.1161/STROKEAHA.115.011695]
   Ransohoff DF, 2005, NAT REV CANCER, V5, P142, DOI 10.1038/nrc1550
   Richter SH, 2010, NAT METHODS, V7, P167, DOI 10.1038/nmeth0310-167
   Richter SH, 2009, NAT METHODS, V6, P257, DOI [10.1038/nmeth.1312, 10.1038/NMETH.1312]
   Rooke EDM, 2011, PARKINSONISM RELAT D, V17, P313, DOI 10.1016/j.parkreldis.2011.02.010
   Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681
   Schmitz C., 2012, LIMESURVEY OPEN SOUR
   Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009
   Steckler T, 2015, SPRINGERPLUS, V4, DOI 10.1186/2193-1801-4-1
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Vaux DL, 2012, NATURE, V492, P180, DOI 10.1038/492180a
   Vesterinen HM, 2010, MULT SCLER J, V16, P1044, DOI 10.1177/1352458510379612
   Voelkl B, 2016, TRENDS PHARMACOL SCI, V37, P509, DOI 10.1016/j.tips.2016.05.003
   Wurbel H, 2000, NAT GENET, V26, P263, DOI 10.1038/81541
   Wurbel H, 2002, GENES BRAIN BEHAV, V1, P3, DOI 10.1046/j.1601-1848.2001.00006.x
NR 63
TC 12
Z9 12
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2016
VL 11
IS 12
AR e0165999
DI 10.1371/journal.pone.0165999
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3TF
UT WOS:000389520600005
PM 27911901
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Avey, MT
   Moher, D
   Sullivan, KJ
   Fergusson, D
   Griffin, G
   Grimshaw, JM
   Hutton, B
   Lalu, MM
   Macleod, M
   Marshall, J
   Mei, SHJ
   Rudnicki, M
   Stewart, DJ
   Turgeon, AF
   Mclntyre, L
AF Avey, Marc T.
   Moher, David
   Sullivan, Katrina J.
   Fergusson, Dean
   Griffin, Gilly
   Grimshaw, Jeremy M.
   Hutton, Brian
   Lalu, Manoj M.
   Macleod, Malcolm
   Marshall, John
   Mei, Shirley H. J.
   Rudnicki, Michael
   Stewart, Duncan J.
   Turgeon, Aexis F.
   Mclntyre, Lauralyn
CA McIntyre, L
TI The Devil Is in the Details: Incomplete Reporting in Preclinical Animal
   Research
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; QUALITY; EFFICACY; DESIGN; IMPACT
AB Incomplete reporting of study methods and results has become a focal point for failures in the reproducibility and translation of findings from preclinical research. Here we demonstrate that incomplete reporting of preclinical research is not limited to a few elements of research design, but rather is a broader problem that extends to the reporting of the methods and results. We evaluated 47 preclinical research studies from a systematic review of acute lung injury that use mesenchymal stem cells (MSCs) as a treatment. We operationalized the ARRIVE (Animal Research: Reporting of In Vivo Experiments) reporting guidelines for pre-clinical studies into 109 discrete reporting sub-items and extracted 5,123 data elements. Overall, studies reported less than half (47%) of all sub-items (median 51 items; range 37-64). Across all studies, the Methods Section reported less than half (45%) and the Results Section reported less than a third (29%). There was no association between journal impact factor and completeness of reporting, which suggests that incomplete reporting of preclinical research occurs across all journals regardless of their perceived prestige. Incomplete reporting of methods and results will impede attempts to replicate research findings and maximize the value of preclinical studies.
C1 [Avey, Marc T.; Moher, David; Sullivan, Katrina J.; Fergusson, Dean; Griffin, Gilly; Grimshaw, Jeremy M.; Hutton, Brian; Lalu, Manoj M.; Mclntyre, Lauralyn] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Avey, Marc T.] Univ Ottawa, Fac Med, Ottawa, ON, Canada.
   [Moher, David; Hutton, Brian] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada.
   [Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
   [Macleod, Malcolm] Univ Edinburgh, Div Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland.
   [Marshall, John] Univ Toronto, Dept Surg Crit Care, Toronto, ON, Canada.
   [Lalu, Manoj M.; Mei, Shirley H. J.; Rudnicki, Michael; Stewart, Duncan J.] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada.
   [Stewart, Duncan J.] Univ Ottawa, Dept Cell & Mol Med, Ottawa, ON, Canada.
   [Turgeon, Aexis F.] Univ Laval, CHU Quebec Enfant Jesus Hosp, Ctr Rech, Populat Hlth & Optimal Hlth Practices Unit Trauma, Quebec City, PQ, Canada.
   [Turgeon, Aexis F.] Univ Laval, Dept Anesthesiol, Div Crit Care Med, Quebec City, PQ, Canada.
   [Mclntyre, Lauralyn] Univ Ottawa, Dept Med, Div Crit Care, Ottawa, ON, Canada.
RP Avey, MT (reprint author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.; Avey, MT (reprint author), Univ Ottawa, Fac Med, Ottawa, ON, Canada.
EM marc.t.avey@gmail.com
RI Macleod, Malcolm Robert/B-2052-2010; Moher, David/I-3408-2019
OI Macleod, Malcolm Robert/0000-0001-9187-9839; Moher,
   David/0000-0003-2434-4206; Fergusson, Dean/0000-0002-3389-2485; Avey,
   Marc/0000-0002-8696-3232; Hutton, Brian/0000-0001-5662-8647; Mei,
   Shirley/0000-0003-4727-1177
FU Canadian Institutes of Health Research [201 21
   OKPD-290743-HTA-ADYP-225697, 340151]; National Centre for the
   Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
   [NC/L000970/1]
FX MTA was funded by the Canadian Institutes of Health Research -
   Post-Doctoral Fellowship (201 21 OKPD-290743-HTA-ADYP-225697). AFT was
   funded by the Canadian Institutes of Health Research - New Investigator
   Award (340151).
CR Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Baker M., 2016, NATURE
   Collins FS, 2014, NATURE, V505, P612, DOI 10.1038/505612a
   Cressey D, 2016, NATURE, DOI [10.1038/nature.2016.19274, DOI 10.1038/NATURE.2016.19274]
   Federation of American Societies for Experimental Biology, 2016, ENH RES REPR REC FED
   Hayden E.C., 2014, NATURE, DOI [10.1038/nature.2014.14938, DOI 10.1038/NATURE.2014.14938]
   Henderson VC, 2015, ELIFE, V4, DOI 10.7554/eLife.08351
   Henderson VC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001489
   Hirst JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098856
   Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8
   Kane RL, 2007, J CLIN EPIDEMIOL, V60, P241, DOI 10.1016/j.jclinepi.2006.06.016
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Lalu MM, 2014, SYST REV, V3, DOI 10.1186/2046-4053-3-48
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   McIntyre LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147170
   Minnerup J, 2010, J CEREBR BLOOD F MET, V30, P1619, DOI 10.1038/jcbfm.2010.74
   Moberg-Mogren E, 2006, AM J OCCUP THER, V60, P226, DOI 10.5014/ajot.60.2.226
   Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   National Institues of Health, 2014, PRINC GUID REP PRECL
   National Institutes of Health, 2014, PHYS SCI WORKF WORK, P1
   Nature, 2013, NATURE
   Gulin JEN, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004194
   Reardon S, 2016, NATURE, V530, P264, DOI 10.1038/nature.2016.19335
   Schwarz F, 2012, J CLIN PERIODONTOL, V39, P63, DOI 10.1111/j.1600-051X.2011.01838.x
   Thomason Reuters, 2015, 2015 J CIT REP SCI E, V2013
   Turner L, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-60
NR 29
TC 11
Z9 11
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 17
PY 2016
VL 11
IS 11
AR e0166733
DI 10.1371/journal.pone.0166733
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC2AC
UT WOS:000387910200049
PM 27855228
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ignacio, RMC
   Kabir, SM
   Lee, ES
   Adunyah, SE
   Son, DS
AF Ignacio, Rosa Mistica C.
   Kabir, Syeda M.
   Lee, Eun-Sook
   Adunyah, Samuel E.
   Son, Deok-Soo
TI NF-kappa B-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian
   Cancer Progression
SO PLOS ONE
LA English
DT Article
ID LYMPH-NODE METASTASIS; NECROSIS-FACTOR-ALPHA; TUMOR-GROWTH; CHEMOKINE
   EXPRESSION; COLORECTAL-CANCER; EOTAXIN-2 CCL24; MURINE MELANOMA;
   CELL-LINE; CXCR2; MICROENVIRONMENT
AB Ovarian cancer is an inflammation-associated malignancy with a high mortality rate. CXCR2 expressing ovarian cancers are aggressive with poorer outcomes. We previously demonstrated that CXCR2-driven ovarian cancer progression potentiated NF-kappa B activation through EGFR-transactivated Akt. Here, we identified the chemokine signature involved in CXCR2-driven ovarian cancer progression using a mouse peritoneal xenograft model for ovarian cancer spreading with CXCR2-negative (SKA) and positive (SKCXCR2) cells generated previously from parental SKOV-3 cells. Compared to SKA bearing mice, SKCXCR2 bearing mice had the following characteristics: 1) shorter survival time, 2) greater tumor spreading in the peritoneal cavity and 3) higher tumor weight in the omentum and pelvic site. Particularly, SKCXCR2-derived tumor tissues induced higher activation of the NF-kappa B signaling pathway, while having no change in EGFR-activated signaling such as Raf, MEK, Akt, mTOR and Erk compared to SKA-derived tumors. Chemokine PCR array revealed that CCL20 mRNA levels were significantly increased in SKCXCR2-derived tumor tissues. The CCL20 promoter activity was regulated by NF-kappa B dependent pathways. Interestingly, all three kappa B-like sites in the CCL20 promoter were involved in regulating CCL20 and the proximal region between -92 and -83 was the most critical kappa B-like site. In addition, SKCXCR2-derived tumor tissues maintained high CCL20 mRNA expression and induced greater CCL24 and CXCR4 compared to SKCXCR2 cells, indicating the shift of chemokine network during the peritoneal spreading of tumor cells via interaction with other cell types in tumor microenvironment. Furthermore, we compared expression profiling array between human ovarian cancer cell lines and tumor tissues based on GEO datasets. The expression profiles in comparison with cell lines revealed that dominant chemokines expressed in ovarian tumor tissues are likely shifted from CXCL1-3 and 8 to CCL20. Taken together, the progression of ovarian cancer in the peritoneal cavity involves NF-kappa B-mediated CCL20 as a main chemokine network, which is potentiated by CXCR2 expression.
C1 [Ignacio, Rosa Mistica C.; Kabir, Syeda M.; Adunyah, Samuel E.; Son, Deok-Soo] Meharry Med Coll, Dept Biochem & Canc Biol, Nashville, TN 37208 USA.
   [Lee, Eun-Sook] Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32307 USA.
RP Son, DS (reprint author), Meharry Med Coll, Dept Biochem & Canc Biol, Nashville, TN 37208 USA.
EM dson@mmc.edu
RI Ignacio, Rosa Mistica/C-8689-2018
OI Ignacio, Rosa Mistica/0000-0002-5343-4190
FU National Institutes of Health (NIH); National Institute of General
   Medical Sciences (NIGMS) [SC1 089630]; National Institute of
   Environmental Health Sciences (NIEHS) [R01ES024756]; National Cancer
   Institute (NCI) [U54CA163069-05, 5U54MD0007593-07, SC1CA200519];
   National Institute of Allergy and Infectious Diseases (NIAID)
   [SC1AI089073]
FX This research was supported, in whole or in part, by National Institutes
   of Health (NIH) as the following grants: National Institute of General
   Medical Sciences (NIGMS) SC1 089630 and National Institute of
   Environmental Health Sciences (NIEHS) R01ES024756 (EL), National Cancer
   Institute (NCI) U54CA163069-05 and 5U54MD0007593-07 (SEA), and National
   Institute of Allergy and Infectious Diseases (NIAID) SC1AI089073 and NCI
   SC1CA200519 (DS). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anthoni M, 2008, BRIT J DERMATOL, V159, P546, DOI 10.1111/j.1365-2133.2008.08696.x
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029
   Baumgarten SC, 2012, MOL ENDOCRINOL, V26, P360, DOI 10.1210/me.2011-1302
   Beider K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005125
   Ben-Yehuda C, 2008, EXP LUNG RES, V34, P467, DOI 10.1080/01902140802220625
   Bobbs AS, 2015, CANCER GROWTH METAST, P29, DOI 10.4137/CGM.S21221
   Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Capes-Davis A, 2010, INT J CANCER, V127, P1, DOI 10.1002/ijc.25242
   Cheadle EJ, 2007, CLIN CANCER RES, V13, P5719, DOI 10.1158/1078-0432.CCR-07-1145
   Chen KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024671
   Chobanian N, 2008, SURG CLIN N AM, V88, P285, DOI 10.1016/j.suc.2007.12.002
   Dobrzycka B, 2009, EUR CYTOKINE NETW, V20, P131, DOI 10.1684/ecn.2009.0161
   Dong YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083789
   Frick VO, 2013, SCAND J IMMUNOL, V78, P298, DOI 10.1111/sji.12087
   Fujiie S, 2001, INT IMMUNOL, V13, P1255, DOI 10.1093/intimm/13.10.1255
   Harant H, 2001, FEBS LETT, V509, P439, DOI 10.1016/S0014-5793(01)03138-6
   Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067
   Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim KY, 2009, ONCOL REP, V22, P1497, DOI 10.3892/or_00000593
   Kirshberg S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024856
   Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970
   Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105
   Lee YS, 2012, BRIT J CANCER, V106, P1833, DOI 10.1038/bjc.2012.177
   Maccio A, 2012, CYTOKINE, V58, P133, DOI 10.1016/j.cyto.2012.01.015
   Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712
   Mestas J, 2005, J IMMUNOL, V175, P5351, DOI 10.4049/jimmunol.175.8.5351
   Murakami T, 2003, J EXP MED, V198, P1337, DOI 10.1084/jem.20030593
   Murakami T, 2002, CANCER RES, V62, P7328
   Oladipo O, 2011, BRIT J CANCER, V104, P480, DOI 10.1038/sj.bjc.6606055
   Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001
   Roberti MP, 2012, CANCER BIOL THER, V13, P1123, DOI 10.4161/cbt.21187
   Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541
   Rubie C, 2006, WORLD J GASTROENTERO, V12, P6627, DOI 10.3748/wjg.v12.i41.6627
   Rubie C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-45
   Sale Sanja, 2006, Drug Discov Today Dis Models, V3, P149, DOI 10.1016/j.ddmod.2006.05.006
   Schaefer D, 2006, INT ARCH ALLERGY IMM, V140, P205, DOI 10.1159/000093206
   Shen H, 2006, PROSTATE, V66, P1721, DOI 10.1002/pros.20476
   Singh Rajesh, 2011, Front Biosci (Schol Ed), V3, P1569
   Siwak DR, 2010, J ONCOL, DOI 10.1155/2010/568938
   Smale ST, 2011, NAT IMMUNOL, V12, P689, DOI 10.1038/ni.2070
   Son DS, 2007, CANCER BIOL THER, V6, P1302
   Son DS, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-25
   Son DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051116
   Szlosarek PW, 2006, MOL CANCER THER, V5, P382, DOI 10.1158/1535-7163.MCT-05-0303
   Vicinus B, 2013, ONCOL REP, V30, P1285, DOI 10.3892/or.2013.2580
   Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638
   Yang G, 2010, CLIN CANCER RES, V16, P3875, DOI 10.1158/1078-0432.CCR-10-0483
   Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023
   Yoshida N, 2007, BIOL PHARM BULL, V30, P1826, DOI 10.1248/bpb.30.1826
   YU DH, 1993, CANCER RES, V53, P891
NR 53
TC 12
Z9 13
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2016
VL 11
IS 10
AR e0164189
DI 10.1371/journal.pone.0164189
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ0CF
UT WOS:000385504100026
PM 27723802
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Dutra, EH
   O'Brien, MH
   Lima, A
   Kalajzic, Z
   Tadinada, A
   Nanda, R
   Yadav, S
AF Dutra, Eliane H.
   O'Brien, Mara H.
   Lima, Alexandro
   Kalajzic, Zana
   Tadinada, Aditya
   Nanda, Ravindra
   Yadav, Sumit
TI Cellular and Matrix Response of the Mandibular Condylar Cartilage to
   Botulinum Toxin
SO PLOS ONE
LA English
DT Article
ID RESISTANT ACID-PHOSPHATASE; INDUCED MUSCLE PARALYSIS;
   TEMPOROMANDIBULAR-JOINT; MASTICATORY MUSCLES; BONE; PAIN; INJECTIONS;
   RABBITS; TISSUES; CELLS
AB Objectives
   To evaluate the cellular and matrix effects of botulinum toxin type A (Botox) on mandibular condylar cartilage (MCC) and subchondral bone.
   Materials and Methods
   Botox (0.3 unit) was injected into the right masseter of 5-week-old transgenic mice (Col10a1-RFPcherry) at day 1. Left side masseter was used as intra-animal control. The following bone labels were intraperitoneally injected: calcein at day 7, alizarin red at day 14 and calcein at day 21. In addition, EdU was injected 48 and 24 hours before sacrifice. Mice were sacrificed 30 days after Botox injection. Experimental and control side mandibles were dissected and examined by x-ray imaging and micro-CT. Subsequently, MCC along with the subchondral bone was sectioned and stained with tartrate resistant acid phosphatase (TRAP), EdU, TUNEL, alkaline phosphatase, toluidine blue and safranin O. In addition, we performed immunohistochemistry for pSMAD and VEGF.
   Results
   Bone volume fraction, tissue density and trabecular thickness were significantly decreased on the right side of the subchondral bone and mineralized cartilage (Botox was injected) when compared to the left side. There was no significant difference in the mandibular length and condylar head length; however, the condylar width was significantly decreased after Botox injection. Our histology showed decreased numbers of Col10a1 expressing cells, decreased cell proliferation and increased cell apoptosis in the subchondral bone and mandibular condylar cartilage, decreased TRAP activity and mineralization of Botox injected side cartilage and subchondral bone. Furthermore, we observed reduced proteoglycan and glycosaminoglycan distribution and decreased expression of pSMAD 1/5/8 and VEGF in the MCC of the Botox injected side in comparison to control side.
   Conclusion
   Injection of Botox in masseter muscle leads to decreased mineralization and matrix deposition, reduced chondrocyte proliferation and differentiation and increased cell apoptosis in the MCC and subchondral bone.
C1 [Dutra, Eliane H.; O'Brien, Mara H.; Lima, Alexandro; Nanda, Ravindra; Yadav, Sumit] Univ Connecticut, Ctr Hlth, Dept Orthodont, Farmington, CT 06030 USA.
   [Kalajzic, Zana] Univ Connecticut, Ctr Hlth, Dept Oral & Maxillofacial Diagnost Sci, Farmington, CT USA.
   [Tadinada, Aditya] Univ Connecticut, Ctr Hlth, Dept Oral & Maxillofacial Radiol, Farmington, CT USA.
RP Yadav, S (reprint author), Univ Connecticut, Ctr Hlth, Dept Orthodont, Farmington, CT 06030 USA.
EM yadav_sumit17@yahoo.com
OI O'Brien, Mara/0000-0002-5646-2541
FU American Association of Orthodontic Foundation
FX The study was funded partially by American Association of Orthodontic
   Foundation and partially by startup funds of Sumit Yadav.
CR Benjamin M, 2004, INT REV CYTOL, V233, P1, DOI 10.1016/S0074-7696(04)33001-9
   Chavan SJ, 2014, PROG ORTHOD, V15, DOI 10.1186/s40510-014-0057-6
   Chen J, 2009, OSTEOARTHR CARTILAGE, V17, P354, DOI 10.1016/j.joca.2008.05.021
   de Paiva A, 1999, P NATL ACAD SCI USA, V96, P3200, DOI 10.1073/pnas.96.6.3200
   FORWOOD MR, 1995, BONE, V17, pS197, DOI 10.1016/8756-3282(95)00292-L
   Grimston SK, 2007, ANN NY ACAD SCI, V1116, P444, DOI 10.1196/annals.1402.009
   Guarda-Nardini L, 2008, CRANIO, V26, P126, DOI 10.1179/crn.2008.017
   Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JY, 2008, ORAL DIS, V14, P626, DOI 10.1111/j.1601-0825.2007.01435.x
   Kim NH, 2005, PLAST RECONSTR SURG, V115, P919, DOI 10.1097/01.PRS.0000153236.79775.A0
   Ljusberg J, 2005, J BIOL CHEM, V280, P28370, DOI 10.1074/jbc.M502469200
   Matthys T, 2015, AM J ORTHOD DENTOFAC, V148, P999, DOI 10.1016/j.ajodo.2015.05.034
   Pirttiniemi P, 2004, EUR J ORTHODONT, V26, P1, DOI 10.1093/ejo/26.1.1
   Rafferty KL, 2012, BONE, V50, P651, DOI 10.1016/j.bone.2011.11.015
   Raphael KG, 2014, J ORAL REHABIL, V41, P555, DOI 10.1111/joor.12180
   Rauch F., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P264
   Reibmann DR, 2007, J DENT, V35, P643
   Reissmann DR, 2012, J OROFAC PAIN, V26, P181
   Retting KN, 2009, DEVELOPMENT, V136, P1093, DOI 10.1242/dev.029926
   Romero-Reyes M, 2014, J PAIN RES, V7, P99, DOI 10.2147/JPR.S37593
   Schwartz M, 2002, CLIN J PAIN, V18, pS198, DOI 10.1097/00002508-200211001-00013
   Shen G, 2005, Orthod Craniofac Res, V8, P11, DOI 10.1111/j.1601-6343.2004.00308.x
   Shen G, 2005, J DENT RES, V84, P691, DOI 10.1177/154405910508400802
   Shibukawa Y, 2007, DEV DYNAM, V236, P426, DOI 10.1002/dvdy.21036
   Tsai CY, 2010, INT J ORAL MAX SURG, V39, P593, DOI 10.1016/j.ijom.2010.02.011
   Tsai CY, 2011, EUR J ORTHODONT, V33, P132, DOI 10.1093/ejo/cjq029
   Tsai CY, 2010, J ORAL MAXIL SURG, V68, P1081, DOI 10.1016/j.joms.2009.12.009
   Utreja A, 2016, OSTEOARTHR CARTILAGE, V24, P335, DOI 10.1016/j.joca.2015.08.010
   Warner SE, 2006, BONE, V38, P257, DOI 10.1016/j.bone.2005.08.009
   Yu CC, 2007, AESTHET PLAST SURG, V31, P445, DOI 10.1007/s00266-007-0081-8
NR 33
TC 8
Z9 8
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2016
VL 11
IS 10
AR e0164599
DI 10.1371/journal.pone.0164599
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ0CF
UT WOS:000385504100076
PM 27723812
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU de Bruin, WCC
   van de Ven, EME
   Hooijmans, CR
AF de Bruin, W. C. C.
   van de Ven, E. M. E.
   Hooijmans, C. R.
TI Efficacy of Soiled Bedding Transfer for Transmission of Mouse and Rat
   Infections to Sentinels: A Systematic Review
SO PLOS ONE
LA English
DT Review
ID RABBIT COLONIES; FUR MITES; MICE; RECOMMENDATIONS; PATHOGENS; QUALITY;
   DESIGN; RISK
AB Purpose This systematic review was conducted to gain insight into the efficacy of transmission of infectious agents to colony sentinels by soiled bedding transfer based on publications studying this subject in mice and rats. This information is essential to establish recommendations for the design of health monitoring programs which use sentinels to determine the microbiological status of laboratory animal colonies.
   Results Fifteen original articles retrieved from PubMed, Embase, and CAB abstracts met the inclusion criteria. The design of the studies varied substantially per infectious agent with regard to dose of soiled bedding, exposure time, and sentinel strains used.
   Conclusion With our conservative criteria for effectiveness, soiled bedding transfer appeared to be effective for MHV, MPV, TMEV, Helicobacter spp., and fur mite infections and ineffective for Sendai virus. For other infectious agents, such as MNV, EDIM, MVM, SDAV, Clostridium piliforme, and pinworms, too few data were available to be able to draw robust conclusions on the efficacy of soiled bedding transfer.
   Recommendation The identified evidence only pertains to a portion of the infectious organisms included in the FELASA 2014 guidelines. As many animal facilities design their health monitoring program according to these recommendations, additional studies are warranted to draw comprehensive conclusions on the effective transmission of the infectious agents listed in these guidelines by soiled bedding transfer.
C1 [de Bruin, W. C. C.; van de Ven, E. M. E.] QM Diagnost BV, Nijmegen, Netherlands.
   [Hooijmans, C. R.] Radboud Univ Nijmegen, Med Ctr, SYRCLE, Cent Anim Lab, Nijmegen, Netherlands.
RP de Bruin, WCC (reprint author), QM Diagnost BV, Nijmegen, Netherlands.
EM Wieke.debruin@qmdiagnostics.org
RI Hooijmans, C.R./L-4390-2015
OI Hooijmans, C.R./0000-0001-6435-5714
FU Netherlands Organisation for Health Research and Development (ZonMw)
   [104024065]
FX This study was supported by the Netherlands Organisation for Health
   Research and Development (ZonMw; grant nr. 104024065).
CR Arbona RJR, 2010, J AM ASSOC LAB ANIM, V49, P564
   Brielmeier M, 2006, LAB ANIM-UK, V40, P247, DOI 10.1258/002367706777611497
   BROWNSTEIN DG, 1981, AM J PATHOL, V105, P156
   Compton SR, 2004, COMPARATIVE MED, V54, P382
   Compton SR, 2012, J AM ASSOC LAB ANIM, V51, P797
   CUNDIFF DD, 1995, LAB ANIM SCI, V45, P219
   de Vries RBM, 2011, LAB ANIM-UK, V45, P268, DOI 10.1258/la.2011.011056
   DILLEHAY DL, 1990, LAB ANIM SCI, V40, P367
   Henderson KS, 2013, J AM ASSOC LAB ANIM, V52, P763
   Hirst JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098856
   Hooijmans C, 2011, LAB ANIM-UK, V45, P61, DOI 10.1258/la.2010.010130
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Jensen ES, 2013, J AM ASSOC LAB ANIM, V52, P28
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   LAREGINA M, 1992, LAB ANIM SCI, V42, P344
   Lindstrom KE, 2011, J AM ASSOC LAB ANIM, V50, P54
   Livingston RS, 1998, LAB ANIM SCI, V48, P291
   Mahler M, 2014, LAB ANIM-UK, V48, P178, DOI 10.1177/0023677213516312
   Manuel CA, 2008, J AM ASSOC LAB ANIM, V47, P31
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   MOTZEL SL, 1992, LAB ANIM SCI, V42, P439
   Myers DD, 2003, CONTEMP TOP LAB ANIM, V42, P16
   Nicklas W, 2002, LAB ANIM-UK, V36, P20, DOI 10.1258/0023677021911740
   THIGPEN JE, 1989, LAB ANIM SCI, V39, P324
NR 25
TC 3
Z9 3
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2016
VL 11
IS 8
AR e0158410
DI 10.1371/journal.pone.0158410
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3LI
UT WOS:000381382100003
PM 27518654
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Javaheri, B
   Hopkinson, M
   Poulet, B
   Pollard, AS
   Shefelbine, SJ
   Chang, YM
   Francis-West, P
   Bou-Gharios, G
   Pitsillides, AA
AF Javaheri, Behzad
   Hopkinson, Mark
   Poulet, Blandine
   Pollard, Andrea S.
   Shefelbine, Sandra J.
   Chang, Yu-Mei
   Francis-West, Philippa
   Bou-Gharios, George
   Pitsillides, Andrew A.
TI Deficiency and Also Transgenic Overexpression of Timp-3 Both Lead to
   Compromised Bone Mass and Architecture In Vivo
SO PLOS ONE
LA English
DT Article
ID HYPERTROPHIC CHONDROCYTES UNDERGO; HUMAN TISSUE INHIBITOR;
   OSTEOBLAST-LIKE CELLS; EXTRACELLULAR-MATRIX; METALLOPROTEINASES-3
   TIMP-3; MESENCHYMAL PROGENITORS; IMAGE-ANALYSIS; LONG BONES;
   DIFFERENTIATION; MICE
AB Tissue inhibitor of metalloproteinases-3 (TIMP-3) regulates extracellular matrix via its inhibition of matrix metalloproteinases and membrane-bound sheddases. Timp-3 is expressed at multiple sites of extensive tissue remodelling. This extends to bone where its role, however, remains largely unresolved. In this study, we have used Micro-CT to assess bone mass and architecture, histological and histochemical evaluation to characterise the skeletal phenotype of Timp-3 KO mice and have complemented this by also examining similar indices in mice harbouring a Timp-3 transgene driven via a Col-2a-driven promoter to specifically target overexpression to chondrocytes. Our data show that Timp-3 deficiency compromises tibial bone mass and structure in both cortical and trabecular compartments, with corresponding increases in osteoclasts. Transgenic overexpression also generates defects in tibial structure predominantly in the cortical bone along the entire shaft without significant increases in osteoclasts. These alterations in cortical mass significantly compromise predicted tibial load-bearing resistance to torsion in both genotypes. Neither Timp-3 KO nor transgenic mouse growth plates are significantly affected. The impact of Timp-3 deficiency and of transgenic overexpression extends to produce modification in craniofacial bones of both endochondral and intramembranous origins. These data indicate that the levels of Timp-3 are crucial in the attainment of functionally-appropriate bone mass and architecture and that this arises from chondrogenic and osteogenic lineages.
C1 [Javaheri, Behzad; Hopkinson, Mark; Pollard, Andrea S.; Chang, Yu-Mei; Pitsillides, Andrew A.] Royal Vet Coll, Dept Comparat Biomed Sci, London, England.
   [Poulet, Blandine; Bou-Gharios, George] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool, Merseyside, England.
   [Shefelbine, Sandra J.] Northeastern Univ, Dept Mech & Ind Engn, Boston, MA 02115 USA.
   [Francis-West, Philippa] Kings Coll London, Dept Craniofacial Dev & Stem Cell Biol, London, England.
RP Javaheri, B (reprint author), Royal Vet Coll, Dept Comparat Biomed Sci, London, England.
EM bjavaheri@rvc.ac.uk
RI Javaheri, Behzad/L-5997-2018
OI Javaheri, Behzad/0000-0001-7941-3104; Poulet,
   Blandine/0000-0002-9224-5253; Bou-Gharios, George/0000-0002-9563-9418
FU BBSRC [BB/I014608/1]; Arthritis Research UK [20413, 20581, 20039];
   Arthritis Research UK [20039, 20581, 20859]; Biotechnology and
   Biological Sciences Research Council [BB/I014608/1]
FX This study was supported by funding from the BBSRC BB/I014608/1 and
   Arthritis Research UK 20413, 20581 and 20039.
CR Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3
   Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X
   AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090
   APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302
   APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016
   BLAVIER L, 1995, J CELL SCI, V108, P3649
   CANCEDDA FD, 1992, J CELL BIOL, V117, P427, DOI 10.1083/jcb.117.2.427
   Carlos Fd, 2011, COMPUT TOMOGR, P169
   Carlson B., 2004, HUMAN EMBRYOLOGY DEV, P527
   Chai Y, 2006, DEV DYNAM, V235, P2353, DOI 10.1002/dvdy.20833
   D'Souza RN, 2010, TOP BONE BIOL, V6, P153, DOI 10.1007/978-1-84882-822-3_10
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Enishi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104638
   GALOTTO M, 1994, J BONE MINER RES, V9, P1239
   GENTILI C, 1993, J CELL BIOL, V122, P703, DOI 10.1083/jcb.122.3.703
   Geoffroy V, 2004, J BONE MINER RES, V19, P811, DOI 10.1359/JBMR.040119
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   HALL BK, 1988, AM SCI, V76, P174
   Hanken J, 1993, SKULL DEV
   Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7
   Holmbeck K, 2003, J CELL BIOL, V163, P661, DOI 10.1083/jcb.200307061
   Horton W. A., 1990, GROWTH GENET HORM, V6, P1
   Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101
   Inada M, 2001, J BONE MINER RES, V16, pS149
   Inada M, 2002, J BONE MINER RES S1, V16
   Jacobsen J, 2008, BIOCHEMISTRY-US, V47, P537, DOI 10.1021/bi701629c
   Javaheri B, 2015, BONE, V81, P277, DOI 10.1016/j.bone.2015.07.035
   Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KIRSCH T, 1992, DIFFERENTIATION, V52, P89, DOI 10.1111/j.1432-0436.1992.tb00503.x
   Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI200112067
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   Lee MH, 2007, J BIOL CHEM, V282, P6887, DOI 10.1074/jbc.M610490200
   MOSKALEWSKI S, 1989, DEVELOPMENT, V107, P473
   Murphy G, 2008, MOL ASPECTS MED, V29, P290, DOI 10.1016/j.mam.2008.05.002
   Nagase H, 2008, THE CANC DEGRADOME, DOI [10.1007/978-0-387-69057-5_37, DOI 10.1007/978-0-387-69057-5_37]
   Nah HD, 2000, J BONE MINER RES, V15, P522, DOI 10.1359/jbmr.2000.15.3.522
   Nakajima H, 2010, BLOOD, V116, P4474, DOI 10.1182/blood-2010-01-266528
   Noden DM, 2005, J ANAT, V207, P575, DOI 10.1111/j.1469-7580.2005.00473.x
   Olafsdottir H, 2007, J ANAT, V211, P37, DOI 10.1111/j.1469-7580.2007.00751.x
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Osteogenesis Gilbert S., DEV BIOL, V6
   Park J, 2015, BIOL OPEN, V4, P608, DOI 10.1242/bio.201411031
   PAVLOFF N, 1992, J BIOL CHEM, V267, P17321
   Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424
   Sahebjam S, 2007, ARTHRITIS RHEUM, V56, P905, DOI 10.1002/art.22427
   Schiltz C, 2008, J CELL BIOCHEM, V104, P1803, DOI 10.1002/jcb.21747
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Serafini M, 2014, STEM CELL RES, V12, P659, DOI 10.1016/j.scr.2014.01.006
   Shen Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013086
   SILBERMANN M, 1983, ANAT REC, V206, P373, DOI 10.1002/ar.1092060404
   StahleBackdahl M, 1997, LAB INVEST, V76, P717
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461
   Suzuki H, 2003, BIOSCI BIOTECH BIOCH, V67, P1737, DOI 10.1271/bbb.67.1737
   Tesson L, 2002, TRANSGENIC RES, V11, P43, DOI 10.1023/A:1013928600442
   THESINGH CW, 1991, BONE MINER, V12, P25, DOI 10.1016/0169-6009(91)90119-K
   Van't Hof R, 2013, BONE, V05, P210
   Wang WM, 2006, BIOCHEM J, V398, P515, DOI 10.1042/BJ20060630
   Yang G, 2014, CELL RES, V24, P1266, DOI 10.1038/cr.2014.111
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
   Zeng Y, 1998, DEV DYNAM, V211, P228
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
NR 67
TC 11
Z9 11
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2016
VL 11
IS 8
AR e0159657
DI 10.1371/journal.pone.0159657
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3LI
UT WOS:000381382100006
PM 27519049
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chen, JR
   Yang, CH
   Guo, B
   Sena, ES
   Macleod, MR
   Yuan, YW
   Hirst, TC
AF Chen, Jiarong
   Yang, Canhong
   Guo, Bin
   Sena, Emily S.
   Macleod, Malcolm R.
   Yuan, Yawei
   Hirst, Theodore C.
TI The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID HER2/NEU-OVEREXPRESSING METASTATIC BREAST; PRACTICE GUIDELINE UPDATE;
   MONOCLONAL-ANTIBODY; CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY;
   PUBLICATION BIAS; PHASE-II; RECEPTOR; GROWTH; CHEMOTHERAPY
AB Background
   Breast cancer is the most frequent cancers and is the second leading cause of cancer death among women. Trastuzumab is an effective treatment, the first monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). To inform the development of other effective treatments we report summary estimates of efficacy of trastuzumab on survival and tumour volume in animal models of breast cancer.
   Methods
   We searched PubMed and EMBASE systematically to identify publications testing trastuzumab in animal models of breast cancer. Data describing tumour volume, median survival and animal features were extracted and we assessed quality using a 12-item checklist. We analysed the impact of study design and quality and evidence for publication bias.
   Results
   We included data from 83 studies reporting 169 experiments using 2076 mice. Trastuzumab treatment caused a substantial reduction in tumour growth, with tumours in treated animals growing to 32.6% of the volume of tumours in control animals (95% CI 27.8%-38.2%). Median survival was prolonged by a factor of 1.45 (1.30-1.62). Many study design and quality features accounted for between-study heterogeneity and we found evidence suggesting publication bias.
   Conclusion
   We have found trastuzumab to be effective in animal breast cancer models across a range of experimental circumstances. However the presence of publication bias and a low prevalence of measures to reduce bias provide a focus for future improvements in preclinical breast cancer research.
C1 [Chen, Jiarong] Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Dept Oncol, Jiangmen 529030, Guangdong, Peoples R China.
   [Chen, Jiarong; Yuan, Yawei] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, 1838 Guangzhou DaDao Bei, Guangzhou 510515, Guangdong, Peoples R China.
   [Yang, Canhong] Southern Med Univ, Affiliated Hosp 3, Dept Neurol, Guangzhou 510630, Guangdong, Peoples R China.
   [Guo, Bin] Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg, Guangzhou 510282, Guangdong, Peoples R China.
   [Sena, Emily S.; Macleod, Malcolm R.; Hirst, Theodore C.] Univ Edinburgh, Ctr Clin Brain Sci, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.
RP Yuan, YW (reprint author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, 1838 Guangzhou DaDao Bei, Guangzhou 510515, Guangdong, Peoples R China.; Hirst, TC (reprint author), Univ Edinburgh, Ctr Clin Brain Sci, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.
EM theodore.hirst@ed.ac.uk
FU NC3Rs; NHS Lothian RD department
FX This work was supported by the NC3Rs and NHS Lothian R&D department. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; The authors
   acknowledge support with study retrieval from Ng Chat Fong MBBS(HK) and
   funding from the NC3Rs and NHS Lothian R&D department.
CR Adam JK, 2003, PHARMACOL THERAPEUT, V99, P113, DOI 10.1016/S0163-7258(03)00056-1
   Albanell J, 2001, J NATL CANCER I, V93, P1830, DOI 10.1093/jnci/93.24.1830
   [Anonymous], 2015, Prescrire Int, V24, P93
   Baselga J, 2014, ANN ONCOL, V25, P592, DOI 10.1093/annonc/mdt543
   Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737
   Bianchini G, 2014, LANCET ONCOL, V15, pE58, DOI 10.1016/S1470-2045(13)70477-7
   Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278
   Borowsky AD, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a009670
   CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285
   Castagnetta L, 2004, ANN NY ACAD SCI, V1028, P233, DOI 10.1196/annnals.1321.028
   Cheng H, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-326
   de Vries RBM, 2014, ILAR J, V55, P427, DOI 10.1093/ilar/ilu043
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Dimitrakakis C, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2413
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Fallowfield L, 2015, BREAST, V24, P166, DOI 10.1016/j.breast.2015.01.002
   Fojo T, 2010, CLIN CANCER RES, V16, P5972, DOI 10.1158/1078-0432.CCR-10-1277
   Higgins JPT, 2008, STAT MED, V27, P6072, DOI 10.1002/sim.3427
   Hirst TC, 2013, BRIT J CANCER, V108, P64, DOI 10.1038/bjc.2012.504
   Hirst TC, 2015, SYSTEMATIC REV METAA, DOI [10.1002/ebm2.6, DOI 10.1002/EBM2.6]
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Ismael G, 2012, LANCET ONCOL, V13, P869, DOI 10.1016/S1470-2045(12)70329-7
   Jiang Zhansheng, 2014, Zhonghua Yi Xue Za Zhi, V94, P3854
   Kawalec P, 2015, CLIN BREAST CANCER, V15, P90, DOI 10.1016/j.clbc.2014.10.006
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Moja L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006243.pub2
   Nuciforo P, 2016, MOL ONCOL, V10, P138, DOI 10.1016/j.molonc.2015.09.002
   Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825
   Pegram M, 2006, ADV DRUG DELIVER REV, V58, P723, DOI 10.1016/j.addr.2006.05.003
   Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659
   Perez EA, 2011, J CLIN ONCOL, V29, P3366, DOI 10.1200/JCO.2011.35.0868
   Pickar James H, 2015, Post Reprod Health, V21, P112, DOI 10.1177/2053369115599090
   Reznikov A., 2015, Experimental Oncology, V37, P162
   Sena ES, 2014, J CEREBR BLOOD F MET, V34, P737, DOI 10.1038/jcbfm.2014.28
   Sena ES, 2010, J CEREBR BLOOD F MET, V30, P1905, DOI 10.1038/jcbfm.2010.116
   SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936
   SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679
   Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Stanislawska-Sachadyn A, 2015, CURR PHARM BIOTECHNO
   Tolaney SM, 2015, NEW ENGL J MED, V372, P134, DOI 10.1056/NEJMoa1406281
   van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915
   Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
   Watzlawick R, 2014, JAMA NEUROL, V71, P91, DOI 10.1001/jamaneurol.2013.4684
   Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984
NR 52
TC 3
Z9 3
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2016
VL 11
IS 7
AR e0158240
DI 10.1371/journal.pone.0158240
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5IJ
UT WOS:000381515900008
PM 27463246
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kaur, S
   Baynes, A
   Lockyer, AE
   Routledge, EJ
   Jones, CS
   Noble, LR
   Jobling, S
AF Kaur, Satwant
   Baynes, Alice
   Lockyer, Anne E.
   Routledge, Edwin J.
   Jones, Catherine S.
   Noble, Leslie R.
   Jobling, Susan
TI Steroid Androgen Exposure during Development Has No Effect on
   Reproductive Physiology of Biomphalaria glabrata
SO PLOS ONE
LA English
DT Article
ID VERTEBRATE SEX STEROIDS; ENDOCRINE DISRUPTORS; LYMNAEA-STAGNALIS;
   GENE-EXPRESSION; ALBUMIN GLAND; SNAIL; MOLLUSCA; RECEPTOR; PULMONATA;
   HORMONES
AB Gastropod mollusks have been proposed as alternative models for male reproductive toxicity testing, due to similarities in their reproductive anatomy compared to mammals, together with evidence that endocrine disrupting chemicals can cause effects in some mollusks analogous to those seen in mammals. To test this hypothesis, we used the freshwater pulmonate snail, Biomphalaria glabrata, for which various genetic tools and a draft genome have recently become available, to investigate the effects of two steroid androgens on the development of mollusk secondary sexual organs. Here we present the results of exposures to two potent androgens, the vertebrate steroid; 5 alpha-dihydrotestosterone (DHT) and the pharmaceutical anabolic steroid; 17 alpha-methyltestosterone (MT), under continuous flow-through conditions throughout embryonic development and up to sexual maturity. Secondary sexual gland morphology, histopathology and differential gene expression analysis were used to determine whether steroid androgens stimulated or inhibited organ development. No significant differences between tissues from control and exposed snails were identified, suggesting that these androgens elicited no biologically detectable response normally associated with exposure to androgens in vertebrate model systems. Identifying no effect of androgens in this mollusk is significant, not only in the context of the suitability of mollusks as alternative model organisms for testing vertebrate androgen receptor agonists but also, if applicable to other similar mollusks, in terms of the likely impacts of androgens and anti-androgenic pollutants present in the aquatic environment.
C1 [Kaur, Satwant; Baynes, Alice; Lockyer, Anne E.; Routledge, Edwin J.; Jobling, Susan] Brunel Univ London, Inst Environm Hlth & Soc, Uxbridge UB8 3PH, Middx, England.
   [Lockyer, Anne E.; Jones, Catherine S.; Noble, Leslie R.] Univ Aberdeen, Sch Biol Sci, Inst Biol & Environm Sci, Aberdeen AB24 2TZ, Scotland.
RP Baynes, A (reprint author), Brunel Univ London, Inst Environm Hlth & Soc, Uxbridge UB8 3PH, Middx, England.
EM Alice.Baynes@Brunel.ac.uk
RI Baynes, Alice L/A-4936-2015; jobling, susan/N-9316-2016
OI Baynes, Alice L/0000-0002-6337-5956; 
FU National Centre for the Replacement, Refinement and Reduction of Animals
   in Research (NC3Rs);  [G0900802/1]; National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NC3Rs) [G0900802/1]
FX The research presented in this manuscript was wholly funded by National
   Centre for the Replacement, Refinement and Reduction of Animals in
   Research (NC3Rs), https://www.nc3rs.org.uk/. 'The Snail Assay as an
   Alternative to the Rodent Hershberger Assay for Detecting Androgens and
   Anti-androgens' funding reference: G0900802/1 to SJ, EJR, CSJ, and LRN.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ankley GT, 2001, ENVIRON TOXICOL CHEM, V20, P1276, DOI 10.1897/1551-5028(2001)020<1276:DAEOAS>2.0.CO;2
   Baron OL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003792
   Bergman A, 2012, TOXICOL LETT, V211, pS3, DOI 10.1016/j.toxlet.2012.03.020
   Blum JL, 2004, MAR ENVIRON RES, V58, P565, DOI 10.1016/j.marenvres.2004.03.046
   BRIDE J, 1995, REPROD NUTR DEV, V35, P559, DOI 10.1051/rnd:19950508
   Czech P, 2001, AQUAT TOXICOL, V53, P103, DOI 10.1016/S0166-445X(00)00169-7
   de Jong-Brink M, 1977, Cell Tissue Res, V181, P37
   DEJONGBRINK M, 1976, CELL TISSUE RES, V171, P195, DOI 10.1007/BF00219406
   Duft M, 2007, ECOTOXICOLOGY, V16, P169, DOI 10.1007/s10646-006-0106-0
   Egonmwan RI, 2004, INVERTEBR REPROD DEV, V46, P159, DOI 10.1080/07924259.2004.9652619
   Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074
   Ghosh S, 2010, EXP CELL RES, V316, P2087, DOI 10.1016/j.yexcr.2010.04.015
   Giusti A, 2014, SCI TOTAL ENVIRON, V493, P147, DOI 10.1016/j.scitotenv.2014.05.130
   Giusti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081086
   Giusti A, 2013, COMP BIOCHEM PHYS C, V158, P187, DOI 10.1016/j.cbpc.2013.08.003
   Giusti A, 2013, ENVIRON TOXICOL CHEM, V32, P1740, DOI 10.1002/etc.2234
   Goto Y, 2012, J MOLLUS STUD, V78, P197, DOI 10.1093/mollus/eys001
   Harrington AJ, 2010, DEV DYNAM, V239, P1282, DOI 10.1002/dvdy.22231
   HERSHBERGER LG, 1953, P SOC EXP BIOL MED, V83, P175
   Hertel LA, 2005, DEV COMP IMMUNOL, V29, P295, DOI 10.1016/j.dci.2004.08.003
   Holm Louis W., 1946, TRANS AMER MICROSC SOC, V65, P45, DOI 10.2307/3223285
   Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B
   Hutchinson TH, 2006, AQUAT TOXICOL, V76, P69, DOI 10.1016/j.aquatox.2005.09.008
   Janer G, 2005, GEN COMP ENDOCR, V143, P211, DOI 10.1016/j.ygen.2005.03.016
   Janer G, 2007, ECOTOXICOLOGY, V16, P145, DOI 10.1007/s10646-006-0110-4
   Kaur S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121259
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klussmann-Kolb A, 2001, ZOOMORPHOLOGY, V120, P215, DOI 10.1007/s004350100041
   Kohler HR, 2007, ECOTOXICOLOGY, V16, P131, DOI 10.1007/s10646-006-0111-3
   Koene JM, 2004, BELG J ZOOL, V134, P41
   Kortner TM, 2008, COMP BIOCHEM PHYS D, V3, P205, DOI 10.1016/j.cbd.2008.04.001
   Lafont R, 2007, ECOTOXICOLOGY, V16, P109, DOI 10.1007/s10646-006-0113-1
   Lavado R, 2006, STEROIDS, V71, P489, DOI 10.1016/j.steroids.2006.01.009
   LEHOUX JG, 1970, STEROIDS, V16, P141, DOI 10.1016/S0039-128X(70)80102-7
   Margiotta-Casaluci L, 2011, GEN COMP ENDOCR, V171, P309, DOI 10.1016/j.ygcen.2011.02.012
   Markov GV, 2009, P NATL ACAD SCI USA, V106, P11913, DOI 10.1073/pnas.0812138106
   MIKSYS SL, 1987, INT J INVER REP DEV, V12, P145, DOI 10.1080/01688170.1987.10510313
   Mukai ST, 2004, J EXP BIOL, V207, P2507, DOI 10.1242/jeb.01052
   Muller PY, 2002, BIOTECHNIQUES, V32, P1372
   Nordkap L, 2012, MOL CELL ENDOCRINOL, V355, P221, DOI 10.1016/j.mce.2011.05.048
   Omran NEE, 2012, REPROD BIOL, V12, P301, DOI 10.1016/j.repbio.2012.10.002
   Owens W, 2007, ENVIRON HEALTH PERSP, V115, P671, DOI 10.1289/ehp.9666
   Prussing K, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-35
   Raghavan N, 2006, TRENDS PARASITOL, V22, P148, DOI 10.1016/j.pt.2006.02.008
   Rivero-Wendt CLG, 2014, GENET MOL RES, V13, P605, DOI 10.4238/2014.January.28.6
   Schulte-Oehlmann U., 2004, PHARM ENV SOURCES FA, P233
   Schulte-Oehlmann U, 2006, ENVIRON HEALTH PERSP, V114, P98, DOI 10.1289/ehp.8060
   Scott AP, 2013, STEROIDS, V78, P268, DOI 10.1016/j.steroids.2012.11.006
   Scott AP, 2012, STEROIDS, V77, P1450, DOI 10.1016/j.steroids.2012.08.009
   Seki M, 2004, ENVIRON TOXICOL CHEM, V23, P774, DOI 10.1897/03-26
   Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972
   Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327
   Stange D, 2012, ECOTOX ENVIRON SAFE, V75, P94, DOI 10.1016/j.ecoenv.2011.09.003
   Sternberg RM, 2008, GEN COMP ENDOCR, V156, P15, DOI 10.1016/j.ygcen.2007.12.002
   Tillmann M, 2001, ECOTOXICOLOGY, V10, P373, DOI 10.1023/A:1012279231373
   Tinwell H, 2007, TOXICOL SCI, V100, P54, DOI 10.1093/toxsci/kfm208
   Vogeler S, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-369
   Wason S, 2003, TOXICOLOGY, V192, P119, DOI 10.1016/S0300-483X(03)00265-8
   Watermann B, 2008, HELGOLAND MAR RES, V62, P167, DOI 10.1007/s10152-008-0105-z
   Zhang SM, 2007, IMMUNOGENETICS, V59, P883, DOI 10.1007/s00251-007-0245-3
NR 60
TC 4
Z9 4
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 22
PY 2016
VL 11
IS 7
AR e0159852
DI 10.1371/journal.pone.0159852
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS5CT
UT WOS:000380799000047
PM 27448327
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kreinest, M
   Reisig, G
   Strobel, P
   Dinter, D
   Attenberger, U
   Lipp, P
   Schwarz, M
AF Kreinest, Michael
   Reisig, Gregor
   Stroebel, Philipp
   Dinter, Dietmar
   Attenberger, Ulrike
   Lipp, Peter
   Schwarz, Markus
TI A Porcine Animal Model for Early Meniscal Degeneration - Analysis of
   Histology, Gene Expression and Magnetic Resonance Imaging Six Months
   after Resection of the Anterior Cruciate Ligament
SO PLOS ONE
LA English
DT Article
ID ARTICULAR-CARTILAGE; CANINE MENISCUS; MESSENGER-RNA; KNEE-JOINT;
   COLLAGEN; OSTEOARTHRITIS; CHONDROCYTES; PROFILES; STIMULATION;
   ARTHROSCOPY
AB Background/Objective
   The menisci of the mammalian knee joint balance the incongruence between femoral condyle and tibial plateau and thus menisci absorb and distribute high loads. Degeneration processes of the menisci lead to pain syndromes in the knee joint. The origin of such degenerative processes on meniscal tissue is rarely understood and may be described best as an imbalance of anabolic and catabolic metabolism. A standardized animal model of meniscal degeneration is needed for further studies. The aim of the current study was to develop a porcine animal model with early meniscal degeneration.
   Material and Methods
   Resection of the anterior cruciate ligament (ACLR) was performed on the left knee joints of eight Gottingen minipigs. A sham operation was carried out on the right knee joint. The grade of degeneration was determined 26 weeks after the operation using histology and magnetic resonance imaging (MRI). Furthermore, the expression of 14 genes which code for extracellular matrix proteins, catabolic matrix metalloproteinases and inflammation mediators were analyzed.
   Results
   Degenerative changes were detected by a histological analysis of the medial meniscus after ACLR. These changes were not detected by MRI. In terms of their gene expression profile, these degenerated medial menisci showed a significantly increased expression of COL1A1.
   Conclusion
   This paper describes a new animal model for early secondary meniscal degeneration in the Gottingen minipig. Histopathological evidence of the degenerative changes could be described. This early degenerative changes could not be seen by NMR imaging.
C1 [Kreinest, Michael; Reisig, Gregor; Schwarz, Markus] Heidelberg Univ, Med Fac Mannheim, Dept Expt Orthoped & Trauma Surg, Mannheim, Germany.
   [Stroebel, Philipp] Univ Med Ctr Gottingen, Dept Pathol, Gottingen, Germany.
   [Dinter, Dietmar; Attenberger, Ulrike] Heidelberg Univ, Med Fac Mannheim, Dept Radiol, Mannheim, Germany.
   [Kreinest, Michael; Lipp, Peter] Univ Saarland, Univ Med Ctr Homburg, Dept Mol Cell Biol, Homburg, Germany.
   [Kreinest, Michael] BG Trauma Ctr Ludwigshafen, Dept Trauma Surg & Orthoped Surg, Ludwigshafen, Germany.
RP Kreinest, M (reprint author), Heidelberg Univ, Med Fac Mannheim, Dept Expt Orthoped & Trauma Surg, Mannheim, Germany.; Kreinest, M (reprint author), Univ Saarland, Univ Med Ctr Homburg, Dept Mol Cell Biol, Homburg, Germany.; Kreinest, M (reprint author), BG Trauma Ctr Ludwigshafen, Dept Trauma Surg & Orthoped Surg, Ludwigshafen, Germany.
EM michael.kreinest@bgu-ludwigshafen.de
FU Medical Faculty Mannheim, Heidelberg University
FX The study was financially supported by Medical Faculty Mannheim,
   Heidelberg University. The funding was received by MK and MS.
CR Aigner T, 2006, EUR CELLS MATER, V12, P49, DOI 10.22203/eCM.v012a06
   Aigner T, 2006, ARTHRITIS RHEUM-US, V54, P3533, DOI 10.1002/art.22174
   ASPDEN RM, 1985, J ANAT, V140, P371
   Biau DJ, 2008, CLIN ORTHOP RELAT R, V466, P2282, DOI 10.1007/s11999-008-0346-9
   Bollen P, 1997, PHARMACOL TOXICOL, V80, P3, DOI 10.1111/j.1600-0773.1997.tb01980.x
   Bydder M, 2007, J MAGN RESON IMAGING, V25, P290, DOI 10.1002/jmri.20850
   Cerejo R, 2002, ARTHRITIS RHEUM, V46, P2632, DOI 10.1002/art.10530
   Curt A, 2012, LEITLINIEN DIAGNOSTI
   Dankof A, 2006, VIRCHOWS ARCH, V449, P230, DOI 10.1007/s00428-006-0221-6
   Fan ZY, 2005, ARTHRITIS RHEUM-US, V52, P136, DOI 10.1002/art.20725
   FERRERROCA O, 1980, CLIN ORTHOP RELAT R, P289
   FITHIAN DC, 1990, CLIN ORTHOP RELAT R, P19
   Gotterbarm T, 2008, LAB ANIM-UK, V42, P71, DOI 10.1258/la.2007.06029e
   Guehring T, 2005, SPINE, V30, P2510, DOI 10.1097/01.brs.0000186591.17114.e9
   Guehring T, 2009, ARTHRITIS RHEUM-US, V60, P1026, DOI 10.1002/art.24407
   HARING F, 1963, ZBL BAKT PARASIT, V189, P521
   Hauger O, 2000, RADIOLOGY, V217, P193, DOI 10.1148/radiology.217.1.r00se36193
   Hsieh YS, 2004, ARTHROSCOPY, V20, P482, DOI 10.1016/j.arthro.2004.03.010
   Jones ARC, 2007, EUR CELLS MATER, V13, P40, DOI 10.22203/eCM.v013a04
   Jones ARC, 2009, ARTHRITIS RHEUM-US, V60, P133, DOI 10.1002/art.24143
   Kaab MJ, 1998, J ANAT, V193, P23, DOI 10.1046/j.1469-7580.1998.19310023.x
   Kambic HE, 2005, J ORTHOP RES, V23, P142, DOI 10.1016/j.orhtres.2004.06.016
   Kiapour AM, 2015, CLIN ORTHOP RELAT R, V473, P639, DOI 10.1007/s11999-014-3974-2
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KREINEST M, 2015, COMP MED IN PRESS
   Krenn V, 2010, Z RHEUMATOL, V69, P644, DOI 10.1007/s00393-010-0609-1
   Krenn V, 2010, ORTHOPADE, V39, P475, DOI 10.1007/s00132-010-1606-4
   Lasch P, 2001, J BIOL CHEM, V276, P9492, DOI 10.1074/jbc.M008528200
   Libicher M, 2005, EUR RADIOL, V15, P390, DOI 10.1007/s00330-004-2486-y
   Lin Z, 2008, J ORTHOP RES, V26, P1230, DOI 10.1002/jor.20523
   Lorenz H, 2005, ARTHRITIS RES THER, V7, pR156, DOI 10.1186/ar1471
   McAlinden A, 2001, OSTEOARTHR CARTILAGE, V9, P33, DOI 10.1053/joca.2000.0347
   Melrose J, 2005, HISTOCHEM CELL BIOL, V124, P225, DOI 10.1007/s00418-005-0005-0
   Nawata K, 1999, KNEE SURG SPORT TR A, V7, P274, DOI 10.1007/s001670050163
   Nygard AB, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-67
   Ochi K, 2003, J HUM GENET, V48, P177, DOI 10.1007/s10038-003-0004-8
   Papageorgiou CD, 2001, AM J SPORT MED, V29, P226, DOI 10.1177/03635465010290021801
   Pond M J, 1973, Ann Rheum Dis, V32, P387, DOI 10.1136/ard.32.4.387
   RAUNEST J, 1994, ARTHROSCOPY, V10, P634, DOI 10.1016/S0749-8063(05)80061-1
   Schumacher BL, 2005, J ORTHOP RES, V23, P562, DOI 10.1016/j.orthres.2004.11.011
   Schwarz ML, 2010, SCAND J LAB ANIM SCI, V37, P13
   Stoker Aaron M, 2006, J Orthop Surg Res, V1, P8, DOI 10.1186/1749-799X-1-8
   Sun YB, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2968
   von Engelhardt LV, 2008, ARCH ORTHOP TRAUM SU, V128, P451, DOI 10.1007/s00402-007-0485-6
   Wang QG, 2009, BIOCHEM BIOPH RES CO, V379, P738, DOI 10.1016/j.bbrc.2008.12.111
   Wildey GM, 2001, J ORTHOPAED RES, V19, P650, DOI 10.1016/S0736-0266(00)00053-X
   Wimmer MA, 2007, ARTHRITIS RHEUM, V56, P3511, DOI 10.1002/art.29973
   Wojtys Edward M, 2005, Instr Course Lect, V54, P323
   Zarins ZA, 2010, OSTEOARTHR CARTILAGE, V18, P1408, DOI 10.1016/j.joca.2010.07.012
NR 49
TC 6
Z9 6
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 19
PY 2016
VL 11
IS 7
AR e0159331
DI 10.1371/journal.pone.0159331
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DR8TG
UT WOS:000380169600048
PM 27434644
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Davies, GF
   Greenhough, BJ
   Hobson-West, P
   Kirk, RGW
   Applebee, K
   Bellingan, LC
   Berdoy, M
   Buller, H
   Cassaday, HJ
   Davies, K
   Diefenbacher, D
   Druglitro, T
   Escobar, MP
   Friese, C
   Herrmann, K
   Hinterberger, A
   Jarrett, WJ
   Jayne, K
   Johnson, AM
   Johnson, ER
   Konold, T
   Leach, MC
   Leonelli, S
   Lewis, DI
   Lilley, EJ
   Longridge, ER
   McLeod, CM
   Miele, M
   Nelson, NC
   Ormandy, EH
   Pallett, H
   Poort, L
   Pound, P
   Ramsden, E
   Roe, E
   Scalway, H
   Schrader, A
   Scotton, CJ
   Scudamore, CL
   Smith, JA
   Whitfield, L
   Wolfensohn, S
AF Davies, Gail F.
   Greenhough, Beth J.
   Hobson-West, Pru
   Kirk, Robert G. W.
   Applebee, Ken
   Bellingan, Laura C.
   Berdoy, Manuel
   Buller, Henry
   Cassaday, Helen J.
   Davies, Keith
   Diefenbacher, Daniela
   Druglitro, Tone
   Escobar, Maria Paula
   Friese, Carrie
   Herrmann, Kathrin
   Hinterberger, Amy
   Jarrett, Wendy J.
   Jayne, Kimberley
   Johnson, Adam M.
   Johnson, Elizabeth R.
   Konold, Timm
   Leach, Matthew C.
   Leonelli, Sabina
   Lewis, David I.
   Lilley, Elliot J.
   Longridge, Emma R.
   McLeod, Carmen M.
   Miele, Mara
   Nelson, Nicole C.
   Ormandy, Elisabeth H.
   Pallett, Helen
   Poort, Lonneke
   Pound, Pandora
   Ramsden, Edmund
   Roe, Emma
   Scalway, Helen
   Schrader, Astrid
   Scotton, Chris J.
   Scudamore, Cheryl L.
   Smith, Jane A.
   Whitfield, Lucy
   Wolfensohn, Sarah
TI Developing a Collaborative Agenda for Humanities and Social Scientific
   Research on Laboratory Animal Science and Welfare
SO PLOS ONE
LA English
DT Article
ID TRANSLATIONAL MEDICINE; CARE; 3RS; INTERDISCIPLINARITY; BIOSCIENCE;
   QUESTIONS; DECISIONS; STANDARDS; SUPPORT; DESIGN
AB Improving laboratory animal science and welfare requires both new scientific research and insights from research in the humanities and social sciences. Whilst scientific research provides evidence to replace, reduce and refine procedures involving laboratory animals (the '3Rs'), work in the humanities and social sciences can help understand the social, economic and cultural processes that enhance or impede humane ways of knowing and working with laboratory animals. However, communication across these disciplinary perspectives is currently limited, and they design research programmes, generate results, engage users, and seek to influence policy in different ways. To facilitate dialogue and future research at this interface, we convened an interdisciplinary group of 45 life scientists, social scientists, humanities scholars, non-governmental organisations and policy-makers to generate a collaborative research agenda. This drew on methods employed by other agenda-setting exercises in science policy, using a collaborative and deliberative approach for the identification of research priorities. Participants were recruited from across the community, invited to submit research questions and vote on their priorities. They then met at an interactive workshop in the UK, discussed all 136 questions submitted, and collectively defined the 30 most important issues for the group. The output is a collaborative future agenda for research in the humanities and social sciences on laboratory animal science and welfare. The questions indicate a demand for new research in the humanities and social sciences to inform emerging discussions and priorities on the governance and practice of laboratory animal research, including on issues around: international harmonisation, openness and public engagement, 'cultures of care', harm-benefit analysis and the future of the 3Rs. The process outlined below underlines the value of interdisciplinary exchange for improving communication across different research cultures and identifies ways of enhancing the effectiveness of future research at the interface between the humanities, social sciences, science and science policy.
C1 [Davies, Gail F.] Univ Exeter, Coll Life & Environm Sci, Dept Geog, Exeter, Devon, England.
   [Greenhough, Beth J.] Univ Oxford, Sch Geog & Environm, Oxford, England.
   [Greenhough, Beth J.] Univ Oxford, Keble Coll, Oxford, England.
   [Hobson-West, Pru] Univ Nottingham, Sch Vet Med & Sci, Ctr Appl Bioeth, Nottingham NG7 2RD, Leics, England.
   [Kirk, Robert G. W.] Univ Manchester, Fac Life Sci, CHSTM, Manchester, Lancs, England.
   [Applebee, Ken] Kings Coll London, Hlth Sch, Biol Serv, London, England.
   [Bellingan, Laura C.; Diefenbacher, Daniela] Soc Biol, Charles Darwin House, London, England.
   [Berdoy, Manuel] Univ Oxford, Biomed Serv, Oxford, England.
   [Cassaday, Helen J.] Univ Nottingham, Sch Psychol, Univ Pk, Nottingham, England.
   [Davies, Keith] Cardiff Univ, Coll Biomed & Life Sci, Joint Biol Serv, Cardiff, S Glam, Wales.
   [Druglitro, Tone] Univ Oslo, Fac Social Sci, TIK Ctr Technol Innovat & Culture, Oslo, Norway.
   [Escobar, Maria Paula] Kings Coll London, Dept Geog, London, England.
   [Friese, Carrie] London Sch Econ, Dept Sociol, London, England.
   [Herrmann, Kathrin] Free Univ Berlin, Inst Pharmacol, Berlin, Germany.
   [Herrmann, Kathrin] Free Univ Berlin, Toxicol Dept Vet Med, Berlin, Germany.
   [Hinterberger, Amy] Univ Warwick, Dept Sociol, Coventry, W Midlands, England.
   [Jarrett, Wendy J.] Understanding Anim Res, London, England.
   [Jayne, Kimberley] Univ Exeter, Ctr Res Anim Behav, Psychol, Exeter, Devon, England.
   [Johnson, Adam M.] Univ Manchester, Fac Life Sci, BSF, Manchester, Lancs, England.
   [Johnson, Elizabeth R.] Hobart & William Smith Coll, Dept Environm Studies, Geneva, NY 14456 USA.
   [Konold, Timm] Anim & Plant Hlth Agency Weybridge, Anim Sci Unit, Addlestone, Surrey, England.
   [Leach, Matthew C.] Newcastle Univ, Sch Agr Food & Rural Dev, Newcastle Upon Tyne, Tyne & Wear, England.
   [Leonelli, Sabina] Univ Exeter, Exeter Ctr Study Life Sci Egen, Exeter, Devon, England.
   [Leonelli, Sabina] Univ Exeter, Dept Sociol Philosophy & Anthropol, Exeter, Devon, England.
   [Lewis, David I.] Univ Leeds, Fac Biol Sci, Sch Biomed Sci, Leeds, W Yorkshire, England.
   [Lilley, Elliot J.] RSPCA, Sci Grp, Res Anim Dept, Wilberforce Way, Southwater, W Sussex, England.
   [Longridge, Emma R.] BBSRC, Swindon, Wilts, England.
   [McLeod, Carmen M.] Univ Nottingham, Fac Med & Hlth Sci, Nottingham NG7 2RD, Leics, England.
   [Miele, Mara] Cardiff Univ, Coll Art Human & Social Sci, Sch Planning & Geog, Cardiff, Wales.
   [Nelson, Nicole C.] Univ Wisconsin, Dept Hist Sci, Madison, WI USA.
   [Ormandy, Elisabeth H.] UBC Anim Welfare Program, Vancouver, BC, Canada.
   [Pallett, Helen] Univ East Anglia, Sch Environm Sci, Norwich, Norfolk, England.
   [Poort, Lonneke] Vrije Univ Amsterdam, Fac Law, Amsterdam, Netherlands.
   [Pound, Pandora] Univ Bristol, Sch Social & Commun Med, Bristol, Avon, England.
   [Ramsden, Edmund] Queen Mary Univ London, Sch Hist, London, England.
   [Roe, Emma] Univ Southampton, Dept Geog & Environm, Southampton, Hants, England.
   [Scalway, Helen] Univ London Royal Holloway & Bedford New Coll, Dept Geog, Honorary Res Associate, London, England.
   [Schrader, Astrid] Univ Exeter, Dept Sociol Philosophy & Anthropol, Exeter, Devon, England.
   [Scotton, Chris J.] Univ Exeter, Sch Med, Inst Biomed & Clin Sci, Exeter, Devon, England.
   [Scudamore, Cheryl L.] MRC Harwell, Mary Lyon Ctr, Harwell, Berks, England.
   [Smith, Jane A.] Open Univ, Fac Sci, Milton Keynes, Bucks, England.
   [Whitfield, Lucy] Royal Vet Coll, Named Vet Surg Grp, London, England.
   [Wolfensohn, Sarah] Univ Surrey, Sch Vet Med, Guildford, Surrey, England.
RP Davies, GF (reprint author), Univ Exeter, Coll Life & Environm Sci, Dept Geog, Exeter, Devon, England.
EM g.f.davies@exeter.ac.uk
RI APHA, publications/E-6082-2010; Konold, Timm/C-6498-2011; Escobar, Maria
   Paula/L-4630-2016
OI Escobar, Maria Paula/0000-0002-0856-114X; Leonelli,
   Sabina/0000-0002-7815-6609; Lilley, Elliot/0000-0001-8770-2432; McLeod,
   Carmen/0000-0003-2005-3778; Hobson-West, Pru/0000-0001-6105-0747
FU Small Grant in Society and Ethics from the Wellcome Trust
   [104339/Z/14/Z]; Medical Research Council [G0901338, MC_UP_1502/1]
FX This study was funded by a Small Grant in Society and Ethics for GFD
   from the Wellcome Trust (104339/Z/14/Z)
   http://www.wellcome.ac.uk/Funding/index.htm. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2015, NATURE, V517, P5, DOI 10.1038/517005a
   Avey MT, 2015, J AM ASSOC LAB ANIM, V54, P153
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Barry A, 2008, ECON SOC, V37, P20, DOI 10.1080/03085140701760841
   Buller H, 2014, J RURAL STUD, V33, P141, DOI 10.1016/j.jrurstud.2013.01.005
   Buller H, 2009, AREA, V41, P395, DOI 10.1111/j.1475-4762.2008.00856.x
   Burgess J, 2007, PUBLIC UNDERST SCI, V16, P299, DOI 10.1177/0963662507077510
   Davies G, 2006, ECON SOC, V35, P232, DOI 10.1080/03085140600635722
   Davies G, 2013, BIOSOCIETIES, V8, P386, DOI 10.1057/biosoc.2013.26
   Davies G, 2012, ENVIRON PLANN D, V30, P623, DOI 10.1068/d3211
   Davies G, 2012, BODY SOC, V18, P126, DOI 10.1177/1357034X12446378
   Davies K, 2010, ANIM TECHNOL WELF, V9, P1
   Deborah Rudacille, 2000, SCALPEL BUTTERFLY WA
   Donovan Josephine, 2007, FEMINIST CARE TRADIT
   Doubleday R, 2007, AREA, V39, P166, DOI 10.1111/j.1475-4762.2007.00742.x
   Ferdowsian HR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024059
   Franco Nuno Henrique, 2013, Animals (Basel), V3, P238, DOI 10.3390/ani3010238
   Freedman LP, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002165
   Friese C, 2013, CURR ANTHROPOL, V54, pS129, DOI 10.1086/670805
   Gibbons M., 1994, NEW PRODUCTION KNOWL
   Graham ML, 2015, EUR J PHARMACOL, V759, P19, DOI 10.1016/j.ejphar.2015.03.040
   Greenhough B, 2011, PROG HUM GEOG, V35, P153, DOI 10.1177/0309132510376258
   Greenhough B, 2011, ENVIRON PLANN D, V29, P47, DOI 10.1068/d17109
   Guerrini A., 2003, EXPT HUMANS ANIMALS
   Hobson-West P, 2010, J MED ETHICS, V36, P46, DOI 10.1136/jme.2009.030817
   Hobson-West P, 2012, SOCIOLOGY, V46, P649, DOI 10.1177/0038038511435058
   Hobson-West P, 2009, ATLA-ALTERN LAB ANIM, V37, P95, DOI 10.1177/026119290903702S11
   Holmberg T, 2012, PUBLIC UNDERST SCI, V21, P354, DOI 10.1177/0963662510372584
   Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8
   Jasanoff S, 2011, DESIGNS NATURE SCI D
   Kilkenny C, 2013, ARRIVE GUIDELINES AN
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Kirk R. G. W., 2014, STRESS SHOCK ADAPTAT, P241
   Kirk RGW, 2010, ISIS, V101, P62, DOI 10.1086/652689
   Kirk RGW, 2009, MED HIST, V53, P513, DOI 10.1017/S0025727300000533
   Klein HJ, 2007, ILAR J, V48, P3, DOI 10.1093/ilar.48.1.3
   MacArthur Clark J, 2007, ALTEX S, V14, P735
   Macleod MR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002273
   Mak IWY, 2014, AM J TRANSL RES, V6, P114
   McLeod C, 2016, PUBLIC UNDERST SCI, V25, P791, DOI 10.1177/0963662515586320
   Mori Ipsos, ATT AN RES 2014
   Olsson A, 2012, ALTEX, VWC8, P333
   Ormandy Elisabeth H, 2014, Animals (Basel), V4, P391, DOI 10.3390/ani4030391
   Pallett H, 2015, PROG HUM GEOG, V39, P146, DOI 10.1177/0309132513518831
   Parker M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096480
   Rose M, 2013, LAB ANIM-UK, V47, P146, DOI 10.1177/0023677213479338
   Russell W. M. S., 1959, PRINCIPLES HUMANE EX
   Schuppli CA, 2011, ANTHROZOOS, V24, P409, DOI 10.2752/175303711X13159027359980
   Sutherland WJ, 2009, CONSERV BIOL, V23, P557, DOI 10.1111/j.1523-1739.2009.01212.x
   Sutherland WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031824
   Sutherland WJ, 2011, METHODS ECOL EVOL, V2, P238, DOI 10.1111/j.2041-210X.2010.00083.x
   Sutherland WJ, 2006, J APPL ECOL, V43, P617, DOI 10.1111/j.1365-2664.2006.01188.x
   Turner PV, 2015, J AM ASSOC LAB ANIM, V54, P174
   Wells D, 2015, DIS MODEL MECH, V8, P1175, DOI 10.1242/dmm.022616
   Yeates JW, 2015, J MED ETHICS, V41, P504, DOI 10.1136/medethics-2015-102939
NR 56
TC 9
Z9 9
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 18
PY 2016
VL 11
IS 7
AR e0158791
DI 10.1371/journal.pone.0158791
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DR8TD
UT WOS:000380169300021
PM 27428071
OA DOAJ Gold, Green Accepted, Green Published
DA 2019-07-07
ER

PT J
AU Mackie, J
   Szabo, EK
   Urgast, DS
   Ballou, ER
   Childers, DS
   MacCallum, DM
   Feldmann, J
   Brown, AJP
AF Mackie, Joanna
   Szabo, Edina K.
   Urgast, Dagmar S.
   Ballou, Elizabeth R.
   Childers, Delma S.
   MacCallum, Donna M.
   Feldmann, Joerg
   Brown, Alistair J. P.
TI Host-Imposed Copper Poisoning Impacts Fungal Micronutrient Acquisition
   during Systemic Candida albicans Infections
SO PLOS ONE
LA English
DT Article
ID IRON; GENE; CERULOPLASMIN; METABOLISM; PROTEIN; EXPRESSION; TOLERANCE;
   TRANSPORT; VIRULENCE; HEPCIDIN
AB Nutritional immunity is a process whereby an infected host manipulates essential micronutrients to defend against an invading pathogen. We reveal a dynamic aspect of nutritional immunity during infection that involves copper assimilation. Using a combination of laser ablation inductively coupled mass spectrometry (LA-ICP MS) and metal mapping, immunohistochemistry, and gene expression profiling from infected tissues, we show that readjustments in hepatic, splenic and renal copper homeostasis accompany disseminated Candida albicans infections in the mouse model. Localized host-imposed copper poisoning manifests itself as a transient increase in copper early in the kidney infection. Changes in renal copper are detected by the fungus, as revealed by gene expression profiling and fungal virulence studies. The fungus responds by differentially regulating the Crp1 copper efflux pump (higher expression during early infection and down-regulation late in infection) and the Ctr1 copper importer (lower expression during early infection, and subsequent up-regulation late in infection) to maintain copper homeostasis during disease progression. Both Crp1 and Ctr1 are required for full fungal virulence. Importantly, copper homeostasis influences other virulence traits-metabolic flexibility and oxidative stress resistance. Our study highlights the importance of copper homeostasis for host defence and fungal virulence during systemic disease.
C1 [Mackie, Joanna; Szabo, Edina K.; Ballou, Elizabeth R.; Childers, Delma S.; MacCallum, Donna M.; Brown, Alistair J. P.] Univ Aberdeen, Inst Med Sci, Sch Med Med Sci & Nutr, Aberdeen Fungal Grp, Foresterhill, Aberdeen AB25 2ZD, Scotland.
   [Urgast, Dagmar S.; Feldmann, Joerg] Univ Aberdeen, Coll Phys Sci, Dept Chem, Trace Element Speciat Lab, Aberdeen AB24 3UE, Scotland.
   [Szabo, Edina K.] Univ Calgary, Biol Sci, 507 Campus Dr NW, Calgary, AB T2N 1N4, Canada.
RP Mackie, J (reprint author), Univ Aberdeen, Inst Med Sci, Sch Med Med Sci & Nutr, Aberdeen Fungal Grp, Foresterhill, Aberdeen AB25 2ZD, Scotland.
EM joanna.potrykus.mackie@gmail.com
RI MacCallum, Donna M./D-7897-2011
OI MacCallum, Donna M./0000-0003-4833-0378; Brown, Alistair
   JP/0000-0003-1406-4251; Ballou, Elizabeth/0000-0001-8051-2302; Feldmann,
   Joerg/0000-0002-0524-8254
FU European Research Council [ERC-2009-AdG-249793]; UK Biotechnology and
   Biological Research Council [BB/F00513X/1, BB/K017365/1]; UK Medical
   Research Council [MR/M026663/1, MR/N006364/1]; Wellcome Trust [097377];
   Biotechnology and Biological Sciences Research Council [BB/K017365/1,
   BB/F00513X/1]; Medical Research Council [MR/N006364/1, MR/M026663/1];
   National Centre for the Replacement, Refinement and Reduction of Animals
   in Research (NC3Rs) [NC/K50046X/1]
FX This work was supported by the European Research Council
   (http://erc.europa.eu/: STRIFE Advanced Grant ERC-2009-AdG-249793).
   A.J.P.B. was also supported by the UK Biotechnology and Biological
   Research Council (www.bbsrc.ac.uk: Research Grants BB/F00513X/1,
   BB/K017365/1), the UK Medical Research Council (www.mrc.ac.uk: Programme
   Grant MR/M026663/1; Centre Grant MR/N006364/1), and the Wellcome Trust
   (www.wellcome.ac.uk: Strategic Award 097377). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmed M S, 2012, ISRN Inflamm, V2012, P953461, DOI 10.5402/2012/953461
   Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367
   Barelle CJ, 2006, CELL MICROBIOL, V8, P961, DOI 10.1111/j.1462-5822.2005.00676.x
   Barnes N, 2009, TRAFFIC, V10, P767, DOI 10.1111/j.1600-0854.2009.00901.x
   Brooks C, 2011, AM J PHYSIOL-CELL PH, V300, pC447, DOI 10.1152/ajpcell.00402.2010
   Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404
   Childers DS, 2016, PLOS PATHOG IN PRESS
   Collins JF, 2010, NUTR REV, V68, P133, DOI 10.1111/j.1753-4887.2010.00271.x
   Collins JF, 2005, AM J PHYSIOL-GASTR L, V288, pG964, DOI 10.1152/ajpgi.00489.2004
   Corbin BD, 2008, SCIENCE, V319, P962, DOI 10.1126/science.1152449
   Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469
   Ding C, 2013, CELL HOST MICROBE, V13, P265, DOI 10.1016/j.chom.2013.02.002
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Eck R, 1999, MICROBIOL-UK, V145, P2415, DOI 10.1099/00221287-145-9-2415
   Ehrensberger KM, 2011, TRENDS BIOCHEM SCI, V36, P524, DOI 10.1016/j.tibs.2011.07.002
   Fradin C, 2005, MOL MICROBIOL, V56, P397, DOI 10.1111/j.1365-2958.2005.04557.x
   GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721
   Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001
   Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457
   Hood MI, 2012, NAT REV MICROBIOL, V10, P525, DOI 10.1038/nrmicro2836
   Hwang CS, 2002, MICROBIOL-SGM, V148, P3705, DOI 10.1099/00221287-148-11-3705
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768
   Kono S, 2010, BBA-MOL BASIS DIS, V1802, P968, DOI 10.1016/j.bbadis.2010.07.011
   Kuo YM, 2006, J NUTR, V136, P21
   Ladomersky E, 2015, METALLOMICS, V7, P957, DOI 10.1039/c4mt00327f
   Li CX, 2015, P NATL ACAD SCI USA, V112, pE5336, DOI 10.1073/pnas.1513447112
   Linder MC, 2013, NUTRIENTS, V5, P4022, DOI 10.3390/nu5104022
   Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594
   MacCallum DM, 2005, MYCOSES, V48, P151, DOI 10.1111/j.1439-0507.2005.01121.x
   MacCallum DM, 2009, EUKARYOT CELL, V8, P373, DOI 10.1128/EC.00387-08
   Marakalala MJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003315
   Marvin ME, 2004, MICROBIOL-SGM, V150, P2197, DOI [10.1099/mic.0.27004-0, 10.1099/mic0.27004-0]
   Marvin ME, 2003, MICROBIOL-SGM, V149, P1461, DOI 10.1099/mic.0.26172-0
   MCMANUS JFA, 1950, J EXP MED, V91, P651, DOI 10.1084/jem.91.6.651
   Meyer LA, 2001, J BIOL CHEM, V276, P36857, DOI 10.1074/jbc.M105361200
   Navarathna DHMLP, 2010, FREE RADICAL BIO MED, V49, P1561, DOI 10.1016/j.freeradbiomed.2010.08.020
   Nevitt T, 2012, BBA-MOL CELL RES, V1823, P1580, DOI 10.1016/j.bbamcr.2012.02.011
   Nose Y, 2006, CELL METAB, V4, P235, DOI 10.1016/j.cmet.2006.08.009
   Nyasae L, 2007, AM J PHYSIOL-GASTR L, V292, pG1181, DOI 10.1152/ajpgi.00472.2006
   Osman D, 2010, J BIOL CHEM, V285, P25259, DOI 10.1074/jbc.M110.145953
   Patterson MJ, 2013, ANTIOXID REDOX SIGN, V19, P2244, DOI 10.1089/ars.2013.5199
   Porcheron Gaelle, 2013, Front Cell Infect Microbiol, V3, P90, DOI 10.3389/fcimb.2013.00090
   Potrykus J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003910
   Potrykus J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003676
   Ramanan N, 2000, SCIENCE, V288, P1062, DOI 10.1126/science.288.5468.1062
   Ramirez MA, 2007, EUKARYOT CELL, V6, P280, DOI 10.1128/EC.00372-06
   Riggle PJ, 2000, J BACTERIOL, V182, P4899, DOI 10.1128/JB.182.17.4899-4905.2000
   Sandai D, 2012, MBIO, V3, DOI 10.1128/mBio.00495-12
   Sardi JCO, 2013, J MED MICROBIOL, V62, P10, DOI 10.1099/jmm.0.045054-0
   Schrettl M, 2004, J EXP MED, V200, P1213, DOI 10.1084/jem.20041242
   Shahana S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100390
   SHERMAN F, 1991, METHOD ENZYMOL, V194, P3
   Sun TS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6550
   Szabo EK, 2014, VIRULENCE, V5, P286, DOI 10.4161/viru.27046
   Tapryal N, 2009, J BIOL CHEM, V284, P1873, DOI 10.1074/jbc.M804079200
   Terada K, 1998, J BIOL CHEM, V273, P1815, DOI 10.1074/jbc.273.3.1815
   Urgast DS, 2012, ANAL BIOANAL CHEM, V402, P287, DOI 10.1007/s00216-011-5461-x
   Wagner D, 2005, J IMMUNOL, V174, P1491, DOI 10.4049/jimmunol.174.3.1491
   Waldron KJ, 2009, NATURE, V460, P823, DOI 10.1038/nature08300
   Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200
   Wang HG, 2001, AM J KIDNEY DIS, V38, P1038, DOI 10.1053/ajkd.2001.28593
   Weissman Z, 2000, P NATL ACAD SCI USA, V97, P3520, DOI 10.1073/pnas.97.7.3520
   Wilson D, 2009, FEMS YEAST RES, V9, P688, DOI 10.1111/j.1567-1364.2009.00524.x
   Wysong DR, 1998, INFECT IMMUN, V66, P1953
   Xu WJ, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002076
   Zhan M, 2013, KIDNEY INT, V83, P568, DOI 10.1038/ki.2012.441
NR 67
TC 16
Z9 16
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 30
PY 2016
VL 11
IS 6
AR e0158683
DI 10.1371/journal.pone.0158683
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DQ0CH
UT WOS:000378865200107
PM 27362522
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Pascual, G
   Sotomayor, S
   Rodriguez, M
   Perez-Kohler, B
   Kuhnhardt, A
   Fernandez-Gutierrez, M
   San Roman, J
   Bellon, JM
AF Pascual, Gemma
   Sotomayor, Sandra
   Rodriguez, Marta
   Perez-Koehler, Barbara
   Kuehnhardt, Andree
   Fernandez-Gutierrez, Mar
   San Roman, Julio
   Manuel Bellon, Juan
TI Cytotoxicity of Cyanoacrylate-Based Tissue Adhesives and Short-Term
   Preclinical In Vivo Biocompatibility in Abdominal Hernia Repair
SO PLOS ONE
LA English
DT Article
ID N-BUTYL CYANOACRYLATE; MESH FIXATION; INITIAL-EXPERIENCE; MEDICAL
   ADHESIVE; PATCH FIXATION; CLINICAL-TRIAL; GLUE; N-BUTYL-2-CYANOACRYLATE;
   SUTURE; SAFETY
AB Background
   Cyanoacrylate(CA)-based tissue adhesives, although not widely used, are a feasible option to fix a mesh during abdominal hernia repair, due to its fast action and great bond strength. Their main disadvantage, toxicity, can be mitigated by increasing the length of their alkyl chain. The objective was to assess the in vitro cytotoxicity and in vivo biocompatibility in hernia repair of CAs currently used in clinical practice (Glubran(n-butyl) and Ifabond(n-hexyl)) and a longer-chain CA (OCA(n-octyl)), that has never been used in the medical field.
   Methods
   Formaldehyde release and cytotoxicity of unpolymerized(UCAs) and polymerized CAs (PCAs) were evaluated by macroscopic visual assessment, flow cytometry and Alamar Blue assays. In the preclinical evaluation, partial defects were created in the rabbit abdominal wall and repaired by fixing polypropylene prostheses using the CAs. At 14 days post-surgery, animals were euthanized for morphology, macrophage response and cell damage analyses.
   Results
   Formaldehyde release was lower as the molecular weight of the monomer increased. The longest side-chain CA(OCA) showed the highest cytotoxicity in the UCA condition. However, after polymerization, was the one that showed better behavior on most occasions. In vivo, all CAs promoted optimal mesh fixation without displacements or detachments. Seroma was evident with the use of Glubran, (four of six animals: 4/6) and Ifabond (2/6), but it was reduced with the use of OCA (1/6). Significantly greater macrophage responses were observed in groups where Glubran and Ifabond were used vs. sutures and OCA. TUNEL-positive cells were significantly higher in the Glubran and OCA groups vs. the suture group.
   Conclusions
   Although mild formaldehyde release occurred, OCA was the most cytotoxic during polymerization but the least once cured. The CAs promoted proper mesh fixation and have potential to replace traditional suturing techniques in hernia repair; the CAs exhibited good tissue integration and effective short-term biocompatibility, with the slightest seroma and macrophage response induced by OCA.
C1 [Pascual, Gemma; Sotomayor, Sandra] Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Med & Med Special, Madrid, Spain.
   [Pascual, Gemma; Sotomayor, Sandra; Rodriguez, Marta; Perez-Koehler, Barbara; Fernandez-Gutierrez, Mar; San Roman, Julio; Manuel Bellon, Juan] Networking Biomed Res Ctr Bioengn Biomat & Nanome, Madrid, Spain.
   [Rodriguez, Marta; Perez-Koehler, Barbara; Kuehnhardt, Andree; Manuel Bellon, Juan] Univ Alcala De Henares, Dept Surg Med & Social Sci, Fac Med & Hlth Sci, Madrid, Spain.
   [Fernandez-Gutierrez, Mar; San Roman, Julio] Inst Polymer Sci & Technol ICTP CSIC, Biomat Grp, Madrid, Spain.
RP Bellon, JM (reprint author), Networking Biomed Res Ctr Bioengn Biomat & Nanome, Madrid, Spain.; Bellon, JM (reprint author), Univ Alcala De Henares, Dept Surg Med & Social Sci, Fac Med & Hlth Sci, Madrid, Spain.
EM juanm.bellon@uah.es
RI Kohler, Barbara Perez/M-1858-2019; Fernandez-Gutierrez, Ma.
   Mar/D-3860-2014; PASCUAL, GEMMA/M-6564-2016
OI Fernandez-Gutierrez, Ma. Mar/0000-0003-1739-1987; PASCUAL,
   GEMMA/0000-0002-1623-4384
FU Ministerio de Economia y Competitividad, Spain [SAF2014-55022-P]
FX The study was supported by Grant SAF2014-55022-P from Ministerio de
   Economia y Competitividad, Spain.
CR Agresta F, 2007, SURG LAPARO ENDO PER, V17, P91, DOI 10.1097/SLE.0b013e31803c9b7f
   Bhatia SK, 2008, CELL BIOL TOXICOL, V24, P315, DOI 10.1007/s10565-007-9040-z
   Dilege E, 2010, J INVEST SURG, V23, P262, DOI 10.3109/08941939.2010.481008
   Duarte AP, 2012, PROG POLYM SCI, V37, P1031, DOI 10.1016/j.progpolymsci.2011.12.003
   Edmonson MB, 2001, AM J EMERG MED, V19, P240
   Farouk R, 1996, BRIT J SURG, V83, P1100, DOI 10.1002/bjs.1800830819
   Fortelny RH, 2007, SURG ENDOSC, V21, P1781, DOI 10.1007/s00464-007-9243-7
   Cerda DG, 2015, SURG TODAY, V45, P939, DOI 10.1007/s00595-014-1056-4
   Hollander JE, 1998, ACAD EMERG MED, V5, P1012, DOI 10.1111/j.1553-2712.1998.tb02782.x
   Jenkins ED, 2010, HERNIA, V14, P505, DOI 10.1007/s10029-010-0670-3
   Jourdan IC, 1998, SURG LAPAROSC ENDOSC, V8, P291, DOI 10.1097/00019509-199808000-00011
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kukleta JF, 2012, HERNIA, V16, P153, DOI 10.1007/s10029-011-0887-9
   Kull S, 2009, J SURG RES, V157, pE15, DOI 10.1016/j.jss.2009.01.034
   Ladwa N, 2013, INT J SURG, V11, P128, DOI 10.1016/j.ijsu.2012.12.013
   Lee YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079761
   Leggat PA, 2007, ANZ J SURG, V77, P209, DOI 10.1111/j.1445-2197.2007.04020.x
   Lim JI, 2012, MATER LETT, V81, P251, DOI 10.1016/j.matlet.2012.05.027
   Lin JC, 2000, J BIOMED MATER RES, V53, P799, DOI 10.1002/1097-4636(2000)53:6<799::AID-JBM22>3.0.CO;2-#
   Losi P, 2010, J SURG RES, V163, pE53, DOI 10.1016/j.jss.2010.05.003
   Mizrahi B, 2011, ACTA BIOMATER, V7, P3150, DOI 10.1016/j.actbio.2011.04.022
   Montanaro L, 2001, BIOMATERIALS, V22, P59, DOI 10.1016/S0142-9612(00)00163-0
   Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561
   Osmond MH, 1999, ACAD EMERG MED, V6, P171, DOI 10.1111/j.1553-2712.1999.tb00151.x
   Paajanen H, 2011, BRIT J SURG, V98, P1245, DOI 10.1002/bjs.7598
   Shen YM, 2012, SURGERY, V151, P550, DOI 10.1016/j.surg.2011.09.031
   Silvestri A, 2006, AESTHET PLAST SURG, V30, P695, DOI 10.1007/s00266-006-0139-z
   Sung HW, 1999, J BIOMAT SCI-POLYM E, V10, P751, DOI 10.1163/156856299X00621
   Taira BR, 2010, J EMERG MED, V38, P546, DOI 10.1016/j.jemermed.2008.10.009
   Testini M, 2010, CAN J SURG, V53, P155
   TORIUMI DM, 1990, ARCH OTOLARYNGOL, V116, P546
   TSENG YC, 1990, J BIOMED MATER RES, V24, P1355, DOI 10.1002/jbm.820241007
   Vauthier C, 2003, ADV DRUG DELIVER REV, V55, P519, DOI 10.1016/S0169-409X(03)00041-3
   Vote BJT, 2000, CLIN EXP OPHTHALMOL, V28, P437, DOI 10.1046/j.1442-9071.2000.00351.x
   Wang MG, 2013, SURG ENDOSC, V27, P3792, DOI 10.1007/s00464-013-2970-z
   Yamamoto LG, 2000, AM J EMERG MED, V18, P511
NR 36
TC 23
Z9 23
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2016
VL 11
IS 6
AR e0157920
DI 10.1371/journal.pone.0157920
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DP0WR
UT WOS:000378212000053
PM 27322731
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Li, ES
   Cheung, PY
   Lee, TF
   Lu, M
   O'Reilly, M
   Schmolzer, GM
AF Li, Elliott S.
   Cheung, Po-Yin
   Lee, Tze-Fun
   Lu, Min
   O'Reilly, Megan
   Schmolzer, Georg M.
TI Return of spontaneous Circulation Is Not Affected by Different Chest
   Compression Rates Superimposed with Sustained Inflations during
   Cardiopulmonary Resuscitation in Newborn Piglets
SO PLOS ONE
LA English
DT Article
ID BIRTH-WEIGHT INFANTS; HIGH AIRWAY PRESSURE; NEONATAL RESUSCITATION;
   CARDIAC-ARREST; DELIVERY-ROOM; BLOOD-FLOW; VENTILATION RATIO; PORCINE
   MODEL; AUGMENTATION; IMPROVES
AB Objective
   Recently, sustained inflations (SI) during chest compression (CC) have been suggested as an alternative to the current approach during neonatal resuscitation. However, the optimal rate of CC during SI has not yet been established. Our aim was to determine whether different CC rates during SI reduce time to return of spontaneous circulation (ROSC) and improve hemodynamic recovery in newborn piglets with asphyxia-induced bradycardia.
   Intervention and measurements
   Term newborn piglets were anesthetized, intubated, instrumented and exposed to 45-min normocapnic hypoxia followed by asphyxia. Resuscitation was initiated when heart rate decreased to 25% of baseline. Piglets were randomized into three groups: CC superimposed by SI at a rate of 90 CC per minute (SI+CC 90, n = 8), CC superimposed by SI at a rate of 120 CC per minute (SI+CC 120, n = 8), or a sham group (n = 6). Cardiac function, carotid blood flow, cerebral oxygenation and respiratory parameters were continuously recorded throughout the experiment.
   Main results
   Both treatment groups had similar time of ROSC, survival rates, hemodynamic and respiratory parameters during cardiopulmonary resuscitation. The hemodynamic recovery in the subsequent 4h was similar in both groups and was only slightly lower than sham-operated piglets at the end of experiment.
   Conclusion
   Newborn piglets resuscitated by SI+CC 120 did not show a significant advantage in ROSC, survival, and hemodynamic recovery as compared to those piglets resuscitated by SI+CC 90.
C1 [Li, Elliott S.] McGill Univ, Fac Sci, Montreal, PQ, Canada.
   [Li, Elliott S.; Cheung, Po-Yin; Lee, Tze-Fun; Lu, Min; O'Reilly, Megan; Schmolzer, Georg M.] Royal Alexandra Hosp, Neonatal Res Unit, Ctr Studies Asphyxia & Resuscitat, Edmonton, AB, Canada.
   [Cheung, Po-Yin; Lee, Tze-Fun; Lu, Min; O'Reilly, Megan; Schmolzer, Georg M.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
RP Schmolzer, GM (reprint author), Royal Alexandra Hosp, Neonatal Res Unit, Ctr Studies Asphyxia & Resuscitat, Edmonton, AB, Canada.; Schmolzer, GM (reprint author), Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
EM georg.schmoelzer@me.com
RI Schmolzer, Georg M/E-7883-2010
OI Schmolzer, Georg M/0000-0001-9798-2415; Cheung,
   Po-Yin/0000-0002-7141-1523
FU Alberta Innovates - Health Solutions Summer-Studentship; Fellowship of
   the Molly Towell Perinatal Foundation; Heart and Stroke
   Foundation/University of Alberta Professorship of Neonatal
   Resuscitation; Heart and Stroke Scholarship; Neonatal Resuscitation
   Program, Canadian Pediatric Society
FX The authors would like to that the public for donation money to our
   funding agencies: Scholarships to support individual authors (salary
   support) was available for the study: ESL was supported by as Alberta
   Innovates - Health Solutions Summer-Studentship. MOR is supported by a
   Fellowship of the Molly Towell Perinatal Foundation. GMS is a recipient
   of the Heart and Stroke Foundation/University of Alberta Professorship
   of Neonatal Resuscitation and a Heart and Stroke Scholarship. The
   authors would like to thank the Neonatal Resuscitation Program, Canadian
   Pediatric Society
   (http://www.cps.ca/en/grants-bourses/details/nrp-research-grant) for
   supporting the study. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2000, CARDIOPULMONARY RESU, V342, P1546
   Babbs CF, 2009, RESUSCITATION, V80, P1280, DOI 10.1016/j.resuscitation.2009.07.014
   Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926
   Berg RA, 2000, CIRCULATION, V101, P1743
   BERKOWITZ ID, 1989, PEDIATR RES, V26, P558, DOI 10.1203/00006450-198912000-00006
   Chalak LF, 2011, PEDIATR RES, V69, P401, DOI 10.1203/PDR.0b013e3182125f7f
   CHANDRA N, 1980, LANCET, V1, P175
   CHANDRA N, 1981, AM J CARDIOL, V48, P1053, DOI 10.1016/0002-9149(81)90320-9
   Chandra N, 1980, LANCET, V315, P175
   Cheung P-Y, 2011, J VIS EXP, P3166
   HALPERIN HR, 1986, CIRCULATION, V73, P539, DOI 10.1161/01.CIR.73.3.539
   Kapadia V, 2012, CLIN PERINATOL, V39, P833, DOI 10.1016/j.clp.2012.09.011
   Keszler M, 2015, CURR OPIN PEDIATR, V27, P145, DOI 10.1097/MOP.0000000000000204
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klingenberg C, 2013, ARCH DIS CHILD-FETAL, V98, pF222, DOI 10.1136/archdischild-2012-301787
   KOEHLER RC, 1983, CIRCULATION, V67, P266, DOI 10.1161/01.CIR.67.2.266
   Li ES-S, 2015, ARCH DIS CHILD FETAL
   McGowan JE, 2014, RESUSCITATION, V85, P161, DOI 10.1016/j.resuscitation.2013.12.004
   Perlman JM, 2015, CIRCULATION, V132, pS204, DOI 10.1161/CIR.0000000000000276
   Pichler G, 2015, NEPHROLOGY, V20, P107, DOI 10.1111/nep.12357
   RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345
   Schmolzer GM, 2014, RESUSCITATION, V85, P270, DOI 10.1016/j.resuscitation.2013.10.011
   Schmolzer GM, 2013, CIRCULATION, V128, P2495, DOI 10.1161/CIRCULATIONAHA.113.002289
   Schmolzer GM, 2014, ARCH DIS CHILD FETAL
   Sobotka KS, 2011, PEDIATR RES, V70, P56, DOI 10.1203/PDR.0b013e31821d06a1
   Solevag AL, 2015, ARCH DIS CHILD FETAL
   Solevag AL, 2011, ARCH DIS CHILD-FETAL, V96, pF417, DOI 10.1136/adc.2010.200386
   Solevag AL, 2010, RESUSCITATION, V81, P1571, DOI 10.1016/j.resuscitation.2010.06.007
   Solevag AL, 2015, RESUSCITATION, V96, P151, DOI 10.1016/j.resuscitation.2015.08.001
   van Os S, 2014, ACTA PAEDIATR, V103, P796, DOI 10.1111/apa.12650
   Wyckoff M, 2000, PEDIATRICS, V106, P618, DOI 10.1542/peds.106.3.618
   Wyckoff MH, 2008, SEMIN FETAL NEONAT M, V13, P410, DOI 10.1016/j.siny.2008.04.012
   Wyckoff MH, 2013, CIRCULATION, V128, P2468, DOI 10.1161/CIRCULATIONAHA.113.006093
   Wyckoff MH, 2012, J PEDIATR-US, V160, P239, DOI 10.1016/j.jpeds.2011.07.041
NR 34
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 15
PY 2016
VL 11
IS 6
AR e0157249
DI 10.1371/journal.pone.0157249
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DO5LO
UT WOS:000377824800043
PM 27304210
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bird, MF
   Cerlesi, MC
   Brown, M
   Malfacini, D
   Vezzi, V
   Molinari, P
   Micheli, L
   Mannelli, LD
   Ghelardini, C
   Guerrini, R
   Calo, G
   Lambert, DG
AF Bird, Mark F.
   Cerlesi, Maria Camilla
   Brown, Mark
   Malfacini, Davide
   Vezzi, Vanessa
   Molinari, Paola
   Micheli, Laura
   Mannelli, Lorenzo Di Cesare
   Ghelardini, Carla
   Guerrini, Remo
   Calo, Girolamo
   Lambert, David G.
TI Characterisation of the Novel Mixed Mu-NOP Peptide Ligand
   Dermorphin-N/OFQ (DeNo)
SO PLOS ONE
LA English
DT Article
ID NOCICEPTIN/ORPHANIN FQ PEPTIDE; DELTA-OPIOID RECEPTORS; SOLID-PHASE
   SYNTHESIS; IN-VITRO; PHARMACOLOGICAL CHARACTERIZATION; PARTIAL AGONIST;
   ORPHANIN-FQ; MORPHINE; MICE; TOLERANCE
AB Introduction
   Opioid receptors are currently classified as Mu (mu), Delta (delta), Kappa (kappa) plus the opioid related nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP). Despite compelling evidence for interactions and benefits of targeting more than one receptor type in producing analgesia, clinical ligands are Mu agonists. In this study we have designed a Mu-NOP agonist named DeNo. The Mu agonist component is provided by dermorphin, a peptide isolated from the skin of Phyllomedusa frogs and the NOP component by the endogenous agonist N/OFQ.
   Methods
   We have assessed receptor binding profile of DeNo and compared with dermorphin and N/OFQ. In a series of functional screens we have assessed the ability to (i) increase Ca2+ in cells coexpressing recombinant receptors and a the chimeric protein G alpha(qi5), (ii) stimulate the binding of GTP gamma[S-35], (iii) inhibit cAMP formation, (iv) activate MAPKinase, (v) stimulate receptor-G protein and arrestin interaction using BRET, (vi) electrically stimulated guinea pig ileum (gpI) assay and (vii) ability to produce analgesia via the intrathecal route in rats.
   Results
   DeNo bound to Mu (pK(i); 9.55) and NOP (pK(i); 10.22) and with reasonable selectivity. This translated to increased Ca2+ in G alpha(qi5) expressing cells (pEC(50) Mu 7.17; NOP 9.69), increased binding of GTP gamma[S-35] (pEC(50) Mu 7.70; NOP 9.50) and receptor-G protein interaction in BRET (pEC(50) Mu 8.01; NOP 9.02). cAMP formation was inhibited and arrestin was activated (pEC(50) Mu 6.36; NOP 8.19). For MAPK DeNo activated p38 and ERK1/2 at Mu but only ERK1/2 at NOP. In the gpI DeNO inhibited electrically-evoked contractions (pEC(50) 8.63) that was sensitive to both Mu and NOP antagonists. DeNo was antinociceptive in rats.
   Conclusion
   Collectively these data validate the strategy used to create a novel bivalent Mu-NOP peptide agonist by combining dermorphin (Mu) and N/OFQ (NOP). This molecule behaves essentially as the parent compounds in vitro. In the antonocicoeptive assays employed in this study DeNo displays only weak antinociceptive properties.
C1 [Bird, Mark F.; Brown, Mark; Lambert, David G.] Univ Leicester, Div Anaesthesia Crit Care & Pain Management, Leicester Royal Infirm, Dept Cardiovascular Sci, Leicester LE2 7LX, Leics, England.
   [Cerlesi, Maria Camilla; Malfacini, Davide; Calo, Girolamo] Univ Ferrara, Pharmacol Sect, Dept Med Sci, I-44100 Ferrara, Italy.
   [Cerlesi, Maria Camilla; Malfacini, Davide; Calo, Girolamo] Univ Ferrara, Natl Inst Neurosci, I-44100 Ferrara, Italy.
   [Vezzi, Vanessa; Molinari, Paola] Ist Super Sanita, Dept Pharmacol, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Micheli, Laura; Mannelli, Lorenzo Di Cesare; Ghelardini, Carla] Univ Florence, Pharmacol & Toxicol Sect, Dept Neurosci Psychol Drug Res & Child Health Neu, Florence, Italy.
   [Guerrini, Remo] Univ Ferrara, Dept Chem & Pharmaceut Sci, I-44100 Ferrara, Italy.
   [Guerrini, Remo] Univ Ferrara, LTTA, I-44100 Ferrara, Italy.
RP Lambert, DG (reprint author), Univ Leicester, Div Anaesthesia Crit Care & Pain Management, Leicester Royal Infirm, Dept Cardiovascular Sci, Leicester LE2 7LX, Leics, England.
EM dgl3@le.ac.uk
RI Vezzi, Vanessa/H-7084-2018; Di Cesare Mannelli, Lorenzo/A-1641-2015
OI Vezzi, Vanessa/0000-0002-7649-345X; GHELARDINI,
   CARLA/0000-0001-9856-8144; Malfacini, Davide/0000-0003-4562-9550;
   Lambert, David/0000-0003-4769-8090; molinari, paola/0000-0002-8454-0121;
   Di Cesare Mannelli, Lorenzo/0000-0001-8374-4432
FU British Journal of Anaesthesia; Italian Ministry of University and
   Research (FIRB grant) [RBFR109SBM]; University of Ferrara (FAR grant)
FX The British Journal of Anaesthesia funded a PhD studentship to MFB.
   Other UK based Departmental miscellaneous funds were used for consumable
   items. Research in Ferrara and Florence was funded by the Italian
   Ministry of University and Research (RBFR109SBM FIRB grant) and the
   University of Ferrara (FAR grant). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299
   Aceto MD, 2012, INT J MED CHEM, DOI 10.1155/2012/327257
   Bigoni R, 1999, N-S ARCH PHARMACOL, V359, P160, DOI 10.1007/PL00005338
   Bird MF, 2015, BRIT J ANAESTH, V114, P646, DOI 10.1093/bja/aeu454
   Bobeck EN, 2016, BEHAV BRAIN RES, V298, P17, DOI 10.1016/j.bbr.2015.10.032
   Brighton PJ, 2011, BRIT J PHARMACOL, V162, P1603, DOI 10.1111/j.1476-5381.2010.01173.x
   BYCROFT BW, 1993, J CHEM SOC CHEM COMM, P778, DOI 10.1039/c39930000778
   Camarda Valeria, 2013, Methods Mol Biol, V937, P293
   Camarda V, 2009, N-S ARCH PHARMACOL, V379, P599, DOI 10.1007/s00210-009-0396-x
   Christie MJ, 2008, BRIT J PHARMACOL, V154, P384, DOI 10.1038/bjp.2008.100
   Ciccarelli A, 2013, NEUROPHARMACOLOGY, V70, P168, DOI 10.1016/j.neuropharm.2012.12.010
   Courteix C, 2004, PAIN, V110, P236, DOI 10.1016/j.pain.2004.03.037
   Cremeans CM, 2012, J PHARMACOL EXP THER, V343, P72, DOI 10.1124/jpet.112.194308
   Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102
   Evans RM, 2010, J BIOL CHEM, V285, P1032, DOI 10.1074/jbc.M109.040634
   Goeldner C, 2008, J NEUROSCI, V28, P2190, DOI 10.1523/JNEUROSCI.3711-07.2008
   Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101
   Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000
   Guerrini R, 2005, J MED CHEM, V48, P1421, DOI 10.1021/jm040106v
   Guerrini R, 2014, BIOORGAN MED CHEM, V22, P3703, DOI 10.1016/j.bmc.2014.05.005
   He SQ, 2011, NEURON, V69, P120, DOI 10.1016/j.neuron.2010.12.001
   Hu E, 2010, PAIN, V148, P107, DOI 10.1016/j.pain.2009.10.026
   Ibba M, 2008, N-S ARCH PHARMACOL, V378, P553, DOI 10.1007/s00210-008-0350-3
   Khroyan TV, 2007, J PHARMACOL EXP THER, V320, P934, DOI 10.1124/jpet.106.111997
   Khroyan TV, 2011, J PHARMACOL EXP THER, V336, P952, DOI 10.1124/jpet.110.175620
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kitayama M, 2007, N-S ARCH PHARMACOL, V375, P369, DOI 10.1007/s00210-007-0170-x
   Ko MC, 2009, J PAIN, V10, P509, DOI 10.1016/j.jpain.2008.11.006
   Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572
   LEIGHTON GE, 1988, BRIT J PHARMACOL, V93, P553, DOI 10.1111/j.1476-5381.1988.tb10310.x
   Linz K, 2014, J PHARMACOL EXP THER, V349, P535, DOI 10.1124/jpet.114.213694
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Malfacini D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132865
   Mazei-Robison MS, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012070
   MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0
   Micheli L, 2015, EUR J PHARMACOL, V754, P79, DOI 10.1016/j.ejphar.2015.02.020
   Molinari P, 2008, BIOCHEM J, V409, P251, DOI 10.1042/BJ20070803
   Molinari S, 2013, BRIT J PHARMACOL, V168, P151, DOI 10.1111/j.1476-5381.2012.02115.x
   MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275
   Nitsche JF, 2002, J NEUROSCI, V22, P10906
   Pan YX, 2002, BIOCHEM BIOPH RES CO, V297, P659, DOI 10.1016/S0006-291X(02)02258-1
   REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792
   Reiss D, 2008, EUR J PHARMACOL, V579, P141, DOI 10.1016/j.ejphar.2007.10.031
   Rizzi A, 2014, BRIT J PHARMACOL, V171, P4138, DOI 10.1111/bph.12799
   Schroder W, 2014, BRIT J PHARMACOL, V171, P3777, DOI 10.1111/bph.12744
   Schunk S, 2014, ACS MED CHEM LETT, V5, P857, DOI 10.1021/ml500117c
   SOLE NA, 1992, J ORG CHEM, V57, P5399, DOI 10.1021/jo00046a022
   Sukhtankar DD, 2013, J PHARMACOL EXP THER, V346, P11, DOI 10.1124/jpet.113.203984
   Tian JH, 1997, BRIT J PHARMACOL, V120, P676, DOI 10.1038/sj.bjp.0700942
   VACHON L, 1987, BIOCHEM PHARMACOL, V36, P2889, DOI 10.1016/0006-2952(87)90199-7
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wang HL, 2005, J NEUROCHEM, V92, P1285, DOI 10.1111/j.1471-4159.2004.02921.x
   Wolfensohn S., 2008, HDB LAB ANIMAL MANAG
   Wu Y L, 1997, Cell Res, V7, P69
   YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9
NR 55
TC 11
Z9 11
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2016
VL 11
IS 6
AR e0156897
DI 10.1371/journal.pone.0156897
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DO1TC
UT WOS:000377561000044
PM 27272042
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sagebakken, G
   Ahnesjo, I
   Kvarnemo, C
AF Sagebakken, Gry
   Ahnesjo, Ingrid
   Kvarnemo, Charlotta
TI Costs and Benefits to Pregnant Male Pipefish Caring for Broods of
   Different Sizes
SO PLOS ONE
LA English
DT Article
ID ROLE-REVERSED PIPEFISH; CLUTCH-SIZE; FILIAL CANNIBALISM;
   SYNGNATHUS-TYPHLE; REPRODUCTIVE SUCCESS; SPECIES SYNGNATHIDAE; PARENTAL
   EFFORT; GASTEROSTEUS-ACULEATUS; ICTALURUS-PUNCTATUS; CHANNEL CATFISH
AB Trade-offs between brood size and offspring size, offspring survival, parental condition or parental survival are classic assumptions in life history biology. A reduction in brood size may lessen these costs of care, but offspring mortality can also result in an energetic gain, if parents are able to utilize the nutrients from the demised young. Males of the broad-nosed pipefish (Syngnathus typhle) care for the offspring by brooding embryos in a brood pouch. Brooding males can absorb nutrients that emanate from embryos, and there is often a reduction in offspring number over the brooding period. In this study, using two experimentally determined brood sizes (partially and fully filled brood pouches), we found that full broods resulted in larger number of developing offspring, despite significantly higher absolute and relative embryo mortality, compared to partial broods. Male survival was also affected by brood size, with males caring for full broods having poorer survival, an effect that together with the reduced embryo survival was found to negate the benefit of large broods. We found that embryo mortality was lower when the brooding males were in good initial condition, that embryos in broods with low embryo mortality weighed more, and surprisingly, that males in higher initial condition had embryos of lower weight. Brood size, however, did not affect embryo weight. Male final condition, but not initial condition, correlated with higher male survival. Taken together, our results show costs and benefits of caring for large brood sizes, where the numerical benefits come with costs in terms of both embryo survival and survival of the brooding father, effects that are often mediated via male condition.
C1 [Sagebakken, Gry; Kvarnemo, Charlotta] Univ Gothenburg, Dept Biol & Environm Sci, Gothenburg, Sweden.
   [Ahnesjo, Ingrid] Uppsala Univ, Dept Ecol & Genet, Uppsala, Sweden.
RP Kvarnemo, C (reprint author), Univ Gothenburg, Dept Biol & Environm Sci, Gothenburg, Sweden.
EM lotta.kvarnemo@bioenv.gu.se
FU Goteborgs Universitets Marina Forskningscentrum (GMF); Helge Ax:son
   Johnssons Stiftelse; Radman och Fru Ernst Collianders Stiftelse; Knut
   och Alice Wallenbergs stiftelse; Wilhelm och Martina Lundgrens
   Vetenskapsfond; Inez Johanssons stiftelse (Uppsala University); GMF;
   Swedish Research Council
FX This work was supported by Goteborgs Universitets Marina
   Forskningscentrum (GMF), Helge Ax:son Johnssons Stiftelse, Radman och
   Fru Ernst Collianders Stiftelse, Knut och Alice Wallenbergs stiftelse
   and Wilhelm och Martina Lundgrens Vetenskapsfond to G.S., Inez
   Johanssons stiftelse (Uppsala University) to I.A. and GMF and the
   Swedish Research Council to C.K.
CR AHNESJO I, 1992, J FISH BIOL, V41, P53, DOI 10.1111/j.1095-8649.1992.tb03868.x
   AHNESJO I, 1992, FUNCT ECOL, V6, P274, DOI 10.2307/2389517
   Ahnesjo I, 1996, BEHAV ECOL SOCIOBIOL, V38, P167, DOI 10.1007/s002650050229
   AHNESJO I, 1995, BEHAV ECOL, V6, P229, DOI 10.1093/beheco/6.2.229
   [Anonymous], 2012, ANIM BEHAV, V83, P301, DOI 10.1016/j.anbehav.2011.10.031
   BERGLUND A, 1986, MAR ECOL PROG SER, V29, P209, DOI 10.3354/meps029209
   BERGLUND A, 1986, BEHAV ECOL SOCIOBIOL, V19, P301, DOI 10.1007/BF00300646
   BERGLUND A, 1988, OIKOS, V51, P184, DOI 10.2307/3565641
   Braga Goncalves I, 2011, J FISH BIOL, V78, P1847, DOI 10.1111/j.1095-8649.2011.02984.x
   Braga Goncalves I, 2015, EVOLUTIONARY PUZZLE, V282, DOI [10.1098/rspb.2015.0690, DOI 10.1098/RSPB.2015.0690]
   Braga Goncalves I, 2015, J EXP BIOL, V218, P1639, DOI 10.1242/jeb.120907
   BROCKELMAN WY, 1975, AM NAT, V109, P677, DOI 10.1086/283037
   Brooker RM, 2013, OECOLOGIA, V172, P409, DOI 10.1007/s00442-012-2521-7
   CHARNOV EL, 1974, IBIS, V116, P217, DOI 10.1111/j.1474-919X.1974.tb00241.x
   CHELLAPPA S, 1989, J FISH BIOL, V35, P275, DOI 10.1111/j.1095-8649.1989.tb02976.x
   Christe P, 2012, P ROY SOC B-BIOL SCI, V279, P1142, DOI 10.1098/rspb.2011.1546
   Clutton- Brock TH., 1991, EVOLUTION PARENTAL C
   CODY ML, 1966, EVOLUTION, V20, P174, DOI 10.1111/j.1558-5646.1966.tb03353.x
   COLEMAN RM, 1985, BEHAV ECOL SOCIOBIOL, V18, P59
   Daan S, 1996, J ANIM ECOL, V65, P539, DOI 10.2307/5734
   Dufresne F, 1990, BEHAV ECOL, V1, P140, DOI 10.1093/beheco/1.2.140
   Elgar MA, 1992, CANNIBALISM ECOLOGY, P1
   Engstrand SM, 2002, FUNCT ECOL, V16, P782, DOI 10.1046/j.1365-2435.2002.00681.x
   Gaylord TG, 2000, J WORLD AQUACULT SOC, V31, P326
   GODFRAY HCJ, 1991, ANNU REV ECOL SYST, V22, P409, DOI 10.1146/annurev.es.22.110191.002205
   Hunt J, 2002, J EVOLUTION BIOL, V15, P57, DOI 10.1046/j.1420-9101.2002.00374.x
   Hussey NE, 2009, MAR ECOL PROG SER, V380, P199, DOI 10.3354/meps07918
   Ito S, 2010, ENVIRON BIOL FISH, V87, P135, DOI 10.1007/s10641-009-9573-5
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kindsvater HK, 2010, EVOL ECOL RES, V12, P327
   Klug H, 2006, EVOLUTION, V60, P2087, DOI 10.1111/j.0014-3820.2006.tb01846.x
   Kvarnemo C, 2011, J FISH BIOL, V78, P1725, DOI 10.1111/j.1095-8649.2011.02989.x
   Lissaker M, 2003, BEHAV ECOL, V14, P374, DOI 10.1093/beheco/14.3.374
   Luo Z, 2009, J APPL ICHTHYOL, V25, P184, DOI 10.1111/j.1439-0426.2009.01216.x
   Manica A, 2002, BIOL REV, V77, P261, DOI 10.1017/S1464793101005905
   MARCONATO A, 1988, J FISH BIOL, V33, P905, DOI 10.1111/j.1095-8649.1988.tb05539.x
   MOCK DW, 1995, TRENDS ECOL EVOL, V10, P130, DOI 10.1016/S0169-5347(00)89014-X
   Mock DW, 1997, EVOLUTION SIBLING RI
   Nord A, 2010, FUNCT ECOL, V24, P1031, DOI 10.1111/j.1365-2435.2010.01719.x
   Paczolt KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124147
   Paczolt KA, 2010, NATURE, V464, P401, DOI 10.1038/nature08861
   Partridge C, 2009, BEHAV ECOL SOCIOBIOL, V63, P345, DOI 10.1007/s00265-008-0668-3
   PARTRIDGE L, 1991, PHILOS T ROY SOC B, V332, P3, DOI 10.1098/rstb.1991.0027
   Payne AG, 2004, ECOL MODEL, V174, P253, DOI 10.1016/j.ecolmodel.2003.09.026
   Payne AG, 2002, P ROY SOC B-BIOL SCI, V269, P2095, DOI 10.1098/rspb.2002.2144
   PERRINS CM, 1965, J ANIM ECOL, V34, P601, DOI 10.2307/2453
   RIDGWAY MS, 1989, ETHOLOGY, V80, P47
   Ripley JL, 2009, COMP BIOCHEM PHYS A, V154, P98, DOI 10.1016/j.cbpa.2009.05.003
   Ripley JL, 2009, J COMP PHYSIOL B, V179, P325, DOI 10.1007/s00360-008-0316-2
   Ripley JL, 2006, J EXP BIOL, V209, P1112, DOI 10.1242/jeb.02119
   Roff Derek A., 1992
   ROHWER S, 1978, AM NAT, V112, P429, DOI 10.1086/283284
   ROSENQVIST G, 1995, ANIM BEHAV, V49, P1039, DOI 10.1006/anbe.1995.0133
   Roth O, 2011, J EVOLUTION BIOL, V24, P1410, DOI 10.1111/j.1420-9101.2011.02273.x
   SABAT AM, 1994, BEHAV ECOL, V5, P195, DOI 10.1093/beheco/5.2.195
   Sagebakken G, 2012, THESIS U GOTHENBURG
   Sagebakken G, 2011, BEHAV ECOL, V22, P625, DOI 10.1093/beheco/arr023
   Sagebakken G, 2010, P ROY SOC B-BIOL SCI, V277, P971, DOI 10.1098/rspb.2009.1767
   Sargent Robert Craig, 1992, P38
   SMITH C, 1995, REV FISH BIOL FISHER, V5, P7, DOI 10.1007/BF01103363
   Sommer S, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-39
   Stearns S. C., 1992, EVOLUTION LIFE HIST
   SVENSSON I, 1988, J ANIM ECOL, V57, P929, DOI 10.2307/5102
   TRIVERS RL, 1974, AM ZOOL, V14, P249
   VINCENT A, 1994, BEHAV ECOL SOCIOBIOL, V34, P435, DOI 10.1007/s002650050060
   Vincent ACJ, 1995, ENVIRON BIOL FISH, V44, P347, DOI 10.1007/BF00008250
   Watanabe S, 2002, ENVIRON BIOL FISH, V65, P319, DOI 10.1023/A:1020510422509
   WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461
   Wilson AB, 2001, J HERED, V92, P159, DOI 10.1093/jhered/92.2.159
   Wolfe RK, 1998, J GREAT LAKES RES, V24, P731
   Wootton RJ, 1998, ECOLOGY TELEOST FISH
NR 71
TC 2
Z9 2
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2016
VL 11
IS 5
AR e0156484
DI 10.1371/journal.pone.0156484
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN5XX
UT WOS:000377146100041
PM 27243937
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hooijmans, CR
   Geessink, FJ
   Ritskes-Hoitinga, M
   Scheffer, GJ
AF Hooijmans, Carlijn R.
   Geessink, Florentine J.
   Ritskes-Hoitinga, Merel
   Scheffer, Gert Jan
TI A Systematic Review of the Modifying Effect of Anaesthetic Drugs on
   Metastasis in Animal Models for Cancer
SO PLOS ONE
LA English
DT Review
ID SEARCH FILTER; RECURRENCE; SURGERY; METAANALYSIS; ANALGESIA; QUALITY;
   REDUCE
AB Background
   Distant metastasis or local recurrence after primary tumour resection remain a major clinical problem. The anaesthetic technique used during oncologic surgery is suggested to influence the metastatic process. While awaiting the results of ongoing randomised controlled trials (RCTs), we have analyzed the evidence regarding the influence of anaesthetic drugs on experimental tumour metastasis in animal studies.
   Methods
   PubMed and Embase were searched until April 21st, 2015. Studies were included in the systematic review when they 1) assessed the effect of an anaesthetic drug used in clinical practice on the number or incidence of metastasis in animal models with experimental cancer, 2) included an appropriate control group, and 3) presented unique data.
   Results
   20 studies met the inclusion criteria (published between 1958-2010). Data on number of metastases could be retrieved from 17 studies. These studies described 41 independent comparisons, 33 of which could be included in the meta-analysis (MA). The incidence of metastases was studied in 3 unique papers. From these 3 papers, data on 7 independent comparisons could be extracted and included in the MA. Locally administered local anaesthetics appear to decrease the number of metastases (SMD -6.15 [-8.42; -3.88]), whereas general anaesthetics (RD: 0.136 [0.045, 0.226]), and more specifically volatile anaesthetics (SMD 0.54 [0.24; 0.84]), appear to increase the number and risk of metastases in animal models for cancer.
   Conclusions
   Anaesthetics influence the number and incidence of metastases in experimental cancer models. Although more high quality experimental research is necessary, based on the currently available evidence from animal studies, there is no indication to suggest that locally administered local anaesthetics are harmful during surgery in cancer patients. Volatile anaesthetics, however, might increase metastasis in animal models and clinical trials investigating this possibly harmful effect should receive priority. The results of our systematic review in animal studies are broadly consistent with clinical reports that anaesthetic technique does seem to affect the tumour metastasis process.
C1 [Hooijmans, Carlijn R.; Ritskes-Hoitinga, Merel] Radboud Univ Nijmegen, Med Ctr, Dept SYstemat Review, Ctr Lab Anim Expt SYRCLE, NL-6500 HB Nijmegen, Netherlands.
   [Hooijmans, Carlijn R.; Geessink, Florentine J.; Scheffer, Gert Jan] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6500 HB Nijmegen, Netherlands.
RP Hooijmans, CR (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept SYstemat Review, Ctr Lab Anim Expt SYRCLE, NL-6500 HB Nijmegen, Netherlands.; Hooijmans, CR (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6500 HB Nijmegen, Netherlands.
EM Carlijn.Hooijmans@radboudumc.nl
RI Hooijmans, C.R./L-4390-2015; Ritskes-Hoitinga, J./H-8083-2014; Scheffer,
   G.J./H-8086-2014
OI Hooijmans, C.R./0000-0001-6435-5714; 
CR Agostino D, 1964, ANESTHETIC EFFECT PU, P735
   Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022
   Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026
   Buggy DJ, 2015, BRIT J ANAESTH, V114, P2, DOI 10.1093/bja/aeu262
   Cakmakkaya OS, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008877.pub2
   Cassinello F, 2015, J CLIN ANESTH, V27, P262, DOI 10.1016/j.jclinane.2015.02.007
   de Vries RBM, 2014, LAB ANIM-UK, V48, P88, DOI 10.1177/0023677213494374
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Forget P, 2010, EUR J ANAESTH, V27, P233, DOI 10.1097/EJA.0b013e32832d540e
   FRID IA, 1984, EKSP ONKOL, V6, P57
   Heaney A, 2012, BRIT J ANAESTH, V109, pI17, DOI 10.1093/bja/aes421
   Hooijmans CR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001482
   Hooijmans CR, 2015, PAIN, V156, P1835, DOI 10.1097/j.pain.0000000000000296
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   Hooijmans CR, 2015, PAIN
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Leenaars M, 2012, LAB ANIM-UK, V46, P24, DOI 10.1258/la.2011.011087
   LUNDY J, 1977, SURGERY, V82, P254
   LUNDY J, 1978, CANCER, V41, P827, DOI 10.1002/1097-0142(197803)41:3<827::AID-CNCR2820410307>3.0.CO;2-#
   Mammoto T, 2002, J CELL PHYSIOL, V192, P351, DOI 10.1002/jcp.10145
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moudgil GC, 1997, CAN J ANAESTH, V44, P90, DOI 10.1007/BF03014331
   NICOLSON GL, 1986, J NATL CANCER I, V76, P511
   PAGE GG, 1993, PAIN, V54, P21, DOI 10.1016/0304-3959(93)90095-7
   POLLARD M, 1977, ONCOLOGY, V34, P129
   Pollard M, 1977, FEDERATION P, V4306
   SCHATTEN WE, 1958, CANCER, V11, P460, DOI 10.1002/1097-0142(195805/06)11:3<460::AID-CNCR2820110304>3.0.CO;2-E
   Sessler DI, 2008, EUR J CANCER PREV, V17, P269, DOI 10.1097/CEJ.0b013e3282f0c005
   SIMON RH, 1980, SCIENCE, V209, P1132, DOI 10.1126/science.6250220
   Singh SK, 1987, SURG RES COMMUNICATI, P19
   Stanculescu M, 1981, ONCOLOGIA, P95
   Stanculescu M, 1983, ONCOLOGIA, P239
   Tavare AN, 2012, INT J CANCER, V130, P1237, DOI 10.1002/ijc.26448
   Votta-Velis EG, 2013, ACTA ANAESTH SCAND, V57, P1211, DOI 10.1111/aas.12210
   Wada H, 2007, ANESTHESIOLOGY, V106, P499, DOI 10.1097/00000542-200703000-00014
   Wigmore TJ, 2016, ANESTHESIOLOGY, V124, P69, DOI 10.1097/ALN.0000000000000936
NR 39
TC 3
Z9 3
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2016
VL 11
IS 5
AR e0156152
DI 10.1371/journal.pone.0156152
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN2GQ
UT WOS:000376882500072
PM 27227779
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Tuncel, J
   Haag, S
   Hoffmann, MH
   Yau, ACY
   Hultqvist, M
   Olofsson, P
   Backlund, J
   Nandakumar, KS
   Weidner, D
   Fischer, A
   Leichsenring, A
   Lange, F
   Haase, C
   Lu, S
   Gulko, PS
   Steiner, G
   Holmdahl, R
AF Tuncel, Jonatan
   Haag, Sabrina
   Hoffmann, Markus H.
   Yau, Anthony C. Y.
   Hultqvist, Malin
   Olofsson, Peter
   Backlund, Johan
   Nandakumar, Kutty Selva
   Weidner, Daniela
   Fischer, Anita
   Leichsenring, Anna
   Lange, Franziska
   Haase, Claus
   Lu, Shemin
   Gulko, Percio S.
   Steiner, Gunter
   Holmdahl, Rikard
TI Animal Models of Rheumatoid Arthritis (I): Pristane-Induced Arthritis in
   the Rat
SO PLOS ONE
LA English
DT Article
ID ADJUVANT-INDUCED ARTHRITIS; MAJOR HISTOCOMPATIBILITY COMPLEX;
   COLLAGEN-INDUCED ARTHRITIS; DA RATS; INFLAMMATORY ARTHRITIS; AUTOIMMUNE
   ARTHRITIS; FREUND ADJUVANT; F344 RATS; T-CELLS; DISEASE
AB Background
   To facilitate the development of therapies for rheumatoid arthritis ( RA), the Innovative Medicines Initiative BTCure has combined the experience from several laboratories worldwide to establish a series of protocols for different animal models of arthritis that reflect the pathogenesis of RA. Here, we describe chronic pristane-induced arthritis (PIA) model in DA rats, and provide detailed instructions to set up and evaluate the model and for reporting data.
   Methods
   We optimized dose of pristane and immunization procedures and determined the effect of age, gender, and housing conditions. We further assessed cage-effects, reproducibility, and frequency of chronic arthritis, disease markers, and efficacy of standard and novel therapies.
   Results
   Out of 271 rats, 99.6% developed arthritis after pristane-administration. Mean values for day of onset, day of maximum arthritis severity and maximum clinical scores were 11.8 +/- 2.0 days, 20.3 +/- 5.1 days and 34.2 +/- 11 points on a 60-point scale, respectively. The mean frequency of chronic arthritis was 86% but approached 100% in long-term experiments over 110 days. Pristane was arthritogenic even at 5 microliters dose but needed to be administrated intradermally to induce robust disease with minimal variation. The development of arthritis was age-dependent but independent of gender and whether the rats were housed in conventional or barrier facilities. PIA correlated well with weight loss and acute phase reactants, and was ameliorated by etanercept, dexamethasone, cyclosporine A and fingolimod treatment.
   Conclusions
   PIA has high incidence and excellent reproducibility. The chronic relapsing-remitting disease and limited systemic manifestations make it more suitable than adjuvant arthritis for long-term studies of joint-inflammation and screening and validation of new therapeutics.
C1 [Tuncel, Jonatan; Haag, Sabrina; Yau, Anthony C. Y.; Backlund, Johan; Nandakumar, Kutty Selva; Holmdahl, Rikard] Karolinska Inst, Dept Med Biochem & Biophys, Div Med Inflammat Res, Stockholm, Sweden.
   [Hoffmann, Markus H.; Weidner, Daniela] Univ Erlangen Nurnberg, Dept Internal Med 3, Erlangen, Germany.
   [Hoffmann, Markus H.; Fischer, Anita; Steiner, Gunter] Med Univ Vienna, Div Rheumatol, Vienna, Austria.
   [Hultqvist, Malin; Olofsson, Peter] Redoxis AB, Lund, Sweden.
   [Leichsenring, Anna; Lange, Franziska] Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany.
   [Haase, Claus] Novo Nordisk AS, Dept Immunopharmacol, Malov, Denmark.
   [Lu, Shemin] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xian 710049, Shaanxi, Peoples R China.
   [Gulko, Percio S.] Icahn Sch Med Mt Sinai, Dept Med, Div Rheumatol, New York, NY 10029 USA.
   [Tuncel, Jonatan] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
RP Tuncel, J; Holmdahl, R (reprint author), Karolinska Inst, Dept Med Biochem & Biophys, Div Med Inflammat Res, Stockholm, Sweden.; Tuncel, J (reprint author), Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
EM jonatan_tuncel@hms.harvard.edu; rikard.holmdahl@ki.se
RI Nandakumar, Kutty Selva/D-5438-2011; Lu, Shemin/M-3350-2018; Yau,
   Anthony CY/P-5379-2016
OI Nandakumar, Kutty Selva/0000-0001-7790-8197; Lu,
   Shemin/0000-0001-8250-850X; Yau, Anthony CY/0000-0002-1570-7813; Lu,
   Shemin/0000-0002-5535-8320; Steiner, Guenter/0000-0002-5089-7405
FU Innovative Medicines Initiative (IMI); European Union; European
   Federation of Pharmaceutical Industries and Associations (EFPIA);
   Swedish Strategic Science Foundation; Knut and Alice Wallenberg
   Foundation; Konung Gustaf V:s 80-ars fond; Swedish Research Council;
   Swedish Rheumatism Association; European Union FP7 Neurinox
FX BTCure is funded by the Innovative Medicines Initiative (IMI), a
   public-private partnership between the European Union and the European
   Federation of Pharmaceutical Industries and Associations (EFPIA). This
   study was also supported by the Swedish Strategic Science Foundation,
   the Knut and Alice Wallenberg Foundation, the Konung Gustaf V:s 80-ars
   fond, the Swedish Research Council, the Swedish Rheumatism Association,
   and European Union FP7 Neurinox to RH. Redoxis provided support in the
   form of salaries for authors MH and PO, but did not have any additional
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript. The specific roles of these
   authors are articulated in the 'author contributions' section. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   AVIGAN J, 1967, BIOCHIM BIOPHYS ACTA, V144, P127, DOI 10.1016/0005-2760(67)90084-7
   Avigan J, 1968, J LIPID RES
   Backdahl L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-391
   Bakharevski O, 1998, J RHEUMATOL, V25, P1945
   Bendele A. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P377
   BJORK J, 1994, SCAND J IMMUNOL, V40, P648, DOI 10.1111/j.1365-3083.1994.tb03518.x
   Bolon B, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/569068
   Brenner M, 2007, ANN RHEUM DIS, V66, P952, DOI 10.1136/ard.2006.066225
   BRODERSON JR, 1989, LAB ANIM SCI, V39, P400
   CANNON GW, 1993, J RHEUMATOL, V20, P7
   Finzel S, 2011, ANN RHEUM DIS, V70, P122, DOI 10.1136/ard.2010.132423
   Guo XS, 2013, GENETICS, V194, P1017, DOI 10.1534/genetics.113.153049
   Haag S, 2015, J IMMUNOL, V194, P2539, DOI 10.4049/jimmunol.1402238
   Hegen M, 2008, ANN RHEUM DIS, V67, P1505, DOI 10.1136/ard.2007.076430
   Herman S, 2012, AUTOIMMUNITY, V45, P602, DOI 10.3109/08916934.2012.719948
   Hoffmann MH, 2007, J IMMUNOL, V179, P7568, DOI 10.4049/jimmunol.179.11.7568
   Hoffmann MH, 2013, ANN RHEUM DIS, V72, P1239, DOI 10.1136/annrheumdis-2012-202218
   Hoffmann MH, 2011, J AUTOIMMUN, V36, P288, DOI 10.1016/j.jaut.2011.02.007
   Holmberg J, 2006, J IMMUNOL, V176, P1172, DOI 10.4049/jimmunol.176.2.1172
   HOLMDAHL R, 1992, IMMUNOLOGY, V76, P197
   Kawahito Y, 1998, J IMMUNOL, V161, P4411
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KLEINAU S, 1995, INT J IMMUNOPHARMACO, V17, P393, DOI 10.1016/0192-0561(95)00020-3
   KOHASHI O, 1979, INFECT IMMUN, V26, P791
   Kollias G, 2011, ANN RHEUM DIS, V70, P1357, DOI 10.1136/ard.2010.148551
   Kuroda Y, 2004, TOXICOL SCI, V78, P222, DOI 10.1093/toxsci/kfh063
   Lange F, 2005, ANN RHEUM DIS, V64, P599, DOI 10.1136/ard.2004.026120
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Meng HC, 2004, ARTHRITIS RHEUM-US, V50, P2695, DOI 10.1002/art.20366
   Mikulowska A., 1997, HUMAN GENOME METHODS, V215, P215
   Nicklas W, 2010, LAB ANIMAL, V39, P43, DOI 10.1038/laban0210-43
   Olofsson P, 2002, ARTHRITIS RHEUM, V46, P259, DOI 10.1002/1529-0131(200201)46:1<259::AID-ART10035>3.0.CO;2-2
   PEARSON CM, 1963, J CHRON DIS, V16, P863, DOI 10.1016/0021-9681(63)90136-X
   Rintisch C, 2008, MAMM GENOME, V19, P420, DOI 10.1007/s00335-008-9125-x
   Rintisch C, 2008, P NATL ACAD SCI USA, V105, P14005, DOI 10.1073/pnas.0803956105
   Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118
   Roubenoff R, 1997, ARTHRITIS RHEUM, V40, P534, DOI 10.1002/art.1780400320
   SAMUELSON CO, 1984, ARTHRITIS RHEUM, V27, P689, DOI 10.1002/art.1780270613
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schett G, 2009, ARTHRITIS RHEUM-US, V60, P2644, DOI 10.1002/art.24767
   Tuncel J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004151
   Tuncel J, 2012, ARTHRITIS RHEUM-US, V64, P2537, DOI 10.1002/art.34461
   van Venrooij WJ, 2011, NAT REV RHEUMATOL, V7, P391, DOI 10.1038/nrrheum.2011.76
   VANDENBROEK MF, 1992, CLIN EXP IMMUNOL, V88, P313
   VANEDEN W, 1989, CURR TOP MICROBIOL, V145, P27
   VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0
   Vingsbo C, 1996, AM J PATHOL, V149, P1675
   Vossenaar ER, 2004, ARTHRITIS RHEUM, V50, P2370, DOI 10.1002/art.20296
   WARD JR, 1962, ARTHRITIS RHEUM, V5, P557, DOI 10.1002/art.1780050604
   Wekerle H, 2012, NAT MED, V18, P66, DOI 10.1038/nm.2635
   Wooley PH, 2004, BEST PRACT RES CL RH, V18, P47, DOI 10.1016/j.berh.2003.09.007
   Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001
NR 54
TC 21
Z9 23
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2016
VL 11
IS 5
AR e0155936
DI 10.1371/journal.pone.0155936
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN2GQ
UT WOS:000376882500043
PM 27227821
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Liu, YL
   Zhao, XX
   Mai, YF
   Li, XX
   Wang, J
   Chen, LL
   Mu, J
   Jin, GX
   Gou, HP
   Sun, WT
   Feng, YC
AF Liu, Yali
   Zhao, Xingxing
   Mai, Yuefen
   Li, Xinxin
   Wang, Jin
   Chen, Lili
   Mu, Jing
   Jin, Gengxue
   Gou, Hongping
   Sun, Wanting
   Feng, Yuchen
TI Adherence to ARRIVE Guidelines in Chinese Journal Reports on Neoplasms
   in Animals
SO PLOS ONE
LA English
DT Article
ID IMPLANT INTEGRATION; SYSTEMATIC REVIEWS; QUALITY; DESIGN; MODELS
AB Background
   The Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines were published in 2010 with the aim of improving the quality of studies involving animals. However, how well Chinese studies involving animal neoplasms adhere to these guidelines has not been assessed.
   Objective
   To evaluate the reporting quality of such experiments published between 2010 and 2012 in Chinese journals with support from the National Natural Science Foundation of China.
   Methods
   We searched the Chinese Science Citation and Chinese Journal Full-Text Databases for articles published between 2010 and 2012 involving neoplasms in animals. The data were extracted into pre-prepared forms. Reporting quality was assessed using the ARRIVE checklist-39 items plus information on blinding.
   Results
   Three hundred and ninety-six animal studies were included in the analysis: 127 studies published in 2010, 140 studies published in 2011, and 129 studies published in 2012. The range of ARRIVE score is from 12 to 27 with a maximum possible score of 40. Studies published in 2012 (P = 0.012), 2011 (P = 0.015), 2010, July similar to Dec (P<0.017) had a significantly larger ARRIVE checklist score than those published in Jan.similar to June, 2010, respectively.
   Conclusions
   Experiments involving neoplasms in animals published in Chinese journals generally have not comprehensively reported the information recommended by the ARRIVE guidelines. We strongly recommend that researchers conducting such studies report this information.
C1 [Liu, Yali; Mai, Yuefen; Sun, Wanting] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.
   [Liu, Yali] Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China.
   [Liu, Yali] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.
   [Zhao, Xingxing] Peking Univ, Hlth Sci Ctr, Beijing 100871, Peoples R China.
   [Mai, Yuefen; Wang, Jin; Mu, Jing; Jin, Gengxue; Feng, Yuchen] Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Peoples R China.
   [Li, Xinxin; Chen, Lili; Gou, Hongping; Sun, Wanting] Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Peoples R China.
RP Liu, YL (reprint author), Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.; Liu, YL (reprint author), Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China.; Liu, YL (reprint author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.
EM lyl_201006@126.com
OI Liu, Yali/0000-0003-0037-6326
FU National Natural Science Foundation of China (NCSF) [81101756]
FX This project was supported by the National Natural Science Foundation of
   China (NCSF) (grant number 81101756) (http://www.nsfc.gov.cn/). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1197/aemj.10.6.684
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Berglundh T, 2012, J CLIN PERIODONTOL, V39, P1, DOI 10.1111/j.1600-051X.2011.01827.x
   Chiyu J, 2006, CHINES J BURNS, V22
   Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   MCCANCE I, 1995, AUST VET J, V72, P322, DOI 10.1111/j.1751-0813.1995.tb07534.x
   Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Schwarz F, 2012, J CLIN PERIODONTOL, V39, P63, DOI 10.1111/j.1600-051X.2011.01838.x
   Smith JA, 1997, LAB ANIM, V31, P312, DOI 10.1258/002367797780596176
   Stadlinger B, 2012, J CLIN PERIODONTOL, V39, P28, DOI 10.1111/j.1600-051X.2011.01835.x
   Thoma DS, 2012, J CLIN PERIODONTOL, V39, P37, DOI 10.1111/j.1600-051X.2011.01833.x
   Vignoletti F, 2012, J CLIN PERIODONTOL, V39, P6, DOI 10.1111/j.1600-051X.2011.01830.x
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI [10.1016/j.ypmed.2007.08.012, 10.7326/0003-4819-147-8-200710160-00010]
   Yali L, 2011, CHINESE J EVIDENCE B, V6, P233
NR 18
TC 9
Z9 9
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2016
VL 11
IS 5
AR e0154657
DI 10.1371/journal.pone.0154657
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DM3XH
UT WOS:000376279500007
PM 27182788
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Carbone, L
   Austin, J
AF Carbone, Larry
   Austin, Jamie
TI Pain and Laboratory Animals: Publication Practices for Better Data
   Reproducibility and Better Animal Welfare
SO PLOS ONE
LA English
DT Article
ID SPINAL-CORD-INJURY; EXPERIMENTAL SURGICAL-PROCEDURES; KILLER-CELL
   ACTIVITY; SYSTEMATIC REVIEWS; NEUROPATHIC PAIN; METASTATIC COLONIZATION;
   LIVER-TRANSPLANTATION; REPORTING GUIDELINES; POSTERIOR PARIETAL;
   CRITICAL-CARE
AB Scientists who perform major survival surgery on laboratory animals face a dual welfare and methodological challenge: how to choose surgical anesthetics and post-operative analgesics that will best control animal suffering, knowing that both pain and the drugs that manage pain can all affect research outcomes. Scientists who publish full descriptions of animal procedures allow critical and systematic reviews of data, demonstrate their adherence to animal welfare norms, and guide other scientists on how to conduct their own studies in the field. We investigated what information on animal pain management a reasonably diligent scientist might find in planning for a successful experiment. To explore how scientists in a range of fields describe their management of this ethical and methodological concern, we scored 400 scientific articles that included major animal survival surgeries as part of their experimental methods, for the completeness of information on anesthesia and analgesia. The 400 articles (250 accepted for publication pre-2011, and 150 in 2014-15, along with 174 articles they reference) included thoracotomies, craniotomies, gonadectomies, organ transplants, peripheral nerve injuries, spinal laminectomies and orthopedic procedures in dogs, primates, swine, mice, rats and other rodents. We scored articles for Publication Completeness (PC), which was any mention of use of anesthetics or analgesics; Analgesia Use (AU) which was any use of post-surgical analgesics, and Analgesia Completeness (a composite score comprising intra-operative analgesia, extended post-surgical analgesia, and use of multimodal analgesia). 338 of 400 articles were PC. 98 of these 338 were AU, with some mention of analgesia, while 240 of 338 mentioned anesthesia only but not post-surgical analgesia. Journals' caliber, as measured by their 2013 Impact Factor, had no effect on PC or AU. We found no effect of whether a journal instructs authors to consult the ARRIVE publishing guidelines published in 2010 on PC or AC for the 150 mouse and rat articles in our 2014-15 dataset. None of the 302 articles that were silent about analgesic use included an explicit statement that analgesics were withheld, or a discussion of how pain management or untreated pain might affect results. We conclude that current scientific literature cannot be trusted to present full detail on use of animal anesthetics and analgesics. We report that publication guidelines focus more on other potential sources of bias in experimental results, under-appreciate the potential for pain and pain drugs to skew data, and thus mostly treat pain management as solely an animal welfare concern, in the jurisdiction of animal care and use committees. At the same time, animal welfare regulations do not include guidance on publishing animal data, even though publication is an integral part of the cycle of research and can affect the welfare of animals in studies building on published work, leaving it to journals and authors to voluntarily decide what details of animal use to publish. We suggest that journals, scientists and animal welfare regulators should revise current guidelines and regulations, on treatment of pain and on transparent reporting of treatment of pain, to improve this dual welfare and data-quality deficiency.
C1 [Carbone, Larry; Austin, Jamie] Univ Calif San Francisco, Lab Anim Resource Ctr, 513 Parnassus, San Francisco, CA 94143 USA.
RP Carbone, L (reprint author), Univ Calif San Francisco, Lab Anim Resource Ctr, 513 Parnassus, San Francisco, CA 94143 USA.
EM larrycarbonedvm@gmail.com
FU United States National Science Foundation Division of Social and
   Economic Sciences [1455838]; National Science Foundation, Science,
   Technology, and Society program [1455838]
FX This study was funded by the United States National Science Foundation
   Division of Social and Economic Sciences. Award #1455838. The funder had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; Elizabeth Yee, Patricia
   Carazo-Ramsey and Maritxu Ravenscroft assisted with data collection.
   Alicia Karas assisted with categorizing anesthetics. David Takacs
   provided editorial review and assistance. The work was supported by
   grant # 1455838 from the National Science Foundation, Science,
   Technology, and Society program.
CR [Anonymous], 2013, NATURE, V496, P398, DOI 10.1038/496398a
   Avey MT, 2015, J AM ASSOC LAB ANIM, V54, P153
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Bara M, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0026-8
   Bara M, 2014, CRIT CARE, V18, DOI 10.1186/cc13694
   Barak O, 2010, J NEUROSCI, V30, P9424, DOI 10.1523/JNEUROSCI.1875-10.2010
   Bignami E, 2013, J CARDIOTHOR VASC AN, V27, P50, DOI 10.1053/j.jvca.2012.06.007
   Buck V, 2007, NATURE, V446, P856, DOI 10.1038/446856d
   Carbone L, 2014, THE IACUC HDB, P211
   Carbone L, 2012, J AM ASS LAB ANIMAL, V51, P1
   Carbone L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021578
   Caro AC, 2014, J AM ASSOC LAB ANIM, V53, P185
   Chase SM, 2010, J NEUROSCI, V30, P13873, DOI 10.1523/JNEUROSCI.2325-10.2010
   Cohen DB, 2006, AM J SPORT MED, V34, P362, DOI 10.1177/0363546505280428
   Committee on Guidelines for Scientific Publications Involving Animal Studies, 2011, GUID DESCR AN RES SC
   Committee on Recognition and Alleviation of Pain in Laboratory Animals Institute for Laboratory Animal Research Division on Earth and Life Studies National Research Council, 2009, REC ALL PAIN LAB AN
   Coulter CA, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-12
   Decosterd I, 2004, ANESTH ANALG, V99, P457
   Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1
   Eisen JA, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001757
   Fish RE, 2008, AM COLL LAB, P1
   Flecknell P. A., 2009, LAB ANIMAL ANAESTHES
   Franchi S, 2007, BRAIN BEHAV IMMUN, V21, P767, DOI 10.1016/j.bbi.2007.01.001
   Gaertner DJ, 2008, AM COLL LAB, P239, DOI 10.1016/B978-012373898-1.50014-0
   Garner JP, 2014, ILAR J, V55, P438, DOI 10.1093/ilar/ilu047
   Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0
   He SQ, 2010, J AM ASSOC LAB ANIM, V49, P45
   Hirst TC, 2013, BRIT J CANCER, V108, P64, DOI 10.1038/bjc.2012.504
   Hish GA, 2014, J AM ASSOC LAB ANIM, V53, P485
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   Hugunin KMS, 2010, SHOCK, V34, P250, DOI 10.1097/SHK.0b013e3181cdc412
   Husmann K, 2015, LAB ANIM-UK, V49, P284, DOI 10.1177/0023677215570989
   Institute for Laboratory Animal Research NRC, 2011, GUIDE CARE USE LAB A
   Joel LA, 1999, AM J NURS, V99, P9
   Jones SP, 2015, CIRC RES, V116, P572, DOI 10.1161/CIRCRESAHA.116.305462
   KAMADA N, 1979, TRANSPLANTATION, V28, P47, DOI 10.1097/00007890-197907000-00011
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Knopp KL, 2015, SCAND J PAIN, V7, P58, DOI 10.1016/j.sjpain.2015.01.006
   Kohn DF, 2007, J AM ASSOC LAB ANIM, V46, P97
   Kolstad AM, 2012, J AM ASSOC LAB ANIM, V51, P448
   Krauth D, 2013, ENVIRON HEALTH PERSP, V121, P985, DOI 10.1289/ehp.1206389
   Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Lee YA, 2012, J AM ASSOC LAB ANIM, V51, P246
   Leenaars M, 2015, ALTEX-ALTERN ANIM EX, V32, P149, DOI 10.14573/altex.1502161
   Lemmon VP, 2014, J NEUROTRAUM, V31, P1354, DOI 10.1089/neu.2014.3400
   Lipman NS, 2008, AM COLL LAB, P299
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386
   Macleod MR, 2004, STROKE, V35, P1203, DOI 10.1161/01.STR.0000125719.25853.20
   Manolagas SC, 2014, J BONE MINER RES, V29, P2131, DOI 10.1002/jbmr.2293
   Martins AR, 2015, ANIMALS, V5, P315, DOI 10.3390/ani5020315
   Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020
   Mathews K, 2014, J SMALL ANIM PRACT, V55, pE10, DOI 10.1111/jsap.12200
   National Pain Management Coordinating Committee VHA, 2000, PAIN 5 VIT SIGN TOOL
   Nature Publishing Group, 2015, REP CHECKL LIF SCI A
   Osborne NJ, 2009, AM J BIOETHICS, V9, P55, DOI 10.1080/15265160903318343
   Padberg J, 2010, J NEUROSCI, V30, P12918, DOI 10.1523/JNEUROSCI.1806-10.2010
   Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6
   Parker JM, 2011, J AM ASSOC LAB ANIM, V50, P466
   Peters JL, 2006, J ENVIRON SCI HEAL B, V41, P1245, DOI 10.1080/03601230600857130
   Rice ASC, 2008, PAIN, V139, P243, DOI 10.1016/j.pain.2008.08.017
   Richardson CA, 2005, ATLA-ALTERN LAB ANIM, V33, P119, DOI 10.1177/026119290503300207
   Roseman M, 2011, JAMA-J AM MED ASSOC, V305, P1008, DOI 10.1001/jama.2011.257
   Rousseau P, 2008, ARCH SURG-CHICAGO, V143, P98, DOI 10.1001/archsurg.2007.23
   Russell W. M. S., 1959, PRINCIPLES HUMANE EX
   Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa
   Sacerdote P, 2012, CURR PHARM DESIGN, V18, P6034, DOI 10.2174/138161212803582496
   Schwarz F, 2012, J CLIN PERIODONTOL, V39, P63, DOI 10.1111/j.1600-051X.2011.01838.x
   Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   Simera I, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-24
   Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97
   Steward O, 2012, EXP NEUROL, V233, P597, DOI 10.1016/j.expneurol.2011.06.017
   Stewart LSA, 2003, COMPARATIVE MED, V53, P29
   Stokes EL, 2009, LAB ANIM-UK, V43, P149, DOI 10.1258/la.2008.008020
   Taylor K, 2010, ATLA-ALTERN LAB ANIM, V38, P495, DOI 10.1177/026119291003800613
   Tilson HA, 2013, ENVIRON HEALTH PERSP, V121, pA320, DOI 10.1289/ehp.1307676
   Tsilidis KK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001609
   United States Department of Agriculture Animal Care, 2011, AN CAR RES GUID
   United States Department of Agriculture Animal Care, 2013, AN CAR AN WELF INSP
   Vallentin D, 2010, EUR J NEUROSCI, V32, P1380, DOI 10.1111/j.1460-9568.2010.07427.x
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010
   Watzlawick R, 2014, JAMA NEUROL, V71, P91, DOI 10.1001/jamaneurol.2013.4684
   Wever KE, 2014, EVIDENCE BASED PRECL, V1, P4
NR 86
TC 33
Z9 33
U1 3
U2 42
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 12
PY 2016
VL 11
IS 5
AR e0155001
DI 10.1371/journal.pone.0155001
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DM8CQ
UT WOS:000376588600097
PM 27171143
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Qian, C
   Li, PC
   Jiao, Y
   Yao, HH
   Chen, YC
   Yang, J
   Ding, J
   Yang, XY
   Teng, GJ
AF Qian, Cheng
   Li, Pei-Cheng
   Jiao, Yun
   Yao, Hong-Hong
   Chen, Yu-Chen
   Yang, Jian
   Ding, Jie
   Yang, Xiang-Yu
   Teng, Gao-Jun
TI Precise Characterization of the Penumbra Revealed by MRI: A Modified
   Photothrombotic Stroke Model Study
SO PLOS ONE
LA English
DT Article
ID CEREBRAL-ARTERY OCCLUSION; SPONTANEOUSLY HYPERTENSIVE-RATS; PERFUSION
   COMPUTED-TOMOGRAPHY; ACUTE ISCHEMIC-STROKE; PLASMINOGEN-ACTIVATOR;
   BRAIN; TISSUE; REPERFUSION; MISMATCH; VOLUME
AB Aims
   To precisely characterize the penumbra by MRI based on a modified photothrombotic stroke mouse model.
   Methods
   The proximal middle cerebral artery was occluded by a convenient laser system in conjunction with an intravenous injection of Rose Bengal in mice. And the suture MCAO model was performed in seven mice as a comparison of the reproducibility. One hour after occlusion, the penumbra was defined in six random photothrombotic stroke mice by mismatch between perfusion-weighted imaging and the apparent diffusion coefficient map on a home-made workstation. After imaging, three random mice of them were chosen to perform the reperfusion surgery. And the other three mice were sacrificed to stain for several potential penumbra markers, such as c-fos and heart shock protein 90. In the remaining mice, the evolution of the lesions was detected on the apparent diffusion coefficient map, diffusion-weighted imaging and T2-weighted imaging at 1, 3, 6, 12 and 24 hours. After evaluating the neurological deficit scores, the brains were sectioned and stained by triphenyltetrazolium chloride and Nissl.
   Results
   The mice subjected to photothrombosis showed significant behavioral deficits. One hour after occlusion, the low perfusion areas on the perfusion-weighted imaging interlaced with the hypointense areas on the apparent diffusion coefficient map, demonstrating that the penumbra was located both surrounding and inside the lesions. This phenomenon was subsequently confirmed by the c-fos and heart shock protein 90 staining. The final T2-weighted images of the mice subjected to the reperfusion surgery were also consistent with the penumbra images at one hour. At early stages, the lesions were clearly identified on the apparent diffusion coefficient map; the volumes of the lesions on the diffusion-weighted imaging and T2-weighted imaging did not reach a maximum until 12 hours. The coefficient of variation (CV) of the final lesions in the photothrombotic stroke mice was 21.7% (0.08 of 0.37) on T2-weighted imaging and 27.8%(0.10 of 0.35) on triphenyltetrazolium chloride, representing a high reproducibility (n = 7). While the CV of the lesions in the MCAO stroke mice was only 70% 0.24 of 0.34, n = 4).
   Conclusions
   This study has provided a precise imaging definition of the penumbra based on a reproducible photothrombotic stroke mouse model.
C1 [Qian, Cheng; Li, Pei-Cheng; Jiao, Yun; Chen, Yu-Chen; Yang, Jian; Ding, Jie; Yang, Xiang-Yu; Teng, Gao-Jun] Southeast Univ, Zhongda Hosp, Jiangsu Key Lab Mol & Funct Imaging, Dept Radiol,Med Sch, Nanjing, Jiangsu, Peoples R China.
   [Yao, Hong-Hong] Southeast Univ, Sch Med, Dept Pharmacol, Nanjing, Jiangsu, Peoples R China.
RP Teng, GJ (reprint author), Southeast Univ, Zhongda Hosp, Jiangsu Key Lab Mol & Funct Imaging, Dept Radiol,Med Sch, Nanjing, Jiangsu, Peoples R China.
EM gjteng@seu.edu.cn
OI Ding, Jie/0000-0001-9162-7850
FU National Key Basic Research Program of China (973 Program)
   [2013CB733800, 013CB733803]; National Natural Science Foundation of
   China [81230034]; Jiangsu Provincial Special Program of Medical Science
   [BL2013029]
FX The National Key Basic Research Program of China (973 Program;
   2013CB733800, 013CB733803, URLs: http://www.nsfc.gov.cn/), CQ PCL YJ HHY
   YCC JY JD XYY GJT; the National Natural Science Foundation of China
   (81230034, URLs: http://www.nsfc.gov.cn/), CQ PCL YJ YCC JY JD XYY GJT;
   the Jiangsu Provincial Special Program of Medical Science (BL2013029,
   URLs: www.jswst.gov.cn), CQ PCL YJ JY JD XYY GJT. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Agulla J, 2014, THERANOSTICS, V4, P90, DOI 10.7150/thno.7088
   Boehm-Sturm P, 2014, BIOMATERIALS, V35, P2218, DOI 10.1016/j.biomaterials.2013.11.085
   Chemmanam T, 2010, NEUROLOGY, V75, P1040, DOI 10.1212/WNL.0b013e3181f39ab6
   Chen F, 2007, RADIOLOGY, V244, P429, DOI 10.1148/radiol.2442061316
   Chen XP, 2015, NAT CHEM BIOL, V11, P19, DOI 10.1038/nchembio.1657
   Del Bene A, 2013, STROKE, V44, P3000, DOI 10.1161/STROKEAHA.113.002227
   Ezura M, 2006, MINIMALLY INVASIVE NEUROSURGERY AND MULTIDISCIPLINARY NEUROTRAUMATOLOGY, P85, DOI 10.1007/4-431-28576-8_13
   Ginsberg MD, 1996, ARCH NEUROL-CHICAGO, V53, P1065, DOI 10.1001/archneur.1996.00550100151024
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Jiang W, 2006, J CEREBR BLOOD F MET, V26, P927, DOI 10.1038/sj.jcbfm.9600245
   Jung S, 2013, BRAIN, V136, P3554, DOI 10.1093/brain/awt246
   Karatas H, 2011, J CEREBR BLOOD F MET, V31, P1452, DOI 10.1038/jcbfm.2011.8
   Kidwell CS, 2003, STROKE, V34, P2729, DOI 10.1161/01.STR.0000097608.38779.CC
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Langer D, 2009, STROKE, V40, P2761, DOI 10.1161/STROKEAHA.108.544957
   Li PY, 2014, STROKE, V45, P857, DOI 10.1161/STROKEAHA.113.004100
   Markus R, 2004, BRAIN, V127, P1427, DOI 10.1093/brain/awh162
   McCabe C, 2009, STROKE, V40, P3864, DOI 10.1161/STROKEAHA.109.559021
   McLeod DD, 2015, INT J STROKE, V10, P553, DOI 10.1111/ijs.12147
   McLeod DD, 2011, INT J STROKE, V6, P284, DOI 10.1111/j.1747-4949.2010.00564.x
   Morris GP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148503
   Muir KW, 2006, J NEUROL NEUROSUR PS, V77, P334, DOI 10.1136/jnnp.2005.074179
   Orset C, 2007, STROKE, V38, P2771, DOI 10.1161/STROKEAHA.107.487520
   Ramos-Cabrer P, 2011, STROKE, V42, pS7, DOI 10.1161/STROKEAHA.110.596684
   Reid E, 2012, J CEREBR BLOOD F MET, V32, P1765, DOI 10.1038/jcbfm.2012.69
   Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010
   Robertson CA, 2015, INT J STROKE, V10, P42, DOI 10.1111/ijs.12327
   Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701
   Rosso C, 2014, CURR OPIN NEUROL, V27, P35, DOI 10.1097/WCO.0000000000000047
   Rosso C, 2009, RADIOLOGY, V250, P184, DOI 10.1148/radiol.2493080107
   Schaefer PW, 2008, STROKE, V39, P2986, DOI 10.1161/STROKEAHA.107.513358
   UMEMURA K, 1993, STROKE, V24, P1077, DOI 10.1161/01.STR.24.7.1077
   Weinstein PR, 2004, STROKE, V35, P2666, DOI 10.1161/01.STR.0000144052.10644.ed
   Wu LJ, 2012, NAT NEUROSCI, V15, P565, DOI 10.1038/nn.3059
   Xu JH, 2003, STROKE, V34, P1287, DOI 10.1161/01.STR.0000066308.25088.64
   Yang ST, 2015, NEUROLOGY, V84, P2381, DOI 10.1212/WNL.0000000000001669
   Yao H, 2003, STROKE, V34, P2716, DOI 10.1161/01.STR.0000094730.38343.73
   Yao H, 2002, NEUROREPORT, V13, P1005, DOI 10.1097/00001756-200206120-00004
   Yao H, 1996, STROKE, V27, P333, DOI 10.1161/01.STR.27.2.333
   Ye MM, 2012, J NANOMATER, DOI 10.1155/2012/583417
NR 40
TC 14
Z9 14
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 19
PY 2016
VL 11
IS 4
AR e0153756
DI 10.1371/journal.pone.0153756
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ9NW
UT WOS:000374541200043
PM 27093556
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Marquez-Ibarra, A
   Huerta, M
   Villalpando-Hernandez, S
   Rios-Silva, M
   Diaz-Reval, MI
   Cruzblanca, H
   Mancilla, E
   Trujillo, X
AF Marquez-Ibarra, Adriana
   Huerta, Miguel
   Villalpando-Hernandez, Salvador
   Rios-Silva, Monica
   Diaz-Reval, Maria I.
   Cruzblanca, Humberto
   Mancilla, Evelyn
   Trujillo, Xochitl
TI The Effects of Dietary Iron and Capsaicin on Hemoglobin, Blood Glucose,
   Insulin Tolerance, Cholesterol, and Triglycerides, in Healthy and
   Diabetic Wistar Rats
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; OVERLOAD; ANEMIA; STORES; MODEL; METABOLISM;
   INCREASES; RECEPTOR; LIPIDS; LIVER
AB Objective
   Our aim was to assess the effects of dietary iron, and the compound capsaicin, on hemoglobin as well as metabolic indicators including blood glucose, cholesterol, triglycerides, insulin, and glucose tolerance.
   Materials and Methods
   Our animal model was the Wistar rat, fed a chow diet, with or without experimentally induced diabetes. Diabetic males were fed control, low, or high-iron diets, the latter, with or without capsaicin. Healthy rats were fed identical diets, but without the capsaicin supplement. We then measured the parameters listed above, using the Student t-test and ANOVA, to compare groups.
   Results
   Healthy rats fed a low-iron diet exhibited significantly reduced total cholesterol and triglyceride levels, compared with rats fed a control diet. Significantly reduced blood lipid was also provoked by low dietary iron in diabetic rats, compared with those fed a control diet. Insulin, and glucose tolerance was only improved in healthy rats fed the low-iron diet. Significant increases in total cholesterol were found in diabetic rats fed a high-iron diet, compared with healthy rats fed the same diet, although no statistical differences were found for triglycerides. Hemoglobin levels, which were not statistically different in diabetic versus healthy rats fed the high-iron diet, fell when capsaicin was added. Capsaicin also provoked a fall in the level of cholesterol and triglycerides in diabetic animals, versus diabetics fed with the high iron diet alone. In conclusion, low levels of dietary iron reduced levels of serum triglycerides, hemoglobin, and cholesterol, and significantly improved insulin, and glucose tolerance in healthy rats. In contrast, a high-iron diet increased cholesterol significantly, with no significant changes to triglyceride concentrations. The addition of capsaicin to the high-iron diet (for diabetic rats) further reduced levels of hemoglobin, cholesterol, and triglycerides. These results suggest that capsaicin, may be suitable for the treatment of elevated hemoglobin, in patients.
C1 [Marquez-Ibarra, Adriana; Huerta, Miguel; Rios-Silva, Monica; Diaz-Reval, Maria I.; Cruzblanca, Humberto; Mancilla, Evelyn; Trujillo, Xochitl] Univ Colima, Ctr Univ Invest Biomed, Unidad Invest Dr Enrico Stefani, Colima, Colima, Mexico.
   [Villalpando-Hernandez, Salvador] Inst Nacl Salud Publ, Ctr Invest Nutr & Salud, Univ 655 Colonia Santa Maria Ahuacatitlan, Cuernavaca, Morelos, Mexico.
RP Trujillo, X (reprint author), Univ Colima, Ctr Univ Invest Biomed, Unidad Invest Dr Enrico Stefani, Colima, Colima, Mexico.
EM rosio@ucol.mx
RI ; Trujillo, Xochitl/P-7020-2017
OI Huerta, Miguel/0000-0001-8515-0777; Villalpando,
   Salvador/0000-0001-6429-3816; Trujillo, Xochitl/0000-0001-7506-1674
FU FRABA-Universidad de Colima-Mexico; CONACyT-Mexico
FX FRABA-Universidad de Colima-Mexico to XT and MH, provided partial
   sponsorship of this research. Part of these results were part of AMI's
   PhD Thesis at Faculty of Medicine, Universidad de Colima, Mexico. AMI
   received a fellowship for PhD studies from CONACyT-Mexico.
CR Abd Allah Eman S H, 2014, Pathophysiology, V21, P293, DOI 10.1016/j.pathophys.2014.06.002
   Alexandrakis M. G., 2012, ISRN HEMATOL, DOI [10.5402/2012/246915, DOI 10.5402/2012/246915]
   BOREL MJ, 1993, AM J PHYSIOL, V264, pE380
   Brunet S, 1999, HEPATOLOGY, V29, P1809, DOI 10.1002/hep.510290612
   Cherng JY, 2005, LIFE SCI, V76, P3001, DOI 10.1016/j.lfs.2004.10.055
   Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, pE1236, DOI 10.1152/ajpendo.00022.2010
   de Almeida MM, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-200
   Dongiovanni P, 2013, AM J PATHOL, V182, P2254, DOI 10.1016/j.ajpath.2013.02.019
   Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348
   Ganz T, 2012, BBA-MOL CELL RES, V1823, P1434, DOI 10.1016/j.bbamcr.2012.01.014
   Graham RM, 2010, HEPATOLOGY, V52, P462, DOI 10.1002/hep.23712
   Huang JY, 2011, DIABETES, V60, P80, DOI 10.2337/db10-0593
   Ikeda Y, 2013, AM J PHYSIOL-RENAL, V304, pF1028, DOI 10.1152/ajprenal.00473.2012
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Kamei A, 2010, PHYSIOL GENOMICS, V42, P149, DOI 10.1152/physiolgenomics.00150.2009
   Kempaiah RK, 2005, MOL CELL BIOCHEM, V275, P7, DOI 10.1007/s11010-005-7643-3
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kundu D, 2013, NIGER J CLIN PRACT, V16, P100, DOI 10.4103/1119-3077.106776
   Lee CG, 2011, DIABETES CARE, V34, P2381, DOI 10.2337/dc11-1032
   Lee CYJ, 2003, PHYTOTHER RES, V17, P454, DOI 10.1002/ptr.1172
   Maaroufi K, 2009, NEUROBIOL LEARN MEM, V92, P345, DOI 10.1016/j.nlm.2009.04.002
   Mehdad A, 2015, J NUTR HEALTH AGING, V19, P846, DOI 10.1007/s12603-015-0541-9
   Merono T, 2011, MEDICINA-BUENOS AIRE, V71, P566
   Minamiyama Y, 2010, AM J PHYSIOL-ENDOC M, V298, pE1140, DOI 10.1152/ajpendo.00620.2009
   Miron VR, 2007, MOL CELL BIOCHEM, V298, P101, DOI 10.1007/s11010-006-9357-6
   Panjeta Mirsad, 2015, Mater Sociomed, V27, P144, DOI 10.5455/msm.2015.27.144-148
   Prakash UNS, 2013, J TRACE ELEM MED BIO, V27, P184, DOI 10.1016/j.jtemb.2012.11.003
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Rios-Silva M, 2014, INT J MED SCI, V11, P448, DOI 10.7150/ijms.8034
   Salonen JT, 1998, BRIT MED J, V317, P727, DOI 10.1136/bmj.317.7160.727
   Smotra S, 2008, JK SCI, V10, P170
   SRINIVASAN MR, 1992, INDIAN J MED RES-B, V96, P133
   TAI MM, 1994, DIABETES CARE, V17, P152, DOI 10.2337/diacare.17.2.152
   Tang N, 2014, FOOD FUNCT, V5, P390, DOI 10.1039/c3fo60292c
   Thomas MC, 2003, DIABETES CARE, V26, P1164, DOI 10.2337/diacare.26.4.1164
   Thompson K, 2006, TOXICOL APPL PHARM, V210, P17, DOI 10.1016/j.taap.2005.05.014
   Uchida K, 2011, ENDOCR J, V58, P1021, DOI 10.1507/endocrj.EJ11-0130
   Whittaker P, 2001, BRIT J NUTR, V86, P587, DOI 10.1079/BJN2001439
   Zhang SY, 2014, OBES SURG, V24, P405, DOI 10.1007/s11695-013-1103-z
   Zhao ZX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041641
   ZHOU XF, 1990, BRIT J PHARMACOL, V100, P523, DOI 10.1111/j.1476-5381.1990.tb15840.x
   Zolghadri Y, 2014, INT J MOL CELL MED, V3, P255
NR 42
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2016
VL 11
IS 4
AR e0152625
DI 10.1371/journal.pone.0152625
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ0KH
UT WOS:000373891000014
PM 27064411
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Oosugi, N
   Yanagawa, T
   Nagasaka, Y
   Fujii, N
AF Oosugi, Naoya
   Yanagawa, Toru
   Nagasaka, Yasuo
   Fujii, Naotaka
TI Social Suppressive Behavior Is Organized by the Spatiotemporal
   Integration of Multiple Cortical Regions in the Japanese Macaque
SO PLOS ONE
LA English
DT Article
ID PREFRONTAL CORTEX; ASPERGER-SYNDROME; DECISION-MAKING; INFORMATION;
   BRAIN; MECHANISMS; COGNITION; NEURONS; MONKEYS; AUTISM
AB Under social conflict, monkeys develop hierarchical positions through social interactions. Once the hierarchy is established, the dominant monkey dominates the space around itself and the submissive monkey tries not to violate this space. Previous studies have shown the contributions of the frontal and parietal cortices in social suppression, but the contributions of other cortical areas to suppressive functions remain elusive. We recorded neural activity in large cortical areas using electrocorticographic (ECoG) arrays while monkeys performed a social food-grab task in which a target monkey was paired with either a dominant or a submissive monkey. If the paired monkey was dominant, the target monkey avoided taking food in the shared conflict space, but not in other areas. By contrast, when the paired monkey was submissive, the target monkey took the food freely without hesitation. We applied decoding analysis to the ECoG data to see when and which cortical areas contribute to social behavioral suppression. Neural information discriminating the social condition was more evident when the conflict space was set in the area contralateral to the recording hemisphere. We found that the information increased as the social pressure increased during the task. Before food presentation, when the pressure was relatively low, the parietal and somatosensory-motor cortices showed sustained discrimination of the social condition. After food presentation, when the monkey faced greater pressure to make a decision as to whether it should take the food, the prefrontal and visual cortices started to develop buildup responses. The social representation was found in a sustained form in the parietal and somatosensory-motor regions, followed by additional buildup form in the visual and prefrontal cortices. The representation was less influenced by reward expectation. These findings suggest that social adaptation is achieved by a higher-order self-regulation process (incorporating motor preparation/execution processes) in accordance with the embodied social contexts.
C1 [Oosugi, Naoya; Yanagawa, Toru; Nagasaka, Yasuo; Fujii, Naotaka] RIKEN, BSI, Lab Adapt Intelligence, Wako, Saitama, Japan.
   [Oosugi, Naoya] Univ Tokyo, Grad Sch Arts & Sci, Meguro Ku, Tokyo, Japan.
RP Fujii, N (reprint author), RIKEN, BSI, Lab Adapt Intelligence, Wako, Saitama, Japan.
EM na@brain.riken.jp
FU JSPS KAKENHI [23118003, 23650225]; RIKEN internal research budget
FX A part of this study was supported by JSPS KAKENHI Grant Numbers
   23118003 and 23650225 (http://www.jsps.go.jp/english/index.html), and
   "Brain Machine Interface Development" performed under the Strategic
   Research Program for Brain Sciences by MEXT, Japan
   (http://www.mext.go.jp/english/). Rest part of the study was supported
   by RIKEN internal research budget. There is no other research funding
   source for this study.
CR Alexander RD, 1987, BIOL MORAL SYSTEMS
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x
   Barraclough DJ, 2004, NAT NEUROSCI, V7, P404, DOI 10.1038/nn1209
   Caggiano V, 2009, SCIENCE, V324, P403, DOI 10.1126/science.1166818
   Chao Zenas C, 2010, Front Neuroeng, V3, P3, DOI 10.3389/fneng.2010.00003
   Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591
   Donner TH, 2011, TRENDS COGN SCI, V15, P191, DOI 10.1016/j.tics.2011.03.007
   Fan RE, 2008, J MACH LEARN RES, V9, P1871
   Fogassi L, 2005, SCIENCE, V308, P662, DOI 10.1126/science.1106138
   Fujii N, 2012, THE PRIMATE MIND, P48
   Fujii N, 2009, SOC NEUROSCI-UK, V4, P73, DOI 10.1080/17470910802046230
   Fujii N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000397
   Gilbert CD, 2007, NEURON, V54, P677, DOI 10.1016/j.neuron.2007.05.019
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kriegeskorte N, 2006, P NATL ACAD SCI USA, V103, P3863, DOI 10.1073/pnas.0600244103
   Nagasaka Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022561
   Nakahara K, 2002, SCIENCE, V295, P1532, DOI 10.1126/science.1067653
   Nelson RJ, 2007, NAT REV NEUROSCI, V8, P536, DOI 10.1038/nrn2174
   Passingham R. E., 1993, OXFORD PSYCHOL SERIE
   Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060
   Rizzolatti G, 2008, CURR OPIN NEUROBIOL, V18, P179, DOI 10.1016/j.conb.2008.08.001
   Sakagami M, 2007, CURR OPIN NEUROBIOL, V17, P228, DOI 10.1016/j.conb.2007.02.008
   Santos GS, 2012, SOC NEUROSCI-UK, V7, P42, DOI 10.1080/17470919.2011.578465
   Shannon BJ, 2011, P NATL ACAD SCI USA, V108, P11241, DOI 10.1073/pnas.1108241108
   Sharma J., 2014, CEREB CORTEX
   Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137
   Stevenson IH, 2011, NAT NEUROSCI, V14, P139, DOI 10.1038/nn.2731
   Takahashi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094657
   Tanji J, 2001, CURR OPIN NEUROBIOL, V11, P164, DOI 10.1016/S0959-4388(00)00192-6
   Tsuchiya N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003892
   Wang XJ, 2010, PHYSIOL REV, V90, P1195, DOI 10.1152/physrev.00035.2008
NR 32
TC 2
Z9 2
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 10
PY 2016
VL 11
IS 3
AR e0150934
DI 10.1371/journal.pone.0150934
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG3TL
UT WOS:000371993000083
PM 26963915
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bonnan, MF
   Shulman, J
   Varadharajan, R
   Gilbert, C
   Wilkes, M
   Horner, A
   Brainerd, E
AF Bonnan, Matthew F.
   Shulman, Jason
   Varadharajan, Radha
   Gilbert, Corey
   Wilkes, Mary
   Horner, Angela
   Brainerd, Elizabeth
TI Forelimb Kinematics of Rats Using XROMM, with Implications for Small
   Eutherians and Their Fossil Relatives
SO PLOS ONE
LA English
DT Article
ID THERIAN MAMMALS; LOCOMOTION; EVOLUTION; MORPHOLOGY; MOVEMENT; HINDLIMB;
   ANATOMY; WALKING; DIVERSIFICATION; MAMMALIAFORM
AB The earliest eutherian mammals were small-bodied locomotor generalists with a forelimb morphology that strongly resembles that of extant rats. Understanding the kinematics of the humerus, radius, and ulna of extant rats can inform and constrain hypotheses concerning typical posture and mobility in early eutherian forelimbs. The locomotion of Rattus norvegicus has been extensively studied, but the three-dimensional kinematics of the bones themselves remains under-explored. Here, for the first time, we use markerless XROMM (Scientific Rotoscoping) to explore the three-dimensional long bone movements in Rattus norvegicus during a normal, symmetrical gait (walking). Our data show a basic kinematic profile that agrees with previous studies on rats and other small therians: rats maintain a crouched forelimb posture throughout the step cycle, and the ulna is confined to flexion/extension in a parasagittal plane. However, our three-dimensional data illuminate long-axis rotation (LAR) movements for both the humerus and the radius for the first time. Medial LAR of the humerus throughout stance maintains an adducted elbow with a caudally-facing olecranon process, which in turn maintains a cranially-directed manus orientation (pronation). The radius also shows significant LAR correlated with manus pronation and supination. Moreover, we report that elbow flexion and manus orientation are correlated in R. norvegicus: as the elbow angle becomes more acute, manus supination increases. Our data also suggest that manus pronation and orientation in R. norvegicus rely on a divided system of labor between the ulna and radius. Given that the radius follows the flexion and extension trajectory of the ulna, it must rotate at the elbow (on the capitulum) so that during the stance phase its distal end lies medial to ulna, ensuring that the manus remains pronated while the forelimb is supporting the body. We suggest that forelimb posture and kinematics in Juramaia, Eomaia, and other basal eutherians were grossly similar to those of rats, and that humerus and radius LAR may have always played a significant role in forelimb and manus posture in small eutherian mammals.
C1 [Bonnan, Matthew F.; Varadharajan, Radha; Wilkes, Mary] Stockton Univ, Biol Program, Galloway, NJ 08205 USA.
   [Shulman, Jason; Gilbert, Corey] Stockton Univ, Phys Program, Galloway, NJ 08205 USA.
   [Horner, Angela] Calif State Univ San Bernardino, Dept Biol, San Bernardino, CA 92407 USA.
   [Brainerd, Elizabeth] Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA.
RP Bonnan, MF (reprint author), Stockton Univ, Biol Program, Galloway, NJ 08205 USA.
EM Matthew.Bonnan@stockton.edu
FU Richard Stockton College of New Jersey; Junior Faculty Award; Junior
   Faculty Grant; REU grant through SU; Biology and Physics Programs,
   former Dean Weiss and interim Dean Straub (School of Natural Sciences
   and Mathematics [NAMS])
FX This research was funded by a Junior Faculty Award and a Research &
   Professional Development Grant from the Richard Stockton College of New
   Jersey to MFB. The funder had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.; We
   thank Stephen Gatesy, David Baier, Ariel Camp, Peter Falkingham, and
   other XROMM gurus for their help, support, and encouragement. We thank
   D. Irschick and an anonymous reviewer for their input and suggestions,
   which improved our manuscript. We thank the Stockton University (SU) and
   Brown University IACUC panels for their assistance in meeting animal
   protocols. At SU, we are grateful for the support of the Biology and
   Physics Programs, former Dean Weiss and interim Dean Straub (School of
   Natural Sciences and Mathematics [NAMS]), NAMS Lab Director Justine
   Ciraolo, NAMS Animal Lab Director John Rokita, and NAMS lab staff,
   especially William Harron. We are also grateful for the assistance of SU
   students Evan Drake and Kadeisha Pinkney in the early stages of this
   research. This research was supported by a Junior Faculty Grant and an
   REU grant through SU for MFB.
CR Alaverdashvili M, 2013, NEUROSCI BIOBEHAV R, V37, P950, DOI 10.1016/j.neubiorev.2013.03.026
   [Anonymous], 2012, MATLAB
   [Anonymous], 2012, MAYA
   Baier DB, 2013, J ANAT, V223, P462, DOI 10.1111/joa.12102
   Baier DB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063982
   Biewener AA, 2005, J EXP BIOL, V208, P1665, DOI 10.1242/jeb.01520
   BIEWENER AA, 1989, BIOSCIENCE, V39, P776, DOI 10.2307/1311183
   Bonnan MF, 2003, J VERTEBR PALEONTOL, V23, P595, DOI 10.1671/A1108
   Brainerd EL, 2010, J EXP ZOOL PART A, V313A, P262, DOI 10.1002/jez.589
   Chen M, 2013, J MAMM EVOL, V20, P159, DOI 10.1007/s10914-012-9199-9
   Cignoni P., 2012, ITALY VISUAL COMPUTI
   Diogo R, 2010, MUSCLES OF VERTEBRAT
   Dyce KM, 2010, TEXTBOOK OF VETERINA
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Fischer MS, 2010, ZOOLOGY, V113, P67, DOI 10.1016/j.zool.2009.07.001
   Fischer MS, 2006, J EXP ZOOL PART A, V305A, P935, DOI 10.1002/jez.a.333
   Fischer MS, 2002, J EXP BIOL, V205, P1315
   Garnier C, 2008, BEHAV BRAIN RES, V186, P57, DOI 10.1016/j.bbr.2007.07.023
   Gatesy SM, 2010, J VERTEBR PALEONTOL, V30, p94A
   Gatesy SM, 2010, J EXP ZOOL PART A, V313A, P244, DOI 10.1002/jez.588
   Gough-Palmer AL, 2008, RADIOGRAPHICS, V28, P501, DOI 10.1148/rg.282075061
   Hildebrand M, 2001, ANALYSIS OF VERTEBRA
   Horner AM, 2011, THESIS
   Hsieh ST, 2003, J EXP BIOL, V206, P4363, DOI 10.1242/jeb.00679
   Hu YM, 1997, NATURE, V390, P137
   Hu YM, 2005, NATURE, V433, P149, DOI 10.1038/nature03102
   IBM Corp, 2010, IBM SPSS STATISTICS
   Irschick DJ, 1999, J EXP BIOL, V202, P1047
   Jenkins F., 1971, J ZOOL
   JENKINS FA, 1973, AM J ANAT, V137, P281, DOI 10.1002/aja.1001370304
   JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022
   JENKINS FA, 1984, J MORPHOL, V182, P197, DOI 10.1002/jmor.1051820207
   JENKINS FA, 1970, EVOLUTION, V24, P230, DOI 10.1111/j.1558-5646.1970.tb01756.x
   JENKINS FA, 1983, SCIENCE, V220, P712, DOI 10.1126/science.220.4598.712
   JENKINS FA, 1974, J MORPHOL, V144, P71, DOI 10.1002/jmor.1051440105
   Ji Q, 2006, SCIENCE, V311, P1123, DOI 10.1126/science.1123026
   Ji Q, 2002, NATURE, V416, P816, DOI 10.1038/416816a
   Kambic RE, 2014, J EXP BIOL, V217, P2770, DOI 10.1242/jeb.101428
   Kardong KV, 2012, VERTEBRATES COMPARAT
   Kielan-Jaworowska Z., 2013, PURSUIT OF EARLY MAM
   Kielan-Jaworowska Z, 2006, ACTA PALAEONTOL POL, V51, P393
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klein A, 2012, NEUROSCI BIOBEHAV R, V36, P1030, DOI 10.1016/j.neubiorev.2011.12.010
   LANDSMEER JMF, 1981, J MORPHOL, V168, P289, DOI 10.1002/jmor.1051680305
   LANDSMEER JMF, 1983, J MORPHOL, V175, P119, DOI 10.1002/jmor.1051750202
   Luo ZX, 2011, NATURE, V476, P442, DOI 10.1038/nature10291
   Luo ZX, 2005, SCIENCE, V308, P103, DOI 10.1126/science.1108875
   Luo ZX, 2003, SCIENCE, V302, P1934, DOI 10.1126/science.1090718
   Mobius J, 2010, P CURVES SURF, V2010, P1
   Moore KL, 1999, CLINICALLY ORIENTED
   Qiang J, 1999, NATURE, V398, P326, DOI [10.1038/18665, DOI 10.1038/18665]
   Reilly SM, 2006, P R SOC B, V273, P1563, DOI 10.1098/rspb.2006.3489
   Russell AP, 2001, COMP BIOCHEM PHYS A, V131, P89, DOI 10.1016/S1095-6433(01)00469-X
   Schmidt A, 2010, J EXP BIOL, V213, P3615, DOI 10.1242/jeb.045278
   Silverman J, 2014, THE IACUC HANDBOOK
   VanBuren CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074842
   Whishaw IQ, 2010, BEHAV BRAIN RES, V206, P21, DOI 10.1016/j.bbr.2009.08.030
   WHISHAW IQ, 1990, BEHAV BRAIN RES, V41, P49, DOI 10.1016/0166-4328(90)90053-H
   Whishaw IQ, 1996, BEHAV BRAIN RES, V77, P135, DOI 10.1016/0166-4328(95)00209-X
   Whishaw IQ, 1996, BEHAV BRAIN RES, V78, P101, DOI 10.1016/0166-4328(95)00236-7
   Witte Hartmut, 2002, Zeitschrift fuer Morphologie und Anthropologie, V83, P221
   Yuan CX, 2013, SCIENCE, V341, P779, DOI 10.1126/science.1237970
   Zhou CF, 2013, NATURE, V500, P163, DOI 10.1038/nature12429
NR 63
TC 9
Z9 9
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 2
PY 2016
VL 11
IS 3
AR e0149377
DI 10.1371/journal.pone.0149377
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG0AN
UT WOS:000371724200028
PM 26933950
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Joubert, M
   Bellevre, D
   Legallois, D
   Elie, N
   Coulbault, L
   Allouche, S
   Manrique, A
AF Joubert, Michael
   Bellevre, Dimitri
   Legallois, Damien
   Elie, Nicolas
   Coulbault, Laurent
   Allouche, Stephane
   Manrique, Alain
TI Hyperglycemia-Induced Hypovolemia Is Involved in Early Cardiac Magnetic
   Resonance Alterations in Streptozotocin-Induced Diabetic Mice: A
   Comparison with Furosemide-Induced Hypovolemia
SO PLOS ONE
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; IN-VIVO; HEART-FAILURE; CARDIOMYOPATHY;
   DYSFUNCTION; INSULIN; RAT; OVEREXPRESSION; MELLITUS; TYPE-1
AB Aims
   The aim of the study was to assess the early features of diabetic cardiomyopathy using cardiac magnetic resonance within the first week after streptozotocin injection in mice. We focused on the relationship between left ventricular function and hypovolemia markers in diabetic animals compared to a hypovolemic rodent model.
   Methods and Results
   Swiss mice were randomized into control (group C), streptozotocin(induced diabetes (group D) and furosemide(induced hypovolemia (group F) groups. Cardiac magnetic resonance, non(invasive blood pressure, urine volume, plasma markers of dehydration and cardiac histology were assessed in all groups. Mean blood glucose was higher in diabetic animals than in groups C and F (30.5 +/- 5.8 compared to 10.4 +/- 2.1 and 11.1 +/- 2.8 mmol/L, respectively; p < 0.01). Diuresis was increased in animals from group D and F compared to C (14650 +/- 11499 and 1533 +/- 540 compared to 192 +/- 111 mu L/24 h; p < 0.05). End diastolic and end systolic volumes were lower in group D than in group C at week 1 (1.52 +/- 0.36 vs. 1.93 +/- 0.35 and 0.54 +/- 0.22 vs. 0.75 +/- 0.18 mL/kg, p < 0.05). These left ventricular volume values in group D were comparable to those observed in the acute hypovolemia model (group F). Increased dehydration plasma markers and an absence of obvious intrinsic myocardial damage (evaluated by cardiac magnetic resonance and histology) suggest that a hemodynamic mechanism underlies the very early drop in left ventricular volumes in group D and provides a potential link to hyperglycemic osmotic diuresis.
   Conclusions Researchers using cardiac magnetic resonance in hyperglycemic rodent models should be aware of this hemodynamic mechanism, which may partially explain modifications in cardiac parameters in addition to diabetic myocardial damage.
C1 [Joubert, Michael] Caen Univ Hosp, Diabet Care Unit, Caen, France.
   [Bellevre, Dimitri; Manrique, Alain] Caen Univ Hosp, Dept Nucl Med, Caen, France.
   [Legallois, Damien] Caen Univ Hosp, Cardiol Unit, Caen, France.
   [Elie, Nicolas] Univ Caen Normandie, IBFA, CMABIO HIQ Facil, ICORE SF4206, Caen, France.
   [Coulbault, Laurent; Allouche, Stephane] Caen Univ Hosp, Biochem Unit, Caen, France.
   [Joubert, Michael; Bellevre, Dimitri; Legallois, Damien; Coulbault, Laurent; Allouche, Stephane; Manrique, Alain] Univ Caen Normandie, EA4650, GIP Cyceron, Caen, France.
RP Joubert, M (reprint author), Caen Univ Hosp, Diabet Care Unit, Caen, France.; Joubert, M (reprint author), Univ Caen Normandie, EA4650, GIP Cyceron, Caen, France.
EM joubert-m@chu-caen.fr
OI Allouche, stephane/0000-0003-3134-7501
FU AIR Association; ANABIM Association
FX MJ received a research grant form AIR Association. DB received a
   research grant from ANABIM Association. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The other authors received no specific
   funding for this work.
CR Aneja A, 2008, AM J MED, V121, P748, DOI 10.1016/j.amjmed.2008.03.046
   Aronson D, 1997, ANN INTERN MED, V126, P296, DOI 10.7326/0003-4819-126-4-199702150-00006
   Becher PM, 2013, INT J MOL MED, V32, P158, DOI 10.3892/ijmm.2013.1368
   Bonito P, 2005, DIABETIC MED, V22, P1720, DOI 10.1111/j.1464-5491.2005.01685.x
   Boudina S, 2010, REV ENDOCR METAB DIS, V11, P31, DOI 10.1007/s11154-010-9131-7
   Brands MW, 2012, AM J PHYSIOL-REG I, V303, pR1101, DOI 10.1152/ajpregu.00390.2012
   Bugger H, 2009, DIS MODEL MECH, V2, P454, DOI 10.1242/dmm.001941
   Bun SS, 2012, INVEST RADIOL, V47, P319, DOI 10.1097/RLI.0b013e318243e062
   Bupha-Intr T, 2011, AM J PHYSIOL-HEART C, V300, pH1661, DOI 10.1152/ajpheart.00411.2010
   Carrabba N, 2004, CIRCULATION, V110, P1974, DOI 10.1161/01.CIR.0000143376.64970.4A
   de Jong S, 2011, J MOL CELL CARDIOL, V51, P974, DOI 10.1016/j.yjmcc.2011.08.024
   Frustaci A, 2000, CIRC RES, V87, P1123, DOI 10.1161/01.RES.87.12.1123
   Gaede P, 2004, DIABETES, V53, pS39, DOI 10.2337/diabetes.53.suppl_3.S39
   Goode Adam, 2013, J Pathol Inform, V4, P27, DOI 10.4103/2153-3539.119005
   HILSTED J, 1993, CLIN PHYSIOL, V13, P1, DOI 10.1111/j.1475-097X.1993.tb00312.x
   Joffe II, 1999, J AM COLL CARDIOL, V34, P2111, DOI 10.1016/S0735-1097(99)00436-2
   Kajstura J, 2001, DIABETES, V50, P1414, DOI 10.2337/diabetes.50.6.1414
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kruger M, 2010, J MOL CELL CARDIOL, V48, P910, DOI 10.1016/j.yjmcc.2010.02.012
   Labombarda F, 2014, DIABETES METAB, V40, P292, DOI 10.1016/j.diabet.2014.03.007
   Loganathan R, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-7
   Luik PT, 2003, EUR J CLIN INVEST, V33, P787, DOI 10.1046/j.1365-2362.2003.01215.x
   Maliha G, 2015, J AM SOC HYPERTENS, V9, P48, DOI 10.1016/j.jash.2014.11.001
   Malone MA, 2007, METABOLISM, V56, P1118, DOI 10.1016/j.metabol.2007.04.005
   Miki T, 2013, HEART FAIL REV, V18, P149, DOI 10.1007/s10741-012-9313-3
   Muniyappa R, 2007, ENDOCR REV, V28, P463, DOI 10.1210/er.2007-0006
   Nielsen LB, 2002, J BIOL CHEM, V277, P27014, DOI 10.1074/jbc.M203458200
   Oh Se Won, 2015, Electrolyte Blood Press, V13, P17, DOI 10.5049/EBP.2015.13.1.17
   Palm F, 2004, DIABETES-METAB RES, V20, P452, DOI 10.1002/dmrr.472
   Radovits T, 2009, AM J PHYSIOL-HEART C, V297, pH125, DOI 10.1152/ajpheart.00165.2009
   Rijzewijk LJ, 2008, J AM COLL CARDIOL, V52, P1793, DOI 10.1016/j.jacc.2008.07.062
   Rijzewijk LJ, 2009, J AM COLL CARDIOL, V54, P1524, DOI 10.1016/j.jacc.2009.04.074
   Setser RM, 2000, J MAGN RESON IMAGING, V12, P430, DOI 10.1002/1522-2586(200009)12:3<430::AID-JMRI8>3.0.CO;2-V
   Shah AM, 2010, EUR J HEART FAIL, V12, P1229, DOI 10.1093/eurjhf/hfq179
   Taylor AC, 2008, AM J PHYSIOL-REG I, V294, pR1285, DOI 10.1152/ajpregu.00003.2008
   Tocci G, 2008, J HYPERTENS, V26, P1477, DOI 10.1097/HJH.0b013e3282fe1d3d
   Trost SU, 2002, DIABETES, V51, P1166, DOI 10.2337/diabetes.51.4.1166
   Vallee JP, 2004, MAGN RESON MATER PHY, V17, P149, DOI 10.1007/s10334-004-0066-4
   Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029
   Yu XC, 2007, CARDIOVASC DIABETOL, V6, DOI 10.1186/1475-2840-6-6
   Zinman B, 2015, N ENGL J MED
NR 41
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2016
VL 11
IS 2
AR e0149808
DI 10.1371/journal.pone.0149808
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF3VL
UT WOS:000371276100155
PM 26901278
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhu, SS
   Zhang, CY
   Wang, J
   Wei, L
   Quan, R
   Yang, JY
   Yan, X
   Li, ZX
   She, RP
   Hu, FJ
   Liu, J
AF Zhu, Shanshan
   Zhang, Chunyan
   Wang, Jing
   Wei, Li
   Quan, Rong
   Yang, Jiayu
   Yan, Xu
   Li, Zixuan
   She, Ruiping
   Hu, Fengjiao
   Liu, Jue
TI Immunity Elicited by an Experimental Vaccine Based on Recombinant
   Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein in Piglets
SO PLOS ONE
LA English
DT Article
ID MULTISYSTEMIC WASTING SYNDROME; COLOSTRUM-DEPRIVED PIGLETS; CELLULAR
   MECHANISMS; PROTECTIVE IMMUNITY; SYNDROME PMWS; IFN-GAMMA; PCV2; PIGS;
   MICE; VIRUS
AB In a recent study, we reported that a recombinant protein from fusion expression of flagellin to porcine circovirus type 2 (PCV2) Cap induced robust humoral and cell-mediated immunity that afforded full protection for PCV2 infection using BALB/c mice. Here, we further evaluated the immunogenicity and protection of the recombinant protein using specific pathogen free (SPF) pigs. Twenty-five 3-week-old piglets without passively acquired immunity were divided into 5 groups. All piglets except negative controls were challenged with a virulent PCV2 at 21 days after booster vaccination and necropsied at 21 days post-challenge. Vaccination of piglets with the recombinant protein without adjuvant induced strong humoral and cellular immune responses as observed by high levels of PCV2-specific IgG antibodies and neutralizing antibodies, as well as frequencies of PCV2-specific IFN-gamma-secreting cells that conferred good protection against PCV2 challenge, with significant reduced PCV2 viremia, mild lesions, low PCV2 antigen-positive cells, as well as improved body weight gain, comparable to piglets vaccinated with a commercial PCV2 subunit vaccine. These results further demonstrated that the recombinant flagellin-Cap fusion protein is capable of inducing solid protective humoral and cellular immunity when administered to pigs, thereby becoming an effective PCV2 vaccine candidate for control of PCV2 infection.
C1 [Zhu, Shanshan; Zhang, Chunyan; Wang, Jing; Wei, Li; Quan, Rong; Yang, Jiayu; Yan, Xu; Li, Zixuan; Liu, Jue] Beijing Acad Agr & Forestry Sci, Beijing Key Lab Prevent & Control Infect Dis Live, Inst Anim Husb & Vet Med, 9 Shuguang Garden Middle Rd, Beijing 100097, Peoples R China.
   [She, Ruiping; Hu, Fengjiao] China Agr Univ, Coll Vet Med, 2 Yuanmingyuan West Rd, Beijing 100197, Peoples R China.
RP Liu, J (reprint author), Beijing Acad Agr & Forestry Sci, Beijing Key Lab Prevent & Control Infect Dis Live, Inst Anim Husb & Vet Med, 9 Shuguang Garden Middle Rd, Beijing 100097, Peoples R China.
EM liujue@263.net
FU National Science Fund for Distinguished Young Scholars [31025028];
   Beijing Municipal Science and Technology Contract Project, People's
   Republic of China [Z07010501780701]
FX This work was supported by grants from the National Science Fund for
   Distinguished Young Scholars (31025028) and the Beijing Municipal
   Science and Technology Contract Project (Z07010501780701), People's
   Republic of China. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Allan G, 1998, VET REC, V142, P467
   Bates JT, 2011, J IMMUNOL, V186, P6255, DOI 10.4049/jimmunol.1001855
   Ben-Yedidia T, 1998, IMMUNOL LETT, V64, P9, DOI 10.1016/S0165-2478(98)00073-X
   Blanchard P, 2003, VACCINE, V21, P4565, DOI 10.1016/S0264-410X(03)00503-6
   Bucarey SA, 2009, VACCINE, V27, P5781, DOI 10.1016/j.vaccine.2009.07.061
   Calsamiglia M, 2002, J CLIN MICROBIOL, V40, P1848, DOI 10.1128/JCM.40.5.1848-1850.2002
   Carasova P, 2007, RES VET SCI, V83, P274, DOI 10.1016/j.rvsc.2006.11.013
   Cheung AK, 2003, VIROLOGY, V305, P168, DOI 10.1006/viro.2002.1733
   Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004
   Darwich L, 2003, J GEN VIROL, V84, P3453, DOI 10.1099/vir.0.19364-0
   Delaney KN, 2010, VIRAL IMMUNOL, V23, P201, DOI 10.1089/vim.2009.0107
   Fan HY, 2008, J VIROL METHODS, V150, P21, DOI 10.1016/j.jviromet.2008.02.011
   Fenaux M, 2004, J VIROL, V78, P6297, DOI 10.1128/JVI.78.12.6297-6303.2004
   Fort M, 2008, VACCINE, V26, P1063, DOI 10.1016/j.vaccine.2007.12.019
   Fort M, 2009, VACCINE, V27, P4031, DOI 10.1016/j.vaccine.2009.04.028
   Fort M, 2007, VET MICROBIOL, V125, P244, DOI 10.1016/j.vetmic.2007.06.004
   Fort M, 2009, VET IMMUNOL IMMUNOP, V129, P101, DOI 10.1016/j.vetimm.2008.12.024
   Gilpin DF, 2003, VET IMMUNOL IMMUNOP, V94, P149, DOI 10.1016/S0165-2427(03)00087-4
   Kamstrup S, 2004, VACCINE, V22, P1358, DOI 10.1016/j.vaccine.2004.01.032
   Kekarainen T, 2008, J GEN VIROL, V89, P760, DOI 10.1099/vir.0.83354-0
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim T, 2009, VET MICROBIOL, V138, P318, DOI 10.1016/j.vetmic.2009.04.014
   Kixmoller M, 2008, VACCINE, V26, P3443, DOI 10.1016/j.vaccine.2008.04.032
   Larochelle R, 2003, CAN J VET RES, V67, P114
   Letran SE, 2011, EUR J IMMUNOL, V41, P29, DOI 10.1002/eji.201040717
   Liu G, 2012, VACCINE, V30, P6833, DOI 10.1016/j.vaccine.2012.09.013
   Liu GM, 2011, VACCINE, V29, P8677, DOI 10.1016/j.vaccine.2011.08.118
   Liu J, 2005, J VIROL, V79, P8262, DOI 10.1128/JVI.79.13.8262-8274.2005
   Martelli P, 2011, VET MICROBIOL, V149, P339, DOI 10.1016/j.vetmic.2010.12.008
   McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000
   McDonald WF, 2007, J INFECT DIS, V195, P1607, DOI 10.1086/517613
   McIntosh KA, 2006, CAN J VET RES, V70, P58
   McSorley SJ, 2002, J IMMUNOL, V169, P3914, DOI 10.4049/jimmunol.169.7.3914
   Meerts P, 2005, VIRAL IMMUNOL, V18, P333, DOI 10.1089/vim.2005.18.333
   Meerts P, 2006, BMC VET RES, V30, P2
   Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156
   Mizel SB, 2009, CLIN VACCINE IMMUNOL, V16, P21, DOI 10.1128/CVI.00333-08
   Nawagitgul P, 2000, J GEN VIROL, V81, P2281, DOI 10.1099/0022-1317-81-9-2281
   Okuda Y, 2003, J VET DIAGN INVEST, V15, P107, DOI 10.1177/104063870301500204
   Opriessnig T, 2009, VACCINE, V27, P1002, DOI 10.1016/j.vaccine.2008.11.105
   Opriessnig T., 2007, J VET DIAGN INVEST, V19, P571
   Opriessnig T, 2008, CLIN VACCINE IMMUNOL, V15, P103
   Perez-Martin E, 2010, VACCINE, V28, P2340, DOI 10.1016/j.vaccine.2009.12.061
   Pino O, 2005, INFECT IMMUN, V73, P6763, DOI 10.1128/IAI.73.10.6763-6770.2005
   Rodriguez-Arrioja GM, 2000, VET REC, V146, P762, DOI 10.1136/vr.146.26.762
   Rosell C, 1999, J COMP PATHOL, V120, P59, DOI 10.1053/jcpa.1998.0258
   Segales Joaquim, 2005, Animal Health Research Reviews, V6, P119, DOI 10.1079/AHR2005106
   Shen HG, 2008, J GEN VIROL, V89, P1857, DOI 10.1099/vir.0.2008/000125-0
   Sibila M, 2004, AM J VET RES, V65, P88, DOI 10.2460/ajvr.2004.65.88
   Sorden SD, 1999, J VET DIAGN INVEST, V11, P528, DOI 10.1177/104063879901100607
   Stenvenson LS, 2006, VIRAL IMMUNOL, V19, P189
   Wang K, 2008, J VIROL METHODS, V150, P1, DOI 10.1016/j.jviromet.2008.02.014
   Wang YP, 2013, VACCINE, V31, P833, DOI 10.1016/j.vaccine.2012.11.062
   Zhang CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129617
NR 54
TC 9
Z9 10
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2016
VL 11
IS 2
AR e0147432
DI 10.1371/journal.pone.0147432
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9PR
UT WOS:000369554000017
PM 26848967
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Farino, ZJ
   Morgenstern, TJ
   Vallaghe, J
   Gregor, N
   Donthamsetti, P
   Harris, PE
   Pierre, N
   Freyberg, R
   Charrier-Savournin, F
   Javitch, JA
   Freyberg, Z
AF Farino, Zachary J.
   Morgenstern, Travis J.
   Vallaghe, Julie
   Gregor, Nathalie
   Donthamsetti, Prashant
   Harris, Paul E.
   Pierre, Nicolas
   Freyberg, Robin
   Charrier-Savournin, Fabienne
   Javitch, Jonathan A.
   Freyberg, Zachary
TI Development of a Rapid Insulin Assay by Homogenous Time-Resolved
   Fluorescence
SO PLOS ONE
LA English
DT Article
ID PANCREATIC BETA-CELLS; DOPAMINE-RECEPTORS; GLUCOSE-TOLERANCE; OBESE
   SUBJECTS; ISLET SIZE; BROMOCRIPTINE; SECRETION; RATS; IMMUNOASSAY;
   ACTIVATION
AB Direct measurement of insulin is critical for basic and clinical studies of insulin secretion. However, current methods are expensive and time-consuming. We developed an insulin assay based on homogenous time-resolved fluorescence that is significantly more rapid and cost-effective than current commonly used approaches. This assay was applied effectively to an insulin secreting cell line, INS-1E cells, as well as pancreatic islets, allowing us to validate the assay by elucidating mechanisms by which dopamine regulates insulin release. We found that dopamine functioned as a significant negative modulator of glucose-stimulated insulin secretion. Further, we showed that bromocriptine, a known dopamine D2/D3 receptor agonist and newly approved drug used for treatment of type II diabetes mellitus, also decreased glucose-stimulated insulin secretion in islets to levels comparable to those caused by dopamine treatment.
C1 [Farino, Zachary J.; Morgenstern, Travis J.; Donthamsetti, Prashant; Javitch, Jonathan A.; Freyberg, Zachary] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
   [Farino, Zachary J.; Morgenstern, Travis J.; Donthamsetti, Prashant; Javitch, Jonathan A.; Freyberg, Zachary] New York State Psychiat Inst & Hosp, Div Mol Therapeut, New York, NY 10032 USA.
   [Vallaghe, Julie; Gregor, Nathalie; Pierre, Nicolas; Charrier-Savournin, Fabienne] Cisbio Bioassays, Res Dept, Codolet, France.
   [Donthamsetti, Prashant; Javitch, Jonathan A.] Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY USA.
   [Harris, Paul E.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Endocrinol, New York, NY USA.
   [Freyberg, Robin] Yeshiva Univ, Stern Coll Women, Dept Psychol, New York, NY 10033 USA.
RP Freyberg, Z (reprint author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.; Freyberg, Z (reprint author), New York State Psychiat Inst & Hosp, Div Mol Therapeut, New York, NY 10032 USA.
EM zf2101@cumc.columbia.edu
RI Freyberg, Zachary/L-4927-2018
OI Freyberg, Zachary/0000-0001-6460-0118; Javitch,
   Jonathan/0000-0001-7395-2967
FU Louis V. Gerstner Jr., Scholars Program (Columbia University); Cisbio
   Bioassays
FX Louis V. Gerstner Jr., Scholars Program (Columbia University) - Z.F.
   Cisbio Bioassays - J.V., N.G., N.P., F.C.S. The funder Cisbio Bioassays
   provided support in the form of salaries for authors J.V., N.G., N.P.,
   F.C.S.; Columbia University provided salary support for Z.F. Neither
   funder had any additional role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   specific roles of these authors are articulated in the 'author
   contributions' section.
CR ARMBRUSTER DA, 1994, CLIN CHEM, V40, P1233
   Armbruster David A, 2008, Clin Biochem Rev, V29 Suppl 1, pS49
   Ayoub MA, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00094
   Burns SM, 2015, CELL METAB, V21, P126, DOI 10.1016/j.cmet.2014.12.010
   Burns SM V A, 2012, HIGH THROUGHPUT SCRE
   Carter JD, 2009, BIOL PROCED ONLINE, V11, P3, DOI 10.1007/s12575-009-9021-0
   Chen Y, 2014, CELL TISSUE RES, V357, P597, DOI 10.1007/s00441-014-1894-9
   Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959
   CINCOTTA AH, 1993, AM J PHYSIOL, V264, pE285
   Cincotta AH, 1997, LIFE SCI, V61, P951, DOI 10.1016/S0024-3205(97)00599-7
   Cincotta AH, 1996, DIABETES CARE, V19, P667, DOI 10.2337/diacare.19.6.667
   CINCOTTA AH, 1991, METABOLISM, V40, P639, DOI 10.1016/0026-0495(91)90057-4
   Claret EJ, 2004, HIGH THROUGHPUT HTRF
   COLELLA RM, 1985, LIFE SCI, V37, P1059, DOI 10.1016/0024-3205(85)90597-1
   Daijo JE, 1999, J PHARMACEUT BIOMED, V19, P335, DOI 10.1016/S0731-7085(98)00126-5
   Degorce Francois, 2009, Curr Chem Genomics, V3, P22, DOI 10.2174/1875397300903010022
   Doucet J, 2013, DIS MARKERS, DOI 10.1155/2013/290670
   Drummond GB, 2010, EXP PHYSIOL, V95, P841, DOI 10.1113/expphysiol.2010.053785
   Duttaroy A, 2004, DIABETES, V53, P1714, DOI 10.2337/diabetes.53.7.1714
   Duvillie B, 1997, P NATL ACAD SCI USA, V94, P5137, DOI 10.1073/pnas.94.10.5137
   Eglen Richard M, 2008, Curr Chem Genomics, V1, P2, DOI 10.2174/1875397300801010002
   Ezrokhi M, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-104
   Garcia-Tornadu I, 2010, ENDOCRINOLOGY, V151, P1441, DOI 10.1210/en.2009-0996
   Granata R, 2007, ENDOCRINOLOGY, V148, P512, DOI 10.1210/en.2006-0266
   Granata R, 2014, DIABETES, V63, P2380, DOI 10.2337/db13-1522
   Hiram-Bab S, 2012, PANCREAS, V41, P238, DOI 10.1097/MPA.0b013e3182277e56
   Holt RIG, 2010, DIABETES OBES METAB, V12, P1048, DOI 10.1111/j.1463-1326.2010.01304.x
   HOPCROFT DW, 1985, HORM METAB RES, V17, P559, DOI 10.1055/s-2007-1013606
   Imai S, 2014, ANAL BIOCH
   JAHR H, 1978, ACTA BIOL MED GER, V37, P659
   Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482
   Kalra S, 2011, RECENT PATENTS ENDOC, V5, P61, DOI 10.2174/187221411794351842
   Kawasaki E, 2000, FRONT BIOSCI, V5, pE181, DOI 10.2741/kawasaki
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kok P, 2006, AM J PHYSIOL-ENDOC M, V291, pE1038, DOI 10.1152/ajpendo.00567.2005
   KRATZSCH J, 1990, EXP CLIN ENDOCRINOL, V95, P229, DOI 10.1055/s-0029-1210957
   LANCRANJAN I, 1981, J NEURAL TRANSM, V51, P61, DOI 10.1007/BF01664005
   LEAHY JL, 1993, DIABETES, V42, P22, DOI 10.2337/diabetes.42.1.22
   Mahajan R, 2009, INDIAN J PHARMACOL, V41, P197, DOI 10.4103/0253-7613.56070
   Mathis G, 1999, J BIOMOL SCREEN, V4, P309, DOI 10.1177/108705719900400605
   MEIER AH, 1992, EXPERIENTIA, V48, P248, DOI 10.1007/BF01930467
   Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099
   Mikhail N, 2011, CURR DRUG DELIV, V8, P511, DOI 10.2174/156720111796642255
   Pijl H, 2000, DIABETES CARE, V23, P1154, DOI 10.2337/diacare.23.8.1154
   REAVEN EP, 1981, HORM METAB RES, V13, P673, DOI 10.1055/s-2007-1019372
   Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1
   Rubi B, 2005, J BIOL CHEM, V280, P36824, DOI 10.1074/jbc.M505560200
   SEEMAN P, 1993, CURR OPIN NEUROL NEU, V6, P602
   Simpson N, 2012, MOL ENDOCRINOL, V26, P1757, DOI 10.1210/me.2012-1101
   Ustione A, 2012, MOL ENDOCRINOL, V26, P1928, DOI 10.1210/me.2012-1226
   Valiquette G, 2011, CARDIOL REV, V19, P272, DOI 10.1097/CRD.0b013e318229d2d2
   van Weenen JED, 2010, BIOCHEM PHARMACOL, V79, P1827, DOI 10.1016/j.bcp.2010.01.029
   Vuojola J, 2014, METHODS APPL FLUORES, V2, DOI 10.1088/2050-6120/2/1/012001
   YALOW RS, 1960, J CLIN INVEST, V39, P1157, DOI 10.1172/JCI104130
   Yan D, 2015, LIFE SCI
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhang Y, 2015, PANCREAS, V44, P925, DOI 10.1097/MPA.0000000000000357
   Zhang ZY, 2010, FASEB J, V24, P1497, DOI 10.1096/fj.09-136572
NR 58
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2016
VL 11
IS 2
AR e0148684
DI 10.1371/journal.pone.0148684
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9PR
UT WOS:000369554000157
PM 26849707
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Li, ESS
   Cheung, PY
   O'Reilly, M
   LaBossiere, J
   Lee, TF
   Cowan, S
   Bigam, DL
   Schmolzer, GM
AF Li, Elliott Shang-shun
   Cheung, Po-Yin
   O'Reilly, Megan
   LaBossiere, Joseph
   Lee, Tze-Fun
   Cowan, Shaun
   Bigam, David L.
   Schmoelzer, Georg Marcus
TI Exhaled CO2 Parameters as a Tool to Assess Ventilation-Perfusion
   Mismatching during Neonatal Resuscitation in a Swine Model of Neonatal
   Asphyxia
SO PLOS ONE
LA English
DT Article
ID TIDAL CARBON-DIOXIDE; CARDIOPULMONARY-RESUSCITATION; CARDIAC-OUTPUT;
   PORCINE MODEL; DELIVERY ROOM; BLOOD-FLOW; GUIDE; BIRTH; NEWBORN; PIGLETS
AB Background
   End-tidal CO2 (ETCO2), partial pressure of exhaled CO2 (PECO2), and volume of expired CO2 (VCO2) can be continuously monitored non-invasively to reflect pulmonary ventilation and perfusion status. Although ETCO2 >= 14mmHg has been shown to be associated with return of an adequate heart rate in neonatal resuscitation and quantifying the PECO2 has the potential to serve as an indicator of resuscitation quality, there is little information regarding capnometric measurement of PECO2 and ETCO2 in detecting return of spontaneous circulation (ROSC) and survivability in asphyxiated neonates receiving cardiopulmonary resuscitation (CPR).
   Methods
   Seventeen newborn piglets were anesthetized, intubated, instrumented, and exposed to 45-minute normocapnic hypoxia followed by apnea to induce asphyxia. Protocolized resuscitation was initiated when heart rate decreased to 25% of baseline. Respiratory and hemo-dynamic parameters including ETCO2, PECO2, VCO2, heart rate, cardiac output, and carotid artery flow were continuously measured and analyzed.
   Results
   There were no differences in respiratory and hemodynamic parameters between surviving and non-surviving piglets prior to CPR. Surviving piglets had significantly higher ETCO2, PECO2, VCO2, cardiac index, and carotid artery flow values during CPR compared to non-surviving piglets.
   Conclusion
   Surviving piglets had significantly better respiratory and hemodynamic parameters during resuscitation compared to non-surviving piglets. In addition to optimizing resuscitation efforts, capnometry can assist by predicting outcomes of newborns requiring chest compressions.
C1 [Li, Elliott Shang-shun] McGill Univ, Fac Sci, Montreal, PQ, Canada.
   [Li, Elliott Shang-shun; Cheung, Po-Yin; O'Reilly, Megan; Lee, Tze-Fun; Schmoelzer, Georg Marcus] Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
   [Cheung, Po-Yin; O'Reilly, Megan; Cowan, Shaun; Schmoelzer, Georg Marcus] Royal Alexandra Hosp, Neonatal Res Unit, Ctr Studies Asphyxia & Resuscitat, Edmonton, AB, Canada.
   [Cheung, Po-Yin; LaBossiere, Joseph; Bigam, David L.] Univ Alberta, Dept Surg, Edmonton, AB, Canada.
   [Cowan, Shaun] Univ Alberta, Fac Sci, Edmonton, AB, Canada.
RP Schmolzer, GM (reprint author), Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
EM georg.schmoelzer@me.com
RI Schmolzer, Georg M/E-7883-2010; Cheung, Po-Yin/C-2804-2013
OI Schmolzer, Georg M/0000-0001-9798-2415; Cheung,
   Po-Yin/0000-0002-7141-1523
FU Laerdal Foundation for Acute Medicine, Norway; Northern Alberta Clinical
   Trials and Research Centre, Faculty of Medicine and Dentistry,
   University of Alberta; Molly Towell Perinatal Research Foundation,
   Edmonton, Alberta, Canada; Heart and Stroke Foundation/University of
   Alberta Professorship of Neonatal Resuscitation; Heart and Stroke
   Foundation Canada Research Scholarship; Neonatal Research Fund; Northern
   Alberta Neonatal Program; Alberta Health Services
FX The authors would like to thank the Laerdal Foundation for Acute
   Medicine, Norway, (http://www.laerdalfoundation.org) for their support
   of the current study. ESL was supported in part by the Northern Alberta
   Clinical Trials and Research Centre, Faculty of Medicine and Dentistry,
   University of Alberta, and Neonatal Research Fund, Northern Alberta
   Neonatal Program, Alberta Health Services. MOR is supported by a
   Fellowship of Molly Towell Perinatal Research Foundation, Edmonton,
   Alberta, Canada. GMS is a recipient of the Heart and Stroke
   Foundation/University of Alberta Professorship of Neonatal Resuscitation
   and a Heart and Stroke Foundation Canada Research Scholarship. No
   relation with industry exists. Respironics (Philips, Wallingford, CT)
   and Fisher & Paykel (Auckland, New Zealand) provided a respiratory
   function monitor and Neopuff T-pieces for the study, respectively. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BEHRMAN RE, 1970, AM J OBSTET GYNECOL, V108, P956, DOI 10.1016/0002-9378(70)90341-8
   CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002
   Chalak LF, 2011, PEDIATR RES, V69, P401, DOI 10.1203/PDR.0b013e3182125f7f
   COHN HE, 1974, AM J OBSTET GYNECOL, V120, P817, DOI 10.1016/0002-9378(74)90587-0
   Dawson JA, 2010, ARCH DIS CHILD-FETAL, V95, pF177, DOI 10.1136/adc.2009.169102
   Dawson JA, 2010, PEDIATRICS, V125, pE1340, DOI 10.1542/peds.2009-1510
   DOMSKY M, 1995, CRIT CARE MED, V23, P1497, DOI 10.1097/00003246-199509000-00009
   FALK JL, 1988, NEW ENGL J MED, V318, P607, DOI 10.1056/NEJM198803103181005
   GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512
   Gratton R, 1996, J SOC GYNECOL INVEST, V3, P60, DOI 10.1016/1071-5576(95)00047-X
   GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630
   Hansen JE, 2007, CHEST, V132, P977, DOI 10.1378/chest.07-0619
   Hooper SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070895
   Kang LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102729
   KERN KB, 1989, J AM COLL CARDIOL, V13, P1184, DOI 10.1016/0735-1097(89)90282-9
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   LaValle T L, 1995, Dimens Crit Care Nurs, V14, P70, DOI 10.1097/00003465-199503000-00002
   LEFFLER CW, 1986, PROSTAGLANDINS, V31, P183, DOI 10.1016/0090-6980(86)90045-6
   Li ES, 2014, NEONATOLOGY, V105, P200, DOI 10.1159/000357609
   Nicoll J, 2013, RESUSCITATION, V84, P1439, DOI 10.1016/j.resuscitation.2013.05.004
   PALMEKILANDER C, 1993, ARCH DIS CHILD, V68, P11, DOI 10.1136/adc.68.1_Spec_No.11
   Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127
   Rabi Y, 2013, SEMIN FETAL NEONAT M, V18, P330, DOI 10.1016/j.siny.2013.08.007
   Schmolzer GM, 2014, RESUSCITATION, V85, P270, DOI 10.1016/j.resuscitation.2013.10.011
   Schmolzer GM, 2013, CIRCULATION, V128, P2495, DOI 10.1161/CIRCULATIONAHA.113.002289
   STEEDMAN DJ, 1990, ARCH EMERG MED, V7, P129
   TREVINO RP, 1985, CRIT CARE MED, V13, P910, DOI 10.1097/00003246-198511000-00012
   van Os S, 2014, ACTA PAEDIATR, V103, P796, DOI 10.1111/apa.12650
   WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011
   Wyckoff M, 2000, PEDIATRICS, V106, P618, DOI 10.1542/peds.106.3.618
NR 30
TC 6
Z9 6
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2016
VL 11
IS 1
AR e0146524
DI 10.1371/journal.pone.0146524
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB4CC
UT WOS:000368459300023
PM 26766424
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chang, YC
   Lee, WF
   Feng, SW
   Huang, HM
   Lin, CT
   Teng, NC
   Chang, WJ
AF Chang, Yu-Chi
   Lee, Wei-Fang
   Feng, Sheng-Wei
   Huang, Haw-Ming
   Lin, Che-Tong
   Teng, Nai-Chia
   Chang, Wei Jen
TI In Vitro Analysis of Fibronectin-Modified Titanium Surfaces
SO PLOS ONE
LA English
DT Article
ID DISCHARGE PLASMA TREATMENT; GLOW-DISCHARGE; EXTRACELLULAR-MATRIX;
   CELL-ADHESION; IMPLANTS; PRETREATMENT; OSTEOBLASTS; PLATES; HEAT;
   OSSEOINTEGRATION
AB Background
   Glow discharge plasma (GDP) procedure is an effective method for grafting various proteins, including albumin, type I collagen, and fibronectin, onto a titanium surface. However, the behavior and impact of titanium (Ti) surface modification is yet to be unraveled. Purpose The purpose of this study is to evaluate and analyze the biological properties of fibronectingrafted Ti surfaces treated by GDP.
   Materials and Methods
   Grade II Ti discs were initially cleaned and autoclaved to obtain original specimens. Subsequently, the specimens were GDP treated and grafted with fibronectin to form Ar-GDP (Argon GDP treatment only) and GDP-fib (fibronectin coating following GDP treatment) groups. Blood coagulation test and MG-63 cell culture were performed to evaluate the biological effects on the specimen.
   Results
   There was no significant difference between Ar-GDP and GDP-fib groups in blood compatibility analysis. While in the MTT test, cellular proliferation was benefited from the presence of fibronectin coating. The numbers of cells on Ar-GDP and GDP-fib specimens were greater than those in the original specimens after 24 h of culturing.
   Conclusions
   GDP treatment combined with fibronectin grafting favored MG-63 cell adhesion, migration, and proliferation on titanium surfaces, which could be attributed to the improved surface properties.
C1 [Chang, Yu-Chi; Feng, Sheng-Wei; Huang, Haw-Ming; Lin, Che-Tong; Teng, Nai-Chia; Chang, Wei Jen] Taipei Med Univ, Coll Oral Med, Sch Dent, Taipei, Taiwan.
   [Lee, Wei-Fang] Taipei Med Univ, Coll Oral Med, Sch Dent Technol, Taipei, Taiwan.
   [Huang, Haw-Ming] Taipei Med Univ, Coll Oral Med, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan.
   [Lin, Che-Tong; Teng, Nai-Chia] Taipei Med Univ Hosp, Dept Dent, Taipei, Taiwan.
   [Chang, Wei Jen] Taipei Med Univ, Shuang Ho Hosp, Dept Dent, Taipei, Taiwan.
RP Chang, WJ (reprint author), Taipei Med Univ, Coll Oral Med, Sch Dent, Taipei, Taiwan.
EM m8404006@tmu.edu.tw
CR Alves CM, 2007, BIOMATERIALS, V28, P307, DOI 10.1016/j.biomaterials.2006.09.010
   Aronsson BO, 1997, J BIOMED MATER RES, V35, P49
   BRANEMARK PI, 1983, J PROSTHET DENT, V50, P399, DOI 10.1016/S0022-3913(83)80101-2
   Chang WJ, 2008, DENT MATER J, V27, P340, DOI 10.4012/dmj.27.340
   Chang Y.C., 2013, CLIN IMPLANT DENT RE
   Cho JH, 2006, BLOOD, V107, P3555, DOI 10.1182/blood-2005-10-4168
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756-3282(94)90305-0
   Cools P, 2014, PLASMA CHEM PLASMA P, V34, P917, DOI 10.1007/s11090-014-9552-2
   Czarnowska E, 2000, J Mater Sci Mater Med, V11, P73, DOI 10.1023/A:1008980631780
   Durual S, 2011, CLIN ORAL IMPLAN RES, V22, P552, DOI 10.1111/j.1600-0501.2010.02033.x
   Duske K., 2015, PLASMA PROCESSES POL
   Feng B, 2004, BIOMATERIALS, V25, P3421, DOI 10.1016/j.biomaterials.2003.10.044
   Gronowicz G, 1996, J ORTHOPAED RES, V14, P878, DOI 10.1002/jor.1100140606
   Huang HM, 2011, MED BIOL ENG COMPUT, V49, P701, DOI 10.1007/s11517-011-0742-2
   Kawai H, 2004, BIOMATERIALS, V25, P1805, DOI 10.1016/j.biomaterials.2003.08.032
   Kieswetter K, 1996, J BIOMED MATER RES, V32, P55, DOI 10.1002/(SICI)1097-4636(199609)32:1<55::AID-JBM7>3.0.CO;2-O
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KOTTKEMARCHANT K, 1989, BIOMATERIALS, V10, P147, DOI 10.1016/0142-9612(89)90017-3
   Kurachi T, 1997, ARCH ORAL BIOL, V42, P465, DOI 10.1016/S0003-9969(97)00019-8
   Lampin M, 1997, J BIOMED MATER RES, V36, P99, DOI 10.1002/(SICI)1097-4636(199707)36:1<99::AID-JBM12>3.0.CO;2-E
   Lazzara RJ, 1999, INT J PERIODONT REST, V19, P117
   Li GC, 2011, BIOMATERIALS, V32, P4691, DOI 10.1016/j.biomaterials.2011.03.025
   MacDonald DE, 2013, J CELL BIOCHEM, V114, P2363, DOI 10.1002/jcb.24585
   Oshida Y., 1994, Bio-Medical Materials and Engineering, V4, P397
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   da Silva JSP, 2011, INT J ORAL MAX IMPL, V26, P237
   Rapuano BE, 2013, J CELL BIOCHEM, V114, P1917, DOI 10.1002/jcb.24536
   Rapuano BE, 2012, J PERIODONTAL IMPLAN, V42, P95, DOI 10.5051/jpis.2012.42.3.95
   Rapuano BE, 2012, EUR J ORAL SCI, V120, P185, DOI [10.1111/j.1600-0722.2012.954_e.x, 10.1111/j.1600-0722.2012.954.x]
   Schwarz F, 2009, J BIOMED MATER RES B, V88B, P544, DOI 10.1002/jbm.b.31233
   Sharma C P, 1991, J Biomater Appl, V6, P72, DOI 10.1177/088532829100600105
   Shibata Y, 2002, INT J ORAL MAX IMPL, V17, P771
   Singh RG, 2011, INT J ORAL MAX IMPL, V26, P998
   Stadelmann W. K., 1998, AM J SURG, DOI [10.1016/S0002-9610(98)00183-4, DOI 10.1016/J.CLINDERMATOL.2009.05.012, 10.1016/s0002-9610(98)00183-4]
   Wennerberg A, 1998, CLIN ORAL IMPLAN RES, V9, P11, DOI 10.1034/j.1600-0501.1998.090102.x
   Yamamoto H, 2005, J DENT RES, V84, P668, DOI 10.1177/154405910508400717
NR 36
TC 5
Z9 5
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 5
PY 2016
VL 11
IS 1
AR e0146219
DI 10.1371/journal.pone.0146219
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA4VZ
UT WOS:000367801400119
PM 26731536
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sandoval-Hernandez, AG
   Buitrago, L
   Moreno, H
   Cardona-Gomez, GP
   Arboleda, G
AF Sandoval-Hernandez, Adrian G.
   Buitrago, Luna
   Moreno, Herman
   Patricia Cardona-Gomez, Gloria
   Arboleda, Gonzalo
TI Role of Liver X Receptor in AD Pathophysiology
SO PLOS ONE
LA English
DT Article
ID NEURAL STEM-CELLS; PROTEIN-SYNTHESIS-DEPENDENCE; AMYLOID BETA-PEPTIDE;
   ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; MOUSE MODELS; SUBVENTRICULAR ZONE;
   REVERSE DEFICITS; ADULT MICE; WILD-TYPE
AB Alzheimer's disease (AD) is the major cause of dementia worldwide. The pharmacological activation of nuclear receptors (Liver X receptors: LXRs or Retinoid X receptors: RXR) has been shown to induce overexpression of the ATP-Binding Cassette A1 (ABCA1) and Apolipoprotein E (ApoE), changes that are associated with improvement in cognition and reduction of amyloid beta pathology in amyloidogenic AD mouse models (i.e. APP, PS1: 2tg-AD). Here we investigated whether treatment with a specific LXR agonist has a measurable impact on the cognitive impairment in an amyloid and Tau AD mouse model (3xTg-AD: 12-months-old; three months treatment). The data suggests that the LXR agonist GW3965 is associated with increased expression of ApoE and ABCA1 in the hippocampus and cerebral cortex without a detectable reduction of the amyloid load. We also report that most cells overexpressing ApoE (86 +/- 12%) are neurons localized in the granular cell layer of the hippocampus and entorhinal cortex. In the GW3965 treated 3xTg-AD mice we also observed reduction in astrogliosis and increased number of stem and proliferating cells in the subgranular zone of the dentate gyrus. Additionally, we show that GW3965 rescued hippocampus long term synaptic plasticity, which had been disrupted by oligomeric amyloid beta peptides. The effect of GW3965 on synaptic function was protein synthesis dependent. Our findings identify alternative functional/molecular mechanisms by which LXR agonists may exert their potential benefits as a therapeutic strategy against AD.
C1 [Sandoval-Hernandez, Adrian G.; Arboleda, Gonzalo] Univ Nacl Colombia, Inst Genet, Grp Muerte Celular, Bogota, Colombia.
   [Buitrago, Luna; Moreno, Herman] Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Neurol, Brooklyn, NY 11203 USA.
   [Buitrago, Luna; Moreno, Herman] Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Physiol Pharmacol, Brooklyn, NY 11203 USA.
   [Patricia Cardona-Gomez, Gloria] Univ Antioquia, Grp Neurociencias Antioquia, Area Neurobiol Celular & Mol, Medellin, Colombia.
RP Arboleda, G (reprint author), Univ Nacl Colombia, Inst Genet, Grp Muerte Celular, Bogota, Colombia.
EM gharboledab@unal.edu.co
RI Cardona-Gomez, Gloria Patricia/D-8100-2016
OI Cardona-Gomez, Gloria Patricia/0000-0002-3814-4494; Sandoval-Hernandez,
   Adrian Gabriel/0000-0002-0661-6872
FU NIA/NIH [R01 AG029802-01]; Colciencias [110151928994]; NIH [AG027476]
FX We want to thank Dr. Jon Collins (GSK, Stevenage, UK) for providing the
   GW683965A. Dr. Sergio Angulo for his help with the hippocampal slice
   recordings, and Dr. Riccardo Bianchi for discussions-Funded by: R01
   AG029802-01 NIA/NIH.2007-2012 Colciencias 110151928994, and NIH AG027476
   to HM
CR Abraham WC, 2008, NEUROBIOL LEARN MEM, V89, P260, DOI 10.1016/j.nlm.2007.10.001
   Annicotte JS, 2004, ANAT REC PART A, V277A, P312, DOI 10.1002/ar.a.20015
   Arboleda GH, 2001, NEUROSCI LETT, V305, P135, DOI 10.1016/S0304-3940(01)01829-8
   BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x
   Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040
   Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b
   BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103
   Caruso D, 2013, NEUROBIOL AGING, V34, P1080, DOI 10.1016/j.neurobiolaging.2012.10.007
   Cepeda-Prado E, 2012, J NEUROSCI, V32, P6456, DOI 10.1523/JNEUROSCI.0388-12.2012
   Chabrier MA, 2014, NEUROBIOL DIS, V64, P107, DOI 10.1016/j.nbd.2014.01.007
   Chen TJ, 2009, J NEUROSCI RES, V87, P2297, DOI 10.1002/jnr.22057
   Chevallier NL, 2005, AM J PATHOL, V167, P151, DOI 10.1016/S0002-9440(10)62962-8
   Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697
   Crespo-Biel Natalia, 2012, Int J Alzheimers Dis, V2012, P251426, DOI 10.1155/2012/251426
   Do TD, 2014, J PHYS CHEM B, V118, P11220, DOI 10.1021/jp506258g
   Donkin JJ, 2010, J BIOL CHEM, V285, P34144, DOI 10.1074/jbc.M110.108100
   Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840
   Fitz NF, 2013, SCIENCE, V340, DOI 10.1126/science.1235809
   Fonseca R, 2006, NAT NEUROSCI, V9, P478, DOI 10.1038/nn1667
   Frisardi V, 2010, J AM GERIATR SOC, V58, P2429, DOI 10.1111/j.1532-5415.2010.03164.x
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Harris JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045881
   Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x
   Haughey NJ, 2002, NEUROMOL MED, V1, P125, DOI 10.1385/NMM:1:2:125
   Hernandez-Ortega K., 2015, BRAIN PATHOL
   Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221
   Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228
   Huang Z, 2009, MOL CELL NEUROSCI, V42, P11, DOI 10.1016/j.mcn.2009.06.003
   Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007
   Ishikawa T, 2013, J CLIN INVEST, V123, P3488, DOI 10.1172/JCI66533
   Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X
   Jones L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013950
   Kang JH, 2012, ENDOCR REV, V33, P715, DOI 10.1210/er.2011-1049
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600
   LaFerla FM, 2005, TRENDS MOL MED, V11, P170, DOI 10.1016/j.molmed.2005.02.009
   LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E
   Li G, 2009, CELL STEM CELL, V5, P634, DOI 10.1016/j.stem.2009.10.015
   Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2
   Ly P.T., 2011, J VIS EXP
   Ma DKK, 2009, CELL STEM CELL, V5, P343, DOI 10.1016/j.stem.2009.09.001
   Mandler M, 2014, ACTA NEUROPATHOL, V128, P67, DOI 10.1007/s00401-014-1296-9
   Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001
   Mitro N, 2007, NATURE, V445, P219, DOI 10.1038/nature05449
   Moreno H, 2009, P NATL ACAD SCI USA, V106, P5901, DOI 10.1073/pnas.0900944106
   MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0
   Moutinho M, 2015, MOL NEUROBIOL, V51, P1489, DOI 10.1007/s12035-014-8828-0
   Mucke L, 2000, J NEUROSCI, V20, P4050
   Naik SU, 2006, CIRCULATION, V113, P90, DOI 10.1161/CIRCULATIONAHA.105.560177
   Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3
   Otaegui-Arrazola A, 2010, FOOD CHEM TOXICOL, V48, P3289, DOI 10.1016/j.fct.2010.09.023
   Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750
   Palop JJ, 2010, NEUROMOL MED, V12, P48, DOI 10.1007/s12017-009-8097-7
   Panzaa F, 2009, NEUROBIOL AGING, V30, P546, DOI 10.1016/j.neurobiolaging.2007.10.019
   PATERSON JA, 1973, J COMP NEUROL, V149, P83, DOI 10.1002/cne.901490106
   Price AR, 2013, SCIENCE, V340, DOI 10.1126/science.1234089
   Rammes G, 2011, NEUROPHARMACOLOGY, V60, P982, DOI 10.1016/j.neuropharm.2011.01.051
   Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199
   Reitz C, 2013, JAMA-J AM MED ASSOC, V309, P1483, DOI 10.1001/jama.2013.2973
   Roberson ED, 2011, J NEUROSCI, V31, P700, DOI 10.1523/JNEUROSCI.4152-10.2011
   Rodriguez JJ, 2013, NEUROSCI LETT
   Rodriguez JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002935
   Sacchetti P, 2009, CELL STEM CELL, V5, P409, DOI 10.1016/j.stem.2009.08.019
   Sheng M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005777
   Spires-Jones TL, 2014, NEURON, V82, P756, DOI 10.1016/j.neuron.2014.05.004
   Terwel D, 2011, J NEUROSCI, V31, P7049, DOI 10.1523/JNEUROSCI.6546-10.2011
   Theofilopoulos S, 2013, NAT CHEM BIOL, V9, P126, DOI [10.1038/NCHEMBIO.1156, 10.1038/nchembio.1156]
   Um JW, 2013, NEURON, V79, P887, DOI 10.1016/j.neuron.2013.06.036
   Vanmierlo T, 2011, NEUROBIOL AGING, V32, P1262, DOI 10.1016/j.neurobiolaging.2009.07.005
   Wen PH, 2002, NEUROBIOL DIS, V10, P8, DOI 10.1006/nbdi.2002.0490
   Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439
   Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006
   Yang CP, 2011, DEVELOPMENT, V138, P4351, DOI 10.1242/dev.065540
   Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010
   Zelcer N, 2007, P NATL ACAD SCI USA, V104, P10601, DOI 10.1073/pnas.0701096104
NR 78
TC 18
Z9 18
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2015
VL 10
IS 12
AR e0145467
DI 10.1371/journal.pone.0145467
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA0TR
UT WOS:000367510900012
PM 26720273
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Perez-Kohler, B
   Garcia-Moreno, F
   Brune, T
   Pascual, G
   Bellon, JM
AF Perez-Koehler, Barbara
   Garcia-Moreno, Francisca
   Brune, Thierry
   Pascual, Gemma
   Manuel Bellon, Juan
TI Preclinical Bioassay of a Polypropylene Mesh for Hernia Repair
   Pretreated with Antibacterial Solutions of Chlorhexidine and Allicin: An
   In Vivo Study
SO PLOS ONE
LA English
DT Article
ID INFECTIONS; VITRO; ANTIBIOTICS; RELEASE; SUTURE; RISK; CONTAMINATION;
   PREVENTION; MANAGEMENT; BIOFILMS
AB Introduction
   Prosthetic mesh infection constitutes one of the major complications following hernia repair. Antimicrobial, non-antibiotic biomaterials have the potential to reduce bacterial adhesion to the mesh surface and adjacent tissues while avoiding the development of novel antibiotic resistance. This study assesses the efficacy of presoaking reticular polypropylene meshes in chlorhexidine or a chlorhexidine and allicin combination (a natural antibacterial agent) for preventing bacterial infection in a short-time hernia-repair rabbit model.
   Methods
   Partial hernia defects (5 x 2 cm) were created on the lateral right side of the abdominal wall of New Zealand White rabbits (n = 21). The defects were inoculated with 0.5 mL of a 106 CFU/mL Staphylococcus aureus ATCC25923 strain and repaired with a DualMesh Plus antimicrobial mesh or a Surgipro mesh presoaked in either chlorhexidine (0.05%) or allicin-chlorhexidine (900 mu g/mL-0.05%). Fourteen days post-implant, mesh contraction was measured and tissue specimens were harvested to evaluate bacterial adhesion to the implant surface (via sonication, S. aureus immunolabeling), host-tissue incorporation (via staining, scanning electron microscopy) and macrophage response (via RAM-11 immunolabeling).
   Results
   The polypropylene mesh showed improved tissue integration relative to the DualMesh Plus. Both the DualMesh Plus and the chlorhexidine-soaked polypropylene meshes exhibited high bacterial clearance, with the latter material showing lower bacterial yields. The implants from the allicin-chlorhexidine group displayed a neoformed tissue containing differently sized abscesses and living bacteria, as well as a diminished macrophage response. The allicin-chlorhexidine coated implants exhibited the highest contraction.
   Conclusions
   The presoaking of reticular polypropylene materials with a low concentration of chlorhexidine provides the mesh with antibacterial activity without disrupting tissue integration. Due to the similarities found with the antimicrobial DualMesh Plus material, the chlorhexidine concentration tested could be utilized as a prophylactic treatment to resist infection by prosthetic mesh during hernia repair.
C1 [Perez-Koehler, Barbara; Garcia-Moreno, Francisca; Manuel Bellon, Juan] Univ Alcala De Henares, Dept Surg Med & Social Sci, Fac Med & Hlth Sci, Madrid, Spain.
   [Brune, Thierry] Covidien Sofradim Prod, Trevoux, France.
   [Pascual, Gemma] Univ Alcala De Henares, Dept Med & Med Specialties, Fac Med & Hlth Sci, Madrid, Spain.
   [Perez-Koehler, Barbara; Garcia-Moreno, Francisca; Pascual, Gemma; Manuel Bellon, Juan] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
RP Bellon, JM (reprint author), Univ Alcala De Henares, Dept Surg Med & Social Sci, Fac Med & Hlth Sci, Madrid, Spain.
EM juanm.bellon@uah.es
RI Kohler, Barbara Perez/M-1858-2019; PASCUAL, GEMMA/M-6564-2016
OI PASCUAL, GEMMA/0000-0002-1623-4384; garcia-moreno nisa,
   francisca/0000-0002-2194-4647; Perez Kohler, Barbara/0000-0002-5061-1526
FU Covidien - Sofradim Production
FX Covidien - Sofradim Production provided support in the form of a
   financial research grant and salaries for TB, but the funders did not
   have any additional role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. There
   are no patents, products in development or marketed products to declare.
   This does not alter the authors' adherence to all the PLOS ONE policies
   on sharing data and materials.
CR Agarwal A, 2012, BIOMATERIALS, V33, P6783, DOI 10.1016/j.biomaterials.2012.05.068
   An YH, 1997, J MICROBIOL METH, V30, P141, DOI 10.1016/S0167-7012(97)00058-4
   Ankri S, 1999, MICROBES INFECT, V1, P125, DOI 10.1016/S1286-4579(99)80003-3
   Aydinuraz K, 2009, J SURG RES, V157, pE79, DOI 10.1016/j.jss.2009.04.008
   Bellon JM, 2004, BRIT J SURG, V91, P489, DOI 10.1002/bjs.4451
   Bellon JM, 2014, REV HISPANOAM HERNIA, V2, P49, DOI 10.1016/j.rehah.2014.02.002
   Binnebosel M, 2011, SEMIN IMMUNOPATHOL, V33, P235, DOI 10.1007/s00281-010-0237-5
   Burger JWA, 2004, ANN SURG, V240, P578
   Carbonell AM, 2005, SURG ENDOSC, V19, P430, DOI 10.1007/s00464-004-8810-4
   Cobb WS, 2009, AM SURGEON, V75, P762
   Costerton JW, 2005, INT J ARTIF ORGANS, V28, P1062
   Cruz-Villalon G, 2011, J APPL MICROBIOL, V110, P723, DOI 10.1111/j.1365-2672.2010.04929.x
   Cutler RR, 2004, BRIT J BIOMED SCI, V61, P71, DOI 10.1080/09674845.2004.11732646
   Deysine M, 1998, SURG CLIN N AM, V78, P1105, DOI 10.1016/S0039-6109(05)70372-8
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002
   Edmiston CE, 2013, AM J INFECT CONTROL, V41, pS49, DOI 10.1016/j.ajic.2012.10.030
   Engelsman AF, 2007, BIOMATERIALS, V28, P2314, DOI 10.1016/j.biomaterials.2007.01.028
   Falagas ME, 2005, CLIN MICROBIOL INFEC, V11, P3, DOI 10.1111/j.1469-0691.2004.01014.x
   Fernandez-Gutierrez M, 2013, ACTA BIOMATER, V9, P6006, DOI 10.1016/j.actbio.2012.12.012
   Garcia-Pumarino R, 2014, J BIOMED MATER RES B, V102, P366, DOI 10.1002/jbm.b.33015
   Giannelli M, 2008, TOXICOL IN VITRO, V22, P308, DOI 10.1016/j.tiv.2007.09.012
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   GRISTINA AG, 1989, MED PROG TECHNOL, V14, P205
   Guillaume O, 2015, ADV HEALTHC MATER, V4, P1763, DOI 10.1002/adhm.201500201
   Guillaume O, 2012, J CONTROL RELEASE, V162, P492, DOI 10.1016/j.jconrel.2012.08.003
   Haase H, 2012, FOOD CHEM, V134, P141, DOI 10.1016/j.foodchem.2012.02.080
   Harrell A G, 2006, Hernia, V10, P120, DOI 10.1007/s10029-005-0056-0
   Harth KC, 2010, J SURG RES, V163, P337, DOI 10.1016/j.jss.2010.03.065
   Hodge G, 2002, CYTOMETRY, V48, P209, DOI 10.1002/cyto.10133
   Sanchez-Manuel FJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003769.pub4
   Katsikogianni M, 2004, Eur Cell Mater, V8, P37
   Keiss HP, 2003, J NUTR, V133, P2171
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kockerling F, 2015, SURG ENDOSC
   Lindsay D, 2006, J HOSP INFECT, V64, P313, DOI 10.1016/j.jhin.2006.06.028
   Luijendijk RW, 2000, NEW ENGL J MED, V343, P392, DOI 10.1056/NEJM200008103430603
   Mann TJ, 2001, ANAESTH INTENS CARE, V29, P600, DOI 10.1177/0310057X0102900606
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Perez-Kohler B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126711
   Sanabria A, 2007, ANN SURG, V245, P392, DOI 10.1097/01.sla.0000250412.08210.8e
   Sanders D, 2013, HERNIA, V17, P779, DOI 10.1007/s10029-013-1124-5
   Sanders DL, 2013, SURG ENDOSC, V27, P978, DOI 10.1007/s00464-012-2545-4
   Sistla SC, 2010, CHEMOTHERAPY, V56, P261, DOI 10.1159/000319901
   Stoikes Nathaniel, 2013, Surg Technol Int, V23, P107
   Tambe SM, 2001, J ANTIMICROB CHEMOTH, V47, P589, DOI 10.1093/jac/47.5.589
   von Eiff C, 2005, DRUGS, V65, P179, DOI 10.2165/00003495-200565020-00003
   Wiegering A, 2014, HERNIA, V18, P691, DOI 10.1007/s10029-014-1293-x
   Yurko Y, 2012, SURG INNOV, V19, P20, DOI 10.1177/1553350611410716
   Zhai HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102760
NR 49
TC 12
Z9 13
U1 3
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 10
PY 2015
VL 10
IS 11
AR e0142768
DI 10.1371/journal.pone.0142768
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV7CT
UT WOS:000364430700173
PM 26556805
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ward, SJ
   Melfi, V
AF Ward, Samantha J.
   Melfi, Vicky
TI Keeper-Animal Interactions: Differences between the Behaviour of Zoo
   Animals Affect Stockmanship
SO PLOS ONE
LA English
DT Article
ID DAIRY-COWS; WELFARE; HUMANS; PIGS
AB Stockmanship is a term used to describe the management of animals with a good stockperson someone who does this in a in a safe, effective, and low-stress manner for both the stock-keeper and animals involved. Although impacts of unfamiliar zoo visitors on animal behaviour have been extensively studied, the impact of stockmanship i.e familiar zoo keepers is a new area of research; which could reveal significant ramifications for zoo animal behaviour and welfare. It is likely that different relationships are formed dependant on the unique keeper-animal dyad (human-animal interaction, HAI). The aims of this study were to (1) investigate if unique keeper-animal dyads were formed in zoos, (2) determine whether keepers differed in their interactions towards animals regarding their attitude, animal knowledge and experience and (3) explore what factors affect keeper-animal dyads and ultimately influence animal behaviour and welfare. Eight black rhinoceros (Diceros bicornis), eleven Chapman's zebra (Equus burchellii), and twelve Sulawesi crested black macaques (Macaca nigra) were studied in 6 zoos across the UK and USA. Subtle cues and commands directed by keepers towards animals were identified. The animals latency to respond and the respective behavioural response (cue-response) was recorded per keeper-animal dyad (n = 93). A questionnaire was constructed following a five-point Likert Scale design to record keeper demographic information and assess the job satisfaction of keepers, their attitude towards the animals and their perceived relationship with them. There was a significant difference in the animals' latency to appropriately respond after cues and commands from different keepers, indicating unique keeper-animal dyads were formed. Stockmanship style was also different between keepers; two main components contributed equally towards this: "attitude towards the animals" and "knowledge and experience of the animals". In this novel study, data demonstrated unique dyads were formed between keepers and zoo animals, which influenced animal behaviour.
C1 [Ward, Samantha J.; Melfi, Vicky] Paignton Zoo Environm Pk, Paignton, Devon, England.
RP Ward, SJ (reprint author), Nottingham Trent Univ, Sch Anim Rural & Environm Sci, Nottingham, England.
EM samantha.ward@ntu.ac.uk
OI Melfi, Vicky/0000-0003-4486-0291; Ward, Samantha/0000-0002-5857-1071
CR ADAIR JG, 1984, J APPL PSYCHOL, V69, P334, DOI 10.1037/0021-9010.69.2.334
   Baker K, 2004, ANIM WELFARE, V13, P239
   Boivin X, 2003, ANIM WELFARE, V12, P479
   Carlstead K, 2009, ZOO BIOL, V28, P589, DOI 10.1002/zoo.20289
   Davey G, 2007, J APPL ANIM WELF SCI, V10, P169, DOI 10.1080/10888700701313595
   Eagly AH, 2007, SOC COGNITION, V25, P582, DOI 10.1521/soco.2007.25.5.582
   Ellingsen K, 2014, APPL ANIM BEHAV SCI, V153, P10, DOI 10.1016/j.applanim.2014.01.011
   Field A., 2013, DISCOVERING STAT USI
   GONYOU HW, 1986, APPL ANIM BEHAV SCI, V16, P269, DOI 10.1016/0168-1591(86)90119-X
   GROSS WB, 1980, AVIAN DIS, V24, P549
   Hemsworth PH, 2009, ANIM WELFARE, V18, P335
   Hemsworth P. H., 2010, HUMAN LIVESTOCK INTE
   Hemsworth P.H., 1998, HUMAN LIVESTOCK INTE
   Hemsworth PH, 1996, APPL ANIM BEHAV SCI, V50, P71, DOI 10.1016/0168-1591(96)01065-9
   Hemsworth PH, 2003, APPL ANIM BEHAV SCI, V81, P185, DOI 10.1016/S0168-1591(02)00280-0
   HEMSWORTH PH, 1989, APPL ANIM BEHAV SCI, V23, P301, DOI 10.1016/0168-1591(89)90099-3
   Hemsworth PH, 2000, J ANIM SCI, V78, P2821
   Hosey G, 2008, APPL ANIM BEHAV SCI, V109, P105, DOI 10.1016/j.applanim.2007.04.013
   Hosey G, 2013, J APPL ANIM WELF SCI, V16, P338, DOI 10.1080/10888705.2013.827916
   Hutcheson G, 1999, MULTIVARIATE SOCIAL
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lensink BJ, 2001, ANIM SCI, V72, P105, DOI 10.1017/S1357729800055600
   Manciocco A, 2009, APPL ANIM BEHAV SCI, V120, P100, DOI 10.1016/j.applanim.2009.05.007
   Melfi VA, 2005, ANTHROZOOS, V18, P304, DOI 10.2752/089279305785594063
   Pedersen LJ, 2003, APPL ANIM BEHAV SCI, V83, P277, DOI 10.1016/S0168-1591(03)00140-0
   Phillips C, 2007, APPL ANIM BEHAV SCI, V106, P244, DOI 10.1016/j.applanim.2007.01.007
   The British Psychological Society, 2010, COD HUM RES ETH
   Waiblinger S, 2002, APPL ANIM BEHAV SCI, V79, P195, DOI 10.1016/S0168-1591(02)00155-7
   Ward SJ, 2013, APPL ANIM BEHAV SCI, V147, P179, DOI 10.1016/j.applanim.2013.05.008
NR 29
TC 11
Z9 11
U1 3
U2 72
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 28
PY 2015
VL 10
IS 10
AR e0140237
DI 10.1371/journal.pone.0140237
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV0DL
UT WOS:000363918100024
PM 26509670
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bao, ZK
   Gao, X
   Zhang, Q
   Lin, J
   Hu, WW
   Yu, HQ
   Chen, JQ
   Yang, Q
   Yu, QH
AF Bao, Zekun
   Gao, Xue
   Zhang, Qiang
   Lin, Jian
   Hu, Weiwei
   Yu, Huiqing
   Chen, Jianquan
   Yang, Qian
   Yu, Qinghua
TI The Effects of GH Transgenic Goats on the Microflora of the Intestine,
   Feces and Surrounding Soil
SO PLOS ONE
LA English
DT Article
ID GENE-TRANSFER; ANTIBIOTIC-RESISTANCE; MOUSE MODEL; PIGS; MICROBIOTA;
   BACTERIA; OOCYTES; PLANTS; FOOD
AB The development of genetically engineered animals has brought with it increasing concerns about biosafety issues. We therefore evaluated the risks of growth hormone from transgenic goats, including the probability of horizontal gene transfer and the impact on the microbial community of the goats' gastrointestinal tracts, feces and the surrounding soil. The results showed that neither the GH nor the neoR gene could be detected in the samples. Moreover, there was no significant change in the microbial community of the gastrointestinal tracts, feces and soil, as tested with PCR-denaturing gradient gel electrophoresis and 16S rDNA sequencing. Finally, phylogenetic analysis showed that the intestinal content, feces and soil samples all contained the same dominant group of bacteria. These results demonstrated that expression of goat growth hormone in the mammary of GH transgenic goat does not influence the microflora of the intestine, feces and surrounding soil.
C1 [Bao, Zekun; Gao, Xue; Zhang, Qiang; Lin, Jian; Hu, Weiwei; Yang, Qian; Yu, Qinghua] Nanjing Agr Univ, Coll Vet Med, Nanjing, Jiangsu, Peoples R China.
   [Yu, Huiqing; Chen, Jianquan] Shanghai Transgen Res Ctr, Shanghai 201210, Peoples R China.
RP Yu, QH (reprint author), Nanjing Agr Univ, Coll Vet Med, Nanjing, Jiangsu, Peoples R China.
EM yuqinghua1981@163.com
FU National Animal Transgenic Breeding Grand Project [2013ZX08008-004,
   2014ZX08008-004]; Priority Academic Program Development of Jiangsu
   Higher Education Institutions
FX This work was supported by grants from the National Animal Transgenic
   Breeding Grand Project (No. 2013ZX08008-004 and 2014ZX08008-004) and A
   Project Funded by the Priority Academic Program Development of Jiangsu
   Higher Education Institutions.
CR Bakke I, 2011, J MICROBIOL METH, V84, P349, DOI 10.1016/j.mimet.2010.12.015
   Cabot RA, 2001, ANIM BIOTECHNOL, V12, P205, DOI 10.1081/ABIO-100108347
   Chan AWS, 1998, P NATL ACAD SCI USA, V95, P14028, DOI 10.1073/pnas.95.24.14028
   Degnan SM, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00638
   DU SJ, 1992, BIO-TECHNOL, V10, P176, DOI 10.1038/nbt0292-176
   EBERT KM, 1991, BIO-TECHNOL, V9, P835, DOI 10.1038/nbt0991-835
   HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0
   Kay E, 2002, APPL ENVIRON MICROB, V68, P3345, DOI 10.1128/AEM.68.7.3345-3351.2002
   Kelly BG, 2009, FOOD CHEM TOXICOL, V47, P978, DOI 10.1016/j.fct.2008.06.012
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Martin FPJ, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb4100190
   Mathur S, 2005, INT J FOOD MICROBIOL, V105, P281, DOI 10.1016/j.ijfoodmicro.2005.03.008
   Metzler BU, 2008, ASIAN AUSTRAL J ANIM, V21, P603, DOI 10.5713/ajas.2008.r.03
   Quigley Eamonn M M, 2013, Gastroenterol Hepatol (N Y), V9, P560
   Russell JB, 2001, SCIENCE, V292, P1119, DOI 10.1126/science.1058830
   van den Eede G, 2004, FOOD CHEM TOXICOL, V42, P1127, DOI 10.1016/j.fct.2004.02.001
   Van Reenen CG, 2001, J ANIM SCI, V79, P1763
   Zeng BH, 2013, CURR MICROBIOL, V67, P313, DOI 10.1007/s00284-013-0360-3
   Zhang Q, 2015, GENET MOL RES, V14, P2006, DOI 10.4238/2015.March.20.10
   Zhang Q, 2014, MOL BIOL REP, V41, P4759, DOI 10.1007/s11033-014-3347-7
NR 20
TC 0
Z9 0
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2015
VL 10
IS 10
AR e0139822
DI 10.1371/journal.pone.0139822
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT0TS
UT WOS:000362510600086
PM 26445136
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Tsai, HJ
   Huang, SS
   Tsou, MT
   Wang, HT
   Chiu, JH
AF Tsai, Hsin-Ju
   Huang, Shiang-Suo
   Tsou, Meng-Ting
   Wang, Hsiao-Ting
   Chiu, Jen-Hwey
TI Role of Opioid Receptors Signaling in Remote Electrostimulation -
   Induced Protection against Ischemia/Reperfusion Injury in Rat Hearts
SO PLOS ONE
LA English
DT Article
ID MEDIAN NERVE-STIMULATION; ACUTE CORONARY SYNDROMES; INDUCED
   CARDIOPROTECTION; ISCHEMIA-REPERFUSION; ACTIVATION; ELECTROACUPUNCTURE;
   PHOSPHORYLATION; ACUPUNCTURE; INVOLVEMENT; MECHANISMS
AB Aims
   Our previous studies demonstrated that remote electro-stimulation (RES) increased myocardial GSK3 phosphorylation and attenuated ischemia/reperfusion (I/R) injury in rat hearts. However, the role of various opioid receptors (OR) subtypes in preconditioned RES-induced myocardial protection remains unknown. We investigated the role of OR subtype signaling in RES-induced cardioprotection against I/R injury of the rat heart.
   Methods & Results
   Male Spraque-Dawley rats were used. RES was performed on median nerves area with/without pretreatment with various receptors antagonists such as opioid receptor (OR) subtype receptors (KOR, DOR, and MOR). The expressions of Akt, GSK3, and PKCe expression were analyzed by Western blotting. When RES was preconditioned before the I/R model, the rat's hemodynamic index, infarction size, mortality and serum CK-MB were evaluated. Our results showed that Akt, GSK3 and PKCe expression levels were significantly increased in the RES group compared to the sham group, which were blocked by pretreatment with specific antagonists targeting KOR and DOR, but not MOR subtype. Using the I/R model, the duration of arrhythmia and infarct size were both significantly attenuated in RES group. The mortality rates of the sham RES group, the RES group, RES group + KOR antagonist, RES group + DOR/MOR antagonists (KOR left), RES group + DOR antagonist, and RES group + KOR/MOR antagonists (DOR left) were 50%, 20%, 67%, 13%, 50% and 55%, respectively.
   Conclusion
   The mechanism of RES-induced myocardial protection against I/R injury seems to involve multiple target pathways such as Akt, KOR and/or DOR signaling.
C1 [Tsai, Hsin-Ju; Chiu, Jen-Hwey] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan.
   [Huang, Shiang-Suo; Wang, Hsiao-Ting] Chung Shan Med Univ, Sch Med, Dept Pharmacol, Taichung, Taiwan.
   [Tsou, Meng-Ting] Mackay Mem Hosp, Dept Family Med, Taipei, Taiwan.
   [Chiu, Jen-Hwey] Taipei Vet Gen Hosp, Div Gen Surg, Dept Surg, Taipei, Taiwan.
   [Chiu, Jen-Hwey] Cheng Hsin Gen Hosp, Div Gen Surg, Dept Surg, Taipei, Taiwan.
RP Chiu, JH (reprint author), Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan.
EM chiujh@mailsrv.ym.edu.tw
FU Ministry of Science and Technology [NSC 101-2320-B-010-051 -MY3]
FX JHC was supported by grants from Ministry of Science and Technology (NSC
   101-2320-B-010-051 -MY3). The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o
   Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298
   BLASZCZYK J, 1994, EXP NEPHROL, V2, P364
   Boren J, 2014, CLIN CHIM ACTA, V431, P131, DOI 10.1016/j.cca.2014.01.015
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Brook RD, 2013, HYPERTENSION, V61, P1360, DOI 10.1161/HYP.0b013e318293645f
   Chiara F, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00016
   Chiu JH, 2012, LIFE SCI, V90, P629, DOI 10.1016/j.lfs.2012.02.007
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Fang SD, 2013, NEUROCHEM RES, V38, P2305, DOI 10.1007/s11064-013-1139-4
   Giricz Z, 2014, J MOL CELL CARDIOL, V68, P75, DOI 10.1016/j.yjmcc.2014.01.004
   Gross ER, 2007, BASIC RES CARDIOL, V102, P341, DOI 10.1007/s00395-007-0651-6
   Gross GJ, 2012, J CARDIOVASC PHARM, V59, P194, DOI 10.1097/FJC.0b013e318241e8c7
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Huang SS, 2005, CLIN BIOCHEM, V38, P943, DOI 10.1016/j.clinbiochem.2005.07.003
   Ishii H, 2014, CURRENT PHARM DESIGN
   Kaladchibachi Sevag A, 2007, J Circadian Rhythms, V5, P3, DOI 10.1186/1740-3391-5-3
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Li P, 1998, CIRCULATION, V97, P1186, DOI 10.1161/01.CIR.97.12.1186
   Li P, 2010, AUTON NEUROSCI-BASIC, V157, P24, DOI 10.1016/j.autneu.2010.03.015
   Liang J, 2006, PEPTIDES, V27, P3307, DOI 10.1016/j.peptides.2006.08.011
   Liao PH, 2011, CIRC J, V75, P443, DOI 10.1253/circj.CJ-10-0381
   Libby P, 2013, NEW ENGL J MED, V368, P2004, DOI 10.1056/NEJMra1216063
   Lichtenauer M, 2011, BASIC RES CARDIOL, V106, P1283, DOI 10.1007/s00395-011-0224-6
   Lin JJ, 2013, CYTOKINE, V61, P842, DOI 10.1016/j.cyto.2013.01.002
   Ma T, 2014, J ALZHEIMERS DIS, V39, P707, DOI 10.3233/JAD-131661
   Miki T, 1998, MOL CELL BIOCHEM, V186, P3, DOI 10.1023/A:1006856124501
   Minagawa M, 2013, AUTON NEUROSCI-BASIC, V179, P151, DOI 10.1016/j.autneu.2013.03.005
   Peart JN, 2008, BASIC RES CARDIOL, V103, P454, DOI 10.1007/s00395-008-0726-z
   Pyle WG, 2001, AM J PHYSIOL-HEART C, V281, pH669
   Rodrigo R, 2013, BIOMED RES INT, DOI 10.1155/2013/437613
   Sayols-Baixeras S, 2014, APPL CLIN GENET, V7, P15, DOI 10.2147/TACG.S35301
   Schultz JE, 1998, CIRCULATION, V97, P1282, DOI 10.1161/01.CIR.97.13.1282
   SCHULTZ JEJ, 1995, AM J PHYSIOL-HEART C, V268, pH2157, DOI 10.1152/ajpheart.1995.268.5.H2157
   Siraskar B, 2011, PFLUG ARCH EUR J PHY, V462, P811, DOI 10.1007/s00424-011-1006-6
   Sobanski P, 2014, HEART VESSELS, V29, P855, DOI 10.1007/s00380-013-0456-5
   Sugden PH, 2008, BRIT J PHARMACOL, V153, pS137, DOI 10.1038/sj.bjp.0707659
   Surendra H, 2013, J MOL CELL CARDIOL, V60, P142, DOI 10.1016/j.yjmcc.2013.04.010
   Tanaka K, 2014, CURR PHARM DESIGN, V20, P5696, DOI 10.2174/1381612820666140204120311
   Tjen-A-Looi SC, 2012, AM J PHYSIOL-REG I, V302, pR833, DOI 10.1152/ajpregu.00440.2011
   Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55
   Tricoci P, 2012, NEW ENGL J MED, V366, P20, DOI 10.1056/NEJMoa1109719
   Tsou MT, 2004, AM J CHINESE MED, V32, P951, DOI 10.1142/S0192415X04002557
   Tsou MT, 2004, INT J MOL MED, V14, P553
   Vigneron F, 2011, CARDIOVASC RES, V90, P49, DOI 10.1093/cvr/cvr002
   Vilimek D, 2006, BIOCHEM CELL BIOL, V84, P20, DOI 10.1139/O05-154
   WHO, 2011, GLOBAL ATLAS CARDIOV
   Zhang CG, 2009, BIOCHEM BIOPH RES CO, V390, P258, DOI 10.1016/j.bbrc.2009.09.101
NR 49
TC 7
Z9 7
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2015
VL 10
IS 10
AR e0138108
DI 10.1371/journal.pone.0138108
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS6HH
UT WOS:000362178700010
PM 26430750
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhang, XD
   Huang, L
   Wu, T
   Feng, YF
   Ding, YY
   Ye, PF
   Yin, ZJ
AF Zhang, Xiaodong
   Huang, Long
   Wu, Tao
   Feng, Yifang
   Ding, Yueyun
   Ye, Pengfei
   Yin, Zongjun
TI Transcriptomic Analysis of Ovaries from Pigs with High And Low Litter
   Size
SO PLOS ONE
LA English
DT Article
ID MESSENGER-RNA EXPRESSION; JEJU NATIVE PIG; PREOVULATORY FOLLICLES;
   MOLECULAR-CLONING; ADULT BERKSHIRE; GENE-EXPRESSION; LARGE WHITE;
   MALE-MICE; SEQ; REPRODUCTION
AB Litter size is one of the most important economic traits for pig production as it is directly related to the production efficiency. Litter size is affected by interactions between multiple genes and the environment. While recent studies have identified some genes associated with prolificacy in pigs, transcriptomic studies of specific genes affecting litter size in porcine ovaries are rare. In order to identify candidate genes associated with litter size in swine, we assessed gene expression differences between the ovaries of Yorkshire pigs with extremely high and low litter sizes using the RNA-Seq method. A total of 1 243 differentially expressed genes were identified: 897 genes were upregulated and 346 genes were down-regulated in high litter size ovary samples compared with low litter size ovary samples. A large number of these genes related to steroid hormone regulation in animal ovaries, including 59 Gene Ontology terms and 27 Kyoto Encyclopedia of Genes and Genomes pathways involved in steroid biosynthesis and ovarian steroidogenesis. From these differentially expressed genes, we identified a total of 11 genes using a bioinformatics screen that may be associated with high litter size in Yorkshire pigs. These results provide a list of new candidate genes for porcine litter size and prolificacy to be further investigated.
C1 [Zhang, Xiaodong; Huang, Long; Wu, Tao; Feng, Yifang; Ding, Yueyun; Ye, Pengfei; Yin, Zongjun] Anhui Agr Univ, Coll Anim Sci & Technol, Key Lab Local Anim Genet Resources Conservat & Bi, Hefei, Anhui, Peoples R China.
RP Yin, ZJ (reprint author), Anhui Agr Univ, Coll Anim Sci & Technol, Key Lab Local Anim Genet Resources Conservat & Bi, Hefei, Anhui, Peoples R China.
EM yinzongjun@ahau.edu.cn
FU National Natural Science Foundation of China [31402037, 31171200]; Anhui
   Provincial Natural Science Foundation [1408085QC55, 1508085QC52];
   Project of Anhui Province Scientific Technology Plan [1301031032]
FX This research was supported by grants from the National Natural Science
   Foundation of China (Nos. 31402037 and 31171200), the Anhui Provincial
   Natural Science Foundation (Nos. 1408085QC55 and 1508085QC52), and the
   Project of Anhui Province Scientific Technology Plan (No. 1301031032).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arango J, 2005, J ANIM SCI, V83, P499
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Cao SL, 2015, CLIN RES HEPATOL GAS, V39, P198, DOI 10.1016/j.clinre.2014.09.003
   Chen HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120170
   Chen K F, 2000, Yi Chuan Xue Bao, V27, P853
   Chen L, 2012, J GENET GENOMICS, V39, P181, DOI 10.1016/j.jgg.2012.03.002
   Distl O, 2007, REPROD DOMEST ANIM, V42, P10, DOI 10.1111/j.1439-0531.2007.00887.x
   Du HL, 2009, GENET MOL BIOL, V32, P69, DOI 10.1590/S1415-47572009000100010
   Duan JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059636
   Fernandez-Rodriguez A, 2011, BIOL REPROD, V84, P299, DOI 10.1095/biolreprod.110.085589
   Franchi NA, 2008, REPRODUCTION, V136, P157, DOI 10.1530/REP-08-0032
   Gan L, 2015, GENE, V560, P96, DOI 10.1016/j.gene.2015.01.051
   Gao HJ, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.100479
   Goluch D, 2009, NEUROENDOCRINOL LETT, V30, P525
   Guo F, 2013, POULTRY SCI, V92, P2737, DOI 10.3382/ps.2013-03189
   Hogarth CA, 2010, DEV DYNAM, V239, P3106, DOI 10.1002/dvdy.22442
   Hsieh CW, 2011, J LIPID RES, V52, P1352, DOI 10.1194/jlr.M012666
   Jacobsen M, 2005, J INFECT DIS, V192, P1211, DOI 10.1086/444428
   Jung WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042198
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kerpedjiev P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-100
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72
   Kwon WS, 2015, MOL CELL PROTEOMICS, V14, P1230, DOI 10.1074/mcp.M114.045369
   Lan DL, 2014, SCI CHINA LIFE SCI, V57, P925, DOI 10.1007/s11427-014-4678-2
   Lee DG, 2015, BIOSCI BIOTECH BIOCH, V79, P1414, DOI 10.1080/09168451.2015.1039478
   Ling YH, 2014, GENE, V550, P148, DOI 10.1016/j.gene.2014.08.008
   Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108
   Metges CC, 2014, J NUTR, V144, P155, DOI 10.3945/jn.113.182691
   Moazeni M, 2012, PARASITOL RES, V110, P2379, DOI 10.1007/s00436-011-2774-9
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Munoz G, 2007, GENET SEL EVOL, V39, P195, DOI 10.1051/gse:2006042
   Nakamoto M, 2012, GEN COMP ENDOCR, V176, P222, DOI 10.1016/j.ygcen.2012.01.019
   Nakazawa H, 2012, J NEUROSCI, V32, P12712, DOI 10.1523/JNEUROSCI.0989-12.2012
   Noguera JL, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-636
   Paeschke K D, 1970, Fortschr Geburtshilfe Gynakol, V43, P1
   Pan ZX, 2012, MOL BIOL REP, V39, P10823, DOI 10.1007/s11033-012-1976-2
   Paradis F, 2009, REPRODUCTION, V138, P115, DOI 10.1530/REP-08-0538
   Ramirez O, 2009, ANIM REPROD SCI, V115, P317, DOI 10.1016/j.anireprosci.2008.12.013
   Rantakari P, 2008, MOL ENDOCRINOL, V22, P665, DOI 10.1210/\e.2007-0257
   ROJAS FJ, 1995, HUM REPROD, V10, P2219
   Rothschild MF, 2007, INT J BIOL SCI, V3, P192
   Sechman A, 2011, DOMEST ANIM ENDOCRIN, V41, P137, DOI 10.1016/j.domaniend.2011.05.007
   Sechman A, 2014, TOXICOL LETT, V225, P264, DOI 10.1016/j.toxlet.2013.12.021
   Shen Z, 2008, J BONE MINER RES, V23, P1217, DOI 10.1359/JBMR.080322
   Shimizu T, 2004, REPRODUCTION, V128, P537, DOI 10.1530/rep.1.00224
   Sodhi SS, 2014, MOL BIOL REP, V41, P6305, DOI 10.1007/s11033-014-3513-y
   Sodhi SS, 2014, GENE, V546, P233, DOI 10.1016/j.gene.2014.06.005
   Spotter A, 2009, REPROD DOMEST ANIM, V44, P100, DOI 10.1111/j.1439-0531.2007.01004.x
   Steibel JP, 2009, GENOMICS, V94, P146, DOI 10.1016/j.ygeno.2009.04.008
   Stephens SM, 2009, AM J PHYSIOL-ENDOC M, V297, pE1235, DOI 10.1152/ajpendo.00575.2009
   Sun Yan-Xiao, 2009, Yichuan, V31, P63, DOI 10.3724/SP.J.1005.2009.00063
   Tian ZC, 2013, INFECT GENET EVOL, V18, P13, DOI 10.1016/j.meegid.2013.04.002
   Tosser-Klopp G, 1998, ANIM GENET, V29, P23, DOI 10.1046/j.1365-2052.1998.00226.x
   Tourtellotte WG, 2000, MOL CELL BIOL, V20, P5261, DOI 10.1128/MCB.20.14.5261-5268.2000
   Tourtellotte WG, 1999, DEVELOPMENT, V126, P5061
   Wang CL, 2013, MOL BIOL REP, V40, P1073, DOI 10.1007/s11033-012-2149-z
   Wang JJ, 2014, REPROD FERT DEVELOP, V26, P587, DOI 10.1071/RD12380
   Wang XL, 2014, GENE, V549, P252, DOI 10.1016/j.gene.2014.07.072
   WEINER S, 1975, FERTIL STERIL, V26, P363
   Wolf J, 2010, J ANIM SCI, V88, P2893, DOI 10.2527/jas.2009-2555
   Xia JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113724
   Zhao H, 2015, CURR PROTEIN PEPT SC, V16, P316, DOI 10.2174/138920371604150429154840
   Zhao YF, 1998, SCI CHINA SER C, V41, P664, DOI 10.1007/BF02882910
   Zhongyi S, 2007, ENDOCRINOLOGY, V148, P3827, DOI 10.1210/en.2007-0365
   Zhou GL, 2010, MEAT SCI, V85, P270, DOI 10.1016/j.meatsci.2010.01.011
   Zhou GL, 2010, MOL BIOL REP, V37, P603, DOI 10.1007/s11033-009-9860-4
NR 68
TC 45
Z9 46
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 1
PY 2015
VL 10
IS 10
AR e0139514
DI 10.1371/journal.pone.0139514
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS6GT
UT WOS:000362177100071
PM 26426260
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Shah, R
   O'Neill, SM
   Hinkle, C
   Caughey, J
   Stephan, S
   Lynch, E
   Bermingham, K
   Lynch, G
   Ahima, RS
   Reilly, MP
AF Shah, Rachana
   O'Neill, Sean M.
   Hinkle, Christine
   Caughey, Jennifer
   Stephan, Stephen
   Lynch, Emma
   Bermingham, Kate
   Lynch, Gina
   Ahima, Rexford S.
   Reilly, Muredach P.
TI Metabolic Effects of CX3CR1 Deficiency in Diet-Induced Obese Mice
SO PLOS ONE
LA English
DT Article
ID FRACTALKINE RECEPTOR CX(3)CR1; INSULIN-RESISTANCE; TARGETED DELETION;
   CHEMOKINE; INFLAMMATION; IDENTIFICATION; LACKING; SYSTEM
AB The fractalkine (CX3CL1-CX3CR1) chemokine system is associated with obesity-related inflammation and type 2 diabetes, but data on effects of Cx3cr1 deficiency on metabolic pathways is contradictory. We examined male C57BL/6 Cx3cr1(-/-) mice on chow and high-fat diet to determine the metabolic effects of Cx3cr1 deficiency. We found no difference in body weight and fat content or feeding and energy expenditure between Cx3cr1(-/-) and WT mice. Cx3cr1(-/-) mice had reduced glucose intolerance assessed by intraperitoneal glucose tolerance tests at chow and high-fat fed states, though there was no difference in glucose-stimulated insulin values. Cx3cr1(-/-) mice also had improved insulin sensitivity at hyperinsulinemic-euglycemic clamp, with higher glucose infusion rate, rate of disposal, and hepatic glucose production suppression compared to WT mice. Enhanced insulin signaling in response to acute intravenous insulin injection was demonstrated in Cx3cr1(-/-) by increased liver protein levels of phosphorylated AKT and GSK3 beta proteins. There were no differences in adipose tissue macrophage populations, circulating inflammatory monocytes, adipokines, lipids, or inflammatory markers. In conclusion, we demonstrate a moderate and reproducible protective effect of Cx3cr1 deficiency on glucose intolerance and insulin resistance.
C1 [Shah, Rachana] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
   [O'Neill, Sean M.; Hinkle, Christine; Caughey, Jennifer; Stephan, Stephen; Lynch, Emma; Bermingham, Kate; Lynch, Gina; Reilly, Muredach P.] Univ Penn, Perelman Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA.
   [Ahima, Rexford S.] Univ Penn, Perelman Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.
RP Shah, R (reprint author), Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
EM shahr@email.chop.edu; muredach@mail.med.upenn.edu
OI Shah, Rachana/0000-0001-7866-557X; Reilly, Muredach/0000-0002-3035-9386
FU National Institutes of Health [R01-DK-090505]; Penn Diabetes Research
   Center Mouse Phenotyping Core [P30-DK-19525];  [K23-DK095913]; 
   [R01-HL-111694];  [R01-HL-108636];  [R01-HL-107643];  [R01-HL-113147]
FX This work is supported by National Institutes of Health grant
   R01-DK-090505 (to MPR) and the Penn Diabetes Research Center Mouse
   Phenotyping Core grant P30-DK-19525. RS is supported by K23-DK095913.
   MPR is also supported by R01-HL-111694, R01-HL-108636, R01-HL-107643 and
   R01-HL-113147. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ahima RS, 2002, DIABETES, V51, P2099, DOI 10.2337/diabetes.51.7.2099
   Apostolakis S, 2013, ACTA PHARMACOL SIN, V34, P1251, DOI 10.1038/aps.2013.92
   Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728
   Cho KW, 2014, METHOD ENZYMOL, V537, P297, DOI 10.1016/B978-0-12-411619-1.00016-1
   Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799
   Cook DN, 2001, MOL CELL BIOL, V21, P3159, DOI 10.1128/MCB.21.9.3159-3165.2001
   Ebert T, 2014, DIABETIC MED, V31, P1014, DOI 10.1111/dme.12451
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   Foussat A, 2000, EUR J IMMUNOL, V30, P87, DOI 10.1002/1521-4141(200001)30:1<87::AID-IMMU87>3.0.CO;2-7
   Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI200112976
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lee YS, 2013, CELL, V153, P413, DOI 10.1016/j.cell.2013.03.001
   McGillicuddy FC, 2009, CIRCULATION, V119, P1135, DOI 10.1161/CIRCULATIONAHA.108.810721
   Morari J, 2014, DIABETES, V63, P3770, DOI 10.2337/db13-1495
   Morris DL, 2012, OBESITY, V20, P1189, DOI 10.1038/oby.2012.7
   Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901
   Nishimura M, 2009, ANN NY ACAD SCI, V1173, P350, DOI 10.1111/j.1749-6632.2009.04738.x
   Polyak A, 2014, BRAIN BEHAV IMMUN, V38, P25, DOI 10.1016/j.bbi.2014.01.010
   Routh VH, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00236
   Shah R, 2011, DIABETES, V60, P1512, DOI 10.2337/db10-0956
   Sirois-Gagnon D, 2010, OBESITY SILVER SPRIN, DOI [10.1038/oby.2010.125, DOI 10.1038/0BY.2010.125]
   Sirois-Gagnon D, 2011, OBESITY, V19, P222, DOI 10.1038/oby.2010.125
   Umehara H, 2004, ARTERIOSCL THROM VAS, V24, P34, DOI 10.1161/01.ATV.0000095360.62479.1F
   White GE, 2012, ARTERIOSCL THROM VAS, V32, P589, DOI 10.1161/ATVBAHA.111.237412
   White GE, 2009, BLOOD, V113, P767, DOI 10.1182/blood-2008-11-189860
   Yin XY, 2014, INT J ENDOCRINOL, DOI 10.1155/2014/715148
NR 28
TC 19
Z9 20
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2015
VL 10
IS 9
AR e0138317
DI 10.1371/journal.pone.0138317
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS0ZW
UT WOS:000361792100051
PM 26393344
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kekalainen, J
   Soler, C
   Veentaus, S
   Huuskonen, H
AF Kekalainen, Jukka
   Soler, Carles
   Veentaus, Sami
   Huuskonen, Hannu
TI Male Investments in High Quality Sperm Improve Fertilization Success,
   but May Have Negative Impact on Offspring Fitness in Whitefish
SO PLOS ONE
LA English
DT Article
ID PARENTAL IDENTITY; ALPINE WHITEFISH; SEXUAL SELECTION; LIFE-HISTORY;
   PERFORMANCE; COMPETITION; TRAITS; GROWTH; FISH
AB Many ejaculate traits show remarkable variation in relation to male social status. Males in disfavoured (subordinate) mating positions often invest heavily on sperm motility but may have less available resources on traits (e.g., secondary sexual ornaments) that improve the probability of gaining matings. Although higher investments in sperm motility can increase the relative fertilization success of subordinate males, it is unclear whether status-dependent differences in sperm traits could have any consequences for offspring fitness. We tested this possibility in whitefish (Coregonus lavaretus L.) by experimentally fertilizing the eggs of 24 females with the sperm of either highly-ornamented (large breeding tubercles, dominant) or less-ornamented (small tubercles, subordinate) males (split-clutch breeding design). In comparison to highly-ornamented individuals, less-ornamented males had higher sperm motility, which fertilized the eggs more efficiently, but produced embryos with impaired hatching success. Also offspring size and body condition were lower among less-ornamented males. Furthermore, sperm motility was positively associated with the fertilization success and offspring size, but only in highly-ornamented males. Together our results indicate that male investments on highly motile (fertile) sperm is not necessarily advantageous during later offspring ontogeny and that male status-dependent differences in sperm phenotype may have important effects on offspring fitness in different life-history stages.
C1 [Kekalainen, Jukka; Veentaus, Sami; Huuskonen, Hannu] Univ Eastern Finland, Dept Biol, Joensuu, Finland.
   [Kekalainen, Jukka] Univ Western Australia, Sch Anim Biol, Ctr Evolutionary Biol, Crawley, Australia.
   [Soler, Carles] Univ Valencia, Dept Biol Func & Antropol Fis, E-46100 Burjassot, Spain.
RP Kekalainen, J (reprint author), Univ Eastern Finland, Dept Biol, Joensuu, Finland.
EM jukka.kekalainen@uwa.edu.au
OI Huuskonen, Hannu/0000-0001-5609-768X
FU Kone Foundation; European Union [PIOF-GA-2013-629472]
FX JK was funded by Kone Foundation (http://www.koneensaatio.fi/en/) and
   the European Union under a Marie Curie International Outgoing Fellowship
   for Career Development (PIOF-GA-2013-629472). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BOLGER T, 1989, J FISH BIOL, V34, P171, DOI 10.1111/j.1095-8649.1989.tb03300.x
   Clark ES, 2011, J BACTERIOL PARASITO, pS4
   Crean AJ, 2014, TRENDS ECOL EVOL, V29, P554, DOI 10.1016/j.tree.2014.07.009
   Crean AJ, 2013, ECOLOGY, V94, P2575, DOI 10.1890/13-0184.1
   Crean AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049167
   Egeland TB, 2015, FRONT ECOL EVOL, V33, P77
   Eilertsen EM, 2009, P ROY SOC B-BIOL SCI, V276, P129, DOI 10.1098/rspb.2008.0884
   Einum S, 1999, P ROY SOC B-BIOL SCI, V266, P2095, DOI 10.1098/rspb.1999.0893
   Evans JP, 2010, P ROY SOC B-BIOL SCI, V277, P3195, DOI 10.1098/rspb.2010.0826
   Fisher DO, 2006, NATURE, V444, P89, DOI 10.1038/nature05206
   Garant D, 2002, EVOL ECOL RES, V4, P537
   Garcia-Gonzalez F, 2005, CURR BIOL, V15, P271, DOI 10.1016/j.cub.2005.01.032
   Garcia-Gonzalez F, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-140
   Hosken DJ, 2003, P ROY SOC B-BIOL SCI, V270, P1933, DOI 10.1098/rspb.2003.2443
   Huuskonen H, 2009, BIOL J LINN SOC, V98, P532, DOI 10.1111/j.1095-8312.2009.01315.x
   Jensen N, 2014, FUNCT ECOL, V28, P724, DOI 10.1111/1365-2435.12195
   Kekalainen J, 2010, EVOLUTION, V64, P3149, DOI 10.1111/j.1558-5646.2010.01084.x
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kustan JM, 2012, P ROY SOC B-BIOL SCI, V279, P434, DOI 10.1098/rspb.2011.0997
   Lupold S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4184
   Marshall DJ, 2015, J EXP BIOL, V218, P107, DOI 10.1242/jeb.106427
   MORAN NA, 1994, ANNU REV ECOL SYST, V25, P573, DOI 10.1146/annurev.es.25.110194.003041
   Neff BD, 2004, BEHAV ECOL, V15, P327, DOI 10.1093/beheco/arh016
   Parker GA, 2013, EVOLUTION, V67, P95, DOI 10.1111/j.1558-5646.2012.01741.x
   Parker GA, 2010, BIOL REV, V85, P897, DOI 10.1111/j.1469-185X.2010.00140.x
   Pitcher TE, 2009, J FISH BIOL, V74, P1450, DOI 10.1111/j.1095-8649.2009.02210.x
   R Core Team, 2014, R LANG ENV STAT COMP
   Reichard M, 2007, ANIM BEHAV, V74, P679, DOI 10.1016/j.anbehav.2007.03.005
   Ritchie H, 2013, J EXP BIOL, V216, P3104, DOI 10.1242/jeb.087221
   Rudolfsen G, 2008, BEHAV ECOL SOCIOBIOL, V62, P561, DOI 10.1007/s00265-007-0480-5
   SCHLUTER D, 1991, P ROY SOC B-BIOL SCI, V246, P11, DOI 10.1098/rspb.1991.0118
   SIMMONS LW, 2006, P NATL ACAD SCI USA, V103, P16349
   Wedekind C, 2001, J EVOLUTION BIOL, V14, P980, DOI 10.1046/j.1420-9101.2001.00349.x
   Wedekind C, 2008, GENETICA, V132, P199, DOI 10.1007/s10709-007-9164-3
   Wiley M. L., 1970, B AM MUS NAT HIST, V143, P143
   Zajitschek S, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0422
NR 36
TC 5
Z9 5
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 21
PY 2015
VL 10
IS 9
AR e0137005
DI 10.1371/journal.pone.0137005
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS0ZM
UT WOS:000361791000005
PM 26389594
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sonnaert, M
   Luyten, FP
   Schrooten, J
   Papantoniou, I
AF Sonnaert, Maarten
   Luyten, Frank P.
   Schrooten, Jan
   Papantoniou, Ioannis
TI Bioreactor-Based Online Recovery of Human Progenitor Cells with
   Uncompromised Regenerative Potential: A Bone Tissue Engineering
   Perspective
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; CLINICAL-GRADE EXPANSION; EX-VIVO EXPANSION;
   OSTEOGENIC DIFFERENTIATION; CHONDROCYTE ISOLATION; EXTRACELLULAR-MATRIX;
   COMPUTED-TOMOGRAPHY; CULTURE; SYSTEM; MICROENVIRONMENT
AB The use of a 3D perfusion culture environment for stem cell expansion has been shown to be beneficial for maintenance of the original cell functionality but due to several system inherent characteristics such as the presence of extracellular matrix, the continued development and implementation of 3D perfusion bioreactor technologies is hampered. Therefore, this study developed a methodology for harvesting a progenitor cell population from a 3D open porous culture surface after expansion in a perfusion bioreactor and performed a functional characterization of the expanded cells. An initial screening showed collagenase to be the most interesting reagent to release the cells from the 3D culture surface as it resulted in high yields without compromising cell viability. Subsequently a Design of Experiment approach was used to obtain optimized 3D harvest conditions by assessing the interplay of flow rate, collagenase concentration and incubation time on the harvest efficiency, viability and single cell fraction. Cells that were recovered with the optimized harvest protocol, by perfusing a 880 U/ml collagenase solution for 7 hours at a flow rate of 4 ml/min, were thereafter functionally analyzed for their characteristics as expanded progenitor cell population. As both the in vitro tri-lineage differentiation capacity and the in vivo bone forming potential were maintained after 3D perfusion bioreactor expansion we concluded that the developed seeding, culture and harvest processes did not significantly compromise the viability and potency of the cells and can contribute to the future development of integrated bioprocesses for stem cell expansion.
C1 [Sonnaert, Maarten; Luyten, Frank P.; Schrooten, Jan; Papantoniou, Ioannis] Katholieke Univ Leuven, Prometheus, Div Skeletal Tissue Engn, Leuven, Belgium.
   [Sonnaert, Maarten; Schrooten, Jan] Katholieke Univ Leuven, Dept Mat Engn, Heverlee, Belgium.
   [Luyten, Frank P.; Papantoniou, Ioannis] Katholieke Univ Leuven, Dept Dev & Regenerat, Skeletal Biol & Engn Res Ctr, Leuven, Belgium.
RP Papantoniou, I (reprint author), Katholieke Univ Leuven, Prometheus, Div Skeletal Tissue Engn, Leuven, Belgium.
EM Ioannis.papantoniou@med.kuleuven.be
FU Agency for Innovation by Science and Technology [IWT/111457]; European
   Research Council under the European Union [294191]
FX MS is supported by a Ph.D. grant of the Agency for Innovation by Science
   and Technology (IWT/111457). IP was supported by the European Research
   Council under the European Union's Seventh Framework Program
   (FP7/2007-2013)/ERC grant agreement REJOIND no294191.
CR Abbasalizadeh S, 2013, BIOTECHNOL ADV, V31, P1600, DOI 10.1016/j.biotechadv.2013.08.009
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Brown MA, 2007, BIOMATERIALS, V28, P3928, DOI 10.1016/j.biomaterials.2007.05.009
   Centola M, 2014, J TISSUE ENG REGEN M, V8, P148
   Chai YC, 2012, BIOMATERIALS, V33, P3127, DOI 10.1016/j.biomaterials.2012.01.015
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Chen YT, 2012, TISSUE ENG PART C-ME, V18, P444, DOI [10.1089/ten.tec.2011.0304, 10.1089/ten.TEC.2011.0304]
   De Bari C, 2001, ARTHRITIS RHEUM, V44, P85, DOI 10.1002/1529-0131(200101)44:1<85::AID-ANR12>3.0.CO;2-6
   dos Santos F, 2014, BIOTECHNOL BIOENG, V111, P1116, DOI 10.1002/bit.25187
   dos Santos F, 2011, TISSUE ENG PART C-ME, V17, P1201, DOI 10.1089/ten.tec.2011.0255
   dos Santos F, 2011, METHODS MOL BIOL, V698, P189, DOI 10.1007/978-1-60761-999-4_15
   dos Santos FF, 2013, BIOTECHNOL J, V8, P644, DOI 10.1002/biot.201200373
   Eibes G, 2010, J BIOTECHNOL, V146, P194, DOI 10.1016/j.jbiotec.2010.02.015
   Eyckmans J, 2006, TISSUE ENG, V12, P2203, DOI 10.1089/ten.2006.12.2203
   Frauenschuh S, 2007, BIOTECHNOL PROGR, V23, P187, DOI 10.1021/bp060155w
   Haycock JW, 2011, METHODS MOL BIOL, V695, P1, DOI 10.1007/978-1-60761-984-0_1
   He F, 2009, TISSUE ENG PT A, V15, P3809, DOI [10.1089/ten.tea.2009.0188, 10.1089/ten.TEA.2009.0188]
   Hewitt CJ, 2011, BIOTECHNOL LETT, V33, P2325, DOI 10.1007/s10529-011-0695-4
   Jakob M, 2003, CONNECT TISSUE RES, V44, P173, DOI 10.1080/03008200390215836
   Kerckhofs G, 2013, ADV ENG MATER, V15, P153, DOI 10.1002/adem.201200156
   Kerckhofs G, 2013, EUR CELLS MATER, V25, P179, DOI 10.22203/eCM.v025a13
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lau TT, 2014, TISSUE ENG TISSUE C
   Li JT, 2011, TISSUE ENG PT A, V17, P703, DOI [10.1089/ten.tea.2010.0339, 10.1089/ten.TEA.2010.0339]
   Martin I, 2004, TRENDS BIOTECHNOL, V22, P80, DOI 10.1016/j.tibtech.2003.12.001
   Mitalipova MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105-19
   Mulhall H, 2011, J TISSUE ENG REGEN M, V5, P629, DOI 10.1002/term.355
   Nienow AW, 2014, BIOCHEM ENG J, V85, P79, DOI 10.1016/j.bej.2014.02.005
   Oseni AO, 2013, J SURG RES, V181, P41, DOI 10.1016/j.jss.2012.05.087
   Papadimitropoulos A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102359
   Papantoniou I, 2014, BIOTECHNOL BIOENG
   Papantoniou I, 2014, TISSUE ENG PART C-ME, V20, P177, DOI [10.1089/ten.tec.2013.0041, 10.1089/ten.TEC.2013.0041]
   Pei M, 2011, TISSUE ENG PT A, V17, P3067, DOI [10.1089/ten.tea.2011.0158, 10.1089/ten.TEA.2011.0158]
   Pyka G, 2012, ADV ENG MATER, V14, P363, DOI 10.1002/adem.201100344
   Rafiq QA, 2013, BIOTECHNOL LETT, V35, P1233, DOI 10.1007/s10529-013-1211-9
   Roberts SJ, 2014, STEM CELL TRANSL MED, V3, P218, DOI 10.5966/sctm.2012-0137
   Roberts SJ, 2011, BIOMATERIALS
   Salter E, 2012, TISSUE ENG PART B-RE, V18, P62, DOI [10.1089/ten.teb.2011.0209, 10.1089/ten.TEB.2011.0209]
   Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957
   Schneider CK, 2010, NAT REV DRUG DISCOV, V9, P195, DOI 10.1038/nrd3052
   Sonnaert M., 2014, TISSUE ENG C
   Sonnaert M, 2014, J TISSUE ENG REGEN M
   Van Bael S, 2011, MAT SCI ENG A-STRUCT, V528, P7423, DOI 10.1016/j.msea.2011.06.045
   van Gastel N, 2012, STEM CELLS, V30, P2460, DOI 10.1002/stem.1210
   Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213
   Wersinger C, 2004, BIOCHEMISTRY-US, V43, P1242, DOI 10.1021/bi035308s
   Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/NMAT3889, 10.1038/nmat3889]
   Yonenaga K, 2010, TISSUE ENG PART C-ME, V16, P1461, DOI [10.1089/ten.tec.2009.0597, 10.1089/ten.TEC.2009.0597]
   Zhou L, 2013, BIOTECHNOL BIOPROC E, V18, P173, DOI 10.1007/s12257-012-0512-5
   Zoro BJH, 2009, BIOTECHNOL BIOENG, V103, P1236, DOI 10.1002/bit.22356
NR 50
TC 7
Z9 7
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 27
PY 2015
VL 10
IS 8
AR e0136875
DI 10.1371/journal.pone.0136875
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP8KZ
UT WOS:000360144000105
PM 26313143
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yasui, M
   Tamura, Y
   Minami, M
   Higuchi, S
   Fujikawa, R
   Ikedo, T
   Nagata, M
   Arai, H
   Murayama, T
   Yokode, M
AF Yasui, Mika
   Tamura, Yukinori
   Minami, Manabu
   Higuchi, Sei
   Fujikawa, Risako
   Ikedo, Taichi
   Nagata, Manabu
   Arai, Hidenori
   Murayama, Toshinori
   Yokode, Masayuki
TI The Prostaglandin E2 Receptor EP4 Regulates Obesity-Related Inflammation
   and Insulin Sensitivity
SO PLOS ONE
LA English
DT Article
ID ALTERNATIVELY ACTIVATED MACROPHAGES; ISCHEMIA-REPERFUSION INJURY;
   ADIPOSE-TISSUE; ARACHIDONIC-ACID; LEPTIN RELEASE; METABOLIC DISEASE;
   RESISTANCE; ADIPONECTIN; E-2; MICE
AB With increasing body weight, macrophages accumulate in adipose tissue. There, activated macrophages secrete numerous proinflammatory cytokines and chemokines, giving rise to chronic inflammation and insulin resistance. Prostaglandin E-2 suppresses macrophage activation via EP4; however, the role of EP4 signaling in insulin resistance and type 2 diabetes mellitus remains unknown. In this study, we treated db/db mice with an EP4-selective agonist, ONO-AE1-329, for 4 weeks to explore the role of EP4 signaling in obesity-related inflammation in vivo. Administration of the EP4 agonist did not affect body weight gain or food intake; however, in the EP4 agonist-treated group, glucose tolerance and insulin resistance were significantly improved over that of the vehicle-treated group. Additionally, administration of the EP4 agonist inhibited the accumulation of F4/80-positive macrophages and the formation of crown-like structures in white adipose tissue, and the adipocytes were significantly smaller. The treatment of the EP4 agonist increased the number of anti-inflammatory M2 macrophages, and in the stromal vascular fraction of white adipose tissue, which includes macrophages, it markedly decreased the levels of proinflammatory cytokines and chemokines. Further, EP4 activation increased the expression of adiponectin and peroxidase proliferator-activated receptors in white adipose tissue. Next, we examined in vitro M1/M2 polarization assay to investigate the impact of EP4 signaling on determining the functional phenotypes of macrophages. Treatment with EP4 agonist enhanced M2 polarization in wild-type peritoneal macrophages, whereas EP4-deficient macrophages were less susceptible to M2 polarization. Notably, antagonizing peroxidase proliferator-activated receptor delta activity suppressed EP4 signaling-mediated shift toward M2 macrophage polarization. Thus, our results demonstrate that EP4 signaling plays a critical role in obesity-related adipose tissue inflammation and insulin resistance by regulating macrophage recruitment and polarization. The activation of EP4 signaling holds promise for treating obesity and type 2 diabetes mellitus.
C1 [Yasui, Mika; Tamura, Yukinori; Minami, Manabu; Higuchi, Sei; Fujikawa, Risako; Ikedo, Taichi; Nagata, Manabu; Murayama, Toshinori; Yokode, Masayuki] Kyoto Univ, Grad Sch Med, Dept Clin Innovat Med, Kyoto, Kyoto, Japan.
   [Tamura, Yukinori] Kinki Univ, Fac Med, Dept Physiol & Regenerat Med, Osaka, Japan.
   [Ikedo, Taichi; Nagata, Manabu] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Kyoto, Japan.
   [Arai, Hidenori] Natl Ctr Geriatr & Gerontol, Obu, Aichi, Japan.
RP Minami, M (reprint author), Kyoto Univ, Grad Sch Med, Dept Clin Innovat Med, Kyoto, Kyoto, Japan.
EM mminami@kuhp.kyoto-u.ac.jp
OI Higuchi, Sei/0000-0002-5134-8619; Fujikawa, Risako/0000-0003-4108-6202
FU Japan Society for the Promotion of Science (JSPS) KAKENHI [20890111,
   23590361, 26460338, 15K08230]; Suzuken Memorial Foundation; Metabolic
   Syndrome Research Forum Fund; Takeda Science Foundation; SENSHIN Medical
   Research Foundation
FX Funding for this work was provided by the the Japan Society for the
   Promotion of Science (JSPS) KAKENHI Grant Numbers 20890111, 23590361,
   and 26460338 (to MM), 15K08230 (to MY):
   https://www.jsps.go.jp/j-grantsinaid/index.html, the Suzuken Memorial
   Foundation (to MM): http://www.suzukenzaidan.or.jp, the Metabolic
   Syndrome Research Forum Fund (to MM), the Takeda Science Foundation (to
   MM): http://www.takeda-sci.or.jp, and the SENSHIN Medical Research
   Foundation (to MM): http://www.mt-pharma.co.jp/zaidan/.
CR Arkan MC, 2005, NAT MED, V11, P191, DOI [10.1038/nm1185, 10.1068/nm1185]
   Brestoff JR, 2015, CELL, V161, P146, DOI 10.1016/j.cell.2015.02.022
   Charo C, 2013, PANCREAS, V42, P467, DOI 10.1097/MPA.0b013e318264d0f8
   Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071
   COLEMAN RA, 1994, PHARMACOL REV, V46, P205
   Fain JN, 2000, PROSTAG OTH LIPID M, V62, P343, DOI 10.1016/S0090-6980(00)00088-5
   Fain JN, 2000, J LIPID RES, V41, P1689
   Fain JN, 2001, METABOLISM, V50, P921, DOI 10.1053/meta.2001.24927
   FAUST IM, 1978, AM J PHYSIOL, V235, pE279
   Fukushima J, 2009, HEPATOL RES, V39, P724, DOI 10.1111/j.1872-034X.2009.00509.x
   Hill AA, 2014, IMMUNOL REV, V262, P134, DOI 10.1111/imr.12216
   Hishikari K, 2009, CARDIOVASC RES, V81, P123, DOI 10.1093/cvr/cvn254
   Hiuge A, 2007, ARTERIOSCL THROM VAS, V27, P635, DOI 10.1161/01.ATV.0000256469.06782.d5
   Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655
   Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459
   Kang K, 2008, CELL METAB, V7, P485, DOI 10.1016/j.cmet.2008.04.002
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021
   Largo R, 2004, ANN RHEUM DIS, V63, P1197, DOI 10.1136/ard.2003.011163
   Liang XB, 2011, J CLIN INVEST, V121, P4362, DOI 10.1172/JCI46279
   Liu PS, 2014, DIABETES, V63, P4021, DOI 10.2337/db14-0619
   Lovren F, 2010, AM J PHYSIOL-HEART C, V299, pH656, DOI 10.1152/ajpheart.00115.2010
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Minami M, 2008, J BIOL CHEM, V283, P9692, DOI 10.1074/jbc.M709663200
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Nakanishi Y, 2011, CARCINOGENESIS, V32, P1333, DOI 10.1093/carcin/bgr128
   NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69
   Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653
   O'Leary VB, 2007, AM J PHYSIOL-ENDOC M, V293, pE421, DOI 10.1152/ajpendo.00123.2007
   Odegaard JI, 2008, CELL METAB, V7, P496, DOI 10.1016/j.cmet.2008.04.003
   Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894
   Ogawa M, 2009, TRANSPLANTATION, V87, P1645, DOI 10.1097/TP.0b013e3181a5c84c
   Ohinata K, 2006, PROSTAG OTH LIPID M, V81, P31, DOI 10.1016/j.prostaglandins.2006.06.008
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Orr JS, 2014, DIABETES, V63, P421, DOI 10.2337/db13-0213
   Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627
   Otani T, 2015, CELL SIGNAL
   Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921
   Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200
   Papadimitriou A, 2007, CELL PHYSIOL BIOCHEM, V20, P607, DOI 10.1159/000107544
   Piya MK, 2013, J ENDOCRINOL, V216, pT1, DOI 10.1530/JOE-12-0498
   Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Sanchez-Alavez M, 2007, P NATL ACAD SCI USA, V104, P3009, DOI 10.1073/pnas.0611209104
   Saraswathi V, 2013, METABOLISM, V62, P1673, DOI 10.1016/j.metabol.2013.07.007
   Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930
   Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461
   Shi J, 2010, J IMMUNOL, V184, P7207, DOI 10.4049/jimmunol.0903487
   Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295
   Stienstra R, 2008, J BIOL CHEM, V283, P22620, DOI 10.1074/jbc.M710314200
   Sugimoto Y, 2004, BIOCHEM BIOPH RES CO, V322, P911, DOI 10.1016/j.bbrc.2004.07.194
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Takayama K, 2006, CIRC RES, V98, P499, DOI 10.1161/01.RES.0000204451.88147.96
   Tang EHC, 2011, CARDIOVASC RES, V89, P234, DOI 10.1093/cvr/cvq262
   Tang EHC, 2011, ARTERIOSCL THROM VAS, V31, P261, DOI 10.1161/ATVBAHA.110.216580
   Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004
   Varma V, 2009, AM J PHYSIOL-ENDOC M, V296, pE1300, DOI 10.1152/ajpendo.90885.2008
   Vennemann A, 2012, DIABETES, V61, P1879, DOI 10.2337/db11-1396
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Xiao CY, 2004, CIRCULATION, V109, P2462, DOI 10.1161/01.CIR.0000128046.54681.97
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yokota T, 2002, J CLIN INVEST, V109, P1303, DOI 10.1172/JCI200214506
   Zahner G, 2009, BIOCHEM J, V422, P563, DOI 10.1042/BJ20090420
NR 63
TC 10
Z9 10
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2015
VL 10
IS 8
AR e0136304
DI 10.1371/journal.pone.0136304
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP7LO
UT WOS:000360069400103
PM 26308623
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Uhlig, C
   Krause, H
   Koch, T
   de Abreu, MG
   Spieth, PM
AF Uhlig, Christopher
   Krause, Hannes
   Koch, Thea
   de Abreu, Marcelo Gama
   Spieth, Peter Markus
TI Anesthesia and Monitoring in Small Laboratory Mammals Used in
   Anesthesiology, Respiratory and Critical Care Research: A Systematic
   Review on the Current Reporting in Top-10 Impact Factor Ranked Journals
SO PLOS ONE
LA English
DT Review
ID GENERAL-ANESTHESIA; PAIN MANAGEMENT; ANIMAL RESEARCH; CARBON-DIOXIDE;
   MICE; HYPOTHERMIA; GUIDELINES; AGE; SENSITIVITY; ANALGESIA
AB Rationale
   This study aimed to investigate the quality of reporting of anesthesia and euthanasia in experimental studies in small laboratory mammals published in the top ten impact factor journals.
   Methods
   A descriptive systematic review was conducted and data was abstracted from the ten highest ranked journals with respect to impact factor in the categories 'Anesthesiology', 'Critical Care Medicine' and 'Respiratory System' as defined by the 2012 Journal Citation Reports. Inclusion criteria according to PICOS criteria were as follows: 1) population: small laboratory mammals; 2) intervention: any form of anesthesia and/or euthanasia; 3) comparison: not specified; 4) primary outcome: type of anesthesia, anesthetic agents and type of euthanasia; secondary outcome: animal characteristics, monitoring, mechanical ventilation, fluid management, postoperative pain therapy, animal care approval, sample size calculation and performed interventions; 5) study: experimental studies. Anesthesia, euthanasia, and monitoring were analyzed per performed intervention in each article.
   Results
   The search yielded 845 articles with 1,041 interventions of interest. Throughout the manuscripts we found poor quality and frequency of reporting with respect to completeness of data on animal characteristics as well as euthanasia, while anesthesia (732/1041, 70.3%) and interventions without survival (970/1041, 93.2%) per se were frequently reported. Premedication and neuromuscular blocking agents were reported in 169/732 (23.1%) and 38/732 (5.2%) interventions, respectively. Frequency of reporting of analgesia during (117/610, 19.1%) and after painful procedures (38/364, 10.4%) was low. Euthanasia practice was reported as anesthesia (348/501, 69%), transcardial perfusion (37/501, 8%), carbon dioxide (26/501, 6%), decapitation (22/501, 5%), exsanguination (23/501, 5%), other (25/501, 5%) and not specified (20/501, 4%, respectively.
   Conclusions
   The present systematic review revealed insufficient reporting of anesthesia and euthanasia methods throughout experimental studies in small laboratory mammals. Specific guidelines for anesthesia and euthanasia regimens should be considered to achieve comparability, quality of animal experiments and animal welfare. These measures are of special interest when translating experimental findings to future clinical applications.
C1 [Uhlig, Christopher; Krause, Hannes; Koch, Thea; de Abreu, Marcelo Gama; Spieth, Peter Markus] Tech Univ Dresden, Univ Hosp Dresden, Pulm Engn Grp, Dept Anesthesiol & Intens Care Therapy, D-01062 Dresden, Germany.
RP Spieth, PM (reprint author), Tech Univ Dresden, Univ Hosp Dresden, Pulm Engn Grp, Dept Anesthesiol & Intens Care Therapy, D-01062 Dresden, Germany.
EM peter.spieth@uniklinikum-dresden.de
RI Spieth, Peter/C-2928-2011
CR Al-Hashimi M, 2013, BRIT J ANAESTH, V111, P80, DOI 10.1093/bja/aet153
   American Veterinary Medical Association, 2013, AVMA GUIDELINES FOR
   Bara M, 2014, CRIT CARE, V18, DOI 10.1186/cc13694
   Beckman B, 2013, VET CLIN N AM-SMALL, V43, P669, DOI 10.1016/j.cvsm.2013.02.006
   Bednarski R, 2011, J AM ANIM HOSP ASSOC, V47, P377, DOI 10.5326/JAAHA-MS-5846
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   BOLANDER HG, 1984, ARCH INT PHARMACOD T, V267, P213
   Bouzom F, 2012, BIOPHARM DRUG DISPOS, V33, P55, DOI 10.1002/bdd.1767
   Boyko M, 2013, J NEUROSURG ANESTH, V25, P174, DOI 10.1097/ANA.0b013e31827ee0ac
   Cesarovic N, 2012, J AM ASSOC LAB ANIM, V51, P209
   Conlee KM, 2005, LAB ANIM-UK, V39, P137, DOI 10.1258/0023677053739747
   Coulter CA, 2009, LAB ANIM-UK, V43, P232, DOI 10.1258/la.2008.008021
   Coulter CA, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-12
   Cove ME, 2012, BEST PRACT RES-CLIN, V26, P453, DOI 10.1016/j.bpa.2012.10.003
   Di Ianni ME, 2012, J CHEM INF MODEL, V52, P3325, DOI 10.1021/ci300423q
   Festing S, 2005, ATLA-ALTERN LAB ANIM, V33, P654, DOI 10.1177/026119290503300603
   FLECKNELL PA, 1993, BRIT J ANAESTH, V71, P885, DOI 10.1093/bja/71.6.885
   Flecknell P, 2007, ALTEX-ALTERN TIEREXP, V24, P82
   Fuentes JM, 2006, CLIN VACCINE IMMUNOL, V13, P281, DOI 10.1128/CVI.13.2.281-288.2006
   Galley HF, 2000, INTENS CARE MED, V26, P267, DOI 10.1007/s001340051149
   Gargiulo S, 2012, ILAR J, V53, pE55, DOI 10.1093/ilar.53.1.55
   Gorska P, 2000, Med Sci Monit, V6, P171
   Gruber Franz P, 2004, ALTEX, V21 Suppl 1, P3
   Guillen J, 2012, J AM ASSOC LAB ANIM, V51, P311
   Hawkins P, 2002, LAB ANIM-UK, V36, P378, DOI 10.1258/002367702320389044
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Huiku M, 2007, BRIT J ANAESTH, V98, P447, DOI 10.1093/bja/aem004
   Kanazawa M, 2010, J NUTR SCI VITAMINOL, V56, P117, DOI 10.3177/jnsv.56.117
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KOBLIN DD, 1983, ANESTHESIOLOGY, V58, P428, DOI 10.1097/00000542-198305000-00006
   Kos M, 2006, SURG ENDOSC, V20, P570, DOI 10.1007/s00464-004-2175-6
   Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/nmeth.1455, 10.1038/NMETH.1455]
   Larsson JE, 1998, ACTA ANAESTH SCAND, V42, P987, DOI 10.1111/j.1399-6576.1998.tb05360.x
   Lindenblatt N, 2005, AM J PHYSIOL-HEART C, V289, pH2680, DOI 10.1152/ajpheart.00425.2005
   Luan F, 2013, BIOORGAN MED CHEM, V21, P1870, DOI 10.1016/j.bmc.2013.01.035
   Merchant R, 2013, CAN J ANESTH, V60, P63, DOI 10.1007/s12630-012-9820-7
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Perry P, 2007, ILAR J, V48, P42, DOI 10.1093/ilar.48.1.42
   Picha B, 2012, NATURE, V485, P41, DOI 10.1038/485041d
   Reinhart K, 2012, INTENS CARE MED, V38, P368, DOI 10.1007/s00134-012-2472-9
   Richardson CA, 2005, ATLA-ALTERN LAB ANIM, V33, P119, DOI 10.1177/026119290503300207
   Riva John J, 2012, J Can Chiropr Assoc, V56, P167
   ROBERTS NJ, 1979, MICROBIOL REV, V43, P241
   Robertson SA, 2002, J AM VET MED ASSOC, V221, P205, DOI 10.2460/javma.2002.221.205
   Roughan JV, 2003, EUR J PAIN, V7, P397, DOI 10.1016/S1090-3801(02)00140-4
   Roughan JV, 2003, LAB ANIM-UK, V37, P172, DOI 10.1258/00236770360563831
   Sasai Y, 2013, NATURE, V493, P318, DOI 10.1038/nature11859
   Urban R, 2011, PAIN, V152, P990, DOI 10.1016/j.pain.2010.12.003
   van den Brink I, 2013, LAB ANIMAL, V42, P253, DOI 10.1038/laban.252
   Wagner AE, 1997, J AM VET MED ASSOC, V210, P1279
   Yatabe T, 2011, J ANESTH, V25, P558, DOI 10.1007/s00540-011-1170-z
   Zambricki EA, 2004, COMPARATIVE MED, V54, P49
NR 52
TC 7
Z9 7
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 25
PY 2015
VL 10
IS 8
AR e0134205
DI 10.1371/journal.pone.0134205
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP6KK
UT WOS:000359995500007
PM 26305700
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Liu, XC
   Lian, W
   Zhang, LJ
   Feng, XC
   Gao, Y
   Li, SX
   Liu, C
   Cheng, Y
   Yang, L
   Wang, XJ
   Chen, L
   Wang, RQ
   Chai, J
   Chen, WS
AF Liu, Xiao-cong
   Lian, Wei
   Zhang, Liang-jun
   Feng, Xin-chan
   Gao, Yu
   Li, Shao-xue
   Liu, Chang
   Cheng, Ying
   Yang, Long
   Wang, Xiao-Juan
   Chen, Lei
   Wang, Rong-quan
   Chai, Jin
   Chen, Wen-sheng
TI Interleukin-18 Down-Regulates Multidrug Resistance-Associated Protein 2
   Expression through Farnesoid X Receptor Associated with Nuclear Factor
   Kappa B and Yin Yang 1 in Human Hepatoma HepG2 Cells
SO PLOS ONE
LA English
DT Article
ID PRIMARY BILIARY-CIRRHOSIS; BILE-ACID TRANSPORTERS;
   NECROSIS-FACTOR-ALPHA; OBSTRUCTIVE CHOLESTASIS; LIVER-INJURY; RAT-LIVER;
   MRP2; MECHANISMS; PATHWAY; GENES
AB Multidrug resistance-associated protein 2 (MRP2) plays an important role in bile acid metabolism by transporting toxic organic anion conjugates, including conjugated bilirubin, glutathione, sulfate, and multifarious drugs. MRP2 expression is reduced in cholestatic patients and rodents. However, the molecular mechanism of MRP2 down-regulation remains elusive. In this report, we treated human hepatoma HepG2 cells with interleukin-18 (IL-18) and measured the expression of MRP2, nuclear factor kappa B (NF-kappa B), farnesoid X receptor (FXR), and the transcription factor Yin Yang 1 (YY1) by quantitative real-time quantitative polymerase chain reaction (PCR) and western blotting. We found that expression of MRP2 was repressed by IL-18 at both the mRNA and protein levels in a dose-and time-dependent manner. Furthermore, the activated NF-kappa B pathway increased YY1 and reduced FXR. These changes were all attenuated in HepG2 cells with knockdown of the NF-kappa B subunit, p65. The reduced expression of FXR and MRP2 in HepG2 cells that had been caused by IL-18 treatment was also attenuated by YY1 knockdown. We further observed significantly elevated IL-18, NF-kappa B, and YY1 expression and decreased FXR and MRP2 expression in bile duct-ligated Sprague Dawley rat livers. Chromatin immunoprecipitation assays also showed that FXR bound to the promoter region in MRP2 was less abundant in liver extracts from bile duct-ligated rats than sham-operated rats. Our findings indicate that IL-18 down-regulates MRP2 expression through the nuclear receptor FXR in HepG2 cells, and may be mediated by NF-kappa B and YY1.
C1 [Liu, Xiao-cong; Lian, Wei; Zhang, Liang-jun; Feng, Xin-chan; Gao, Yu; Li, Shao-xue; Liu, Chang; Cheng, Ying; Yang, Long; Chen, Lei; Wang, Rong-quan; Chai, Jin; Chen, Wen-sheng] Third Mil Med Univ, Dept Gastroenterol, Southwest Hosp, Chongqing, Peoples R China.
   [Liu, Xiao-cong] Chengdu Mil Gen Hosp, Dept Gastroenterol, Chengdu, Sichuan, Peoples R China.
   [Wang, Xiao-Juan] Chengdu Mil Gen Hosp, Dept Burn & Plast Surg, Chengdu, Sichuan, Peoples R China.
RP Chen, WS (reprint author), Third Mil Med Univ, Dept Gastroenterol, Southwest Hosp, Chongqing, Peoples R China.
EM wenshengchen@hotmail.com
FU National Natural Science Foundation of China [81170430, 81370560,
   81470850, 81470880, 81101427]; Chongqing Natural Science Foundation of
   China [CSTC 2012jjB0079]
FX This work was supported by National Natural Science Foundation of China
   (81170430 to W.S. Chen, 81370560 to W.S. Chen, 81470850 to L Chen,
   81470880 to J Chai and 81101427 to X.J. Wang) and Chongqing Natural
   Science Foundation of China (CSTC 2012jjB0079 to W.S. Chen). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Chai J, 2012, HEPATOLOGY, V55, P1485, DOI 10.1002/hep.24801
   Chen HL, 2008, PEDIATR RES, V63, P667, DOI 10.1203/PDR.0b013e318170a6b5
   Cherrington NJ, 2013, AM J PHYSIOL-GASTR L, V304, pG48, DOI 10.1152/ajpgi.00317.2012
   Dawiskiba Janusz, 2002, HPB (Oxford), V4, P11, DOI 10.1080/136518202753598681
   Denson LA, 2000, J BIOL CHEM, V275, P8835, DOI 10.1074/jbc.275.12.8835
   El-Sayed IH, 2003, CLIN CHIM ACTA, V336, P123, DOI 10.1016/S0009-8981(03)00336-X
   Geier A, 2003, HEPATOLOGY, V38, P345, DOI 10.1053/jhep.2003.50317
   Grube M, 2005, DRUG METAB DISPOS, V33, P31, DOI 10.1124/dmd.104.001560
   Halilbasic E, 2013, J HEPATOL, V58, P155, DOI 10.1016/j.jhep.2012.08.002
   Jedlitschky G, 2006, EXPERT OPIN DRUG MET, V2, P351, DOI 10.1517/17425255.2.3.351
   Jin Ping, 2011, Zhonghua Fu Chan Ke Za Zhi, V46, P329
   Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200
   Keppler D, 1996, Prog Liver Dis, V14, P55
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960
   Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236
   Kubitz R, 1999, GASTROENTEROLOGY, V116, P401, DOI 10.1016/S0016-5085(99)70138-1
   Kullak-Ublick GA, 2002, HEPATOL RES, V23, P78, DOI 10.1016/S1386-6346(01)00159-0
   Lickteig AJ, 2007, DRUG METAB DISPOS, V35, P402, DOI 10.1124/dmd.106.012138
   Lu Y, 2014, GUT, V63, P170, DOI 10.1136/gutjnl-2012-303150
   Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362
   Martinez-Paniagua MA, 2012, MOL CANCER THER, V11, P572, DOI 10.1158/1535-7163.MCT-11-0635
   Matsumoto S, 1997, BIOCHEM BIOPH RES CO, V234, P454, DOI 10.1006/bbrc.1997.6665
   Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1
   Shoda J, 2001, AM J GASTROENTEROL, V96, P3368
   Siewert E, 2004, BIOCHEM BIOPH RES CO, V322, P232, DOI 10.1016/j.bbrc.2004.07.102
   Sun PY, 2014, PHARMACOL REP, V66, P311, DOI 10.1016/j.pharep.2014.02.013
   Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9
   Trauner M, 1997, GASTROENTEROLOGY, V113, P255, DOI 10.1016/S0016-5085(97)70103-3
   Trauner M, 2005, J CLIN GASTROENTEROL, V39, pS111, DOI 10.1097/01.mcg.0000155551.37266.26
   Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707
   Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06
   Wen X, 2014, AM J PATHOL, V184, P1299, DOI 10.1016/j.ajpath.2014.01.025
   Yamada T, 2005, LANGENBECK ARCH SURG, V390, P421, DOI 10.1007/s00423-005-0564-5
   Yamamoto N, 2008, INT J MOL MED, V22, P43
   Yamano T, 2000, CLIN EXP IMMUNOL, V122, P227, DOI 10.1046/j.1365-2249.2000.01356.x
   Zhang JH, 2014, GENE, V537, P230, DOI 10.1016/j.gene.2013.12.062
   Zollner G, 2001, HEPATOLOGY, V33, P633, DOI 10.1053/jhep.2001.22646
NR 38
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 20
PY 2015
VL 10
IS 8
AR e0136215
DI 10.1371/journal.pone.0136215
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP5KH
UT WOS:000359919900066
PM 26292095
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wolf, SJ
   Reske, AP
   Hammermuller, S
   Costa, ELV
   Spieth, PM
   Hepp, P
   Carvalho, AR
   Krassler, J
   Wrigge, H
   Amato, MBP
   Reske, AW
AF Wolf, Samuel J.
   Reske, Alexander P.
   Hammermueller, Soeren
   Costa, Eduardo L. V.
   Spieth, Peter M.
   Hepp, Pierre
   Carvalho, Alysson R.
   Krassler, Jens
   Wrigge, Hermann
   Amato, Marcelo B. P.
   Reske, Andreas W.
TI Correlation of Lung Collapse and Gas Exchange - A Computer Tomographic
   Study in Sheep and Pigs with Atelectasis in Otherwise Normal Lungs
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; HYPOXIC
   PULMONARY VASOCONSTRICTION; GENERAL-ANESTHESIA; ALVEOLAR RECRUITMENT;
   OXYGEN CONCENTRATION; ABDOMINAL-SURGERY; VENOUS ADMIXTURE;
   CARDIAC-SURGERY; VENTILATION
AB Background
   Atelectasis can provoke pulmonary and non-pulmonary complications after general anaesthesia. Unfortunately, there is no instrument to estimate atelectasis and prompt changes of mechanical ventilation during general anaesthesia. Although arterial partial pressure of oxygen (PaO2) and intrapulmonary shunt have both been suggested to correlate with atelectasis, studies yielded inconsistent results. Therefore, we investigated these correlations.
   Methods
   Shunt, PaO2 and atelectasis were measured in 11 sheep and 23 pigs with otherwise normal lungs. In pigs, contrasting measurements were available 12 hours after induction of acute respiratory distress syndrome (ARDS). Atelectasis was calculated by computed tomography relative to total lung mass (M-total). We logarithmically transformed PaO2 (lnPaO(2)) to linearize its relationships with shunt and atelectasis. Data are given as median (interquartile range).
   Results
   M-total was 768 (715-884) g in sheep and 543 (503-583) g in pigs. Atelectasis was 26 (16-47)% in sheep and 18 (13-23) % in pigs. PaO2 (FiO(2) = 1.0) was 242 (106-414) mmHg in sheep and 480 (437-514) mmHg in pigs. Shunt was 39 (29-51)% in sheep and 15 (11-20) % in pigs. Atelectasis correlated closely with lnPaO(2) (R-2 = 0.78) and shunt (R-2 = 0.79) in sheep (P-values<0.0001). The correlation of atelectasis with lnPaO(2) (R-2 = 0.63) and shunt (R-2 = 0.34) was weaker in pigs, but R-2 increased to 0.71 for lnPaO(2) and 0.72 for shunt 12 hours after induction of ARDS. In both, sheep and pigs, changes in atelectasis correlated strongly with corresponding changes in lnPaO(2) and shunt.
   Discussion and Conclusion
   In lung-healthy sheep, atelectasis correlates closely with lnPaO(2) and shunt, when blood gases are measured during ventilation with pure oxygen. In lung-healthy pigs, these correlations were significantly weaker, likely because pigs have stronger hypoxic pulmonary vasoconstriction (HPV) than sheep and humans. Nevertheless, correlations improved also in pigs after blunting of HPV during ARDS. In humans, the observed relationships may aid in assessing anaesthesia-related atelectasis.
C1 [Wolf, Samuel J.; Hammermueller, Soeren; Wrigge, Hermann; Reske, Andreas W.] Univ Hosp Leipzig, Dept Anaesthesiol & Intens Care Med, Leipzig, Germany.
   [Reske, Alexander P.; Krassler, Jens] Fachkrankenhaus Coswig, Anaesthesiol & Intens Care Med, Coswig Meissen, Germany.
   [Costa, Eduardo L. V.; Amato, Marcelo B. P.] Univ Sao Paulo, Cardio Pulm Dept, Div Pulm, Hosp Clin, Sao Paulo, Brazil.
   [Costa, Eduardo L. V.] Hosp Sirio Libanes, Res & Educ Inst, Sao Paulo, Brazil.
   [Spieth, Peter M.] Univ Hosp Carl Gustav Carus, Dept Anaesthesiol & Intens Care Med, Dresden, Germany.
   [Hepp, Pierre] Univ Hosp Leipzig, Dept Orthoped Trauma & Plast Surg, Leipzig, Germany.
   [Carvalho, Alysson R.] Univ Fed Rio de Janeiro, Carlos Chagas Biophys Inst, Rio De Janeiro, Brazil.
RP Reske, AW (reprint author), Univ Hosp Leipzig, Dept Anaesthesiol & Intens Care Med, Leipzig, Germany.
EM andreas.reske@medizin.uni-leipzig.de
RI Spieth, Peter/C-2928-2011; Reske, Andreas/E-8141-2010; amato, Marcelo
   Britto Passo/L-5001-2016; Costa, Eduardo/K-5841-2012
OI Reske, Andreas/0000-0002-2759-0245; amato, Marcelo Britto
   Passo/0000-0003-3525-8282; Costa, Eduardo/0000-0002-6941-3626; Carvalho,
   Alysson/0000-0003-2708-7735
FU Deutsche Forschungsgemeinschaft [DFG WR 47/1-1]; German Research
   Foundation (DFG); Universitat Leipzig [SCHU 1672/3-2]
FX This work was supported by Deutsche Forschungsgemeinschaft to Hermann
   Wrigge, www.dfg.de, Grant Number DFG WR 47/1-1. The authors acknowledge
   support from the German Research Foundation (DFG) and Universitat
   Leipzig within the program of Open Access Publishing (grant number SCHU
   1672/3-2). No individuals employed or contracted by the funders (other
   than the named authors) played any role in study design. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Araos JD, 2012, AM J VET RES, V73, P2013, DOI 10.2460/ajvr.73.12.2013
   Asadi AK, 2014, J APPL PHYSL
   Berggren SM, 1942, ACTA PHYSIOL SCA S11, V11, P1
   BLAND JM, 1986, LANCET, V1, P307
   Borges JB, 2006, AM J RESP CRIT CARE, V174, P268, DOI 10.1164/rccm.200506-97OC
   Brower RG, 2000, NEW ENGL J MED, V342, P1301
   Caironi P, 2010, AM J RESP CRIT CARE, V181, P578, DOI 10.1164/rccm.200905-0787OC
   Cressoni M, 2008, CRIT CARE MED, V36, P669, DOI 10.1097/01.CCM.0000300276.12074.E1
   Dewitte K, 2002, CLIN CHEM, V48, P799
   Duggan M, 2005, ANESTHESIOLOGY, V102, P838, DOI 10.1097/00000542-200504000-00021
   Edmark L, 2003, ANESTHESIOLOGY, V98, P28, DOI 10.1097/00000542-200301000-00008
   Futier E, 2013, NEW ENGL J MED, V369, P428, DOI 10.1056/NEJMoa1301082
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121
   GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005
   HACHENBERG T, 1992, ACTA ANAESTH SCAND, V36, P800, DOI 10.1111/j.1399-6576.1992.tb03568.x
   HEDENSTIERNA G, 1986, ACTA ANAESTH SCAND, V30, P183, DOI 10.1111/j.1399-6576.1986.tb02393.x
   Hemmes SNT, 2014, LANCET, V384, P495, DOI 10.1016/S0140-6736(14)60416-5
   Henzler D, 2005, CRIT CARE, V9, pR471, DOI 10.1186/cc3772
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim H, 2005, P INT C TOOLS ART IN, P607, DOI [10.1109/ICTAI.2005.43, DOI 10.1109/ICTAI.2005.43]
   LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358
   Li G, 2009, PHYS MED BIOL, V54, P4113, DOI 10.1088/0031-9155/54/13/010
   Li RJ, 2009, PHYS MED BIOL, V54, P4821, DOI 10.1088/0031-9155/54/15/012
   LUNDQUIST H, 1995, ACTA RADIOL, V36, P626, DOI 10.3109/02841859509176761
   Malbouisson LM, 2001, AM J RESP CRIT CARE, V163, P1444, DOI 10.1164/ajrccm.163.6.2005001
   Markstaller K, 2003, BRIT J ANAESTH, V91, P699, DOI 10.1093/bja/aeg246
   MARSHALL BE, 1994, INTENS CARE MED, V20, P291, DOI 10.1007/BF01708968
   MORRELL NW, 1995, RESP PHYSIOL, V100, P271, DOI 10.1016/0034-5687(95)00002-U
   Muders T, 2012, CRIT CARE MED, V40, P903, DOI 10.1097/CCM.0b013e318236f452
   Nagendran J, 2006, CURR OPIN ANESTHESIO, V19, P34, DOI 10.1097/01.aco.0000192777.09527.9e
   Nakayama M, 1999, ANESTHESIOLOGY, V91, P760, DOI 10.1097/00000542-199909000-00029
   Neumann P, 1999, ACTA ANAESTH SCAND, V43, P295, DOI 10.1034/j.1399-6576.1999.430309.x
   NUNN JF, 1965, BRIT J ANAESTH, V37, P898, DOI 10.1093/bja/37.12.898
   ONEILL M, 1995, BRIT J ANAESTH, V75, P603, DOI 10.1093/bja/75.5.603
   PEAKE MD, 1981, J APPL PHYSIOL, V51, P1214
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reske AW, 2010, INTENS CARE MED, V36, P1836, DOI 10.1007/s00134-010-2014-2
   Reske AW, 2013, CRIT CARE MED, V41, P732, DOI 10.1097/CCM.0b013e3182711b6e
   Reske AW, 2011, CRIT CARE, V15, DOI 10.1186/cc10563
   Reske AW, 2011, CRIT CARE, V15, DOI 10.1186/cc10060
   Richard JC, 2004, CRIT CARE, V8, P163, DOI 10.1186/cc2391
   Rothen HU, 1999, BRIT J ANAESTH, V82, P551
   Rouby JJ, 2000, INTENS CARE MED, V26, P1046, DOI 10.1007/s001340051317
   Schreiter D, 2004, CRIT CARE MED, V32, P968, DOI 10.1097/01.CCM.0000120050.85798.38
   Serpa Neto A, 2015, ANESTHESIOLOGY
   Strumper D, FETAL DIAGN THER, V20, P377
   Suarez-Sipmann F, 2007, CRIT CARE MED, V35, P214, DOI 10.1097/01.CCM.0000251131.40301.E2
   Sylvester JT, 2012, PHYSIOL REV, V92, P367, DOI 10.1152/physrev.00041.2010
   Tenling A, 1998, ANESTHESIOLOGY, V89, P371, DOI 10.1097/00000542-199808000-00013
   TERRY PB, 1987, J APPL PHYSIOL, V62, P1028
NR 51
TC 3
Z9 3
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2015
VL 10
IS 8
AR e0135272
DI 10.1371/journal.pone.0135272
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO7PJ
UT WOS:000359352600053
PM 26258686
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Acosta-Herrera, M
   Lorenzo-Diaz, F
   Pino-Yanes, M
   Corrales, A
   Valladares, F
   Klassert, TE
   Valladares, B
   Slevogt, H
   Ma, SF
   Villar, J
   Flores, C
AF Acosta-Herrera, Marialbert
   Lorenzo-Diaz, Fabian
   Pino-Yanes, Maria
   Corrales, Almudena
   Valladares, Francisco
   Klassert, Tilman E.
   Valladares, Basilio
   Slevogt, Hortense
   Ma, Shwu-Fan
   Villar, Jesus
   Flores, Carlos
TI Lung Transcriptomics during Protective Ventilatory Support in
   Sepsis-Induced Acute Lung Injury
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; MECHANICAL VENTILATION;
   NEUROEPITHELIAL BODIES; ANGIOGENESIS; RESPONSES; MODELS; MICROARRAYS;
   VALIDATION; RECEPTORS
AB Acute lung injury (ALI) is a severe inflammatory process of the lung. The only proven life-saving support is mechanical ventilation (MV) using low tidal volumes (LVT) plus moderate to high levels of positive end-expiratory pressure (PEEP). However, it is currently unknown how they exert the protective effects. To identify the molecular mechanisms modulated by protective MV, this study reports transcriptomic analyses based on microarray and microRNA sequencing in lung tissues from a clinically relevant animal model of sepsis-induced ALI. Sepsis was induced by cecal ligation and puncture (CLP) in male Sprague-Dawley rats. At 24 hours post-CLP, septic animals were randomized to three ventilatory strategies: spontaneous breathing, LVT (6 ml/kg) plus 10 cmH(2)O PEEP and high tidal volume (HVT, 20 ml/kg) plus 2 cmH2O PEEP. Healthy, non-septic, non-ventilated animals served as controls. After 4 hours of ventilation, lung samples were obtained for histological examination and gene expression analysis using microarray and microRNA sequencing. Validations were assessed using parallel analyses on existing publicly available genome-wide association study findings and transcriptomic human data. The catalogue of deregulated processes differed among experimental groups. The 'response to microorganisms' was the most prominent biological process in septic, non-ventilated and in HVT animals. Unexpectedly, the 'neuron projection morphogenesis' process was one of the most significantly deregulated in LVT. Further support for the key role of the latter process was obtained by microRNA studies, as four species targeting many of its genes (Mir-27a, Mir-103, Mir-17-5p and Mir-130a) were found deregulated. Additional analyses revealed 'VEGF signaling' as a central underlying response mechanism to all the septic groups (spontaneously breathing or mechanically ventilated). Based on this data, we conclude that a co-deregulation of 'VEGF signaling' along with 'neuron projection morphogenesis', which have been never anticipated in ALI pathogenesis, promotes lung-protective effects of LVT with high levels of PEEP.
C1 [Acosta-Herrera, Marialbert; Lorenzo-Diaz, Fabian; Pino-Yanes, Maria; Corrales, Almudena; Valladares, Francisco; Villar, Jesus; Flores, Carlos] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
   [Acosta-Herrera, Marialbert; Lorenzo-Diaz, Fabian; Pino-Yanes, Maria; Corrales, Almudena; Flores, Carlos] Hosp Univ NS Candelaria, Res Unit, Santa Cruz De Tenerife, Spain.
   [Acosta-Herrera, Marialbert; Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Las Palmas Gran Canaria, Spain.
   [Lorenzo-Diaz, Fabian; Valladares, Basilio; Flores, Carlos] Univ La Laguna, Inst Univ Enfermedades Trop & Salud Publ Canarias, Santa Cruz De Tenerife, Spain.
   [Pino-Yanes, Maria] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Valladares, Francisco] Univ La Laguna, Dept Anat Pathol & Histol, Santa Cruz De Tenerife, Spain.
   [Klassert, Tilman E.; Slevogt, Hortense] Jena Univ Hosp, Sept Res Ctr, Jena, Germany.
   [Ma, Shwu-Fan] Univ Chicago, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA.
   [Villar, Jesus] St Michaels Hosp, Li KaShing Knowledge Inst, Keenan Res Ctr Biomed Sci, Toronto, ON M5B 1W8, Canada.
RP Flores, C (reprint author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
EM cflores@ull.edu.es
RI Villar, Jesus/R-4526-2019; Pino-Yanes, Maria/R-8749-2019; Flores,
   Carlos/R-1159-2019; Diaz, Fabian Lorenzo/M-2259-2016; Corrales,
   Almudena/G-5391-2017; Pino-Yanes, Maria/C-8498-2017
OI Villar, Jesus/0000-0001-5687-3562; Pino-Yanes,
   Maria/0000-0003-0332-437X; Diaz, Fabian Lorenzo/0000-0002-3398-198X;
   Corrales, Almudena/0000-0002-2207-5463; Pino-Yanes,
   Maria/0000-0003-0332-437X
FU Instituto de Salud Carlos III, Spain [CB06/06/1088, PI10/0393,
   PI14/00844]; European Regional Development Funds; European Union;
   Instituto de Salud Carlos III [FI11/00074, CD13/00304]; Fundacion Ramon
   Areces; German Research Foundation (Collaborative Research Center)
   [Transregio 124, A5]; German Federal Ministry of Education and Research
   (BMBF) [03Z2JN22]
FX This work was supported by CB06/06/1088, PI10/0393 and PI14/00844 from
   Instituto de Salud Carlos III, Spain, and co-financed by the European
   Regional Development Funds, "A way of making Europe" from the European
   Union to JV and CF. MAH and FLD were supported with fellowships from
   Instituto de Salud Carlos III (FI11/00074 and Sara Borrell CD13/00304,
   respectively). MPY was funded by Fundacion Ramon Areces. TEK and HS were
   supported by the German Research Foundation (Collaborative Research
   Center/Transregio 124, A5) and the German Federal Ministry of Education
   and Research (BMBF 03Z2JN22). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Acosta-Herrera M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00020
   Adriaensen D, 2006, J APPL PHYSIOL, V101, P960, DOI 10.1152/japplphysiol.00267.2006
   Altemeier WA, 2004, AM J PHYSIOL-LUNG C, V287, pL533, DOI 10.1152/ajplung.00004.2004
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Barratt S, 2014, RESPIRATION, V87, P329, DOI 10.1159/000356034
   Becker PM, 2001, AM J PHYSIOL-LUNG C, V281, pL1500
   Bigham A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001116
   Bregeon F, 2005, ANESTHESIOLOGY, V102, P331
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Christie JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028268
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Copland IB, 2003, AM J RESP CRIT CARE, V168, P1051, DOI 10.1164/rccm.200208-964OC
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102
   de Paulis A, 2006, J IMMUNOL, V177, P7322, DOI 10.4049/jimmunol.177.10.7322
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   dos Santos CC, 2004, PHYSIOL GENOMICS, V19, P331, DOI 10.1152/physiolgenomics.00153.2004
   Eichstaedt CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093314
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gharib SA, 2006, AM J RESP CRIT CARE, V173, P653, DOI 10.1164/rccm.200509-1473OC
   Glaab E, 2012, BIOINFORMATICS, V28, pI451, DOI 10.1093/bioinformatics/bts389
   Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34
   Herrera MT, 2003, INTENS CARE MED, V29, P1345, DOI 10.1007/s00134-003-1756-5
   Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626
   Howrylak JA, 2009, PHYSIOL GENOMICS, V37, P133, DOI 10.1152/physiolgenomics.90275.2008
   Huang CQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-46
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Isella C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-382
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Larrivee B, 2009, CIRC RES, V104, P428, DOI 10.1161/CIRCRESAHA.108.188144
   Liu J, 2014, RESP PHYSIOL NEUROBI, V193, P52, DOI 10.1016/j.resp.2014.01.002
   Madala SK, 2012, AM J RESP CELL MOL, V46, P380, DOI 10.1165/rcmb.2011-0237OC
   Morey JS, 2006, BIOL PROCED ONLINE, V8, P175, DOI 10.1251/bpo126
   Nagy JA, 2003, TRENDS CARDIOVAS MED, V13, P169, DOI 10.1016/S1050-1738(03)00056-2
   PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024
   Pogach MS, 2007, J CELL BIOCHEM, V100, P1415, DOI 10.1002/jcb.21142
   Poli-De-Figueiredo LF, 2008, SHOCK, V30, P53, DOI 10.1097/SHK.0b013e318181a343
   R Core Team, 2008, R LANG ENV STAT COMP
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Segura I, 2009, TRENDS MOL MED, V15, P439, DOI 10.1016/j.molmed.2009.08.005
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Thickett DR, 2002, AM J RESP CRIT CARE, V166, P1332, DOI 10.1164/rccm.2105057
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4
   Villar J, 2011, INTENS CARE MED, V37, P1201, DOI 10.1007/s00134-011-2234-0
   Villar J, 2010, INTENS CARE MED, V36, P1049, DOI 10.1007/s00134-010-1799-3
   Villar J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-27
   Villar J, 2009, ANESTHESIOLOGY, V110, P1341, DOI 10.1097/ALN.0b013e31819fcba9
   Wang HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038885
   Wurfel Mark M, 2007, Proc Am Thorac Soc, V4, P77, DOI 10.1513/pats.200608-149JG
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Xing GQ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002342
   Yang GH, 2015, GENE, V562, P138, DOI 10.1016/j.gene.2015.02.065
   Zacchigna S, 2008, NAT REV NEUROSCI, V9, P169, DOI 10.1038/nrn2336
   Zhang R, 2015, AM J RESP CRIT CARE
NR 59
TC 10
Z9 12
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 6
PY 2015
VL 10
IS 7
AR e0132296
DI 10.1371/journal.pone.0132296
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1DQ
UT WOS:000358157600234
PM 26147972
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Couch, Y
   Xie, Q
   Lundberg, L
   Sharp, T
   Anthony, DC
AF Couch, Yvonne
   Xie, Qin
   Lundberg, Louise
   Sharp, Trevor
   Anthony, Daniel C.
TI A Model of Post-Infection Fatigue Is Associated with Increased TNF and
   5-HT2A Receptor Expression in Mice
SO PLOS ONE
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; BACILLE CALMETTE-GUERIN; TRYPTOPHAN DEPLETION;
   CEREBROSPINAL-FLUID; SICKNESS BEHAVIOR; MAJOR DEPRESSION; OPEN-FIELD;
   ACTIVATION; ANXIETY; INFLAMMATION
AB It is well documented that serotonin (5-HT) plays an important role in psychiatric illness. For example, myalgic encephalomyelitis (ME/CFS), which is often provoked by infection, is a disabling illness with an unknown aetiology and diagnosis is based on symptom-specific criteria. However, 5-HT2A receptor expression and peripheral cytokines are known to be upregulated in ME. We sought to examine the relationship between the 5-HT system and cytokine expression following systemic bacterial endotoxin challenge (LPS, 0.5mg/kg i.p.), at a time when the acute sickness behaviours have largely resolved. At 24 hours post-injection mice exhibit no overt changes in locomotor behaviour, but do show increased immobility in a forced swim test, as well as decreased sucrose preference and reduced marble burying activity, indicating a depressive-like state. While peripheral IDO activity was increased after LPS challenge, central activity levels remained stable and there was no change in total brain 5-HT levels or 5-HIAA/5-HT. However, within the brain, levels of TNF and 5-HT2A receptor mRNA within various regions increased significantly. This increase in receptor expression is reflected by an increase in the functional response of the 5-HT2A receptor to agonist, DOI. These data suggest that regulation of fatigue and depressive-like moods after episodes of systemic inflammation may be regulated by changes in 5-HT receptor expression, rather than by levels of enzyme activity or cytokine expression in the CNS.
C1 [Couch, Yvonne; Xie, Qin; Lundberg, Louise; Sharp, Trevor; Anthony, Daniel C.] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England.
   [Lundberg, Louise] Publ Hlth England, Ctr Radiat Chem & Environm Hazards, Didcot OX11 0RQ, Oxon, England.
RP Couch, Y (reprint author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.
EM yvonne.couch@rdm.ox.ac.uk
OI Sharp, Trevor/0000-0001-7434-9713; Anthony, Daniel/0000-0003-1380-6655
FU Biology and Biotechnology Research Society (UK)
FX This work was supported by the Biology and Biotechnology Research
   Society (UK) in vivo additional studentship to YC/DA/TS.
CR Alesci S, 2005, J CLIN ENDOCR METAB, V90, P2522, DOI 10.1210/jc.2004-1667
   Barton DA, 2008, ARCH GEN PSYCHIAT, V65, P38, DOI 10.1001/archgenpsychiatry.2007.11
   Benedetti F, 2008, PROG NEURO-PSYCHOPH, V32, P1863, DOI 10.1016/j.pnpbp.2008.08.017
   Bhagwagar Z, 2006, AM J PSYCHIAT, V163, P1580, DOI 10.1176/appi.ajp.163.9.1580
   BLUTHE RM, 1991, EUR J PHARMACOL, V209, P281, DOI 10.1016/0014-2999(91)90184-R
   Bluthe RM, 2000, EUR J NEUROSCI, V12, P4447, DOI 10.1046/j.1460-9568.2000.01348.x
   Cadusseau J, 2014, CURR MED CHEM, V21, P511
   Capuron L, 2002, NEUROPSYCHOPHARMACOL, V26, P643, DOI 10.1016/S0893-133X(01)00407-9
   Couch Y, 2013, NEUROIMAGE, V75, P177, DOI 10.1016/j.neuroimage.2013.02.046
   Couch Y, 2013, BRAIN BEHAV IMMUN, V29, P136, DOI 10.1016/j.bbi.2012.12.017
   Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P547, DOI 10.1016/j.neubiorev.2005.03.008
   Cunningham C, 2009, BIOL PSYCHIAT, V65, P304, DOI 10.1016/j.biopsych.2008.07.024
   Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006
   Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20
   GJERRIS A, 1987, J AFFECT DISORDERS, V12, P13, DOI 10.1016/0165-0327(87)90056-5
   Gonzalez-Maeso J, 2007, NEURON, V53, P439, DOI 10.1016/j.neuron.2007.01.008
   Hale MW, 2008, NEUROSCIENCE, V157, P733, DOI 10.1016/j.neuroscience.2008.09.050
   Hughes MM, 2012, BRAIN BEHAV IMMUN, V26, P979, DOI 10.1016/j.bbi.2012.05.010
   Jennings KA, 2006, J NEUROSCI, V26, P8955, DOI 10.1523/JNEUROSCI.5356-05.2006
   Jiang Y, 2008, NEUROBIOL DIS, V32, P125, DOI 10.1016/j.nbd.2008.06.017
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Levine J, 1999, NEUROPSYCHOBIOLOGY, V40, P171, DOI 10.1159/000026615
   Maes M, 1997, CYTOKINE, V9, P853, DOI 10.1006/cyto.1997.0238
   Maes M, 1995, J AFFECT DISORDERS, V36, P29, DOI 10.1016/0165-0327(95)00049-6
   Maes M, 2007, NEUROENDOCRINOL LETT, V28, P826
   Maes M, 2012, PSYCHOTHER PSYCHOSOM, V81, P286, DOI 10.1159/000336803
   Maes M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-66
   MANN JJ, 1986, ARCH GEN PSYCHIAT, V43, P954
   Miller KJ, 1998, ANN NY ACAD SCI, V861, P169, DOI 10.1111/j.1749-6632.1998.tb10188.x
   Miyaoka T, 2012, PROG NEURO-PSYCHOPH, V37, P222, DOI 10.1016/j.pnpbp.2012.02.002
   Moreau M, 2005, J INFECT DIS, V192, P537, DOI 10.1086/431603
   Murphy CF, 2004, AM J GERIAT PSYCHIAT, V12, P50, DOI 10.1176/appi.ajgp.12.1.50
   Nau F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075426
   O'Connor JC, 2009, MOL PSYCHIATR, V14, P511, DOI 10.1038/sj.mp.4002148
   O'Connor JC, 2009, J IMMUNOL, V182, P3202, DOI 10.4049/jimmunol.0802722
   Pang TYC, 2009, HUM MOL GENET, V18, P753, DOI 10.1093/hmg/ddn385
   Pitychoutis PM, 2009, NEUROSCIENCE, V159, P1216, DOI 10.1016/j.neuroscience.2009.01.072
   Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X
   Serres F, 1999, EUR PSYCHIAT, V14, P451, DOI 10.1016/S0924-9338(99)00222-9
   Simen BB, 2006, BIOL PSYCHIAT, V59, P775, DOI 10.1016/j.biopsych.2005.10.013
   Slattery DA, 2012, NAT PROTOC, V7, P1009, DOI 10.1038/nprot.2012.044
   Smith AK, 2008, PSYCHONEUROENDOCRINO, V33, P188, DOI 10.1016/j.psyneuen.2007.11.001
   STANLEY M, 1983, LANCET, V1, P214
   Stanley M, 1986, Ann N Y Acad Sci, V487, P122, DOI 10.1111/j.1749-6632.1986.tb27892.x
   Strekalova T, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-9
   Sullivan GM, 2006, INT J NEUROPSYCHOPH, V9, P547, DOI 10.1017/S1461145703006231
   Thomas A, 2009, PSYCHOPHARMACOLOGY, V204, P361, DOI 10.1007/s00213-009-1466-y
   Tyring S, 2006, LANCET, V367, P29, DOI 10.1016/S0140-6736(05)67763-X
   Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44
   WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358
   Wu C, 1999, EXP NEUROL, V158, P529, DOI 10.1006/exnr.1999.7105
   Yu BN, 2008, J PHARMACOL EXP THER, V327, P316, DOI 10.1124/jpet.108.143461
   Zhang XQ, 2009, J CHROMATOGR B, V877, P1678, DOI 10.1016/j.jchromb.2009.04.013
   Zhang YQ, 2001, ACTA PHARMACOL SIN, V22, P923
NR 54
TC 8
Z9 8
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 6
PY 2015
VL 10
IS 7
AR e0130643
DI 10.1371/journal.pone.0130643
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1DQ
UT WOS:000358157600042
PM 26147001
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kurbatova, N
   Mason, JC
   Morgan, H
   Meehan, TF
   Karp, NA
AF Kurbatova, Natalja
   Mason, Jeremy C.
   Morgan, Hugh
   Meehan, Terrence F.
   Karp, Natasha A.
TI PhenStat: A Tool Kit for Standardized Analysis of High Throughput
   Phenotypic Data
SO PLOS ONE
LA English
DT Article
ID KNOCKOUT MICE; RAT GENETICS; MOUSE; CONSORTIUM; GENOME; RESOURCES;
   PROJECT; POINT
AB The lack of reproducibility with animal phenotyping experiments is a growing concern among the biomedical community. One contributing factor is the inadequate description of statistical analysis methods that prevents researchers from replicating results even when the original data are provided. Here we present PhenStat - a freely available R package that provides a variety of statistical methods for the identification of phenotypic associations. The methods have been developed for high throughput phenotyping pipelines implemented across various experimental designs with an emphasis on managing temporal variation. PhenStat is targeted to two user groups: small-scale users who wish to interact and test data from large resources and large-scale users who require an automated statistical analysis pipeline. The software provides guidance to the user for selecting appropriate analysis methods based on the dataset and is designed to allow for additions and modifications as needed. The package was tested on mouse and rat data and is used by the International Mouse Phenotyping Consortium (IMPC). By providing raw data and the version of PhenStat used, resources like the IMPC give users the ability to replicate and explore results within their own computing environment.
C1 [Kurbatova, Natalja; Mason, Jeremy C.; Meehan, Terrence F.] EMBL European Bioinformat Inst, Hinxton, Cambs, England.
   [Morgan, Hugh] Med Res Council Harwell, Harwell, Oxon, England.
   [Karp, Natasha A.] Wellcome Trust Sanger Inst, Mouse Informat Grp, Hinxton, Cambs, England.
RP Kurbatova, N (reprint author), EMBL European Bioinformat Inst, Wellcome Trust Genome Campus, Hinxton, Cambs, England.
EM natalja@ebi.ac.uk
OI Kurbatova, Natalja/0000-0002-3973-2909; Meehan,
   Terrence/0000-0003-1980-3228; Karp, Natasha/0000-0002-8404-2907;
   /0000-0002-2796-5123
FU Wellcome Trust [WT098051]; National Institutes of Health [1 U54
   HG006370-01]
FX This work was supported by the Wellcome Trust (grant number: WT098051,
   http:/www.wellcome.ac.ukFundingindex.htm) and the National Institutes of
   Health (grant number: 1 U54 HG006370-01,
   http:/grants.nih.govgrantsoer.htm).
CR Aitman TJ, 2008, NAT GENET, V40, P516, DOI 10.1038/ng.147
   [Anonymous], 2012, NATURE, V483, P509, DOI DOI 10.1038/483509A
   Ayadi A, 2012, MAMM GENOME, V23, P600, DOI 10.1007/s00335-012-9418-y
   Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211
   Brown SDM, 2012, MAMM GENOME, V23, P632, DOI 10.1007/s00335-012-9427-x
   Clark RA, 2012, J PSYCHOPHARMACOL, V26, P1136, DOI 10.1177/0269881111420313
   Collins FS, 2014, NATURE, V505, P612, DOI 10.1038/505612a
   Cook MN, 2007, MAMM GENOME, V18, P559, DOI 10.1007/s00335-007-9035-3
   Deans AR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002033
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755
   Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521
   Flanagan KL, 2014, T ROY SOC TROP MED H, V108, P385, DOI 10.1093/trstmh/tru079
   Hahne F, 2008, USE R, P1, DOI 10.1007/978-0-387-77240-0_1
   Jacob HJ, 2002, NAT REV GENET, V3, P33, DOI 10.1038/nrg702
   Karp NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111239
   Karp NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052410
   Kettleborough RNW, 2013, NATURE, V496, P494, DOI 10.1038/nature11992
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koscielny G, 2014, NUCLEIC ACIDS RES, V42, pD802, DOI 10.1093/nar/gkt977
   Lees H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100916
   Pettitt SJ, 2009, NAT METHODS, V6, P493, DOI 10.1038/nmeth.1342
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   R Development Core Team R, R LANG ENV STAT COMP
   Reed DR, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-4
   Ringwald M, 2011, NUCLEIC ACIDS RES, V39, pD849, DOI 10.1093/nar/gkq879
   Simon MM, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r82
   Valdar W, 2006, GENETICS, V174, P959, DOI 10.1534/genetics.106.060004
   West BT, 2014, LINEAR MIXED MODELS
   White JK, 2013, CELL, V154, P452, DOI 10.1016/j.cell.2013.06.022
NR 31
TC 18
Z9 18
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 6
PY 2015
VL 10
IS 7
AR e0131274
DI 10.1371/journal.pone.0131274
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1DQ
UT WOS:000358157600079
PM 26147094
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Flores-Tellez, TNJ
   Lopez, TV
   Garzon, VRV
   Villa-Trevino, S
AF Flores-Tellez, Teresita N. J.
   Lopez, Tania V.
   Vasquez Garzon, Veronica Rocio
   Villa-Trevino, Saul
TI Co-Expression of Ezrin-CLIC5-Podocalyxin Is Associated with Migration
   and Invasiveness in Hepatocellular Carcinoma
SO PLOS ONE
LA English
DT Article
ID TUMOR AGGRESSIVENESS; PHOSPHORYLATED EZRIN; CANCER PROGRESSION;
   GENE-EXPRESSION; LIVER EPITHELIA; CELL CARCINOMA; PODOCALYXIN; CLIC5;
   MEMBRANE; COMPLEX
AB Background and Aim
   Prognostic markers are important for predicting the progression and staging of hepatocellular carcinoma (HCC). Ezrin (EZR) and Podocalyxin (PODXL) are proteins associated with invasion, migration and poor prognosis in various types of cancer. Recently, it has been observed that chloride intracellular channel 5 (CLIC5) forms a complex with EZR and PODXL and that it is required for podocyte structure and function. In this study, we evaluated the overexpression of EZR, PODXL and CLIC5 in HCC.
   Methods
   The modified resistant hepatocyte model (MRHR), human biopsies and HCC cell lines (HepG2, Huh7 and SNU387) were used in this study. Gene and protein expression levels were evaluated in the MRHR by qRT-PCR, Western blot and immunohistochemistry analyses, and protein expression in the human biopsies was evaluated by immunohistochemistry. Protein expression in the HCC cell lines was evaluated by immunofluorescence and Western blot, also the migration and invasive abilities of Huh7 cells were evaluated using shRNA-mediated inhibition.
   Results
   Our results indicated that these genes and proteins were overexpressed in HCC. Moreover, when the expression of CLIC5 and PODXL was inhibited in Huh7 cells, we observed decreased migration and invasion.
   Conclusion
   This study suggested that EZR, CLIC5 and PODXL could be biological markers to predict the prognosis of HCC and that these proteins participate in migration and invasion processes.
C1 [Flores-Tellez, Teresita N. J.; Villa-Trevino, Saul] CINVESTAV, IPN, Ctr Invest & Estudios Adv, Dept Cellular Biol, Mexico City 07360, DF, Mexico.
   [Lopez, Tania V.] Inst Nacl Med Genom INMEGEN, Ciudad Mexico 14610, DF, Mexico.
   [Vasquez Garzon, Veronica Rocio] Univ Benito Juarez Oaxaca, Fac Med & Cirugia, Mexico City 68120, Oaxaca, Mexico.
RP Lopez, TV (reprint author), Inst Nacl Med Genom INMEGEN, Perifer 4809, Ciudad Mexico 14610, DF, Mexico.
EM tvlopez@inmegen.gob.mx; svilla@cell.cinvestav.mx
OI Vasquez-Garzon, Veronica Rocio/0000-0002-4861-8235
FU  [178558]
FX This work was supported by a scholarship (TNJFT), a grant contribution
   (178558).
CR Arpin M, 2011, CELL ADHES MIGR, V5, P199, DOI 10.4161/cam.5.2.15081
   Barbe L, 2008, MOL CELL PROTEOMICS, V7, P499, DOI 10.1074/mcp.M700325-MCP200
   Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509
   Calvin D., 2012, ADV CANC MANAGEMENT, P40
   Casey G, 2006, HUM MOL GENET, V15, P735, DOI 10.1093/hmg/ddi487
   Chen Y, 2011, CANCER RES, V71, P1721, DOI 10.1158/0008-5472.CAN-09-4683
   Claperon A, 2013, CLIN RES HEPATOL GAS, V37, P142, DOI 10.1016/j.clinre.2013.02.001
   Cui YZ, 2010, CANCER INVEST, V28, P242, DOI 10.3109/07357900903124498
   Curto M, 2004, CANCER CELL, V5, P113, DOI 10.1016/S1535-6108(04)00031-5
   Dozynkiewicz MA, 2012, DEV CELL, V22, P131, DOI 10.1016/j.devcel.2011.11.008
   Elliott BE, 2005, BREAST CANCER RES, V7, pR365, DOI 10.1186/bcr1006
   Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143
   Gagnon LH, 2006, J NEUROSCI, V26, P10188, DOI 10.1523/JNEUROSCI.2166-06.2006
   Hsu YH, 2010, AM J PATHOL, V176, P3050, DOI 10.2353/ajpath.2010.090539
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kang YK, 2010, MOL CARCINOGEN, V49, P798, DOI 10.1002/mc.20653
   Kelley TW, 2005, AM J CLIN PATHOL, V124, P134, DOI 10.1309/7BHLAHHU0N4MHT7Q
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Li FN, 2010, J CELL BIOCHEM, V110, P1013, DOI 10.1002/jcb.22615
   Li FN, 2010, CELL BIOL INT, V34, P379, DOI 10.1042/CBI20090334
   Li G, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.7
   Li QC, 2012, TUMOR BIOL, V33, P1493, DOI 10.1007/s13277-012-0400-9
   Lin CW, 2014, CARCINOGENESIS, V35, P2425, DOI 10.1093/carcin/bgu139
   Lin CW, 2014, INT J ONCOL, V45, P710, DOI 10.3892/ijo.2014.2427
   Nielsen JS, 2009, J AM SOC NEPHROL, V20, P1669, DOI 10.1681/ASN.2008070782
   Paige M, 2014, BIOORGAN MED CHEM, V22, P478, DOI 10.1016/j.bmc.2013.11.003
   Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068
   Perez-Carreon JI, 2006, NEOPLASIA, V8, P373, DOI 10.1593/neo.05841
   Pierchala BA, 2010, KIDNEY INT, V78, P868, DOI [10.1038/ki.010.212, 10.1038/ki.2010.212]
   POWER C, 1987, CARCINOGENESIS, V8, P797, DOI 10.1093/carcin/8.6.797
   RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517
   Schopperle WM, 2003, BIOCHEM BIOPH RES CO, V300, P285
   Shukla A, 2014, ONCOGENE, V33, P842, DOI 10.1038/onc.2013.18
   Singh H, 2007, FEBS J, V274, P6306, DOI 10.1111/j.1742-4658.2007.06145.x
   Somasiri A, 2004, CANCER RES, V64, P5068, DOI 10.1158/0008-5472.CAN-04-0240
   Stevenson RP, 2012, J CELL SCI, P7
   Supiot S, 2013, WORLD J GASTROENTERO, V19, P3249, DOI 10.3748/wjg.v19.i21.3249
   Wang L, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-44
   Wegner B, 2010, AM J PHYSIOL-RENAL, V298, pF1492, DOI 10.1152/ajprenal.00030.2010
   Yasuoka H, 2012, J CLIN PATHOL, V65, P399, DOI 10.1136/jclinpath-2011-200359
   Yau C, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3567
   Zhang Y, 2006, J CANCER RES CLIN, V132, P685, DOI 10.1007/s00432-006-0117-5
NR 42
TC 11
Z9 14
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 2
PY 2015
VL 10
IS 7
AR e0131605
DI 10.1371/journal.pone.0131605
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1CS
UT WOS:000358154400058
PM 26135398
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Noyan, H
   El-Mounayri, O
   Isserlin, R
   Arab, S
   Momen, A
   Cheng, HS
   Wu, J
   Afroze, T
   Li, RK
   Fish, JE
   Bader, GD
   Husain, M
AF Noyan, Hossein
   El-Mounayri, Omar
   Isserlin, Ruth
   Arab, Sara
   Momen, Abdul
   Cheng, Henry S.
   Wu, Jun
   Afroze, Talat
   Li, Ren-Ke
   Fish, Jason E.
   Bader, Gary D.
   Husain, Mansoor
TI Cardioprotective Signature of Short-Term Caloric Restriction
SO PLOS ONE
LA English
DT Article
ID CARDIOMYOCYTE CIRCADIAN CLOCK; ACTIVATED PROTEIN-KINASE; DIETARY
   RESTRICTION; LIFE-SPAN; MEDIATES CARDIOPROTECTION; MITOCHONDRIAL
   BIOGENESIS; MYOCARDIAL-ISCHEMIA; OXIDATIVE STRESS; RHESUS-MONKEYS;
   DISEASE
AB Objective
   To understand the molecular pathways underlying the cardiac preconditioning effect of short-term caloric restriction (CR).
   Background
   Lifelong CR has been suggested to reduce the incidence of cardiovascular disease through a variety of mechanisms. However, prolonged adherence to a CR life-style is difficult. Here we reveal the pathways that are modulated by short-term CR, which are associated with protection of the mouse heart from ischemia.
   Methods
   Male 10-12 wk old C57bl/6 mice were randomly assigned to an ad libitum(AL) diet with free access to regular chow, or CR, receiving 30% less food for 7 days (d), prior to myocardial infarction (MI) via permanent coronary ligation. At d8, the left ventricles (LV) of AL and CR mice were collected for Western blot, mRNA and microRNA (miR) analyses to identify cardio-protective gene expression signatures. In separate groups, infarct size, cardiac hemodynamics and protein abundance of caspase 3 was measured at d2 post-MI.
   Results
   This short-term model of CR was associated with cardio-protection, as evidenced by decreased infarct size (18.5 +/- 2.4% vs. 26.6 +/- 1.7%, N=10/group; P=0.01). mRNA and miR profiles pre-MI (N=5/group) identified genes modulated by short-term CR to be associated with circadian clock, oxidative stress, immune function, apoptosis, metabolism, angiogenesis, cytoskeleton and extracellular matrix (ECM). Western blots pre-MI revealed CR-associated increases in phosphorylated Akt and GSK3 beta, reduced levels of phosphorylated AMPK and mitochondrial related proteins PGC-1 alpha, cytochrome C and cyclooxygenase (COX) IV, with no differences in the levels of phosphorylated eNOS or MAPK (ERK1/2; p38). CR regimen was also associated with reduced protein abundance of cleaved caspase 3 in the infarcted heart and improved cardiac function.
C1 [Noyan, Hossein; El-Mounayri, Omar; Arab, Sara; Momen, Abdul; Afroze, Talat; Husain, Mansoor] Toronto Gen Res Inst, Div Expt Therapeut, Toronto, ON, Canada.
   [Isserlin, Ruth; Bader, Gary D.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Cheng, Henry S.; Wu, Jun; Li, Ren-Ke; Fish, Jason E.] Toronto Gen Res Inst, Div Adv Diagnost, Toronto, ON, Canada.
   [Fish, Jason E.; Husain, Mansoor] Univ Toronto, Dept Lab Med Pathobiol, Toronto, ON, Canada.
   [Li, Ren-Ke; Fish, Jason E.; Husain, Mansoor] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence Cardi, Toronto, ON, Canada.
   [Bader, Gary D.] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada.
   [Li, Ren-Ke; Fish, Jason E.; Husain, Mansoor] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada.
   [Husain, Mansoor] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Husain, Mansoor] Univ Hlth Network, Ted Rogers Ctr Heart Res, Toronto, ON, Canada.
RP Husain, M (reprint author), Toronto Gen Res Inst, Div Expt Therapeut, Toronto, ON, Canada.
EM mansoor.husain@uhn.ca
RI Bader, Gary/C-1176-2009
OI Bader, Gary/0000-0003-0185-8861; Husain, Mansoor/0000-0002-3740-6739;
   Cheng, Henry/0000-0002-4254-962X; Li, Ren-Ke/0000-0002-2584-060X; Fish,
   Jason/0000-0003-0640-7277
FU Heart and Stroke Foundation of Ontario (HSFO) [T6757]; Career
   Investigator Award of the HSFO [CI6824]
FX This study was funded by an operating grant to MH from the Heart and
   Stroke Foundation of Ontario (HSFO; T6757). MH is recipient of a Career
   Investigator Award of the HSFO (CI6824).
CR Arad M, 2007, CIRC RES, V100, P474, DOI 10.1161/01.RES.0000258446.23525.37
   Aurora AB, 2012, J CLIN INVEST, V122, P1222, DOI 10.1172/JCI59327
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188
   Bonney S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071493
   Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616
   Bornfeldt KE, 2011, CELL METAB, V14, P575, DOI 10.1016/j.cmet.2011.07.015
   Broderick TL, 2002, MOL CELL BIOCHEM, V233, P119, DOI 10.1023/A:1015506327849
   Calvillo L, 2011, J CARDIOVASC PHARM, V58, P500, DOI 10.1097/FJC.0b013e31822b7204
   Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598
   Cava E, 2013, AGING-US, V5, P507, DOI 10.18632/aging.100581
   Chandrasekar B, 2001, AM J PHYSIOL-HEART C, V280, pH2094
   Chung KW, 2013, EXP GERONTOL, V48, P1049, DOI 10.1016/j.exger.2012.11.007
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC
   Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101
   Dolinsky VW, 2011, BBA-MOL BASIS DIS, V1812, P1477, DOI 10.1016/j.bbadis.2011.06.010
   Durgan DJ, 2010, CIRC RES, V106, P647, DOI 10.1161/CIRCRESAHA.109.209957
   Durgan DJ, 2010, CIRC RES, V106, P546, DOI 10.1161/CIRCRESAHA.109.209346
   Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728
   Edwards AG, 2010, MECH AGEING DEV, V131, P739, DOI 10.1016/j.mad.2010.09.007
   Fan D, 2014, CIRC RES, V114, P889, DOI 10.1161/CIRCRESAHA.114.302335
   Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Han XF, 2012, J NUTR BIOCHEM, V23, P1592, DOI 10.1016/j.jnutbio.2011.11.002
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Juhaszova M, 2009, CIRC RES, V104, P1240, DOI 10.1161/CIRCRESAHA.109.197996
   Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y
   KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kunuthur SP, 2012, J CELL MOL MED, V16, P1739, DOI 10.1111/j.1582-4934.2011.01491.x
   Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105
   Lee J, 2010, AGING-US, V2, P527, DOI 10.18632/aging.100184
   Lemmer B, 2006, PHARMACOL THERAPEUT, V111, P629, DOI 10.1016/j.pharmthera.2005.11.008
   Libby P, 2000, CIRCULATION, V102, P1874, DOI 10.1161/01.CIR.102.16.1874
   Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013
   Liu N, 2010, DEV CELL, V18, P510, DOI 10.1016/j.devcel.2010.03.010
   Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008
   Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103
   Maillet M, 2013, NAT REV MOL CELL BIO, V14, P38, DOI 10.1038/nrm3495
   Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016
   Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059
   Marzetti E, 2009, CLIN GERIATR MED, V25, P715, DOI 10.1016/j.cger.2009.07.002
   Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432
   MCCAY CM, 1989, NUTRITION, V5, P155
   Mercken EM, 2013, AGING CELL, V12, P645, DOI 10.1111/acel.12088
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mishra PK, 2013, BBA-MOL BASIS DIS, V1832, P2271, DOI 10.1016/j.bbadis.2013.09.004
   Noyan-Ashraf MH, 2005, NUTR NEUROSCI, V8, P101, DOI 10.1080/10284150500069470
   Noyan-Ashraf MH, 2006, FASEB J, V20, P371, DOI 10.1096/fj.05-4889fje
   Noyan-Ashraf MH, 2013, CIRCULATION, V127, P74, DOI 10.1161/CIRCULATIONAHA.112.091215
   Noyan-Ashraf MH, 2009, DIABETES, V58, P975, DOI 10.2337/db08-1193
   Oshima Y, 2005, CARDIOVASC RES, V65, P428, DOI 10.1016/j.cardiores.2004.10.021
   Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001
   Paschos GK, 2010, CIRC RES, V106, P833, DOI 10.1161/CIRCRESAHA.109.211706
   Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105
   Piper MDW, 2008, CELL METAB, V8, P99, DOI 10.1016/j.cmet.200;3.06.012
   Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047
   Robertson LT, 2013, EXP GERONTOL, V48, P1043, DOI 10.1016/j.exger.2013.01.009
   Rose BA, 2010, PHYSIOL REV, V90, P1507, DOI 10.1152/physrev.00054.2009
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shinmura K, 2005, J MOL CELL CARDIOL, V39, P285, DOI 10.1016/j.yjmcc.2005.03.010
   Shinmura K, 2011, CIRC RES, V109, P396, DOI 10.1161/CIRCRESAHA.111.243097
   Shinmura K, 2008, AM J PHYSIOL-HEART C, V295, pH2348, DOI 10.1152/ajpheart.00602.2008
   Silver AC, 2012, IMMUNITY, V36, P251, DOI 10.1016/j.immuni.2011.12.017
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Small EM, 2010, CIRCULATION, V121, P1022, DOI 10.1161/CIRCULATIONAHA.109.889048
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sussman MA, 2011, PHYSIOL REV, V91, P1023, DOI 10.1152/physrev.00024.2010
   Swindell WR, 2008, MECH AGEING DEV, V129, P138, DOI 10.1016/j.mad.2007.11.003
   Swindell WR, 2011, AGEING RES REV, V10, P132, DOI 10.1016/j.arr.2010.09.007
   Swindell WR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-585
   Swindell WR, 2008, MECH AGEING DEV, V129, P580, DOI 10.1016/j.mad.2008.06.001
   Trepanowski JF, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-107
   Ungvari Z, 2008, CIRC RES, V102, P519, DOI 10.1161/CIRCRESAHA.107.168369
   van Heemst D, 2005, AGING CELL, V4, P79, DOI 10.1111/j.1474-9728.2005.00148.x
   Varady KA, 2007, AM J CLIN NUTR, V86, P7
   Vigneron F, 2011, CARDIOVASC RES, V90, P49, DOI 10.1093/cvr/cvr002
   Vora M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003737
   Wang Q, 2011, ONCOGENE, V30, P3875, DOI 10.1038/onc.2011.103
   WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854
   Wu LY, 2004, P NATL ACAD SCI USA, V101, P7094, DOI 10.1073/pnas.0402004101
   Wu QL, 2012, SHOCK, V38, P165, DOI 10.1097/SHK.0b013e31825b5633
   Zhang LH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-290
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 87
TC 24
Z9 24
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2015
VL 10
IS 6
AR e0130658
DI 10.1371/journal.pone.0130658
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL3FM
UT WOS:000356835800090
PM 26098549
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhang, CY
   Zhu, SS
   Wei, L
   Yan, X
   Wang, J
   Quan, R
   She, RP
   Hu, FJ
   Liu, J
AF Zhang, Chunyan
   Zhu, Shanshan
   Wei, Li
   Yan, Xu
   Wang, Jing
   Quan, Rong
   She, Ruiping
   Hu, Fengjiao
   Liu, Jue
TI Recombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein
   Promotes Protective Immune Responses in Mice
SO PLOS ONE
LA English
DT Article
ID MULTISYSTEMIC WASTING SYNDROME; MUCOSAL ADJUVANT ACTIVITY; TOLL-LIKE
   RECEPTOR-5; BACTERIAL FLAGELLIN; RESPIRATORY CHALLENGE; CELLULAR
   MECHANISMS; ADAPTIVE IMMUNITY; IFN-GAMMA; IN-VIVO; PCV2
AB The Cap protein of porcine circovirus type 2 (PCV2) that serves as a major host-protective immunogen was used to develop recombinant vaccines for control of PCV2-associated diseases. Growing research data have demonstrated the high effectiveness of flagellin as an adjuvant for humoral and cellular immune responses. Here, a recombinant protein was designed by fusing a modified version of bacterial flagellin to PCV2 Cap protein and expressed in a baculovirus system. When administered without adjuvant to BALB/c mice, the flagellin-Cap fusion protein elicited stronger PCV2-specific IgG antibody response, higher neutralizing antibody levels, milder histopathological changes and lower viremia, as well as higher secretion of cytokines such as TNF-alpha and IFN-gamma that conferred better protection against virus challenge than those in the recombinant Cap alone-inoculated mice. These results suggest that the recombinant Cap protein when fused to flagellin could elicit better humoral and cellular immune responses against PCV2 infection in a mouse model, thereby acting as an attractive candidate vaccine for control of the PCV2-associated diseases.
C1 [Zhang, Chunyan; Zhu, Shanshan; Wei, Li; Yan, Xu; Wang, Jing; Liu, Jue] Beijing Acad Agr & Forestry Sci, Inst Anim Husb & Vet Med, Beijing Key Lab Prevent & Control Infect Dis Live, Beijing 100097, Peoples R China.
   [Quan, Rong; She, Ruiping; Hu, Fengjiao] China Agr Univ, Coll Vet Med, Beijing 100197, Peoples R China.
RP Liu, J (reprint author), Beijing Acad Agr & Forestry Sci, Inst Anim Husb & Vet Med, Beijing Key Lab Prevent & Control Infect Dis Live, 9 Shuguang Garden Middle Rd, Beijing 100097, Peoples R China.
EM liujue@263.net
FU National Science Fund for Distinguished Young Scholars [31025028];
   Beijing Municipal Science and Technology; People's Republic of China
FX This work was supported by grants from the National Science Fund for
   Distinguished Young Scholars (31025028) and the Beijing Municipal
   Science and Technology Contract Project (Z07010501780701), People's
   Republic of China. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Allan G, 1998, VET REC, V142, P467
   ALLAN GM, 1995, VET MICROBIOL, V44, P49, DOI 10.1016/0378-1135(94)00136-K
   Bates JT, 2008, MECH AGEING DEV, V129, P271, DOI 10.1016/j.mad.2008.01.009
   Bates JT, 2011, J IMMUNOL, V186, P6255, DOI 10.4049/jimmunol.1001855
   Ben-Yedidia T, 1998, IMMUNOL LETT, V64, P9, DOI 10.1016/S0165-2478(98)00073-X
   Blanchard P, 2003, VACCINE, V21, P4565, DOI 10.1016/S0264-410X(03)00503-6
   Bucarey SA, 2009, VACCINE, V27, P5781, DOI 10.1016/j.vaccine.2009.07.061
   Carasova P, 2007, RES VET SCI, V83, P274, DOI 10.1016/j.rvsc.2006.11.013
   Cheung AK, 2003, VIROLOGY, V305, P168, DOI 10.1006/viro.2002.1733
   Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004
   Del Prete G, 1998, Int Rev Immunol, V16, P427, DOI 10.3109/08830189809043004
   Delaney KN, 2010, VIRAL IMMUNOL, V23, P201, DOI 10.1089/vim.2009.0107
   Fan HY, 2008, J VIROL METHODS, V150, P21, DOI 10.1016/j.jviromet.2008.02.011
   Fort M, 2008, VACCINE, V26, P1063, DOI 10.1016/j.vaccine.2007.12.019
   Fort M, 2009, VACCINE, V27, P4031, DOI 10.1016/j.vaccine.2009.04.028
   Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882
   Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106
   Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006
   Honko AN, 2005, IMMUNOL RES, V33, P83, DOI 10.1385/IR:33:1:083
   Ju CM, 2005, VET MICROBIOL, V109, P179, DOI 10.1016/j.vetmic.2005.06.001
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim T, 2009, VET MICROBIOL, V138, P318, DOI 10.1016/j.vetmic.2009.04.014
   Kiupel M, 2001, VET PATHOL, V38, P74, DOI 10.1354/vp.38-1-74
   Kixmoller M, 2008, VACCINE, V26, P3443, DOI 10.1016/j.vaccine.2008.04.032
   Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006
   Letran SE, 2011, EUR J IMMUNOL, V41, P29, DOI 10.1002/eji.201040717
   Liu G, 2012, VACCINE, V30, P6833, DOI 10.1016/j.vaccine.2012.09.013
   Liu GM, 2011, VACCINE, V29, P8677, DOI 10.1016/j.vaccine.2011.08.118
   Liu J, 2005, J VIROL, V79, P8262, DOI 10.1128/JVI.79.13.8262-8274.2005
   Liu J, 2006, J VIROL, V80, P5065, DOI 10.1128/JVI.80.10.5065-5073.2006
   Liu Q, 2001, PROTEIN EXPRES PURIF, V21, P115, DOI 10.1006/prep.2000.1356
   Mankertz A, 1998, J GEN VIROL, V79, P381, DOI 10.1099/0022-1317-79-2-381
   Martelli P, 2011, VET MICROBIOL, V149, P339, DOI 10.1016/j.vetmic.2010.12.008
   McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000
   McDonald WF, 2007, J INFECT DIS, V195, P1607, DOI 10.1086/517613
   McIntosh KA, 2006, CAN J VET RES, V70, P58
   McSorley SJ, 2002, J IMMUNOL, V169, P3914, DOI 10.4049/jimmunol.169.7.3914
   Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165
   Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156
   Mizel SB, 2009, CLIN VACCINE IMMUNOL, V16, P21, DOI 10.1128/CVI.00333-08
   Nawagitgul P, 2000, J GEN VIROL, V81, P2281, DOI 10.1099/0022-1317-81-9-2281
   Opriessnig T, 2009, VACCINE, V27, P1002, DOI 10.1016/j.vaccine.2008.11.105
   Opriessnig T., 2007, J VET DIAGN INVEST, V19, P571
   Perez-Martin E, 2010, VACCINE, V28, P2340, DOI 10.1016/j.vaccine.2009.12.061
   Pino O, 2005, INFECT IMMUN, V73, P6763, DOI 10.1128/IAI.73.10.6763-6770.2005
   Quintana J, 2002, VET RES, V33, P229, DOI 10.1051/vetres:2002011
   Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239
   Segales J, 2004, VET MICROBIOL, V98, P151, DOI 10.1016/j.vetmic.2003.10.007
   Segales Joaquim, 2005, Animal Health Research Reviews, V6, P119, DOI 10.1079/AHR2005106
   Shen HG, 2008, J GEN VIROL, V89, P1857, DOI 10.1099/vir.0.2008/000125-0
   TISCHER I, 1987, ARCH VIROL, V96, P39, DOI 10.1007/BF01310989
   Wang K, 2008, J VIROL METHODS, V150, P1, DOI 10.1016/j.jviromet.2008.02.014
   Wang XW, 2007, VET MICROBIOL, V121, P215, DOI 10.1016/j.vetmic.2006.11.027
   Wang XW, 2006, VACCINE, V24, P3374, DOI 10.1016/j.vaccine.2005.12.068
   Wang YP, 2013, VACCINE, V31, P833, DOI 10.1016/j.vaccine.2012.11.062
NR 55
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2015
VL 10
IS 6
AR e0129617
DI 10.1371/journal.pone.0129617
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK6GR
UT WOS:000356327000096
PM 26070075
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wang, H
   Tatsuo, S
   Wang, SD
   Zhang, Q
   Hou, JF
   Wang, J
   Jin, C
   Qian, HY
   Yang, YJ
AF Wang Hong
   Tatsuo, Shimosawa
   Wang Shou-Dong
   Zhang Qian
   Hou Jian-Feng
   Wang Jue
   Jin Chen
   Qian Hai-Yan
   Yang Yue-Jin
TI Resveratrol Upregulates Cardiac SDF-1 in Mice with Acute Myocardial
   Infarction through the Deacetylation of Cardiac p53
SO PLOS ONE
LA English
DT Article
ID STEM-CELL RECRUITMENT; HISTONE DEACETYLASE; STROMAL FIBROBLASTS;
   HEART-FAILURE; FACTOR-I; EXPRESSION; INJURY; SIRT1; MODEL; MOBILIZATION
AB Aims
   We previously demonstrated that resveratrol (RSV) administration causes cardiac stromal cell-derived factor (SDF)-1 upregulation and can enhance the mobilization of stem cells in mice with acute myocardial infarction (AMI). However, the upstream signal transduction involved in SDF-1 regulation in the setting of AMI and RSV administration remains unclear. Because RSV is a sirtuin 1 (SIRT1) activator and SIRT proteins act as deacetylases, we investigated the role of SIRT1 in SDF-1 upregulation and its subsequent effects.
   Methods and Results
   In vitro experiments with H9C2 cardiomyocytes under hypoxia and serum-deprivation conditions showed that p53 acted upstream of SDF-1. RSV could not regulate SDF-1 effectively after SIRT1 silencing, indicating that it is dependent on SIRT1. Subsequently, male C57BL/6 mice were divided into four groups: 1) sham, 2) MI, 3) MI+RSV, and 4) MI+RSV plus nicotinamide, an inhibitor of the deacetylase activity of SIRT (MI+RSV+NAM). Compared with the sham mice, AMI caused a slight increase in the cardiac p53 level and resulted in significant SIRT1 downregulation and p53 acetylation or activation. Compared with the MI mice, MI+RSV administration improved the cardiac SDF-1 level and reversed the reduction of SIRT1 and the activation of p53. Furthermore, we observed less cardiac dysfunction in MI+RSV mice and determined that NAM abolished the effects of RSV.
   Conclusions
   RSV enhances cardiac SDF-1 excretion after AMI partially through a SIRT1 normalization/p53 inactivation pathway.
C1 [Wang Hong] Capital Med Univ, Beijing Anzhen Hosp, Ctr Cardiac Intens Care, Beijing, Peoples R China.
   [Tatsuo, Shimosawa] Univ Tokyo, Fac Med, Dept Clin Lab, Tokyo 113, Japan.
   [Wang Shou-Dong] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
   [Zhang Qian; Hou Jian-Feng; Wang Jue; Jin Chen; Qian Hai-Yan; Yang Yue-Jin] Chinese Acad Med Sci, Fuwai Hosp, State Key Lab Cardiovasc Dis, Beijing 100730, Peoples R China.
   [Zhang Qian; Hou Jian-Feng; Wang Jue; Jin Chen; Qian Hai-Yan; Yang Yue-Jin] Chinese Acad Med Sci, Cardiovasc Inst, Beijing 100730, Peoples R China.
   [Zhang Qian; Hou Jian-Feng; Wang Jue; Jin Chen; Qian Hai-Yan; Yang Yue-Jin] Peking Union Med Coll, Beijing 100021, Peoples R China.
RP Yang, YJ (reprint author), Chinese Acad Med Sci, Fuwai Hosp, State Key Lab Cardiovasc Dis, Beijing 100730, Peoples R China.
EM yangyjfw@163.com
FU National Natural Science Foundation of China [81170129]; Health and
   Medical Development Foundation of China [2011-H25]; Basic Clinical
   Research Collaboration Fund of Capital Medical University [14JL61]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81170129 to Y.J. Yang), the Health and Medical
   Development Foundation of China (2011-H25 to Y.J. Yang), and the Basic
   Clinical Research Collaboration Fund of Capital Medical University
   (14JL61 to H. Wang). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF
   Addadi Y, 2010, CANCER RES, V70, P9650, DOI 10.1158/0008-5472.CAN-10-1146
   Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff
   Anderson GD, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00021
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Borradaile NM, 2009, CURR PHARM DESIGN, V15, P110, DOI 10.2174/138161209787185742
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011
   Hsu CP, 2010, CIRCULATION, V122, P2170, DOI 10.1161/CIRCULATIONAHA.110.958033
   Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331
   Jian BX, 2012, MOL MED, V18, P209, DOI 10.2119/molmed.2011.00365
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Mohsin S, 2011, CIRC RES, V109, P1415, DOI 10.1161/CIRCRESAHA.111.243071
   Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323
   Nadtochiy SM, 2011, CARDIOVASC RES, V89, P643, DOI 10.1093/cvr/cvq287
   Nguyen PD, 2010, WOUND REPAIR REGEN, V18, P553, DOI 10.1111/j.1524-475X.2010.00638.x
   Olive M, 2008, J CLIN INVEST, V118, P2050, DOI 10.1172/JCI31244
   Penn MS, 2012, GENE THER, V19, P583, DOI 10.1038/gt.2012.32
   Penn MS, 2013, CIRC RES, V112, P816, DOI 10.1161/CIRCRESAHA.111.300440
   Samuel SM, 2008, J AGR FOOD CHEM, V56, P9692, DOI 10.1021/jf802050h
   Segers VFM, 2007, CIRCULATION, V116, P1683, DOI 10.1161/CIRCULATIONAHA.107.718718
   Singh S, 2009, CLIN CARDIOL, V32, P176, DOI 10.1002/clc.20470
   Tang JM, 2010, MOL BIOL REP, V37, P1957, DOI 10.1007/s11033-009-9642-z
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Wang H, 2012, PHYSIOL RES, V61, P543
   Wang H, 2012, HEART FAIL REV, V17, P437, DOI 10.1007/s10741-011-9260-4
   Wang YG, 2006, J MOL CELL CARDIOL, V41, P478, DOI 10.1016/j.yjmcc.2006.06.074
   Wei SG, 2012, HYPERTENSION, V59, P991, DOI 10.1161/HYPERTENSIONAHA.111.188086
   Xu W, 2014, SHOCK, V42, P440, DOI 10.1097/SHK.0000000000000225
   Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006
NR 30
TC 7
Z9 11
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 8
PY 2015
VL 10
IS 6
AR UNSP e0128978
DI 10.1371/journal.pone.0128978
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK1GM
UT WOS:000355955300073
PM 26053177
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Jiang, N
   Leithold, LHE
   Post, J
   Ziehm, T
   Mauler, J
   Gremer, L
   Cremer, M
   Schartmann, E
   Shah, NJ
   Kutzsche, J
   Langen, KJ
   Breitkreutz, J
   Willbold, D
   Willuweit, A
AF Jiang, Nan
   Leithold, Leonie H. E.
   Post, Julia
   Ziehm, Tamar
   Mauler, Joerg
   Gremer, Lothar
   Cremer, Markus
   Schartmann, Elena
   Shah, N. Jon
   Kutzsche, Janine
   Langen, Karl-Josef
   Breitkreutz, Joerg
   Willbold, Dieter
   Willuweit, Antje
TI Preclinical Pharmacokinetic Studies of the Tritium Labelled
   D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer's
   Disease
SO PLOS ONE
LA English
DT Article
ID IMAGE PHAGE DISPLAY; DOUBLE TRANSGENIC MICE; PROTEIN; MIRROR;
   INFLAMMATION; DELIVERY; MODELS; BRAIN; BLOOD; BODY
AB Targeting toxic amyloid beta (A beta) oligomers is currently a very attractive drug development strategy for treatment of Alzheimer's disease. Using mirror-image phage display against A beta 1-42, we have previously identified the fully D-enantiomeric peptide D3, which is able to eliminate A beta oligomers and has proven therapeutic potential in transgenic Alzheimer's disease animal models. However, there is little information on the pharmacokinetic behaviour of D-enantiomeric peptides in general. Therefore, we conducted experiments with the tritium labelled D-peptide D3 (H-3-D3) in mice with different administration routes to study its distribution in liver, kidney, brain, plasma and gastrointestinal tract, as well as its bioavailability by i.p. and p.o. administration. In addition, we investigated the metabolic stability in liver microsomes, mouse plasma, brain, liver and kidney homogenates, and estimated the plasma protein binding. Based on its high stability and long biological half-life, our pharmacokinetic results support the therapeutic potential of D-peptides in general, with D3 being a new promising drug candidate for Alzheimer's disease treatment.
C1 [Jiang, Nan; Leithold, Leonie H. E.; Post, Julia; Ziehm, Tamar; Gremer, Lothar; Schartmann, Elena; Kutzsche, Janine; Willbold, Dieter] Forschungszentrum Julich, Inst Complex Syst ICS 6, Struct Biochem, D-52425 Julich, Germany.
   [Mauler, Joerg; Shah, N. Jon; Langen, Karl-Josef; Willuweit, Antje] Forschungszentrum Julich, Inst Neurosci & Med INM 4, Med Imaging Phys, D-52425 Julich, Germany.
   [Gremer, Lothar] Forschungszentrum Julich, Inst Neurosci & Med INM 1, Struct & Funct Org Brain, D-52425 Julich, Germany.
   [Langen, Karl-Josef] Rhein Westfal TH Aachen, Univ Klinikum, Dept Nucl Med, D-52062 Aachen, Germany.
   [Breitkreutz, Joerg] Univ Dusseldorf, Inst Pharmaceut & Biopharmaceut, Dusseldorf, Germany.
   [Willbold, Dieter] Univ Dusseldorf, Inst Phys Biol, Dusseldorf, Germany.
RP Willbold, D (reprint author), Forschungszentrum Julich, Inst Complex Syst ICS 6, Struct Biochem, D-52425 Julich, Germany.
EM D.Willbold@fz-juelich.de; A.Willuweit@fz-juelich.de
RI Willbold, Dieter/A-6280-2013; Gremer, Lothar/H-9128-2013; Gremer,
   Lothar/O-7760-2019; Shah, N. Jon/H-5849-2013; Breitkreutz,
   Joerg/B-9581-2017; Kutzsche, Janine/G-6287-2013; Langen,
   Karl-Josef/H-4396-2013
OI Willbold, Dieter/0000-0002-0065-7366; Gremer,
   Lothar/0000-0001-7065-5027; Gremer, Lothar/0000-0001-7065-5027; Shah, N.
   Jon/0000-0002-8151-6169; Breitkreutz, Joerg/0000-0002-3982-9823;
   Kutzsche, Janine/0000-0003-0271-7390; Langen,
   Karl-Josef/0000-0003-1101-5075; Willuweit, Antje/0000-0002-6725-0755
FU Portfolio Technology and Medicine; Helmholtz-Validierungsfonds of the
   Impuls und Vernetzungs-Fonds der Helmholtzgemeinschaft; "Portfolio Drug
   Design" of the Impuls und Vernetzungs-Fonds der Helmholtzgemeinschaft
FX DW was supported by grants from the "Portfolio Technology and Medicine"
   and the Helmholtz-Validierungsfonds of the Impuls und Vernetzungs-Fonds
   der Helmholtzgemeinschaft; KJL and DW were supported by the "Portfolio
   Drug Design" of the Impuls und Vernetzungs-Fonds der
   Helmholtzgemeinschaft
   (http://www.helmholtz.de/ueber_uns/impuls_und_vernetzungsfonds; no grant
   numbers available). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Berchtold NC, 1998, NEUROBIOL AGING, V19, P173, DOI 10.1016/S0197-4580(98)00052-9
   Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699
   Chapman ME, 2010, AM J PHYSIOL-RENAL, V299, pF280, DOI 10.1152/ajprenal.00113.2010
   Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896
   Fletcher Lydia C B, 2013, GMS Health Technol Assess, V9, pDoc01, DOI 10.3205/hta000107
   Funke SA, 2010, ACS CHEM NEUROSCI, V1, P639, DOI 10.1021/cn100057j
   Kayed R, 2013, J ALZHEIMERS DIS, V33, pS67, DOI 10.3233/JAD-2012-129001
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lalatsa A, 2012, MOL PHARMACEUT, V9, P1764, DOI 10.1021/mp300068j
   Liu M, 2010, P NATL ACAD SCI USA, V107, P14321, DOI 10.1073/pnas.1008930107
   Mason JM, 2010, FUTURE MED CHEM, V2, P1813, DOI 10.4155/FMC.10.259
   Mikulca JA, 2014, J CLIN PHARM THER, V39, P25, DOI 10.1111/jcpt.12112
   MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320
   Nygaard HB, 2013, CLIN THER, V35, P1480, DOI 10.1016/j.clinthera.2013.09.009
   Pollaro L, 2010, MEDCHEMCOMM, V1, P319, DOI 10.1039/c0md00111b
   Reichel A, 2006, CURR DRUG METAB, V7, P183, DOI 10.2174/138920006775541525
   Schenk D, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006387
   Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741
   Stockley JH, 2008, CELL MOL LIFE SCI, V65, P3265, DOI 10.1007/s00018-008-8271-3
   Sun N, 2012, MINI-REV MED CHEM, V12, P388, DOI 10.2174/138955712800493942
   Takagi H, 2010, PEPTIDES, V31, P1421, DOI 10.1016/j.peptides.2010.04.032
   Tamaoka Akira, 2013, Rinsho Byori, V61, P1060
   TD B, 1993, GENEREVIEWS R
   van Groen T, 2013, J ALZHEIMERS DIS, V34, P609, DOI 10.3233/JAD-121792
   van Groen T, 2012, ADV PROTEIN CHEM STR, V88, P133, DOI 10.1016/B978-0-12-398314-5.00005-2
   van Groen T, 2008, CHEMMEDCHEM, V3, P1848, DOI 10.1002/cmdc.200800273
   van Groen T, 2009, CHEMMEDCHEM, V4, P276, DOI 10.1002/cmdc.200800289
   Wiesehan K, 2003, CHEMBIOCHEM, V4, P811, DOI 10.1002/cbic.200300570
   Wong TW, 2010, J DRUG TARGET, V18, P79, DOI 10.3109/10611860903302815
   ZAWADZKE LE, 1992, J AM CHEM SOC, V114, P4002, DOI 10.1021/ja00036a073
NR 31
TC 16
Z9 16
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 5
PY 2015
VL 10
IS 6
AR e0128553
DI 10.1371/journal.pone.0128553
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ7CR
UT WOS:000355652200078
PM 26046986
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lei, XG
   Li, H
   Huang, BH
   Rizak, J
   Li, L
   Xu, LQ
   Liu, L
   Wu, J
   Lu, LB
   Wang, ZB
   Hu, YZ
   Le, WD
   Deng, XL
   Li, JL
   Yao, YG
   Xu, L
   Hu, XT
   Zhang, BR
AF Lei, Xiaoguang
   Li, Hao
   Huang, Baihui
   Rizak, Joshua
   Li, Ling
   Xu, Liqi
   Liu, Li
   Wu, Jing
   Lu, Longbao
   Wang, Zhengbo
   Hu, Yingzhou
   Le, Weidong
   Deng, Xingli
   Li, Jiali
   Yao, Yonggang
   Xu, Lin
   Hu, Xintian
   Zhang, Baorong
TI 1-Methyl-4-Phenylpyridinium Stereotactic Infusion Completely and
   Specifically Ablated the Nigrostriatal Dopaminergic Pathway in Rhesus
   Macaque
SO PLOS ONE
LA English
DT Article
ID MPTP-TREATED MONKEYS; PARKINSONS-DISEASE; ANIMAL-MODELS; ESSENTIAL
   TREMOR; BRAIN; MECHANISMS; NEURONS; 6-HYDROXYDOPAMINE; PATHOPHYSIOLOGY;
   COMMUNICATION
AB Introduction
   Complete and specific ablation of a single dopaminergic (DA) pathway is a critical step to distinguish the roles of DA pathways in vivo. However, this kind of technique has not been reported in non-human primates. This study aimed to establish a lesioning method with a complete and specific ablation.
   Method
   A carefully designed infusion route based on a MRI stereotactic technique was developed to deliver the highly selective dopaminergic toxin 1-methyl-4-phenylpyridinium (MPP+) unilaterally into multiple sites of compact part of substantia nigra (SNc) and striatum in monkeys. The nigrostriatal DA pathway was selected because lesioning of this pathway may induce symptoms that are suitable for evaluation. The pathological, behavioral, neuropharmacological, and clinical laboratorial data were collected to evaluate the lesioning effects.
   Result
   Pathological examination revealed a complete ablation of tyrosine hydroxylase positive (TH+) neurons in the SNc, while preserving intact TH+ neurons in the ventral tegmental area (VTA) nearby. TH+ projections in the striatum were also unilaterally lost. The monkeys displayed stable (>28 weeks) rotations and symptoms which were expected with loss of DA neurons in the SNc, with rest tremor being an exception. No item implied the presence of a severe side effect caused by the operation or the intracerebral MPP+ infusion. The results suggested that rest tremor may not directly rely on the nigrostriatal pathway.
   Conclusion
   Taken together, in addition to providing a specific nigrostriatal DA lesioned model, this method, combined with brain stimulation or other techniques, can be applied as a powerful tool for the complete lesion of any desired DA pathway in order to study its specific functions in the brain.
C1 [Lei, Xiaoguang; Zhang, Baorong] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou 310027, Zhejiang, Peoples R China.
   [Li, Hao; Huang, Baihui; Rizak, Joshua; Wu, Jing; Wang, Zhengbo; Hu, Yingzhou; Li, Jiali; Yao, Yonggang; Xu, Lin; Hu, Xintian] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China.
   [Li, Hao; Huang, Baihui] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Li, Ling; Xu, Liqi; Liu, Li] Kunming Gen Hosp PLA, Dept Med Imaging, Kunming, Yunnan, Peoples R China.
   [Lu, Longbao] Chinese Acad Sci, Kunming Primate Res Ctr, Kunming Inst Zool, Kunming, Yunnan, Peoples R China.
   [Le, Weidong] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China.
   [Deng, Xingli] Kunming Med Univ, Affiliated Hosp 1, Dept Neurosurg, Kunming, Yunnan, Peoples R China.
   [Yao, Yonggang; Xu, Lin; Hu, Xintian] Chinese Acad Sci, Ctr Excellence Brain Sci, Shanghai, Peoples R China.
RP Zhang, BR (reprint author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou 310027, Zhejiang, Peoples R China.
EM xthu@mail.kiz.ac.cn; brzhang@zju.edu.cn
OI Yao, Yong-Gang/0000-0002-2955-0693; wang, zhengbo/0000-0002-4717-5137;
   Li, Jiali/0000-0002-0039-3671; Xu, Lin/0000-0002-2710-3507
FU CAS [XDB02020000]; National Program on Key Basic Research Project (973
   Programs) [2015CB755605, 2012CB825503, 2012CBA01304]; Chinese Academy of
   Sciences [KZCC-EW-103-2]; National Natural Science Foundation of China
   [91332120, 31271167, 81271495, 81471312, 81271248]; Yunnan Provincial
   Project to Attract One-hundred Exceptional Talents from Overseas; CAS;
   Zhejiang Province Department of Science and Technology [2011C14026]
FX This work was supported by grants from the Strategic Priority Research
   Program of CAS (XDB02020000), National Program on Key Basic Research
   Project (973 Programs 2015CB755605, 2012CB825503, 2012CBA01304), Key
   Program of the Chinese Academy of Sciences (KZCC-EW-103-2), Training
   Program of the Major Research Plan of the National Natural Science
   Foundation of China (91332120), National Natural Science Foundation of
   China (31271167, 81271495, 81471312, 81271248), The Yunnan Provincial
   Project to Attract One-hundred Exceptional Talents from Overseas,
   Selected Frontier Scientific Significant Breakthrough Project of CAS,
   International Cooperation Projection (2011C14026) of Zhejiang Province
   Department of Science and Technology. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anderson G, 2007, EXP NEUROL, V207, P4, DOI 10.1016/j.expneurol.2007.05.010
   [Anonymous], 2011, GUIDE CARE USE LAB A
   Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550
   Bergman H, 2002, MOVEMENT DISORD, V17, pS28, DOI 10.1002/mds.10140
   Bezard E, 2011, MOVEMENT DISORD, V26, P993, DOI 10.1002/mds.23696
   Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006
   Blandini F, 2012, FEBS J, V279, P1156, DOI 10.1111/j.1742-4658.2012.08491.x
   Blesa J, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/845618
   Boulet S, 2008, J NEUROSCI, V28, P9575, DOI 10.1523/JNEUROSCI.3465-08.2008
   Bucher SF, 1997, ANN NEUROL, V41, P32, DOI 10.1002/ana.410410108
   CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0
   Collier TJ, 2003, EXP NEUROL, V183, P258, DOI 10.1016/S0014-4886(03)00246-2
   DAMATO RJ, 1986, SCIENCE, V231, P987, DOI 10.1126/science.3080808
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   Duty S, 2011, BRIT J PHARMACOL, V164, P1357, DOI 10.1111/j.1476-5381.2011.01426.x
   Fox SH, 2012, MOVEMENT DISORD, V27, P1373, DOI 10.1002/mds.25133
   Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788
   Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871
   Helmich RC, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0378-8
   Imbert C, 2000, J NEUROSCI METH, V96, P71, DOI 10.1016/S0165-0270(99)00184-3
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81
   KRAEMER GW, 1981, PSYCHOPHARMACOLOGY, V73, P1, DOI 10.1007/BF00431091
   Lieu CA, 2012, BRAIN RES BULL, V87, P1, DOI 10.1016/j.brainresbull.2011.09.013
   Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983
   Mikula S, 2007, NEUROIMAGE, V35, P9, DOI 10.1016/j.neuroimage.2006.11.053
   Mounayar S, 2007, BRAIN, V130, P2898, DOI 10.1093/brain/awm208
   Muthuraman M, 2012, NEUROIMAGE, V60, P1331, DOI 10.1016/j.neuroimage.2012.01.088
   Neumane S, 2012, NEUROBIOL DIS, V48, P27, DOI 10.1016/j.nbd.2012.06.002
   OpackaJuffry J, 1996, J NEURAL TRANSM, V103, P1429, DOI 10.1007/BF01271256
   Pain S, 2013, EXP TOXICOL PATHOL, V65, P689, DOI 10.1016/j.etp.2012.09.001
   Paxinos G, 1999, RHESUS MONKEY BRAIN
   Porras G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009308
   Potts LF, 2013, EXP NEUROL
   SABEL BA, 1982, PHYSIOL BEHAV, V28, P1017, DOI 10.1016/0031-9384(82)90169-X
   Saper CB, 1999, BRAIN, V122, P1401, DOI 10.1093/brain/122.8.1401
   Schnitzler A, 2005, NAT REV NEUROSCI, V6, P285, DOI 10.1038/nrn1650
   SMITH RD, 1993, NEUROSCIENCE, V52, P7, DOI 10.1016/0306-4522(93)90176-G
   Storch A, 2004, J NEURAL TRANSM, V111, P1267, DOI 10.1007/s00702-004-0203-2
   Tande D, 2006, BRAIN, V129, P1194, DOI 10.1093/brain/awl041
   Tieu K, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a009316
   Timmermann L, 2003, BRAIN, V126, P199, DOI 10.1093/brain/awg022
   Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100
   Watanabe Y, 2005, MED SCI MONITOR, V11, pRA17
   Wu J, 2010, J NEUROSCI METH, V193, P203, DOI 10.1016/j.jneumeth.2010.07.039
   Yan T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088404
   Yazdani U, 2006, EXP NEUROL, V200, P172, DOI 10.1016/j.expneurol.2006.02.002
NR 47
TC 2
Z9 2
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2015
VL 10
IS 5
AR e0127953
DI 10.1371/journal.pone.0127953
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ0QZ
UT WOS:000355183900170
PM 26010745
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yaacob, NS
   Yankuzo, HM
   Devaraj, S
   Wong, JKM
   Lai, CS
AF Yaacob, Nik Soriani
   Yankuzo, Hassan Muhammad
   Devaraj, Sutha
   Wong, Jimmy Ka Ming
   Lai, Choon-Sheen
TI Anti-Tumor Action, Clinical Biochemistry Profile and Phytochemical
   Constituents of a Pharmacologically Active Fraction of S. crispus in
   NMU-Induced Rat Mammary Tumour Model
SO PLOS ONE
LA English
DT Article
ID STROBILANTHES-CRISPUS; HUMAN BREAST; CHEMICAL-CONSTITUENTS; MARIGOLD
   EXTRACT; DIETARY LUTEIN; ORAL TOXICITY; CANCER; CARCINOGENESIS;
   PREVENTION; INDUCTION
AB Cancer patients seek alternative remedies such as traditional medicinal plants for safe and effective treatment and help overcome the side effects of conventional therapy. Current knowledge indicates that extracts of Strobilanthes crispus of the Acanthaceae family exhibit potent anticancer properties in vitro and are non-toxic in vivo. S. crispus was also reported to be protective against chemical hepatocarcinogenesis. We previously showed that a bioactive fraction of S. crispus leaves also synergized with tamoxifen to cause apoptosis of human breast cancer cell lines without damaging non-malignant epithelial cells. The present study aimed to evaluate the antitumor effect of S. crispus dichloromethane fraction (F3) using N-methyl-N-Nitrosourea (NMU)-induced rat mammary tumor model. Tumor regression was observed in 75% of the rats following 8-week oral administration of F3 with no secondary tumour formation and no signs of anemia or infection. However, no improvement in the liver and renal function profiles was observed. Major constituents of F3 were identified as lutein, 13(1)-hydroxy-13(2)-oxo-pheophytin a, campesterol, stigmasterol, beta-sitosterol, pheophytin a and 13(2)-hydroxy-pheophytin a. These compounds however, may not significantly contribute to the antitumor effect of F3.
C1 [Yaacob, Nik Soriani; Yankuzo, Hassan Muhammad] Univ Sains Malaysia, Sch Med Sci, Dept Chem Pathol, Kubang Kerian, Kelantan, Malaysia.
   [Devaraj, Sutha; Wong, Jimmy Ka Ming; Lai, Choon-Sheen] Univ Sains Malaysia, Ctr Drug Res, George Town, Malaysia.
RP Yaacob, NS (reprint author), Univ Sains Malaysia, Sch Med Sci, Dept Chem Pathol, Kubang Kerian, Kelantan, Malaysia.
EM niksoriani@usm.my; cs_lai@usm.my
RI Lai, Choon-Sheen/B-6941-2011
FU Universiti Sains Malaysia Research University Grant [1001/PPSP/853002];
   Malaysian Ministry of Education; Universiti Sains Malaysia Fellowship
FX This work was funded by the Universiti Sains Malaysia Research
   University Grant (no. 1001/PPSP/853002). SD and JKMW are recipients of
   MyBrain scholarship funded by the Malaysian Ministry of Education. HMY
   received the Universiti Sains Malaysia Fellowship. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Al-Henhena N, 2011, J MED PLANTS RES, V5, P3660
   Asmah Rahmat, 2006, International Journal of Cancer Research (USA), V2, P47
   Bakar AFM, 2006, INT J CANC RES, V2, P152
   Bernstein L, J NATL CANC I, V199, P1654
   BRUMMITT R. K., 1992, AUTHORS PLANT NAMES
   Burkill IH, 1935, DICT EC PRODUCTS MAL, P2086
   Cameron JS, 1998, OXFORD TXB CLIN NEPH
   Chan MM, 2005, CARCINOGENESIS, V26, P1343, DOI 10.1093/carcin/bgi100
   Chang CL, 2013, J DENT SCI, V8, P8, DOI 10.1016/j.jds.2012.09.006
   Chang YC, 2012, ARCH TOXICOL, V86, P315, DOI 10.1007/s00204-011-0753-7
   Cheng HH, 2001, J NAT PROD, V64, P915, DOI 10.1021/np000595b
   Chew BP, 1996, ANTICANCER RES, V16, P3689
   Chew BP, 2003, ANTICANCER RES, V23, P3333
   Chong HZ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-35
   Nogueira TBDD, 2013, MOLECULES, V18, P11086, DOI 10.3390/molecules180911086
   Donaldson MS, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-19
   Dubben HH, 1998, RADIOTHER ONCOL, V47, P167, DOI 10.1016/S0167-8140(97)00215-6
   Endrini S., 2007, J MED SCI, V7, P1098, DOI DOI 10.3923/JMS.2007.1098.1102
   Fadzelly ABM, 2006, PLANT FOOD HUM NUTR, V61, P7, DOI 10.1007/s11130-006-0002-z
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Ge XX, 2013, ASIAN PAC J CANCER P, V14, P1911, DOI 10.7314/APJCP.2013.14.3.1911
   Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752
   Goh K L, 2004, KLANG GOH KONG LING, P249
   HYNNINEN PH, 1973, ACTA CHEM SCAND, V27, P1478, DOI 10.3891/acta.chem.scand.27-1478
   Ina A, 2007, INT J DEV NEUROSCI, V25, P63, DOI 10.1016/j.ijdevneu.2006.09.323
   Ismail M, 2000, J NUTR BIOCHEM, V11, P536, DOI 10.1016/S0955-2863(00)00108-X
   KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim YS, 2010, Republic Korean Kongkae Taeho Kongbo, Patent No. [KR20100024793, 20100024793]
   Koay YC, 2013, REC NAT PROD, V7, P59
   Krishnan P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-259
   Kull DR, 1997, J AGR FOOD CHEM, V45, P4201, DOI 10.1021/jf960945t
   Lai CS, 2010, J ETHNOPHARMACOL, V127, P486, DOI 10.1016/j.jep.2009.10.009
   Lim Kean Tatt, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P948, DOI 10.1016/S2221-1691(13)60005-2
   Liza MS, 2010, FOOD BIOPROD PROCESS, V88, P319, DOI 10.1016/j.fbp.2009.02.001
   Matsuo A, 1996, PHYTOCHEMISTRY, V42, P427, DOI 10.1016/0031-9422(96)00017-9
   Molnar P, 2006, HELV CHIM ACTA, V89, P667, DOI 10.1002/hlca.200690067
   Muslim NS, 2010, INT J PHARMACOL, V6, P591, DOI 10.3923/ijp.2010.591.599
   Norfarizan-Hanoon NA, 2012, SAINS MALAYS, V41, P403
   Nurraihana H., 2013, International Food Research Journal, V20, P2045
   Park JS, 1998, J NUTR, V128, P1650
   Putzbach K, 2005, J AGR FOOD CHEM, V53, P671, DOI 10.1021/jf0487506
   Rahmat A., 2006, J BIOL SCI, V6, P1005, DOI DOI 10.3923/JBS.2006.1005.1010
   RIVERA ES, 1994, CANCER LETT, V86, P223, DOI 10.1016/0304-3835(94)90082-5
   Russell WMS, 2009, PRINCIPLES HUMANE EX, V1959, P238
   Sakdarat S, 2009, BIOORGAN MED CHEM, V17, P1857, DOI 10.1016/j.bmc.2009.01.059
   Samuel AJSJ, 2010, J ETHNOBIOL ETHNOMED, V6, DOI 10.1186/1746-4269-6-5
   Soares-Maia R, 2013, J ENVIRON PATHOL TOX, V32, P2013
   Soediro I, 1987, ACTA PHARM INDONES, VXII, P1
   Suherman J., 2004, Pakistan Journal of Biological Sciences, V7, P947
   Suherman Jaksa, 2005, Journal of Medical Sciences (Pakistan), V5, P130
   THOMPSON HJ, 1992, CARCINOGENESIS, V13, P1535, DOI 10.1093/carcin/13.9.1535
   Tsubura A, 2011, IN VIVO, V25, P11
   Usunomena U, 2012, BR J PHARM TOXICOL, V3, P165
   Yaacob NS, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-252
   Yaacob NS, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-42
   Sun Z, 2007, ASIA PAC J CLIN NUTR, V16, P447
NR 57
TC 10
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2015
VL 10
IS 5
AR e0126426
DI 10.1371/journal.pone.0126426
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7GR
UT WOS:000354931700018
PM 26000968
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lin, MB
   Sun, W
   Gong, W
   Zhou, ZY
   Ding, YS
   Hou, Q
AF Lin, Mingbao
   Sun, Wei
   Gong, Wan
   Zhou, Zhiyu
   Ding, Yasi
   Hou, Qi
TI Methylophiopogonanone A Protects against Cerebral Ischemia/Reperfusion
   Injury and Attenuates Blood-Brain Barrier Disruption In Vitro
SO PLOS ONE
LA English
DT Article
ID ACUTE ISCHEMIC-STROKE; ARTERY OCCLUSION; OPHIOPOGON-JAPONICUS;
   REPERFUSION INJURY; FOCAL ISCHEMIA; RAT-BRAIN; DYSFUNCTION; TRIALS;
   EDEMA; MODEL
AB Methylophiopogonanone A (MO-A), an active homoisoflavonoid of the Chinese herb Ophiopogon japonicus which has been shown to have protective effects on cerebral ischemia/reperfusion (I/R) injury, has been demonstrated to have anti-inflammatory and anti-oxidative properties. However, little is known about its role in cerebral I/R injury. Therefore, in this study, by using a middle cerebral artery occlusion (MCAO) and reperfusion rat model, the effect of MO-A on cerebral I/R injury was examined. The results showed that MO-A treatment reduced infarct volume and brain edema, improved neurological deficit scores, reversed animal body weight decreases, and increased animal survival time in the stroke groups. Western blotting showed that MO-A suppressed MMP-9, but restored the expression of claudin-3 and claudin-5. Furthermore, transmission electron microscopy were monitored to determine the blood-brain barrier (BBB) alterations in vitro. The results showed that MO-A markedly attenuated BBB damage in vitro. Additionally, MO-A inhibited ROS production in ECs and MMP-9 release in differentiated THP-1 cells in vitro, and suppressed ICAM-1 and VCAM-1 expression in ECs and leukocyte/EC adhesion. In conclusion, our data indicate that MO-A has therapeutic potential against cerebral I/R injury through its ability to attenuate BBB disruption by regulating the expression of MMP-9 and tight junction proteins.
C1 [Lin, Mingbao; Ding, Yasi; Hou, Qi] Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100730, Peoples R China.
   [Lin, Mingbao; Ding, Yasi; Hou, Qi] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Sun, Wei] Capital Med Univ, Beijing Friendship Hosp, Clin Lab Ctr, Beijing, Peoples R China.
   [Gong, Wan] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou, Zhejiang, Peoples R China.
   [Zhou, Zhiyu] Jiangxi Univ Tradit Chinese Med, Coll Basic Med Sci, Nanchang, Peoples R China.
RP Hou, Q (reprint author), Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100730, Peoples R China.
EM houq@imm.ac.cn
FU National Twelfth-Five Year Research Program of China
   [2012ZX09301002001002]; National Natural Science Foundation of China
   [81473398]; scientific research foundation of Beijing Friendship
   Hospital [Z20140512030022]
FX The current study was supported by research grants from the National
   Twelfth-Five Year Research Program of China (2012ZX09301002001002), the
   National Natural Science Foundation of China (Grant No. 81473398) and
   the scientific research foundation of Beijing Friendship Hospital
   (Z20140512030022). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Asahi M, 2001, J NEUROSCI, V21, P7724
   Cheng Yu Dennis, 2004, NeuroRx, V1, P36, DOI 10.1602/neurorx.1.1.36
   Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007
   Curry SH, 2003, ANN NY ACAD SCI, V993, P69, DOI 10.1111/j.1749-6632.2003.tb07512.x
   Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015
   Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003
   Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51
   Gu JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061641
   Guan T, 2013, EUR J PHARMACOL, V714, P303, DOI 10.1016/j.ejphar.2013.07.036
   Jin G, 2008, STROKE, V39, P2538, DOI 10.1161/STROKEAHA.108.514927
   Khatri R, 2012, NEUROLOGY, V79, pS52, DOI 10.1212/WNL.0b013e3182697e70
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Li LH, 2013, CHIN J NAT MEDICINES, V11, P222, DOI [10.1016/S1875-5364(13)60020-5, 10.3724/SP.J.1009.2013.00222]
   Li N, 2012, FITOTERAPIA, V83, P1042, DOI 10.1016/j.fitote.2012.05.011
   Lijnen HR, 2001, THROMB HAEMOSTASIS, V86, P324
   Lin YN, 2010, J PHARMACEUT BIOMED, V52, P757, DOI 10.1016/j.jpba.2010.02.016
   Liu FD, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/464701
   Liu Y, 2014, BRAIN RES, V1544, P45, DOI 10.1016/j.brainres.2013.11.031
   Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Miyazaki T, 2011, STROKE, V42, P1097, DOI 10.1161/STROKEAHA.110.598359
   Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902
   Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032
   Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11
   Sasaki Masanori, 2009, V549, P187, DOI 10.1007/978-1-60327-931-4_13
   Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332
   Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012
   Wang Q, 2009, STROKE, V40, P2157, DOI 10.1161/STROKEAHA.108.541490
   Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195
   Wardlaw JM, 2009, ANN NEUROL, V65, P194, DOI 10.1002/ana.21549
   Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375
   Zehendner CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082823
   Zhang RL, 1999, STROKE, V30, P624, DOI 10.1161/01.STR.30.3.624
   Zhou Yi-Feng, 2008, Chinese Journal of Natural Medicines, V6, P201, DOI 10.3724/SP.J.1009.2008.00201
   Zhu HR, 2010, NEUROPHARMACOLOGY, V59, P70, DOI 10.1016/j.neuropharm.2010.03.017
NR 35
TC 16
Z9 16
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 21
PY 2015
VL 10
IS 4
AR e0124558
DI 10.1371/journal.pone.0124558
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG3XJ
UT WOS:000353212600072
PM 25897666
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Cruz, Y
   Lorea, J
   Mestre, H
   Kim-Lee, JH
   Herrera, J
   Mellado, R
   Galvez, V
   Cuellar, L
   Musri, C
   Ibarra, A
AF Cruz, Yolanda
   Lorea, Jonathan
   Mestre, Humberto
   Hyuna Kim-Lee, Jennifer
   Herrera, Judith
   Mellado, Raul
   Galvez, Vanesa
   Cuellar, Leopoldo
   Musri, Carolina
   Ibarra, Antonio
TI Copolymer-1 Promotes Neurogenesis and Improves Functional Recovery after
   Acute Ischemic Stroke in Rats
SO PLOS ONE
LA English
DT Article
ID CEREBRAL-ARTERY OCCLUSION; GLATIRAMER ACETATE; T-CELLS; ADULT
   NEUROGENESIS; MULTIPLE-SCLEROSIS; BRAIN; NEUROPROTECTION; INFLAMMATION;
   EXPRESSION; THERAPY
AB Stroke triggers a systemic inflammatory response that exacerbates the initial injury. Immunizing with peptides derived from CNS proteins can stimulate protective autoimmunity (PA). The most renowned of these peptides is copolymer-1 (Cop-1) also known as glatiramer acetate. This peptide has been approved for use in the treatment of multiple sclerosis. Cop-1-specific T cells cross the blood-brain barrier and secrete neurotrophins and anti-inflammatory cytokines that could stimulate proliferation of neural precursor cells and recruit them to the injury site; making it an ideal therapy for acute ischemic stroke. The aim of this work was to evaluate the effect of Cop-1 on neurogenesis and neurological recovery during the acute phase (7 days) and the chronic phase of stroke (60 days) in a rat model of transient middle cerebral artery occlusion (tMCAo). BDNF and NT-3 were quantified and infarct volumes were measured. We demonstrated that Cop-1 improves neurological deficit, enhances neurogenesis (at 7 and 60 days) in the SVZ, SGZ, and cerebral cortex through an increase in NT-3 production. It also decreased infarct volume even at the chronic phase of tMCAo. The present manuscript fortifies the support for the use of Cop-1 in acute ischemic stroke.
C1 [Cruz, Yolanda; Lorea, Jonathan; Mestre, Humberto; Hyuna Kim-Lee, Jennifer; Herrera, Judith; Mellado, Raul; Galvez, Vanesa; Cuellar, Leopoldo; Musri, Carolina; Ibarra, Antonio] Univ Anahuac Mexico Norte, Fac Ciencias Salud, Huixquilucan, Estado De Mexic, Mexico.
   [Ibarra, Antonio] Ctr Invest Proyecto CAMINA AC, Distrito Fed, Mexico.
RP Ibarra, A (reprint author), Univ Anahuac Mexico Norte, Fac Ciencias Salud, Huixquilucan, Estado De Mexic, Mexico.
EM iantonio65@yahoo.com
OI Cruz, Yolanda/0000-0001-5559-2339; /0000-0002-4030-3749
FU CONACyT [57204]
FX This publication was funded by the CONACyT (Grant #57204). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aharoni R, 2003, P NATL ACAD SCI USA, V100, P14157, DOI 10.1073/pnas.2336171100
   Aharoni R, 2014, J AUTOIMMUN, V54, P81, DOI 10.1016/j.jaut.2014.05.005
   Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747
   Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967
   Blanco Y, 2006, NEUROSCI LETT, V406, P270, DOI 10.1016/j.neulet.2006.07.043
   Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006
   Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103
   Del Rayo Garrido M, 2012, BASIC CLIN PHARMACOL, V5, P314
   Dell Ralph B, 2002, ILAR J, V43, P207
   Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052
   Famakin BM, 2014, AGING DIS, V5, P307, DOI 10.14336/AD.2014.0500307
   Garcia E, 2012, J NEUROSCI RES, V90, P656, DOI 10.1002/jnr.22771
   Go AS, 2013, CIRCULATION, V128
   Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5
   Ibarra A, 2007, NEUROSCI LETT, V425, P110, DOI 10.1016/j.neulet.2007.08.038
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kokaia Z, 2006, CEREB CORTEX, V16, pI162, DOI 10.1093/cercor/bbhj174
   Kraft P, 2014, EXP TRANSL STROKE ME, V6, P1, DOI [10.1186/2040-7378-6-1, DOI 10.1186/2040-7378-6-1]
   Laurie C, 2007, J NEUROIMMUNOL, V183, P60, DOI 10.1016/j.jneuroim.2006.11.009
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Ma MM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-117
   Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001
   Niv F, 2012, STROKE, V43, P2468, DOI 10.1161/STROKEAHA.112.660977
   Poittevin M, 2013, J NEUROIMMUNOL, V254, P55, DOI 10.1016/j.jneuroim.2012.09.009
   SCHROETER M, 1994, J NEUROIMMUNOL, V55, P195, DOI 10.1016/0165-5728(94)90010-8
   Stern JNH, 2008, P NATL ACAD SCI USA, V105, P5172, DOI 10.1073/pnas.0712131105
   Xing CH, 2012, INT J STROKE, V7, P378, DOI 10.1111/j.1747-4949.2012.00839.x
   Yang BB, 2010, J OCUL PHARMACOL TH, V26, P11, DOI 10.1089/jop.2009.0037
   Ziemssen T, 2002, BRAIN, V125, P2381, DOI 10.1093/brain/awf252
   Ziv Y, 2007, STROKE, V38, P774, DOI 10.1161/01.STR.0000255784.27298.23
NR 30
TC 9
Z9 9
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 30
PY 2015
VL 10
IS 3
AR e0121854
DI 10.1371/journal.pone.0121854
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE9AD
UT WOS:000352134700132
PM 25821957
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Cheng, Z
   Liu, F
   Zhu, S
   Tian, HM
   Wang, L
   Wang, YH
AF Cheng, Zhe
   Liu, Fan
   Zhu, Shan
   Tian, Huimin
   Wang, Liang
   Wang, Yanhai
TI A Rapid and Convenient Method for Fluorescence Analysis of In Vitro
   Cultivated Metacestode Vesicles from Echinococcus multilocularis
SO PLOS ONE
LA English
DT Article
ID GROWTH; CELLS
AB We here describe a convenient method for preparation, fixation and fluorescence analysis of in vitro cultivated metacestode vesicles from E. multilocularis. Parasite materials could be prepared in one hour, did not need to be sectioned, and were subsequently utilized for further whole-mount staining assays directly. Using these preparations, in combination with conventional fluorescence staining techniques, we could detect the expression and subcellular localization of a specific protein and identify in situ proliferative or apoptotic cells in the germinal layer of metacestode vesicles. Based on this approach, future molecular and cellular analysis of Echinococcus metacestode vesicles in the in vitro system will be greatly facilitated.
C1 [Cheng, Zhe; Zhu, Shan; Wang, Liang; Wang, Yanhai] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China.
   [Liu, Fan; Tian, Huimin] Xiamen Univ, Coll Med, Xiamen, Fujian, Peoples R China.
RP Wang, YH (reprint author), Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China.
EM wangyh@xmu.edu.cn
OI Wang, Yanhai/0000-0002-0002-2467
FU Fundamental Research Funds for the Central Universities of People's
   Republic of China [2012121044]; National Natural Science Foundation of
   China [81000740, 81171596, 81201305, 81471970]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities of People's Republic of China (No. 2012121044) and
   the National Natural Science Foundation of China (No. 81000740,
   81171596, 81201305, 81471970) (http://www.nsfc.gov.cn/). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Brehm K, 2010, PARASITOLOGY, V137, P537, DOI 10.1017/S0031182009991727
   Brehm K, 2008, EXP PARASITOL, V119, P506, DOI 10.1016/j.exppara.2008.03.007
   Diaz A, 2011, TRENDS PARASITOL, V27, P204, DOI 10.1016/j.pt.2010.12.012
   Eckert J, 2004, CLIN MICROBIOL REV, V17, P107, DOI 10.1128/CMR.17.1.107-135.2004
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koziol U, 2014, EVODEVO, V5, DOI 10.1186/2041-9139-5-10
   Koziol U, 2013, FRONT ZOOL, V10, DOI 10.1186/1742-9994-10-24
   Kummer L, 2013, CHEM BIOL, V20, P847, DOI 10.1016/j.chembiol.2013.04.016
   Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105
   Spiliotis M, 2006, INT J PARASITOL, V36, P1097, DOI 10.1016/j.ijpara.2006.05.008
   Spiliotis Markus, 2009, V470, P245, DOI 10.1007/978-1-59745-204-5_17
   Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4
NR 12
TC 4
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 23
PY 2015
VL 10
IS 2
AR e0118215
DI 10.1371/journal.pone.0118215
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC9BI
UT WOS:000350662100155
PM 25705880
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kumar, J
   Dhar, P
   Tayade, AB
   Gupta, D
   Chaurasia, OP
   Upreti, DK
   Toppo, K
   Arora, R
   Suseela, MR
   Srivastava, RB
AF Kumar, Jatinder
   Dhar, Priyanka
   Tayade, Amol B.
   Gupta, Damodar
   Chaurasia, Om P.
   Upreti, Dalip K.
   Toppo, Kiran
   Arora, Rajesh
   Suseela, M. R.
   Srivastava, Ravi B.
TI Chemical Composition and Biological Activities of Trans-Himalayan Alga
   Spirogyra porticalis (Muell.) Cleve
SO PLOS ONE
LA English
DT Article
ID COLD DESERT LADAKH; TRADITIONAL MEDICINAL-PLANTS; FUNCTIONAL FOOD
   INGREDIENTS; TOTAL PHENOLIC CONTENT; ANTIOXIDANT ACTIVITY; ETHYL
   LINOLEATE; OXIDATIVE STRESS; HYPOBARIC HYPOXIA; CAPSICUM-ANNUUM; DRUG
   DISCOVERY
AB The freshwater alga Spirogyra porticalis (Muell.) Cleve, a filamentous charophyte, collected from the Indian trans-Himalayan cold desert, was identified on the basis of morpho-anatomical characters. Extracts of this alga were made using solvents of varying polarity viz. n-hexane, acetonitrile, methanol and water. The antioxidant capacities and phenolic profile of the extracts were estimated. The methanol extract showing highest antioxidant capacity and rich phenolic attributes was further investigated and phytochemical profiling was conducted by gas chromatography-mass spectrometry (GC/MS) hyphenated technique. The cytotoxic activity of methanol extract was evaluated on human hepatocellular carcinoma HepG2 and colon carcinoma RKO cell lines. The anti-hypoxic effect of methanol extract of the alga was tested on in vivo animal system to confirm its potential to ameliorate oxidative stress. The antioxidant assays viz. ferric reducing antioxidant power (FRAP), 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), 1,1-diphenyl-2-picrylhydrazyl (DPPH) and nitric oxide (NO) radical scavenging capacities, beta-carotene-linoleic acid bleaching property and lipid peroxidation exhibited analogous results, wherein the algal extracts showed significantly high antioxidant potential. The extracts were also found to possess high content of total proanthocyanidin, flavonoid and polyphenol. GC/MS analysis revealed the presence of thirteen chemotypes in the methanol extract representing different phytochemical groups like fatty acid esters, sterols, unsaturated alcohols, alkynes etc. with substantial phyto-pharmaceutical importance. The methanol extract was observed to possess anticancer activity as revealed from studies on HepG2 and RKO cell lines. In the present study, Spirogyra porticalis methanol extract also provided protection from hypoxia-induced oxidative stress and accelerated the onset of adaptative changes in rats during exposure to hypobaric hypoxia. The bioactive phytochemicals present in this trans-Himalayan alga are of enormous interest and can be utilized sustainably for discovery of novel drugs against oxidative stress.
C1 [Kumar, Jatinder; Dhar, Priyanka; Tayade, Amol B.; Chaurasia, Om P.; Srivastava, Ravi B.] Def Res & Dev Org, Def Inst High Altitude Res, Leh Ladakh, Jammu & Kashmir, India.
   [Gupta, Damodar; Arora, Rajesh] Def Res & Dev Org, Inst Nucl Med & Allied Sci, Med & Aromat Plants Lab, Radiat Biotechnol Grp, Delhi, India.
   [Arora, Rajesh] Off Director General Life Sci, New Delhi, India.
   [Upreti, Dalip K.; Toppo, Kiran; Suseela, M. R.] Natl Bot Res Inst, Lucknow 226001, Uttar Pradesh, India.
RP Chaurasia, OP (reprint author), Def Res & Dev Org, Def Inst High Altitude Res, Leh Ladakh, Jammu & Kashmir, India.
EM dropchaurasiadihardrdo@gmail.com
OI Arora, Dr. Rajesh/0000-0001-7307-9221
FU Defence Research & Development Organisation (DRDO), Ministry of Defence,
   Government of India
FX The study was entirely supported by Defence Research & Development
   Organisation (DRDO), Ministry of Defence, Government of India. The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ando H, 1998, ARCH DERMATOL RES, V290, P375, DOI 10.1007/s004030050320
   Ando H, 2006, BIOCHEM J, V394, P43, DOI 10.1042/BJ20051419
   Austin Institutional Animal Care and Use Committee Guidelines, 2013, GUID 003 US CARB DIO, P1, DOI [10.1097/ACC.0b013e31829c6877, DOI 10.1097/ACC.0B013E31829C6877]
   Bajpai PK, 2014, LWT-FOOD SCI TECHNOL, V59, P981, DOI 10.1016/j.lwt.2014.07.055
   Balboa EM, 2013, FOOD CHEM, V138, P1764, DOI 10.1016/j.foodchem.2012.11.026
   Ballabh B, 2008, J ETHNOPHARMACOL, V118, P331, DOI 10.1016/j.jep.2008.04.022
   Ballabh B, 2007, J ETHNOPHARMACOL, V112, P341, DOI 10.1016/j.jep.2007.03.020
   Ballabh B, 2009, INDIAN J TRADIT KNOW, V8, P185
   BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203
   Boyd MR, 1992, ANTITUMOR DRUG DISCO, P11
   BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25
   Brieger K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13659
   Burritt DJ, 2002, PLANTA, V215, P829, DOI 10.1007/s00425-002-0805-6
   Cardozo KHM, 2007, COMP BIOCHEM PHYS C, V146, P60, DOI 10.1016/j.cbpc.2006.05.007
   Chacon-Lee TL, 2010, COMPR REV FOOD SCI F, V9, P655, DOI 10.1111/j.1541-4337.2010.00132.x
   Chandrasekar MJN, 2006, PHARM BIOL, V44, P100, DOI 10.1080/13880200600592046
   Charakida A, 2007, BRIT J DERMATOL, V157, P569, DOI 10.1111/j.1365-2133.2007.08083.x
   Chaurasia OP, 2007, ETHNOBOTANY PLANT TR, P1, DOI [10.1007/s12033-007-0062-9PMID: 23934597, DOI 10.1007/S12033-007-0062-9]
   COMPERE P, 1983, B SOC ROY BOT BELG, V116, P141
   Cragg GM, 2014, J NAT PROD, V77, P703, DOI 10.1021/np5000796
   Dai F, 2009, BIOL PLANTARUM, V53, P257, DOI 10.1007/s10535-009-0048-5
   Dapkevicius A, 1998, J SCI FOOD AGR, V77, P140, DOI 10.1002/(SICI)1097-0010(199805)77:1<140::AID-JSFA18>3.0.CO;2-K
   De Rosa S, 2003, Z NATURFORSCH C, V58, P325
   Dhar P, 2013, THESIS BHARATHIAR U
   Dhar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083008
   Dhar P, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-259
   DOWNING DT, 1986, J AM ACAD DERMATOL, V14, P221, DOI 10.1016/S0190-9622(86)70025-X
   Duval B, 1999, J APPL PHYCOL, V11, P559, DOI 10.1023/A:1008178208949
   Frankel EN, 2000, J SCI FOOD AGR, V80, P1925, DOI 10.1002/1097-0010(200010)80:13<1925::AID-JSFA714>3.0.CO;2-4
   Freile-Pelegrin Y, 2014, BIOACTIVE COMPOUNDS, P113
   Frikha F, 2011, CIENC MAR, V37, P113, DOI 10.7773/cm.v37i2.1712
   Gad HA, 2013, PHYTOCHEM ANALYSIS, V24, P1, DOI 10.1002/pca.2378
   Gao XQ, 2000, J AGR FOOD CHEM, V48, P1485, DOI 10.1021/jf991072g
   Goiris K, 2012, J APPL PHYCOL, V24, P1477, DOI 10.1007/s10811-012-9804-6
   Guiry MD, 2014, SPIROGYRA PORTICALIS
   Gullberg J, 2004, ANAL BIOCHEM, V331, P283, DOI 10.1016/j.ab.2004.04.037
   Hajimahmoodi M, 2010, J APPL PHYCOL, V22, P43, DOI 10.1007/s10811-009-9424-y
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2
   HOLMER G, 1962, Z ERNAHRUNGSWISS, V2, P223, DOI 10.1007/BF02020814
   Hota KB, 2011, INNOVATIONS AGROANIM, P277
   Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c
   HUTSELL TC, 1967, LIPIDS, V2, P342, DOI 10.1007/BF02532123
   Ikram EHK, 2009, J FOOD COMPOS ANAL, V22, P388, DOI 10.1016/j.jfca.2009.04.001
   Ilavazhagan G, 1996, DIPAS2696
   Ismail Amin Jr, 2002, Malays J Nutr, V8, P167
   JELENKO C, 1975, ANN SURG, V182, P562, DOI 10.1097/00000658-197511000-00005
   Jeong WY, 2011, J SEP SCI, V34, P2967, DOI 10.1002/jssc.201100524
   JUNTHIP R, 2013, ADV MAT RES, V699, P693
   Kashiwagi T, 2005, Z NATURFORSCH C, V60, P739
   Khalid MN, 2012, PAK J BOT, V44, P1815
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kimura J, 2002, J NAT PROD, V65, P57, DOI 10.1021/np0103057
   Korekar G, 2014, LWT-FOOD SCI TECHNOL, V55, P157, DOI 10.1016/j.lwt.2013.09.006
   Kovacik J, 2010, PHOTOCHEM PHOTOBIOL, V86, P612, DOI 10.1111/j.1751-1097.2010.00708.x
   Kumar J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098696
   Kumar KS, 2008, FOOD CHEM, V107, P289, DOI 10.1016/j.foodchem.2007.08.016
   Lagunin AA, 2014, NAT PROD REP, V31, P1585, DOI 10.1039/c4np00068d
   LEBEL CP, 1990, TOXICOL APPL PHARM, V104, P17, DOI 10.1016/0041-008X(90)90278-3
   Lee Seung-Hong, 2010, Algae, V25, P45, DOI 10.4490/algae.2010.25.1.45
   Li HB, 2007, FOOD CHEM, V102, P771, DOI 10.1016/j.foodchem.2006.06.022
   Lifongo LL, 2014, NAT PRODUCT BIOPROSP, V4, P1, DOI 10.1007/s13659-014-0005-7
   Lordan S, 2011, MAR DRUGS, V9, P1056, DOI 10.3390/md9061056
   Maiti P, 2006, NEUROCHEM INT, V49, P709, DOI 10.1016/j.neuint.2006.06.002
   MIZUGUCHI K, 1993, EUR J PHARMACOL, V235, P221, DOI 10.1016/0014-2999(93)90140-D
   MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757
   Mungmai L, 2014, CHIANG MAI J SCI, V41, P14
   Nabavi SF, 2013, J AQUAT FOOD PROD T, V22, P58, DOI 10.1080/10498850.2011.624292
   Naik AA, 2012, INT MULTIDISCIPLINAR, V2, P13
   Nakanishi I, 1995, J PHYSIOL-LONDON, V489, P869, DOI 10.1113/jphysiol.1995.sp021099
   Natrah FMI, 2007, J APPL PHYCOL, V19, P711, DOI 10.1007/s10811-007-9192-5
   Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   OKADA N, 1994, PHYTOCHEMISTRY, V37, P281, DOI 10.1016/0031-9422(94)85042-9
   OKUNADE AL, 1985, J NAT PROD, V48, P472, DOI 10.1021/np50039a020
   Ontawong A, 2013, BIOMED RES INT, DOI 10.1155/2013/820786
   Ordonez AAL, 2006, FOOD CHEM, V97, P452, DOI 10.1016/j.foodchem.2005.05.024
   Percot A, 2009, NAT PROD RES, V23, P460, DOI 10.1080/14786410802076069
   Plaza M, 2008, TRENDS FOOD SCI TECH, V19, P31, DOI 10.1016/j.tifs.2007.07.012
   Ponnamma SU, 2012, INT J PHARM BIO SCI, V3, P570
   PRASAD TK, 1994, PLANT CELL, V6, P65, DOI 10.1105/tpc.6.1.65
   Prescott GW, 1951, ALGAE W GREAT LAKES, P318
   Priyadarshani I, 2012, J ALGAL BIOMASS UTLN, V3, P89, DOI DOI 10.1263/JBB.101.87
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   RILEY V, 1960, P SOC EXP BIOL MED, V104, P751
   Rodriguez-Garcia I, 2008, FOOD CHEM, V108, P1023, DOI 10.1016/j.foodchem.2007.11.059
   Roessner U, 2001, PLANT CELL, V13, P11, DOI 10.1105/tpc.13.1.11
   Ruberto G, 2000, PLANTA MED, V66, P687, DOI 10.1055/s-2000-9773
   RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113
   Rubio L, 2013, CRIT REV FOOD SCI, V53, P943, DOI 10.1080/10408398.2011.574802
   SaiRam M, 1998, INT J BIOMETEOROL, V42, P55, DOI 10.1007/s004840050084
   Sarker Satyajit D, 2012, Methods Mol Biol, V864, P301, DOI 10.1007/978-1-61779-624-1_12
   Satoh N, 2007, DIABETES CARE, V30, P144, DOI 10.2337/dc06-1179
   Shalaby EA, 2011, PLANT SIGNAL BEHAV, V6, P1338, DOI 10.4161/psb.6.9.16779
   Shellie RA, 2009, J SEP SCI, V32, P3720, DOI 10.1002/jssc.200900422
   Singh B, 2000, ACTA HORTIC, V523, P65
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Solecka D, 1997, ACTA PHYSIOL PLANT, V19, P257, DOI 10.1007/s11738-997-0001-1
   Sun JS, 1998, BURNS, V24, P225, DOI 10.1016/S0305-4179(97)00115-0
   Tayade AB, 2013, J FOOD SCI, V78, pC402, DOI 10.1111/1750-3841.12054
   Tayade AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052797
   Thumvijit Tarika, 2013, Interdiscip Toxicol, V6, P152, DOI 10.2478/intox-2013-0024
   Wang ZH, 2009, FOOD CHEM, V112, P914, DOI 10.1016/j.foodchem.2008.06.078
   Yano T, 1997, LIFE SCI, V61, P2007, DOI 10.1016/S0024-3205(97)00859-X
   YANO T, 1995, YAKUGAKU ZASSHI, V115, P843, DOI 10.1248/yakushi1947.115.10_843
   Yoshimura Y, 1997, ARCTIC ALPINE RES, V29, P126, DOI 10.2307/1551843
   Zhang DL, 2004, FOOD CHEM, V88, P503, DOI 10.1016/j.foodchem.2004.01.065
   Zheng W, 2001, J AGR FOOD CHEM, V49, P5165, DOI 10.1021/jf010697n
   Ziboh VA, 2000, AM J CLIN NUTR, V71, p361S, DOI 10.1093/ajcn/71.1.361s
NR 108
TC 6
Z9 6
U1 0
U2 37
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2015
VL 10
IS 2
AR e0118255
DI 10.1371/journal.pone.0118255
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC0WZ
UT WOS:000350061500112
PM 25693168
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Platas-Neri, D
   Hidalgo-Tobon, S
   Alonso, BD
   de Leon, FCP
   Munoz-Delgado, J
   Phillips, KA
AF Platas-Neri, Diana
   Hidalgo-Tobon, Silvia
   da Celis Alonso, Benito
   Chico-Ponce de Leon, Fernando
   Munoz-Delgado, Jairo
   Phillips, Kimberley A.
TI Tractography of the Spider Monkey (Ateles geoffroyi) Corpus Callosum
   Using Diffusion Tensor Magnetic Resonance Imaging
SO PLOS ONE
LA English
DT Article
ID RHESUS-MONKEY; HUMAN THALAMUS; HUMAN BRAIN; ORGANIZATION; PRIMATES;
   CORTEX; SIZE; TOPOGRAPHY; EVOLUTION; MRI
AB The objective of this research was to describe the organization, connectivity and microstructure of the corpus callosum of the spider monkey (Ateles geoffroyi). Non-invasive magnetic resonance imaging and diffusion-tensor imaging were obtained from three subjects using a 3T Philips scanner. We hypothesized that the arrangement of fibers in spider monkeys would be similar to that observed in other non-human primates. A repeated measure (n = 3) of fractional anisotropy values was obtained of each subject and for each callosal subdivision. Measurements of the diffusion properties of corpus callosum fibers exhibited a similar pattern to those reported in the literature for humans and chimpanzees. No statistical difference was reached when comparing this parameter between the different CC regions (p = 0.066). The highest fractional anisotropy values corresponded to regions projecting from the corpus callosum to the posterior cortical association areas, premotor and supplementary motor cortices. The lowest fractional anisotropy corresponded to projections to motor and sensory cortical areas. Analyses indicated that approximately 57% of the fibers projects to the frontal cortex and 43% to the post-central cortex. While this study had a small sample size, the results provided important information concerning the organization of the corpus callosum in spider monkeys.
C1 [Platas-Neri, Diana] Univ Autonoma Estado Morelos, Inst Profes Reg Sur, Jojutla, Morelos, Mexico.
   [Hidalgo-Tobon, Silvia; Chico-Ponce de Leon, Fernando] Hosp Infantil Mexico Dr Federico Gomez, Dept Neurocirugia, Mexico City, DF, Mexico.
   [Hidalgo-Tobon, Silvia] Univ Autonoma Metropolitana Iztapalapa, Dept Fis, Mexico City, DF, Mexico.
   [da Celis Alonso, Benito] Benemerita Univ Puebla, Fac Ciencias Fis & Matemat, Puebla, Puebla, Mexico.
   [Munoz-Delgado, Jairo] Inst Nacl Psiquiatria Ramon de la Fuente Muniz, Direcc Neurociencias, Mexico City, DF, Mexico.
   [Munoz-Delgado, Jairo] Univ Nacl Autonoma Mexico, Fac Psicol, Mexico City 04510, DF, Mexico.
   [Phillips, Kimberley A.] Trinity Univ, Dept Psychol, San Antonio, TX 78212 USA.
RP Platas-Neri, D (reprint author), Univ Autonoma Estado Morelos, Inst Profes Reg Sur, Jojutla, Morelos, Mexico.
EM dplatasn@gmail.com
RI Phillips, Kimberley/P-1212-2016
OI Phillips, Kimberley/0000-0002-5517-3596; Platas,
   Diana/0000-0001-6738-0974; De Celis Alonso, Benito/0000-0003-2124-1084
FU Council for Science and Technology, Mexico (CONACYT) [109147];
   Fulbright-COMEXUS
FX This work was supported by the Council for Science and Technology,
   Mexico (CONACYT) ( project 109147) and Fulbright-COMEXUS (grant to DPN)
   (www.cies.org;www.comexus.org.mx). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abbie AA, 1940, J COMP NEUROL, V72, P9
   ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C
   Aboitiz F, 1992, Biol Res, V25, P51
   Alexander AL, 2000, MAGNET RESON MED, V44, P283, DOI 10.1002/1522-2594(200008)44:2<283::AID-MRM16>3.0.CO;2-V
   Allman J, 1991, EVOLVING BRAINS
   Aureli F, 2011, PRIMATES PERSPECTIVE, P236
   Aureli F, 2008, CURR ANTHROPOL, V49, P627, DOI 10.1086/586708
   BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306
   Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610
   Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075
   Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609
   Chao YP, 2009, HUM BRAIN MAPP, V30, P3172, DOI 10.1002/hbm.20739
   CHAPMAN CA, 1995, BEHAV ECOL SOCIOBIOL, V36, P59, DOI 10.1007/BF00175729
   CHAPMAN CA, 1989, OIKOS, V54, P315, DOI 10.2307/3565291
   CHAPMAN CA, 1990, AM J PRIMATOL, V22, P279, DOI 10.1002/ajp.1350220407
   Chico-Ponce de Len Fernando, 2009, Rev. Cienc. Salud, V7, P10
   Connolly CJ, 1950, EXTERNAL MORPHOLOGY
   Dunbar R. I. M., 1992, J HUM EVOL, V20, P469, DOI DOI 10.1016/0047-2484(92)90081-J)
   Duong TQ, 2010, METHODS, V50, P125, DOI 10.1016/j.ymeth.2009.08.001
   Fillard P, 2003, LECT NOTES COMPUT SC, V2879, P16
   Hartwig W, 2011, ANAT REC, V294, P2207, DOI 10.1002/ar.21515
   Hinkley LBN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039804
   Hofer S, 2008, CEREB CORTEX, V18, P1079, DOI 10.1093/cercor/bhm141
   Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044
   Hopkins WD, 2000, BEHAV NEUROSCI, V114, P739, DOI 10.1037//0735-7044.114.4.739
   Huxley TH, 1861, ZOOL SOC LONDON SCI, P493
   Jancke L, 1997, CEREB CORTEX, V7, P48, DOI 10.1093/cercor/7.1.48
   Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105
   Kaufman JA, 2005, ANAT REC PART A, V287A, P1026, DOI 10.1002/ar.a.20264
   Kier EL, 1996, AM J NEURORADIOL, V17, P1631
   Kier EL, 1987, SURG 3 VENTRICLE, P37
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   LAMANTIA AS, 1990, J COMP NEUROL, V291, P520, DOI 10.1002/cne.902910404
   Link A, 2011, PRIMATES PERSPECTIVE, P155
   Luppino G, 2000, NEWS PHYSIOL SCI, V15, P219
   Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.3.CO;2-A
   Phillips KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031941
   Platas D., 2011, THESIS U NACL AUTONO
   PUBOLS BH, 1972, BRAIN BEHAV EVOLUT, V5, P342
   PUBOLS BH, 1971, J COMP NEUROL, V141, P63, DOI 10.1002/cne.901410106
   Ramayya AG, 2009, CEREB CORTEX, V20, P507, DOI [10.1093/cercor/bhp141, DOI 10.1093/CERCOR/BHP141]
   Ramos-Fernandez G, 2011, PRIMATES PERSPECTIVE, P220
   Rilling JK, 1999, NEUROREPORT, V10, P1453, DOI 10.1097/00001756-199905140-00012
   Semendeferi K, 2001, EVOLUTIONARY ANATOMY OF THE PRIMATE CEREBRAL CORTEX, P257
   STEPHAN H, 1987, J HIRNFORSCH, V28, P571
   SYMINGTON MM, 1990, INT J PRIMATOL, V11, P47, DOI 10.1007/BF02193695
   SYMINGTON MM, 1988, BEHAVIOUR, V105, P117
   Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640
   WITELSON SF, 1985, SCIENCE, V229, P665, DOI 10.1126/science.4023705
   Youlatos D, 2011, PRIMATES PERSPECTIVE, P185
NR 50
TC 4
Z9 4
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2015
VL 10
IS 2
AR e0117367
DI 10.1371/journal.pone.0117367
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC0WZ
UT WOS:000350061500051
PM 25693078
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU An, YH
   Guo, WJ
   Li, LN
   Xu, CW
   Yang, DX
   Wang, SS
   Lu, YX
   Zhang, Q
   Zhai, JD
   Fan, HX
   Qiu, CJ
   Qi, J
   Chen, Y
   Yuan, SJ
AF An, Yinghong
   Guo, Wanjun
   Li, Linna
   Xu, Chengwang
   Yang, Dexuan
   Wang, Shanshan
   Lu, Yaxin
   Zhang, Quan
   Zhai, Jiadai
   Fan, Hongxia
   Qiu, Chuanjiang
   Qi, Jie
   Chen, Yue
   Yuan, Shoujun
TI Micheliolide Derivative DMAMCL Inhibits Glioma Cell Growth In Vitro and
   In Vivo
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; ADJUVANT TEMOZOLOMIDE; GLIOBLASTOMA CELLS; PROGENITOR CELLS;
   BRAIN-TUMORS; PARTHENOLIDE; APOPTOSIS; EFFICACY; PROLIFERATION;
   RADIOTHERAPY
AB Background
   There is no highly effective chemotherapy for malignant gliomas to date. We found that dimethylaminomicheliolide (DMAMCL), a selective inhibitor of acute myeloid leukemia (AML) stem/progenitor cells, inhibited the growth of glioma cells.
   Methods
   The distribution of DMAMCL in brain was analyzed by an ultraperformance liquid chromatography-mass spectrometry (UPLC-MS/MS) system. The anti-tumor evaluations of DMAMCL in vitro were performed by MTT, FACS and RT-PCR. In vivo, the mixture of C6 cells and matrigel was injected into caudatum, and the anti-tumor activity of DMAMCL was evaluated by tumor growth and rat survival. The toxicity of DMAMCL was evaluated by body weight, daily food intake, hematological or serum biochemical analyses, and histological appearance of tissues.
   Results
   The IC50 values of DMAMCL against the C6 and U-87MG cell lines in vitro were 27.18 +/- 1.89 mu M and 20.58 +/- 1.61 mu M, respectively. DAMMCL down-regulated the anti-apoptosis gene Bcl-2 and increased apoptosis in C6 and U-87MG cells in a dose-dependent manner. In a C6 rat tumor model, daily administration of DMAMCL for 21 days reduced the burden of C6 tumors by 60% to 88% compared to controls, and more than doubled the mean lifespan of tumor-bearing rats. Distribution analysis showed that the DMAMCL concentration was higher in the brain than in plasma. Evaluations for toxicity revealed that oral administration of DMAMCL at 200 or 300 mg/kg once a day for 21 days did not result in toxicity.
   Conclusions
   These results suggest that DMAMCL is highly promising for the treatment of glioma.
C1 [An, Yinghong] Chinese PLA Air Force Gen Hosp, Clin Lab Ctr, Beijing 100142, Peoples R China.
   [Guo, Wanjun; Li, Linna; Xu, Chengwang; Yang, Dexuan; Wang, Shanshan; Yuan, Shoujun] Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Lu, Yaxin; Zhang, Quan; Zhai, Jiadai; Fan, Hongxia] Nankai Univ, Coll Pharm, State Key Lab Elementoorgan Chem, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300071, Peoples R China.
   [Lu, Yaxin; Zhang, Quan; Zhai, Jiadai; Fan, Hongxia] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300071, Peoples R China.
   [Qiu, Chuanjiang; Qi, Jie; Chen, Yue] Accendatech Co Ltd, Tianjin 300384, Peoples R China.
RP Chen, Y (reprint author), Accendatech Co Ltd, Tianjin 300384, Peoples R China.
EM yuechenayh@163.com; yuansj@nic.bmi.ac.cn
FU National Natural Science Foundation of China (NSFC) [21072106, 21372129,
   81001377, 81370086]; Fok Ying Tong Education Foundation [122037];
   National Program on Key Basic Research Project [2013CB967200]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC) (NO. 21072106 and NO. 21372129 to Y.C., NO. 81001377 and
   NO. 81370086 to Q.Z.), Fok Ying Tong Education Foundation (No. 122037),
   and National Program on Key Basic Research Project (No. 2013CB967200).
CR Abbott N Joan, 2004, Drug Discov Today Technol, V1, P407, DOI 10.1016/j.ddtec.2004.11.014
   Anderson KN, 2008, J PHARMACOL SCI, V106, P318, DOI 10.1254/jphs.SC0060164
   [Anonymous], 2010, FDA APPR TEM
   [Anonymous], 2010, BRAIN SPIN CORD TUM
   Carlisi D, 2011, J CELL PHYSIOL, V226, P1632, DOI 10.1002/jcp.22494
   Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130
   Chen Y, 2010, W.C.N. Patent, Patent No. [201,010,153,701.0, 2010101537010]
   Colpo A, 2012, ONCOLOGY-BASEL, V82, P165, DOI 10.1159/000336602
   DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207
   Dell'Agli M, 2009, BIOORG MED CHEM LETT, V19, P1858, DOI 10.1016/j.bmcl.2009.02.080
   Feng MR, 2002, CURR DRUG METAB, V3, P647, DOI 10.2174/1389200023337063
   Guo M, 2006, J PHARMACOL EXP THER, V317, P97, DOI 10.1124/jpet.105.097782
   Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Jin P, 2007, AAPS PHARMSCITECH, V8, pE105, DOI 10.1208/pt0804105
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089
   Li D, 2012, INT J NANOMED, V7, P6105, DOI 10.2147/IJN.S38927
   Mrugala MM, 2013, DISCOV MED, V15, P221
   Murphy S, 2007, J NEURO-ONCOL, V85, P181, DOI 10.1007/s11060-007-9406-3
   Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724
   Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0
   Nieto-Sampedro M, 2011, CLIN MED INSIGHTS-ON, V5, P265, DOI 10.4137/CMO.S7685
   Patt S, 2005, J NEUROONCOL, V72, P209
   Sampson JH, 2011, NEURO-ONCOLOGY, V13, P324, DOI 10.1093/neuonc/noq157
   Sengupta S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/831090
   Strik H, 1999, J NEUROL NEUROSUR PS, V67, P763, DOI 10.1136/jnnp.67.6.763
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Sun J, 2014, ASIAN PAC J CANCER P, V15, P4897, DOI 10.7314/APJCP.2014.15.12.4897
   Tyler B, 2011, NEURO-ONCOLOGY, V13, P700, DOI 10.1093/neuonc/nor050
   Wang XH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018490
   Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060
   Zhai JD, 2012, J ORG CHEM, V77, P7103, DOI 10.1021/jo300888s
   Zhang Q, 2012, J MED CHEM, V55, P8757, DOI 10.1021/jm301064b
NR 35
TC 12
Z9 12
U1 1
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2015
VL 10
IS 2
AR e0116202
DI 10.1371/journal.pone.0116202
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CB2GK
UT WOS:000349444900031
PM 25658946
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sato, T
   Kinoshita, M
   Yamamoto, TS
   Ito, M
   Nishida, T
   Takeuchi, M
   Saitoh, DZ
   Seki, SH
   Mukai, YS
AF Sato, Tomohito
   Kinoshita, Manabu
   Yamamoto, Tetsuo
   Ito, Masataka
   Nishida, Takafumi
   Takeuchi, Masaru
   Saitoh, Daizoh
   Seki, Shuhji
   Mukai, Yasuo
TI Treatment of Irradiated Mice with High-Dose Ascorbic Acid Reduced
   Lethality
SO PLOS ONE
LA English
DT Article
ID ACUTE OXALATE NEPHROPATHY; IONIZING-RADIATION; VITAMIN-C; CELLS;
   DEFICIENCY; HEMOLYSIS; RADICALS; INJURY; DAMAGE; TUMOR
AB Ascorbic acid is an effective antioxidant and free radical scavenger. Therefore, it is expected that ascorbic acid should act as a radioprotectant. We investigated the effects of post-radiation treatment with ascorbic acid on mouse survival. Mice received whole body irradiation (WBI) followed by intraperitoneal administration of ascorbic acid. Administration of 3 g/kg of ascorbic acid immediately after exposure significantly increased mouse survival after WBI at 7 to 8 Gy. However, administration of less than 3 g/kg of ascorbic acid was ineffective, and 4 or more g/kg was harmful to the mice. Post-exposure treatment with 3 g/kg of ascorbic acid reduced radiation-induced apoptosis in bone marrow cells and restored hematopoietic function. Treatment with ascorbic acid (3 g/kg) up to 24 h (1, 6, 12, or 24 h) after WBI at 7.5 Gy effectively improved mouse survival; however, treatments beyond 36 h were ineffective. Two treatments with ascorbic acid (1.5 g/kg x 2, immediately and 24 h after radiation, 3 g/kg in total) also improved mouse survival after WBI at 7.5 Gy, accompanied with suppression of radiation-induced free radical metabolites. In conclusion, administration of high-dose ascorbic acid might reduce radiation lethality in mice even after exposure.
C1 [Sato, Tomohito; Yamamoto, Tetsuo; Nishida, Takafumi; Mukai, Yasuo] Mil Med Res Unit, Tokyo, Setagaya, Japan.
   [Kinoshita, Manabu; Seki, Shuhji] Natl Def Med Coll, Dept Immunol Microbiol, Tokorozawa, Saitama 359, Japan.
   [Ito, Masataka] Natl Def Med Coll, Dept Dev Anat & Regenerat Biol, Tokorozawa, Saitama 359, Japan.
   [Takeuchi, Masaru] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
   [Saitoh, Daizoh] Natl Def Med Coll, Res Inst, Div Traumatol, Tokorozawa, Saitama 359, Japan.
RP Kinoshita, M (reprint author), Natl Def Med Coll, Dept Immunol Microbiol, Tokorozawa, Saitama 359, Japan.
EM manabu@ndmc.ac.jp
FU National Defense Medical College; Ministry of Defense
FX This work was supported by a grant-in-aid for Special Research Program
   (Host stress responses to internal and external factors) from the
   National Defense Medical College to M.K. and S.S. and a grant-in-aid for
   Promoted Research Program of Defense Medicine (Host defense against
   radiation) from the Ministry of Defense to M.K. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anscher MS, 2010, ONCOLOGIST, V15, P350, DOI 10.1634/theoncologist.2009-S101
   Archambeau JO, 2013, REDOX BIOL, V1, P599, DOI 10.1016/j.redox.2013.10.002
   Brown SL, 2010, RADIAT RES, V173, P462, DOI 10.1667/RR1716.1
   Buonocore G, 2000, PEDIATR RES, V47, P221, DOI 10.1203/00006450-200002000-00012
   CAMPBELL GD, 1975, ANN INTERN MED, V82, P810, DOI 10.7326/0003-4819-82-6-810_1
   Cesarone MR, 1999, INT ANGIOL, V18, P127
   Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102
   Cole A, 1965, CELLULAR RAD BIOL, P267
   DiCarlo AL, 2011, DISASTER MED PUBLIC, V5, pS32, DOI 10.1001/dmp.2011.17
   Dohi K, 2005, IN VIVO, V19, P855
   FLOMENBERG N, 1992, BONE MARROW TRANSPL, V10, P115
   Gridley DS, 2007, ANTICANCER RES, V27, P3101
   Guelman LR, 2005, INT J DEV NEUROSCI, V23, P1, DOI 10.1016/j.ijdevneu.2004.10.001
   Hensley ML, 1999, J CLIN ONCOL, V17, P3333, DOI 10.1200/JCO.1999.17.10.3333
   Hoffer LJ, 2008, ANN ONCOL, V19, P1969, DOI 10.1093/annonc/mdn377
   Hogan DE, 2002, AM J MED SCI, V323, P341, DOI 10.1097/00000441-200206000-00006
   Ito Y, 2013, INT J MOL SCI, V14, P19618, DOI 10.3390/ijms141019618
   Jia D, 2010, RADIAT RES, V173, P579, DOI 10.1667/RR2030.1
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koenig KL, 2005, ANN EMERG MED, V45, P643, DOI 10.1016/j.annemergmed.2005.01.020
   Koyama S, 1998, MUTAT RES-FUND MOL M, V421, P45, DOI 10.1016/S0027-5107(98)00153-5
   LAWTON JM, 1985, ARCH INTERN MED, V145, P950, DOI 10.1001/archinte.145.5.950
   MCALLISTER CJ, 1984, JAMA-J AM MED ASSOC, V252, P1684, DOI 10.1001/jama.1984.03350130016019
   OKUNIEFF P, 1991, AM J CLIN NUTR, V54, pS1281
   Padayatty SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011414
   REES DC, 1993, BRIT MED J, V306, P841, DOI 10.1136/bmj.306.6881.841
   ROOTS R, 1975, RADIAT RES, V64, P306, DOI 10.2307/3574267
   Van der Meeren A, 2005, RADIAT RES, V163, P144, DOI 10.1667/RR3293
   Waselenko JK, 2004, ANN INTERN MED, V140, P1037, DOI 10.7326/0003-4819-140-12-200406150-00015
   Weiss JF, 2003, TOXICOLOGY, V189, P1, DOI 10.1016/S0300-483X(03)00149-5
   WONG K, 1994, AUST NZ J MED, V24, P410, DOI 10.1111/j.1445-5994.1994.tb01477.x
   Yamamoto T, 2010, J RADIAT RES, V51, P145, DOI 10.1269/jrr.09078
NR 32
TC 15
Z9 15
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 4
PY 2015
VL 10
IS 2
AR e0117020
DI 10.1371/journal.pone.0117020
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA9NG
UT WOS:000349250700009
PM 25651298
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chen, CC
   Hung, TH
   Lee, CY
   Wang, LF
   Wu, CH
   Ke, CH
   Chen, SF
AF Chen, Chien-Cheng
   Hung, Tai-Ho
   Lee, Chao Yu
   Wang, Liang-Fei
   Wu, Chun-Hu
   Ke, Chia-Hua
   Chen, Szu-Fu
TI Berberine Protects against Neuronal Damage via Suppression of
   Glia-Mediated Inflammation in Traumatic Brain Injury
SO PLOS ONE
LA English
DT Article
ID CONTROLLED CORTICAL IMPACT; COPTIDIS-RHIZOMA EXTRACT; CEREBRAL-ISCHEMIA;
   INTESTINAL INJURY; TYROSINE KINASE; NERVOUS-SYSTEM; NITRIC-OXIDE;
   IN-VITRO; MICROGLIA; MICE
AB Traumatic brain injury (TBI) triggers a series of neuroinflammatory processes that contribute to evolution of neuronal injury. The present study investigated the neuroprotective effects and anti-inflammatory actions of berberine, an isoquinoline alkaloid, in both in vitro and in vivo TBI models. Mice subjected to controlled cortical impact injury were injected with berberine (10 mg.kg(-1)) or vehicle 10 min after injury. In addition to behavioral studies and histology analysis, blood-brain barrier (BBB) permeability and brain water content were determined. Expression of PI3K/Akt and Erk signaling and inflammatory mediators were also analyzed. The protective effect of berberine was also investigated in cultured neurons either subjected to stretch injury or exposed to conditioned media with activated microglia. Berberine significantly attenuated functional deficits and brain damage associated with TBI up to day 28 post-injury. Berberine also reduced neuronal death, apoptosis, BBB permeability, and brain edema at day 1 post-injury. These changes coincided with a marked reduction in leukocyte infiltration, microglial activation, matrix metalloproteinase-9 activity, and expression of inflammatory mediators. Berberine had no effect on Akt or Erk 1/2 phosphorylation. In mixed glial cultures, berberine reduced TLR4/MyD88/NF-kappa B signaling. Berberine also attenuated neuronal death induced by microglial conditioned media; however, it did not directly protect cultured neurons subjected to stretch injury. Moreover, administration of berberine at 3 h post-injury also reduced TBI-induced neuronal damage, apoptosis and inflammation in vivo. Berberine reduces TBI-induced brain damage by limiting the production of inflammatory mediators by glial cells, rather than by a direct neuroprotective effect.
C1 [Chen, Chien-Cheng; Lee, Chao Yu; Ke, Chia-Hua; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.
   [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan.
   [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan.
   [Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan.
   [Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan.
   [Wang, Liang-Fei; Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
RP Chen, SF (reprint author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.
EM szufuchen@yahoo.com.tw
RI Hung, Tai-Ho/C-7584-2011
FU National Science Council of Taiwan, R.O.C. (NSC)
   [101-2314-B-350-001-MY3]; Cheng Hsin General Hospital
FX This work was supported by 1. SFC: Grants from the National Science
   Council of Taiwan, R.O.C. (NSC 101-2314-B-350-001-MY3); 2. SFC and CCC:
   Cheng Hsin General Hospital. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208
   Amasheh M, 2010, J CELL SCI, V123, P4145, DOI 10.1242/jcs.070896
   Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164
   Baskaya MK, 1997, NEUROSCI LETT, V226, P33
   Batchelor PE, 1999, J NEUROSCI, V19, P1708
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04
   Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9
   Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399
   Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A
   Chai YS, 2013, EUR J PHARMACOL, V708, P44, DOI 10.1016/j.ejphar.2013.02.041
   Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023
   Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294
   Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5
   Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345
   Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763
   Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236
   Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x
   Durairajan SSK, 2012, NEUROBIOL AGING, V33, P2903, DOI 10.1016/j.neurobiolaging.2012.02.016
   Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51
   Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013
   Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142
   Hu J, 2012, EUR J PHARMACOL, V674, P132, DOI 10.1016/j.ejphar.2011.11.014
   Jara JH, 2007, J NEUROCHEM, V100, P1407, DOI 10.1111/j.1471-4159.2006.04330.x
   Jia LY, 2012, J PHARM PHARMACOL, V64, P1510, DOI 10.1111/j.2042-7158.2012.01529.x
   Jiang-Shieh YF, 2005, J NEUROSCI RES, V82, P515, DOI 10.1002/jnr.20663
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/S0006-8993(96)00417-9
   Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129
   Kulkarni SK, 2010, PHYTOTHER RES, V24, P317, DOI 10.1002/ptr.2968
   Li HM, 2011, ACTA PHARMACOL SIN, V32, P1364, DOI 10.1038/aps.2011.102
   Liao YJ, 2013, NEW ENGL J MED, V368, P2014, DOI 10.1056/NEJMicm1205007
   Lu DY, 2010, J CELL BIOCHEM, V110, P697, DOI 10.1002/jcb.22580
   Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400
   Ma YY, 2004, NAT IMMUNOL, V5, P380, DOI 10.1038/ni1054
   McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000
   Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0
   Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237
   Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797
   Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262
   Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087
   Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738
   Song B, 2012, CELL IMMUNOL, V276, P91, DOI 10.1016/j.cellimm.2012.04.006
   Tan XS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077969
   Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186
   Wang XL, 2005, AM J CHINESE MED, V33, P935, DOI 10.1142/S0192415X05003557
   Wang XL, 2005, LIFE SCI, V77, P3058, DOI 10.1016/j.lfs.2005.02.033
   Wang XY, 2000, J NEUROSCI, V20, P7037
   Wang YQ, 2009, CARDIOVASC RES, V82, P484, DOI 10.1093/cvr/cvp078
   Zhang QA, 2011, FOOD CHEM TOXICOL, V49, P61, DOI 10.1016/j.fct.2010.09.032
   Zhang XL, 2012, BRAIN RES, V1459, P61, DOI 10.1016/j.brainres.2012.03.065
   Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008
   Zhou XQ, 2008, NEUROSCI LETT, V447, P31, DOI 10.1016/j.neulet.2008.09.064
   Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083
NR 54
TC 27
Z9 32
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2014
VL 9
IS 12
AR e115694
DI 10.1371/journal.pone.0115694
PG 30
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX7UN
UT WOS:000347120200055
PM 25546475
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Mueller, KF
   Briel, M
   Strech, D
   Meerpohl, JJ
   Lang, B
   Motschall, E
   Gloy, V
   Lamontagne, F
   Bassler, D
AF Mueller, Katharina F.
   Briel, Matthias
   Strech, Daniel
   Meerpohl, Joerg J.
   Lang, Britta
   Motschall, Edith
   Gloy, Viktoria
   Lamontagne, Francois
   Bassler, Dirk
TI Dissemination Bias in Systematic Reviews of Animal Research: A
   Systematic Review
SO PLOS ONE
LA English
DT Article
ID PUBLICATION BIAS; METAANALYSES; PROTOCOL
AB Background: Systematic reviews of preclinical studies, in vivo animal experiments in particular, can influence clinical research and thus even clinical care. Dissemination bias, selective dissemination of positive or significant results, is one of the major threats to validity in systematic reviews also in the realm of animal studies. We conducted a systematic review to determine the number of published systematic reviews of animal studies until present, to investigate their methodological features especially with respect to assessment of dissemination bias, and to investigate the citation of preclinical systematic reviews on clinical research.
   Methods: Eligible studies for this systematic review constitute systematic reviews that summarize in vivo animal experiments whose results could be interpreted as applicable to clinical care. We systematically searched Ovid Medline, Embase, ToxNet, and ScienceDirect from 1st January 2009 to 9th January 2013 for eligible systematic reviews without language restrictions. Furthermore we included articles from two previous systematic reviews by Peters et al. and Korevaar et al.
   Results: The literature search and screening process resulted in 512 included full text articles. We found an increasing number of published preclinical systematic reviews over time. The methodological quality of preclinical systematic reviews was low. The majority of preclinical systematic reviews did not assess methodological quality of the included studies (71%), nor did they assess heterogeneity (81%) or dissemination bias (87%). Statistics quantifying the importance of clinical research citing systematic reviews of animal studies showed that clinical studies referred to the preclinical research mainly to justify their study or a future study (76%).
   Discussion: Preclinical systematic reviews may have an influence on clinical research but their methodological quality frequently remains low. Therefore, systematic reviews of animal research should be critically appraised before translating them to a clinical context.
C1 [Mueller, Katharina F.] Univ Childrens Hosp Tuebingen, Ctr Pediat Clin Studies, Tubingen, Germany.
   [Briel, Matthias; Gloy, Viktoria] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland.
   [Briel, Matthias] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
   [Strech, Daniel] Leibniz Univ Hannover, CELLS, D-30167 Hannover, Germany.
   [Meerpohl, Joerg J.; Lang, Britta] Univ Freiburg, Med Ctr, German Cochrane Ctr, D-79106 Freiburg, Germany.
   [Motschall, Edith] Univ Freiburg, Med Ctr, Ctr Med Biometry & Med Informat, D-79106 Freiburg, Germany.
   [Lamontagne, Francois] Univ Sherbrooke, CHU Sherbrooke, Clin Res Ctr Clin, Sherbrooke, PQ J1K 2R1, Canada.
   [Bassler, Dirk] Univ Zurich Hosp, Dept Neonatol, CH-8091 Zurich, Switzerland.
RP Bassler, D (reprint author), Univ Zurich Hosp, Dept Neonatol, CH-8091 Zurich, Switzerland.
EM dirk.bassler@usz.ch
RI Meerpohl, Joerg J/J-4224-2013
OI Meerpohl, Joerg J/0000-0002-1333-5403; Strech,
   Daniel/0000-0002-9153-079X; Motschall, Edith/0000-0001-7795-242X; Briel,
   Matthias/0000-0002-2070-5230; Lang, Britta/0000-0002-2113-4708
FU European Union Seventh Framework Programme (FP7) [285453]
FX The OPEN Project (www. open-project. eu) is funded by the European Union
   Seventh Framework Programme (FP7 - HEALTH.2011.4.12) under grant
   agreement no 285453. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Briel M, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-23
   Crossley NA, 2008, STROKE, V39, P929, DOI 10.1161/STROKEAHA.107.498725
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Korevaar DA, 2011, LAB ANIM-UK, V45, P225, DOI 10.1258/la.2011.010121
   Liu Shimin, 2009, J Exp Stroke Transl Med, V2, P16
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Mignini Luciano E, 2006, BMC Med Res Methodol, V6, P10, DOI 10.1186/1471-2288-6-10
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Mueller KF, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-60
   Muller KF, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-34
   Nordmann AJ, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13518
   Perrin S, 2014, NATURE, V507, P423, DOI 10.1038/507423a
   Peters JL, 2006, J ENVIRON SCI HEAL B, V41, P1245, DOI 10.1080/03601230600857130
   Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514
   Pound P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3387
   Sandercock P, 2002, LANCET, V360, P586, DOI 10.1016/S0140-6736(02)09812-4
   Schardt C, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-16
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   Song F, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14080
   ter Riet G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043404
   Tsilidis KK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001609
   Varga O, 2010, EMBO REP, V11, P500, DOI 10.1038/embor.2010.91
   Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010
NR 25
TC 9
Z9 9
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2014
VL 9
IS 12
AR e116016
DI 10.1371/journal.pone.0116016
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX9RO
UT WOS:000347239900127
PM 25541734
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ikeda, T
   Hirata, S
   Takamatsu, K
   Haruta, M
   Tsukamoto, H
   Ito, T
   Uchino, M
   Ando, Y
   Nagafuchi, S
   Nishimura, Y
   Senju, S
AF Ikeda, Tokunori
   Hirata, Shinya
   Takamatsu, Koutaro
   Haruta, Miwa
   Tsukamoto, Hirotake
   Ito, Takaaki
   Uchino, Makoto
   Ando, Yukio
   Nagafuchi, Seiho
   Nishimura, Yasuharu
   Senju, Satoru
TI Suppression of Th1-Mediated Autoimmunity by Embryonic Stem Cell-Derived
   Dendritic Cells
SO PLOS ONE
LA English
DT Article
ID NONOBESE DIABETIC MICE; GLUTAMIC-ACID DECARBOXYLASE; REGULATORY T-CELLS;
   CENTRAL-NERVOUS-SYSTEM; NOD MOUSE MODEL; MULTIPLE-SCLEROSIS; IN-VIVO;
   ADOPTIVE TRANSFER; IMMUNE-RESPONSE; GENE-EXPRESSION
AB We herein demonstrate the immune-regulatory effect of embryonic stem cell-derived dendritic cells (ES-DCs) using two models of autoimmune disease, namely non-obese diabetic (NOD) mice and experimental autoimmune encephalomyelitis (EAE). Treatment of pre-diabetic NOD mice with ES-DCs exerted almost complete suppression of diabetes development during the observation period for more than 40 weeks. The prevention of diabetes by ES-DCs was accompanied with significant reduction of insulitis and decreased number of Th1 and Th17 cells in the spleen. Development of EAE was also inhibited by the treatment with ES-DCs, and the therapeutic effect was obtained even if ES-DCs were administrated after the onset of clinical symptoms. Treatment of EAE-induced mice with ES-DCs reduced the infiltration of inflammatory cells into the spinal cord and suppressed the T cell response to the myelin antigen. Importantly, the ES-DC treatment did not affect T cell response to an exogenous antigen. As the mechanisms underlying the reduction of the number of infiltrating Th1 cells, we observed the inhibition of differentiation and proliferation of Th1 cells by ES-DCs. Furthermore, the expression of VLA-4 alpha on Th1 cells was significantly inhibited by ES-DCs. Considering the recent advances in human induced pluripotent stem cell-related technologies, these results suggest a clinical application for pluripotent stem cell-derived dendritic cells as a therapy for T cell-mediated autoimmune diseases.
C1 [Ikeda, Tokunori; Takamatsu, Koutaro; Haruta, Miwa; Tsukamoto, Hirotake; Nishimura, Yasuharu; Senju, Satoru] Kumamoto Univ, Grad Sch Med Sci, Dept Immunogenet, Kumamoto, Japan.
   [Ikeda, Tokunori; Takamatsu, Koutaro; Haruta, Miwa; Senju, Satoru] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan.
   [Hirata, Shinya] Kumamoto Univ, Grad Sch Med Sci, Dept Hematol, Kumamoto, Japan.
   [Takamatsu, Koutaro; Ando, Yukio] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan.
   [Ito, Takaaki] Kumamoto Univ, Grad Sch Med Sci, Dept Pathol & Expt Med, Kumamoto, Japan.
   [Uchino, Makoto] Jonan Hosp, Kumamoto, Japan.
   [Nagafuchi, Seiho] Kyushu Univ, Dept Med Sci & Technol, Grad Sch Med Sci, Fukuoka 812, Japan.
RP Ikeda, T (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Immunogenet, Kumamoto, Japan.
EM ryousei@kumamoto-u.ac.jp
RI Ikeda, Tokunori/S-6043-2019; Tsukamoto, Hirotake/S-2448-2019
OI Ando, Yukio/0000-0001-7115-9105; Tsukamoto, Hirotake/0000-0003-3214-1652
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT)
   [25870540, 23659158, 26290057, 23650609, 24300334]; Japan Science and
   Technology Agency (JST), Japan
FX This work was supported by Grants Numbers 25870540 (to TI), 23659158 and
   26290057 (to SS), and 23650609 and 24300334 (to YN) from the Ministry of
   Education, Culture, Sports, Science and Technology (MEXT) KAKENHI,
   grants from the Japan Science and Technology Agency (JST), Japan,
   http://www.jst.go.jp/EN/index.html. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript
CR Ablamunits V, 2012, DIABETES, V61, P145, DOI 10.2337/db11-1033
   Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887
   Archambault AS, 2006, J NEUROIMMUNOL, V181, P122, DOI 10.1016/j.jneuroim.2006.08.012
   Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442
   Baeke F, 2012, DIABETOLOGIA, V55, P2723, DOI 10.1007/s00125-012-2630-1
   Besin G, 2008, DIABETES, V57, P2107, DOI 10.2337/db08-0171
   Birk OS, 1996, P NATL ACAD SCI USA, V93, P1032, DOI 10.1073/pnas.93.3.1032
   BURKLY LC, 1994, DIABETES, V43, P529, DOI 10.2337/diabetes.43.4.529
   Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399
   CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123
   Cheatem D, 2009, CLIN IMMUNOL, V131, P260, DOI 10.1016/j.clim.2008.12.001
   Chen W, 2001, J IMMUNOL, V167, P4926, DOI 10.4049/jimmunol.167.9.4926
   CLARESALZLER MJ, 1992, J CLIN INVEST, V90, P741, DOI 10.1172/JCI115946
   Comabella M, 2010, NAT REV NEUROL, V6, P499, DOI 10.1038/nrneurol.2010.112
   DANIEL D, 1995, EUR J IMMUNOL, V25, P1056, DOI 10.1002/eji.1830250430
   Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956
   Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1
   Emamaullee JA, 2009, DIABETES, V58, P1302, DOI 10.2337/db08-1113
   Feili-Hariri M, 2002, EUR J IMMUNOL, V32, P2021, DOI 10.1002/1521-4141(200207)32:7<2021::AID-IMMU2021>3.0.CO;2-J
   Fujii S, 1998, HUM IMMUNOL, V59, P607, DOI 10.1016/S0198-8859(98)00058-5
   Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732
   Gutcher I, 2007, J CLIN INVEST, V117, P1119, DOI 10.1172/JC131720
   Han GC, 2005, J IMMUNOL, V174, P4516, DOI 10.4049/jimmunol.174.8.4516
   Hirata S, 2005, J IMMUNOL, V174, P1888, DOI 10.4049/jimmunol.174.4.1888
   Hirata S, 2007, J IMMUNOL, V178, P918, DOI 10.4049/jimmunol.178.2.918
   Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435
   Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295
   Ikeda T, 2010, J IMMUNOL, V185, P5259, DOI 10.4049/jimmunol.0902797
   KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0
   Kayagaki N, 1999, J IMMUNOL, V163, P1906
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566
   Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564
   Lees JR, 2008, J EXP MED, V205, P2633, DOI 10.1084/jem.20080155
   Lionakis MS, 2003, LANCET, V362, P1828, DOI 10.1016/S0140-6736(03)14904-5
   Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726
   Machen J, 2004, J IMMUNOL, V173, P4331, DOI 10.4049/jimmunol.173.7.4331
   Matsuyoshi H, 2004, J IMMUNOL, V172, P776, DOI 10.4049/jimmunol.172.2.776
   McFarland HF, 2007, NAT IMMUNOL, V8, P913, DOI 10.1038/ni1507
   Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341
   Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696
   Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734
   Nagafuchi S, 1999, FEBS LETT, V455, P101, DOI 10.1016/S0014-5793(99)00801-7
   Odoardi F, 2012, NATURE, V488, P675, DOI 10.1038/nature11337
   Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036
   Quinn A, 2001, J IMMUNOL, V166, P2982, DOI 10.4049/jimmunol.166.5.2982
   Quinn A, 1996, J AUTOIMMUN, V9, P365, DOI 10.1006/jaut.1996.0049
   RABINOVITCH A, 1995, J IMMUNOL, V154, P4874
   Rioux JD, 2005, NATURE, V435, P584, DOI 10.1038/nature03723
   Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183
   Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401
   Senju S, 2003, BLOOD, V101, P3501, DOI 10.1182/blood-2002-07-2554
   Senju S, 2007, STEM CELLS, V25, P2720, DOI 10.1634/stemcells.2007-0321
   Senju S, 2009, STEM CELLS, V27, P1021, DOI 10.1002/stem.33
   Solvason N, 2008, J IMMUNOL, V181, P8298, DOI 10.4049/jimmunol.181.12.8298
   Steinbrink K, 2002, BLOOD, V99, P2468, DOI 10.1182/blood.V99.7.2468
   Steinman L, 2013, NAT MED, V19, P139, DOI 10.1038/nm.3088
   Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411
   Stromnes IM, 2008, NAT MED, V14, P337, DOI 10.1038/nm1715
   Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5
   TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0
   TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817
   Verginis P, 2005, J IMMUNOL, V174, P7433, DOI 10.4049/jimmunol.174.11.7433
   YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494
   YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0
NR 65
TC 6
Z9 8
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2014
VL 9
IS 12
AR e115198
DI 10.1371/journal.pone.0115198
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA4AC
UT WOS:000348845600025
PM 25522369
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bate, S
   Karp, NA
AF Bate, Simon
   Karp, Natasha A.
TI A Common Control Group - Optimising the Experiment Design to Maximise
   Sensitivity
SO PLOS ONE
LA English
DT Article
ID STATISTICAL POWER ANALYSIS; HISTORICAL CONTROL DATA
AB Methods for choosing an appropriate sample size in animal experiments have received much attention in the statistical and biological literature. Due to ethical constraints the number of animals used is always reduced where possible. However, as the number of animals decreases so the risk of obtaining inconclusive results increases. By using a more efficient experimental design we can, for a given number of animals, reduce this risk. In this paper two popular cases are considered, where planned comparisons are made to compare treatments back to control and when researchers plan to make all pairwise comparisons. By using theoretical and empirical techniques we show that for studies where all pairwise comparisons are made the traditional balanced design, as suggested in the literature, maximises sensitivity. For studies that involve planned comparisons of the treatment groups back to the control group, which are inherently more sensitive due to the reduced multiple testing burden, the sensitivity is maximised by increasing the number of animals in the control group while decreasing the number in the treated groups.
C1 [Bate, Simon] GlaxoSmithKline, Stat Sci Europe, Stevenage, Herts, England.
   [Karp, Natasha A.] Wellcome Trust Sanger Inst, Mouse Informat Grp, Cambridge, England.
RP Bate, S (reprint author), GlaxoSmithKline, Stat Sci Europe, Stevenage, Herts, England.
EM simon.t.bate@gsk.com
OI Karp, Natasha/0000-0002-8404-2907
FU National Institutes of Health [1 U54 HG006370-01]
FX This work was supported by the National Institutes of Health
   (www.nih.gov), grant number 1 U54 HG006370-01 (Natasha Karp). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bate S.T., 2014, DESIGN STAT ANAL ANI
   Clark RA, 2012, J PSYCHOPHARMACOL, V26, P1136, DOI 10.1177/0269881111420313
   Cohen J, 1988, STAT POWER ANAL BEHA
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Garcia-Perez MA, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00325
   Greim H, 2003, HUM EXP TOXICOL, V22, P541, DOI 10.1191/0960327103ht394oa
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Lee SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095733
   Lenth RV, 2001, AM STAT, V55, P187, DOI 10.1198/000313001317098149
   Nekohashi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097901
   Perel P, 2007, BMJ-BRIT MED J, V334, P197, DOI 10.1136/bmj.39048.407928.BE
   Rozza AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086686
   Russell W. M. S., 1959, PRINCIPLES HUMANE EX
   Ruxton G. D., 2006, EXPT DESIGN LIFE SCI
   Snedecor GW, 1989, STAT METHODS
   Sun TT, 2004, NAT REV MOL CELL BIO, V5, P577, DOI 10.1038/nrm1429
   Thomas L, 1996, ANIM BEHAV, V52, P856, DOI 10.1006/anbe.1996.0232
   Viele K, 2014, PHARM STAT, V13, P41, DOI 10.1002/pst.1589
   Zar JH, 1998, BIOSTATISTICAL ANAL
   Zhou KK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098905
NR 22
TC 5
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 11
PY 2014
VL 9
IS 12
AR e114872
DI 10.1371/journal.pone.0114872
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX8FY
UT WOS:000347146700062
PM 25504147
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Suzuki, H
   Oku, H
   Horie, T
   Morishita, S
   Tonari, M
   Oku, K
   Okubo, A
   Kida, T
   Mimura, M
   Fukumoto, M
   Kojima, S
   Takai, S
   Ikeda, T
AF Suzuki, Hiroyuki
   Oku, Hidehiro
   Horie, Taeko
   Morishita, Seita
   Tonari, Masahiro
   Oku, Kazuma
   Okubo, Akiko
   Kida, Teruyo
   Mimura, Masashi
   Fukumoto, Masanori
   Kojima, Shota
   Takai, Shinji
   Ikeda, Tsunehiko
TI Changes in Expression of Aquaporin-4 and Aquaporin-9 in Optic Nerve
   after Crushing in Rats
SO PLOS ONE
LA English
DT Article
ID RETINAL GANGLION-CELLS; DIABETIC-RETINOPATHY; WATER TRANSPORT; BRAIN
   EDEMA; GLIAL-CELLS; INJURY; KIR4.1; MICE; REGENERATION; SURVIVAL
AB The purpose of this study was to determine the temporal and spatial changes in the expression of AQP4 and AQP9 in the optic nerve after it is crushed. The left optic nerves of rats were either crushed (crushed group) or sham operated (sham group), and they were excised before, and at 1, 2, 4, 7, and 14 days later. Four optic nerves were pooled for each time point in both groups. The expression of AQP4 and AQP9 was determined by western blot analyses. Immunohistochemistry was used to determine the spatial expression of AQP4, AQP9, and GFAP in the optic nerve. Optic nerve edema was determined by measuring the water content in the optic nerve. The barrier function of the optic nerve vessels was determined by the extravasated Evans blue dye on days 7 and 14. The results showed that the expression of AQP4 was increased on day 1 but the level was significantly lower than that in the sham group on days 4 and 7 (P<0.05). In contrast, the expression of AQP9 gradually increased, and the level was significantly higher than that in the sham group on days 7 and 14 (P<0.05, Tukey-Kramer). The down-regulation of AQP4 was associated with crush-induced optic nerve edema, and the water content of the nerve was significantly increased by 4.3% in the crushed optic nerve from that of the untouched fellow nerve on day 7. The expression of AQP4 and GFAP was reduced at the crushed site where AQP4-negative and AQP9-positive astrocytes were present. The barrier function was impaired at the crushed site on days 7 and 14, restrictedly where AQP4-negative and AQP9-positive astrocytes were present. The presence of AQP9-positive astrocytes at the crushed site may counteract the metabolic damage but this change did not fully compensate for the barrier function defect.
C1 [Suzuki, Hiroyuki; Oku, Hidehiro; Horie, Taeko; Morishita, Seita; Tonari, Masahiro; Oku, Kazuma; Okubo, Akiko; Kida, Teruyo; Mimura, Masashi; Fukumoto, Masanori; Kojima, Shota; Takai, Shinji; Ikeda, Tsunehiko] Osaka Med Coll, Dept Ophthalmol, Osaka, Japan.
RP Oku, H (reprint author), Osaka Med Coll, Dept Ophthalmol, Osaka, Japan.
EM hidehirooku@aol.com
OI Mimura, Masashi/0000-0002-2396-5636
FU Japanese Ministry of Education [25462763]
FX This study was supported by Japanese Ministry of Education Grant
   25462763 (HO). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252
   Badaut J, 2004, NEUROSCIENCE, V129, P971, DOI 10.1016/j.neuroscience.2004.06.035
   Badaut J, 2010, NEUROSCIENCE, V168, P1047, DOI 10.1016/j.neuroscience.2009.10.030
   Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001
   Bosco A, 2005, INVEST OPHTH VIS SCI, V46, P3869, DOI 10.1167/iovs.050385
   Cui B, 2012, EXP EYE RES, V98, P37, DOI 10.1016/j.exer.2012.02.013
   Da T, 2004, INVEST OPHTH VIS SCI, V45, P4477, DOI 10.1167/iovs.04-0940
   Dibaj P, 2007, J NEUROCHEM, V103, P2620, DOI 10.1111/j.1471-4159.2007.04979.x
   Dibas A, 2007, PHARMACOL RES, V55, P378, DOI 10.1016/j.phrs.2007.01.021
   Dibas A, 2010, MOL VIS, V16, P330
   Fukuda M, 2010, EXP EYE RES, V90, P17, DOI 10.1016/j.exer.2009.09.003
   Haj-Yasein NN, 2011, P NATL ACAD SCI USA, V108, P17815, DOI 10.1073/pnas.1110655108
   Hollborn M, 2012, CURR EYE RES, V37, P524, DOI 10.3109/02713683.2012.658133
   Hollborn M, 2011, CURR EYE RES, V36, P850, DOI 10.3109/02713683.2011.593108
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kofuji P, 2002, GLIA, V39, P292, DOI 10.1002/glia.10112
   Kurimoto T, 2006, NEUROREPORT, V17, P1525, DOI 10.1097/01.wnr.0000234749.80936.54
   Li XM, 2014, NEUROL SCI
   Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256
   Miki A, 2013, AM J PATHOL, V182, P1727, DOI 10.1016/j.ajpath.2013.01.027
   Morishita S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084387
   Naka M, 2010, INVEST OPHTH VIS SCI, V51, P4618, DOI 10.1167/iovs.09-4712
   Nielsen S, 1997, J NEUROSCI, V17, P171
   Pannicke T, 2004, MOL CELL NEUROSCI, V26, P493, DOI 10.1016/j.mcn.2004.04.005
   Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje
   Qin YW, 2012, INVEST OPHTH VIS SCI, V53, P3047, DOI 10.1167/iovs.11-9154
   Qin YW, 2009, EXP EYE RES, V89, P741, DOI 10.1016/j.exer.2009.06.020
   Ransom BR, 1997, GLIA, V21, P134
   ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961
   Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680
   Schey KL, 2014, BBA-GEN SUBJECTS, V1840, P1513, DOI 10.1016/j.bbagen.2013.10.037
   Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174
   Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010
   Tonari M, 2012, INVEST OPHTH VIS SCI, V53, P3490, DOI 10.1167/iovs.11-9415
   Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784
   Yang MH, 2013, BIOSCI REP, V33
   Zhang Y, 2011, J INT MED RES, V39, P464, DOI 10.1177/147323001103900214
   Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb
   Zickler P, 2010, CELL PHYSIOL BIOCHEM, V26, P483, DOI 10.1159/000320571
NR 39
TC 7
Z9 7
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2014
VL 9
IS 12
AR e114694
DI 10.1371/journal.pone.0114694
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX4MS
UT WOS:000346907200113
PM 25479407
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Solberg, MF
   Fjelldal, PG
   Nilsen, F
   Glover, KA
AF Solberg, Monica Favneboe
   Fjelldal, Per Gunnar
   Nilsen, Frank
   Glover, Kevin Alan
TI Hatching Time and Alevin Growth Prior to the Onset of Exogenous Feeding
   in Farmed, Wild and Hybrid Norwegian Atlantic Salmon
SO PLOS ONE
LA English
DT Article
ID GENE-TRANSCRIPTION PROFILES; SALAR L.; EGG SIZE; FRESH-WATER;
   COMPETITIVE INTERACTIONS; ONCORHYNCHUS-KETA; INCUBATION-TIME; OFFSPRING
   SIZE; POPULATIONS; TEMPERATURE
AB The onset of exogenous feeding, when juveniles emerge from the gravel, is a critical event for salmonids where early emergence and large size provide a competitive advantage in the wild. Studying 131 farmed, hybrid and wild Norwegian Atlantic salmon families, originating from four wild populations and two commercial strains, we investigated whether approximately 10 generations of selection for faster growth has also resulted in increased somatic growth prior to the onset of exogenous feeding. In addition, we tested whether relaxed selection in farms has allowed for alterations in hatching time between farmed and wild salmon. Across three cohorts, wild salmon families hatched earlier than farmed salmon families, while hybrid families displayed intermediate hatching times. While the observed differences were small, i. e., 1-15 degree-days (0-3 days, as water temperatures were c. 5-6 degrees C), these data suggest additive genetic variation for hatching time. Alevin length prior to exogenous feeding was positively related to egg size. After removal of egg size effects, no systematic differences in alevin length were observed between the wild and farmed salmon families. While these results indicate additive genetic variation for egg development timing, and wild salmon families consistently hatched earlier than farmed salmon families, these differences were so small they are unlikely to significantly influence early life history competition of farmed and wild salmon in the natural environment. This is especially the case given that the timing of spawning among females can vary by several weeks in some rivers. The general lack of difference in size between farmed and wild alevins, strongly suggest that the documented differences in somatic growth rate between wild and farmed Norwegian Atlantic salmon under hatchery conditions are first detectable after the onset of exogenous feeding.
C1 [Solberg, Monica Favneboe; Glover, Kevin Alan] Inst Marine Res, Populat Genet Res Grp, N-5024 Bergen, Norway.
   [Fjelldal, Per Gunnar] Inst Marine Res, Reprod & Dev Biol Res Grp, Matre Res Stn, Matredal, Norway.
   [Nilsen, Frank; Glover, Kevin Alan] Univ Bergen, Sea Lice Res Ctr, Dept Biol, Bergen, Norway.
RP Solberg, MF (reprint author), Inst Marine Res, Populat Genet Res Grp, POB 1870, N-5024 Bergen, Norway.
EM monica.solberg@imr.no
FU project INTERACT - Research Council of Norway
FX This project was funded within the project INTERACT, funded by the
   Research Council of Norway. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2013, STATUS NORSKE LAKSEB, P124
   Bates D., 2013, IME4 LINEAR MIXED EF
   BEACHAM TD, 1987, CAN J FISH AQUAT SCI, V44, P244, DOI 10.1139/f87-034
   BEACHAM TD, 1990, T AM FISH SOC, V119, P927, DOI 10.1577/1548-8659(1990)119<0927:TESADO>2.3.CO;2
   BEACHAM TD, 1985, CAN J ZOOL, V63, P847, DOI 10.1139/z85-125
   Berg OK, 1999, J FISH BIOL, V54, P636, DOI 10.1006/jfbi.1998.0902
   Bicskei B, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-884
   Bourret V, 2011, HEREDITY, V106, P500, DOI 10.1038/hdy.2010.165
   BRANNAS E, 1995, EVOL ECOL, V9, P411, DOI 10.1007/BF01237763
   CROZIER WW, 1993, AQUACULTURE, V113, P19, DOI 10.1016/0044-8486(93)90337-X
   Cutts CJ, 1999, J FISH BIOL, V55, P784, DOI 10.1111/j.1095-8649.1999.tb00717.x
   Debes PV, 2013, HEREDITY, V111, P238, DOI 10.1038/hdy.2013.43
   Devlin RH, 2009, P NATL ACAD SCI USA, V106, P3047, DOI 10.1073/pnas.0809798106
   Donaghy MJ, 1997, J FISH BIOL, V51, P211, DOI 10.1006/jfbi.1997.0417
   Einum S, 2000, NATURE, V405, P565, DOI 10.1038/35014600
   Einum S, 2000, EVOLUTION, V54, P628, DOI 10.1111/j.0014-3820.2000.tb00064.x
   ELLIOTT JM, 1986, J ANIM ECOL, V55, P907, DOI 10.2307/4424
   Fleming IA, 1996, J APPL ECOL, V33, P893, DOI 10.2307/2404960
   Fleming IA, 2002, CAN J FISH AQUAT SCI, V59, P1323, DOI [10.1139/f02-082, 10.1139/F02-082]
   Fleming IA, 2000, P ROY SOC B-BIOL SCI, V267, P1517, DOI 10.1098/rspb.2000.1173
   Fraser DJ, 2010, CAN J FISH AQUAT SCI, V67, P1768, DOI 10.1139/F10-094
   Fraser DJ, 2010, ECOL APPL, V20, P935, DOI 10.1890/09-0694.1
   Friedland KD, 2009, ICES J MAR SCI, V66, P289, DOI 10.1093/icesjms/fsn210
   Gilbey J, 2005, J FISH BIOL, V67, P1359, DOI 10.1111/j.1095-8649.2005.00831.x
   Gilbey J, 2009, J FISH BIOL, V75, P2820, DOI 10.1111/j.1095-8649.2009.02497.x
   GJEDREM T, 1991, AQUACULTURE, V98, P41, DOI 10.1016/0044-8486(91)90369-I
   GJEDREM T, 1979, Z TIERZ ZUCHTUNGSBIO, V96, P56
   GJEDREM T, 1983, AQUACULTURE, V33, P51, DOI 10.1016/0044-8486(83)90386-1
   GJERDE B, 1986, AQUACULTURE, V57, P37, DOI 10.1016/0044-8486(86)90179-1
   Glover KA, 2006, AQUACULTURE, V254, P72, DOI 10.1016/j.aquaculture.2005.10.040
   Glover KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043129
   Glover KA, 2009, AQUACULTURE, V286, P203, DOI 10.1016/j.aquaculture.2008.09.023
   Glover KA, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-74
   Green BS, 2008, ADV MAR BIOL, V54, P1, DOI 10.1016/S0065-2881(08)00001-1
   Hansen MM, 2009, MOL ECOL, V18, P2549, DOI 10.1111/j.1365-294X.2009.04198.x
   Heath DD, 1999, EVOLUTION, V53, P1605, DOI [10.2307/2640906, 10.1111/j.1558-5646.1999.tb05424.x]
   HEGGBERGET TG, 1988, CAN J FISH AQUAT SCI, V45, P845, DOI 10.1139/f88-102
   Henderson JN, 2003, CAN J FISH AQUAT SCI, V60, P32, DOI 10.1139/F03-001
   Houde ALS, 2010, ICES J MAR SCI, V67, P657, DOI 10.1093/icesjms/fsp272
   JENSEN AJ, 1991, ENVIRON BIOL FISH, V30, P379, DOI 10.1007/BF02027981
   Johnsson JI, 1999, J FISH BIOL, V54, P469, DOI 10.1006/jfbi.1998.0881
   KAZAKOV RV, 1981, J FISH BIOL, V19, P353, DOI 10.1111/j.1095-8649.1981.tb05838.x
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kuznetsova A, 2014, IMERTEST TESTS RANDO
   Kvingedal E, 2011, BEHAV ECOL SOCIOBIOL, V65, P1295, DOI 10.1007/s00265-011-1143-0
   Lund RA, 1989, RES REPORT NORWEGIAN, V1, P1
   McGinnity P, 1997, ICES J MAR SCI, V54, P998, DOI 10.1006/jmsc.1997.0286
   McGinnity P, 2003, P ROY SOC B-BIOL SCI, V270, P2443, DOI 10.1098/rspb.2003.2520
   Mousseau TA, 1998, TRENDS ECOL EVOL, V13, P403, DOI 10.1016/S0169-5347(98)01472-4
   Overturf K, 2010, AQUACULTURE, V307, P111, DOI 10.1016/j.aquaculture.2010.06.010
   Quinn TP, 2002, T AM FISH SOC, V131, P591, DOI 10.1577/1548-8659(2002)131<0591:ASAECC>2.0.CO;2
   R Development Core Team, 2014, R LANG ENV STAT COMP
   Riedl C, 2013, ECOL FRESHW FISH, V22, P384, DOI 10.1111/eff.12033
   Roberge C, 2006, MOL ECOL, V15, P9, DOI 10.1111/j.1365-294X.2005.02807.x
   Robertsen G, 2013, CAN J FISH AQUAT SCI, V70, P5, DOI 10.1139/cjfas-2012-0152
   Saegrov H, 1997, ICES J MAR SCI, V54, P1166, DOI 10.1016/S1054-3139(97)80023-9
   Skaala O, 2005, J FISH BIOL, V67, P118, DOI 10.1111/j.1095-8649.2005.00843.x
   Skaala O, 2006, ICES J MAR SCI, V63, P1224, DOI 10.1016/j.icesjms.2006.04.005
   Skaala O, 2012, CAN J FISH AQUAT SCI, V69, P1994, DOI 10.1139/f2012-118
   Skoglund H, 2012, FUNCT ECOL, V26, P104, DOI 10.1111/j.1365-2435.2011.01901.x
   Skoglund H, 2011, CAN J FISH AQUAT SCI, V68, P1470, DOI [10.1139/F2011-056, 10.1139/f2011-056]
   Skoglund H, 2011, J ANIM ECOL, V80, P365, DOI 10.1111/j.1365-2656.2010.01783.x
   Solberg Monica F., 2012, BMC Research Notes, V5, P672, DOI 10.1186/1756-0500-5-672
   Solberg MF, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-234
   Solberg MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054469
   SRIVASTAVA RK, 1991, CAN J ZOOL, V69, P2436, DOI 10.1139/z91-342
   Tatara CP, 2012, ENVIRON BIOL FISH, V94, P7, DOI 10.1007/s10641-011-9906-z
   Teletchea F, 2009, J FISH BIOL, V74, P652, DOI 10.1111/j.1095-8649.2008.02160.x
   Thodesen J, 2001, AQUACULTURE, V194, P273, DOI 10.1016/S0044-8486(00)00527-5
   Thodesen J, 1999, AQUACULTURE, V180, P237, DOI 10.1016/S0044-8486(99)00204-5
   THORPE JE, 1984, AQUACULTURE, V43, P289, DOI 10.1016/0044-8486(84)90030-9
   Webb JH, 1996, CAN J FISH AQUAT SCI, V53, P2739, DOI 10.1139/cjfas-53-12-2739
   Weir LK, 2004, J ANIM ECOL, V73, P1069, DOI 10.1111/j.0021-8790.2004.00876.x
NR 73
TC 13
Z9 13
U1 1
U2 38
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 1
PY 2014
VL 9
IS 12
AR e113697
DI 10.1371/journal.pone.0113697
PG 28
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX7SK
UT WOS:000347114900065
PM 25438050
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Prokopec, SD
   Watson, JD
   Pohjanvirta, R
   Boutros, PC
AF Prokopec, Stephenie D.
   Watson, John D.
   Pohjanvirta, Raimo
   Boutros, Paul C.
TI Identification of Reference Proteins for Western Blot Analyses in Mouse
   Model Systems of 2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD) Toxicity
SO PLOS ONE
LA English
DT Article
ID ARYL-HYDROCARBON RECEPTOR; POLYMERASE-CHAIN-REACTION; MESSENGER-RNA
   EXPRESSION; GENE-EXPRESSION; HOUSEKEEPING GENES; TRANSCRIPTOMIC
   RESPONSES; DIFFERENTIAL EXPRESSION; REVERSE TRANSCRIPTION; RAT STRAIN;
   PCR DATA
AB Western blotting is a well-established, inexpensive and accurate way of measuring protein content. Because of technical variation between wells, normalization is required for valid interpretation of results across multiple samples. Typically this involves the use of one or more endogenous controls to adjust the measured levels of experimental molecules. Although some endogenous controls are widely used, validation is required for each experimental system. This is critical when studying transcriptional-modulators, such as toxicants like 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD). To address this issue, we examined hepatic tissue from 192 mice representing 47 unique combinations of strain, sex, Ahr-genotype, TCDD dose and treatment time. We examined 7 candidate reference proteins in each animal and assessed consistency of protein abundance through: 1) TCDD-induced fold-difference in protein content from basal levels, 2) inter-and intra-animal stability, and 3) the ability of each candidate to reduce instability of the other candidates. Univariate analyses identified HPRT as the most stable protein. Multivariate analysis indicated that stability generally increased with the number of proteins used, but gains from using >3 proteins were small. Lastly, by comparing these new data to our previous studies of mRNA controls on the same animals, we were able to show that the ideal mRNA and protein control-genes are distinct, and use of only 2-3 proteins provides strong stability, unlike in mRNA studies in the same cohort, where larger control-gene batteries were needed.
C1 [Prokopec, Stephenie D.; Watson, John D.; Boutros, Paul C.] Ontario Inst Canc Res, Informat & Biocomp Program, Toronto, ON, Canada.
   [Pohjanvirta, Raimo] Natl Inst Hlth & Welf, Toxicol Lab, Kuopio, Finland.
   [Pohjanvirta, Raimo] Univ Helsinki, Dept Food Hyg & Environm Hlth, Helsinki, Finland.
   [Boutros, Paul C.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   [Boutros, Paul C.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada.
RP Boutros, PC (reprint author), Ontario Inst Canc Res, Informat & Biocomp Program, Toronto, ON, Canada.
EM Paul.Boutros@oicr.on.ca
RI Pohjanvirta, Raimo/I-4509-2019
OI Pohjanvirta, Raimo/0000-0003-0952-5746; Boutros,
   Paul/0000-0003-0553-7520
FU Academy of Finland [123345, 261232]; Canadian Institutes of Health
   [MOP-57903]; Ontario Institute for Cancer Research; Government of
   Ontario
FX This study was conducted with the support of the Academy of Finland
   (grant nos. 123345 and 261232 to RP), the Canadian Institutes of Health
   Research (grant no. MOP-57903 to ABO and PCB), and the Ontario Institute
   for Cancer Research to PCB through funding provided by the Government of
   Ontario. Dr. Boutros was supported by a Terry Fox Research Institute New
   Investigator Award and a CIHR New Investigator Salary Award. The above
   funding sources had no involvement in the study design, in the
   collection, analysis and interpretation of data, in the writing of the
   document, or in the decision to submit the work for publication.
CR Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Anderson LVB, 1999, AM J PATHOL, V154, P1017, DOI 10.1016/S0002-9440(10)65354-0
   Baumgartner R, 2013, J PROTEOMICS, V94, P540, DOI 10.1016/j.jprot.2013.10.015
   Bertazzi PA, 1997, EPIDEMIOLOGY, V8, P646, DOI 10.1097/00001648-199710000-00006
   Boutros PC, 2011, TOXICOL APPL PHARM, V251, P119, DOI 10.1016/j.taap.2010.12.010
   Boutros PC, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-419
   Boverhof DR, 2006, TOXICOL SCI, V94, P398, DOI 10.1093/toxsci/kfl100
   Boverhof DR, 2005, TOXICOL SCI, V85, P1048, DOI 10.1093/toxsci/kfi162
   CHAPMAN DE, 1985, TOXICOL APPL PHARM, V78, P147, DOI 10.1016/0041-008X(85)90314-X
   Deindl E, 2002, MOL CELL BIOCHEM, V236, P139, DOI 10.1023/A:1016166127465
   Eaton SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072457
   Ferguson RE, 2005, PROTEOMICS, V5, P566, DOI 10.1002/pmic.200400941
   Franc MA, 2008, ARCH TOXICOL, V82, P809, DOI 10.1007/s00204-008-0303-0
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Gerk PM, 2011, J PHARMACOL TOX MET, V63, P279, DOI 10.1016/j.vascn.2011.01.003
   Greer S, 2010, J IMMUNOL METHODS, V355, P76, DOI 10.1016/j.jim.2010.02.006
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720
   Hanlon PR, 2005, TOXICOL APPL PHARM, V202, P215, DOI 10.1016/j.taap.2004.06.018
   Hinson JA, 2000, TOXICOL SCI, V53, P467, DOI 10.1093/toxsci/53.2.467
   Hoene V, 2009, BRIT J CANCER, V101, P1481, DOI 10.1038/sj.bjc.6605276
   Karge W H 3rd, 1998, Methods Mol Biol, V110, P43
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim S, 2009, TOXICOL SCI, V112, P229, DOI 10.1093/toxsci/kfp189
   Kislinger T, 2006, CELL, V125, P173, DOI 10.1016/j.cell.2006.01.044
   Kislinger T, 2005, J AM SOC MASS SPECTR, V16, P1207, DOI 10.1016/j.jasms.2005.02.015
   Li XM, 2011, J EXP BOT, V62, P4763, DOI 10.1093/jxb/err084
   Linden J, 2012, ANAL BIOCHEM, V428, P81, DOI 10.1016/j.ab.2012.06.010
   Longnecker MP, 2000, EPIDEMIOLOGY, V11, P44, DOI 10.1097/00001648-200001000-00010
   Marinkovic N, 2010, ARH HIG RADA TOKSIKO, V61, P445, DOI 10.2478/10004-1254-61-2010-2024
   OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2
   Okey AB, 2007, TOXICOL SCI, V98, P5, DOI 10.1093/toxsci/kfm096
   Pastorelli R, 2006, MOL CELL PROTEOMICS, V5, P882, DOI 10.1074/mcp.M500415-MCP200
   Pohjanvirta R, 1998, MOL PHARMACOL, V54, P86
   Pohjanvirta R, 2006, CHEM-BIOL INTERACT, V160, P134, DOI 10.1016/j.cbi.2006.01.001
   POHJANVIRTA R, 1993, PHARMACOL TOXICOL, V73, P52, DOI 10.1111/j.1600-0773.1993.tb01958.x
   Pohjanvirta R, 2011, AH RECEPTOR BIOL TOX
   Pohjanvirta R, 2012, TOXICOL APPL PHARM, V262, P167, DOI 10.1016/j.taap.2012.04.032
   Pohjanvirta R, 2009, TOXICOL APPL PHARM, V236, P166, DOI 10.1016/j.taap.2009.01.005
   POLAND A, 1994, MOL PHARMACOL, V46, P915
   Prokopec SD, 2013, CHEM-BIOL INTERACT, V205, P63, DOI 10.1016/j.cbi.2013.06.008
   Puga Alvaro, 2004, Cardiovasc Toxicol, V4, P385, DOI 10.1385/CT:4:4:385
   Schecter A, 2006, ENVIRON RES, V101, P419, DOI 10.1016/j.envres.2005.12.003
   Schutz-Geschwender A, 2004, QUANTITATIVE 2 COLOR
   SEEFELD MD, 1984, TOXICOL APPL PHARM, V73, P311, DOI 10.1016/0041-008X(84)90337-5
   Shen CF, 2009, ENVIRON INT, V35, P50, DOI 10.1016/j.envint.2008.07.005
   Silver N, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-33
   Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02
   Teste MA, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-99
   Tramm T, 2013, DIAGN MOL PATHOL, V22, P181, DOI 10.1097/PDM.0b013e318285651e
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Walter RF, 2013, PATHOL RES PRACT
   Watson JD, 2013, TOXICOL APPL PHARM
   Weisglas-Kuperus N, 2000, ENVIRON HEALTH PERSP, V108, P1203, DOI 10.2307/3434834
   Weldon S, 2008, ANAL BIOCHEM, V375, P156, DOI 10.1016/j.ab.2007.11.035
   Yao CDQ, 2012, TOXICOL APPL PHARM, V260, P135, DOI 10.1016/j.taap.2012.02.001
   Zeng L, 2013, ELECTROPHORESIS, V34, P2234, DOI 10.1002/elps.201300140
   Zhu MM, 2012, MOL VIS, V18, P1156
NR 57
TC 2
Z9 2
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2014
VL 9
IS 10
AR e110730
DI 10.1371/journal.pone.0110730
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AT8TF
UT WOS:000345204100104
PM 25329058
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bennett, EJ
   Mead, RJ
   Azzouz, M
   Shaw, PJ
   Grierson, AJ
AF Bennett, Ellen J.
   Mead, Richard J.
   Azzouz, Mimoun
   Shaw, Pamela J.
   Grierson, Andrew J.
TI Early Detection of Motor Dysfunction in the SOD1(G93A) Mouse Model of
   Amyotrophic Lateral Sclerosis (ALS) Using Home Cage Running Wheels
SO PLOS ONE
LA English
DT Article
ID TRANSGENIC MODEL; NEURON LOSS; DISEASE; SOD1; RILUZOLE; MICE; MUTATIONS
AB The SOD1(G93A) mouse has been used since 1994 for preclinical testing in amyotrophic lateral sclerosis (ALS). Despite recent genetic advances in our understanding of ALS, transgenic mice expressing mutant SOD1 remain the best available, and most widely used, vertebrate model of the disease. We previously described an optimised and rapid approach for preclinical studies in the SOD1(G93A) mouse. Here we describe improvements to this approach using home cage running wheels to obtain daily measurements of motor function, with minimal intervention. We show that home cage running wheels detect reductions in motor function at a similar time to the rotarod test, and that the data obtained are less variable allowing the use of smaller groups of animals to obtain satisfactory results. This approach refines use of the SOD1(G93A) model, and reduces the number of animals undergoing procedures of substantial severity, two central principles of the 3Rs (replacement, reduction and refinement of animal use in research). The small group sizes and rapid timescales enable affordable large-scale therapeutic pre-screening in the SOD1(G93A) mouse, as well as rapid validation of published positive effects in a second laboratory, one of the major stumbling blocks in ALS preclinical therapy development.
C1 [Bennett, Ellen J.; Mead, Richard J.; Azzouz, Mimoun; Shaw, Pamela J.; Grierson, Andrew J.] Univ Sheffield, Sheffield Inst Translat Neurosci, Dept Neurosci, Sheffield, S Yorkshire, England.
RP Grierson, AJ (reprint author), Univ Sheffield, Sheffield Inst Translat Neurosci, Dept Neurosci, Sheffield, S Yorkshire, England.
EM a.j.grierson@sheffield.ac.uk
RI Grierson, Andy/A-5067-2009; Azzouz, Mimoun/B-3979-2009; Mead,
   Richard/B-4779-2009
OI Grierson, Andy/0000-0001-7039-6731; Bennett, Ellen/0000-0002-9818-827X;
   Shaw, Pamela/0000-0002-8925-2567; Azzouz, Mimoun/0000-0001-6564-5967;
   Mead, Richard/0000-0002-3207-0068
FU NC3Rs project grant [G0700628]; NC3Rs small award [26102007]; Project
   MitoTarget [HEALTH-F2-2008-223388]; National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NC3Rs) [G0700628/1];
   National Institute for Health Research [NF-SI-0512-10082]
FX This work was supported by an NC3Rs project grant: G0700628 to AJG PJS
   MA and RJM, NC3Rs small award: Grierson. A. 26102007 to AJG, and Project
   MitoTarget: Grant Agreement HEALTH-F2-2008-223388 to AJG and PJS. PJS is
   an NIHR senior investigator. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Acevedo-Arozena A, 2011, DIS MODEL MECH, V4, P686, DOI 10.1242/dmm.007237
   Aggarwal A, 2002, J NEUROL NEUROSUR PS, V73, P199, DOI 10.1136/jnnp.73.2.199
   Barneoud P, 1999, EXP NEUROL, V155, P243, DOI 10.1006/exnr.1998.6984
   Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015
   BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901
   BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292
   Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X
   CAVANAGH JB, 1964, INT REV EXP PATHOL, V3, P219
   De Bono JP, 2006, AM J PHYSIOL-REG I, V290, pR926, DOI 10.1152/ajpregue.00694.2005
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Ferraiuolo L, 2011, NAT REV NEUROL, V7, P616, DOI 10.1038/nrneurol.2011.152
   Ferraiuolo L, 2009, J NEUROCHEM, V109, P1714, DOI 10.1111/j.1471-4159.2009.06080.x
   Festing MFW, 2002, DESIGN ANIMAL EXPT
   Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004
   Frey D, 2000, J NEUROSCI, V20, P2534
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203
   Hayworth CR, 2009, NEUROSCIENCE, V164, P975, DOI 10.1016/j.neuroscience.2009.08.031
   Joyce PI, 2011, MAMM GENOME, V22, P420, DOI 10.1007/s00335-011-9339-1
   Kennel PF, 1996, NEUROREPORT, V7, P1427, DOI 10.1097/00001756-199605310-00021
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470
   Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3
   Ludolph Albert C, 2007, Amyotroph Lateral Scler, V8, P217, DOI 10.1080/17482960701292837
   Ludolph AC, 2010, AMYOTROPH LATERAL SC, V11, P38, DOI 10.3109/17482960903545334
   Mead RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023244
   Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653
   Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584
NR 28
TC 3
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2014
VL 9
IS 9
AR e107918
DI 10.1371/journal.pone.0107918
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6CW
UT WOS:000343671700053
PM 25268710
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yanala, UR
   Johanning, JM
   Pipinos, II
   Larsen, G
   Velander, WH
   Carlson, MA
AF Yanala, Ujwal R.
   Johanning, Jason M.
   Pipinos, Iraklis I.
   Larsen, Gustavo
   Velander, William H.
   Carlson, Mark A.
TI Development of a Fatal Noncompressible Truncal Hemorrhage Model with
   Combined Hepatic and Portal Venous Injury in Normothermic Normovolemic
   Swine
SO PLOS ONE
LA English
DT Article
ID COMBAT CASUALTY CARE; OPERATION-IRAQI-FREEDOM; FIBRIN SEALANT FOAM;
   FLUID RESUSCITATION; ABDOMINAL HEMORRHAGE; TORSO HEMORRHAGE;
   ENDURING-FREEDOM; LIVER-INJURIES; CLOSED-ABDOMEN; BLOOD-LOSS
AB Noncompressible truncal hemorrhage and brain injury currently account for most early mortality of warfighters on the battlefield. There is no effective treatment for noncompressible truncal hemorrhage, other than rapid evacuation to a surgical facility. The availability of an effective field treatment for noncompressible truncal hemorrhage could increase the number of warfighters salvaged from this frequently-lethal scenario. Our intent was to develop a porcine model of noncompressible truncal hemorrhage with a similar to 50% one-hour mortality so that we could develop new treatments for this difficult problem. Normovolemic normothermic domestic swine (barrows, 3 months old, 34-36 kg) underwent one of three injury types through a midline incision: 1) central stellate injury (N = 6); 2) excision of a portal vein branch distal to the main PV trunk (N = 6); or 3) hemi-transection of the left lateral lobe of the liver at its base (N = 10). The one-hour mortality of these injuries was 0, 82, and 40%, respectively; the final mean arterial pressure was 65, 24, and 30 mm Hg, respectively; and the final hemoglobin was 8.3, 2.3, and 3.6 g/dL, respectively. Hemi-transection of the left lateral lobe of the liver appeared to target our desired mortality rate better than the other injury mechanisms.
C1 [Yanala, Ujwal R.; Carlson, Mark A.] Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68182 USA.
   [Johanning, Jason M.; Pipinos, Iraklis I.] Univ Nebraska, Med Ctr, Dept Vasc Surg, Omaha, NE USA.
   [Carlson, Mark A.] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA.
   [Yanala, Ujwal R.; Johanning, Jason M.; Pipinos, Iraklis I.; Carlson, Mark A.] VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE USA.
   [Larsen, Gustavo; Velander, William H.] Univ Nebraska, Dept Chem & Biomol Engn, Lincoln, NE USA.
RP Carlson, MA (reprint author), Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68182 USA.
EM macarlso@unmc.edu
FU United States Army [W81XWH-11-1-0836]
FX This study was supported by a grant from the United States Army
   (http://www.usamraa.army.mil) to MAC, contract number W81XWH-11-1-0836.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR American Veterinary Medical Association Panel on Euthanasia, 2013, AVMA GUID EUTH AN
   Bebarta VS, 2013, J TRAUMA ACUTE CARE, V75, P920, DOI 10.1097/TA.0b013e3182a539b8
   BELLAMY RF, 1986, ANN EMERG MED, V15, P1384, DOI 10.1016/S0196-0644(86)80920-9
   BELLAMY RF, 1984, MIL MED, V149, P55
   BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701
   Blackbourne LH, 2012, J TRAUMA ACUTE CARE, V73, pS372, DOI 10.1097/TA.0b013e3182755662
   Blackbourne LH, 2010, J TRAUMA, V69, pS1, DOI 10.1097/TA.0b013e3181e4206f
   Burris D, 1999, J TRAUMA, V46, P216, DOI 10.1097/00005373-199902000-00003
   BUSH JA, 1955, AM J PHYSIOL, V181, P9
   Butler F, 2011, J TRAUMA, V70, pS11, DOI 10.1097/TA.0b013e31821a4b90
   Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850
   Calcaterra J, 2013, BIOMACROMOLECULES, V14, P169, DOI 10.1021/bm301579p
   Carlson MA, 2014, J SURG RES, V187, P334, DOI 10.1016/j.jss.2013.09.039
   Chambers LW, 2006, J TRAUMA, V60, P1155, DOI 10.1097/01.ta.000220340.91356.7e
   Chandler WL, 1995, SEMIN THROMB HEMOST, V21, P1
   Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUIDE CARE USE LAB A
   Devlin JJ, 2009, J TRAUMA, V67, P895, DOI 10.1097/TA.0b013e3181b837ab
   Duggan M, 2013, J TRAUMA ACUTE CARE, V74, P1462, DOI 10.1097/TA.0b013e31828da937
   Duggan MJ, 2014, J SURG RES, V187, P536, DOI 10.1016/j.jss.2013.12.005
   Duggan MJ, 2013, J SURG RES, V182, P101, DOI 10.1016/j.jss.2012.07.048
   Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020
   Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc
   Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b
   Frith D, 2012, THROMB RES, V129, P551, DOI 10.1016/j.thromres.2011.11.053
   Gerhardt R, 2012, COMBAT CASUALTY CARE, P85
   Holcomb JB, 2003, J TRAUMA, V54, pS46, DOI 10.1097/01.TA.0000051936.91915.A2
   Holcomb JB, 1999, J TRAUMA, V46, P49, DOI 10.1097/00005373-199901000-00009
   Holcomb JB, 2000, J TRAUMA, V49, P246, DOI 10.1097/00005373-200008000-00010
   Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98
   Katzenell U, 2012, MIL MED, V177, P1065, DOI 10.7205/MILMED-D-12-00161
   Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb
   Kheirabadi BS, 2008, J SURG RES, V144, P145, DOI 10.1016/j.jss.2007.02.012
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lowe GDO, 2004, ANN CLIN BIOCHEM, V41, P430, DOI 10.1258/0004563042466884
   McSwain NE, 2011, J TRAUMA, V70, pS2, DOI 10.1097/TA.0b013e31821b201d
   Morrison JJ, 2013, J TRAUMA ACUTE CARE, V75, pS263, DOI 10.1097/TA.0b013e318299da0a
   Neter J., 1990, APPL LINEAR STAT MOD
   Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875
   Peev MP, 2014, J TRAUMA ACUTE CARE, V76, P619, DOI 10.1097/TA.0000000000000126
   Pusateri AE, 2006, J TRAUMA, V60, P674, DOI 10.1097/01.ta.0000196672.47783.fd
   Simmons JW, 2011, J TRAUMA, V71, pS82, DOI 10.1097/TA.0b013e3182218ddb
   United States Department of Agriculture, 2013, AN WELF ACT AN WELF
   Wachtel TL, 1972, 734 US ARM AER RES L
   White JM, 2011, J TRAUMA, V71, pS131, DOI 10.1097/TA.0b013e3182219302
   White JM, 2011, ANN SURG, V253, P1184, DOI [10.2165/11537150-000000000-00000, 10.1097/SLA.0b013e31820752e3]
NR 45
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2014
VL 9
IS 9
AR e108293
DI 10.1371/journal.pone.0108293
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ0SJ
UT WOS:000342492700107
PM 25251401
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Spratt, NJ
   Tomkins, AJ
   Pepperall, D
   McLeod, DD
   Calford, MB
AF Spratt, Neil J.
   Tomkins, Amelia J.
   Pepperall, Debbie
   McLeod, Damian D.
   Calford, Mike B.
TI Allopregnanolone and Its Precursor Progesterone Do Not Reduce Injury
   after Experimental Stroke in Hypertensive Rats - Role of Postoperative
   Temperature Regulation?
SO PLOS ONE
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; ACUTE ISCHEMIC-STROKE;
   CELL-DEATH; NEUROPROTECTIVE PROPERTIES; OCCLUSION; HYPOTHERMIA;
   RECOMMENDATIONS; METAANALYSIS; METABOLITE
AB Allopregnanolone is a neurosteroid synthesized from progesterone in brain. It increases inhibition through modulation of the gamma-aminobutyric acid type A (GABA-A) receptor. Both agents are putative neuroprotectants after ischemic stroke. We sought to confirm their effectiveness in a hypertensive rat stroke model, with intra-and post-operative temperature regulation. The primary study compared allopregnanolone, progesterone or vehicle control treatments, administered 105 minutes after induction of temporary middle cerebral artery occlusion in spontaneously hypertensive rats. Temperature was controlled intraoperatively and a heat mat used in the 6 hours postoperatively to permit animal temperature self-regulation. The primary outcome was infarct volume and secondary outcomes were tests of sensory and motor function. There was no significant effect of treatment on any outcome measure. Given prior reports of GABA-A receptor agonists causing hypothermia, follow-up experiments were conducted to examine postoperative temperature regulation. These did not reveal a difference in postoperative temperature in neurosteroid-treated animals compared to control. However, in all rats maintained postoperatively in ambient temperature, moderate hypothermia was observed. This was in contrast to rats maintained over a heat mat. The lowest mean postoperative temperature was between 34.4-34.9 degrees C in all 3 groups. These data do not support a neuroprotective effect of allopregnanolone or progesterone in ischemic stroke in hypertensives in the setting of normothermia. Given previous evidence of synergy between neuroprotective agents and hypothermia, demonstration of neuroprotective effect of these agents in the absence of postoperative hypothermia would be prudent before consideration of these agents for further clinical investigation.
C1 [Spratt, Neil J.; Tomkins, Amelia J.; Pepperall, Debbie; McLeod, Damian D.; Calford, Mike B.] Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2300, Australia.
   [Spratt, Neil J.; Tomkins, Amelia J.; Pepperall, Debbie; McLeod, Damian D.; Calford, Mike B.] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Spratt, Neil J.] Hunter New England Local Hlth Dist, Newcastle, NSW, Australia.
   [Calford, Mike B.] Univ Tasmania, Sch Med, Hobart, Tas, Australia.
RP Spratt, NJ (reprint author), Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2300, Australia.
EM neil.spratt@newcastle.edu.au
RI MCLEOD, DAMIAN/G-7704-2013; Spratt, Neil/N-3167-2019
OI MCLEOD, DAMIAN/0000-0002-1297-8984; Spratt, Neil/0000-0002-9023-6177
FU Greater Building Society/Hunter Medical Research Institute; Sylvia and
   Charles Viertel charitable foundation; Royal Australian College of
   Physicans / High Blood Pressure Foundation; NHMRC [454417, APP1035465]
FX This work was supported by grants from the Greater Building
   Society/Hunter Medical Research Institute, the Sylvia and Charles
   Viertel charitable foundation, the Royal Australian College of Physicans
   / High Blood Pressure Foundation and by the NHMRC (program grant
   454417). Dr. Spratt was supported by a NHMRC Career Development
   Fellowship, APP1035465. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Agis-Balboa RC, 2006, P NATL ACAD SCI USA, V103, P14602, DOI 10.1073/pnas.0606544103
   Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161
   Armstrong SR, 2005, J VET EMERG CRIT CAR, V15, P32, DOI 10.1111/j.1476-4431.2005.04033.x
   Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022
   Azcoitia I, 1999, J NEUROCYTOL, V28, P699, DOI 10.1023/A:1007025219044
   Berger C, 2004, EXP NEUROL, V185, P305, DOI 10.1016/j.expneurol.2003.10.008
   Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067
   Campbell K, 2008, BRAIN RES B
   Chaulk D, 2003, EXP NEUROL, V182, P476, DOI 10.1016/S0014-4886(03)00121-3
   Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6
   Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023
   Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106
   Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752
   Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128
   GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O
   He J, 2004, RESTOR NEUROL NEUROS, V22, P19
   Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848
   Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138
   Lust WD, 2002, METAB BRAIN DIS, V17, P113, DOI 10.1023/A:1015420222334
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MM, 2008, GOOD LAB PRACTICE PR
   O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011
   O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465
   O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034
   Parker SM, 2005, J CEREB BLOOD FLOW M, V25, pS21
   Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7
   Saalmann YB, 2007, J NEUROENDOCRINOL, V19, P272, DOI 10.1111/j.1365-2826.2006.01527.x
   Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011
   Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151
   SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518
   Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240
   Spratt NJ, 2006, J NEUROSCI METH, V155, P285, DOI 10.1016/j.jneumeth.2006.01.020
   Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001
   van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083
   VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015
   Wong R, 2013, J CEREBR BLOOD F MET, V33, P1362, DOI 10.1038/jcbfm.2013.120
   Zivin JA, 2008, STROKE, V39, P2697, DOI 10.1161/STROKEAHA.108.519488
NR 39
TC 5
Z9 5
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2014
VL 9
IS 9
AR e107752
DI 10.1371/journal.pone.0107752
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AP8TL
UT WOS:000342351800034
PM 25248155
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Itoh, M
   Nakadate, K
   Horibata, Y
   Matsusaka, T
   Xu, JL
   Hunziker, W
   Sugimoto, H
AF Itoh, Masahiko
   Nakadate, Kazuhiko
   Horibata, Yasuhiro
   Matsusaka, Taiji
   Xu, Jianliang
   Hunziker, Walter
   Sugimoto, Hiroyuki
TI The Structural and Functional Organization of the Podocyte Filtration
   Slits Is Regulated by Tjp1/ZO-1
SO PLOS ONE
LA English
DT Article
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; CONGENITAL NEPHROTIC SYNDROME;
   JUNCTION PROTEIN ZO-1; GLOMERULAR-DISEASE; AMINONUCLEOSIDE NEPHROSIS;
   CD2-ASSOCIATED PROTEIN; ACTIN CYTOSKELETON; KIDNEY PODOCYTES; TIGHT
   JUNCTIONS; DEFICIENT MICE
AB Blood filtration in the kidney glomerulus is essential for physiological homeostasis. The filtration apparatus of the kidney glomerulus is composed of three distinct components: the fenestrated endothelial cells, the glomerular basement membrane, and interdigitating foot processes of podocytes that form the slit diaphragm. Recent studies have demonstrated that podocytes play a crucial role in blood filtration and in the pathogenesis of proteinuria and glomerular sclerosis; however, the molecular mechanisms that organize the podocyte filtration barrier are not fully understood. In this study, we suggest that tight junction protein 1 (Tjp1 or ZO-1), which is encoded by Tjp1 gene, plays an essential role in establishing the podocyte filtration barrier. The podocyte-specific deletion of Tjp1 down-regulated the expression of podocyte membrane proteins, impaired the interdigitation of the foot processes and the formation of the slit diaphragm, resulting in glomerular dysfunction. We found the possibility that podocyte filtration barrier requires the integration of two independent units, the pre-existing epithelial junction components and the newly synthesized podocyte-specific components, at the final stage in glomerular morphogenesis, for which Tjp1 is indispensable. Together with previous findings that Tjp1 expression was decreased in glomerular diseases in human and animal models, our results indicate that the suppression of Tjp1 could directly aggravate glomerular disorders, highlights Tjp1 as a potential therapeutic target.
C1 [Itoh, Masahiko; Horibata, Yasuhiro; Sugimoto, Hiroyuki] Dokkyo Med Univ, Sch Med, Dept Biochem, Mibu, Tochigi, Japan.
   [Nakadate, Kazuhiko] Meiji Pharmaceut Univ, Dept Basic Biol, Educ & Res Ctr Pharm, Tokyo, Japan.
   [Matsusaka, Taiji] Tokai Univ, Sch Med, Dept Internal Med, Isehara, Kanagawa 25911, Japan.
   [Xu, Jianliang; Hunziker, Walter] Natl Univ Singapore, Inst Mol & Cell Biol, Epithelial Cell Biol Lab, Singapore 117548, Singapore.
RP Itoh, M (reprint author), Dokkyo Med Univ, Sch Med, Dept Biochem, Mibu, Tochigi, Japan.
EM mitoh@dokkyomed.ac.jp; hunziker@imcb.a-star.edu.sg
RI ASTAR, IMCB/E-2320-2012; Hunziker, Walter/M-6045-2019; Hunziker,
   Walter/B-3140-2010
OI Hunziker, Walter/0000-0002-5265-4933
FU JSPS KAKENHI [23590242]
FX This work was supported by JSPS KAKENHI to M.I. (Grant Number 23590242).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Asano T, 2005, J AM SOC NEPHROL, V16, P2257, DOI 10.1681/ASN.2004121134
   Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400
   Boute N, 2000, NAT GENET, V24, P349
   Brinkkoetter PT, 2013, NAT REV NEPHROL, V9, P328, DOI 10.1038/nrneph.2013.78
   CAULFIELD JP, 1976, LAB INVEST, V34, P43
   D'Agati V, 2003, SEMIN NEPHROL, V23, P117, DOI 10.1053/snep.2003.50012
   D'Agati VD, 2011, NEW ENGL J MED, V365, P2398, DOI 10.1056/NEJMra1106556
   Dai CS, 2009, J AM SOC NEPHROL, V20, P1997, DOI 10.1681/ASN.2009010019
   Fukasawa H, 2009, J AM SOC NEPHROL, V20, P1491, DOI 10.1681/ASN.2008101117
   George B, 2012, SEMIN NEPHROL, V32, P307, DOI 10.1016/j.semnephrol.2012.06.002
   George B, 2012, J CLIN INVEST, V122, P674, DOI 10.1172/JCI60070
   Grahammer F, 2013, NAT REV NEPHROL, V9, P587, DOI 10.1038/nrneph.2013.169
   Haraldsson B, 2008, PHYSIOL REV, V88, P451, DOI 10.1152/physrev.00055.2006
   Jones N, 2006, NATURE, V440, P818, DOI 10.1038/nature04662
   Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456
   Katsuno T, 2008, MOL BIOL CELL, V19, P2465, DOI 10.1091/mbc.E07-12-1215
   Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068
   Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988
   KURIHARA H, 1992, AM J PATHOL, V141, P805
   Li H, 2004, J AM SOC NEPHROL, V15, P3006, DOI 10.1097/01.ASN.0000146689.88078.80
   Li YJ, 2008, AM J PATHOL, V172, P299, DOI 10.2353/ajpath.2008.070057
   Ma H, 2009, J AM SOC NEPHROL, V21, P1145
   Miner JH, 2002, J CLIN INVEST, V109, P1065, DOI 10.1172/JCi200213954
   Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739
   Niimura F, 1995, J CLIN INVEST, V96, P2947, DOI 10.1172/JCI118366
   Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002
   Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1
   Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025
   Reiser J, 2000, J AM SOC NEPHROL, V11, P1
   Rincon-Choles H, 2006, DIABETES, V55, P894, DOI 10.2337/diabetes.55.04.06.db05-0355
   Rohr C, 2002, J CLIN INVEST, V109, P1073, DOI 10.1172/JCI200213961
   Roselli S, 2004, MOL CELL BIOL, V24, P550, DOI 10.1128/MCB.24.2.550-560.2004
   SCHNABEL E, 1990, J CELL BIOL, V111, P1255, DOI 10.1083/jcb.111.3.1255
   Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312
   Shono A, 2007, J AM SOC NEPHROL, V18, P2525, DOI 10.1681/ASN.2006101084
   Tryggvason K, 2006, CELL, V125, P221, DOI 10.1016/j.cell.2006.04.002
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Weavers H, 2009, NATURE, V457, P322, DOI 10.1038/nature07526
NR 40
TC 23
Z9 23
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 3
PY 2014
VL 9
IS 9
AR e106621
DI 10.1371/journal.pone.0106621
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3TB
UT WOS:000341257700094
PM 25184792
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Miranda, JA
   Stanley, P
   Gore, K
   Turner, J
   Dias, R
   Rees, H
AF Miranda, Jason A.
   Stanley, Phil
   Gore, Katrina
   Turner, Jamie
   Dias, Rebecca
   Rees, Huw
TI A Preclinical Physiological Assay to Test Modulation of Knee Joint Pain
   in the Spinal Cord: Effects of Oxycodone and Naproxen
SO PLOS ONE
LA English
DT Article
ID IODOACETATE-INDUCED OSTEOARTHRITIS; PRIMARY AFFERENT NEURONS; CANCER
   PAIN; RAT MODELS; MORPHINE; RESPONSES; EFFICACY; PHARMACOKINETICS;
   PHARMACODYNAMICS; NOCICEPTORS
AB Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a test of the prediction that two clinically effective compounds, naproxen (an NSAID) and oxycodone (an opiate), are efficacious in reducing the response of spinal dorsal horn neurons to noxious knee joint rotation in the monosodium iodoacetate (MIA) sensitized rat. The overall objective for these experiments was to develop a high quality in vivo electrophysiology assay to confidently test novel compounds for efficacy against pain. Given the recent calls for improved preclinical experimental quality we also developed and implemented an Assay Capability Tool to determine the quality of our assay and ensure the quality of our results. Spinal dorsal horn neurons receiving input from the hind limb knee joint were recorded in anesthetized rats 14 days after they were sensitized with 1 mg of MIA. Intravenous administered oxycodone and naproxen were each tested separately for their effects on phasic, tonic, ongoing and afterdischarge action potential counts in response to innocuous and noxious knee joint rotation. Oxycodone reduced tonic spike counts more than the other measures, doing so by up to 85%. Tonic counts were therefore designated the primary endpoint when testing naproxen which reduced counts by up to 81%. Both reductions occurred at doses consistent with clinically effective doses for osteoarthritis. These results demonstrate that clinically effective doses of standard treatments for osteoarthritis reduce pain processing measured at the level of the spinal cord for two different mechanisms. The Assay Capability Tool helped to guide experimental design leading to a high quality and robust preclinical assay to use in discovering novel treatments for pain.
C1 [Miranda, Jason A.; Turner, Jamie; Dias, Rebecca; Rees, Huw] Pfizer, Neusentis Res Unit, Cambridge, England.
   [Stanley, Phil; Gore, Katrina] Pfizer, Clin Res, Res Stat, Cambridge, England.
RP Miranda, JA (reprint author), Pfizer, Neusentis Res Unit, Cambridge, England.
EM jason.miranda2@pfizer.com
RI Miranda, Jason/B-8043-2009
OI Miranda, Jason/0000-0002-1459-2022
FU Pfizer LTD
FX All work was funded by Pfizer LTD. Pfizer LTD. provided support in the
   form of salaries for all authors, but did not have any additional role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. The specific roles of these authors
   are articulated in the 'author contributions' section.
CR Allen EA, 2012, NEURON, V74, P603, DOI 10.1016/j.neuron.2012.05.001
   [Anonymous], 2013, NATURE, V496, P398, DOI 10.1038/496398a
   Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063-4584(03)0163-8
   BROGDEN RN, 1979, DRUGS, V18, P241, DOI 10.2165/00003495-197918040-00001
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Campbell JN, 2006, NEURON, V52, P77, DOI 10.1016/j.neuron.2006.09.021
   Chu KL, 2011, BRAIN RES, V1369, P158, DOI 10.1016/j.brainres.2010.10.101
   COGGESHALL RE, 1983, BRAIN RES, V272, P185, DOI 10.1016/0006-8993(83)90379-7
   Combe R, 2004, NEUROSCI LETT, V370, P236, DOI 10.1016/j.neulet.2004.08.023
   Currie GL, 2013, PAIN, V154, P917, DOI 10.1016/j.pain.2013.02.033
   Davies NM, 1997, CLIN PHARMACOKINET, V32, P268, DOI 10.2165/00003088-199732040-00002
   Ferland CE, 2011, PHARMACOL BIOCHEM BE, V97, P603, DOI 10.1016/j.pbb.2010.11.003
   Ferland CE, 2011, NEUROPEPTIDES, V45, P423, DOI 10.1016/j.npep.2011.07.007
   GLARE PA, 1993, J CLIN ONCOL, V11, P973, DOI 10.1200/JCO.1993.11.5.973
   Gregory MH, 2012, ARTHRITIS, DOI 10.1155/2012/764621
   Grubb BD, 1996, NEUROSCIENCE, V74, P1077, DOI 10.1016/0306-4522(96)00272-2
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   HANESCH U, 1991, NEUROSCIENCE, V45, P185, DOI 10.1016/0306-4522(91)90114-4
   Harvey VL, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-18
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Im HJ, 2010, ARTHRITIS RHEUM-US, V62, P2995, DOI 10.1002/art.27608
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Patino-Camacho SI, 2013, DRUG DEVELOP RES, V74, P31, DOI 10.1002/ddr.21053
   JURNA I, 1988, PAIN, V35, P349, DOI 10.1016/0304-3959(88)90144-3
   Just S, 2000, J NEUROSCI METH, V103, P157, DOI 10.1016/S0165-0270(00)00310-1
   KALSO E, 1990, PHARMACOL TOXICOL, V67, P322, DOI 10.1111/j.1600-0773.1990.tb00838.x
   KAYSER V, 1981, BRAIN RES, V226, P344, DOI 10.1016/0006-8993(81)91110-0
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JH, 2011, J NEUROPHYSIOL, V105, P2043, DOI 10.1152/jn.00852.2010
   Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Lee Y, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-39
   Li J, 1999, PAIN, V79, P75, DOI 10.1016/S0304-3959(98)00154-7
   Macleod MR, 2004, STROKE, V35, P1203, DOI 10.1161/01.STR.0000125719.25853.20
   Malfait AM, 2013, OSTEOARTHR CARTILAGE, V21, P1316, DOI 10.1016/j.joca.2013.06.003
   McDougall JJ, 2004, AM J PHYSIOL-REG I, V286, pR634, DOI 10.1152/ajpregu.00464.2003
   Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002
   Michaelis M, 1996, CLIN EXP PHARMACOL P, V23, P99, DOI 10.1111/j.1440-1681.1996.tb02579.x
   Miller TR, 2013, EUR J PAIN, V17, P692, DOI 10.1002/j.1532-2149.2012.00232.x
   Moonesinghe R, 2007, PLOS MED, V4, P218, DOI 10.1371/journal.pmed.0040028
   Nagase H, 2012, J PHARMACOL TOX MET, V65, P29, DOI 10.1016/j.vascn.2011.10.002
   Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022
   OBRIEN C, 1989, NEUROSCIENCE, V32, P493, DOI 10.1016/0306-4522(89)90096-1
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-134
   Peers IS, 2014, NAT REV DRUG DISCOV, V13, DOI 10.1038/nrd4090-c1
   POYHIA R, 1992, PHARMACOL TOXICOL, V70, P125
   Prochazkova M, 2009, PHYSIOL RES, V58, P419
   Rahman W, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-45
   Rashid MH, 2013, EUR J PAIN, V17, P210, DOI 10.1002/j.1532-2149.2012.00176.x
   Richter F, 2012, ARTHRITIS RHEUM-US, V64, P4125, DOI 10.1002/art.37695
   Sagar DR, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-88
   Salo PT, 1997, J ANAT, V190, P515, DOI 10.1046/j.1469-7580.1997.19040515.x
   SATTERWHITE JH, 1995, EXP GERONTOL, V30, P505, DOI 10.1016/0531-5565(95)00012-6
   Schiff M, 2004, J RHEUMATOL, V31, P1373
   Schuelert N, 2008, ARTHRITIS RHEUM, V58, P145, DOI 10.1002/art.23156
   Schuelert N, 2011, PAIN, V152, P975, DOI 10.1016/j.pain.2010.11.025
   Schuelert N, 2009, NEUROSCI LETT, V465, P184, DOI 10.1016/j.neulet.2009.08.063
   Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   Senn S, 2006, STAT MED, V25, P4334, DOI 10.1002/sim.2682
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Smith ESJ, 2009, J COMP PHYSIOL A, V195, P1089, DOI 10.1007/s00359-009-0482-z
   Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006
   Thakur M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033730
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Vesterinen HV, 2011, J CEREBR BLOOD F MET, V31, P1064, DOI 10.1038/jcbfm.2010.217
   Vickers A J, 2001, BMC Med Res Methodol, V1, P6, DOI 10.1186/1471-2288-1-6
   Walters ET, 1996, NEUROBIOLOGY NOCICEP, P92
   Zhang RX, 2013, OSTEOARTHR CARTILAGE, V21, P1308, DOI 10.1016/j.joca.2013.06.013
NR 69
TC 6
Z9 6
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2014
VL 9
IS 8
AR e106108
DI 10.1371/journal.pone.0106108
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO4JK
UT WOS:000341303200089
PM 25157947
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Welsh, TN
   Hirst, JJ
   Palliser, H
   Zakar, T
AF Welsh, Toni N.
   Hirst, Jonathan J.
   Palliser, Hannah
   Zakar, Tamas
TI Progesterone Receptor Expression Declines in the Guinea Pig Uterus
   during Functional Progesterone Withdrawal and in Response to
   Prostaglandins
SO PLOS ONE
LA English
DT Article
ID HUMAN MYOMETRIAL CELLS; HUMAN-PREGNANCY; GENE-EXPRESSION; FETAL
   MEMBRANES; UTERINE CERVIX; PARTURITION; DECIDUA; ESTRADIOL; MECHANISM;
   FAILURE
AB Progesterone withdrawal is essential for parturition, but the mechanism of this pivotal hormonal change is unclear in women and other mammals that give birth without a pre-labor drop in maternal progesterone levels. One possibility suggested by uterine tissue analyses and cell culture models is that progesterone receptor levels change at term decreasing the progesterone responsiveness of the myometrium, which causes progesterone withdrawal at the functional level and results in estrogen dominance enhancing uterine contractility. In this investigation we have explored whether receptor mediated functional progesterone withdrawal occurs during late pregnancy and labor in vivo. We have also determined whether prostaglandins that induce labor cause functional progesterone withdrawal by altering myometrial progesterone receptor expression. Pregnant guinea pigs were used, since this animal loses progesterone responsiveness at term and gives birth in the presence of high maternal progesterone level similarly to primates. We found that progesterone receptor mRNA and protein A and B expression decreased in the guinea pig uterus during the last third of gestation and in labor. Prostaglandin administration reduced while prostaglandin synthesis inhibitor treatment increased progesterone receptor A protein abundance. Estrogen receptor-1 protein levels remained unchanged during late gestation, in labor and after prostaglandin or prostaglandin synthesis inhibitor administration. Steroid receptor levels were higher in the non-pregnant than in the pregnant uterine horns. We conclude that the decreasing expression of both progesterone receptors A and B is a physiological mechanism of functional progesterone withdrawal in the guinea pig during late pregnancy and in labor. Further, prostaglandins administered exogenously or produced endogenously stimulate labor in part by suppressing uterine progesterone receptor A expression, which may cause functional progesterone withdrawal, promote estrogen dominance and foster myometrial contractions.
C1 [Welsh, Toni N.; Zakar, Tamas] John Hunter Hosp, Dept Obstet & Gynaecol, New Lambton Hts, NSW, Australia.
   [Hirst, Jonathan J.; Palliser, Hannah] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.
   [Welsh, Toni N.; Zakar, Tamas] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.
   [Welsh, Toni N.; Hirst, Jonathan J.; Palliser, Hannah; Zakar, Tamas] Mothers & Babies Res Ctr, New Lambton Hts, NSW, Australia.
   [Hirst, Jonathan J.; Palliser, Hannah; Zakar, Tamas] Hunter Med Res Inst, New Lambton Hts, NSW, Australia.
RP Zakar, T (reprint author), John Hunter Hosp, Dept Obstet & Gynaecol, New Lambton Hts, NSW, Australia.
EM Tamas.Zakar@newcastle.edu.au
OI Zakar, Tamas/0000-0002-1690-1159
FU National Health and Medical Research Council of Australia [569282];
   Royal Australian and New Zealand College of Obstetricians and
   Gynaecologists
FX This work was supported by the National Health and Medical Research
   Council of Australia (www.nhmrc.gov.au; Project Grant 569282) and The
   Royal Australian and New Zealand College of Obstetricians and
   Gynaecologists (www.ranzcog.rdu.au; Ella Macknight Memorial Fellowship
   for TW). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR CHALLIS JRG, 1971, J ENDOCRINOL, V51, P333, DOI 10.1677/joe.0.0510333
   ELGER W, 1985, ACTA PHYSIOL HUNG, V65, P415
   GLASIER MA, 1993, STEROIDS, V58, P478, DOI 10.1016/0039-128X(93)90006-9
   Goldman S, 2005, MOL HUM REPROD, V11, P269, DOI 10.1093/molehr/gah161
   Haluska GJ, 2002, J SOC GYNECOL INVEST, V9, P125, DOI 10.1016/S1071-5576(02)00144-2
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Madsen G, 2004, J CLIN ENDOCR METAB, V89, P1010, DOI 10.1210/jc.2003-031037
   Merlino AA, 2007, J CLIN ENDOCR METAB, V92, P1927, DOI 10.1210/jc.2007-0077
   Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924
   Mesiano S, 2011, REPROD SCI, V18, P6, DOI 10.1177/1933719110382922
   Nnamani Mauris C., 2013, Evolution Medicine and Public Health, P273, DOI 10.1093/emph/eot022
   Palliser HK, 2010, REPROD SCI, V17, P776, DOI 10.1177/1933719110371517
   PORTER DG, 1970, J ENDOCRINOL, V46, P425, DOI 10.1677/joe.0.0460425
   Rodriguez HA, 2008, J STEROID BIOCHEM, V111, P247, DOI 10.1016/j.jsbmb.2008.06.012
   Rodriguez HA, 2003, MOL HUM REPROD, V9, P807, DOI 10.1093/molehr/gag099
   Schellenberg JC, 1997, PROSTAGLANDINS, V54, P625, DOI 10.1016/S0090-6980(97)00129-9
   Stjernholm-Vladic Y, 2004, GYNECOL ENDOCRINOL, V18, P41, DOI 10.1080/09513590310001651777
   Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681
   Tan HQ, 2012, J CLIN ENDOCR METAB, V97, pE719, DOI 10.1210/jc.2011-3251
   Terakawa K, 2002, J SOC GYNECOL INVEST, V9, P68, DOI 10.1016/S1071-5576(01)00157-5
   TULCHINSKY D, 1972, AM J OBSTET GYNECOL, V112, P1095, DOI 10.1016/0002-9378(72)90185-8
   Untergasser A, 2007, NUCLEIC ACIDS RES, V35, pW71, DOI 10.1093/nar/gkm306
   VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244
   WALSH SW, 1984, J CLIN ENDOCR METAB, V58, P629, DOI 10.1210/jcem-58-4-629
   Welsh T, 2005, J PHYSIOL-LONDON, V569, P903, DOI 10.1113/jphysiol.2005.098129
   Zakar T, 2007, AM J OBSTET GYNECOL, V196, P289, DOI 10.1016/j.ajog.2006.09.005
NR 27
TC 4
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2014
VL 9
IS 8
AR e105253
DI 10.1371/journal.pone.0105253
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO4JK
UT WOS:000341303200026
PM 25157946
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yao, LB
   Li, CH
   Ge, XL
   Wang, HD
   Xu, KS
   Zhang, AQ
   Dong, JH
AF Yao, Libin
   Li, Chonghui
   Ge, Xinlan
   Wang, Hongdong
   Xu, Kesen
   Zhang, Aiqun
   Dong, Jiahong
TI Establishment of a Rat Model of Portal Vein Ligation Combined with In
   Situ Splitting
SO PLOS ONE
LA English
DT Article
ID POSTOPERATIVE LIVER-FAILURE; MAJOR HEPATECTOMY;
   HEPATOCELLULAR-CARCINOMA; HEPATIC RESECTION; ALPPS APPROACH;
   EMBOLIZATION; REGENERATION; RESECTABILITY; HYPERTROPHY; INCREASE
AB Background: Portal vein ligation (PVL) combined with in situ splitting (ISS) has been shown to induce remarkable liver regeneration in patients. The purpose of this study was to establish a model of PVL+ISS in rats for exploring the possible mechanisms of liver regeneration using these techniques.
   Materials and Methods: Rats were randomly assigned to three experimental groups: selective PVL, selective PVL+ISS and sham operation. The hepatic regeneration rate (HRR), Ki-67, liver biochemical determinations and histopathology were assessed at 24, 48, and 72 h and 7 days after the operation. The microcirculation of the median lobes before and after ISS was examined by laser speckle contrast imaging. Meanwhile, cytokines such as TNF-alpha, IL-6, HGF and HSP70 in regenerating liver lobes at 24 h was investigated by RT-PCR and ELISA.
   Results: The HRR of PVL+ISS was much higher than that of the PVL at 72 h and 7 days after surgery (p<0.01). The expression of Ki-67 in hepatocytes in the regenerating liver lobe was stronger in the PVL+ISS group than in the PVL group at 48 and 72 h (p<0.01). There was a significant reduction in microcirculation blood perfusion of the left median lobe before and after ISS. Liver biochemical determinations and histopathology demonstrated more severe hepatocyte injury in the PVL+ISS group. Both the mRNA levels of TNF-alpha and IL-6 and the protein levels of TNF-alpha, IL-6 and HGF in regenerating liver lobes were higher in the PVL+ISS than the PVL alone.
   Conclusions: The higher HRR in the PVL+ISS compared with the PVL confirmed that we had successfully established a PVL+ISS model in rats. The possible mechanisms included the reduced microcirculation blood perfusion of the left median lobe and up-regulation of cytokines in the regenerating lobes after ISS.
C1 [Yao, Libin; Wang, Hongdong; Xu, Kesen; Dong, Jiahong] Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan 250100, Shandong, Peoples R China.
   [Li, Chonghui; Ge, Xinlan; Zhang, Aiqun; Dong, Jiahong] Chinese Peoples Liberat Army Gen Hosp, Hosp & Inst Hepatobiliary Surg, Beijing, Peoples R China.
RP Dong, JH (reprint author), Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan 250100, Shandong, Peoples R China.
EM dongjh301@163.com
FU National Key Technology R&D Program of China [2012BAI06B01]; National
   Natural Science Foundation of China [81271738]
FX This work was supported by the National Key Technology R&D Program of
   China (2012BAI06B01) and the Project of the National Natural Science
   Foundation of China (81271738). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdalla EK, 2010, J SURG ONCOL, V102, P960, DOI 10.1002/jso.21654
   Abulkhir A, 2008, ANN SURG, V247, P49, DOI 10.1097/SLA.0b013e31815f6e5b
   Clavien P, 2007, NEW ENGL J MED, V356, P1545, DOI 10.1056/NEJMra065156
   de Santibanes E, 2012, ANN SURG, V255, P415, DOI 10.1097/SLA.0b013e318248577d
   Fujiyoshi M, 2011, J HEPATO-BIL-PAN SCI, V18, P13, DOI 10.1007/s00534-010-0304-2
   Jaeck D, 2004, ANN SURG, V240, P1037, DOI 10.1097/01.sla.0000145965.86383.89
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kishi Y, 2009, T M AM SURG ASS, V127, P171
   Liu H, 2009, AM J SURG, V197, P686, DOI [10.1016/j.amjsurg.2008.04.022, 10.1016/j.amjsurg.2008.04.006]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Machado MA, 2013, ANN SURG ONCOL, V20, P1491, DOI 10.1245/s10434-013-2920-y
   MAKUUCHI M, 1990, SURGERY, V107, P521
   McGuire PG, 2010, J SURG RES, V164, pE201, DOI 10.1016/j.jss.2010.07.059
   Neumann UP, 2013, BRIT J SURG, V100, P310, DOI 10.1002/bjs.9050
   Pahlavan PS, 2006, J SURG RES, V134, P238, DOI 10.1016/j.jss.2005.12.011
   Ribero D, 2007, BRIT J SURG, V94, P1386, DOI 10.1002/bjs.5836
   Ribero D, 2008, ANN SURG ONCOL, V15, P986, DOI 10.1245/s10434-007-9731-y
   Schnitzbauer AA, 2012, ANN SURG, V255, P405, DOI 10.1097/SLA.0b013e31824856f5
   Seyama Y, 2007, WORLD J GASTROENTERO, V13, P1505, DOI 10.3748/wjg.v13.i10.1505
   Shirabe K, 1999, J AM COLL SURGEONS, V188, P304, DOI 10.1016/S1072-7515(98)00301-9
   Sturesson C, 2013, MICROVASC RES, V87, P34, DOI 10.1016/j.mvr.2013.01.004
   Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489
   Tschuor C, 2013, EJSO-EUR J SURG ONC, V39, P1230, DOI 10.1016/j.ejso.2013.08.009
   Vetelainen R, 2006, J VASC INTERV RADIOL, V17, P1181, DOI 10.1097/01.RVI.0000228460.48294.2E
NR 24
TC 20
Z9 26
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2014
VL 9
IS 8
AR e105511
DI 10.1371/journal.pone.0105511
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO1WL
UT WOS:000341106100075
PM 25144490
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yang, F
   Zhao, JF
   Shou, QY
   Huang, XJ
   Chen, G
   Yang, KB
   Zhang, SG
   Lv, BD
   Fu, HY
AF Yang, Fan
   Zhao, Jian F.
   Shou, Qi Y.
   Huang, Xiao J.
   Chen, Gang
   Yang, Ke B.
   Zhang, Shi G.
   Lv, Bo D.
   Fu, Hui Y.
TI Phenotypic Modulation of Corpus Cavernosum Smooth Muscle Cells in a Rat
   Model of Cavernous Neurectomy
SO PLOS ONE
LA English
DT Article
ID ERECTILE DYSFUNCTION; RADICAL PROSTATECTOMY; MOLECULAR-MECHANISMS; NERVE
   ABLATION; FIBROSIS; DIFFERENTIATION; PROLIFERATION; NEUROTOMY; HYPOXIA
AB Background: Patients undergoing radical prostatectomy (RP) are at high risk for erectile dysfunction (ED) due to potential cavernous nerve (CN) damage during surgery. Penile hypoxia after RP is thought to significantly contribute to ED pathogenesis.
   Aim: We previously showed that corpora cavernosum smooth muscle cells (CCSMCs) undergo phenotypic modulation under hypoxic conditions in vitro. Here, we studied such changes in an in vivo post-RP ED model by investigating CCSMCs in bilateral cavernous neurectomy (BCN) rats.
   Methods: Sprague-Dawley rats underwent sham (n = 12) or BCN (n = 12) surgery. After 12 weeks, they were injected with apomorphine to determine erectile function. The penile tissues were harvested and assessed for fibrosis using Masson trichrome staining and for molecular markers of phenotypic modulation using immunohistochemistry and western blotting. CCSMC morphological structure was evaluated by hematoxylin-eosin (H&E) staining and transmission electron microscopy (TEM).
   Results: Erectile function was significantly lower in BCN rats than in sham rats. BCN increased hypoxia-inducible factor-1 alpha and collagen protein expression in corpora cavernous tissue. H&E staining and TEM showed that CCSMCs in BCN rats underwent hypertrophy and showed rough endoplasmic reticulum formation. The expression of CCSMC phenotypic markers, such as smooth muscle alpha-actin, smooth muscle myosin heavy chain, and desmin, was markedly lower, whereas vimentin protein expression was significantly higher in BCN rats than in control rats.
   Conclusions: CCSMCs undergo phenotype modulation in rats with cavernous neurectomy. The results have unveiled physiological transformations that occur at the cellular and molecular levels and have helped characterize CN injury-induced ED.
C1 [Yang, Fan; Zhao, Jian F.; Huang, Xiao J.; Chen, Gang; Yang, Ke B.; Zhang, Shi G.; Lv, Bo D.] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Dept Urol, Hangzhou, Zhejiang, Peoples R China.
   [Shou, Qi Y.] Zhejiang Chinese Med Univ, Lab Anim Res Ctr, Hangzhou, Zhejiang, Peoples R China.
   [Fu, Hui Y.] Zhejiang Chinese Med Univ, Clin Med Coll 2, Cent Lab, Hangzhou, Zhejiang, Peoples R China.
   [Lv, Bo D.; Fu, Hui Y.] Zhejiang Prov Key Lab Tradit Chinese Med, Androl Lab Integrat Chinese & Western Med, Hangzhou, Zhejiang, Peoples R China.
RP Lv, BD (reprint author), Zhejiang Chinese Med Univ, Affiliated Hosp 2, Dept Urol, Hangzhou, Zhejiang, Peoples R China.
EM lbd168@126.com; fhy131@126.com
FU  [WKJ2010-2-020];  [2009ZA009];  [Y2111167]
FX This work was supported by the following: WKJ2010-2-020
   (http://www.zjwst.gov.cn/), 2009ZA009 (http://zgj.zjtcm.net/), and
   Y2111167 (http://www.zjnsf.gov.cn/). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Asada H, 2005, J VASC SURG, V42, P772, DOI 10.1016/j.jvs.2005.05.046
   CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1
   Ferrini MG, 2009, J SEX MED, V6, P415, DOI 10.1111/j.1743-6109.2008.01105.x
   Halayko AJ, 2001, J APPL PHYSIOL, V90, P358
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   HEDIN U, 1987, DIFFERENTIATION, V33, P239, DOI 10.1111/j.1432-0436.1987.tb01563.x
   Hu WL, 2004, ASIAN J ANDROL, V6, P111
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Leungwattanakij S, 2003, J ANDROL, V24, P239
   Li FF, 2012, J IMMUNOL, V189, P3159, DOI 10.4049/jimmunol.1200197
   Liu K, 2012, J ANDROL, V33, P1186, DOI 10.2164/jandrol.112.016642
   Magheli A, 2009, NAT REV UROL, V6, P415, DOI 10.1038/nrurol.2009.126
   Meng MV, 2003, J UROLOGY, V170, P2279, DOI 10.1097/01.ju.0000094190.46523.b2
   Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865
   Meuleman EJH, 2003, EUR UROL, V43, P95, DOI 10.1016/S0302-2838(02)00546-8
   Montorsi F, 1997, J UROLOGY, V158, P1408, DOI 10.1016/S0022-5347(01)64227-7
   Moreland RB, 1998, INT J IMPOT RES, V10, P113, DOI 10.1038/sj.ijir.3900328
   Nehra A, 1996, J UROLOGY, V156, P1320, DOI 10.1016/S0022-5347(01)65578-2
   Orr AW, 2009, ARTERIOSCL THROM VAS, V29, P225, DOI 10.1161/ATVBAHA.108.178749
   Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003
   OWENS GK, 1995, PHYSIOL REV, V75, P487
   Prakash YS, 2013, AM J PHYSIOL-LUNG C, V305, pL912, DOI 10.1152/ajplung.00259.2013
   Thakar RG, 2009, BIOPHYS J, V96, P3423, DOI 10.1016/j.bpj.2008.11.074
   Vignozzi L, 2006, J SEX MED, V3, P419, DOI 10.1111/j.1743-6109.2006.00208.x
   Wei AY, 2012, INT J IMPOT RES, V24, P196, DOI 10.1038/ijir.2012.16
   Welliver RC, 2014, J SEX MED, V11, P1071, DOI 10.1111/jsm.12445
   Zhang XH, 2002, CHINESE MED J-PEKING, V115, P1179
NR 27
TC 8
Z9 12
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2014
VL 9
IS 8
AR e105186
DI 10.1371/journal.pone.0105186
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN8UD
UT WOS:000340879300090
PM 25127037
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hernandez-Jimenez, C
   Garcia-Torrentera, R
   Olmos-Zuniga, JR
   Jasso-Victoria, R
   Gaxiola-Gaxiola, MO
   Baltazares-Lipp, M
   Gutierrez-Gonzalez, LH
AF Hernandez-Jimenez, Claudia
   Garcia-Torrentera, Rogelio
   Olmos-Zuniga, J. Raul
   Jasso-Victoria, Rogelio
   Gaxiola-Gaxiola, Miguel O.
   Baltazares-Lipp, Matilde
   Gutierrez-Gonzalez, Luis H.
TI Respiratory Mechanics and Plasma Levels of Tumor Necrosis Factor Alpha
   and Interleukin 6 Are Affected by Gas Humidification during Mechanical
   Ventilation in Dogs
SO PLOS ONE
LA English
DT Article
ID NITROGEN WASHOUT/WASHIN TECHNIQUE; DRY; RECEPTORS; RELEASE; RATS; AIR
AB The use of dry gases during mechanical ventilation has been associated with the risk of serious airway complications. The goal of the present study was to quantify the plasma levels of TNF-alpha and IL-6 and to determine the radiological, hemodynamic, gasometric, and microscopic changes in lung mechanics in dogs subjected to short-term mechanical ventilation with and without humidification of the inhaled gas. The experiment was conducted for 24 hours in 10 dogs divided into two groups: Group I (n = 5), mechanical ventilation with dry oxygen dispensation, and Group II (n = 5), mechanical ventilation with oxygen dispensation using a moisture chamber. Variance analysis was used. No changes in physiological, hemodynamic, or gasometric, and radiographic constants were observed. Plasma TNF-alpha levels increased in group I, reaching a maximum 24 hours after mechanical ventilation was initiated (ANOVA p = 0.77). This increase was correlated to changes in mechanical ventilation. Plasma IL-6 levels decreased at 12 hours and increased again towards the end of the study (ANOVA p>0.05). Both groups exhibited a decrease in lung compliance and functional residual capacity values, but this was more pronounced in group I. Pplat increased in group I (ANOVA p=0.02). Inhalation of dry gas caused histological lesions in the entire respiratory tract, including pulmonary parenchyma, to a greater extent than humidified gas. Humidification of inspired gases can attenuate damage associated with mechanical ventilation.
C1 [Hernandez-Jimenez, Claudia; Olmos-Zuniga, J. Raul; Jasso-Victoria, Rogelio; Baltazares-Lipp, Matilde] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Expt Surg, Mexico City, DF, Mexico.
   [Garcia-Torrentera, Rogelio] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Mexico City, DF, Mexico.
   [Gaxiola-Gaxiola, Miguel O.] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Lab Morphol, Mexico City, DF, Mexico.
   [Gutierrez-Gonzalez, Luis H.] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Virol & Mycol, Mexico City, DF, Mexico.
RP Hernandez-Jimenez, C (reprint author), Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Expt Surg, Mexico City, DF, Mexico.
EM claudia_herjim@iner.gob.mx
OI Gutierrez-Gonzalez, Luis Horacio/0000-0003-0708-0448
FU National Institute of Respiratory Diseases "Ismael CosIo Villegas"
FX This study was supported by the National Institute of Respiratory
   Diseases "Ismael CosIo Villegas." The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arancibia F, 2010, REV CHIL MED INT, V25, P205
   BALLS M, 1994, LAB ANIM, V28, P193, DOI 10.1258/002367794780681714
   Branson Richard D, 2006, Respir Care Clin N Am, V12, P253
   Chidekel A, 2012, PULM MED, DOI 10.1155/2012/380686
   COHEN IL, 1988, CRIT CARE MED, V16, P277, DOI 10.1097/00003246-198803000-00013
   Dellamonica J, 2011, CRIT CARE, V15, DOI 10.1186/cc10587
   Dorsch JA, 1999, UNDERSTANDING ANESTH, P309
   Doyle A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2011.02.004
   FONKALSRUD EW, 1975, SURGERY, V78, P373
   FROESE AB, 1974, ANESTHESIOLOGY, V41, P242, DOI 10.1097/00000542-197409000-00006
   Goldsmith A, 2009, ANAEST INTENS CARE M, V10, P465, DOI 10.1016/j.mpaic.2009.07.003
   Gorayb Susane Bruder Silveira, 2004, Rev. Bras. Anestesiol., V54, P20, DOI 10.1590/S0034-70942004000100004
   GREENSPAN JS, 1991, J PEDIATR-US, V118, P443, DOI 10.1016/S0022-3476(05)82165-1
   Haitsma JJ, 2003, CLIN PHYSIOL FUNCT I, V23, P349, DOI 10.1046/j.1475-0961.2003.00518.x
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koksel O, 2005, EXP LUNG RES, V31, P483, DOI 10.1080/01902140590918876
   Lellouche F, 2004, AM J RESP CRIT CARE, V170, P1073, DOI 10.1164/rccm.200309-124SOC
   Lellouche FO, 2002, INTENS CARE MED, V28, P1582, DOI 10.1007/s00134-002-1518-9
   MARFATIA S, 1975, J PEDIATR SURG, V10, P583, DOI 10.1016/0022-3468(75)90360-7
   MERCKE U, 1975, ACTA OTO-LARYNGOL, V79, P133, DOI 10.3109/00016487509124665
   MODELL JH, 1967, ANESTHESIOLOGY, V28, P680, DOI 10.1097/00000542-196707000-00013
   NIH, 2011, GUIDE CARE USE LAB A
   Olegard C, 2005, ANESTH ANALG, V101, P206, DOI 10.1213/01.ANE.0000165823.90368.55
   On LS, 2001, AM J RESP CRIT CARE, V163, P1320, DOI 10.1164/ajrccm.163.6.2002129
   Parsons PE, 2005, AM J PHYSIOL-LUNG C, V288, pL426, DOI 10.1152/ajplung.00302.2004
   Prez M., 2006, Med. Intensiva, V30, P440
   Pillow JJ, 2009, INTENS CARE MED, V35, P2157, DOI 10.1007/s00134-009-1624-z
   RASHAD K, 1967, ANESTH ANAL CURR RES, V46, P127
   Roze H, 2010, BRIT J ANAESTH, V105, P377, DOI 10.1093/bja/aeq130
   SAGARPA (Secretaria de Agricultura Ganaderia Desarrollo Rural Pesca y Alimentacion), 1999, DIARIO OFICIAL FEDER
   Sottiaux Thierry M, 2006, Respir Care Clin N Am, V12, P233
   Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603
   TABKA Z, 1988, CHEST, V94, P81, DOI 10.1378/chest.94.1.81
   Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/01.CCM.0000021645.73615.D9
   von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052
NR 35
TC 3
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 18
PY 2014
VL 9
IS 7
AR e101952
DI 10.1371/journal.pone.0101952
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1OC
UT WOS:000339615200030
PM 25036811
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Noratto, GD
   Garcia-Mazcorro, JF
   Markel, M
   Martino, HS
   Minamoto, Y
   Steiner, JM
   Byrne, D
   Suchodolski, JS
   Mertens-Talcott, SU
AF Noratto, Giuliana D.
   Garcia-Mazcorro, Jose F.
   Markel, Melissa
   Martino, Hercia S.
   Minamoto, Yasushi
   Steiner, Joerg M.
   Byrne, David
   Suchodolski, Jan S.
   Mertens-Talcott, Susanne U.
TI Carbohydrate-Free Peach (Prunus persica) and Plum (Prunus domestica)
   Juice Affects Fecal Microbial Ecology in an Obese Animal Model
SO PLOS ONE
LA English
DT Article
ID EUTERPE-OLERACEA MART.; DIET-INDUCED OBESITY; GUT MICROBIOTA; IN-VITRO;
   INTESTINAL MICROBIOTA; BACTERIAL MICROBIOTA; TEA POLYPHENOLS;
   METABOLIC-FATE; RIBOSOMAL-RNA; RED WINE
AB Background: Growing evidence shows the potential of nutritional interventions to treat obesity but most investigations have utilized non-digestible carbohydrates only. Peach and plum contain high amounts of polyphenols, compounds with demonstrated anti-obesity effects. The underlying process of successfully treating obesity using polyphenols may involve an alteration of the intestinal microbiota. However, this phenomenon is not well understood.
   Methodology/Principal Findings: Obese Zucker rats were assigned to three groups (peach, plum, and control, n = 10 each), wild-type group was named lean (n = 10). Carbohydrates in the fruit juices were eliminated using enzymatic hydrolysis. Fecal samples were obtained after 11 weeks of fruit or control juice administration. Real-time PCR and 454-pyrosequencing were used to evaluate changes in fecal microbiota. Over 1,500 different Operational Taxonomic Units at 97% similarity were detected in all rats. Several bacterial groups (e. g. Lactobacillus and members of Ruminococcacea) were found to be more abundant in the peach but especially in the plum group (plum juice contained 3 times more total polyphenolics compared to peach juice). Principal coordinate analysis based on Unifrac-based unweighted distance matrices revealed a distinct separation between the microbiota of control and treatment groups. These changes in fecal microbiota occurred simultaneously with differences in fecal short-chain acids concentrations between the control and treatment groups as well as a significant decrease in body weight in the plum group.
   Conclusions: This study suggests that consumption of carbohydrate-free peach and plum juice has the potential to modify fecal microbial ecology in an obese animal model. The separate contribution of polyphenols and non-polyphenols compounds (vitamins and minerals) to the observed changes is unknown.
C1 [Noratto, Giuliana D.; Martino, Hercia S.; Mertens-Talcott, Susanne U.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA.
   [Garcia-Mazcorro, Jose F.] Univ Autonoma Nuevo Leon, Fac Med Vet & Zootecnia, Nuevo Leon, Mexico.
   [Markel, Melissa; Minamoto, Yasushi; Steiner, Joerg M.; Suchodolski, Jan S.] Texas A&M Univ, Gastrointestinal Lab, College Stn, TX USA.
   [Byrne, David] Texas A&M Univ, Dept Hort Sci, College Stn, TX 77843 USA.
   [Mertens-Talcott, Susanne U.] Texas A&M Univ, College Stn, TX USA.
RP Mertens-Talcott, SU (reprint author), Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA.
EM SMTalcott@tamu.edu
RI ; Garcia-Mazcorro, Jose F./O-5799-2018
OI Mertens-Talcott, Susanne/0000-0003-2828-4044; Stampini Duarte Martino,
   Hercia/0000-0002-8565-8439; Suchodolski, Jan/0000-0002-2176-6932;
   Garcia-Mazcorro, Jose F./0000-0001-6047-4361
FU Vegetable and Fruit Improvement Center at Texas AM University; National
   Counsel of Technological and Scientific Development (CNPq-Brazil)
   [200382/2011-0]; CONACYT (Mexico) through the National System of
   Researchers program
FX This research was supported by the Vegetable and Fruit Improvement
   Center (http://vfic.tamu.edu/) at Texas A&M University. Hercia S.
   Martino thanks the National Counsel of Technological and Scientific
   Development (CNPq-Brazil) for the scholarship (reference number:
   200382/2011-0). Jose F Garcia-Mazcorro is financially supported by
   CONACYT (Mexico) through the National System of Researchers (SNI, for
   initials in Spanish) program
   (http://www.conacyt.mx/index.php/el-conacyt/sistema-nacional-de-investig
   adores). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ahn YJ, 1998, J APPL MICROBIOL, V84, P439, DOI 10.1046/j.1365-2672.1998.00363.x
   Albrecht M, 2004, J MED FOOD, V7, P274, DOI 10.1089/1096620041938704
   Bialonska D, 2010, INT J FOOD MICROBIOL, V140, P175, DOI 10.1016/j.ijfoodmicro.2010.03.038
   Bolca S, 2013, CURR OPIN BIOTECH, V24, P220, DOI 10.1016/j.copbio.2012.09.009
   Bravo L, 1998, NUTR REV, V56, P317
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chiva-Blanch G, 2012, J BERRY RES, V2, P63, DOI 10.3233/JBR-2012-028
   Coccia A, 2012, INT J FOOD SCI TECH, V47, P1620, DOI 10.1111/j.1365-2621.2012.03012.x
   Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879
   Crozier A, 2009, NAT PROD REP, V26, P1001, DOI 10.1039/b802662a
   Cueva C, 2013, FEMS MICROBIOL ECOL, V83, P792, DOI 10.1111/1574-6941.12037
   Delzenne NM, 2011, ANNU REV NUTR, V31, P15, DOI 10.1146/annurev-nutr-072610-145146
   Duncan SH, 2008, INT J OBESITY, V32, P1720, DOI 10.1038/ijo.2008.155
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461
   Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110
   Gallagher EJ, 2010, MT SINAI J MED, V77, P511, DOI 10.1002/msj.20212
   Garcia-Mazcorro JF, 2012, FEMS MICROBIOL ECOL, V80, P624, DOI 10.1111/j.1574-6941.2012.01331.x
   LeBlanc JG, 2013, CURR OPIN BIOTECH, V24, P160, DOI 10.1016/j.copbio.2012.08.005
   Hammer O., 2001, PALAEONTOL ELECTRON, V4, P1, DOI DOI 10.1016/J.BCP.2008.05.025
   Hidalgo M, 2012, J AGR FOOD CHEM, V60, P3882, DOI 10.1021/jf3002153
   Holvoet P, 2008, Verh K Acad Geneeskd Belg, V70, P193
   Hunter D.C., 2012, PHYTOCHEMICALS NUTRA, P225
   Ikeda I, 2005, J NUTR, V135, P155
   Queipo-Ortuno MI, 2012, AM J CLIN NUTR, V95, P1323, DOI 10.3945/ajcn.111.027847
   Jellinger Paul S, 2007, Clin Cornerstone, V8 Suppl 7, pS30, DOI 10.1016/S1098-3597(07)80019-6
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Lacombe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067497
   Lee HC, 2006, RES MICROBIOL, V157, P876, DOI 10.1016/j.resmic.2006.07.004
   Lei F, 2007, INT J OBESITY, V31, P1023, DOI 10.1038/sj.ijo.0803502
   Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102
   Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725
   Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138
   Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005
   Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015
   Malinen E, 2005, AM J GASTROENTEROL, V100, P373, DOI 10.1111/j.1572-0241.2005.40312.x
   Mertens-Talcott SU, 2008, J AGR FOOD CHEM, V56, P7796, DOI 10.1021/jf8007037
   Meydani M, 2010, NUTRIENTS, V2, P737, DOI 10.3390/nu2070737
   MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030
   Moreau NM, 2003, J CHROMATOGR B, V784, P395, DOI 10.1016/S1570-0232(02)00827-9
   Muhling M, 2008, ISME J, V2, P379
   MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695
   Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1016/jf047814+
   Niswender KD, 2011, POSTGRAD MED, V123, P27, DOI 10.3810/pgm.2011.07.2301
   Pacheco-Palencia LA, 2008, J AGR FOOD CHEM, V56, P3593, DOI 10.1021/jf8001608
   Parkar SG, 2008, INT J FOOD MICROBIOL, V124, P295, DOI 10.1016/j.ijfoodmicro.2008.03.017
   Png CW, 2010, AM J GASTROENTEROL, V105, P2420, DOI 10.1038/ajg.2010.281
   Presley LL, 2010, APPL ENVIRON MICROB, V76, P936, DOI 10.1128/AEM.01561-09
   Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105
   Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051907
   Suchodolski JS, 2010, VET MICROBIOL, V142, P394, DOI 10.1016/j.vetmic.2009.11.002
   SWAIN T., 1959, Journal of the Science of Food and Agriculture, V10, P63, DOI 10.1002/jsfa.2740100110
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Tzounis X, 2008, BRIT J NUTR, V99, P782, DOI 10.1017/S0007114507853384
   Tzounis X, 2011, AM J CLIN NUTR, V93, P62, DOI 10.3945/ajcn.110.000075
   van Baarlen P, 2011, P NATL ACAD SCI USA, V108, P4562, DOI 10.1073/pnas.1000079107
   van Dorsten FA, 2010, MOL NUTR FOOD RES, V54, P897, DOI 10.1002/mnfr.200900212
   van Duynhoven J, 2011, P NATL ACAD SCI USA, V108, P4531, DOI 10.1073/pnas.1000098107
   Waldram A, 2009, J PROTEOME RES, V8, P2361, DOI 10.1021/pr8009885
NR 61
TC 19
Z9 19
U1 0
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 9
PY 2014
VL 9
IS 7
AR e101723
DI 10.1371/journal.pone.0101723
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL3PK
UT WOS:000339040600061
PM 25007331
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sloff, M
   de Vries, R
   Geutjes, P
   in't Hout, J
   Ritskes-Hoitinga, M
   Oosterwijk, E
   Feitz, W
AF Sloff, Marije
   de Vries, Rob
   Geutjes, Paul
   in't Hout, Joanna
   Ritskes-Hoitinga, Merel
   Oosterwijk, Egbert
   Feitz, Wout
TI Tissue Engineering in Animal Models for Urinary Diversion: A Systematic
   Review
SO PLOS ONE
LA English
DT Article
ID SMALL-INTESTINAL SUBMUCOSA; BLADDER REGENERATION; MACROPHAGE PHENOTYPE;
   CONDUIT; GRAFT; COMPLICATIONS; AUGMENTATION; BIOMATERIALS; IMPLANTATION;
   METAANALYSIS
AB Tissue engineering and regenerative medicine (TERM) approaches may provide alternatives for gastrointestinal tissue in urinary diversion. To continue to clinically translatable studies, TERM alternatives need to be evaluated in (large) controlled and standardized animal studies. Here, we investigated all evidence for the efficacy of tissue engineered constructs in animal models for urinary diversion. Studies investigating this subject were identified through a systematic search of three different databases (PubMed, Embase and Web of Science). From each study, animal characteristics, study characteristics and experimental outcomes for meta-analyses were tabulated. Furthermore, the reporting of items vital for study replication was assessed. The retrieved studies (8 in total) showed extreme heterogeneity in study design, including animal models, biomaterials and type of urinary diversion. All studies were feasibility studies, indicating the novelty of this field. None of the studies included appropriate control groups, i. e. a comparison with the classical treatment using GI tissue. The meta-analysis showed a trend towards successful experimentation in larger animals although no specific animal species could be identified as the most suitable model. Larger animals appear to allow a better translation to the human situation, with respect to anatomy and surgical approaches. It was unclear whether the use of cells benefits the formation of a neo urinary conduit. The reporting of the methodology and data according to standardized guidelines was insufficient and should be improved to increase the value of such publications. In conclusion, animal models in the field of TERM for urinary diversion have probably been chosen for reasons other than their predictive value. Controlled and comparative long term animal studies, with adequate methodological reporting are needed to proceed to clinical translatable studies. This will aid in good quality research with the reduction in the use of animals and an increase in empirical evidence of biomedical research.
C1 [Sloff, Marije; Geutjes, Paul; Oosterwijk, Egbert; Feitz, Wout] Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Urol, Nijmegen, Netherlands.
   [de Vries, Rob; Ritskes-Hoitinga, Merel] Radboud Univ Nijmegen Med Ctr, Cent Anim Lab, SYRCLE SYstemat Review Ctr Lab Anim Experimentat, Nijmegen, Netherlands.
   [in't Hout, Joanna] Radboud Univ Nijmegen Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands.
RP Sloff, M (reprint author), Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Urol, Nijmegen, Netherlands.
EM marije.sloff@radboudumc.nl
RI Ritskes-Hoitinga, J./H-8083-2014; Vries, R.B.M./L-4732-2015; Oosterwijk,
   Egbert/P-5466-2014; Geutjes, P.J./L-4320-2015; IntHout,
   Joanna/A-1863-2016; Feitz, W.F.J./H-8028-2014
OI IntHout, Joanna/0000-0002-6127-0747; 
FU Fonds NutsOhra: Kunststoma [1102-56]
FX This work is funded by Fonds NutsOhra: Kunststoma
   1102-56(http://www.stichtingnutsohra.nl/). The funders had no role in
   study design, data collection and analysis, decision to publish or
   preparation of the manuscript.
CR [Anonymous], 2010, NIH PUBL
   Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140-6736(06)68438-9
   Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264
   Basu J, 2010, TISSUE ENG PART A, V18, P1025
   Beiko DT, 2004, J UROLOGY, V171, P2438, DOI 10.1097/01.ju.0000125001.56045.6c
   BERTRAM TA, 2009, FASEB J, V23, P291
   Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040
   ClinicalTrials.gov, 2014, INC UR DIV US AUT NE
   De Filippo RE, 2002, J UROLOGY, V168, P1789, DOI 10.1097/01.ju.0000027662.69103.72
   De Filippo R, 2009, J UROLOGY, V181, P267, DOI 10.1016/S0022-5347(09)60763-1
   De Vries RB, 2011, LAB ANIM, V45, P168
   de Vries RBM, 2012, TISSUE ENG PART B-RE, V18, P427, DOI [10.1089/ten.teb.2012.0059, 10.1089/ten.TEB.2012.0059]
   DORFLINGER T, 1985, NEUROUROL URODYNAM, V4, P47, DOI 10.1002/nau.1930040108
   Drewa T, 2007, TRANSPL P, V39, P1647, DOI 10.1016/j.transproceed.2007.02.092
   Drewa T, 2006, TRANSPLANT P, V38, P133, DOI 10.1016/j.transproceed.2005.11.086
   Drewa T, 2012, NAT REV UROL, V9, P561, DOI 10.1038/nrurol.2012.158
   Evans K, 2005, J UROLOGY, V173, P858, DOI 10.1097/01.ju.0000152578.07262.1c
   Geutjes P, 2012, J UROLOGY, V188, P653, DOI 10.1016/j.juro.2012.03.119
   GROVER PK, 1994, MINER ELECTROL METAB, V20, P361
   Hautmann RE, 2003, J UROLOGY, V169, P834, DOI 10.1097/01.ju.0000029010.97686.eb
   Hautmann RE, 2011, NAT REV UROL, V8, P667, DOI 10.1038/nrurol.2011.147
   Hooijmans CR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001482
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   Kaefer M, 1998, J UROLOGY, V160, P2187, DOI 10.1016/S0022-5347(01)62290-0
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim BS, 2000, WORLD J UROL, V18, P2, DOI 10.1007/s003450050002
   Kloskowski T, 2012, J TISSUE ENG REGEN M, V6, P23
   Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482
   Knight J, 2003, NATURE, V422, P554, DOI 10.1038/422554a
   Lee YS, 2009, KOREAN J UROL, V50, P282
   Leenaars M, 2012, LAB ANIM-UK, V46, P24, DOI 10.1258/la.2011.011087
   Liao WB, 2013, J SURG RES, V182, P185, DOI 10.1016/j.jss.2012.10.024
   Nieuwenhuijzen JA, 2008, EUR UROL, V53, P834, DOI 10.1016/j.eururo.2007.09.008
   Nordgren A, 2004, BIOMATERIALS, V25, P1723, DOI 10.1016/S0142-9612(03)00506-4
   Nuininga JE, 2004, BIOMATERIALS, V25, P1657, DOI 10.1016/S0142-9612(03)00519-2
   Orabi H, 2013, EUR UROL, V63, P531, DOI 10.1016/j.eururo.2012.07.041
   Pannek J, 1998, UROL INT, V60, P1
   Probst M, 2000, BJU INT, V85, P362, DOI 10.1046/j.1464-410x.2000.00442.x
   R Core Team, 2012, R LANG ENV STAT COMP
   Raya-Rivera A, 2011, LANCET, V377, P1175, DOI 10.1016/S0140-6736(10)62354-9
   Roosen A, 2011, BJU INT, V109, P6
   Roth CC, 2011, BJU INT, V108, P148, DOI 10.1111/j.1464-410X.2010.09757.x
   Rucker G, 2009, STAT MED, V28, P721, DOI 10.1002/sim.3511
   Sievert KD, 2006, WORLD J UROL, V24, P101, DOI 10.1007/s00345-006-0052-8
   Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   Wood MW, 2007, AATEX, V14, P303
   Zhang YY, 2004, TISSUE ENG, V10, P181, DOI 10.1089/107632704322791835
NR 49
TC 15
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2014
VL 9
IS 6
AR e98734
DI 10.1371/journal.pone.0098734
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8WO
UT WOS:000338709500005
PM 24964011
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chen, JM
   Chiazza, F
   Collino, M
   Patel, NSA
   Coldewey, SM
   Thiemermann, C
AF Chen, Jianmin
   Chiazza, Fausto
   Collino, Massimo
   Patel, Nimesh S. A.
   Coldewey, Sina M.
   Thiemermann, Christoph
TI Gender Dimorphism of the Cardiac Dysfunction in Murine Sepsis:
   Signalling Mechanisms and Age-Dependency
SO PLOS ONE
LA English
DT Article
ID FACTOR-ALPHA EXPRESSION; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; SEPTIC
   SHOCK; TRAUMA-HEMORRHAGE; ESTROGEN-RECEPTOR; INFLAMMATORY RESPONSE;
   CONTRACTILE FUNCTION; REPERFUSION INJURY; ORGAN DYSFUNCTION
AB Development of cardiac dysfunction is associated with increased morbidity and mortality in patients with sepsis. Increasing evidence shows that gender determines the degree of inflammatory response of the host and that females tolerate sepsis better than males. It is unknown whether gender affects the cardiac dysfunction in animals or patients with sepsis. To investigate this, male or female C57BL/6 mice were subjected to either lipopolysaccharide (LPS)/peptidoglycan (PepG) co-administration or cecal ligation and puncture (CLP). At 18 hours after LPS/PepG injection or 24 hours after CLP, cardiac function was evaluated by echocardiography. The septic insult caused a significant cardiac dysfunction in both genders. However, the cardiac dysfunction was significantly less pronounced in females in comparison with males subjected to LPS (3 mg/kg)/PepG (0.1 mg/kg) or CLP. Compared with males injected with LPS (3 mg/kg)/PepG (0.1 mg/kg), western blotting analysis of the myocardium from females injected with LPS/PepG revealed i) profound increases in phosphorylation of Akt and eNOS; ii) significant decreases in phosphorylation of I kappa B alpha, nuclear translocation of the NF-kappa B subunit p65, decreased expression of iNOS and decreased synthesis of TNF-alpha and IL-6 in the heart. However, the gender dimorphism of the cardiac dysfunction secondary to LPS/PepG was not observed when higher doses of LPS (9 mg/kg)/PepG (1 mg/kg) were used. In conclusion, the cardiac dysfunction caused by sepsis was less pronounced in female than in male mice. The protection of female hearts against the dysfunction associated with sepsis is (at least in part) attributable to cardiac activation of the Akt/eNOS survival pathway, decreased activation of NF-kappa B, and decreased expression of iNOS, TNF-alpha and IL-6. It should be noted that the observed gender dimorphism of the cardiac dysfunction in sepsis was not seen when a very severe stimulus (high dose of LPS/PepG co-administration) was used to cause cardiac dysfunction.
C1 [Chen, Jianmin; Patel, Nimesh S. A.; Thiemermann, Christoph] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England.
   [Chiazza, Fausto; Collino, Massimo] Univ Turin, Dept Drug Sci & Technol, Turin, Italy.
   [Coldewey, Sina M.] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany.
RP Thiemermann, C (reprint author), Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England.
EM c.thiemermann@qmul.ac.uk
RI Chiazza, Fausto/I-5559-2015
FU PhD-studentship of the China Scholarship Council [201206240146]; Queen
   Mary University of London (QMUL); Research Fellowship of the German
   Research Foundation (Deutsche Forschungsgemeinschaft); DFG [CO 912/1-1];
   Bart's and The London Charity [753/1722]; William Harvey Research
   Foundation; University of Turin (Ricerca Locale); National Institute of
   Health Research; Barts and The London Charity [753/1722]
FX JC is supported by a jointly funded PhD-studentship of the China
   Scholarship Council (grant number 201206240146) and Queen Mary
   University of London (QMUL). SMC is supported by a Research Fellowship
   of the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG
   CO 912/1-1). NSAP is, in part, supported by the Bart's and The London
   Charity (753/1722). This work is supported, in part, by the William
   Harvey Research Foundation and by a grant from the University of Turin
   (Ricerca Locale ex-60% 2013). This work forms part of the research
   themes contributing to the translational research portfolio of Barts and
   the London Cardiovascular Biomedical Research Unit, which is supported
   and funded by the National Institute of Health Research. This work also
   contributes to the Organ Protection research theme of the Barts Centre
   for Trauma Sciences, supported by the Barts and The London Charity
   (Award 753/1722). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Angele MK, 1997, ARCH SURG-CHICAGO, V132, P1207
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Bae SC, 2005, J PHARMACOL EXP THER, V315, P1125, DOI 10.1124/jpet.105.090803
   Barth E, 2006, CRIT CARE MED, V34, P307, DOI 10.1097/01.CCM.0000199070.46812.21
   Blanco J, 2008, CRIT CARE, V12, DOI 10.1186/cc7157
   BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452
   Brown MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1201, DOI 10.2741/1304
   Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858
   Coldewey SM, 2013, DIS MODEL MECH, V6, P1031, DOI 10.1242/dmm.012435
   Collino M, 2013, DIS MODEL MECH, V6, P1012, DOI 10.1242/dmm.011528
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   Drechsler S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051457
   Fernandes CJ, 1999, INTENS CARE MED, V25, P1165, DOI 10.1007/s001340051030
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218
   Ghuman AK, 2013, J PEDIATR-US, V163, P835, DOI 10.1016/j.jpeds.2013.04.018
   Horton JW, 2004, AM J PHYSIOL-HEART C, V286, pH202, DOI 10.1152/ajpheart.00706.2003
   Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473-3099(13)70001-X
   Hsieh YC, 2007, AM J PHYSIOL-LUNG C, V292, pL1227, DOI 10.1152/ajplung.00479.2006
   Hsu JT, 2009, CRIT CARE MED, V37, P2338, DOI 10.1097/CCM.0b013e3181a030ce
   Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0
   Kapoor A, 2010, AM J RESP CRIT CARE, V182, P1506, DOI 10.1164/rccm.201002-0240OC
   Khan AI, 2013, DIS MODEL MECH, V6, P1021, DOI 10.1242/dmm.011908
   Khan R, 2010, SHOCK, V33, P242, DOI 10.1097/SHK.0b013e3181b0f96f
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim YD, 1996, CIRCULATION, V94, P2901, DOI 10.1161/01.CIR.94.11.2901
   Kleinert H, 1998, HYPERTENSION, V31, P582, DOI 10.1161/01.HYP.31.2.582
   Kolodgie FD, 1997, J MOL CELL CARDIOL, V29, P2403, DOI 10.1006/jmcc.1997.0476
   Liu CJ, 2009, J CELL MOL MED, V13, P3655, DOI 10.1111/j.1582-4934.2009.00669.x
   Mahmood K, 2012, CRIT CARE, V16, DOI [10.1186/cc11355, 10.1186/CC11355]
   Mannella P, 2006, J NEUROSCI, V26, P9439, DOI 10.1523/JNEUROSCI.1443-06.2006
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Melamed A, 2009, CRIT CARE, V13, DOI 10.1186/cc7733
   MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2
   NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823
   NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327
   Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019
   Padkin A, 2003, CRIT CARE MED, V31, P2332, DOI 10.1097/01.CCM.0000085141.75513.2B
   PARRILLO JE, 1985, J CLIN INVEST, V76, P1539, DOI 10.1172/JCI112135
   Rajesh KG, 2005, J MOL CELL CARDIOL, V39, P766, DOI 10.1016/j.yjmcc.2005.07.014
   Ren J, 2003, AM J PHYSIOL-HEART C, V284, pH1800, DOI 10.1152/ajpheart.00866.2002
   Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200
   Sener G, 2005, J SURG RES, V128, P70, DOI 10.1016/j.jss.2005.02.019
   Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   STEIN B, 1995, MOL CELL BIOL, V15, P4971
   Szalay L, 2006, AM J PHYSIOL-REG I, V290, pR812, DOI 10.1152/ajpregu.00658.2005
   THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B
   Von Aulock S, 2006, J INTERF CYTOK RES, V26, P887
   Wang MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE321, DOI 10.1152/ajpendo.00278.2004
   WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212
   Weixelbaumer KM, 2014, SHOCK, V41, P145, DOI 10.1097/SHK.0000000000000070
   Wichmann MW, 2000, INTENS CARE MED, V26, P167, DOI 10.1007/s001340050041
   WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2
   Yu HP, 2007, ANN SURG, V245, P971, DOI 10.1097/01.sla.0000254417.15591.88
   Zellweger R, 1997, CRIT CARE MED, V25, P106, DOI 10.1097/00003246-199701000-00021
   Zhu HQ, 2009, J MOL CELL CARDIOL, V47, P264, DOI 10.1016/j.yjmcc.2009.05.002
NR 56
TC 14
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2014
VL 9
IS 6
AR e100631
DI 10.1371/journal.pone.0100631
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN6QP
UT WOS:000340721500100
PM 24945834
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Shahab, M
   Verma, M
   Pathak, M
   Mitra, K
   Misra-Bhattacharya, S
AF Shahab, Mohd
   Verma, Meenakshi
   Pathak, Manisha
   Mitra, Kalyan
   Misra-Bhattacharya, Shailja
TI Cloning, Expression and Characterization of UDP-N-Acetylglucosamine
   Enolpyruvyl Transferase (MurA) from Wolbachia Endosymbiont of Human
   Lymphatic Filarial Parasite Brugia malayi
SO PLOS ONE
LA English
DT Article
ID LIPID II BIOSYNTHESIS; PEPTIDOGLYCAN BIOSYNTHESIS; CELL-WALL; BACTERIAL
   ENDOSYMBIONTS; ANTIBIOTIC FOSFOMYCIN; ANTIFILARIAL ACTIVITY;
   ESCHERICHIA-COLI; IN-VITRO; PROTEIN; IDENTIFICATION
AB Wolbachia, an endosymbiont of filarial nematode, is considered a promising target for treatment of lymphatic filariasis. Although functional characterization of the Wolbachia peptidoglycan assembly has not been fully explored, the Wolbachia genome provides evidence for coding all of the genes involved in lipid II biosynthesis, a part of peptidoglycan biosynthesis pathway. UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is one of the lipid II biosynthesis pathway enzymes and it has inevitably been recognized as an antibiotic target. In view of the vital role of MurA in bacterial viability and survival, MurA ortholog from Wolbachia endosymbiont of Brugia malayi (wBm-MurA) was cloned, expressed and purified for further molecular characterization. The enzyme kinetics and inhibition studies were undertaken using fosfomycin. wBm-MurA was found to be expressed in all the major life stages of B. malayi and was immunolocalized in Wolbachia within the microfilariae and female adults by the confocal microscopy. Sequence analysis suggests that the amino acids crucial for enzymatic activity are conserved. The purified wBm-MurA was shown to possess the EPSP synthase (3-phosphoshikimate 1-carboxyvinyltransferase) like activity at a broad pH range with optimal activity at pH 7.5 and 37 degrees C temperature. The apparent affinity constant (K-m) for the substrate UDP-N-acetylglucosamine was found to be 0.03149 mM and for phosphoenolpyruvate 0.009198 mM. The relative enzymatic activity was inhibited similar to 2 fold in presence of fosfomycin. Superimposition of the wBm-MurA homology model with the structural model of Haemophilus influenzae (Hi-MurA) suggests binding of fosfomycin at the same active site. The findings suggest wBm-MurA to be a putative antifilarial drug target for screening of novel compounds.
C1 [Shahab, Mohd; Verma, Meenakshi; Mitra, Kalyan; Misra-Bhattacharya, Shailja] AcSIR, New Delhi, India.
   [Shahab, Mohd; Verma, Meenakshi; Pathak, Manisha; Misra-Bhattacharya, Shailja] CSIR Cent Drug Res Inst, Div Parasitol, Lucknow, Uttar Pradesh, India.
   [Mitra, Kalyan] CSIR Cent Drug Res Inst, Lucknow, Uttar Pradesh, India.
RP Misra-Bhattacharya, S (reprint author), AcSIR, New Delhi, India.
EM shailja_cdri@rediffmail.com
FU Indian Council of Medical Research (ICMR), New Delhi, India; CSIR
   Network Project SPLenDID
FX The financial supports in the form of research fellowships by Indian
   Council of Medical Research (ICMR), New Delhi, India to MS, MV and MP
   along with the financial assistance in the form of CSIR Network Project
   SPLenDID were gratefully acknowledged. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2012, WKLY EPIDEMIOL REC, V37, P346
   Bandi C, 1999, INT J PARASITOL, V29, P357, DOI 10.1016/S0020-7519(98)00200-8
   Bandi C, 2001, VET PARASITOL, V98, P215, DOI 10.1016/S0304-4017(01)00432-0
   Barreteau H, 2008, FEMS MICROBIOL REV, V32, P168, DOI 10.1111/j.1574-6976.2008.00104.x
   Baum EZ, 2001, ANTIMICROB AGENTS CH, V45, P3182, DOI 10.1128/AAC.45.11.3182-3188.2001
   Blake KL, 2009, MOL MICROBIOL, V72, P335, DOI 10.1111/j.1365-2958.2009.06648.x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   BROWN ED, 1995, J BACTERIOL, V177, P4194, DOI 10.1128/jb.177.14.4194-4197.1995
   BUGG TDH, 1992, NAT PROD REP, V9, P199, DOI 10.1039/np9920900199
   De Smet KAL, 1999, MICROBIOL-UK, V145, P3177, DOI 10.1099/00221287-145-11-3177
   Du WS, 2000, J BACTERIOL, V182, P4146, DOI 10.1128/JB.182.15.4146-4152.2000
   Eschenburg S, 2000, PROTEINS, V40, P290, DOI 10.1002/(SICI)1097-0134(20000801)40:2<290::AID-PROT90>3.0.CO;2-0
   Eschenburg S, 2005, J BIOL CHEM, V280, P3757, DOI 10.1074/jbc.M411325200
   Felsenstein J., 2005, PHYLIP PHYLOGENY INF
   Fenn K, 2004, TRENDS ECOL EVOL, V19, P163, DOI 10.1016/j.tree.2004.01.002
   Foster J, 2005, PLOS BIOL, V3, P599, DOI 10.1371/journal.pbio.0030121
   Gautam A, 2011, APPL MICROBIOL BIOT, V92, P211, DOI 10.1007/s00253-011-3512-z
   Ghedin E, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000525
   Haegeman A, 2009, INT J PARASITOL, V39, P1045, DOI 10.1016/j.ijpara.2009.01.006
   Henrichfreise B, 2009, MOL MICROBIOL, V73, P913, DOI 10.1111/j.1365-2958.2009.06815.x
   Hertig M, 1924, J MED RES, V44, P329
   Hilgenboecker K, 2008, FEMS MICROBIOL LETT, V281, P215, DOI 10.1111/j.1574-6968.2008.01110.x
   James CE, 2009, TRENDS PARASITOL, V25, P328, DOI 10.1016/j.pt.2009.04.004
   Johnson KA, 2011, BIOCHEMISTRY-US, V50, P8264, DOI 10.1021/bi201284u
   KAHAN FM, 1974, ANN NY ACAD SCI, V235, P364, DOI 10.1111/j.1749-6632.1974.tb43277.x
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Langworthy NG, 2000, P ROY SOC B-BIOL SCI, V267, P1063, DOI 10.1098/rspb.2000.1110
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860
   Lentz CS, 2013, CHEM BIOL, V20, P177, DOI 10.1016/j.chembiol.2012.11.009
   Letunic I, 2012, NUCLEIC ACIDS RES, V40, pD302, DOI 10.1093/nar/gkr931
   Li HJ, 2012, J HARD TISSUE BIOL, V21, P17, DOI 10.2485/jhtb.21.17
   Li Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035834
   MARQUARDT JL, 1994, BIOCHEMISTRY-US, V33, P10646, DOI 10.1021/bi00201a011
   MCCALL JW, 1973, J PARASITOL, V59, P436, DOI 10.2307/3278767
   McCoy AJ, 2003, J BACTERIOL, V185, P1218, DOI 10.1128/JB.185.4.1218-1228.2003
   Mizyed S, 2005, BIOCHEMISTRY-US, V44, P4011, DOI 10.1021/bi047704w
   PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6
   Pfarr K, 2005, PLOS MED, V2, P289, DOI 10.1371/journal.pmed.0020110
   Punkosdy GA, 2001, J INFECT DIS, V184, P385, DOI 10.1086/322023
   Rana AK, 2013, ANTIMICROB AGENTS CH, V57, P3843, DOI 10.1128/AAC.02264-12
   Samland AK, 1999, BIOCHEMISTRY-US, V38, P13162, DOI 10.1021/bi991041e
   SANGER I, 1981, ACTA TROP, V38, P277
   Schiefer A, 2013, J ANTIMICROB CHEMOTH, V68, P1790, DOI 10.1093/jac/dkt105
   Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857
   Shahab Mohd, 2012, Current Pharmacogenomics & Personalized Medicine, V10, P148
   Shrivastava N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041113
   Silver LL, 2006, BIOCHEM PHARMACOL, V71, P996, DOI 10.1016/j.bcp.2005.10.029
   SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404
   Skarzynski T, 1996, STRUCTURE, V4, P1465, DOI 10.1016/S0969-2126(96)00153-0
   SUZUKI T, 1979, JPN J EXP MED, V49, P117
   Takahata S, 2010, INT J ANTIMICROB AG, V35, P333, DOI 10.1016/j.ijantimicag.2009.11.011
   Taylor MJ, 2005, ADV PARASIT, V60, P245, DOI 10.1016/S0065-308X(05)60004-8
   Taylor MJ, 1999, PARASITOL TODAY, V15, P437, DOI 10.1016/S0169-4758(99)01533-1
   Vollmer J, 2013, INT J MED MICROBIOL, V303, P140, DOI 10.1016/j.ijmm.2013.01.002
   Vollmer W, 2008, FEMS MICROBIOL REV, V32, P149, DOI 10.1111/j.1574-6976.2007.00094.x
   Voronin D, 2012, P NATL ACAD SCI USA, V109, pE1638, DOI 10.1073/pnas.1203519109
   Werren JH, 2008, NAT REV MICROBIOL, V6, P741, DOI 10.1038/nrmicro1969
   Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010
   Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024
   Yoon HJ, 2008, PROTEINS, V71, P1032, DOI 10.1002/prot.21959
NR 63
TC 5
Z9 5
U1 1
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2014
VL 9
IS 6
AR e99884
DI 10.1371/journal.pone.0099884
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK6AC
UT WOS:000338508200050
PM 24941309
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Fuqua, BK
   Lu, Y
   Darshan, D
   Frazer, DM
   Wilkins, SJ
   Wolkow, N
   Bell, AG
   Hsu, J
   Yu, CC
   Chen, HJ
   Dunaief, JL
   Anderson, GJ
   Vulpe, CD
AF Fuqua, Brie K.
   Lu, Yan
   Darshan, Deepak
   Frazer, David M.
   Wilkins, Sarah J.
   Wolkow, Natalie
   Bell, Austin G.
   Hsu, JoAnn
   Yu, Catherine C.
   Chen, Huijun
   Dunaief, Joshua L.
   Anderson, Gregory J.
   Vulpe, Chris D.
TI The Multicopper Ferroxidase Hephaestin Enhances Intestinal Iron
   Absorption in Mice
SO PLOS ONE
LA English
DT Article
ID LINKED ANEMIA; CERULOPLASMIN; CELLS; EXPRESSION; TRANSPORT; ANAEMIA;
   EFFLUX; MOUSE; GENE; FERROPORTIN
AB Hephaestin is a vertebrate multicopper ferroxidase important for the transfer of dietary iron from intestinal cells to the blood. Hephaestin is mutated in the sex-linked anemia mouse, resulting in iron deficiency. However, sex-linked anemia mice still retain some hephaestin ferroxidase activity. They survive, breed, and their anemia improves with age. To gain a better understanding of the role of hephaestin in iron homeostasis, we used the Cre-lox system to generate knockout mouse models with whole body or intestine-specific (Villin promoter) ablation of hephaestin. Both types of mice were viable, indicating that hephaestin is not essential and that other mechanisms, multicopper ferroxidase-dependent or not, must compensate for hephaestin deficiency. The knockout strains, however, both developed a microcytic, hypochromic anemia, suggesting severe iron deficiency and confirming that hephaestin plays an important role in body iron acquisition. Consistent with this, the knockout mice accumulated iron in duodenal enterocytes and had reduced intestinal iron absorption. In addition, the similarities of the phenotypes of the whole body and intestine-specific hephaestin knockout mice clarify the important role of hephaestin specifically in intestinal enterocytes in maintaining whole body iron homeostasis. These mouse models will serve as valuable tools to study the role of hephaestin and associated proteins in iron transport in the small intestine and other tissues.
C1 [Fuqua, Brie K.; Bell, Austin G.; Hsu, JoAnn; Yu, Catherine C.; Vulpe, Chris D.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
   [Fuqua, Brie K.; Lu, Yan; Darshan, Deepak; Frazer, David M.; Wilkins, Sarah J.; Anderson, Gregory J.] QIMR Berghofer Med Res Inst, Iron Metab Lab, Brisbane, Qld, Australia.
   [Wolkow, Natalie; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Chen, Huijun] Nanjing Univ, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Anderson, Gregory J.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
RP Anderson, GJ (reprint author), QIMR Berghofer Med Res Inst, Iron Metab Lab, Brisbane, Qld, Australia.
EM Greg.Anderson@qimrberghofer.edu.au
RI Anderson, Gregory/G-4148-2013; Frazer, David/L-3570-2014
OI Anderson, Gregory/0000-0002-8814-5866; Frazer,
   David/0000-0003-4098-1379; Vulpe, Chris/0000-0001-5134-8929
FU National Institutes of Health (NIH)/NIGMS [1R01GM083198-01A1];
   California Agricultural Experiment Station, University of California,
   Berkeley through NIFA Hatch Project [CA-B-NTS-0020H]; Australian
   Research Council [DP120103746]; NIH (NEI) [EY015240]; National Science
   Foundation; National Health and Medical Research Council of Australia
FX This work was supported by research funding from the National Institutes
   of Health (NIH)/NIGMS, http://www.nih.gov, grant number
   1R01GM083198-01A1, to CDV; the California Agricultural Experiment
   Station, University of California, Berkeley through NIFA Hatch Project
   CA-B-NTS-0020H, to CDV; the Australian Research Council, www.arc.gov.au,
   grant number DP120103746, to GJA and CDV; the NIH (NEI), grant number
   EY015240, to JLD; and the National Science Foundation graduate research
   fellowship to BKF. GJA is the recipient of a Senior Research Fellowship
   from the National Health and Medical Research Council of Australia. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BANNERMAN RM, 1967, BRIT J HAEMATOL, V13, P1000, DOI 10.1111/j.1365-2141.1967.tb08869.x
   Bouabe H, 2013, METHODS MOL BIOL, V1064, P315, DOI 10.1007/978-1-62703-601-6_23
   Chen HJ, 2004, BLOOD, V103, P3933, DOI 10.1182/blood-2003-09-3139
   Chen HJ, 2003, BLOOD, V102, P1893, DOI 10.1182/blood-2003-02-0347
   Chen HJ, 2010, J NUTR, V140, P1728, DOI 10.3945/jn.109.117531
   Chen HJ, 2009, BIOMETALS, V22, P827, DOI 10.1007/s10534-009-9229-0
   Chen HJ, 2009, J CELL BIOCHEM, V107, P803, DOI 10.1002/jcb.22178
   Cherukuri S, 2005, CELL METAB, V2, P309, DOI 10.1016/j.cmet.2005.10.003
   Collins JF, 2012, PHYSL GASTROINTESTIN, P1921
   CREAMER B, 1961, GUT, V2, P110, DOI 10.1136/gut.2.2.110
   Darshan D, 2010, HAEMATOL-HEMATOL J, V95, P1660, DOI 10.3324/haematol.2010.022426
   De Domenico I, 2007, EMBO J, V26, P2823, DOI 10.1038/sj.emboj.7601735
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Frazer DM, 2001, AM J PHYSIOL-GASTR L, V281, pG931
   GREWAL MS, 1962, GENET RES, V3, P238, DOI 10.1017/S0016672300035023
   Hudson DM, 2009, AM J PHYSL GASTROINT
   Jankowska Ewa A, 2010, Heart Fail Clin, V6, P295, DOI 10.1016/j.hfc.2010.03.003
   Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kono S, 2010, BBA-MOL BASIS DIS, V1802, P968, DOI 10.1016/j.bbadis.2010.07.011
   Kuo YM, 2004, GUT, V53, P201, DOI 10.1136/gut.2003.019026
   OSAKI S, 1966, J BIOL CHEM, V241, P2746
   Perls M., 1867, VIRCHOW ARCH A, V39, P42, DOI 10. 1007/bf01878983
   PINKERTO.PH, 1967, NATURE, V216, P482, DOI 10.1038/216482a0
   PINKERTON PH, 1970, BRIT J HAEMATOL, V18, P211, DOI 10.1111/j.1365-2141.1970.tb01435.x
   Qian ZM, 2007, BBA-MOL BASIS DIS, V1772, P527, DOI 10.1016/j.bbadis.2007.02.006
   Qian ZM, 2007, J CELL BIOCHEM, V102, P1225, DOI 10.1002/jcb.21352
   Ranganathan PN, 2012, P NATL ACAD SCI USA, V109, P3564, DOI 10.1073/pnas.1120833109
   Schulz K, 2011, J NEUROSCI, V31, P13301, DOI 10.1523/JNEUROSCI.2838-11.2011
   SORBIE J, 1974, BRIT J HAEMATOL, V27, P559, DOI 10.1111/j.1365-2141.1974.tb06621.x
   Spasic MV, 2007, BLOOD, V109, P4511, DOI 10.1182/blood-2006-07-036186
   Syed BA, 2002, PROTEIN ENG, V15, P205, DOI 10.1093/protein/15.3.205
   TORRANCE J D, 1968, South African Journal of Medical Sciences, V33, P9
   Vulpe CD, 1999, NAT GENET, V21, P195
   Welch S., 1992, TRANSFERRIN IRON CAR
   Wolkow N, 2012, AM J PATHOL, V180, P1614, DOI 10.1016/j.ajpath.2011.12.041
NR 36
TC 35
Z9 37
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2014
VL 9
IS 6
AR e98792
DI 10.1371/journal.pone.0098792
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK4YO
UT WOS:000338430700080
PM 24896847
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Guillot, M
   Taylor, PM
   Rialland, P
   Klinck, MP
   Martel-Pelletier, J
   Pelletier, JP
   Troncy, E
AF Guillot, Martin
   Taylor, Polly M.
   Rialland, Pascale
   Klinck, Mary P.
   Martel-Pelletier, Johanne
   Pelletier, Jean-Pierre
   Troncy, Eric
TI Evoked Temporal Summation in Cats to Highlight Central Sensitization
   Related to Osteoarthritis-Associated Chronic Pain: A Preliminary Study
SO PLOS ONE
LA English
DT Article
ID DEGENERATIVE JOINT DISEASE; 2ND PAIN; NMDA RECEPTOR; WIND-UP;
   SENSITIVITY; SENSATIONS; DIAGNOSIS; RESPONSES; NEURONS; RELIEF
AB In cats, osteoarthritis causes significant chronic pain. Chronicity of pain is associated with changes in the central nervous system related to central sensitization, which have to be quantified. Our objectives were 1) to develop a quantitative sensory testing device in cats for applying repetitive mechanical stimuli that would evoke temporal summation; 2) to determine the sensitivity of this test to osteoarthritis-associated pain, and 3) to examine the possible correlation between the quantitative sensory testing and assessment using other pain evaluation methods. We hypothesized that mechanical sub-threshold repetitive stimuli would evoke temporal summation, and that cats with osteoarthritis would show a faster response. A blinded longitudinal study was performed in 4 non-osteoarthritis cats and 10 cats with naturally occurring osteoarthritis. Quantification of chronic osteoarthritis pain-related disability was performed over a two week period using peak vertical force kinetic measurement, motor activity intensity assessment and von Frey anesthesiometer-induced paw withdrawal threshold testing. The cats afflicted with osteoarthritis demonstrated characteristic findings consistent with osteoarthritis-associated chronic pain. After a 14-day acclimation period, repetitive mechanical sub-threshold stimuli were applied using a purpose-developed device. Four stimulation profiles of predetermined intensity, duration and time interval were applied randomly four times during a four-day period. The stimulation profiles were different (P<0.001): the higher the intensity of the stimulus, the sooner it produced a consistent painful response. The cats afflicted with osteoarthritis responded more rapidly than cats osteoarthritis free (P = 0.019). There was a positive correlation between the von Frey anesthesiometer-induced paw withdrawal threshold and the response to stimulation profiles #2 (2N/0.4 Hz) and #4 (2N/0.4 Hz): Rho(s) = 0.64 (P = 0.01) and 0.63 (P = 0.02) respectively. This study is the first report of mechanical temporal summation in awake cats. Our results suggest that central sensitization develops in cats with naturally occurring osteoarthritis, providing an opportunity to improve translational research in osteoarthritis-associated chronic pain.
C1 [Guillot, Martin; Rialland, Pascale; Klinck, Mary P.; Troncy, Eric] Univ Montreal, Fac Vet Med, Dept Biomed Sci, GREPAQ, St Hyacinthe, PQ J2S 7C6, Canada.
   [Guillot, Martin; Rialland, Pascale; Klinck, Mary P.; Martel-Pelletier, Johanne; Pelletier, Jean-Pierre; Troncy, Eric] Univ Montreal, Notre Dame Hosp, Ctr Hosp, Osteoarthrit Res Unit, Montreal, PQ H3C 3J7, Canada.
   [Taylor, Polly M.] Gravel Head Farm, Topcat Metrol, Nr Ely, Cambs, England.
RP Troncy, E (reprint author), Univ Montreal, Fac Vet Med, Dept Biomed Sci, GREPAQ, St Hyacinthe, PQ J2S 7C6, Canada.
EM eric.troncy@umontreal.ca
RI Troncy, Eric/J-6650-2013; Taylor, Polly/M-3239-2015
OI Troncy, Eric/0000-0003-0209-5261; Taylor, Polly/0000-0003-1322-3468
FU Quebec Bio-Imaging Network of the Fonds de recherche du Quebec - Sante
   [5886]; ArthroLab, Inc. from the Natural Sciences and Engineering
   Research Council (NSERC) of Canada; New Opportunities Fund grant [9483];
   Leader Opportunity Fund grant [24601]; Alexander Graham Bell NSERC
   Canada Graduate Scholarship; Canadian Institutes of Health Research -
   MENTOR Strategic Training Initiative in Health Research Program; NSERC
   of Canada [406726]; Fonds de recherche du Quebec - Nature et
   Technologies [144812]; ArthroLab, Inc.;  [327158-2008];  [441651-2013]; 
   [RDCPJ 418399-11]
FX This study was supported in part by a Pilot Study grant from the Quebec
   Bio-Imaging Network (#5886) of the Fonds de recherche du Quebec - Sante
   (Pr. Eric Troncy), by a Discovery grant (#327158-2008, #441651-2013,
   supporting salaries) and a Collaborative Research and Development grant
   (#RDCPJ 418399-11, supporting operations and salaries) in partnership
   with ArthroLab, Inc. from the Natural Sciences and Engineering Research
   Council (NSERC) of Canada (Pr. Eric Troncy), as well as an ongoing New
   Opportunities Fund grant (#9483) and a Leader Opportunity Fund grant
   (#24601), supporting pain/function equipment from the Canada Foundation
   for Innovation (Pr. Eric Troncy). The funding sources were not involved
   in the study design, collection, analysis and interpretation of data,
   writing of the manuscript, nor in the decision to submit the manuscript
   for publication. Dr. Martin Guillot was the recipient of an Alexander
   Graham Bell NSERC Canada Graduate Scholarship for doctorate research,
   and a Doctoral Scholarship from the Canadian Institutes of Health
   Research - MENTOR Strategic Training Initiative in Health Research
   Program. Dr. Pascale Rialland received a doctoral Industrial Innovation
   Scholarship from a partnership including NSERC of Canada (#406726),
   Fonds de recherche du Quebec - Nature et Technologies (#144812) and
   ArthroLab, Inc. Dr. Mary Klinck was the recipient of a Zoetis - Morris
   Animal Foundation (#D10-901) doctoral scholarship. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Arendt-Nielsen L, 2011, BEST PRACT RES CL RH, V25, P209, DOI 10.1016/j.berh.2010.01.013
   Arendt-Nielsen L, 2011, REGION ANESTH PAIN M, V36, P585, DOI 10.1097/AAP.0b013e31822b0db0
   Arendt-Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003
   Beale BS, 2005, VET CLIN N AM-SMALL, V35, P655, DOI 10.1016/j.cvsin.2005.01.001
   Bennett D, 2012, J FELINE MED SURG, V14, P65, DOI 10.1177/1098612X11432828
   Bennett D, 2009, J FELINE MED SURG, V11, P997, DOI 10.1016/j.jfms.2009.09.016
   Boyce-Rustay JM, 2010, NEUROPHARMACOLOGY, V58, P537, DOI 10.1016/j.neuropharm.2009.08.008
   Brown H, 2006, APPL MIXED MODELS ME, P107
   Brown H, 2006, APPL MIXED MODELS ME, P215
   Brydges NM, 2012, VET J, V193, P545, DOI 10.1016/j.tvjl.2012.01.019
   D'Anjou MA, 2008, VET SURG, V37, P166, DOI 10.1111/j.1532-950X.2007.00363.x
   DICKENSON AH, 1987, NEUROPHARMACOLOGY, V26, P1235, DOI 10.1016/0028-3908(87)90275-9
   Dixon MJ, 2010, LAB ANIM-UK, V44, P247, DOI 10.1258/la.2010.009080
   Dolgin E, 2010, NAT MED, V16, P1237, DOI 10.1038/nm1110-1237
   Frakes EP, 2011, CURR MED RES OPIN, V27, P2361, DOI 10.1185/03007995.2011.633502
   Guillot M, 2013, VET J, V196, P360, DOI 10.1016/j.tvjl.2013.01.009
   Guillot M, 2012, VET SURG, V41, P328, DOI 10.1111/j.1532-950X.2012.00976.x
   Hardie EM, 2002, J AM VET MED ASSOC, V220, P628, DOI 10.2460/javma.2002.220.628
   Hendiani JA, 2003, J PAIN, V4, P203, DOI 10.1016/S1526-5900(03)00557-1
   Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9
   Imamura M, 2008, ARTHRIT RHEUM-ARTHR, V59, P1424, DOI 10.1002/art.24120
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klinck MP, 2012, CAN VET J, V53, P1181
   Lascelles BDX, 2010, J VET INTERN MED, V24, P487, DOI 10.1111/j.1939-1676.2010.0495.x
   Lascelles BDX, 2007, J VET INTERN MED, V21, P410, DOI 10.1892/0891-6640(2007)21[410:EOCOMA]2.0.CO;2
   Lascelles BDX, 2013, VET J, V197, P115, DOI 10.1016/j.tvjl.2013.02.025
   Lascelles BDX, 2010, VET SURG, V39, P2, DOI 10.1111/j.1532-950X.2009.00597.x
   Littell R.C., 2006, SAS MIXED MODELS, P159
   Lomas LM, 2005, PSYCHOPHARMACOLOGY, V180, P84, DOI 10.1007/s00213-005-2153-2
   Mease PJ, 2011, J RHEUMATOL, V38, P1546, DOI 10.3899/jrheum.100759
   MENDELL LM, 1965, NATURE, V206, P97, DOI 10.1038/206097a0
   Moreau M, 2013, RES VET SCI, V95, P219, DOI 10.1016/j.rvsc.2013.01.020
   Navratilova E, 2013, ANN NY ACAD SCI, V1282, P1, DOI 10.1111/nyas.12095
   PRICE DD, 1977, PAIN, V3, P57, DOI 10.1016/0304-3959(77)90035-5
   PRICE DD, 1994, PAIN, V59, P165, DOI 10.1016/0304-3959(94)90069-8
   Slingerland LI, 2011, VET J, V187, P304, DOI [10.1016/j.tvjl.2009.12.014, 10.1016/j.tvl.2009.12.014]
   Staud R, 2001, PAIN, V91, P165, DOI 10.1016/S0304-3959(00)00432-2
   Staud R, 2011, CURR RHEUMATOL REP, V13, P513, DOI 10.1007/s11926-011-0206-6
   Stroup WW, 2013, GEN LINEAR MIXED MOD, P413
   Suokas AK, 2012, OSTEOARTHR CARTILAGE, V20, P1075, DOI 10.1016/j.joca.2012.06.009
   Vierck CJ, 1997, J NEUROPHYSIOL, V78, P992
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   YEOMANS DC, 1995, BRAIN RES, V670, P297, DOI 10.1016/0006-8993(94)01349-M
   Zamprogno H, 2010, AM J VET RES, V71, P1417, DOI 10.2460/ajvr.71.12.1417
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 45
TC 15
Z9 15
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 23
PY 2014
VL 9
IS 5
AR e97347
DI 10.1371/journal.pone.0097347
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4ML
UT WOS:000336839400013
PM 24859251
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wang, H
   Sun, W
   Zhang, WZ
   Ge, CY
   Zhang, JT
   Liu, ZY
   Fan, YZ
AF Wang, Hui
   Sun, Wei
   Zhang, Wen-Zhong
   Ge, Chun-Yan
   Zhang, Jing-Tao
   Liu, Zhong-Yan
   Fan, Yue-Zu
TI Inhibition of Tumor Vasculogenic Mimicry and Prolongation of Host
   Survival in Highly Aggressive Gallbladder Cancers by Norcantharidin via
   Blocking the Ephrin Type a Receptor 2/Focal Adhesion Kinase/Paxillin
   Signaling Pathway
SO PLOS ONE
LA English
DT Article
ID HUMAN-MELANOMA CELLS; GBC-SD CELLS; IN-VITRO; HEPG2 CELLS; NUDE-MICE;
   GROWTH; APOPTOSIS; KINASE; CARCINOMA; VIVO
AB Vasculogenic mimicry (VM) is a newly-defined tumor microcirculation pattern in highly aggressive malignant tumors. We recently reported tumor growth and VM formation of gallbladder cancers through the contribution of the ephrin type a receptor 2 (EphA2)/focal adhesion kinase (FAK)/Paxillin signaling pathways. In this study, we further investigated the anti-VM activity of norcantharidin (NCTD) as a VM inhibitor for gallbladder cancers and the underlying mechanisms. In vivo and in vitro experiments to determine the effects of NCTD on tumor growth, host survival, VM formation of GBC-SD nude mouse xenografts, and vasculogenic-like networks, malignant phenotypes i.e., proliferation, apoptosis, invasion and migration of GBC-SD cells. Expression of VM signaling-related markers EphA2, FAK and Paxillin in vivo and in vitro were examined by immunofluorescence, western blotting and real-time polymerase chain reaction (RT-PCR), respectively. The results showed that after treatment with NCTD, GBC-SD cells were unable to form VM structures when injecting into nude mouse, growth of the xenograft was inhibited and these observations were confirmed by facts that VM formation by three-dimensional (3-D) matrix, proliferation, apoptosis, invasion, migration of GBC-SD cells were affected; and survival time of the xenograft mice was prolonged. Furthermore, expression of EphA2, FAK and Paxillin proteins/mRNAs of the xenografts was downregulated. Thus, we concluded that NCTD has potential anti-VM activity against human gallbladder cancers; one of the underlying mechanisms may be via blocking the EphA2/FAK/Paxillin signaling pathway.
C1 [Wang, Hui; Zhang, Jing-Tao; Liu, Zhong-Yan; Fan, Yue-Zu] Tongji Univ, Sch Med, Dept Surg, Tongji Hosp, Shanghai 200092, Peoples R China.
   [Sun, Wei] Tongji Univ, Sch Med, Dept Surg, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
   [Zhang, Wen-Zhong] Shanghai Pudong New Area Peoples Hosp, Dept Surg, Shanghai, Peoples R China.
   [Ge, Chun-Yan] Shanghai Yangpu Geriatr Hosp, Dept Oncol, Shanghai, Peoples R China.
RP Fan, YZ (reprint author), Tongji Univ, Sch Med, Dept Surg, Tongji Hosp, Shanghai 200092, Peoples R China.
EM fanyuezu@hotmail.com
FU National Nature Science Foundation of China [30672073, 81372614]
FX This study was supported by grants from the National Nature Science
   Foundation of China (30672073, 81372614). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR An W, 2004, J KOREAN MED SCI, V19, P560, DOI 10.3346/jkms.2004.19.4.560
   Baeten CIM, 2009, DIS COLON RECTUM, V52, P2028, DOI 10.1007/DCR.0b013e3181beb4ff
   Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679
   Chakravarty KD, 2009, DIGESTION, V79, P151, DOI 10.1159/000210131
   Chang C, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-145
   Chen LX, 2011, CANCER BIOL THER, V11, P229, DOI 10.4161/cbt.11.2.13842
   Chen YN, 2002, INT J CANCER, V100, P158, DOI 10.1002/ijc.10479
   Chen YN, 2003, BRIT J PHARMACOL, V140, P461, DOI 10.1038/sj.bjp.0705461
   Chen YJ, 2009, LIFE SCI, V85, P642, DOI 10.1016/j.lfs.2009.09.003
   Cheng N, 2002, MOL CANCER RES, V1, P2
   Cong RH, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-124
   Emmett MS, 2011, AM J CANCER RES, V1, P852
   Fan YZ, 2007, HEPATOB PANCREAT DIS, V6, P72
   Fan YZ, 2005, WORLD J GASTROENTERO, V11, P2431, DOI 10.3748/wjg.v11.i16.2431
   Fan YZ, 2010, WORLD J GASTRO SURG, V2, P117, DOI 10.4240/wjgs.v2.i4.117
   Fan YZ, 2010, HEPATOB PANCREAT DIS, V9, P414
   Fan Yue-zu, 2006, Zhonghua Yi Xue Za Zhi, V86, P693
   Fan Yue-zu, 2007, Zhonghua Yi Xue Za Zhi, V87, P145
   Fan YZ, 2012, SURG RES NEW TECH, V1, P13
   Folberg R, 2004, APMIS, V112, P508, DOI 10.1111/j.1600-0463.2004.apm11207-0810.x
   Fu DH, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-146
   Gourgiotis S, 2008, AM J SURG, V196, P252, DOI 10.1016/j.amjsurg.2007.11.011
   Hart ME, 2004, BIOORG MED CHEM LETT, V14, P1969, DOI 10.1016/j.bmcl.2004.01.093
   Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447
   Hess AR, 2006, CELL CYCLE, V5, P478, DOI 10.4161/cc.5.5.2518
   Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172
   Hess AR, 2001, CANCER RES, V61, P3250
   Higa GM, 2009, EXPERT REV ANTICANC, V9, P999, DOI [10.1586/era.09.68, 10.1586/ERA.09.68]
   Ho YP, 2001, J MED CHEM, V44, P2065, DOI 10.1021/jm000476t
   Hong CY, 2000, BIOCHEM BIOPH RES CO, V276, P278, DOI 10.1006/bbrc.2000.3341
   Hsing AW, 1998, INT J CANCER, V75, P368, DOI 10.1002/(SICI)1097-0215(19980130)75:3<368::AID-IJC7>3.0.CO;2-0
   Ishii H, 2004, ONCOLOGY-BASEL, V66, P138, DOI 10.1159/000077440
   Itzhaki O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057160
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Konstantinidis IT, 2009, ARCH SURG-CHICAGO, V144, P441, DOI 10.1001/archsurg.2009.46
   Lazcano-Ponce EC, 2001, CA-CANCER J CLIN, V51, P349, DOI 10.3322/canjclin.51.6.349
   Li JL, 2006, ANTI-CANCER DRUG, V17, P307, DOI 10.1097/00001813-200603000-00009
   Li M, 2010, PATHOL ONCOL RES, V16, P259, DOI 10.1007/s12253-009-9220-7
   Liao HF, 2011, TOXICOL IN VITRO, V25, P206, DOI 10.1016/j.tiv.2010.11.001
   Liu Jian, 2003, Zhong Yao Cai, V26, P453
   LIU XH, 1995, EUR J CANCER, V31A, P953, DOI 10.1016/0959-8049(95)00050-X
   Lu XS, 2013, INT J ONCOL, V42, P2103, DOI 10.3892/ijo.2013.1897
   Mahantshetty Umesh M, 2006, J Cancer Res Ther, V2, P52
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   McNamara MG, 2013, CURR OPIN ONCOL, V25, P425, DOI 10.1097/CCO.0b013e3283620fd8
   Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008
   Reddy SK, 2009, SURG ONCOL CLIN N AM, V18, P307, DOI 10.1016/j.soc.2008.12.004
   Rybak SM, 2003, CANCER RES, V63, P2812
   Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786
   Seftor REB, 2001, CANCER RES, V61, P6322
   Shirakawa K, 2002, INT J CANCER, V99, P821, DOI 10.1002/ijc.10423
   Shukla PJ, 2009, ANN SURG ONCOL, V16, P2084, DOI 10.1245/s10434-009-0541-2
   Sood AK, 2004, AM J OBSTET GYNECOL, V190, P899, DOI 10.1016/j.ajog.2004.02.011
   Sun BC, 2006, ONCOL REP, V16, P693
   Sun W, 2012, ONCOL REP, V27, P1990, DOI 10.3892/or.2012.1746
   Sun W, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-46
   Thies A, 2001, J PATHOL, V195, P537, DOI 10.1002/path.988
   van der Schaft DWJ, 2004, JNCI-J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267
   WANG GS, 1989, J ETHNOPHARMACOL, V26, P147, DOI 10.1016/0378-8741(89)90062-7
   Warso MA, 2001, CLIN CANCER RES, V7, P473
   Yang EB, 1997, CANCER LETT, V117, P93, DOI 10.1016/S0304-3835(97)00206-1
   YI SN, 1991, LEUKEMIA RES, V15, P883, DOI 10.1016/0145-2126(91)90163-N
   Zhang JT, 2012, INT J ONCOL, V40, P1501, DOI 10.3892/ijo.2011.1314
   Zhang SW, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-60
NR 64
TC 14
Z9 15
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2014
VL 9
IS 5
AR e96982
DI 10.1371/journal.pone.0096982
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK1XT
UT WOS:000338213300100
PM 24811250
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ciuffreda, MC
   Tolva, V
   Casana, R
   Gnecchi, M
   Vanoli, E
   Spazzolini, C
   Roughan, J
   Calvillo, L
AF Ciuffreda, Maria Chiara
   Tolva, Valerio
   Casana, Renato
   Gnecchi, Massimiliano
   Vanoli, Emilio
   Spazzolini, Carla
   Roughan, John
   Calvillo, Laura
TI Rat Experimental Model of Myocardial Ischemia/Reperfusion Injury: An
   Ethical Approach to Set up the Analgesic Management of Acute
   Post-Surgical Pain
SO PLOS ONE
LA English
DT Article
ID POSTOPERATIVE PAIN; INFARCT SIZE; TRAMADOL; REPERFUSION; RESPONSES;
   CARPROFEN; ISCHEMIA
AB Rationale: During the past 30 years, myocardial ischemia/reperfusion injury in rodents became one of the most commonly used model in cardiovascular research. Appropriate pain-prevention appears critical since it may influence the outcome and the results obtained with this model. However, there are no proper guidelines for pain management in rats undergoing thoracic surgery. Accordingly, we evaluated three analgesic regimens in cardiac ischemia/reperfusion injury. This study was strongly focused on 3R's ethic principles, in particular the principle of Reduction.
   Methods: Rats undergoing surgery were treated with pre-surgical tramadol (45 mg/kg intra-peritoneal), or carprofen (5 mg/kg sub-cutaneous), or with pre-surgical administration of carprofen followed by 2 post-surgery tramadol injections (multi-modal group). We assessed behavioral signs of pain and made a subjective evaluation of stress and suffering one and two hours after surgery.
   Results: Multi-modal treatment significantly reduced the number of signs of pain compared to carprofen alone at both the first hour (61 +/- 42 vs 123 +/- 47; p < 0.05) and the second hour (43 +/- 21 vs 74 +/- 24; p < 0.05) post-surgery. Tramadol alone appeared as effective as multi-modal treatment during the first hour, but signs of pain significantly increased one hour later (from 66 +/- 72 to 151 +/- 86, p < 0.05). Carprofen alone was more effective at the second hour post-surgery when signs of pain reduced to 74 +/- 24 from 113 +/- 40 in the first hour (p < 0.05). Stress behaviors during the second hour were observed in only 20% of rats in the multi-modal group compared to 75% and 86% in the carprofen and tramadol groups, respectively (p < 0.05).
   Conclusions: Multi-modal treatment with carprofen and tramadol was more effective in preventing pain during the second hour after surgery compared with both tramadol or carprofen. Our results suggest that the combination of carprofen and tramadol represent the best therapy to prevent animal pain after myocardial ischemia/reperfusion. We obtained our results accordingly with the ethical principle of Reduction.
C1 [Ciuffreda, Maria Chiara; Gnecchi, Massimiliano] Fdn IRCCS, Policlin San Matteo, IRCCS Inst Treatment & Res, Dept Cardiothorac & Vasc Sci,Coronary Care Unit, I-27100 Pavia, Italy.
   [Ciuffreda, Maria Chiara; Gnecchi, Massimiliano] Fdn IRCCS, Policlin San Matteo, IRCCS Inst Treatment & Res, Lab Clin & Expt Cardiol, I-27100 Pavia, Italy.
   [Ciuffreda, Maria Chiara; Gnecchi, Massimiliano] Fdn IRCCS Policlin San Matteo, Lab Expt Cardiol Cell & Mol Therapy, I-27100 Pavia, Italy.
   [Tolva, Valerio; Casana, Renato] IRCCS Ist Auxol Italiano, Dept Surg, Milan, Italy.
   [Gnecchi, Massimiliano] Univ Pavia, Dept Mol Med, Unit Cardiol, I-27100 Pavia, Italy.
   [Gnecchi, Massimiliano] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa.
   [Vanoli, Emilio] IRCCS Multimedia, Dept Cardiol, Milan, Italy.
   [Spazzolini, Carla] IRCCS Ist Auxol Italiano, Ctr Cardiac Arrhythmias Genet Base, Milan, Italy.
   [Roughan, John] Univ Newcastle, Comparat Biol Ctr, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Calvillo, Laura] IRCCS Ist Auxol Italiano, Lab Cardiac Arrhythmias Genet Base, Milan, Italy.
RP Calvillo, L (reprint author), IRCCS Ist Auxol Italiano, Lab Cardiac Arrhythmias Genet Base, Milan, Italy.
EM l.calvillo@auxologico.it
RI calvillo, laura/K-1901-2019; Gnecchi, Massimiliano/J-8609-2018
OI calvillo, laura/0000-0002-5151-8243; Gnecchi,
   Massimiliano/0000-0001-7435-4328; tolva, valerio/0000-0002-4642-0727;
   Ciuffreda, Maria Chiara/0000-0003-1673-313X; Casana,
   Renato/0000-0002-1049-9656
FU UK NC3Rs; Ministero Italiano della Sanita [GR-2008-1142871,
   GR-2010-2320533]; Fondazione Cariplo [2007-5984]; Ministero Italiano
   degli Affari Esteri [ZA11GR2]; National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NC3Rs) [G0900763/1]
FX Dr. Roughan is funded by the UK NC3Rs (http://www.nc3rs.org.uk/). This
   work was supported by the Ministero Italiano della Sanita
   (GR-2008-1142871; GR-2010-2320533)(http://www.salute.gov.it/), the
   Fondazione Cariplo
   (2007-5984)(http://www.fondazionecariplo.it/it/index.html) and the
   Ministero Italiano degli Affari Esteri (ZA11GR2)(http://www.esteri.
   it/MAE/IT). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Calvillo L, 2003, CARDIOVASC DRUG THER, V17, P199, DOI 10.1023/A:1026182404805
   Calvillo L, 2011, J CARDIOVASC PHARM, V58, P500, DOI 10.1097/FJC.0b013e31822b7204
   Cannon CZ, 2010, LAB ANIMAL, V39, P342, DOI 10.1038/laban1110-342
   Cannon Zegre, 2011, LAB ANIM NY, V40, P85
   Ceyhan A, 2005, J VET MED A, V52, P249, DOI 10.1111/j.1439-0442.2005.00719.x
   Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0
   Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kongara K, 2012, NEW ZEAL VET J, V60, P129, DOI 10.1080/00480169.2011.641156
   Liu YM, 2008, J ZHEJIANG UNIV-SC B, V9, P895, DOI 10.1631/jzus.B0820039
   McIntyre AR, 2007, J AM ASSOC LAB ANIM, V46, P65
   Michael LH, 1999, AM J PHYSIOL-HEART C, V277, pH660
   Roughan JV, 2004, LAB ANIM-UK, V38, P286, DOI 10.1258/002367704323133673
   Roughan JV, 2001, PAIN, V90, P65, DOI 10.1016/S0304-3959(00)00387-0
   SELYE H., 1960, ANGIOLOGY, V11, P398, DOI 10.1177/000331976001100505
   Valtchanova-Matchouganska A, 2004, LIFE SCI, V75, P901, DOI 10.1016/j.lfs.2003.12.029
   Wright-Williams S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075948
   Zhang LZ, 2009, EUR J ANAESTH, V26, P1048, DOI 10.1097/EJA.0b013e32832c785d
NR 18
TC 6
Z9 6
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2014
VL 9
IS 4
AR e5913
DI 10.1371/journal.pone.0095913
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2IS
UT WOS:000335240300118
PM 24756074
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yildirim, F
   Ji, SB
   Kronenberg, G
   Barco, A
   Olivares, R
   Benito, E
   Dirnagl, U
   Gertz, K
   Endres, M
   Harms, C
   Meisel, A
AF Yildirim, Ferah
   Ji, Shengbo
   Kronenberg, Golo
   Barco, Angel
   Olivares, Roman
   Benito, Eva
   Dirnagl, Ulrich
   Gertz, Karen
   Endres, Matthias
   Harms, Christoph
   Meisel, Andreas
TI Histone Acetylation and CREB Binding Protein Are Required for Neuronal
   Resistance against Ischemic Injury
SO PLOS ONE
LA English
DT Article
ID RUBINSTEIN-TAYBI-SYNDROME; SUBEROYLANILIDE HYDROXAMIC ACID;
   LONG-TERM-MEMORY; CEREBRAL-ISCHEMIA; MEDIATED NEUROPROTECTION;
   DEACETYLASE INHIBITION; HUNTINGTONS-DISEASE; MUTANT HUNTINGTIN;
   BRAIN-INJURY; CBP
AB Epigenetic transcriptional regulation by histone acetylation depends on the balance between histone acetyltransferase (HAT) and deacetylase activities (HDAC). Inhibition of HDAC activity provides neuroprotection, indicating that the outcome of cerebral ischemia depends crucially on the acetylation status of histones. In the present study, we characterized the changes in histone acetylation levels in ischemia models of focal cerebral ischemia and identified cAMP-response element binding protein (CREB)-binding protein (CBP) as a crucial factor in the susceptibility of neurons to ischemic stress. Both neuron-specific RNA interference and neurons derived from CBP heterozygous knockout mice showed increased damage after oxygen-glucose deprivation (OGD) in vitro. Furthermore, we demonstrated that ischemic preconditioning by a short (5 min) subthreshold occlusion of the middle cerebral artery (MCA), followed 24 h afterwards by a 30 min occlusion of the MCA, increased histone acetylation levels in vivo. Ischemic preconditioning enhanced CBP recruitment and histone acetylation at the promoter of the neuroprotective gene gelsolin leading to increased gelsolin expression in neurons. Inhibition of CBP's HAT activity attenuated neuronal ischemic preconditioning. Taken together, our findings suggest that the levels of CBP and histone acetylation determine stroke outcome and are crucially associated with the induction of an ischemia-resistant state in neurons.
C1 [Yildirim, Ferah; Ji, Shengbo; Kronenberg, Golo; Dirnagl, Ulrich; Gertz, Karen; Endres, Matthias; Harms, Christoph; Meisel, Andreas] Charite, Dept Expt Neurol, Ctr Stroke Res Berlin CSB, D-13353 Berlin, Germany.
   [Yildirim, Ferah; Ji, Shengbo; Kronenberg, Golo; Dirnagl, Ulrich; Gertz, Karen; Endres, Matthias; Harms, Christoph; Meisel, Andreas] Charite, Klin & Hsch Ambulanz Neurol, D-13353 Berlin, Germany.
   [Barco, Angel; Olivares, Roman; Benito, Eva] Univ Miguel Hernandez, CSIC, Inst Neurociencias Alicante, Alicante, Spain.
   [Kronenberg, Golo] Charite, Psychiat Klin & Poliklin, D-13353 Berlin, Germany.
   [Dirnagl, Ulrich; Gertz, Karen; Endres, Matthias; Meisel, Andreas] Charite, ExcellenceCluster NeuroCure, D-13353 Berlin, Germany.
RP Harms, C (reprint author), Charite, Dept Expt Neurol, Ctr Stroke Res Berlin CSB, D-13353 Berlin, Germany.
EM christoph.harms@charite.de
RI Gertz, Karen/J-1603-2015; Kronenberg, Golo/F-8772-2010; Barco,
   Angel/C-3062-2008
OI Barco, Angel/0000-0002-0653-3751; Dirnagl, Ulrich/0000-0003-0755-6119;
   Kronenberg, Golo/0000-0002-5310-9849; Meisel,
   Andreas/0000-0001-7233-5342; Harms, Christoph/0000-0002-2063-2860;
   Benito, Eva/0000-0003-0094-0257
FU German Research Foundation [Exc 257]; Federal Ministry of Education and
   Research [01 EO 08 01]; Helmholtz Association [SO-022NG]; European
   Community [201024]
FX This work was supported by the German Research Foundation (Exc 257), the
   Federal Ministry of Education and Research (01 EO 08 01), the Helmholtz
   Association (SO-022NG) and has received funding from the European
   Community's Seventh Framework Programme (FP7/2007-2013) under grant
   agreement no. 201024 (all given to AM). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alarcon JM, 2004, NEURON, V42, P947, DOI 10.1016/j.neuron.2004.05.021
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Barrett RM, 2011, NEUROPSYCHOPHARMACOL, V36, P1545, DOI 10.1038/npp.2011.61
   Belayev L, 1996, NEUROREPORT, V8, P55, DOI 10.1097/00001756-199612200-00012
   Chen GQ, 2010, J NEUROSCI, V30, P13066, DOI 10.1523/JNEUROSCI.2378-10.2010
   Cong SY, 2005, MOL CELL NEUROSCI, V30, P12, DOI 10.1016/j.mcn.2005.05.003
   Datwyler AL, 2011, J CEREBR BLOOD F MET, V31, P2152, DOI 10.1038/jcbfm.2011.112
   Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074
   Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953
   Endres M, 2000, J NEUROSCI, V20, P3175, DOI 10.1523/JNEUROSCI.20-09-03175.2000
   Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912
   Hara T, 2003, J NEUROCHEM, V86, P805, DOI 10.1046/j.1471-4159.2003.01847.x
   Harms C, 2004, MOL CELL NEUROSCI, V25, P69, DOI 10.1016/j.mcn.2003.09.012
   Hauck L, 2008, NAT MED, V14, P315, DOI 10.1038/nm1729
   Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100
   HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345
   Jiang HB, 2006, NEUROBIOL DIS, V23, P543, DOI 10.1016/j.nbd.2006.04.011
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kontopoulos E, 2006, HUM MOL GENET, V15, P3012, DOI 10.1093/hmg/ddl243
   Langley Brett, 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P41, DOI 10.2174/1568007053005091
   Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008
   McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197
   Meisel A, 2006, J NEUROCHEM, V98, P1019, DOI 10.1111/j.1471-4159.2006.04016.x
   Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024
   Mergenthaler P, 2011, J PHYSIOL-LONDON, V589, P4147, DOI 10.1113/jphysiol.2011.209718
   Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784
   PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0
   Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x
   Rouaux C, 2004, BIOCHEM PHARMACOL, V68, P1157, DOI 10.1016/j.bcp.2004.05.035
   Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615
   Ruscher K, 2002, J NEUROSCI, V22, P10291
   Sadri-Vakili G, 2006, NAT CLIN PRACT NEURO, V2, P330, DOI 10.1038/ncpneuro0199
   Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769
   Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006
   Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568
   Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c
   Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1
   Takahashi J, 2002, BRAIN, V125, P1534, DOI 10.1093/brain/awf154
   Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215
   Taylor JP, 2003, GENE DEV, V17, P1463, DOI 10.1101/gad.1087503
   Valor LM, 2011, J NEUROSCI, V31, P1652, DOI 10.1523/JNEUROSCI.4737-10.2011
   Yildirim F, 2008, EXP NEUROL, V210, P531, DOI 10.1016/j.expneurol.2007.11.031
NR 42
TC 27
Z9 29
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2014
VL 9
IS 4
AR e95465
DI 10.1371/journal.pone.0095465
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2DP
UT WOS:000335226500104
PM 24748101
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU van Luijk, J
   Bakker, B
   Rovers, MM
   Ritskes-Hoitinga, M
   de Vries, RBM
   Leenaars, M
AF van Luijk, Judith
   Bakker, Brenda
   Rovers, Maroeska M.
   Ritskes-Hoitinga, Merel
   de Vries, Rob B. M.
   Leenaars, Marlies
TI Systematic Reviews of Animal Studies; Missing Link in Translational
   Research?
SO PLOS ONE
LA English
DT Review
ID SEARCH FILTER; BIAS; METAANALYSES; QUALITY
AB Background: The methodological quality of animal studies is an important factor hampering the translation of results from animal studies to a clinical setting. Systematic reviews of animal studies may provide a suitable method to assess and thereby improve their methodological quality.
   Objectives: The aims of this study were: 1) to evaluate the risk of bias assessment in animal-based systematic reviews, and 2) to study the internal validity of the primary animal studies included in these systematic reviews.
   Data Sources: We systematically searched Pubmed and Embase for SRs of preclinical animal studies published between 2005 and 2012.
   Results: A total of 91 systematic reviews met our inclusion criteria. The risk of bias was assessed in 48 (52.7%) of these 91 systematic reviews. Thirty-three (36.3%) SRs provided sufficient information to evaluate the internal validity of the included studies. Of the evaluated primary studies, 24.6% was randomized, 14.6% reported blinding of the investigator/caretaker, 23.9% blinded the outcome assessment, and 23.1% reported drop-outs.
   Conclusions: To improve the translation of animal data to clinical practice, systematic reviews of animal studies are worthwhile, but the internal validity of primary animal studies needs to be improved. Furthermore, risk of bias should be assessed by systematic reviews of animal studies to provide insight into the reliability of the available evidence.
C1 [van Luijk, Judith; Bakker, Brenda; Ritskes-Hoitinga, Merel; de Vries, Rob B. M.; Leenaars, Marlies] Radboud Univ Nijmegen, Med Ctr, SYRCLE Cent Anim Lab, NL-6525 ED Nijmegen, Netherlands.
   [Rovers, Maroeska M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6525 ED Nijmegen, Netherlands.
   [Rovers, Maroeska M.] Radboud Univ Nijmegen, Med Ctr, Dept Operating Rooms, NL-6525 ED Nijmegen, Netherlands.
RP van Luijk, J (reprint author), Radboud Univ Nijmegen, Med Ctr, SYRCLE Cent Anim Lab, NL-6525 ED Nijmegen, Netherlands.
EM Judith.vanLuijk@radboudumc.nl
RI Leenaars, P.P.A.M./L-4478-2015; Vries, R.B.M./L-4732-2015;
   Ritskes-Hoitinga, J./H-8083-2014; Rovers, Maroeska M/F-2969-2014
OI Leenaars, P.P.A.M./0000-0002-9855-708X; Rovers, Maroeska
   M/0000-0002-3095-170X
CR Baker D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001756
   Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1197/aemj.10.6.684
   de Vries RB, 2013, LAB ANIM
   de Vries RBM, 2011, LAB ANIM-UK, V45, P268, DOI 10.1258/la.2011.011056
   Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752
   Henderson VC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001489
   Hooijmans CR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001482
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Korevaar DA, 2011, LAB ANIM-UK, V45, P225, DOI 10.1258/la.2011.010121
   Krauth D, 2013, ENVIRON HEALTH PERSP, V121, P985, DOI 10.1289/ehp.1206389
   Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386
   Mignini Luciano E, 2006, BMC Med Res Methodol, V6, P10, DOI 10.1186/1471-2288-6-10
   Peters JL, 2006, J ENVIRON SCI HEAL B, V41, P1245, DOI 10.1080/03601230600857130
NR 16
TC 26
Z9 26
U1 1
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 26
PY 2014
VL 9
IS 3
AR e89981
DI 10.1371/journal.pone.0089981
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE0SR
UT WOS:000333677000005
PM 24670965
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Maguire, S
   Estabel, J
   Ingham, N
   Pearson, S
   Ryder, E
   Carragher, DM
   Walker, N
   Bussell, J
   Chan, WI
   Keane, TM
   Adams, DJ
   Scudamore, CL
   Lelliott, CJ
   Ramirez-Solis, R
   Karp, NA
   Steel, KP
   White, JK
   Gerdin, AK
AF Maguire, Simon
   Estabel, Jeanne
   Ingham, Neil
   Pearson, Selina
   Ryder, Edward
   Carragher, Damian M.
   Walker, Nicolas
   Bussell, James
   Chan, Wai-In
   Keane, Thomas M.
   Adams, David J.
   Scudamore, Cheryl L.
   Lelliott, Christopher J.
   Ramirez-Solis, Ramiro
   Karp, Natasha A.
   Steel, Karen P.
   White, Jacqueline K.
   Gerdin, Anna-Karin
CA Sanger MGP Slc25a21 Project Team
TI Targeting of Slc25a21 Is Associated with Orofacial Defects and Otitis
   Media Due to Disrupted Expression of a Neighbouring Gene
SO PLOS ONE
LA English
DT Article
ID ALPHA-AMINOADIPIC ACIDURIA; TRANSPORTER FAMILY SLC25; LOCUS-CONTROL
   REGION; REGULATORY ELEMENTS; MOLAR OLIGODONTIA; GENOME-WIDE; PAX9 GENE;
   MOUSE; IDENTIFICATION; MICE
AB Homozygosity for Slc25a21(tm1a(KOMP)Wtsi) results in mice exhibiting orofacial abnormalities, alterations in carpal and rugae structures, hearing impairment and inflammation in the middle ear. In humans it has been hypothesised that the 2oxoadipate mitochondrial carrier coded by SLC25A21 may be involved in the disease 2-oxoadipate acidaemia. Unexpectedly, no 2-oxoadipate acidaemia-like symptoms were observed in animals homozygous for Slc25a21(tm1a(KOMP)Wtsi) despite confirmation that this allele reduces Slc25a21 expression by 71.3%. To study the complete knockout, an allelic series was generated using the loxP and FRT sites typical of a Knockout Mouse Project allele. After removal of the critical exon and neomycin selection cassette, Slc25a21 knockout mice homozygous for the Slc25a21(tm1b(KOMP)Wtsi) and Slc25a21(tm1d(KOMP)Wtsi) alleles were phenotypically indistinguishable from wild-type. This led us to explore the genomic environment of Slc25a21 and to discover that expression of Pax9, located 3' of the target gene, was reduced in homozygous Slc25a21(tm1a(KOMP)Wtsi) mice. We hypothesize that the presence of the selection cassette is the cause of the down regulation of Pax9 observed. The phenotypes we observed in homozygous Slc25a21(tm1a(KOMP)Wtsi) mice were broadly consistent with a hypomorphic Pax9 allele with the exception of otitis media and hearing impairment which may be a novel consequence of Pax9 down regulation. We explore the ramifications associated with this particular targeted mutation and emphasise the need to interpret phenotypes taking into consideration all potential underlying genetic mechanisms.
C1 [Maguire, Simon; Estabel, Jeanne; Ingham, Neil; Pearson, Selina; Ryder, Edward; Carragher, Damian M.; Walker, Nicolas; Bussell, James; Keane, Thomas M.; Adams, David J.; Lelliott, Christopher J.; Ramirez-Solis, Ramiro; Karp, Natasha A.; Steel, Karen P.; White, Jacqueline K.; Gerdin, Anna-Karin; Sanger MGP Slc25a21 Project Team] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
   [Walker, Nicolas] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, Cambs, England.
   [Chan, Wai-In] Cambridge Inst Med Res, Dept Haematol, Cambridge, Cambs, England.
   [Scudamore, Cheryl L.] Royal Vet Coll, Dept Pathol & Infect Dis, Hatfield, Herts, England.
RP White, JK (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton, Cambs, England.
EM jkw@sanger.ac.uk
RI Carragher, Damian/O-4183-2019; Carragher, Damian/E-6673-2016
OI Carragher, Damian/0000-0003-4341-4943; Carragher,
   Damian/0000-0003-4341-4943; Ryder, Edward/0000-0002-1799-9899; Karp,
   Natasha/0000-0002-8404-2907; Keane, Thomas/0000-0001-7532-6898;
   Vancollie, Valerie/0000-0003-1547-1975
FU Wellcome Trust [098051]; European Union [282510]; Medical Research
   Council [G0300212, G0901338, MC_UP_1502/1, MC_qA137918]
FX This work was supported by the Wellcome Trust (grant no 098051 to WTSI)
   (http://www.wellcome.ac.uk/) and the European Union's Seventh Framework
   program under grant agreement number 282510 - BLUEPRINT (NW)
   (www.blueprint-epigenome.eu/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams DJ, 2008, PHYSIOL GENOMICS, V34, P225, DOI 10.1152/physiolgenomics.90242.2008
   Chevalier-Mariette C, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r53
   Collins FS, 2007, CELL, V128, P9, DOI 10.1016/j.cell.2006.12.018
   Das P, 2003, AM J MED GENET A, V118A, P35, DOI 10.1002/ajmg.a.10011
   DURAN M, 1984, J INHERIT METAB DIS, V7, P61, DOI 10.1007/BF01805803
   FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469
   Fiermonte G, 2001, J BIOL CHEM, V276, P8225, DOI 10.1074/jbc.M009607200
   FISCHER MH, 1980, AM J MED GENET, V5, P35, DOI 10.1002/ajmg.1320050106
   Frazier-Bowers SA, 2002, J DENT RES, V81, P129, DOI 10.1177/154405910208100209
   Hug BA, 1996, MOL CELL BIOL, V16, P2906
   Ingham Neil J, 2011, Curr Protoc Mouse Biol, V1, P279, DOI 10.1002/9780470942390.mo110059
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kist R, 2005, HUM MOL GENET, V14, P3605, DOI 10.1093/hmg/ddi388
   Kleinjan DA, 2008, ADV GENET, V61, P339, DOI 10.1016/S0065-2660(07)00013-2
   Kleinjan Dirk-Jan, 2009, Briefings in Functional Genomics & Proteomics, V8, P317, DOI 10.1093/bfgp/elp022
   Lang D, 2007, BIOCHEM PHARMACOL, V73, P1, DOI 10.1016/j.bcp.2006.06.024
   Mataki S, 1991, STUDIES TRANSPORT ME, P298
   Meier ID, 2010, FASEB J, V24, P1714, DOI 10.1096/fj.09-140749
   Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074
   NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248
   Nieminen P, 2001, EUR J HUM GENET, V9, P743, DOI 10.1038/sj.ejhg.5200715
   Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9
   Ovchinnikov D, 2009, COLD SPRING HARB PRO
   Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7
   Palmieri F, 2013, MOL ASPECTS MED, V34, P465, DOI 10.1016/j.mam.2012.05.005
   Peters H, 1997, MAMM GENOME, V8, P62, DOI 10.1007/s003359900351
   Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735
   Pettitt SJ, 2009, NAT METHODS, V6, P493, DOI 10.1038/nmeth.1342
   Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090
   PRZYREMBEL H, 1976, CLIN CHIM ACTA, V66, P227, DOI 10.1016/0009-8981(76)90060-7
   Ryder E, 2013, MAMM GENOME, V24, P286, DOI 10.1007/s00335-013-9467-x
   Santagati F, 2003, GENETICS, V165, P235
   Sasaki Y, 2007, ARCH ORAL BIOL, V52, P260, DOI 10.1016/j/archoralbio.2006.09.012
   Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163
   Tyrer HE, 2013, CURR ALLERGY ASTHM R, V13, P501, DOI 10.1007/s11882-013-0360-1
   van der Weyden L, 2011, GENOME BIOL, V12, DOI [10.1186/gb-2011-12-6-224, 10.1186/gb-2010-12-6-224]
   White JK, 2013, CELL, V154, P452, DOI 10.1016/j.cell.2013.06.022
   WILSON RW, 1975, PEDIATR RES, V9, P522, DOI 10.1203/00006450-197506000-00002
NR 38
TC 12
Z9 12
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 18
PY 2014
VL 9
IS 3
AR e91807
DI 10.1371/journal.pone.0091807
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AD4ZE
UT WOS:000333259900037
PM 24642684
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lai, MS
   Cheng, YS
   Chen, PR
   Tsai, SJ
   Huang, BM
AF Lai, Meng-Shao
   Cheng, Yu-Sheng
   Chen, Pei-Rong
   Tsai, Shaw-Jenq
   Huang, Bu-Miin
TI Fibroblast Growth Factor 9 Activates Akt and MAPK Pathways to Stimulate
   Steroidogenesis in Mouse Leydig Cells
SO PLOS ONE
LA English
DT Article
ID HUMAN GLIOMA-CELLS; REGULATES STEROIDOGENESIS; FACTOR RECEPTORS; KINASE
   PATHWAYS; LUNG-CANCER; TUMOR-CELLS; EXPRESSION; BOVINE; DIFFERENTIATION;
   SB202190
AB Fibroblast growth factor 9 (FGF9) is a multifunctional polypeptide belonging to the FGF family and has functions related to bone formation, lens-fiber differentiation, nerve development, gap-junction formation and sex determination. In a previous study, we demonstrated that FGF9 stimulates the production of testosterone in mouse Leydig cells. In the present study, we used both primary mouse Leydig cells and MA-10 mouse Leydig tumor cells to further investigate the molecular mechanism of FGF9-stimulated steroidogenesis. Results showed that FGF9 significantly activated steroidogenesis in both mouse primary and tumor Leydig cells (p<0.05). Furthermore, FGF9 significantly induced the expression of phospho-Akt at 0.5 and 24 hr, phospho-JNK at 0.25, 0.5, and 24 hr, phospho-p38 at 0.5 hr, and phospho-ERK1/2 from 0.25 to 24 hr in primary Leydig cells (p<0.05). Also, FGF9 significantly up-regulated the expression of phospho-Akt at 3 hr, phospho-JNK at 0.25 hr, and phospho-ERK1/2 at 1 and 3 hr in MA-10 cells (p<0.05). Using specific inhibitors of Akt, JNK, p38, and ERK1/2, we further demonstrated that the inhibitors of Akt and ERK1/2 significantly suppressed the stimulatory effect of FGF9 on steroidogenesis in mouse Leydig cells. In conclusion, FGF9 specifically activated the Akt and ERK1/2 in normal mouse Leydig cells and the Akt, JNK and ERK1/2 in MA-10 mouse Leydig tumor cells to stimulate steroidogenesis.
C1 [Lai, Meng-Shao; Huang, Bu-Miin] Natl Cheng Kung Univ, Coll Med, Inst Basic Med, Tainan 70101, Taiwan.
   [Lai, Meng-Shao; Chen, Pei-Rong; Huang, Bu-Miin] Natl Cheng Kung Univ, Coll Med, Dept Cell Biol & Anat, Tainan 70101, Taiwan.
   [Cheng, Yu-Sheng] Natl Cheng Kung Univ Hosp, Douliou Branch, Dept Urol, Yunlin, Taiwan.
   [Tsai, Shaw-Jenq] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan.
RP Huang, BM (reprint author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med, Tainan 70101, Taiwan.
EM bumiin@mail.ncku.edu.tw
OI TSAI, SHAW-JENQ/0000-0002-3569-5813
FU National Science Council Grants of Taiwan, Republic of China
   [NSC101-2320-B-006-005-MY3]; National Cheng Kung University Hospital
   Grant [NCKUH-10205009]
FX This work was supported by National Science Council Grants of Taiwan,
   Republic of China (NSC101-2320-B-006-005-MY3) and National Cheng Kung
   University Hospital Grant (NCKUH-10205009). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahn SW, 2013, J BIOL CHEM, V288, P15937, DOI 10.1074/jbc.M113.451773
   ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88
   Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141
   Brion L, 2011, ENDOCRINOLOGY, V152, P2665, DOI 10.1210/en.2011-0021
   Chung CL, 2013, FERTIL STER IN PRESS
   Coffey E, 2013, J HISTOCHEM CYTOCHEM, V61, P671, DOI 10.1369/0022155413497366
   Cohen RI, 2000, J NEUROSCI RES, V61, P273, DOI 10.1002/1097-4547(20000801)61:3<273::AID-JNR5>3.0.CO;2-I
   Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Falvella FS, 2009, INT J CANCER, V124, P2880, DOI 10.1002/ijc.24302
   Guijarro MV, 2012, ONCOGENE, V31, P4447, DOI 10.1038/onc.2011.619
   Hirakawa T, 2002, ENDOCRINOLOGY, V143, P1026, DOI 10.1210/endo.143.3.8702
   Hiramatsu R, 2010, DEVELOPMENT, V137, P303, DOI 10.1242/dev.040519
   Hiramatsu R, 2009, DEVELOPMENT, V136, P129, DOI 10.1242/dev.029587
   Hirosawa M, 2009, LEUKEMIA RES, V33, P693, DOI 10.1016/j.leukres.2008.09.028
   JOHNSON DE, 1993, ADV CANCER RES, V60, P1
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim JY, 2010, TOXICOL LETT, V193, P200, DOI 10.1016/j.toxlet.2010.01.011
   Lin YM, 2010, INT J ANDROL, V33, P545, DOI 10.1111/j.1365-2605.2009.00966.x
   Lovicu FJ, 1998, DEVELOPMENT, V125, P3365
   Maillard V, 2011, REPRODUCTION, V141, P467, DOI 10.1530/REP-10-0419
   Manna PR, 2011, J SIGNAL TRANSDUCT, V2011, P1, DOI DOI 10.1155/2011/821615
   Matsui Y, 2007, CANCER RES, V67, P1212, DOI 10.1158/0008-5472.CAN-06-3283
   Menon MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023054
   MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068
   Muniyappa H, 2008, CELL SIGNAL, V20, P675, DOI 10.1016/j.cellsig.2007.12.003
   NARUO K, 1993, J BIOL CHEM, V268, P2857
   Niederst MJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004652
   Norman M, 2012, J CELL SCI, V125, P59, DOI 10.1242/jcs.085803
   Pao HY, 2012, J AGR FOOD CHEM, V60, P4905, DOI 10.1021/jf205091b
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Qiao DH, 2013, MOL CELL BIOL, V33, P4408, DOI 10.1128/MCB.00238-13
   Reuss B, 2000, GLIA, V30, P231, DOI 10.1002/(SICI)1098-1136(200005)30:3<231::AID-GLIA3>3.0.CO;2-1
   Romero I, 2012, ENDOCRINOLOGY, V153, P1593, DOI 10.1210/en.2011-2123
   SAEZ JM, 1994, ENDOCR REV, V15, P574, DOI 10.1210/er.15.5.574
   Schreiber NB, 2012, J ENDOCRINOL, V215, P167, DOI 10.1530/JOE-12-0293
   Schreiber NB, 2012, ENDOCRINOLOGY, V153, P4491, DOI 10.1210/en.2012-1003
   Wang Q, 2013, ENDOCRINOLOGY, V154, P956, DOI 10.1210/en.2012-1836
   Yao B, 2011, ASIAN J ANDROL, V13, P438, DOI 10.1038/aja.2010.158
NR 40
TC 21
Z9 22
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2014
VL 9
IS 3
AR e90243
DI 10.1371/journal.pone.0090243
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC4ID
UT WOS:000332483600035
PM 24603862
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Maxim, L
   van der Sluijs, JP
AF Maxim, Laura
   van der Sluijs, Jeroen P.
TI Qualichem In Vivo: A Tool for Assessing the Quality of In Vivo Studies
   and Its Application for Bisphenol A
SO PLOS ONE
LA English
DT Article
ID DEVELOPMENTAL NEUROTOXICITY; UNCERTAINTY; IMPACT
AB In regulatory toxicology, quality assessment of in vivo studies is a critical step for assessing chemical risks. It is crucial for preserving public health studies that are considered suitable for regulating chemicals are robust. Current procedures for conducting quality assessments in safety agencies are not structured, clear or consistent. This leaves room for criticism about lack of transparency, subjective influence and the potential for insufficient protection provided by resulting safety standards. We propose a tool called "Qualichem in vivo'' that is designed to systematically and transparently assess the quality of in vivo studies used in chemical health risk assessment. We demonstrate its use here with 12 experts, using two controversial studies on Bisphenol A (BPA) that played an important role in BPA regulation in Europe. The results obtained with Qualichem contradict the quality assessments conducted by expert committees in safety agencies for both of these studies. Furthermore, they show that reliance on standardized guidelines to ensure scientific quality is only partially justified. Qualichem allows experts with different disciplinary backgrounds and professional experiences to express their individual and sometimes divergent views-an improvement over the current way of dealing with minority opinions. It provides a transparent framework for expressing an aggregated, multi-expert level of confidence in a study, and allows a simple graphical representation of how well the study integrates the best available scientific knowledge. Qualichem can be used to compare assessments of the same study by different health agencies, increasing transparency and trust in the work of expert committees. In addition, it may be used in systematic evaluation of in vivo studies submitted by industry in the dossiers that are required for compliance with the REACH Regulation. Qualichem provides a balanced, common framework for assessing the quality of studies that may or may not be following standardized guidelines.
C1 [Maxim, Laura] CNRS, UPS 3088, Inst Commun Sci, Paris, France.
   [van der Sluijs, Jeroen P.] Univ Utrecht, Copernicus Inst, Utrecht, Netherlands.
RP Maxim, L (reprint author), CNRS, UPS 3088, Inst Commun Sci, Paris, France.
EM laura.maxim@iscc.cnrs.fr
RI van der Sluijs, Jeroen/B-6302-2008; Maxim, Laura/F-4605-2019
OI van der Sluijs, Jeroen/0000-0002-1346-5953; Maxim,
   Laura/0000-0001-9641-6649
FU French Ministry of Ecology
FX This work has been funded by the French Ministry of Ecology in the
   framework of the PNRPE 2010 programme (URL: http://www.pnrpe.fr/), as
   part of the project "Toolkit for uncertainty and knowledge quality
   analysis of endocrine disruptors' risk assessments: the case study of
   Bisphenol A'' (DICO-Risk). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ansari MT, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000151
   ANSES (Agence Nationale de Securite Sanitaire Alimentation Environnement Travail), 2013, PERT END EV RISQ BIS, V1
   Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454
   Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007
   Brozek JL, 2011, ALLERGY, V66, P588, DOI 10.1111/j.1398-9995.2010.02530.x
   Chateauraynaud F, 2011, DOSE TOUJOURS POISON
   Craye MJP, 2005, INT J RISK ASSESSMEN, V5, P216, DOI DOI 10.1504/IJRAM.2005.007169
   de Jong A, 2012, ENVIRON SCI POLICY, V16, P114, DOI 10.1016/j.envsci.2011.11.012
   E.F.S. Association, 2006, EFSA J, V428, P1, DOI DOI 10.2903/J.EFSA.2007A28
   ECB, 2003, EUR UN RISK ASS REP, p[179, 214]
   ECHA, 2011, GUID INF REQ CHEM SA
   EFSA, 2010, EFSA J, V8, P116
   EFSA, 2010, EFSA J, V8, P67
   Funtowicz S., 1990, UNCERTAINTY QUALITY
   Hartung T, 2009, ALTEX-ALTERN TIEREXP, V26, P75
   Hillier S, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-23
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klimisch HJ, 1997, REGUL TOXICOL PHARM, V25, P1, DOI 10.1006/rtph.1996.1076
   Kloprogge P, 2011, ENVIRON MODELL SOFTW, V26, P289, DOI 10.1016/j.envsoft.2009.06.009
   Knol AB, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-19
   Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167
   Makris SL, 2009, ENVIRON HEALTH PERSP, V117, P17, DOI 10.1289/ehp.11447
   Maxim L, 2010, ENVIRON RES LETT, V5, DOI 10.1088/1748-9326/5/1/014006
   Maxim L, 2013, SCI PRECAUTIONARY PR, P401
   Maxim L, 2011, ENVIRON SCI POLICY, V14, P482, DOI 10.1016/j.envsci.2011.01.003
   Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173
   Noelle-Neumann E, 1986, SPIRAL SILENCE
   OECD, 2007, OECD GUID TEST CHEM
   OECD, 2001, OECD GUID TEST CHEM
   OECD, 2000, OECD SER PRINC GOOD, V5
   Organisation for Economic Co-operation and Development, 1998, OECD SER PRINC GOOD, V1
   Ruden C, 2001, REGUL TOXICOL PHARM, V34, P3, DOI 10.1006/rtph.2001.1482
   SCF, 2002, OP SCI COMM FOOD BIS, P7
   Schneider K, 2009, TOXICOL LETT, V189, P138, DOI 10.1016/j.toxlet.2009.05.013
   Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251
   Stump DG, 2009, DIETARY DEV NEUROTOX, V1
   Stump DG, 2010, TOXICOL SCI, V115, P167, DOI 10.1093/toxsci/kfq025
   Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121
   Tyl RW, 2006, 80057 CAS BPA RTI IN
   U.S EPA, 1998, HLTH EFF TEST GUID
   U.S EPA, 1998, HLTH EFF TEST GUID O
   van der Sluijs JP, 2007, ENVIRON MODELL SOFTW, V22, P590, DOI 10.1016/j.envsoft.2005.12.020
   van der Sluijs JP, 2005, RISK ANAL, V25, P481, DOI 10.1111/j.1539-6924.2005.00604.x
   Van der Sluijs JP, 2005, ENVIRON MONIT ASSESS, V105, P229, DOI 10.1007/s10661-005-3697-7
   van der Sluijs JP, 2002, FUTURES, V34, P133, DOI 10.1016/S0016-3287(01)00051-9
   Van Gijlswijk R, 2004, UNCERTAINTY ASSESSME
   Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1
   vom Saal FS, 2010, TOXICOL SCI, V115, P612, DOI 10.1093/toxsci/kfq048
   Wandall B, 2007, ARCH TOXICOL, V81, P605, DOI 10.1007/s00204-007-0194-5
NR 50
TC 10
Z9 10
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2014
VL 9
IS 1
AR e87738
DI 10.1371/journal.pone.0087738
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301ZC
UT WOS:000330570000175
PM 24489958
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Shi, C
   Boehme, S
   Bentley, AH
   Hartmann, EK
   Klein, KU
   Bodenstein, M
   Baumgardner, JE
   David, M
   Ullrich, R
   Markstaller, K
AF Shi, Chang
   Boehme, Stefan
   Bentley, Alexander H.
   Hartmann, Erik K.
   Klein, Klaus U.
   Bodenstein, Marc
   Baumgardner, James E.
   David, Matthias
   Ullrich, Roman
   Markstaller, Klaus
TI Assessment of Regional Ventilation Distribution: Comparison of Vibration
   Response Imaging (VRI) with Electrical Impedance Tomography (EIT)
SO PLOS ONE
LA English
DT Article
ID END-EXPIRATORY PRESSURE; LUNG VENTILATION; SOUNDS; PIGS; STETHOSCOPE;
   AGREEMENT; MODEL; ARDS; CT
AB Background: Vibration response imaging (VRI) is a bedside technology to monitor ventilation by detecting lung sound vibrations. It is currently unknown whether VRI is able to accurately monitor the local distribution of ventilation within the lungs. We therefore compared VRI to electrical impedance tomography (EIT), an established technique used for the assessment of regional ventilation.
   Methodology/Principal Findings: Simultaneous EIT and VRI measurements were performed in the healthy and injured lungs (ALI; induced by saline lavage) at different PEEP levels (0, 5, 10, 15 mbar) in nine piglets. Vibration energy amplitude (VEA) by VRI, and amplitudes of relative impedance changes (rel.Delta Z) by EIT, were evaluated in seven regions of interest (ROIs). To assess the distribution of tidal volume (V-T) by VRI and EIT, absolute values were normalized to the V-T obtained by simultaneous spirometry measurements. Redistribution of ventilation by ALI and PEEP was detected by VRI and EIT. The linear correlation between pooled V-T by VEA and rel.Delta Z was R-2 = 0.96. Bland-Altman analysis showed a bias of -1.07 +/- 24.71 ml and limits of agreement of -49.05 to +47.36 ml. Within the different ROIs, correlations of V-T-distribution by EIT and VRI ranged between R-2 values of 0.29 and 0.96. ALI and PEEP did not alter the agreement of V-T between VRI and EIT.
   Conclusions/Significance: Measurements of regional ventilation distribution by VRI are comparable to those obtained by EIT.
C1 [Shi, Chang; Boehme, Stefan; Bentley, Alexander H.; Hartmann, Erik K.; Klein, Klaus U.; Bodenstein, Marc; David, Matthias; Markstaller, Klaus] Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Med Ctr, D-55122 Mainz, Germany.
   [Boehme, Stefan; Klein, Klaus U.; Ullrich, Roman; Markstaller, Klaus] Med Univ Vienna, Dept Anaesthesia Gen Intens Care & Pain Managemen, Vienna, Austria.
   [Shi, Chang] Natl Beijing Ctr Drug Safety Evaluat & Res, Beijing Inst Pharmacol & Toxicol, Beijing, Peoples R China.
   [Baumgardner, James E.] Oscillogy LLC, Folsom, PA USA.
RP Boehme, S (reprint author), Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Med Ctr, D-55122 Mainz, Germany.
EM stefan_boehme@web.de
RI Ullrich, Roman/J-8826-2019
OI Klein, Klaus Ulrich/0000-0001-7446-0542
FU German Research Foundation [DFG PAK 415]; G.E. Healthcare Inc.,
   Milwaukee, USA;  [Ma 2398/6-1];  [Ma 2398/7-1]
FX The study was funded by German Research Foundation grant No. DFG PAK
   415; Ma 2398/6-1, Ma 2398/7-1 and in part by G.E. Healthcare Inc.,
   Milwaukee, USA. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Becker HD, 2009, RESPIRATION, V77, P236, DOI 10.1159/000181147
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   BLAND JM, 1986, LANCET, V1, P307
   Charleston-Villalobos S, 2004, MED BIOL ENG COMPUT, V42, P618, DOI 10.1007/BF02347543
   Cochrane CG, 1999, CHEST, V116, p85S, DOI 10.1378/chest.116.suppl_1.85S
   Dellinger RP, 2008, RESPIRATION, V75, P60, DOI 10.1159/000103558
   Dellinger RP, 2007, CRIT CARE, V11, DOI 10.1186/cc5706
   Frerichs I, 2003, INTENS CARE MED, V29, P2312, DOI 10.1007/s00134-003-2029-z
   Frerichs I, 2002, J APPL PHYSIOL, V93, P660, DOI 10.1152/japplphysiol.00081.2002
   HAHN G, 1995, PHYSIOL MEAS, V16, pA161, DOI 10.1088/0967-3334/16/3A/016
   Hickling KG, 1998, AM J RESP CRIT CARE, V158, P194, DOI 10.1164/ajrccm.158.1.9708049
   Hinz J, 2003, CHEST, V124, P314, DOI 10.1378/chest.124.1.314
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kompis M, 2001, CHEST, V120, P1309, DOI 10.1378/chest.120.4.1309
   Kunst PWA, 1998, PHYSIOL MEAS, V19, P481, DOI 10.1088/0967-3334/19/4/003
   Lev S, 2009, CRIT CARE, V13, DOI 10.1186/cc7871
   Markstaller K, 2003, BRIT J ANAESTH, V91, P699, DOI 10.1093/bja/aeg246
   Pasterkamp H, 1997, AM J RESP CRIT CARE, V156, P974, DOI 10.1164/ajrccm.156.3.9701115
   Pulletz S, 2006, PHYSIOL MEAS, V27, pS115, DOI 10.1088/0967-3334/27/5/S10
   Richard JC, 2009, CRIT CARE, V13, DOI 10.1186/cc7900
   Stenqvist O, 2003, BRIT J ANAESTH, V91, P92, DOI 10.1093/bja/aeg141
   Vena A, 2006, CLIN PHYSIOL FUNCT I, V26, P45, DOI 10.1111/j.1475-097X.2005.00652.x
   Victorino JA, 2004, AM J RESP CRIT CARE, V169, P791, DOI 10.1164/rccm.200301-133OC
   Yigla M, 2008, AM J ROENTGENOL, V191, P845, DOI 10.2214/AJR.07.3151
   Zar JH, 1984, BIOSTATISTICAL ANAL
NR 25
TC 14
Z9 14
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2014
VL 9
IS 1
AR e86638
DI 10.1371/journal.pone.0086638
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301BI
UT WOS:000330507300096
PM 24475160
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ballesteros, CI
   Galvao, BD
   Maisonette, S
   Landeira-Fernandez, J
AF Ballesteros, Carolina Irurita
   Galvao, Bruno de Oliveira
   Maisonette, Silvia
   Landeira-Fernandez, J.
TI Effect of Dorsal and Ventral Hippocampal Lesions on Contextual Fear
   Conditioning and Unconditioned Defensive Behavior Induced by Electrical
   Stimulation of the Dorsal Periaqueductal Gray
SO PLOS ONE
LA English
DT Article
ID DIFFERENTIAL CONTRIBUTIONS; ENTORHINAL CORTEX; RATS; AMYGDALA; ANXIETY;
   PROJECTIONS; EXPRESSION; MIDLINE; NUCLEI; MAZE
AB The dorsal (DH) and ventral (VH) subregions of the hippocampus are involved in contextual fear conditioning. However, it is still unknown whether these two brain areas also play a role in defensive behavior induced by electrical stimulation of the dorsal periaqueductal gray (dPAG). In the present study, rats were implanted with electrodes into the dPAG to determine freezing and escape response thresholds after sham or bilateral electrolytic lesions of the DH or VH. The duration of freezing behavior that outlasted electrical stimulation of the dPAG was also measured. The next day, these animals were subjected to contextual fear conditioning using footshock as an unconditioned stimulus. Electrolytic lesions of the DH and VH impaired contextual fear conditioning. Only VH lesions disrupted conditioned freezing immediately after footshock and increased the thresholds of aversive freezing and escape responses to dPAG electrical stimulation. Neither DH nor VH lesions disrupted post-dPAG stimulation freezing. These results indicate that the VH but not DH plays an important role in aversively defensive behavior induced by dPAG electrical stimulation. Interpretations of these findings should be made with caution because of the fact that a non-fiber-sparing lesion method was employed.
C1 [Ballesteros, Carolina Irurita; Galvao, Bruno de Oliveira; Maisonette, Silvia; Landeira-Fernandez, J.] Pontificia Univ Catolica Rio de Janeiro, Dept Psicol, Rio De Janeiro, RJ, Brazil.
RP Landeira-Fernandez, J (reprint author), Pontificia Univ Catolica Rio de Janeiro, Dept Psicol, Rio De Janeiro, RJ, Brazil.
EM landeira@puc-rio.br
RI Landeira-Fernandez, J./F-6818-2012
OI Landeira-Fernandez, J./0000-0002-8395-8008
FU Brazilian National Research Council (CNPq); CNPq
FX SM and JLF were supported by grants from the Brazilian National Research
   Council (CNPq). BOG was supported by graduate student fellowships from
   CNPq, and CIB was an international student from Colombia. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bannerman DM, 2003, BEHAV BRAIN RES, V139, P197, DOI 10.1016/S0166-4328(02)00268-1
   Bland BH, 1998, NEUROSCI BIOBEHAV R, V22, P259, DOI 10.1016/S0149-7634(97)00013-4
   Brandao ML, 2008, BEHAV BRAIN RES, V188, P1, DOI 10.1016/j.bbr.2007.10.018
   BRANDAO ML, 1982, PHARMACOL BIOCHEM BE, V16, P397, DOI 10.1016/0091-3057(82)90441-5
   Carvalho MC, 2008, PEPTIDES, V29, P1191, DOI 10.1016/j.peptides.2008.02.014
   Degroot A, 2002, BRAIN RES, V949, P60, DOI 10.1016/S0006-8993(02)02965-7
   FANSELOW MS, 1980, PAVLOVIAN J BIOL SCI, V15, P177
   Kenny PJ, 2000, NEUROPHARMACOLOGY, V39, P300, DOI 10.1016/S0028-3908(99)00114-8
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kjelstrup KG, 2002, P NATL ACAD SCI USA, V99, P10825, DOI 10.1073/pnas.152112399
   KOHLER C, 1985, NEUROSCIENCE, V16, P85, DOI 10.1016/0306-4522(85)90049-1
   Krout KE, 2002, J COMP NEUROL, V448, P53, DOI 10.1002/cne.10236
   Landeira-Fernandez J, 1999, BEHAV NEUROSCI, V113, P1049
   Lee I, 2004, HIPPOCAMPUS, V14, P301, DOI 10.1002/hipo.10177
   Maren S, 1997, BEHAV BRAIN RES, V88, P261, DOI 10.1016/S0166-4328(97)00088-0
   Maren S, 1997, NEUROBIOL LEARN MEM, V67, P142, DOI 10.1006/nlme.1996.3752
   Martinez RCR, 2006, NEUROBIOL LEARN MEM, V85, P58, DOI 10.1016/j.nlm.2005.08.007
   McEown K, 2009, BRAIN RES, V1251, P185, DOI 10.1016/j.brainres.2008.11.041
   McHugh SB, 2004, BEHAV NEUROSCI, V118, P63, DOI 10.1037/0735-7044.118.1.63
   Menard J, 2001, BRAIN RES, V888, P163, DOI 10.1016/S0006-8993(00)03046-8
   Oliveira LC, 2004, NEUROREPORT, V15, P2281, DOI 10.1097/00001756-200410050-00028
   PAXINOS G, 1986, RAT BRAIN STEREOTAXI
   Pentkowski NS, 2006, EUR J NEUROSCI, V23, P2185, DOI 10.1111/j.1460-9568.2006.04754.x
   PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274
   Pitkanen A, 2000, ANN NY ACAD SCI, V911, P369
   Richmond MA, 1999, BEHAV NEUROSCI, V113, P1189, DOI 10.1037/0735-7044.113.6.1189
   Rogers JL, 2006, NEUROBIOL LEARN MEM, V86, P72, DOI 10.1016/j.nlm.2006.01.002
   Ruiz-Martinez RC, 2006, NEUROBIOL LEARN MEM, V85, P58
   RUTH RE, 1982, J COMP NEUROL, V209, P69, DOI 10.1002/cne.902090107
   Spolidorio PCM, 2007, PSYCHOPHARMACOLOGY, V195, P183, DOI 10.1007/s00213-007-0890-0
   Trivedi MA, 2004, NEUROBIOL LEARN MEM, V81, P172, DOI 10.1016/j.nlm.2004.02.005
   Vertes RP, 2006, NEUROSCIENCE, V142, P1, DOI 10.1016/j.neuroscience.2006.06.027
   Vianna DML, 2001, LEARN MEMORY, V8, P164, DOI 10.1101/lm.36101
   WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9
   Yoon T, 2007, NEUROBIOL LEARN MEM, V87, P464, DOI 10.1016/j.nlm.2006.12.006
NR 35
TC 14
Z9 14
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 3
PY 2014
VL 9
IS 1
AR e83342
DI 10.1371/journal.pone.0083342
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 286IH
UT WOS:000329460800013
PM 24404134
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Eini, R
   Stoop, H
   Gillis, AJM
   Biermann, K
   Dorssers, LCJ
   Looijenga, LHJ
AF Eini, Ronak
   Stoop, Hans
   Gillis, Ad J. M.
   Biermann, Katharina
   Dorssers, Lambert C. J.
   Looijenga, Leendert H. J.
TI Role of SOX2 in the Etiology of Embryonal Carcinoma, Based on Analysis
   of the NCCIT and NT2 Cell Lines
SO PLOS ONE
LA English
DT Article
ID TUMOR-INITIATING CELLS; STEM-CELLS; BREAST-CANCER; GERM-CELLS;
   DIFFERENTIATION; EXPRESSION; ONCOGENE; PROLIFERATION; INHIBITION; OCT3/4
AB The transcription factor SOX2, associated with amongst others OCT3/4, is essential for maintenance of pluripotency and self-renewal of embryonic stem cells. SOX2 is highly expressed in embryonal carcinoma (EC), the stem cell component of malignant nonseminomatous germ cell tumors, referred to as germ cell cancer (GCC). In fact, OCT3/4 together with SOX2 is an informative diagnostic tool for EC in a clinical setting. Several studies support the hypothesis that SOX2 is a relevant oncogenic factor in various cancers and recently, SOX2 has been suggested as a putative therapeutic target for early stage EC. We demonstrate the presence of genomic amplification of SOX2 in an EC cell line, NCCIT, using array comparative genome hybridization and fluorescence in situ hybridization. Down-regulation of SOX2 by targeted siRNA provokes NCCIT cells towards apoptosis, while inhibition of OCT3/4 expression induced differentiation, with retained SOX2 levels. Mice pluripotent xenografts from NCCIT (N-NCCIT and N2-NCCIT) show a consistent SOX2 expression, in spite of loss of the expression of OCT3/4, and differentiation, with retained presence of genomic amplification. No SOX2 amplification has been identified in primary pure and mixed EC in vivo patient samples so far. The data presented in this study are based on a single EC cell line with a SOX2 amplification, with NT2 as control EC cell line, showing no profound induction of apoptosis upon SOX2 downregulation. The findings are of relevance to identify mechanisms involved in the pathogenesis of EC tumors, and support the model of SOX2-oncogene dependency of EC, which however, does not exclude induction of differentiation. This finding is likely related to the presence of wild type p53 in GCC, resulting in expression of downstream target genes, amongst others miR-34a, miR-145 and SOX2, associated to the unique sensitivity of GCC to DNA damaging agents.
C1 [Eini, Ronak; Stoop, Hans; Gillis, Ad J. M.; Biermann, Katharina; Dorssers, Lambert C. J.; Looijenga, Leendert H. J.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pathol, Rotterdam, Netherlands.
RP Looijenga, LHJ (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Pathol, Rotterdam, Netherlands.
EM l.looijenga@erasmusmc.nl
RI Looijenga, Leendert/B-8145-2019
OI Looijenga, Leendert/0000-0002-8146-1911
FU Dutch Cancer Society [KWF: 2006-3607]
FX This work was supported by a grant from the Dutch Cancer Society (KWF:
   2006-3607). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Andrews PW, 2005, BIOCHEM SOC T, V33, P1526, DOI 10.1042/BST0331526
   ANDREWS PW, 1994, LAB INVEST, V71, P243
   Andrews PW, 2002, PHILOS T ROY SOC B, V357, P405, DOI 10.1098/rstb.2002.1058
   ANDREWS PW, 1987, INT J ANDROL, V10, P95, DOI 10.1111/j.1365-2605.1987.tb00170.x
   Andrews PW, 1996, INT J CANCER, V66, P806, DOI 10.1002/(SICI)1097-0215(19960611)66:6<806::AID-IJC17>3.0.CO;2-0
   Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503
   Bae KM, 2010, J UROLOGY, V183, P2045, DOI 10.1016/j.juro.2009.12.092
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Bauer S, 2010, EUR UROL, V57, P679, DOI 10.1016/j.eururo.2009.06.014
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200
   DAMJANOV I, 1983, CANCER RES, V43, P2190
   DAMJANOV I, 1993, LAB INVEST, V68, P220
   de Jong J, 2008, J PATHOL, V215, P21, DOI 10.1002/path.2332
   de Jong J, 2005, J PATHOL, V206, P242, DOI 10.1002/path.1766
   de Jong J, 2008, GENE CHROMOSOME CANC, V47, P185, DOI 10.1002/gcc.20520
   Eini R, 2013, INT J DEV BIOL, V57, P319, DOI 10.1387/ijdb.130020re
   Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003
   Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493
   Gearhart J, 1998, SCIENCE, V282, P1061, DOI 10.1126/science.282.5391.1061
   Gillis AJM, 2007, J PATHOL, V213, P319, DOI 10.1002/path.2230
   Gillis AJM, 2011, INT J ANDROL, V34, pE160, DOI 10.1111/j.1365-2605.2011.01148.x
   Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225
   Honecker F, 2006, J PATHOL, V208, P395, DOI 10.1002/path.1872
   Horwich A, 2006, LANCET, V367, P754, DOI 10.1016/S0140-6736(06)68305-0
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   Hussenet T, 2010, CELL CYCLE, V9, P1480, DOI 10.4161/cc.9.8.11203
   Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960
   Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268
   Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42
   Leung ELH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014062
   Lim JH, 2012, AM J VET RES, V73, P1963, DOI 10.2460/ajvr.73.12.1963
   Lin YJ, 2012, MOL CELL, V48, P627, DOI 10.1016/j.molcel.2012.08.030
   Looijenga LHJ, 2003, CANCER RES, V63, P2244
   LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934
   Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022
   Masters JR, 2003, BJU INT, V92, P661, DOI 10.1046/j.1464-410X.2003.04481-04484.x
   Nettersheim D, 2011, GENE CHROMOSOME CANC, V50, P1033, DOI 10.1002/gcc.20918
   Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568
   Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x
   Park SW, 2012, FEBS LETT, V586, P3529, DOI 10.1016/j.febslet.2012.08.013
   Preston SL, 2003, J CLIN PATHOL-MOL PA, V56, P86, DOI 10.1136/mp.56.2.86
   Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907
   SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656
   Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06
   SKAKKEBAEK NE, 1972, LANCET, V2, P516
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TESHIMA S, 1988, LAB INVEST, V59, P328
   ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001
   Ushida H, 2012, J UROLOGY, V187, P1876, DOI 10.1016/j.juro.2011.12.058
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Walsh J, 2003, APMIS, V111, P197, DOI 10.1034/j.1600-0463.2003.1110124.x
   Wang YL, 2009, J CELL PHYSIOL, V218, P251, DOI 10.1002/jcp.21607
   Woodward PJ, 2004, WHO CLASSIFICATION T
   Xu XL, 2010, CARCINOGENESIS, V31, P167, DOI 10.1093/carcin/bgp232
   Yamada N, 2013, CANCER LETT, V335, P332, DOI 10.1016/j.canlet.2013.02.060
   Yang S, 2012, CELL PROLIFERAT, V45, P299, DOI 10.1111/j.1365-2184.2012.00827.x
   Yuan P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009112
   Zhang Y, 2012, J BIOL CHEM
   Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2
NR 65
TC 5
Z9 5
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 3
PY 2014
VL 9
IS 1
AR e83585
DI 10.1371/journal.pone.0083585
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 286IH
UT WOS:000329460800014
PM 24404135
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Tian, Y
   Ding, WC
   Wang, YY
   Ji, T
   Sun, SJ
   Mo, QQ
   Chen, PB
   Fang, Y
   Liu, J
   Wang, BB
   Zhou, JF
   Ma, D
   Wu, P
AF Tian, Yuan
   Ding, Wencheng
   Wang, Yingying
   Ji, Teng
   Sun, Shujuan
   Mo, Qingqing
   Chen, Pingbo
   Fang, Yong
   Liu, Jia
   Wang, Beibei
   Zhou, Jianfeng
   Ma, Ding
   Wu, Peng
TI Ubiquitin B in Cervical Cancer: Critical for the Maintenance of Cancer
   Stem-Like Cell Characters
SO PLOS ONE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; MOLECULAR-MECHANISMS; POLYUBIQUITIN;
   IRRADIATION; TUMORS; GENES
AB Cervical cancer cells exhibit an increased requirement for ubiquitin-dependent protein degradation associated with an elevated metabolic turnover rate. Ubiquitin, which is a small, highly conserved protein expressed in all eukaryotic cells, can be covalently linked to certain target proteins to mark them for degradation by the ubiquitin-proteasome system. Previous studies highlight the essential role of Ubiquitin B (UbB) and UbB-dependent proteasomal protein degradation in histone deacetylase inhibitor (HDACi) -induced tumor selectivity. We hypothesized that UbB plays a critical role in the function of cervical cancer stem cells. We measured endogenous UbB levels in mammospheres in vitro by real-time PCR and Western blotting. The function of UbB in cancer stem-like cells was assessed after knockdown of UbB expression in prolonged Trichostatin A-selected HeLa cells (HeLa/TSA) by measuring in vitro cell proliferation, cell apoptosis, invasion, and chemotherapy resistance as well as by measuring in vivo growth in an orthotopic model of cervical cancer. We also assessed the cancer stem cell frequency, tumorsphere formation, and in vivo growth of human cervical cancer xenografts after UbB silencing. We found that HeLa/TSA were resistant to chemotherapy, highly expressed the UbB gene and the stem cell markers Sox2, Oct4 and Nanog. These cells also displayed induced differentiation abilities, including enhanced migration/invasion/malignancy capabilities in vitro and in vivo. Furthermore, an elevated expression of UbB was shown in the tumor samples of chemotherapy patients. Silencing of UbB inhibited tumorsphere formation, lowered the expression of stem cell markers and decreased cervical xenograft growth. Our results demonstrate that UbB was significantly increased in prolonged Trichostatin A-selected HeLa cells and it played a key role in the maintenance of cervical cancer stem-like cells.
C1 [Tian, Yuan; Ding, Wencheng; Ji, Teng; Sun, Shujuan; Mo, Qingqing; Chen, Pingbo; Fang, Yong; Liu, Jia; Wang, Beibei; Zhou, Jianfeng; Ma, Ding; Wu, Peng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Biol Res Ctr, Wuhan 430074, Hubei, Peoples R China.
   [Wang, Yingying] Zhengzhou Univ, Affiliated Hosp 3, Dept Gynecol, Zhengzhou 450052, Henan, Peoples R China.
RP Wu, P (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Biol Res Ctr, Wuhan 430074, Hubei, Peoples R China.
EM pengwu8626@126.com
RI wu, peng/M-1812-2019
OI wu, peng/0000-0002-4016-6641
FU National Science Foundation of China [81372806, 81101962, 81101965,
   81202060]
FX This work was supported by National Science Foundation of China (No.
   81372806; 81101962; 81101965; 81202060). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bosch FX, 2012, VACCINE, V30, pF1, DOI 10.1016/j.vaccine.2012.05.090
   Cadron I, 2007, GYNECOL ONCOL, V107, pS113, DOI 10.1016/j.ygyno.2007.07.004
   Calcagno AM, 2010, J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361
   DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875
   FINCH JS, 1992, CELL GROWTH DIFFER, V3, P269
   Hemmings C, 2010, PATHOLOGY, V42, P105, DOI 10.3109/00313020903488773
   KENWARD N, 1994, J NEUROCHEM, V62, P1870
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   NENOI M, 1992, INT J RADIAT BIOL, V61, P205, DOI 10.1080/09553009214550831
   Peralta-Zaragoza O, 2012, ONCOTARGETS THER, V5, P315, DOI 10.2147/OTT.S25123
   Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788
   Todaro M, 2010, CELL CYCLE, V9, P1238
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wu P, 2010, CELL DEATH DIFFER, V17, P109, DOI 10.1038/cdd.2009.142
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
NR 18
TC 7
Z9 9
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2013
VL 8
IS 12
AR e84457
DI 10.1371/journal.pone.0084457
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HL
UT WOS:000328740300141
PM 24367661
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hou, YM
   Hu, JL
   Po, SS
   Wang, H
   Zhang, L
   Zhang, F
   Wang, K
   Zhou, Q
AF Hou, Yuemei
   Hu, Jialu
   Po, Sunny S.
   Wang, Huan
   Zhang, Ling
   Zhang, Feng
   Wang, Kun
   Zhou, Qina
TI Catheter-Based Renal Sympathetic Denervation Significantly Inhibits
   Atrial Fibrillation Induced by Electrical Stimulation of the Left
   Stellate Ganglion and Rapid Atrial Pacing
SO PLOS ONE
LA English
DT Article
ID DRUG-RESISTANT HYPERTENSION; SUDDEN CARDIAC DEATH; RADIOFREQUENCY
   ABLATION; PULMONARY VEINS; BLOOD-PRESSURE; CANINE MODEL; INNERVATION;
   INDUCIBILITY; TACHYCARDIA
AB Background: Sympathetic activity involves the pathogenesis of atrial fibrillation (AF). Renal sympathetic denervation (RSD) decreases sympathetic renal afferent nerve activity, leading to decreased central sympathetic drive. The aim of this study was to identify the effects of RSD on AF inducibility induced by hyper-sympathetic activity in a canine model.
   Methods: To establish a hyper-sympathetic tone canine model of AF, sixteen dogs were subjected to stimulation of left stellate ganglion (LSG) and rapid atrial pacing (RAP) for 3 hours. Then animals in the RSD group (n = 8) underwent radiofrequency ablation of the renal sympathetic nerve. The control group (n = 8) underwent the same procedure except for ablation. AF inducibility, effective refractory period (ERP), ERP dispersion, heart rate variability and plasma norepinephrine levels were measured at baseline, after stimulation and after ablation.
   Results: LSG stimulation combined RAP significantly induced higher AF induction rate, shorter ERP, larger ERP dispersion at all sites examined and higher plasma norepinephrine levels (P < 0.05 in all values), compared to baseline. The increased AF induction rate, shortened ERP, increased ERP dispersion and elevated plasma norepinephrine levels can be almost reversed by RSD, compared to the control group (P, 0.05). LSG stimulation combined RAP markedly shortened RR-interval and standard deviation of all RR-intervals (SDNN), Low-frequency (LF), high-frequency (HF) and LF/HF ratio (P < 0.05). These changes can be reversed by RSD, compared to the control group (P < 0.05).
   Conclusions: RSD significantly reduced AF inducibility and reversed the atrial electrophysiological changes induced by hyper-sympathetic activity.
C1 [Hou, Yuemei] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Cardiovasc Dis, Shanghai 200030, Peoples R China.
   [Hu, Jialu] Fudan Univ, Zhongshan Hosp, Dept Cardiovasc Dis, Shanghai 200433, Peoples R China.
   [Po, Sunny S.] Univ Oklahoma, Hlth Sci Ctr, Heart Rhythm Inst, Oklahoma City, OK USA.
   [Po, Sunny S.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
   [Wang, Huan; Zhang, Ling; Zhang, Feng; Wang, Kun; Zhou, Qina] Xinjiang Med Univ, Affiliated Hosp 1, Arrhythmia Res Lab, Urumqi, Peoples R China.
RP Zhou, Q (reprint author), Xinjiang Med Univ, Affiliated Hosp 1, Arrhythmia Res Lab, Urumqi, Peoples R China.
EM zhouqina_5217@sina.com
FU International Science and Technology Cooperation Project of the Ministry
   of Science and Technology of China [2011DFA32860]; Shanghai Science and
   Technology Commission Research Projects [10411956900]
FX This study was supported by the International Science and Technology
   Cooperation Project of the Ministry of Science and Technology of China
   (2011DFA32860) and the Shanghai Science and Technology Commission
   Research Projects (10411956900). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmed H, 2012, JACC-CARDIOVASC INTE, V5, P758, DOI 10.1016/j.jcin.2012.01.027
   BARAJAS L, 1978, FED PROC, V37, P1192
   Cao JM, 2000, CIRC RES, V86, P816, DOI 10.1161/01.RES.86.7.816
   Chang CM, 2001, CIRCULATION, V103, P22
   Chen SA, 1999, CIRCULATION, V100, P1879, DOI 10.1161/01.CIR.100.18.1879
   Esler MD, 2010, LANCET, V376, P1903, DOI 10.1016/S0140-6736(10)62039-9
   Gould PA, 2006, PACE, V29, P821, DOI 10.1111/j.1540-8159.2006.00447.x
   Heusser K, 2010, HYPERTENSION, V55, P619, DOI 10.1161/HYPERTENSIONAHA.109.140665
   Ishida Yuji, 2008, Okajimas Folia Anatomica Japonica, V84, P133, DOI 10.2535/ofaj.84.133
   Jayachandran JV, 2000, CIRCULATION, V101, P1185, DOI 10.1161/01.CIR.101.10.1185
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kuhlkamp V, 2000, J AM COLL CARDIOL, V36, P139, DOI 10.1016/S0735-1097(00)00693-8
   Lehnart SE, 2004, BIOCHEM BIOPH RES CO, V322, P1267, DOI 10.1016/j.bbrc.2004.08.032
   Linz D, 2013, J CARDIOVASC ELECTRO, DOI 10:1111/jce.12284
   Linz D, 2012, HYPERTENSION, V60, P172, DOI 10.1161/HYPERTENSIONAHA.112.191965
   Lu ZB, 2008, CIRC-ARRHYTHMIA ELEC, V1, P184, DOI 10.1161/CIRCEP.108.784272
   Ogawa M, 2009, HEART RHYTHM, V6, P1772, DOI 10.1016/j.hrthm.2009.08.011
   Oral H, 2008, J CARDIOVASC ELECTR, V19, P466, DOI 10.1111/j.1540-8167.2007.01089.x
   Patterson E, 2006, J AM COLL CARDIOL, V47, P1196, DOI 10.1016/j.jacc.2005.12.023
   Prochnau D, 2012, EUROINTERVENTION, V7, P1077, DOI 10.4244/EIJV7I9A171
   Qina Z, 2012, HEART, V98, pE30
   RAGER G, 1979, STAIN TECHNOL, V54, P193, DOI 10.3109/10520297909112682
   Schlaich MP, 2004, HYPERTENSION, V43, P169, DOI 10.1161/01.HYP.0000103160.35395.9E
   Sharifov OF, 2004, J AM COLL CARDIOL, V43, P483, DOI 10.1016/j.jacc.2003.09.030
   Shi Z, 2009, PFLUG ARCH EUR J PHY, V458, P247, DOI 10.1007/s00424-008-0627-x
   Sobotka PA, 2011, CLIN RES CARDIOL, V100, P1049, DOI 10.1007/s00392-011-0335-y
   Swissa M, 2005, AM J PHYSIOL-HEART C, V289, pH1851, DOI 10.1152/ajpheart.00083.2005
   Tan AY, 2008, CIRCULATION, V118, P916, DOI 10.1161/CIRCULATIONAHA.108.776203
   Ukena C, 2012, CLIN RES CARDIOL, V101, P63, DOI 10.1007/s00392-011-0365-5
   Ukena C, 2011, J AM COLL CARDIOL, V58, P1176, DOI 10.1016/j.jacc.2011.05.036
   Vonend O, 2003, J HYPERTENS, V21, P1709, DOI 10.1097/01.hjh.0000084733.53355.c3
   Witkowski A, 2011, HYPERTENSION, V58, P559, DOI 10.1161/HYPERTENSIONAHA.111.173799
   Zhao QY, 2012, J INTERV CARD ELECTR, V35, P119, DOI 10.1007/s10840-012-9717-y
NR 33
TC 25
Z9 26
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 6
PY 2013
VL 8
IS 11
AR e78218
DI 10.1371/journal.pone.0078218
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 247XD
UT WOS:000326656200032
PM 24223140
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zheng, LZ
   Liu, Z
   Lei, M
   Peng, J
   He, YX
   Xie, XH
   Man, CW
   Huang, L
   Wang, XL
   Fong, DTP
   Xiao, DM
   Wang, DP
   Chen, Y
   Feng, JQ
   Liu, Y
   Zhang, G
   Qin, L
AF Zheng, Li-Zhen
   Liu, Zhong
   Lei, Ming
   Peng, Jiang
   He, Yi-Xin
   Xie, Xin-Hui
   Man, Chi-Wai
   Huang, Le
   Wang, Xin-Luan
   Fong, Daniel Tik-Pui
   Xiao, De-Ming
   Wang, Da-Ping
   Chen, Yang
   Feng, Jian Q.
   Liu, Ying
   Zhang, Ge
   Qin, Ling
TI Steroid-Associated Hip Joint Collapse in Bipedal Emus
SO PLOS ONE
LA English
DT Article
ID FEMORAL-HEAD OSTEONECROSIS; ACUTE-RESPIRATORY-SYNDROME;
   CORTICOSTEROID-INDUCED OSTEONECROSIS; BONE-MARROW EDEMA; NONTRAUMATIC
   OSTEONECROSIS; PHYTOMOLECULE ICARITIN; AVASCULAR NECROSIS; SUBCHONDRAL
   BONE; NATURAL-HISTORY; DEFECT REPAIR
AB In this study we established a bipedal animal model of steroid-associated hip joint collapse in emus for testing potential treatment protocols to be developed for prevention of steroid-associated joint collapse in preclinical settings. Five adult male emus were treated with a steroid-associated osteonecrosis (SAON) induction protocol using combination of pulsed lipopolysaccharide (LPS) and methylprednisolone (MPS). Additional three emus were used as normal control. Post-induction, emu gait was observed, magnetic resonance imaging (MRI) was performed, and blood was collected for routine examination, including testing blood coagulation and lipid metabolism. Emus were sacrificed at week 24 post-induction, bilateral femora were collected for micro-computed tomography (micro-CT) and histological analysis. Asymmetric limping gait and abnormal MRI signals were found in steroid-treated emus. SAON was found in all emus with a joint collapse incidence of 70%. The percentage of neutrophils (Neut %) and parameters on lipid metabolism significantly increased after induction. Micro-CT revealed structure deterioration of subchondral trabecular bone. Histomorphometry showed larger fat cell fraction and size, thinning of subchondral plate and cartilage layer, smaller osteoblast perimeter percentage and less blood vessels distributed at collapsed region in SAON group as compared with the normal controls. Scanning electron microscope (SEM) showed poor mineral matrix and more osteo-lacunae outline in the collapsed region in SAON group. The combination of pulsed LPS and MPS developed in the current study was safe and effective to induce SAON and deterioration of subchondral bone in bipedal emus with subsequent femoral head collapse, a typical clinical feature observed in patients under pulsed steroid treatment. In conclusion, bipedal emus could be used as an effective preclinical experimental model to evaluate potential treatment protocols to be developed for prevention of ON-induced hip joint collapse in patients.
C1 [Zheng, Li-Zhen; Liu, Zhong; Peng, Jiang; He, Yi-Xin; Xie, Xin-Hui; Man, Chi-Wai; Huang, Le; Wang, Xin-Luan; Fong, Daniel Tik-Pui; Zhang, Ge; Qin, Ling] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Lei, Ming; Xiao, De-Ming; Wang, Da-Ping; Chen, Yang] Shenzhen Second Peoples Hosp, Dept Orthopaed & Traumatol, Shenzhen, Peoples R China.
   [Wang, Xin-Luan; Qin, Ling] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Hlth Engn, Translat Med R&D Ctr, Shenzhen, Peoples R China.
   [Peng, Jiang] Chinese Peoples Liberat Army, Gen Hosp, Orthoped Res Inst, Beijing, Peoples R China.
   [Feng, Jian Q.; Liu, Ying] Univ Missouri, Baylor Coll Dent, Kansas City, MO 64110 USA.
   [Lei, Ming; Xiao, De-Ming] Beijing Univ, Shenzhen Hosp, Dept Orthopead, Shenzhen, Peoples R China.
   [Xie, Xin-Hui] Southeast Univ, Zhongda Hosp, Dept Orthopaed, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
RP Zhang, G (reprint author), Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
EM zhangge@ort.cuhk.edu.hk; lingqin@cuhk.edu.hk
RI Zhang, Ge/K-9118-2019; Zhang, Ge/N-4150-2013; Zheng, Lizhen/C-6550-2014;
   Qin, Ling/J-9047-2018
OI Zhang, Ge/0000-0002-7807-7695; Zhang, Ge/0000-0002-7807-7695; Qin,
   Ling/0000-0001-6173-6167; Fong, Daniel Tik-Pui/0000-0001-7314-189X; Man,
   Chi Wai/0000-0002-8608-9688
FU Hong Kong ITC [GHP/001/08]; Hong Kong ITF [ITS/451/09FP]; Shenzhen
   Science & Technology Fund [SG200810200101A/02/A]; NIDCR/NIH [DE018486]
FX This work was funded by Hong Kong ITC (GHP/001/08 and ITF Tier 2
   ITS/451/09FP): https://www.itf.gov.hk/; Shenzhen Science & Technology
   Fund (SG200810200101A/02/A): http://www.szsti.gov.cn/; and DE018486 from
   NIDCR/NIH: http://www.nidcr.nih.gov/. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Asada T, 2008, RHEUMATOLOGY, V47, P591, DOI 10.1093/rheumatology/ken037
   Assouline-Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
   Bitto A, 2009, J ENDOCRINOL, V201, P321, DOI 10.1677/JOE-08-0552
   Bradway J K, 1993, J Arthroplasty, V8, P383, DOI 10.1016/S0883-5403(06)80036-7
   Chan MHM, 2006, PATHOLOGY, V38, P229, DOI 10.1080/00313020600696231
   Chen SH, 2013, ACTA BIOMATER, V9, P6711, DOI 10.1016/j.actbio.2013.01.024
   Chen SH, 2012, ACTA BIOMATER, V8, P3128, DOI 10.1016/j.actbio.2012.04.030
   Conzemius MG, 2002, J ORTHOPAED RES, V20, P303, DOI 10.1016/S0736-0266(01)00108-5
   Cui QJ, 2000, CONNECT TISSUE RES, V41, P45
   Cui QJ, 1997, CLIN ORTHOP RELAT R, P8
   Davis ET, 2006, J BONE JOINT SURG AM, V88A, P110, DOI 10.2106/JBJS.F.00771
   Drescher W, 2004, J ORTHOPAED RES, V22, P501, DOI 10.1016/j.orthres.2003.10.002
   Drescher W, 2001, J BONE JOINT SURG BR, V83B, P274, DOI 10.1302/0301-620X.83B2.10323
   Drescher W, 2006, J BONE JOINT SURG AM, V88A, P162, DOI 10.2106/JBJS.F.00452
   Fan M, 2011, J INT MED RES, V39, P187, DOI 10.1177/147323001103900120
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   FORDYCE MJF, 1993, J BONE JOINT SURG BR, V75, P365
   Fujioka M, 2001, MAGN RESON IMAGING, V19, P985, DOI 10.1016/S0730-725X(01)00424-6
   Goetz JE, 2008, J BIOMECH, V41, P2197, DOI [10.1016/j.jbiomech.2008.04.032, 10.1016/j.jbiomech.2005.04.032]
   Goetz JE, 2008, J BIOMECH, V41, P770, DOI 10.1016/j.jbiomech.2007.11.022
   Griffith JF, 2005, RADIOLOGY, V235, P168, DOI 10.1148/radiol.2351040100
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600-0714.2006.00391.x
   Hernigou P, 1999, J BONE JOINT SURG BR, V81B, P349, DOI 10.1302/0301-620X.81B2.8818
   Irisa T, 2001, BONE, V28, P641, DOI 10.1016/S8756-3282(01)00460-4
   Ito H, 2006, AM J ROENTGENOL, V186, P1761, DOI 10.2214/AJR.05.0086
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koo KH, 1999, RADIOLOGY, V213, P715, DOI 10.1148/radiology.213.3.r99dc06715
   Kubo T, 1997, MAGN RESON IMAGING, V15, P1017, DOI 10.1016/S0730-725X(97)00159-8
   LANE LB, 1977, J BONE JOINT SURG BR, V59, P272
   Lau EMC, 2005, BONE, V37, P420, DOI 10.1016/j.bone.2005.04.018
   Law RKY, 2008, WORK, V30, P17
   Li Zi-rong, 2005, Zhonghua Wai Ke Za Zhi, V43, P1048
   Lieberman Jay R, 2003, Instr Course Lect, V52, P337
   Lv H, 2009, TROP MED INT HEALTH, V14, P79, DOI 10.1111/j.1365-3156.2008.02187.x
   MARTIN DM, 1978, J MICROSC-OXFORD, V112, P345, DOI 10.1111/j.1365-2818.1978.tb00085.x
   MILLER SC, 1985, J DENT RES, V64, P1062, DOI 10.1177/00220345850640080701
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P1117, DOI 10.2106/JBJS.E.01041
   Moskal J T, 1997, Am J Orthop (Belle Mead NJ), V26, P609
   Nishii T, 2002, CLIN ORTHOP RELAT R, P149
   Okazaki S, 2009, RHEUMATOLOGY, V48, P227, DOI 10.1093/rheumatology/ken462
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Plenk H, 2001, CLIN ORTHOP RELAT R, P42
   Qin L, 2006, BONE, V39, P863, DOI 10.1016/j.bone.2006.04.018
   Reed KL, 2003, J BIOMECH, V36, P1317, DOI 10.1016/S0021-9290(03)00154-4
   Resources IoLA, 1996, GUIDE CARE USED LAB
   Shen Jun, 2006, Zhonghua Jiehe He Huxi Zazhi, V29, P189
   Sheng H, 2009, J ORTHOP RES, V27, P742, DOI 10.1002/jor.20765
   Solomon DH, 2006, ARTHRIT RHEUM-ARTHR, V55, P873, DOI 10.1002/art.22350
   Sun W, 2006, INT ORTHOP, V30, P143, DOI 10.1007/s00264-005-0067-6
   Sun Y, 2009, JOINT BONE SPINE, V76, P685, DOI 10.1016/j.jbspin.2009.04.002
   Takano-Murakami R, 2009, TOHOKU J EXP MED, V217, P51, DOI 10.1620/tjem.217.51
   Troy KL, 2009, J BIOMECH, V42, P2495, DOI 10.1016/j.jbiomech.2009.07.017
   TURNER DA, 1989, RADIOLOGY, V171, P135, DOI 10.1148/radiology.171.1.2928517
   Wang SX, 2007, ARTHRITIS RHEUM-US, V56, P1537, DOI 10.1002/art.22574
   Wang XL, 2013, J ORTHOP RES, V31, P164, DOI 10.1002/jor.22188
   Xie XH, 2011, J BONE JOINT SURG BR, V93B, P558, DOI 10.1302/0301-620X.93B4.25442
   Xie XH, 2012, ARTHRITIS RHEUM-US, V64, P1562, DOI 10.1002/art.34525
   Yamamoto T, 1997, ARTHRITIS RHEUM, V40, P2055, DOI 10.1002/art.1780401119
   YAMAMOTO T, 1995, CLIN ORTHOP RELAT R, P235
   Yamamoto T, 2006, J RHEUMATOL, V33, P1701
   Yang L, 2009, J ORTHOP RES, V27, P169, DOI 10.1002/jor.20733
   Zhang G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006419
   Zhang G, 2009, BONE, V44, P345, DOI 10.1016/j.bone.2008.10.035
NR 63
TC 7
Z9 14
U1 2
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 21
PY 2013
VL 8
IS 10
AR e76797
DI 10.1371/journal.pone.0076797
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239NN
UT WOS:000326032600011
PM 24204675
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhang, SP
   Suo, ML
   Liu, SL
   Liang, W
AF Zhang, Shuping
   Suo, Mingli
   Liu, Shenglin
   Liang, Wei
TI Do Major Roads Reduce Gene Flow in Urban Bird Populations?
SO PLOS ONE
LA English
DT Article
ID LANDSCAPE; WILDLIFE; HABITAT; EXTINCTION; PROXIMITY; DIVERSITY;
   ABUNDANCE; WOODLAND; IMPACT
AB Background: Although the negative effects of roads on the genetics of animal populations have been extensively reported, the question of whether roads reduce gene flow in volant, urban bird populations has so far not been addressed. In this study, we assess whether highways decreased gene flow and genetic variation in a small passerine bird, the tree sparrow (Passer montanus).
   Methodology: We assessed genetic differences among tree sparrows (Passer montanus) sampled at 19 sites within Beijing Municipality, China, using 7 DNA microsatellites as genetic markers.
   Results: AMOVA showed that genetic variation between sites, between urban and rural populations, and between opposite sides of the same highway, were very weak. Mantel tests on all samples, and on urban samples only, indicated that the age and number of highways, and the number of ordinary roads, were uncorrelated with genetic differences (FST) among tree sparrows from different urban sites. Birds sampled at urban sites had similar levels of genetic diversity to those at rural sites. There was, however, evidence of some weak genetic structure between urban sites. Firstly, there were significant genetic differences (FST) between birds from opposite sides of the same highway, but no significant FST values between those from sites that were not separated by highways. Secondly, birds from eleven urban sites had loci that significantly deviated from the Hardy-Weinberg equilibrium but no such deviation was found in birds from rural sites.
   Conclusion: We cannot, therefore, conclusively reject the hypothesis that highways have no effect on the gene flow of tree sparrow populations. Furthermore, since the significance of these results may increase with time, we suggested that research on the influence of highways on gene flow in urban bird populations needs to be conducted over several decades.
C1 [Zhang, Shuping; Suo, Mingli; Liu, Shenglin] Minzu Univ China, Coll Life & Environm Sci, Beijing, Peoples R China.
   [Liang, Wei] Hainan Normal Univ, Coll Life Sci, Minist Educ, Key Lab Trop Anim & Plant Ecol, Haikou, Peoples R China.
RP Liang, W (reprint author), Hainan Normal Univ, Coll Life Sci, Minist Educ, Key Lab Trop Anim & Plant Ecol, Haikou, Peoples R China.
EM liangwei@hainnu.edu.cn
FU National Natural Science Foundation of China [30900181, 31071938,
   31272328, 31372225]; Program for New Century Excellent Talents in
   University [NCET-10-0111]; 985 Program in Minzu University of China
   [MUC98504-14, MUC98507- 08]
FX This study was supported by the National Natural Science Foundation of
   China (Nos. 30900181, 31071938, 31272328 and 31372225), Program for New
   Century Excellent Talents in University (NCET-10-0111), and 985 Program
   in Minzu University of China (MUC98504-14, MUC98507- 08). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR ANDREWS A, 1990, Australian Zoologist, V26, P130
   Balkenhol N, 2009, MOL ECOL, V18, P4151, DOI 10.1111/j.1365-294X.2009.04322.x
   BARTON NH, 1995, PHILOS T ROY SOC B, V349, P49, DOI 10.1098/rstb.1995.0090
   Brotons L, 2001, LANDSCAPE URBAN PLAN, V57, P77, DOI 10.1016/S0169-2046(01)00191-8
   Clevenger AP, 2000, CONSERV BIOL, V14, P47, DOI 10.1046/j.1523-1739.2000.00099-085.x
   Corlatti L, 2009, CONSERV BIOL, V23, P548, DOI 10.1111/j.1523-1739.2008.01162.x
   Dyer SJ, 2001, J WILDLIFE MANAGE, V65, P531, DOI 10.2307/3803106
   Epps CW, 2005, ECOL LETT, V8, P1029, DOI 10.1111/j.1461-0248.2005.00804.x
   EXCOFFIER L, 1992, GENETICS, V131, P479
   Field RH, 2004, IBIS, V146, P60, DOI 10.1111/j.1474-919X.2004.00356.x
   Forman RTT, 1998, ANNU REV ECOL SYST, V29, P207, DOI 10.1146/annurev.ecolsys.29.1.207
   Forman RTT, 2003, ROAD ECOLOGY
   Frankham R, 1996, CONSERV BIOL, V10, P1500, DOI 10.1046/j.1523-1739.1996.10061500.x
   Frankham R, 2005, BIOL CONSERV, V126, P131, DOI 10.1016/j.biocon.2005.05.002
   Gagnon JW, 2007, J WILDLIFE MANAGE, V71, P2318, DOI 10.2193/2006-224
   Gauffre B, 2008, MOL ECOL, V17, P4619, DOI 10.1111/j.1365-294X.2008.03950.x
   Griffith SC, 1999, BIOL J LINN SOC, V68, P303, DOI 10.1111/j.1095-8312.1999.tb01171.x
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   Holderegger R, 2010, BASIC APPL ECOL, V11, P522, DOI 10.1016/j.baae.2010.06.006
   Jaarsma CF, 2006, TRANSPORT RES D-TR E, V11, P264, DOI 10.1016/j.trd.2006.05.001
   Johansson M, 2005, GLOBAL CHANGE BIOL, V11, P1664, DOI 10.1111/j.1365-2486.2005.01005.x
   Kalinowski ST, 2005, MOL ECOL NOTES, V5, P187, DOI 10.1111/j.1471-8286.2004.00845.x
   Keller I, 2003, P ROY SOC B-BIOL SCI, V270, P417, DOI 10.1098/rspb.2002.2247
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Murphy MA, 2008, ECOGRAPHY, V31, P685, DOI 10.1111/j.1600-0587.2008.05428.x
   Pan Chao, 2003, Journal of Beijing Normal University (Natural Science), V39, P537
   Partecke J, 2006, ECOLOGY, V87, P1945, DOI 10.1890/0012-9658(2006)87[1945:SATCUA]2.0.CO;2
   REIJNEN R, 1995, J APPL ECOL, V32, P187, DOI 10.2307/2404428
   Rheindt FE, 2003, J ORNITHOL, V144, P295, DOI 10.1007/BF02465629
   RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x
   Roedenbeck IA, 2008, EUR J WILDLIFE RES, V54, P425, DOI 10.1007/s10344-007-0166-3
   Ruan X., 1991, P99
   Saccheri I, 1998, NATURE, V392, P491, DOI 10.1038/33136
   Slatkin M, 1996, HEREDITY, V76, P377, DOI 10.1038/hdy.1996.55
   Spellerberg IF, 1998, GLOBAL ECOL BIOGEOGR, V7, P317, DOI 10.2307/2997681
   SUMMERSSMITH JD, 1995, TREE SPARROW
   Trombulak SC, 2000, CONSERV BIOL, V14, P18, DOI 10.1046/j.1523-1739.2000.99084.x
   VANDERZANDE AN, 1980, BIOL CONSERV, V18, P299, DOI 10.1016/0006-3207(80)90006-3
   Yang CC, 2013, J AVIAN BIOL, V44, P216, DOI 10.1111/j.1600-048X.2013.00123.x
   Zhang S, 2008, FRONT BIOL CHINA, V3, P122
   Zhang SN, 2010, SCI CHINA PHYS CHEM, V53, P1, DOI 10.1007/s11433-010-0065-6
NR 41
TC 1
Z9 1
U1 1
U2 70
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 18
PY 2013
VL 8
IS 10
AR e77026
DI 10.1371/journal.pone.0077026
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239MM
UT WOS:000326029300075
PM 24204724
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU te Pas, MFW
   Koopmans, SJ
   Kruijt, L
   Calus, MPL
   Smits, MA
AF te Pas, Marinus F. W.
   Koopmans, Sietse-Jan
   Kruijt, Leo
   Calus, Mario P. L.
   Smits, Mari A.
TI Plasma Proteome Profiles Associated with Diet-Induced Metabolic Syndrome
   and the Early Onset of Metabolic Syndrome in a Pig Model
SO PLOS ONE
LA English
DT Article
ID EARLY ATHEROSCLEROSIS; INSULIN-RESISTANCE; GENE-EXPRESSION; DIABETIC
   PIGS; STREPTOZOTOCIN; FAT; DYSFUNCTION; ALLOXAN; OBESITY; LEPTIN
AB Obesity and related diabetes are important health threatening multifactorial metabolic diseases and it has been suggested that 25% of all diabetic patients are unaware of their patho-physiological condition. Biomarkers for monitoring and control are available, but early stage predictive biomarkers enabling prevention of these diseases are still lacking. We used the pig as a model to study metabolic disease because humans and pigs share a multitude of metabolic similarities. Diabetes was chemically induced and control and diabetic pigs were either fed a high unsaturated fat (Mediterranean) diet or a high saturated fat/cholesterol/sugar (cafeteria) diet. Physiological parameters related to fat metabolism and diabetes were measured. Diabetic pigs' plasma proteome profiles differed more between the two diets than control pigs plasma proteome profiles. The expression levels of several proteins correlated well with (patho) physiological parameters related to the fat metabolism (cholesterol, VLDL, LDL, NEFA) and diabetes (Glucose) and to the diet fed to the animals. Studying only the control pigs as a model for metabolic syndrome when fed the two diets showed correlations to the same parameters but now more focused on insulin, glucose and abdominal fat depot parameters. We conclude that proteomic profiles can be used as a biomarker to identify pigs with developing metabolic syndrome (prediabetes) and diabetes when fed a cafeteria diet. It could be developed into a potential biomarkers for the early recognition of metabolic diseases.
C1 [te Pas, Marinus F. W.; Kruijt, Leo; Calus, Mario P. L.; Smits, Mari A.] Wageningen UR Livestock Res, ABGC, Lelystad, Netherlands.
   [Koopmans, Sietse-Jan] Wageningen Univ, Adaptat Physiol Grp, Dept Anim Sci, Wageningen, Netherlands.
RP te Pas, MFW (reprint author), Wageningen UR Livestock Res, ABGC, Lelystad, Netherlands.
EM marinus.tepas@wur.nl
RI Calus, Mario/H-7627-2019; smits, mari/J-4892-2013
OI Calus, Mario/0000-0002-3213-704X; smits, mari/0000-0002-3493-291X
FU Dutch ministry ELI [KB 15-011-003-ASG-V-1]
FX The proteomics work has been funded by a grant from the Dutch ministry
   EL&I, grant no. KB 15-011-003-ASG-V-1. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bell LN, 2010, AM J PHYSIOL-GASTR L, V298, pG746, DOI 10.1152/ajpgi.00485.2009
   Dherty MK, 2008, PROTEOM CLIN APPL, V2, P135
   Groenen MAM, 2012, NATURE, V491, P393, DOI 10.1038/nature11622
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Ichimura A, 2012, NATURE, V483, P350, DOI 10.1038/nature10798
   Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koopmans SJ, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-64
   Koopmans SJ, 2006, METABOLISM, V55, P960, DOI 10.1016/j.metabol.2006.03.004
   Kussmann M, 2006, J BIOTECHNOL, V124, P758, DOI 10.1016/j.jbiotec.2006.02.014
   Lam QLK, 2007, CELL MOL IMMUNOL, V4, P1
   Liotta LA, 2003, NATURE, V425, P905, DOI 10.1038/425905a
   Mach N, 2010, J ANIM SCI, V88, P1522, DOI 10.2527/jas.2009-2256
   MANSFORD KR, 1968, LANCET, V1, P670
   MERKS JWM, 2000, OCCASIONAL PUBLICATI, V27, P8
   Moore RE, 2007, BIOMARK INSIGHTS, V2, P185
   Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627
   Perrini S, 2008, DIABETOLOGIA, V51, P155, DOI 10.1007/s00125-007-0841-7
   Rao PV, 2009, J PROTEOME RES, V8, P239, DOI 10.1021/pr8003776
   RERUP C C, 1970, Pharmacological Reviews, V22, P485
   ROSSINI AA, 1977, P NATL ACAD SCI USA, V74, P2485, DOI 10.1073/pnas.74.6.2485
   Sundsten T, 2009, MOL CELL ENDOCRINOL, V297, P93, DOI 10.1016/j.mce.2008.06.018
   Szkudelski T, 2001, PHYSIOL RES, V50, P537
   van den Heuvel M, 2012, AM J PHYSIOL-HEART C, V302, pH85, DOI 10.1152/ajpheart.00311.2011
   Vodicka P, 2005, ANN NY ACAD SCI, V1049, P161, DOI 10.1196/j.annals.1334.015
   Zhang YY, 2002, AM J PHYSIOL-REG I, V282, pR226, DOI 10.1152/ajpregu.00392.2001
NR 26
TC 8
Z9 8
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2013
VL 8
IS 9
AR e73087
DI 10.1371/journal.pone.0073087
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 246EK
UT WOS:000326520200006
PM 24086269
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Gonzalez-Serrano, AF
   Pirro, V
   Ferreira, CR
   Oliveri, P
   Eberlin, LS
   Heinzmann, J
   Lucas-Hahn, A
   Niemann, H
   Cooks, RG
AF Gonzalez-Serrano, Andres Felipe
   Pirro, Valentina
   Ferreira, Christina R.
   Oliveri, Paolo
   Eberlin, Livia S.
   Heinzmann, Julia
   Lucas-Hahn, Andrea
   Niemann, Heiner
   Cooks, Robert Graham
TI Desorption Electrospray Ionization Mass Spectrometry Reveals Lipid
   Metabolism of Individual Oocytes and Embryos
SO PLOS ONE
LA English
DT Article
ID PREIMPLANTATION BOVINE EMBRYOS; MESSENGER-RNA EXPRESSION; VITRO
   CULTURE-CONDITIONS; FATTY-ACID-COMPOSITION; IN-VITRO; DAIRY-COWS; DNA
   METHYLATION; SINGLE EMBRYO; FERTILIZATION; BLASTOCYSTS
AB Alteration of maternal lipid metabolism early in development has been shown to trigger obesity, insulin resistance, type 2 diabetes and cardiovascular diseases later in life in humans and animal models. Here, we set out to determine (i) lipid composition dynamics in single oocytes and preimplantation embryos by high mass resolution desorption electrospray ionization mass spectrometry (DESI-MS), using the bovine species as biological model, (ii) the metabolically most relevant lipid compounds by multivariate data analysis and (iii) lipid upstream metabolism by quantitative real-time PCR (qRT-PCR) analysis of several target genes (ACAT1, CPT 1b, FASN, SREBP1 and SCAP). Bovine oocytes and blastocysts were individually analyzed by DESI-MS in both positive and negative ion modes, without lipid extraction and under ambient conditions, and were profiled for free fatty acids (FFA), phospholipids (PL), cholesterol-related molecules, and triacylglycerols (TAG). Principal component analysis (PCA) and linear discriminant analysis (LDA), performed for the first time on DESI-MS fused data, allowed unequivocal discrimination between oocytes and blastocysts based on specific lipid profiles. This analytical approach resulted in broad and detailed lipid annotation of single oocytes and blastocysts. Results of DESI-MS and transcript regulation analysis demonstrate that blastocysts produced in vitro and their in vivo counterparts differed significantly in the homeostasis of cholesterol and FFA metabolism. These results should assist in the production of viable and healthy embryos by elucidating in vivo embryonic lipid metabolism.
C1 [Gonzalez-Serrano, Andres Felipe; Heinzmann, Julia; Lucas-Hahn, Andrea; Niemann, Heiner] Friedrich Loeffler Inst, Inst Farm Anim Genet, Neustadt, Germany.
   [Pirro, Valentina] Univ Turin, Dept Chem, Turin, Italy.
   [Ferreira, Christina R.; Eberlin, Livia S.; Cooks, Robert Graham] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
   [Oliveri, Paolo] Univ Genoa, Dept Pharm, Genoa, Italy.
RP Niemann, H (reprint author), Friedrich Loeffler Inst, Inst Farm Anim Genet, Neustadt, Germany.
EM heiner.niemann@fli.bund.de; cooks@purdue.edu
RI Cooks, R/G-1051-2015; Ferreira, Christina R/F-4744-2012; Oliveri,
   Paolo/K-4359-2015; Pirro, Valentina/M-5678-2014
OI Cooks, R/0000-0002-9581-9603; Ferreira, Christina R/0000-0003-3988-6454;
   Oliveri, Paolo/0000-0002-3722-9461; 
FU German Academic Exchange Service (DAAD); Fundacion Gran Mariscal
   Ayacucho (FUNDAYACUCHO); L'Oreal/UNESCO Italia per le Donne e la Scienza
   grant; Purdue University Center for Cancer Research; Brazilian National
   Council for Scientific and Technological Development (CNPq); NSF IDBR
   [0852740]
FX AFGS was supported from the German Academic Exchange Service (DAAD) and
   the Fundacion Gran Mariscal Ayacucho (FUNDAYACUCHO); VP was supported
   from the "L'Oreal/UNESCO Italia per le Donne e la Scienza 2013" grant;
   CF was supported from the Purdue University Center for Cancer Research
   Small Grants and from the Brazilian National Council for Scientific and
   Technological Development (CNPq); RGC by NSF IDBR 0852740. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aardema H, 2011, BIOL REPROD, V85, P62, DOI 10.1095/biolreprod.110.088815
   Adamiak SJ, 2006, REPRODUCTION, V131, P247, DOI 10.1530/rep.1.00871
   Blanchet L, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-254
   Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041
   BUNGARTZ L, 1995, THERIOGENOLOGY, V43, P667, DOI 10.1016/0093-691X(94)00072-3
   Campbell BK, 2003, REPRODUCTION, P429
   Chen MX, 2011, CURR DIABETES REV, V7, P426, DOI 10.2174/157339911797579151
   Dabelea D, 2011, DIABETES, V60, P1849, DOI 10.2337/db11-0400
   Diederich M, 2012, REPRODUCTION, V144, P319, DOI 10.1530/REP-12-0134
   Driver AM, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-118
   Eberlin LS, 2013, P NATL ACAD SCI USA, V110, P1611, DOI 10.1073/pnas.1215687110
   Eberlin LS, 2011, CHEMBIOCHEM, V12, P2129, DOI 10.1002/cbic.201100411
   ECKERT J, 1995, THERIOGENOLOGY, V43, P1211, DOI 10.1016/0093-691X(95)00093-N
   Fahy E, 2007, NUCLEIC ACIDS RES, V35, pW606, DOI 10.1093/nar/gkm324
   Ferreira CR, 2012, J MASS SPECTROM, V47, P29, DOI 10.1002/jms.2022
   Ferreira CR, 2012, ANAL BIOANAL CHEM, V404, P2915, DOI 10.1007/s00216-012-6426-4
   Ferreira CR, 2010, J LIPID RES, V51, P1218, DOI 10.1194/jlr.D001768
   Fouladi-Nashta AA, 2009, REPRODUCTION, V138, P771, DOI 10.1530/REP-08-0391
   Gad A, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.099697
   Garcia-Reyes JF, 2009, ANAL CHEM, V81, P820, DOI 10.1021/ac802166v
   Gulliver CE, 2012, ANIM REPROD SCI, V131, P9, DOI 10.1016/j.anireprosci.2012.02.002
   Haaf T, 2006, CURR TOP MICROBIOL, V310, P13
   Heinzmann J, 2011, MOL REPROD DEV, V78, P188, DOI 10.1002/mrd.21281
   Jackson AU, 2011, ANAL BIOANAL CHEM, V399, P367, DOI 10.1007/s00216-010-4349-5
   Jolliffe I, 2002, PRINCIPAL COMPONENT
   Jungheim ES, 2011, BIOL REPROD, V85, P678, DOI 10.1095/biolreprod.111.092148
   Kennedy JH, 2010, ANAL CHEM, V82, P7502, DOI 10.1021/ac101295g
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim SK, 2012, ADV FOOD NUTR RES, V65, P223, DOI 10.1016/B978-0-12-416003-3.00014-7
   Konigsdorf CAI, 2012, OBESITY FACTS, V5, P575, DOI 10.1159/000342583
   Kues WA, 2008, P NATL ACAD SCI USA, V105, P19768, DOI 10.1073/pnas.0805616105
   Lazzari G, 2002, BIOL REPROD, V67, P767, DOI 10.1095/biolreprod.102.004481
   Leroy JLMR, 2010, HUM REPROD, V25, P768, DOI 10.1093/humrep/dep420
   Leroy JLMR, 2005, REPRODUCTION, V130, P485, DOI 10.1530/rep.1.00735
   Leroy JLMR, 2005, THERIOGENOLOGY, V64, P2022, DOI 10.1016/j.theriogenology.2005.05.003
   LOEWENSTEIN JE, 1964, J EMBRYOL EXP MORPH, V12, P113
   Marei WF, 2012, REPROD FERT DEVELOP, V24, P679, DOI 10.1071/RD11204
   Marei WF, 2010, REPRODUCTION, V139, P979, DOI 10.1530/REP-09-0503
   Marei WF, 2009, BIOL REPROD, V81, P1064, DOI 10.1095/biolreprod.109.076851
   Matorras R, 1998, HUM REPROD, V13, P2227, DOI 10.1093/humrep/13.8.2227
   McEvoy TG, 2000, J REPROD FERTIL, V118, P163, DOI 10.1530/reprod/118.1.163
   McKeegan PJ, 2012, REPROD FERT DEVELOP, V24, P59, DOI 10.1071/RD11907
   Niemann H, 2000, THERIOGENOLOGY, V53, P21, DOI 10.1016/S0093-691X(99)00237-X
   Niemann H, 2010, CELL REPROGRAM, V12, P33, DOI 10.1089/cell.2009.0063
   Pereira RM, 2008, CELL TISSUE BANK, V9, P267, DOI 10.1007/s10561-008-9075-2
   Pirro V, 2012, ANALYST, V137, P2374, DOI 10.1039/c2an35122f
   Prates EG, 2013, IN VITRO CELL DEV-AN, V49, P335, DOI 10.1007/s11626-013-9624-2
   Rienzi L, 2012, HUM REPROD, V27, P1606, DOI 10.1093/humrep/des088
   Seal JR, 2003, J AM SOC MASS SPECTR, V14, P872, DOI 10.1016/S1044-0305(03)00339-8
   Sinclair KD, 2000, HUM REPROD, V15, P68, DOI 10.1093/humrep/15.suppl_5.68
   Spanova M, 2012, BBA-MOL CELL BIOL L, V1821, P647, DOI 10.1016/j.bbalip.2012.01.015
   Ta MT, 2012, FEBS J, V279, P4231, DOI 10.1111/febs.12015
   Van Hoeck V, 2013, REPRODUCTION, V145, P33, DOI 10.1530/REP-12-0174
   Van Hoeck V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023183
   WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001
   WALKER SK, 1992, THERIOGENOLOGY, V37, P111, DOI 10.1016/0093-691X(92)90250-U
   Wrenzycki C, 2001, HUM REPROD, V16, P893, DOI 10.1093/humrep/16.5.893
   Wrenzycki C, 2007, THERIOGENOLOGY, V68, pS77, DOI 10.1016/j.theriogenology.2007.04.028
   Wrenzycki C, 2000, J REPROD FERTIL, V118, P69, DOI 10.1530/reprod/118.1.69
   Wrenzycki Christine, 2005, Birth Defects Res C Embryo Today, V75, P1, DOI 10.1002/bdrc.20035
   Wu LDL, 2012, MOL ENDOCRINOL, V26, P562, DOI 10.1210/me.2011-1362
   Wu LLY, 2012, REPROD FERT DEVELOP, V24, P29, DOI 10.1071/RD11904
   Wu LLY, 2010, ENDOCRINOLOGY, V151, P5438, DOI 10.1210/en.2010-0551
   2013, FERTIL STERIL, V99, P37, DOI DOI 10.1016/J.FERTNSTERT.2012.09.028.PUBMED:23083924
NR 64
TC 35
Z9 38
U1 2
U2 66
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 20
PY 2013
VL 8
IS 9
AR UNSP e74981
DI 10.1371/journal.pone.0074981
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 222YC
UT WOS:000324768000040
PM 24073231
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Monz, D
   Tutdibi, E
   Mildau, C
   Shen, J
   Kasoha, M
   Laschke, MW
   Roolfs, T
   Schmiedl, A
   Tschernig, T
   Bieback, K
   Gortner, L
AF Monz, Dominik
   Tutdibi, Erol
   Mildau, Celine
   Shen, Jie
   Kasoha, Mariz
   Laschke, Matthias W.
   Roolfs, Torge
   Schmiedl, Andreas
   Tschernig, Thomas
   Bieback, Karen
   Gortner, Ludwig
TI Human Umbilical Cord Blood Mononuclear Cells in a Double-Hit Model of
   Bronchopulmonary Dysplasia in Neonatal Mice
SO PLOS ONE
LA English
DT Article
ID INDUCED LUNG INJURY; MESENCHYMAL STEM-CELLS; REAL-TIME PCR; MOUSE MODEL;
   TRANSFORMING GROWTH-FACTOR-BETA-1; MTOR; DISEASE; PREVENTION; THERAPY;
   HYPOXIA
AB Background: Bronchopulmonary dysplasia (BPD) presents a major threat of very preterm birth and treatment options are still limited. Stem cells from different sources have been used successfully in experimental BPD, induced by postnatal hyperoxia.
   Objectives: We investigated the effect of umbilical cord blood mononuclear cells (MNCs) in a new double-hit mouse model of BPD.
   Methods: For the double-hit, date mated mice were subjected to hypoxia and thereafter the offspring was exposed to hyperoxia. Human umbilical cord blood MNCs were given intraperitoneally by day P7. As outcome variables were defined: physical development (auxology), lung structure (histomorphometry), expression of markers for lung maturation and inflammation on mRNA and protein level. Pre- and postnatal normoxic pups and sham treated double-hit pups served as control groups.
   Results: Compared to normoxic controls, sham treated double-hit animals showed impaired physical and lung development with reduced alveolarization and increased thickness of septa. Electron microscopy revealed reduced volume density of lamellar bodies. Pulmonary expression of mRNA for surfactant proteins B and C, Mtor and Crabp1 was reduced. Expression of Igf1 was increased. Treatment with umbilical cord blood MNCs normalized thickness of septa and mRNA expression of Mtor to levels of normoxic controls. Tgfb3 mRNA expression and pro-inflammatory IL-1 beta protein concentration were decreased.
   Conclusion: The results of our study demonstrate the therapeutic potential of umbilical cord blood MNCs in a new double-hit model of BPD in newborn mice. We found improved lung structure and effects on molecular level. Further studies are needed to address the role of systemic administration of MNCs in experimental BPD.
C1 [Monz, Dominik; Tutdibi, Erol; Mildau, Celine; Shen, Jie; Kasoha, Mariz; Gortner, Ludwig] Univ Saarland, Dept Pediat & Neonatol, Homburg, Saar, Germany.
   [Shen, Jie] Third Mil Med Univ, Daping Hosp, Dept Pediat, Chongqing, Peoples R China.
   [Laschke, Matthias W.] Univ Saarland, Inst Clin & Expt Surg, Homburg, Saar, Germany.
   [Roolfs, Torge; Schmiedl, Andreas] Hannover Med Sch, Inst Funct & Appl Anat, Hannover, Germany.
   [Tschernig, Thomas] Univ Saarland, Inst Anat & Cell Biol, Homburg, Saar, Germany.
   [Bieback, Karen] Heidelberg Univ, Inst Transfus Med & Immunol, Mannheim, Germany.
RP Gortner, L (reprint author), Univ Saarland, Dept Pediat & Neonatol, Homburg, Saar, Germany.
EM ludwig.gortner@uks.eu
FU Sino-German Center for Research Promotion
FX This work was in part supported by the Sino-German Center for Research
   Promotion. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. No
   additional external funding received for this study.
CR Ahlfeld SK, 2012, BIRTH DEFECTS RES A, V94, P3, DOI 10.1002/bdra.22869
   Alejandre-Alcazar MA, 2007, AM J PHYSIOL-LUNG C, V292, pL537, DOI 10.1152/ajplung.00050.2006
   Aslam M, 2009, AM J RESP CRIT CARE, V180, P1122, DOI 10.1164/rccm.200902-0242OC
   Baker CD, 2013, THORAX, V68, P402, DOI 10.1136/thoraxjnl-2012-202661
   Bassler D, 2009, PEDIATRICS, V123, P313, DOI 10.1542/peds.2008-0377
   Bry K, 2010, SEMIN PERINATOL, V34, P211, DOI [10.1053/j.sempen.2010.02.006, 10.1053/j.semperi.2010.02.006]
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cerny L, 2008, LUNG, V186, P75, DOI 10.1007/s00408-007-9069-z
   Chang YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052419
   Chang YS, 2009, CELL TRANSPLANT, V18, P869, DOI 10.3727/096368909X471189
   Deakins KM, 2009, RESP CARE, V54, P1252
   FEHRENBACH H, 1998, METHODS PULMONARY RE, P429, DOI DOI 10.1007/978-3-0348-8855-4_17
   Fielhaber JA, 2012, J IMMUNOL, V188, P4535, DOI 10.4049/jimmunol.1003655
   Gauldie J, 2003, AM J PATHOL, V163, P2575, DOI 10.1016/S0002-9440(10)63612-7
   Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473
   Gluckman PD, 2007, AM J HUM BIOL, V19, P1, DOI 10.1002/ajhb.20590
   Goncharova EA, 2013, FASEB J, V27, P1796, DOI 10.1096/fj.12-222224
   Gortner L, 2005, BIOL NEONATE, V88, P129, DOI 10.1159/000085895
   Gortner L, 2013, ANN ANAT, V195, P351, DOI 10.1016/j.aanat.2013.02.010
   Gortner L, 2011, NEONATOLOGY, V99, P112, DOI 10.1159/000313024
   Heimfeld S, 2003, LEUKEMIA, V17, P856, DOI 10.1038/sj.leu.2402893
   Hochberg Ze'ev, 2011, Front Endocrinol (Lausanne), V2, P41, DOI 10.3389/fendo.2011.00041
   Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST
   Hwang SK, 2011, BMB REP, V44, P506, DOI 10.5483/BMBRep.2011.44.8.506
   Jobe AH, 2011, CURR OPIN PEDIATR, V23, P167, DOI 10.1097/MOP.0b013e3283423e6b
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kogler G, 2009, BONE MARROW TRANSPL, V44, P683, DOI 10.1038/bmt.2009.287
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Maritz GS, 2001, PEDIATR PULM, V32, P201, DOI 10.1002/ppul.1109
   Mayani H, 2003, ARCH MED RES, V34, P476, DOI 10.1016/j.arcmed.2003.08.004
   O'Reilly M, 2013, CLIN EXP PHARM PHYSL
   Pereira-Cunha FG, 2013, TRANSFUSION, V53, P2034, DOI 10.1111/trf.12078
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pierro M, 2012, THORAX, V68, P475
   Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4
   Rosner M, 2008, MUTAT RES-REV MUTAT, V659, P284, DOI 10.1016/j.mrrev.2008.06.001
   Santibanez JF, 2011, CLIN SCI, V121, P233, DOI 10.1042/CS20110086
   Sng J, 2012, STEM CELLS INT, V2012, DOI DOI 10.1155/2012/521343
   Tutdibi E, 2012, J PERINAT MED, V40, P527, DOI 10.1515/jpm-2011-0204
   van Haaften T, 2009, AM J RESP CRIT CARE, V180, P1131, DOI 10.1164/rccm.200902-0179OC
   Van Marter LJ, 2011, ARCH DIS CHILD-FETAL, V96, pF20, DOI 10.1136/adc.2010.183012
   Vicencio AG, 2004, AM J RESP CELL MOL, V31, P650, DOI 10.1165/rcmb.2004-0092OC
   Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x
   Warburton D, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S2
   Wright RJ, 2010, BIOL PSYCHOL, V84, P46, DOI 10.1016/j.biopsycho.2010.01.007
   Yeh TF, 2004, NEW ENGL J MED, V350, P1304, DOI 10.1056/NEJMoa032089
   Zeitlin J, 2010, J PEDIATR-US, V157, P733, DOI 10.1016/j.jpeds.2010.05.002
   Zhang XY, 2012, CELL BIOL INT, V36, P589, DOI 10.1042/CBI20110447
NR 48
TC 23
Z9 24
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2013
VL 8
IS 9
AR e74740
DI 10.1371/journal.pone.0074740
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 223BC
UT WOS:000324777300042
PM 24069341
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Li, XH
   Wang, JJ
   Jia, ZQ
   Cui, QH
   Zhang, CG
   Wang, WP
   Chen, P
   Ma, KT
   Zhou, CY
AF Li, Xianhui
   Wang, Jiaji
   Jia, Zhuqing
   Cui, Qinghua
   Zhang, Chenguang
   Wang, Weiping
   Chen, Ping
   Ma, Kangtao
   Zhou, Chunyan
TI MiR-499 Regulates Cell Proliferation and Apoptosis during Late-Stage
   Cardiac Differentiation via Sox6 and Cyclin D1
SO PLOS ONE
LA English
DT Article
ID DOWN-REGULATION; EXPRESSION; HEART; GENE; REGENERATION; MICRORNA; DEATH
AB Background: MiR-499 is a cardiac-abundant miRNA. However, the biological functions of miR-499 in differentiated cardiomyocytes or in the cardiomyocyte differentiation process is not very clear. Sox6 is believed to be one of its targets, and is also believed to play a role in cardiac differentiation. Therefore, our aim was to investigate the association between Sox6 and miR-499 during cardiac differentiation.
   Methodology/Principal Findings: Using a well-established in vitro cardiomyocyte differentiation system, mouse P19CL6 cells, we found that miR-499 was highly expressed in the late stage of cardiac differentiation. In cells stably transfected with miR-499 (P-499 cells), it was found that miR-499 could promote the differentiation into cardiomyocytes at the early stage of cardiac differentiation. Notably, cell viability assay, EdU incorporation assay, and cell cycle profile analysis all showed that the P-499 cells displayed the distinctive feature of hyperplastic growth. Further investigation confirmed that miR-499 could promote neonatal rat cardiomyocyte proliferation. MiR-499 knockdown enhanced apoptosis in the late differentiation stage in P19CL6 cells, but overexpression of miR-499 resulted in a decrease in the apoptosis rate. Sox6 was identified as a direct target of miR-499 and its expression was detected from day 8 or day 10 of cardiac differentiation of P19CL6 cells. Sox6 played a role in cell viability, inhibited cell proliferation and promoted cell apoptosis in P19CL6 cells and cardiomyocytes. The overexpression of Sox6 could reverse the proliferation and anti-apoptosis effects of miR-499. It was also found that miR-499 might exert its function by regulating cyclin D1 via its influence on Sox6.
   Conclusions/Significance: miR-499 probably regulates the proliferation and apoptosis of P19CL6 cells in the late stage of cardiac differentiation via its effects on Sox6 and cyclin D1.
C1 [Li, Xianhui; Wang, Jiaji; Jia, Zhuqing; Zhang, Chenguang; Wang, Weiping; Chen, Ping; Ma, Kangtao; Zhou, Chunyan] Peking Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Mol Cardiovasc Sci,Minist Educ China, Beijing 100871, Peoples R China.
   [Cui, Qinghua] Peking Univ, Sch Basic Med Sci, Dept Biomed Informat, Beijing 100871, Peoples R China.
RP Jia, ZQ (reprint author), Peking Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Mol Cardiovasc Sci,Minist Educ China, Beijing 100871, Peoples R China.
EM zhuqingjia@bjmu.edu.cn; chunyanzhou@bjmu.edu.cn
FU National Natural Science Foundation of China [81070112, 81071675,
   81170713]; Specialized Research Fund for the Doctoral Program of Higher
   Education [20110001130001]; Natural Science Foundation of Beijing, China
   [5122021]; Leading Academic Discipline Project of Beijing Education
   Bureau; 111 Project of China [B07001]
FX This work was supported by the National Natural Science Foundation of
   China (81070112, 81071675, 81170713), Specialized Research Fund for the
   Doctoral Program of Higher Education (20110001130001), the Natural
   Science Foundation of Beijing, China (5122021), Leading Academic
   Discipline Project of Beijing Education Bureau, and the 111 Project of
   China (B07001). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006
   Batista-Brito R, 2009, NEURON, V63, P466, DOI 10.1016/j.neuron.2009.08.005
   Bell ML, 2010, MOL CELL BIOL, V30, P1937, DOI 10.1128/MCB.01370-09
   Buja LM, 2008, CARDIOVASC PATHOL, V17, P349, DOI 10.1016/j.carpath.2008.02.004
   Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753
   Cohen-Barak G, 2001, GENE, V265, P157, DOI 10.1016/S0378-1119(01)00346-8
   Cohen-Barak O, 2003, NUCLEIC ACIDS RES, V31, P5941, DOI 10.1093/nar/gkg807
   Dumitriu B, 2006, BLOOD, V108, P1198, DOI 10.1182/blood-2006-02-004184
   EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280
   Fu JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027417
   HabaraOhkubo A, 1996, CELL STRUCT FUNCT, V21, P101, DOI 10.1247/csf.21.101
   Hagiwara N, 2000, P NATL ACAD SCI USA, V97, P4180, DOI 10.1073/pnas.97.8.4180
   Hosoda T, 2011, CIRCULATION, V123, P1287, DOI 10.1161/CIRCULATIONAHA.110.982918
   Iguchi H, 2007, J BIOL CHEM, V282, P19052, DOI 10.1074/jbc.M700460200
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Li FQ, 1996, J MOL CELL CARDIOL, V28, P1737, DOI 10.1006/jmcc.1996.0163
   McCarthy JJ, 2009, PHYSIOL GENOMICS, V39, P219, DOI 10.1152/physiolgenomics.00042.2009
   Monzen K, 2002, BIOCHEM BIOPH RES CO, V298, P493, DOI 10.1016/S0006-291X(02)02497-X
   Nishi K, 2009, J CELL BIOCHEM, V106, P63, DOI 10.1002/jcb.21978
   Shieh JTC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019481
   Sluijter JPG, 2010, ARTERIOSCL THROM VAS, V30, P859, DOI 10.1161/ATVBAHA.109.197434
   Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X
   Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15
   van Amerongen MJ, 2008, J CELL MOL MED, V12, P2233, DOI 10.1111/j.1582-4934.2008.00439.x
   van Rooij E, 2009, DEV CELL, V17, P662, DOI 10.1016/j.devcel.2009.10.013
   Wilson KD, 2010, CIRC-CARDIOVASC GENE, V3, P426, DOI 10.1161/CIRCGENETICS.109.934281
NR 26
TC 36
Z9 44
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 11
PY 2013
VL 8
IS 9
AR e74504
DI 10.1371/journal.pone.0074504
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 248VW
UT WOS:000326734500098
PM 24040263
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wang, HD
   Li, CH
   Hu, JJ
   Xu, HB
   Ji, X
   Wang, XF
   Wang, XD
   Luo, YK
   Li, HL
   Xu, KS
   Ye, S
   Zhang, AQ
   Dong, JH
AF Wang, Hongdong
   Li, Chonghui
   Hu, Jianjun
   Xu, Hongbin
   Ji, Xu
   Wang, Xiaofeng
   Wang, Xuedong
   Luo, Yukun
   Li, Hailin
   Xu, Kesen
   Ye, Sheng
   Zhang, Aiqun
   Dong, Jiahong
TI Effect of Different Suprahepatic Vena Cava Reconstruction Methods on the
   Hemodynamics of Rats after Liver Transplantation
SO PLOS ONE
LA English
DT Article
ID TIME TISSUE ELASTOGRAPHY; CUFF TECHNIQUE; SPLANCHNIC HEMODYNAMICS;
   NONINVASIVE ASSESSMENT; CIRRHOTIC RATS; FIBROSIS; ANASTOMOSIS;
   HEPATITIS; DIAGNOSIS
AB Background: There are few studies on the hemodynamic changes after orthotopic liver transplantation in rats. In this study, we aimed to evaluate the effect of different suprahepatic vena cava (SHVC) reconstruction methods on the hemodynamics of rats after liver transplantation.
   Materials and Methods: Three rat liver transplantation groups were created according to the SHVC reconstruction method: Kamada's two-cuff technique, a modified veno-lined stent technique, and Harihara's three-cuff technique. Ten rats of similar weight were grouped as the control. Anatomical, ultrasonic, and hemodynamic parameters and the microcirculation of the liver were measured after transplantation. The detailed operation time, operative complications, and animal survival were recorded.
   Results: All the recipients showed portal hypertension one month after transplantation. The portal hypertension in the group with the modified veno-lined stent technique was the most severe. The value measured with real-time elastography was significantly higher in the recipients using the modified veno-lined stent technique than in the other two groups (P<0.01). There was no difference in the graft microcirculation after reperfusion among the three groups. The survival rate of the three groups displayed no difference, but the modified veno-lined stent technique led to more venous complications than the other two techniques.
   Conclusions: The hemodynamics after liver transplantation in rats is determined not only by the cuff used for portal vein reconstruction but also by the cuff or stent for the SHVC. Some SHVC reconstruction methods, such as the modified veno-lined stent technique, Miyata's or Settaf's three-cuff techniques, significantly affect the hemodynamics.
C1 [Wang, Hongdong; Li, Hailin; Xu, Kesen; Dong, Jiahong] Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan 250100, Shandong, Peoples R China.
   [Li, Chonghui; Hu, Jianjun; Xu, Hongbin; Wang, Xiaofeng; Wang, Xuedong; Ye, Sheng; Zhang, Aiqun; Dong, Jiahong] Peoples Liberat Army Gen Hosp, Hosp & Inst Hepatobiliary Surg, Beijing, Peoples R China.
   [Ji, Xu] PLA, Hosp 302, Dept Hepatobiliary Surg, Beijing, Peoples R China.
   [Luo, Yukun] Peoples Liberat Army Gen Hosp, Dept Ultrasound, Beijing, Peoples R China.
RP Dong, JH (reprint author), Peoples Liberat Army Gen Hosp, Hosp & Inst Hepatobiliary Surg, Beijing, Peoples R China.
EM dongjh301@163.com
FU National Natural Science Foundation of China [81070383, 30972950,
   81271588]
FX This study was supported by Grants from National Natural Science
   Foundation of China, No. (81070383), No. (30972950), and No. (81271588).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Blain B, 2001, MICROSURG, V21, P80, DOI 10.1002/micr.1014
   Cao H, 2003, CHINESE MED J-PEKING, V116, P405
   Cao H, 2000, CHINESE MED J-PEKING, V113, P1108
   Colombo S, 2012, J GASTROENTEROL, V47, P461, DOI 10.1007/s00535-011-0509-4
   Delriviere L, 1998, MICROSURG, V18, P12, DOI 10.1002/(SICI)1098-2752(1998)18:1<12::AID-MICR4>3.0.CO;2-W
   Delriviere Luc, 1996, Microsurgery, V17, P690, DOI 10.1002/(SICI)1098-2752(1996)17:12<690::AID-MICR6>3.0.CO;2-R
   Friedrich-Rust M, 2009, ULTRASCHALL MED, V30, P478, DOI 10.1055/s-0028-1109488
   Friedrich-Rust M, 2007, AM J ROENTGENOL, V188, P758, DOI 10.2214/AJR.06.0322
   HARIHARA Y, 1992, TRANSPLANTATION, V53, P707
   Higgins GM, 1931, ARCH PATHOL, V12, P186
   Holzen JP, 2005, MICROSURG, V25, P614, DOI 10.1002/micr.20174
   Hori T, 2010, WORLD J GASTROENTERO, V16, P3120, DOI 10.3748/wjg.v16.i25.3120
   Imamura H, 1997, HEPATOLOGY, V26, P198
   Ishii E, 2013, J NIPPON MED SCH, V80, P4, DOI 10.1272/jnms.80.4
   KAMADA N, 1983, SURGERY, V93, P64
   Kanamoto M, 2009, J HEPATO-BILIARY-PAN, V16, P463, DOI 10.1007/s00534-009-0075-9
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koizumi Y, 2011, RADIOLOGY, V258, P610, DOI 10.1148/radiol.10100319
   KUZNETSOVA LV, 1995, AM J PHYSIOL-GASTR L, V269, pG153
   McGuire PG, 2010, J SURG RES, V164, pE201, DOI 10.1016/j.jss.2010.07.059
   MIYATA M, 1980, TRANSPLANTATION, V30, P335, DOI 10.1097/00007890-198011000-00005
   Ochi H, 2012, HEPATOLOGY, V56, P1271, DOI 10.1002/hep.25756
   SETTAF A, 1986, TRANSPLANTATION, V42, P330
   Tan FQ, 2005, MICROSURG, V25, P556, DOI 10.1002/micr.20161
   TSUCHIMOTO S, 1988, TRANSPLANTATION, V45, P1153
   Wong J, 2001, CAN J GASTROENTEROL, V15, P435, DOI 10.1155/2001/190508
   ZHAO DL, 1993, HEPATOLOGY, V17, P310, DOI 10.1002/hep.1840170224
NR 27
TC 1
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 4
PY 2013
VL 8
IS 9
AR e72695
DI 10.1371/journal.pone.0072695
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219OE
UT WOS:000324515600036
PM 24023763
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Rieger, T
   Merkler, D
   Gunther, S
AF Rieger, Toni
   Merkler, Doron
   Guenther, Stephan
TI Infection of Type I Interferon Receptor-Deficient Mice with Various Old
   World Arenaviruses: A Model for Studying Virulence and Host Species
   Barriers
SO PLOS ONE
LA English
DT Article
ID LASSA VIRUS-INFECTION; HUMAN DENDRITIC CELLS; MASTOMYS-NATALENSIS;
   RHESUS-MONKEYS; WEST-AFRICA; FEVER ENCEPHALOPATHY; MOPEIA VIRUS;
   SIERRA-LEONE; GUINEA-PIGS; NUCLEOPROTEIN
AB Lassa virus causes hemorrhagic Lassa fever in humans, while the related Old World arenaviruses Mopeia, Morogoro, and Mobala are supposedly apathogenic to humans and cause only inapparent infection in non-human primates. Here, we studied whether the virulence of Old World arenaviruses in humans and non-human primates is reflected in type I interferon receptor deficient (IFNAR(-/-)) mice by testing several strains of Lassa virus vs. the apathogenic viruses Mopeia, Morogoro, and Mobala. All Lassa virus strains tested-Josiah, AV, BA366, and Nig04-10-replicated to high titers in blood, lung, kidney, heart, spleen, brain, and liver and caused disease as evidenced by weight loss and elevation of aspartate and alanine aminotransferase (AST and ALT) levels with a high AST/ALT ratio. Lassa fever-like pathology included acute hepatitis, interstitial pneumonia, and pronounced disturbance of splenic cytoarchitecture. Infiltrations of activated monocytes/macrophages expressing inducible nitric oxide synthase and T cells were found in liver and lung. In contrast, Mopeia, Morogoro, and Mobala virus replicated poorly in the animals and acute inflammatory alterations were not noted. Depletion of CD4(+) and CD8(+) T cells strongly enhanced susceptibility of IFNAR(-/-) mice to the apathogenic viruses. In conclusion, the virulence of Old World arenaviruses in IFNAR(-/-) mice correlates with their virulence in humans and non-human primates. In addition to the type I interferon system, T cells seem to regulate whether or not an arenavirus can productively infect non-host rodent species. The observation that Lassa virus overcomes the species barrier without artificial depletion of T cells suggests it is able to impair T cell functionality in a way that corresponds to depletion.
C1 [Rieger, Toni; Guenther, Stephan] Bernhard Nocht Inst Trop Med, Dept Virol, D-20359 Hamburg, Germany.
   [Rieger, Toni; Guenther, Stephan] German Ctr Infect Res DZIF, Hamburg, Germany.
   [Merkler, Doron] Univ Gottingen, Dept Neuropathol, D-37073 Gottingen, Germany.
   [Merkler, Doron] Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland.
   [Merkler, Doron] Dept Pathol & Immunol, Geneva, Switzerland.
RP Gunther, S (reprint author), Bernhard Nocht Inst Trop Med, Dept Virol, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
EM guenther@bni.uni-hamburg.de
RI Merkler, Doron/N-9157-2016
OI Merkler, Doron/0000-0002-0247-2007; Gunther, Stephan/0000-0002-6562-0230
FU European Community [228292]; Swiss National Science Foundation [PP00P3
   128372]
FX This study was supported by grant 228292 (European Virus Archive) from
   the European Community. DM is supported by the Swiss National Science
   Foundation (PP00P3 128372). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Asogun DA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001839
   Baize S, 2004, J IMMUNOL, V172, P2861, DOI 10.4049/jimmunol.172.5.2861
   Baize S, 2009, J VIROL, V83, P5890, DOI 10.1128/JVI.01948-08
   CALLIS RT, 1982, AM J TROP MED HYG, V31, P1038, DOI 10.4269/ajtmh.1982.31.1038
   Coulibaly-N'Golo D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020893
   CUMMINS D, 1992, J TROP MED HYG, V95, P197
   Fichet-Calvet E, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000388
   FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857
   Flatz L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000836
   FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670
   Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752
   GONZALEZ JP, 1983, INTERVIROLOGY, V19, P105, DOI 10.1159/000149344
   Grove JN, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-314
   Gunther S, 2009, EMERG INFECT DIS, V15, P2008, DOI 10.3201/eid1512.090864
   Gunther S, 2000, EMERG INFECT DIS, V6, P466, DOI 10.3201/eid0605.000504
   Gunther S, 2004, CRIT REV CL LAB SCI, V41, P339, DOI 10.1080/10408360490497456
   Gunther S, 2001, J INFECT DIS, V184, P345, DOI 10.1086/322033
   HUFERT FT, 1989, ARCH VIROL, V106, P201, DOI 10.1007/BF01313953
   JAHRLING PB, 1980, J INFECT DIS, V141, P580, DOI 10.1093/infdis/141.5.580
   JAHRLING PB, 1985, T ROY SOC TROP MED H, V79, P374, DOI 10.1016/0035-9203(85)90386-4
   JAHRLING PB, 1982, INFECT IMMUN, V37, P771
   JOHNSON KM, 1981, AM J TROP MED HYG, V30, P1291, DOI 10.4269/ajtmh.1981.30.1291
   Kerber R, 2011, J VIROL, V85, P12518, DOI 10.1128/JVI.05091-11
   KILEY MP, 1979, LANCET, V2, P738
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   LANGE JV, 1985, AM J TROP MED HYG, V34, P999, DOI 10.4269/ajtmh.1985.34.999
   Lecompte E, 2006, EMERG INFECT DIS, V12, P1971
   LUKASHEVICH IS, 1992, VIROLOGY, V188, P600, DOI 10.1016/0042-6822(92)90514-P
   LUKASHEVICH IS, 1983, ACTA VIROL, V27, P282
   Mahanty S, 2003, J IMMUNOL, V170, P2797, DOI 10.4049/jimmunol.170.6.2797
   Martinez-Sobrido L, 2006, J VIROL, V80, P9192, DOI 10.1128/JVI.00555-06
   Martinez-Sobrido L, 2009, J VIROL, V83, P11330, DOI 10.1128/JVI.00763-09
   MCCORMICK JB, 1986, AM J TROP MED HYG, V35, P401, DOI 10.4269/ajtmh.1986.35.401
   MONATH TP, 1974, SCIENCE, V185, P263, DOI 10.1126/science.185.4147.263
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221
   Omilabu SA, 2005, EMERG INFECT DIS, V11, P1642, DOI 10.3201/eid1110.041343
   Pannetier D, 2011, J VIROL, V85, P8293, DOI 10.1128/JVI.02120-10
   PETERS CJ, 1987, CURR TOP MICROBIOL, V134, P5
   Safronetz D, 2010, EMERG INFECT DIS, V16, P1123, DOI 10.3201/eid1607.100146
   Schmitz H, 2002, MICROBES INFECT, V4, P43, DOI 10.1016/S1286-4579(01)01508-8
   WALKER DH, 1975, AM J PATHOL, V80, P261
   WALKER DH, 1975, B WORLD HEALTH ORGAN, V52, P523
   WALKER DH, 1982, J INFECT DIS, V146, P360, DOI 10.1093/infdis/146.3.360
   WALKER DH, 1982, AM J PATHOL, V107, P349
   WINN WC, 1975, B WORLD HEALTH ORGAN, V52, P535
   WULFF H, 1979, B WORLD HEALTH ORGAN, V57, P631
   WULFF H, 1977, B WORLD HEALTH ORGAN, V55, P441
   Yun NE, 2012, J VIROL, V86, P3389, DOI 10.1128/JVI.06284-11
   Zhou XH, 2004, COMPARATIVE MED, V54, P176
NR 50
TC 19
Z9 19
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2013
VL 8
IS 8
AR e72290
DI 10.1371/journal.pone.0072290
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 218ZA
UT WOS:000324470700034
PM 23991083
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Darias, MJ
   Andree, KB
   Boglino, A
   Rotllant, J
   Cerda-Reverter, JM
   Estevez, A
   Gisbert, E
AF Darias, Maria J.
   Andree, Karl B.
   Boglino, Anais
   Rotllant, Josep
   Miguel Cerda-Reverter, Jose
   Estevez, Alicia
   Gisbert, Enric
TI Morphological and Molecular Characterization of Dietary-Induced
   Pseudo-Albinism during Post-Embryonic Development of Solea senegalensis
   (Kaup, 1858)
SO PLOS ONE
LA English
DT Article
ID AGOUTI-SIGNALING PROTEIN; ZEBRAFISH NEURAL CREST; PIGMENT PATTERN;
   HIPPOGLOSSUS-HIPPOGLOSSUS; HUMAN MELANOCYTES; ARACHIDONIC-ACID; ATLANTIC
   HALIBUT; LIVE PREY; CELL FATE; C-KIT
AB The appearance of the pseudo-albino phenotype was investigated in developing Senegalese sole (Solea senegalensis, Kaup 1858) larvae at morphological and molecular levels. In order to induce the development of pseudo-albinos, Senegalese sole larvae were fed Artemia enriched with high levels of arachidonic acid (ARA). The development of their skin pigmentation was compared to that of a control group fed Artemia enriched with a reference commercial product. The relative amount of skin melanophores, xanthophores and iridophores revealed that larval pigmentation developed similarly in both groups. However, results from different relative proportions, allocation patterns, shapes and sizes of skin chromatophores revealed changes in the pigmentation pattern between ARA and control groups from 33 days post hatching onwards. The new populations of chromatophores that should appear at post-metamorphosis were not formed in the ARA group. Further, spatial patterns of distribution between the already present larval xanthophores and melanophores were suggestive of short-range interaction that seemed to be implicated in the degradation of these chromatophores, leading to the appearance of the pseudo-albino phenotype. The expression profile of several key pigmentation-related genes revealed that melanophore development was promoted in pseudo-albinos without a sufficient degree of terminal differentiation, thus preventing melanogenesis. Present results suggest the potential roles of asip1 and slc24a5 genes on the down-regulation of trp1 expression, leading to defects in melanin production. Moreover, gene expression data supports the involvement of pax3, mitf and asip1 genes in the developmental disruption of the new post-metamorphic populations of melanophores, xanthophores and iridophores.
C1 [Darias, Maria J.; Andree, Karl B.; Boglino, Anais; Estevez, Alicia; Gisbert, Enric] Inst Recerca & Tecnol Agroalimentaries, San Carlos de la Rapita, Catalunya, Spain.
   [Rotllant, Josep] CSIC, Inst Invest Marinas, Vigo, Galicia, Spain.
   [Miguel Cerda-Reverter, Jose] CSIC, Inst Acuicultura Torre Sal, Valencia, Spain.
RP Darias, MJ (reprint author), Inst Recerca & Tecnol Agroalimentaries, San Carlos de la Rapita, Catalunya, Spain.
EM maria.darias@ird.fr
RI Estevez, Alicia/K-7863-2014; Andree, Karl/L-7465-2014; Darias, Maria
   J./D-5715-2012; Gisbert, Enric/I-7224-2019; Rotllant, Josep/K-1146-2014;
   Cerda-Reverter, Jose Miguel/K-4934-2014; Gisbert, Enric/B-3654-2011
OI Estevez, Alicia/0000-0002-7776-0521; Andree, Karl/0000-0001-6564-0015;
   Darias, Maria J./0000-0003-1954-6284; Gisbert,
   Enric/0000-0002-7457-8468; Rotllant, Josep/0000-0001-5331-807X;
   Cerda-Reverter, Jose Miguel/0000-0003-1405-5750; Gisbert,
   Enric/0000-0002-7457-8468; Estevez, Alicia/0000-0002-3690-0532
FU Ministry of Science and Innovation (MICIIN) of the Spanish Government
   [AGL2008-03897-C04-01/ACU]; Juan de la Cierva post-doctoral contract
   (MICIIN, Spain)
FX This work was funded by the Ministry of Science and Innovation (MICIIN)
   of the Spanish Government (project AGL2008-03897-C04-01/ACU). MD was
   supported by a Juan de la Cierva post-doctoral contract (MICIIN, Spain).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125
   Aoki H, 2002, LIFE SCI, V71, P2171, DOI 10.1016/S0024-3205(02)01996-3
   Boglino A, 2012, AQUACULTURE, V324, P290, DOI 10.1016/j.aquaculture.2011.11.018
   Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907
   Canavate JP, 2006, AQUACULTURE, V258, P368, DOI 10.1016/j.aquaculture.2006.04.009
   Cerda-Reverter JM, 2003, ENDOCRINOLOGY, V144, P2336, DOI 10.1210/en.2002-0213
   Cerda-Reverter JM, 2005, ENDOCRINOLOGY, V146, P1597, DOI 10.1210/en.2004-1346
   Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254
   Curran K, 2010, DEV BIOL, V344, P107, DOI 10.1016/j.ydbio.2010.04.023
   Darias MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063005
   Fernandez-Diaz C, 2001, J FISH BIOL, V58, P1086, DOI 10.1006/jfbi.2000.1514
   Fujii R, 2000, PIGM CELL RES, V13, P300, DOI 10.1034/j.1600-0749.2000.130502.x
   Fukamachi S, 2004, P NATL ACAD SCI USA, V101, P10661, DOI 10.1073/pnas.0401278101
   Fukamachi S, 2009, GENE, V442, P81, DOI 10.1016/j.gene.2009.04.010
   Galibert MD, 1999, J BIOL CHEM, V274, P26894, DOI 10.1074/jbc.274.38.26894
   Gimenez G, 2006, AQUAC RES, V37, P1130, DOI 10.1111/j.1365-2109.2006.01537.x
   Ginger RS, 2008, J BIOL CHEM, V283, P5486, DOI 10.1074/jbc.M707521200
   Guillot R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048526
   Guo XL, 2010, PIGM CELL MELANOMA R, V23, P252, DOI 10.1111/j.1755-148X.2010.00677.x
   Hathaway Jessica Diann, 2011, Open Cancer J, V4, P1
   Hofreiter M, 2010, CELL MOL LIFE SCI, V67, P2591, DOI 10.1007/s00018-010-0333-7
   HUNT G, 1995, J INVEST DERMATOL, V104, P83, DOI 10.1111/1523-1747.ep12613565
   Kelsh RN, 1996, DEVELOPMENT, V123, P369
   Kelsh RN, 2004, PIGM CELL RES, V17, P326, DOI 10.1111/j.1600-0749.2004.00174.x
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klovins J, 2004, MOL BIOL EVOL, V21, P563, DOI 10.1093/molbev/msh050
   Kubic JD, 2008, PIGM CELL MELANOMA R, V21, P627, DOI 10.1111/j.1755-148X.2008.00514.x
   Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238
   Levy C, 2011, TRANSCR-AUSTIN, V2, P19, DOI 10.4161/trns.2.1.13650
   Lister JA, 2002, MICROSC RES TECHNIQ, V58, P435, DOI 10.1002/jemt.10161
   Lister JA, 1999, DEVELOPMENT, V126, P3757
   Logan DW, 2003, GENOMICS, V81, P184, DOI 10.1016/S0888-7543(02)00037-x
   Lund I, 2010, AQUACULTURE, V308, P159, DOI 10.1016/j.aquaculture.2010.08.004
   LUO D, 1995, MELANOMA RES, V5, P303, DOI 10.1097/00008390-199510000-00002
   Manchado M, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-107
   Mellgren EM, 2002, TRENDS GENET, V18, P128, DOI 10.1016/S0168-9525(01)02614-2
   Minchin JEN, 2008, DEV BIOL, V317, P508, DOI 10.1016/j.ydbio.2008.02.058
   Montoliu L., 2011, COLOR GENES
   Nadeau N, 2008, GENETICS, V178, P777, DOI 10.1534/genetics.107.077073
   Nakamasu A, 2009, P NATL ACAD SCI USA, V106, P8429, DOI 10.1073/pnas.0808622106
   Parichy DM, 2001, DEV GENES EVOL, V211, P319, DOI 10.1007/s004270100155
   Parichy DM, 2003, DEVELOPMENT, V130, P817, DOI 10.1242/dev.00307
   Patton EE, 2010, PIGM CELL MELANOMA R, V23, P314, DOI 10.1111/j.1755-148X.2010.00693.x
   Schallreuter KU, 2008, EXP DERMATOL, V17, P395, DOI 10.1111/j.1600-0625.2007.00675.x
   Seikai Tadahisa, 1994, Journal of the World Aquaculture Society, V25, P78, DOI 10.1111/j.1749-7345.1994.tb00807.x
   Solbakken JS, 1999, ENVIRON BIOL FISH, V56, P53, DOI 10.1023/A:1007542526040
   Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717
   Sviderskaya EV, 2001, DEV DYNAM, V221, P373, DOI 10.1002/dvdy.1153
   Uong A, 2010, J CELL PHYSIOL, V222, P38, DOI 10.1002/jcp.21935
   Villalta M, 2008, AQUACULT NUTR, V14, P120, DOI 10.1111/j.1365-2095.2007.00511.x
   Villalta M, 2005, AQUACULTURE, V245, P193, DOI 10.1016/j.aquaculture.2004.11.035
   Vogel P, 2008, VET PATHOL, V45, P264, DOI 10.1354/vp.45-2-264
   Yamada T, 2010, DEV DYNAM, V239, P3147, DOI 10.1002/dvdy.22440
NR 53
TC 8
Z9 8
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2013
VL 8
IS 7
AR e68844
DI 10.1371/journal.pone.0068844
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 186SF
UT WOS:000322064300074
PM 23874785
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Song, L
   Yang, YJ
   Dong, QT
   Qian, HY
   Gao, RL
   Qiao, SB
   Shen, R
   He, ZX
   Lu, MJ
   Zhao, SH
   Geng, YJ
   Gersh, BJ
AF Song, Lei
   Yang, Yue-Jin
   Dong, Qiu-Ting
   Qian, Hai-Yan
   Gao, Run-Lin
   Qiao, Shu-Bin
   Shen, Rui
   He, Zuo-Xiang
   Lu, Min-Jie
   Zhao, Shi-Hua
   Geng, Yong-Jian
   Gersh, Bernard J.
TI Atorvastatin Enhance Efficacy of Mesenchymal Stem Cells Treatment for
   Swine Myocardial Infarction via Activation of Nitric Oxide Synthase
SO PLOS ONE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; IN-VIVO; IMPROVES SURVIVAL; PROTEIN-KINASE;
   CARDIAC REPAIR; TRANSPLANTATION; HEARTS; TRACKING; STATINS
AB Background: In a swine model of acute myocardial infarction (AMI), Statins can enhance the therapeutic efficacy of mesenchymal stem cell (MSCs) transplantation. However, the mechanisms remain unclear. This study aims at assessing whether atorvastatin (Ator) facilitates the effects of MSCs through activation of nitric oxide synthase (NOS), especially endothelial nitric oxide synthase (eNOS), which is known to protect against ischemic injury.
   Methods and Results: 42 miniswines were randomized into six groups (n = 7/group): Sham operation; AMI control; Ator only; MSC only, Ator+MSCs and Ator+MSCs+NG-nitrol-L-arginine (L-NNA), an inhibitor of NOS. In an open-heart surgery, swine coronary artery ligation and reperfusion model were established, and autologous bone-marrow MSCs were injected intramyocardium. Four weeks after transplantation, compared with the control group, Ator+MSCs animals exhibited decreased defect areas of both "perfusion" defined by Single-Photon Emission Computed Tomography (-6.2 +/- 1.8% vs. 2.0 +/- 5.1%, P = 0.0001) and "metabolism" defined by Positron Emission Tomography (-3.00 +/- 1.41% vs. 4.20 +/- 4.09%, P = 0.0004); Ejection fraction by Magnetic Resonance Imaging increased substantially (14.22 +/- 12.8% vs. 1.64 +/- 2.64%, P = 0.019). In addition, indices of inflammation, fibrosis, and apoptosis were reduced and survivals of MSCs or MSC-derived cells were increased in Ator+MSCs animals. In Ator or MSCs alone group, perfusion, metabolism, inflammation, fibrosis or apoptosis were reduced but there were no benefits in terms of heart function and cell survival. Furthermore, the above benefits of Ator+MSCs treatment could be partially blocked by L-NNA.
   Conclusions: Atorvastatin facilitates survival of implanted MSCs, improves function and morphology of infarcted hearts, mediated by activation of eNOS and alleviated by NOS inhibitor. The data reveal the cellular and molecular mechanism for anti-AMI therapy with a combination of statin and stem cells.
C1 [Song, Lei; Yang, Yue-Jin; Dong, Qiu-Ting; Qian, Hai-Yan; Gao, Run-Lin; Qiao, Shu-Bin] Chinese Acad Med Sci, Fuwai Hosp, Coronary Heart Dis Ctr, Dept Cardiol, Beijing 100730, Peoples R China.
   [Song, Lei; Yang, Yue-Jin; Dong, Qiu-Ting; Qian, Hai-Yan; Gao, Run-Lin; Qiao, Shu-Bin; Shen, Rui; He, Zuo-Xiang; Lu, Min-Jie; Zhao, Shi-Hua] Chinese Acad Med Sci, Cardiovasc Inst, State Key Lab Cardiovasc Dis, Beijing 100730, Peoples R China.
   [Song, Lei; Yang, Yue-Jin; Dong, Qiu-Ting; Qian, Hai-Yan; Gao, Run-Lin; Qiao, Shu-Bin; Shen, Rui; He, Zuo-Xiang; Lu, Min-Jie; Zhao, Shi-Hua] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Shen, Rui; He, Zuo-Xiang] Chinese Acad Med Sci, Fuwai Hosp, Dept Nucl Med, Beijing 100730, Peoples R China.
   [Lu, Min-Jie; Zhao, Shi-Hua] Chinese Acad Med Sci, Fuwai Hosp, Dept Radiol, Beijing 100730, Peoples R China.
   [Geng, Yong-Jian] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Ctr Cardiovasc Biol & Atherosclerosis Res,Div Car, Houston, TX 77225 USA.
   [Gersh, Bernard J.] Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN USA.
RP Yang, YJ (reprint author), Chinese Acad Med Sci, Fuwai Hosp, Coronary Heart Dis Ctr, Dept Cardiol, Beijing 100730, Peoples R China.
EM yangyjfw@yahoo.com.cn
RI Zhao, Shihua/A-7553-2019
OI Zhao, Shihua/0000-0003-1339-7476
FU National High Technology Research and Development Program (863 Program)
   [2011AA020110]; China Health and Medical Development Foundation
   [2011-H25]; Research Fund of Capital Medical Development [2007-2018];
   National Natural Science Foundation of China [81070169, 81170129,
   81000091, 81000130]
FX This work was supported by the National High Technology Research and
   Development Program (863 Program) [2011AA020110], the China Health and
   Medical Development Foundation [2011-H25], Research Fund of Capital
   Medical Development [2007-2018], and the National Natural Science
   Foundation of China [81070169, 81170129, 81000091, 81000130]. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Blum A, 2009, ATHEROSCLEROSIS, V203, P325, DOI 10.1016/j.atherosclerosis.2008.08.022
   BUXTON ILO, 1993, CIRC RES, V72, P387, DOI 10.1161/01.RES.72.2.387
   Cannon RO, 2005, NAT CLIN PRACT CARD, V2, P88, DOI 10.1038/ncpcardio0096
   Cao Qi-lin, 2008, V438, P361, DOI 10.1007/978-1-59745-133-8_28
   Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469
   Chen SF, 2004, CHINESE MED J-PEKING, V117, P1443
   Chen Z, 2009, CIRC RES, V104, P496, DOI 10.1161/CIRCRESAHA.108.187567
   Dai WD, 2005, CIRCULATION, V112, P214, DOI 10.1161/CIRCULATIONAHA.104.527937
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
   Dong Q, 2010, INT J CARDIOL, V153, P311
   Forrester JS, 2009, JACC-CARDIOVASC INTE, V2, P1, DOI 10.1016/j.jcin.2008.10.010
   Forte A, 2009, CURR VASC PHARMACOL, V7, P381, DOI 10.2174/157016109788340776
   Gonon AT, 2008, CARDIOVASC RES, V78, P116, DOI 10.1093/cvr/cvn017
   Jiang CY, 2008, J ZHEJIANG UNIV-SC B, V9, P630, DOI 10.1631/jzus.B0820004
   Katritsis DG, 2005, CATHETER CARDIO INTE, V65, P321, DOI 10.1002/ccd.20406
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Li LL, 2009, MOL BIOL REP, V36, P725, DOI 10.1007/s11033-008-9235-2
   Nyolczas N, 2009, REGEN MED, V4, P407, DOI 10.2217/RME.09.14
   Ohkawara H, 2010, CARDIOVASC RES, V88, P492, DOI 10.1093/cvr/cvq221
   Pons J, 2008, BIOCHEM BIOPH RES CO, V376, P419, DOI 10.1016/j.bbrc.2008.09.003
   Psaltis PJ, 2008, STEM CELLS, V29, P2201
   Qian HY, 2007, CHINESE MED J-PEKING, V120, P1416, DOI 10.1097/00029330-200708020-00008
   Rho GJ, 2009, FRONT BIOSCI-LANDMRK, V14, P3942, DOI 10.2735/3503
   Robey TE, 2008, J MOL CELL CARDIOL, V45, P567, DOI 10.1016/j.yjmcc.2008.03.009
   Rosanio S, 2006, CARDIOVASC DRUG THER, V20, P27, DOI 10.1007/s10557-005-5203-4
   Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3
   van den Bos EJ, 2005, EUR J HEART FAIL, V7, P435, DOI 10.1016/j.ejheart.2003.12.022
   Volz HC, 2011, EUR J HEART FAIL, V13, P1052, DOI 10.1093/eurjhf/hfr098
   WEBER KT, 1990, CIRCULATION, V82, P1387, DOI 10.1161/01.CIR.82.4.1387
   Weir C, 2008, HEART LUNG CIRC, V17, P395, DOI 10.1016/j.hlc.2008.01.006
   Wolf D, 2009, STEM CELLS DEV, V18, P321, DOI 10.1089/scd.2008.0019
   Xu RX, 2008, J CELL BIOCHEM, V103, P256, DOI 10.1002/jcb.21402
   Yang YJ, 2008, EUR HEART J, V29, P1578, DOI 10.1093/eurheartj/ehn167
   Yang YJ, 2007, EUR J HEART FAIL, V9, P30, DOI 10.1016/j.ejheart.2006.04.013
   Yang YJ, 2009, ARTERIOSCL THROM VAS, V29, P2076, DOI 10.1161/ATVBAHA.109.189662
NR 35
TC 32
Z9 38
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR e65702
DI 10.1371/journal.pone.0065702
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900222
PM 23741509
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Darias, MJ
   Andree, KB
   Boglino, A
   Fernandez, I
   Estevez, A
   Gisbert, E
AF Darias, Maria J.
   Andree, Karl B.
   Boglino, Anais
   Fernandez, Ignacio
   Estevez, Alicia
   Gisbert, Enric
TI Coordinated Regulation of Chromatophore Differentiation and
   Melanogenesis during the Ontogeny of Skin Pigmentation of Solea
   senegalensis (Kaup, 1858)
SO PLOS ONE
LA English
DT Article
ID HALIBUT HIPPOGLOSSUS-HIPPOGLOSSUS; FLOUNDER PARALICHTHYS-OLIVACEUS;
   AGOUTI-SIGNALING PROTEIN; ZEBRAFISH NEURAL CREST; JAPANESE FLOUNDER;
   C-KIT; TRANSCRIPTION FACTOR; MELANOCORTIN SYSTEM; MICROARRAY ANALYSIS;
   ARTEMIA ENRICHMENT
AB Abnormal pigmentation of Senegalese sole has been described as one problem facing the full exploitation of its commercial production. To improve our understanding of flatfish pigmentation of this commercially important species we have evaluated eleven genes related to two different processes of pigmentation: melanophore differentiation, and melanin production. The temporal distribution of gene expression peaks corresponds well with changes in pigmentation patterns and the intensity of skin melanization. Several gene ratios were also examined to put in perspective possible genetic markers for the different stages of normal pigmentation development. Further, the phenotypic changes that occur during morphogenesis correspond well with the main transitions in gene expression that occur. Given the dramatic phenotypic alterations which flatfish undergo, including the asymmetric coloration that occurs between the ocular and the blind side, and the synchrony of the two processes of morphogenesis and pigmentation ontogenesis, these species constitute an interesting model for the study of pigmentation. In this study we present a first approximation towards explaining the genetic mechanisms for regulating pigmentation ontogeny in Senegalese sole, Solea senegalensis.
C1 [Darias, Maria J.; Andree, Karl B.; Boglino, Anais; Estevez, Alicia; Gisbert, Enric] Inst Recerca & Tecnol Agroalimentaries, Ctr St Carles de la Rapita, Unitat Cultius Expt, San Carlos de la Rapita, Catalonia, Spain.
   [Fernandez, Ignacio] Univ Algarve, Ctr Ciencias Mar, Evolutionary & Dev Gene Express Dept, Faro, Portugal.
RP Darias, MJ (reprint author), Inst Rech Dev, Inst Sci Evolut Montpellier, Dept Conservat & Domesticat, UMR226, Montpellier, Herault, France.
EM maria.darias@ird.fr
RI Gisbert, Enric/I-7224-2019; Darias, Maria J./D-5715-2012; Gisbert,
   Enric/B-3654-2011; Fernandez, Ignacio/B-1527-2017; Andree,
   Karl/L-7465-2014; Estevez, Alicia/K-7863-2014
OI Gisbert, Enric/0000-0002-7457-8468; Darias, Maria
   J./0000-0003-1954-6284; Gisbert, Enric/0000-0002-7457-8468; Fernandez,
   Ignacio/0000-0002-8088-7902; Andree, Karl/0000-0001-6564-0015; Estevez,
   Alicia/0000-0002-7776-0521; Estevez, Alicia/0000-0002-3690-0532
FU Ministry of Science and Innovation (MICIIN) of the Spanish Government
   [AGL2008-03897-C04-01/ACU]; European Community
   [FP7/2007-2013-222719-LIFECYCLE]; Spanish Government
FX This research was partially funded by the Ministry of Science and
   Innovation (MICIIN) of the Spanish Government (project
   AGL2008-03897-C04-01/ACU) and by the European Community's Seventh
   Framework program (FP7/2007-2013-222719-LIFECYCLE). I. F. and M.J.D.
   were supported by a pre-doctoral fellowship and a post-doctoral contract
   "Juan de la Cierva'' of the Spanish Government, respectively. The
   funders had no role in industry design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125
   [Anonymous], 2002, GEN CLUST TREE VIEW
   Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827
   Boglino A, 2012, AQUACULTURE, V324, P290, DOI 10.1016/j.aquaculture.2011.11.018
   Bolker JA, 2000, J FISH BIOL, V56, P1029, DOI 10.1006/jfbi.2000.1260
   Braasch I, 2009, PIGM CELL MELANOMA R, V22, P839, DOI 10.1111/j.1755-148X.2009.00614.x
   Brenner Michaela, 2008, Drug Discov Today Dis Mech, V5, pe189, DOI 10.1016/j.ddmec.2008.02.001
   BURCHILL SA, 1993, J ENDOCRINOL, V137, P189, DOI 10.1677/joe.0.1370189
   Burton D, 2008, J FISH BIOL, V73, P639, DOI 10.1111/j.1095-8649.2008.01960.x
   Burton D, 2002, MICROSC RES TECHNIQ, V58, P481, DOI 10.1002/jemt.10166
   Burton D, 2010, REV FISH BIOL FISHER, V20, P31, DOI 10.1007/s11160-009-9119-0
   Camacho-Hubner A, 2002, GENE, V285, P59, DOI 10.1016/S0378-1119(02)00411-0
   Campinho MA, 2012, CELL TISSUE RES, V350, P333, DOI 10.1007/s00441-012-1473-x
   Canavate JP, 2006, AQUACULTURE, V258, P368, DOI 10.1016/j.aquaculture.2006.04.009
   Carlson JA, 2007, DERMATOL CLIN, V25, P541, DOI 10.1016/j.det.2007.06.005
   Cerda-Reverter JM, 2003, ENDOCRINOLOGY, V144, P2336, DOI 10.1210/en.2002-0213
   Cerda-Reverter JM, 2005, ENDOCRINOLOGY, V146, P1597, DOI 10.1210/en.2004-1346
   Couldridge VCK, 2002, BEHAV ECOL, V13, P59, DOI 10.1093/beheco/13.1.59
   Cunningham JT, 1893, PHILOS T R SOC B, V184, P765, DOI DOI 10.1098/RSTB.1893.0010
   Curran K, 2010, DEV BIOL, V344, P107, DOI 10.1016/j.ydbio.2010.04.023
   Darias MJ, 2008, MAR BIOTECHNOL, V10, P416, DOI 10.1007/s10126-007-9078-1
   Dorsky RI, 2000, GENE DEV, V14, P158
   Estevez A, 1995, AQUACULT NUTR, V1, P159, DOI 10.1111/j.1365-2095.1995.tb00040.x
   Fu YS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022957
   Fujii R, 2000, PIGM CELL RES, V13, P300, DOI 10.1034/j.1600-0749.2000.130502.x
   Fukamachi S, 2004, P NATL ACAD SCI USA, V101, P10661, DOI 10.1073/pnas.0401278101
   Fukamachi S, 2009, GENE, V442, P81, DOI 10.1016/j.gene.2009.04.010
   Gantz I, 2003, AM J PHYSIOL-ENDOC M, V284, pE468, DOI 10.1152/ajpendo.00434.2002
   Geffen AJ, 2007, J SEA RES, V58, P35, DOI 10.1016/j.seares.2007.02.004
   Ginger RS, 2008, J BIOL CHEM, V283, P5486, DOI 10.1074/jbc.M707521200
   Gross JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000326
   Guillot R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048526
   Guo XL, 2010, PIGM CELL MELANOMA R, V23, P252, DOI 10.1111/j.1755-148X.2010.00677.x
   Haffter P, 1996, DEVELOPMENT, V123, P1
   Hallsson JH, 2004, GENETICS, V167, P233, DOI 10.1534/genetics.167.1.233
   Hamre K, 2007, AQUACULT NUTR, V13, P65, DOI 10.1111/j.1365-2095.2007.00467.x
   Hamre K, 2008, AQUACULTURE, V277, P101, DOI 10.1016/j.aquaculture.2008.02.020
   Hathaway Jessica Diann, 2011, Open Cancer J, V4, P1
   Healey EG, 1999, J FISH BIOL, V55, P937
   Hoekstra HE, 2006, SCIENCE, V313, P101, DOI 10.1126/science.1126121
   Hoshino T, 2010, J BIOL CHEM, V285, P13254, DOI 10.1074/jbc.M110.103051
   HUNT G, 1995, J INVEST DERMATOL, V104, P83, DOI 10.1111/1523-1747.ep12613565
   HUNTER JR, 1984, MARINE FISH LARVAE M, P33
   INAGAKI H, 1994, GENE, V150, P319
   Ito S, 2008, PHOTOCHEM PHOTOBIOL, V84, P582, DOI 10.1111/j.1751-1097.2007.00238.x
   Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124
   JOHNSON SL, 1995, DEV BIOL, V167, P27, DOI 10.1006/dbio.1995.1004
   Kanazawa Akio, 1993, Journal of the World Aquaculture Society, V24, P162, DOI 10.1111/j.1749-7345.1993.tb00005.x
   Kelsh RN, 1996, DEVELOPMENT, V123, P369
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Klovins J, 2004, MOL BIOL EVOL, V21, P563, DOI 10.1093/molbev/msh050
   KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x
   Kubic JD, 2008, PIGM CELL MELANOMA R, V21, P627, DOI 10.1111/j.1755-148X.2008.00514.x
   Kuntz A., 1918, Bulletin of the Bureau of Fisheries Washington, V35
   Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238
   Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905
   Le Pape E, 2009, P NATL ACAD SCI USA, V106, P1802, DOI 10.1073/pnas.0806753106
   Levy C, 2011, TRANSCR-AUSTIN, V2, P19, DOI 10.4161/trns.2.1.13650
   Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660
   Lister JA, 1999, DEVELOPMENT, V126, P3757
   LUO D, 1995, MELANOMA RES, V5, P303, DOI 10.1097/00008390-199510000-00002
   Mast SO, 1914, B US BUR FISH, V34, P177
   MATSUMOTO J, 1992, PIGM CELL RES, P275
   Minchin JEN, 2008, DEV BIOL, V317, P508, DOI 10.1016/j.ydbio.2008.02.058
   Nadeau N, 2008, GENETICS, V178, P777, DOI 10.1534/genetics.107.077073
   Nakamasu A, 2009, P NATL ACAD SCI USA, V106, P8429, DOI 10.1073/pnas.0808622106
   Nakamura M, 2010, FISHERIES SCI, V76, P243, DOI 10.1007/s12562-009-0209-7
   Olivares C, 2001, BIOCHEM J, V354, P131, DOI 10.1042/0264-6021:3540131
   Parichy DM, 1999, DEVELOPMENT, V126, P3425
   Parichy DM, 2001, DEV GENES EVOL, V211, P319, DOI 10.1007/s004270100155
   Parichy DM, 2003, DEVELOPMENT, V130, P817, DOI 10.1242/dev.00307
   Parra G, 2001, J EXP BIOL, V204, P2175
   Patton EE, 2010, PIGM CELL MELANOMA R, V23, P314, DOI 10.1111/j.1755-148X.2010.00693.x
   Pederzoli A, 2003, PIGM CELL RES, V16, P50, DOI 10.1034/j.1600-0749.2003.00013.x
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Power DM, 2008, REV FISH SCI, V16, P95, DOI 10.1080/10641260802325377
   Prota G, 1995, Fortschr Chem Org Naturst, V64, P93
   Puebla O, 2007, P R SOC B, V274, P1265, DOI 10.1098/rspb.2006.0435
   RANDALL JOHN E., 1960, BULL MAR SCI GULF AND CARIBBEAN, V10, P444
   RANDWEAVER M, 1992, J ENDOCRINOL, V133, P393, DOI 10.1677/joe.0.1330393
   Rawls JF, 2000, DEVELOPMENT, V127, P3715
   ROBERTS RJ, 1972, J FISH BIOL, V4, P87, DOI 10.1111/j.1095-8649.1972.tb05656.x
   Sarasquete C, 1996, HISTOL HISTOPATHOL, V11, P881
   SCHIOTH HB, 1995, EUR J PHARM-MOLEC PH, V288, P311, DOI 10.1016/0922-4106(95)90043-8
   SEIKAI T, 1987, PIGM CELL RES, V1, P143, DOI 10.1111/j.1600-0749.1987.tb00405.x
   Seikai Tadahisa, 1994, Journal of the World Aquaculture Society, V25, P78, DOI 10.1111/j.1749-7345.1994.tb00807.x
   Sumner FB, 1911, J EXP ZOOL, V11, P409
   Sviderskaya EV, 2001, DEV DYNAM, V221, P373, DOI 10.1002/dvdy.1153
   Villalta M, 2005, AQUACULTURE, V249, P353, DOI 10.1016/j.aquaculture.2005.03.037
   Villalta M, 2005, AQUACULTURE, V245, P193, DOI 10.1016/j.aquaculture.2004.11.035
   Vogel P, 2008, VET PATHOL, V45, P264, DOI 10.1354/vp.45-2-264
   Yamada T, 2010, DEV DYNAM, V239, P3147, DOI 10.1002/dvdy.22440
   Yamashita M, 2008, J EXP BIOL, V211, P1874, DOI 10.1242/jeb.012690
   Yamashita Y, 2010, EXP DERMATOL, V19, pE340, DOI 10.1111/j.1600-0625.2009.01061.x
   Zhu Y, 1997, GEN COMP ENDOCR, V105, P127, DOI 10.1006/gcen.1996.6810
   Zhu Y, 1996, GEN COMP ENDOCR, V101, P21, DOI 10.1016/S0016-6480(96)90191-4
NR 96
TC 12
Z9 13
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 9
PY 2013
VL 8
IS 5
AR e63005
DI 10.1371/journal.pone.0063005
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 155HD
UT WOS:000319737700033
PM 23671650
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Jung, F
   Stephan, KE
   Backes, H
   Moran, R
   Gramer, M
   Kumagai, T
   Graf, R
   Endepols, H
   Tittgemeyer, M
AF Jung, Fabienne
   Stephan, Klaas Enno
   Backes, Heiko
   Moran, Rosalyn
   Gramer, Markus
   Kumagai, Tetsuya
   Graf, Rudolf
   Endepols, Heike
   Tittgemeyer, Marc
TI Mismatch Responses in the Awake Rat: Evidence from Epidural Recordings
   of Auditory Cortical Fields
SO PLOS ONE
LA English
DT Article
ID STIMULUS-SPECIFIC ADAPTATION; EVENT-RELATED POTENTIALS; NEGATIVITY MMN
   GENERATION; SENSORY MEMORY; FREQUENCY DISCRIMINATION; EVOKED-POTENTIALS;
   ANESTHETIZED RATS; CORTEX; PROBABILITY; DEVIANCE
AB Detecting sudden environmental changes is crucial for the survival of humans and animals. In the human auditory system the mismatch negativity (MMN), a component of auditory evoked potentials (AEPs), reflects the violation of predictable stimulus regularities, established by the previous auditory sequence. Given the considerable potentiality of the MMN for clinical applications, establishing valid animal models that allow for detailed investigation of its neurophysiological mechanisms is important. Rodent studies, so far almost exclusively under anesthesia, have not provided decisive evidence whether an MMN analogue exists in rats. This may be due to several factors, including the effect of anesthesia. We therefore used epidural recordings in awake black hooded rats, from two auditory cortical areas in both hemispheres, and with bandpass filtered noise stimuli that were optimized in frequency and duration for eliciting MMN in rats. Using a classical oddball paradigm with frequency deviants, we detected mismatch responses at all four electrodes in primary and secondary auditory cortex, with morphological and functional properties similar to those known in humans, i.e., large amplitude biphasic differences that increased in amplitude with decreasing deviant probability. These mismatch responses significantly diminished in a control condition that removed the predictive context while controlling for presentation rate of the deviants. While our present study does not allow for disambiguating precisely the relative contribution of adaptation and prediction error processing to the observed mismatch responses, it demonstrates that MMN-like potentials can be obtained in awake and unrestrained rats.
C1 [Jung, Fabienne; Backes, Heiko; Gramer, Markus; Graf, Rudolf; Endepols, Heike; Tittgemeyer, Marc] Max Planck Inst Neurol Res, D-50931 Cologne, Germany.
   [Stephan, Klaas Enno] Univ Zurich, Inst Biomed Engn, TNU, Zurich, Switzerland.
   [Stephan, Klaas Enno] Swiss Fed Inst Technol, Zurich, Switzerland.
   [Stephan, Klaas Enno] Univ Zurich, Lab Social & Neural Syst Res SNS, Zurich, Switzerland.
   [Stephan, Klaas Enno; Moran, Rosalyn] UCL, Wellcome Trust Ctr Neuroimaging, London, England.
   [Kumagai, Tetsuya] Osaka Univ, Grad Sch Med, Dept Neurosurg, Osaka, Japan.
RP Jung, F (reprint author), Max Planck Inst Neurol Res, Gleueler Str 50, D-50931 Cologne, Germany.
EM fabienne.jung@nf.mpg.de
OI Stephan, Klaas Enno/0000-0002-8594-9092
FU German Research Foundation; clinical research group 219
FX Funding of the German Research Foundation and the clinical research
   group 219 supported this study. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Astikainen P, 2006, NEUROREPORT, V17, P1561, DOI 10.1097/01.wnr.0000233097.13032.7d
   Astikainen P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024208
   Baldeweg T, 2006, INT J PSYCHOPHYSIOL, V59, P49, DOI 10.1016/j.ijpsycho.2005.07.014
   Baldeweg T, 1999, ANN NEUROL, V45, P495, DOI 10.1002/1531-8249(199904)45:4<495::AID-ANA11>3.0.CO;2-M
   BARTH DS, 1990, J NEUROPHYSIOL, V64, P1527
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   BORG E, 1982, HEARING RES, V8, P101, DOI 10.1016/0378-5955(82)90069-7
   Cheung SW, 2001, HEARING RES, V156, P115, DOI 10.1016/S0378-5955(01)00272-6
   CSEPE V, 1995, EAR HEARING, V16, P91, DOI 10.1097/00003446-199502000-00007
   Doron NN, 2002, J COMP NEUROL, V453, P345, DOI 10.1002/cne.10412
   Farley BJ, 2010, J NEUROSCI, V30, P16475, DOI 10.1523/JNEUROSCI.2793-10.2010
   Friston KJ, 2005, PHILOS T R SOC B, V360, P815, DOI 10.1098/rstb.2005.1622
   Gaese BH, 2001, J NEUROPHYSIOL, V86, P1062
   Garrido MI, 2008, NEUROIMAGE, V42, P936, DOI 10.1016/j.neuroimage.2008.05.018
   Garrido MI, 2009, NEUROIMAGE, V48, P269, DOI 10.1016/j.neuroimage.2009.06.034
   Garrido MI, 2009, CLIN NEUROPHYSIOL, V120, P453, DOI 10.1016/j.clinph.2008.11.029
   Groppe DM, 2011, PSYCHOPHYSIOLOGY, V48, P1711, DOI 10.1111/j.1469-8986.2011.01273.x
   Haenschel C, 2005, J NEUROSCI, V25, P10494, DOI 10.1523/JNEUROSCI.1227-05.2005
   IMADA T, 1993, ELECTROEN CLIN NEURO, V87, P144, DOI 10.1016/0013-4694(93)90120-K
   Jaaskelainen IP, 2004, P NATL ACAD SCI USA, V101, P6809, DOI 10.1073/pnas.0303760101
   Jacobsen T, 2001, PSYCHOPHYSIOLOGY, V38, P723, DOI 10.1111/1469-8986.3840723
   JAVITT DC, 1994, BRAIN RES, V667, P192, DOI 10.1016/0006-8993(94)91496-6
   Javitt DC, 1996, P NATL ACAD SCI USA, V93, P11962, DOI 10.1073/pnas.93.21.11962
   Javitt DC, 1998, EVOKED POTENTIAL, V108, P143, DOI 10.1016/S0168-5597(97)00073-7
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KRAUS N, 1994, J NEUROPHYSIOL, V72, P1270
   Lazar R, 2003, HEARING RES, V181, P51, DOI 10.1016/S0378-5955(03)00166-7
   May PJC, 2010, PSYCHOPHYSIOLOGY, V47, P66, DOI 10.1111/j.1469-8986.2009.00856.x
   Naatanen R, 2005, PSYCHOPHYSIOLOGY, V42, P25, DOI 10.1111/j.1469-8986.2005.00256.x
   Naatanen R, 2001, TRENDS NEUROSCI, V24, P283, DOI 10.1016/S0166-2236(00)01790-2
   Naatanen R, 2003, INT J PSYCHOPHYSIOL, V48, P179, DOI 10.1016/S0167-8760(03)00053-9
   Naatanen R, 2004, CLIN NEUROPHYSIOL, V115, P140, DOI 10.1016/j.clinph.2003.04.001
   Naatanen R, 1992, ATTENTION BRAIN FUNC, P193
   Naatanen R, PSYCHOL B, V125, P826
   Nakamura T, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00367
   Nelken I, 2007, J PSYCHOPHYSIOL, V21, P214, DOI 10.1027/0269-8803.21.34.214
   Picton TW, 2000, AUDIOL NEURO-OTOL, V5, P111, DOI 10.1159/000013875
   Pincze Z, 2001, CLIN NEUROPHYSIOL, V112, P778, DOI 10.1016/S1388-2457(01)00509-0
   Roger C, 2009, PSYCHOPHYSIOLOGY, V46, P1028, DOI 10.1111/j.1469-8986.2009.00840.x
   Ruusuvirta T, 1998, NEUROSCI LETT, V248, P45, DOI 10.1016/S0304-3940(98)00330-9
   Ruusuvirta T, 1996, NEUROREPORT, V7, P1266, DOI 10.1097/00001756-199605170-00009
   Sabri M, 2001, COGNITIVE BRAIN RES, V12, P171, DOI 10.1016/S0926-6410(01)00026-X
   SAMS M, 1985, ELECTROEN CLIN NEURO, V62, P437, DOI 10.1016/0168-5597(85)90054-1
   Shelley AM, 1999, SCHIZOPHR RES, V37, P65, DOI 10.1016/S0920-9964(98)00138-8
   SIMPSON GV, 1993, BRAIN RES, V602, P251, DOI 10.1016/0006-8993(93)90690-O
   Sonnadara RR, 2006, BRAIN RES, V1071, P175, DOI 10.1016/j.brainres.2005.11.088
   Taaseh N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023369
   Tikhonravov D, 2010, NEUROSCIENCE, V167, P1175, DOI 10.1016/j.neuroscience.2010.03.014
   Tikhonravov D, 2008, BRAIN RES, V1203, P97, DOI 10.1016/j.brainres.2008.02.006
   Ulanovsky N, 2004, J NEUROSCI, V24, P10440, DOI 10.1523/JNEUROSCI.1905-04.2004
   Ulanovsky N, 2003, NAT NEUROSCI, V6, P391, DOI 10.1038/nn1032
   Umbricht D, 2005, CLIN NEUROPHYSIOL, V116, P353, DOI 10.1016/j.clinph.2004.08.015
   Umbricht D, 2005, SCHIZOPHR RES, V76, P1, DOI 10.1016/j.schres.2004.12.002
   von der Behrens W, 2009, J NEUROSCI, V29, P13837, DOI 10.1523/JNEUROSCI.3475-09.2009
   Winkler I, 1996, BRAIN RES, V742, P239, DOI 10.1016/S0006-8993(96)01008-6
   Winkler I, 2009, TRENDS COGN SCI, V13, P532, DOI 10.1016/j.tics.2009.09.003
   ZURITA P, 1994, NEUROSCI RES, V19, P303, DOI 10.1016/0168-0102(94)90043-4
NR 57
TC 18
Z9 19
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2013
VL 8
IS 4
AR e63203
DI 10.1371/journal.pone.0063203
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146GG
UT WOS:000319077300154
PM 23646197
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kawada, H
   Kaneko, M
   Sawanobori, M
   Uno, T
   Matsuzawa, H
   Nakamura, Y
   Matsushita, H
   Ando, K
AF Kawada, Hiroshi
   Kaneko, Mitsuyo
   Sawanobori, Masakazu
   Uno, Tomoko
   Matsuzawa, Hideyuki
   Nakamura, Yoshihiko
   Matsushita, Hiromichi
   Ando, Kiyoshi
TI High Concentrations of L-Ascorbic Acid Specifically Inhibit the Growth
   of Human Leukemic Cells via Downregulation of HIF-1 alpha Transcription
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; ACUTE MYELOID-LEUKEMIA; DOSE VITAMIN-C; HYPOXIA-INDUCIBLE
   FACTOR-1-ALPHA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TERMINAL HUMAN CANCER;
   HYDROGEN-PEROXIDE; TUMOR-GROWTH; SUPPLEMENTAL ASCORBATE; DEHYDROASCORBIC
   ACID
AB We examined the antileukemic effects of high concentrations of L-ascorbic acid (high AA) on human leukemic cells. In vitro, high AA markedly induced apoptosis in various leukemic cell lines by generating hydrogen peroxide (H2O2) but not in normal hematopoietic stem/progenitor cells. High AA significantly repressed leukemic cell proliferation as well as neoangiogenesis in immunodeficient mice. We then noted that in leukemic cells, HIF-1 alpha transcription was strongly suppressed by high AA and correlated with the transcription of VEGF. Our data indicate that exposure to high AA markedly increased the intracellular AA content of leukemic cells and inhibited the nuclear translocation of NF-kappa B, which mediates expression of HIF-1 alpha. We next generated K562 cells that overexpressed HIF-1 alpha (K562-HIF1 alpha cells) and assessed the mechanistic relationship between inhibition of HIF-1 alpha transcription and the antileukemic effect of high AA. The ability of high AA to induce apoptosis was significantly lower in K562-HIF1 alpha cells than in K562 cells in vitro. We found that expression of HIF-1 alpha-regulated antiapoptotic proteins of the Bcl-2 family, such as Mcl-1, Bcl-x(L), and Bcl-2, was significantly suppressed by high AA in K562 cells, but was sustained at higher levels in K562-HIF1 alpha cells, regardless of high AA exposure. Moreover, repression of cell proliferation and neoangiogenesis by high AA was completely abrogated in mice receiving transplants of K562-HIF1 alpha cells. These results indicate that, along with H2O2 generation, downregulation of HIF-1 alpha transcription plays a crucial role in growth inhibition of human leukemic cells by high AA.
C1 [Kawada, Hiroshi; Kaneko, Mitsuyo; Sawanobori, Masakazu; Ando, Kiyoshi] Tokai Univ, Sch Med, Dept Med, Div Hematol Oncol, Isehara, Kanagawa 25911, Japan.
   [Kawada, Hiroshi; Kaneko, Mitsuyo; Uno, Tomoko; Matsuzawa, Hideyuki; Nakamura, Yoshihiko; Matsushita, Hiromichi; Ando, Kiyoshi] Tokai Univ, Sch Med, Res Ctr Regenerat Med, Isehara, Kanagawa 25911, Japan.
   [Matsushita, Hiromichi] Tokai Univ, Sch Med, Dept Lab Med, Isehara, Kanagawa 25911, Japan.
RP Kawada, H (reprint author), Tokai Univ, Sch Med, Dept Med, Div Hematol Oncol, Isehara, Kanagawa 25911, Japan.
EM hkawada@is.icc.u-tokai.ac.jp
OI Matsushita, Hiromichi/0000-0002-1629-6630
FU Tokai University; The Ministry of Education, Culture, Sports, Science,
   and Technology of Japan (MEXT)
FX This work was supported by grants from Tokai University and The Ministry
   of Education, Culture, Sports, Science, and Technology of Japan
   (MEXT)-Supported Program for the Strategic Research Foundation at
   Private Universities. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdel-Wahab O, 2010, J EXP MED, V207, P677, DOI 10.1084/jem.20100523
   Aguayo A, 1999, BLOOD, V94, P3717
   Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874
   Broome HE, 2002, LEUKEMIA RES, V26, P311, DOI 10.1016/S0145-2126(01)00118-7
   CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685
   CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538
   Carcamo JM, 2004, MOL CELL BIOL, V24, P6645, DOI 10.1128/mcb.24.15.6645-6652.2004
   Chen N, 2009, J BIOL CHEM, V284, P10004, DOI 10.1074/jbc.M805997200
   Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102
   Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105
   Chen Q, 2007, P NATL ACAD SCI USA, V104, P8749, DOI 10.1073/pnas.0702854104
   CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303
   Deeb G, 2011, LEUKEMIA RES, V35, P579, DOI 10.1016/j.leukres.2010.10.020
   DEJONG L, 1982, BIOCHIM BIOPHYS ACTA, V704, P326, DOI 10.1016/0167-4838(82)90162-5
   Del Principe MI, 2005, HEMATOLOGY, V10, P25, DOI 10.1080/10245330400020454
   Del Principe MI, 2003, BRIT J HAEMATOL, V121, P730, DOI 10.1046/j.1365-2141.2003.04343.x
   Drisko JA, 2003, J AM COLL NUTR, V22, P118, DOI 10.1080/07315724.2003.10719284
   Du J, 2012, BBA-REV CANCER, V1826, P443, DOI 10.1016/j.bbcan.2012.06.003
   Espey MG, 2011, FREE RADICAL BIO MED, V50, P1610, DOI 10.1016/j.freeradbiomed.2011.03.007
   Glaser SP, 2012, GENE DEV, V26, P120, DOI 10.1101/gad.182980.111
   Gonzalez MS, 2010, BLOOD CELL MOL DIS, V45, P192, DOI 10.1016/j.bcmd.2010.07.011
   Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920
   Hoffer LJ, 2008, ANN ONCOL, V19, P1969, DOI 10.1093/annonc/mdn377
   Jung MS, 2004, J BIOL CHEM, V279, P17765, DOI 10.1074/jbc.M305015200
   Jutooru I, 2010, J BIOL CHEM, V285, P25332, DOI 10.1074/jbc.M109.095240
   Jutooru I, 2010, MOL PHARMACOL, V78, P226, DOI 10.1124/mol.110.064451
   Jutooru I, 2010, EXP CELL RES, V316, P2174, DOI 10.1016/j.yexcr.2010.04.027
   Kawada H, 1999, EXP HEMATOL, V27, P904, DOI 10.1016/S0301-472X(99)00012-0
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Knowles HJ, 2003, CANCER RES, V63, P1764
   Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005
   Krishna S, 2011, BIOCHEM J, V435, P545, DOI 10.1042/BJ20101996
   LIEBES L, 1981, P NATL ACAD SCI-BIOL, V78, P6481, DOI 10.1073/pnas.78.10.6481
   Lin MT, 2001, CARCINOGENESIS, V22, P1947, DOI 10.1093/carcin/22.12.1947
   Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768
   Maxwell PH, 2005, EXP PHYSIOL, V90, P791, DOI 10.1113/expphysiol.2005.030924
   MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301
   MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0
   Nemoto S, 1996, J NUTR SCI VITAMINOL, V42, P77
   Ohno S, 2009, ANTICANCER RES, V29, P809
   Packham G, 2008, BRIT J HAEMATOL, V143, P3, DOI 10.1111/j.1365-2141.2008.07284.x
   Padayatty SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011414
   Padayatty SJ, 2006, CAN MED ASSOC J, V174, P937, DOI 10.1503/cmaj.050346
   Padayatty SJ, 2004, ANN INTERN MED, V140, P533, DOI 10.7326/0003-4819-140-7-200404060-00010
   Pathi SS, 2011, NUTR CANCER, V63, P1133, DOI 10.1080/01635581.2011.605984
   Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200
   Reikvam Hakon, 2009, Critical Reviews in Oncogenesis, V15, P1
   RIORDAN NH, 1995, MED HYPOTHESES, V44, P207, DOI 10.1016/0306-9877(95)90137-X
   Ruas JL, 2005, SEMIN CELL DEV BIOL, V16, P514, DOI 10.1016/j.semcdb.2005.04.001
   Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Sestili P, 1996, J PHARMACOL EXP THER, V277, P1719
   STADTMAN ER, 1991, AM J CLIN NUTR, V54, pS1125, DOI 10.1093/ajcn/54.6.1125s
   van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476
   VERA JC, 1994, BLOOD, V84, P1628
   Verstovsek S, 2002, BLOOD, V99, P2265, DOI 10.1182/blood.V99.6.2265
   Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006
   Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929
   Wellmann S, 2004, LEUKEMIA, V18, P926, DOI 10.1038/sj.leu.2403332
   Yang CC, 2009, TRANSPLANTATION, V88, P1251, DOI 10.1097/TP.0b013e3181bb4a07
NR 61
TC 20
Z9 21
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2013
VL 8
IS 4
AR e62717
DI 10.1371/journal.pone.0062717
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 131QH
UT WOS:000318008400215
PM 23626851
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU de Tullio, MB
   Castelletto, V
   Hamley, IW
   Adami, PVM
   Morelli, L
   Castano, EM
AF de Tullio, Matias B.
   Castelletto, Valeria
   Hamley, Ian W.
   Martino Adami, Pamela V.
   Morelli, Laura
   Castano, Eduardo M.
TI Proteolytically Inactive Insulin-Degrading Enzyme Inhibits Amyloid
   Formation Yielding Non-Neurotoxic A beta Peptide Aggregates
SO PLOS ONE
LA English
DT Article
ID HEAT-SHOCK PROTEINS; CHAPERONE-LIKE ACTIVITY; ALZHEIMERS-DISEASE;
   TRANSGENIC MICE; EXTRACELLULAR CHAPERONE; PLAQUE-FORMATION;
   CULTURED-CELLS; IN-VIVO; BRAIN; CLUSTERIN
AB Insulin-degrading enzyme (IDE) is a neutral Zn2+ peptidase that degrades short peptides based on substrate conformation, size and charge. Some of these substrates, including amyloid beta (A beta) are capable of self-assembling into cytotoxic oligomers. Based on IDE recognition mechanism and our previous report of the formation of a stable complex between IDE and intact Ab in vitro and in vivo, we analyzed the possibility of a chaperone-like function of IDE. A proteolytically inactive recombinant IDE with Glu111 replaced by Gln (IDEQ) was used. IDEQ blocked the amyloidogenic pathway of A beta yielding non-fibrillar structures as assessed by electron microscopy. Measurements of the kinetics of A beta aggregation by light scattering showed that 1) IDEQ effect was promoted by ATP independent of its hydrolysis, 2) end products of A beta-IDEQ co-incubation were incapable of "seeding" the assembly of monomeric A beta and 3) IDEQ was ineffective in reversing A beta aggregation. Moreover, Ab aggregates formed in the presence of IDEQ were non-neurotoxic. IDEQ had no conformational effects upon insulin (a non-amyloidogenic protein under physiological conditions) and did not disturb insulin receptor activation in cultured cells. Our results suggest that IDE has a chaperone-like activity upon amyloid-forming peptides. It remains to be explored whether other highly conserved metallopeptidases have a dual protease-chaperone function to prevent the formation of toxic peptide oligomers from bacteria to mammals.
C1 [de Tullio, Matias B.; Martino Adami, Pamela V.; Morelli, Laura; Castano, Eduardo M.] Consejo Nacl Invest Cient & Tecn CONICET, Fdn Inst Leloir, Buenos Aires, DF, Argentina.
   [de Tullio, Matias B.; Martino Adami, Pamela V.; Morelli, Laura; Castano, Eduardo M.] Consejo Nacl Invest Cient & Tecn CONICET, Inst Invest Bioquim Buenos Aires, Buenos Aires, DF, Argentina.
   [Castelletto, Valeria; Hamley, Ian W.] Univ Reading, Dept Chem, Reading RG6 2AD, Berks, England.
RP Castano, EM (reprint author), Consejo Nacl Invest Cient & Tecn CONICET, Fdn Inst Leloir, Buenos Aires, DF, Argentina.
EM ecastano@leloir.org.ar
RI Hamley, Ian/D-1643-2009
OI Hamley, Ian/0000-0002-4549-0926
FU John Simon Guggenheim Foundation; Alzheimer's Association
   [IIRG-03-5312]; CONICET [PIP2009-693]; EPSRC [EP/F048114/1,
   EP/G030952/1, EP/G026203/1]; Engineering and Physical Sciences Research
   Council [EP/F048114/1, EP/G026203/1, EP/G030952/1]
FX This work was supported by a John Simon Guggenheim Foundation
   fellowship, Alzheimer's Association grant IIRG-03-5312 (to EMC), a
   CONICET grant PIP2009-693 (to LM), and EPSRC grants EP/F048114/1,
   EP/G030952/1 and EP/G026203/1 (to IWH). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arimon M, 2008, J MOL BIOL, V384, P1157, DOI 10.1016/j.jmb.2008.09.063
   Bernstein SL, 2009, NAT CHEM, V1, P326, DOI [10.1038/NCHEM.247, 10.1038/nchem.247]
   Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699
   Bolognesi B, 2010, ACS CHEM BIOL, V5, P735, DOI 10.1021/cb1001203
   Bruinsma IB, 2011, J NEUROSCI, V31, P11992, DOI 10.1523/JNEUROSCI.0945-11.2011
   Bulloj A, 2010, J ALZHEIMERS DIS, V19, P79, DOI 10.3233/JAD-2010-1206
   Bulloj A, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-22
   CACERES A, 1986, J NEUROSCI, V6, P714
   Calero M, 2005, SUB CELL BIOCHEM, V38, P273
   Cheng IH, 2007, J BIOL CHEM, V282, P23818, DOI 10.1074/jbc.M701078200
   Chow KM, 2009, BIOCHEMISTRY-US, V48, P2868, DOI 10.1021/bi8016125
   Cordes CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018138
   de Tullio MB, 2008, PRION, V2, P51, DOI 10.4161/pri.2.2.6710
   Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200
   Evans CG, 2006, J BIOL CHEM, V281, P33182, DOI 10.1074/jbc.M606192200
   Falkevall A, 2006, J BIOL CHEM, V281, P29096, DOI 10.1074/jbc.M602532200
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4
   Fernandez-Gamba A, 2009, CURR PHARM DESIGN, V15, P3644, DOI 10.2174/138161209789271799
   Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006
   French K, 2008, BIOCHEMISTRY-US, V47, P1176, DOI 10.1021/bi701976f
   Friedrich RP, 2010, P NATL ACAD SCI USA, V107, P1942, DOI 10.1073/pnas.0904532106
   Gau JT, 2002, AM J PATHOL, V160, P731, DOI 10.1016/S0002-9440(10)64893-6
   Grbovic OM, 2003, J BIOL CHEM, V278, P31261, DOI 10.1074/jbc.M304122200
   HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0
   HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8
   Hulko M, 2007, PROTEIN SCI, V16, P644, DOI 10.1110/ps.062478607
   Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875
   Im H, 2007, J BIOL CHEM, V282, P25453, DOI 10.1074/jbc.M701590200
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008
   Johnson KA, 2006, EMBO J, V25, P1977, DOI 10.1038/sj.emboj.7601080
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328
   Konarkowska B, 2006, FEBS J, V273, P3614, DOI 10.1111/j.1742-4658.2006.05367.x
   Kumar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018759
   Kuo YM, 2001, MOL MED, V7, P609, DOI 10.1007/BF03401867
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   Lee S, 2006, BIOCHEM BIOPH RES CO, V347, P527, DOI 10.1016/j.bbrc.2006.06.128
   LI D, 1992, J BIOL CHEM, V267, P2414
   Lia LJ, 2004, J BIOL CHEM, V279, P37061, DOI 10.1074/jbc.M403672200
   Llovera RE, 2008, J BIOL CHEM, V283, P17039, DOI 10.1074/jbc.M706316200
   Manolopoulou M, 2009, J BIOL CHEM, V284, P14177, DOI 10.1074/jbc.M900068200
   Martin-Rehrmann MD, 2005, NEUROTOX RES, V7, P231, DOI 10.1007/BF03036452
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Morelli L, 2005, BIOCHEM BIOPH RES CO, V332, P808, DOI 10.1016/j.bbrc.2005.05.020
   Morelli L, 2004, J BIOL CHEM, V279, P56004, DOI 10.1074/jbc.M407283200
   Mzhavia N, 1999, DNA CELL BIOL, V18, P369, DOI 10.1089/104454999315268
   Necula M, 2007, J BIOL CHEM, V282, P10311, DOI 10.1074/jbc.M608207200
   Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887
   Noinaj N, 2012, J BIOL CHEM, V287, P48, DOI 10.1074/jbc.M111.264614
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851
   Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103
   Roher AE, 2009, ALZHEIMERS DEMENT, V5, P18, DOI 10.1016/j.jalz.2008.10.004
   Schumann W, 1999, FEMS MICROBIOL REV, V23, P1
   Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143
   Shinall H, 2005, BIOCHEMISTRY-US, V44, P15345, DOI 10.1021/bi050650l
   Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200
   Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295
   Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X
   Tsika E, 2010, J NEUROSCI, V30, P3409, DOI 10.1523/JNEUROSCI.4977-09.2010
   Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200
   Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097
   Vidal R, 1999, NATURE, V399, P776
   Wang CC, 1998, FEBS LETT, V425, P382, DOI 10.1016/S0014-5793(98)00272-5
   Wang YQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.208934
   Yerbury JJ, 2005, BIOCHEMISTRY-US, V44, P10914, DOI 10.1021/bi050764x
   Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com
   Yerbury JJ, 2009, J BIOL CHEM, V284, P4246, DOI 10.1074/jbc.M807242200
NR 70
TC 17
Z9 17
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2013
VL 8
IS 4
AR e59113
DI 10.1371/journal.pone.0059113
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 123JA
UT WOS:000317383200002
PM 23593132
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Boehme, S
   Duenges, B
   Klein, KU
   Hartwich, V
   Mayr, B
   Consiglio, J
   Baumgardner, JE
   Markstaller, K
   Basciani, R
   Vogt, A
AF Boehme, Stefan
   Duenges, Bastian
   Klein, Klaus U.
   Hartwich, Volker
   Mayr, Beate
   Consiglio, Jolanda
   Baumgardner, James E.
   Markstaller, Klaus
   Basciani, Reto
   Vogt, Andreas
TI Multi Frequency Phase Fluorimetry (MFPF) for Oxygen Partial Pressure
   Measurement: Ex Vivo Validation by Polarographic Clark-Type Electrode
SO PLOS ONE
LA English
DT Article
ID BRAIN-TISSUE OXYGEN; END-EXPIRATORY PRESSURE; BLOOD-GAS ANALYSIS;
   IN-VITRO ACCURACY; RESPIRATORY RATE; ARTERIAL-BLOOD; TEMPERATURE; LICOX;
   OSCILLATIONS; AGREEMENT
AB Background: Measurement of partial pressure of oxygen (P-O2) at high temporal resolution remains a technological challenge. This study introduces a novel P-O2 sensing technology based on Multi-Frequency Phase Fluorimetry (MFPF). The aim was to validate MFPF against polarographic Clark-type electrode (CTE) P-O2 measurements.
   Methodology/Principal Findings: MFPF technology was first investigated in N = 8 anaesthetised pigs at F-IO2 of 0.21, 0.4, 0.6, 0.8 and 1.0. At each F-IO2 level, blood samples were withdrawn and P-O2 was measured in vitro with MFPF using two FOXY-AL300 probes immediately followed by CTE measurement. Secondly, MFPF-P-O2 readings were compared to CTE in an artificial circulatory setup (human packed red blood cells, haematocrit of 30%). The impacts of temperature (20, 30, 40 degrees C) and blood flow (0.8, 1.6, 2.4, 3.2, 4.0 L min(-1)) on MFPF-P-O2 measurements were assessed. MFPF response time in the gas- and blood-phase was determined. Porcine MFPF-P-O2 ranged from 63 to 749 mmHg; the corresponding CTE samples from 43 to 712 mmHg. Linear regression: CTE = 15.59+1.18*MFPF (R-2 = 0.93; P < 0.0001). Bland Altman analysis: mean(diff) 69.2 mmHg, range(diff) -50.1/215.6 mmHg, 1.96-SD limits -56.3/194.8 mmHg. In artificial circulatory setup, MFPF-P-O2 ranged from 20 to 567 mmHg and CTE samples from 11 to 575 mmHg. Linear regression: CTE = 28.73+1.05*MFPF (R-2 = 0.99; P < 0.0001). Bland-Altman analysis: mean(diff) 6.6 mmHg, range(diff) -9.7/20.5 mmHg, 1.96-SD limits -12.7/25.8 mmHg. Differences between MFPF and CTE-P-O2 due to variations of temperature were less than 6 mmHg (range 0-140 mmHg) and less than 35 mmHg (range 140-750 mmHg); differences due to variations in blood flow were less than 15 mmHg (all P-values>0.05). MFPF response-time (monoexponential) was 1.48+/-0.26 s for the gas-phase and 1.51+/-0.20 s for the blood-phase.
   Conclusions/Significance: MFPF-derived P-O2 readings were reproducible and showed excellent correlation and good agreement with Clark-type electrode-based P-O2 measurements. There was no relevant impact of temperature and blood flow upon MFPF-P-O2 measurements. The response time of the MFPF FOXY-AL300 probe was adequate for real-time sensing in the blood phase.
C1 [Boehme, Stefan; Klein, Klaus U.; Markstaller, Klaus] Med Univ Vienna, Dept Anaesthesia Gen Intens Care & Pain Managemen, Vienna, Austria.
   [Boehme, Stefan; Duenges, Bastian; Klein, Klaus U.; Markstaller, Klaus] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany.
   [Baumgardner, James E.] Oscillogy, Folsom, PA USA.
   [Hartwich, Volker; Basciani, Reto; Vogt, Andreas] Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, Inselspital, CH-3010 Bern, Switzerland.
   [Hartwich, Volker; Basciani, Reto; Vogt, Andreas] Univ Bern, Bern, Switzerland.
   [Mayr, Beate; Consiglio, Jolanda] Univ Hosp Bern, Dept Cardiovasc Surg, Swiss Cardiovasc Ctr, CH-3010 Bern, Switzerland.
RP Boehme, S (reprint author), Med Univ Vienna, Dept Anaesthesia Gen Intens Care & Pain Managemen, Vienna, Austria.
EM stefan_boehme@web.de
OI Klein, Klaus Ulrich/0000-0001-7446-0542; Vogt,
   Andreas/0000-0002-3676-7188
FU German Research Council [DFG PAK 415/7-1, Ma 2398-3]; Swiss National
   Foundation [SNF POIB 117065/1]; Research Department of Anesthesiology
   and Pain Therapy, Inselspital, Bern, Switzerland; Covidien Europe
FX The study was supported by research grants of the German Research
   Council (DFG PAK 415/7-1, Ma 2398-3) and Swiss National Foundation (SNF
   POIB 117065/1), and by an institutional grant of the Research Department
   of Anesthesiology and Pain Therapy, Inselspital, Bern, Switzerland. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; JEB is President
   of Fa. Oscillogy. RB received lecture honoraria from Medtronic
   Switzerland for lectures in the field of anesthetic management for
   transcatheter aortic valve implantation. RB received lecture honoraria
   and a travel grant from Covidien Europe for speaking at the meeting of
   the European Association of Cardiothoracic Anaesthesiologists (EACTA) in
   the field of near-infrared spectroscopy for cerebral tissue oximetry in
   thoracic aortic surgery. In the authors' opinion, these conflicts are in
   no way related to being competitive in the field of our manuscript:
   these conflicts do not interfere with, or could be perceived as
   interfering with, the complete and objective presentation, peer review,
   editorial decision-making, or publication of the manuscript. There are
   no conflicts related to being competative researchers in this field.
   Overall, this does not alter the authors' adherence to all the PLOS ONE
   policies on sharing data and materials.
CR Baumgardner JE, 2002, AM J RESP CRIT CARE, V166, P1556, DOI 10.1164/rccm.200207.717OC
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   BLAND JM, 1986, LANCET, V1, P307
   Burkhardt H, 2008, SCAND J CLIN LAB INV, V68, P171, DOI 10.1080/00365510701601665
   Citerio G, 2004, ACTA NEUROCHIR, V146, P1221, DOI 10.1007/s00701-004-0351-z
   CLARK LC, 1953, J APPL PHYSIOL, V6, P189
   Ganter M, 2003, BRIT J ANAESTH, V91, P397, DOI 10.1093/bja/aeg176
   GRUNDMANN A, 1992, ADV EXP MED BIOL, V317, P213
   Hahn CEW, 1998, ANALYST, V123, p57R
   Haitsma I, 2008, ACTA NEUROCHIR SUPPL, V102, P197, DOI 10.1007/978-3-211-85578-2_39
   Hartmann EK, 2012, CRIT CARE, V16, DOI 10.1186/cc11147
   Herweling A, 2005, RESUSCITATION, V65, P71, DOI 10.1016/j.resusitation.2004.04.017
   Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8
   Huschak G, 2009, J NEUROSURG ANESTH, V21, P155, DOI 10.1097/ANA.0b013e31818f2eac
   Jaeger M, 2005, ACT NEUR S, V95, P79
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kimmich H P, 1976, Adv Exp Med Biol, V75, P33
   Klein KU, 2011, J NEUROSURG ANESTH, V23, P341, DOI 10.1097/ANA.0b013e31822cf893
   Lakowicz JR, 2008, J BIOMED OPT, V13
   MADIEDO G, 1980, J CLIN PATHOL, V33, P864, DOI 10.1136/jcp.33.9.864
   MAHUTTE CK, 1994, INTENS CARE MED, V20, P85, DOI 10.1007/BF01707657
   Orakcioglu B, 2010, NEUROSURGERY, V67, P1716, DOI 10.1227/NEU.0b013e3181f9bb5b
   Picandet V, 2007, J VET INTERN MED, V21, P476, DOI 10.1892/0891-6640(2007)21[476:EOSTAS]2.0.CO;2
   PURVES MJ, 1966, RESP PHYSIOL, V1, P281, DOI 10.1016/0034-5687(66)90047-8
   Sakowitz OW, 2011, NEUROSURGERY, V67, P1722
   Severinghaus JW, 2002, ANESTHESIOLOGY, V97, P253, DOI 10.1097/00000542-200207000-00031
   Stewart C, 2008, NEUROSURGERY, V63, P1159, DOI 10.1227/01.NEU.0000333265.19131.7C
   Urbaniak GC, 2010, RES RANDOMIZER VERSI
   Williams EM, 2000, BRIT J ANAESTH, V85, P456, DOI 10.1093/bja/85.3.456
   Zaugg M, 1998, ANESTH ANALG, V87, P647, DOI 10.1097/00000539-199809000-00030
NR 30
TC 6
Z9 6
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2013
VL 8
IS 4
AR e60591
DI 10.1371/journal.pone.0060591
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 127RY
UT WOS:000317717300130
PM 23565259
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Akhtar, S
   Grizenkova, J
   Wenborn, A
   Hummerich, H
   de Marco, MF
   Brandner, S
   Collinge, J
   Lloyd, SE
AF Akhtar, Shaheen
   Grizenkova, Julia
   Wenborn, Adam
   Hummerich, Holger
   de Marco, Mar Fernandez
   Brandner, Sebastian
   Collinge, John
   Lloyd, Sarah E.
TI Sod1 Deficiency Reduces Incubation Time in Mouse Models of Prion Disease
SO PLOS ONE
LA English
DT Article
ID CREUTZFELDT-JAKOB-DISEASE; QUANTITATIVE TRAIT LOCI; AMYLOID PRECURSOR
   PROTEIN; KNOCKOUT MICE; GENE; SCRAPIE; SUSCEPTIBILITY; IDENTIFICATION;
   RESISTANT; PERIOD
AB Prion infections, causing neurodegenerative conditions such as Creutzfeldt-Jakob disease and kuru in humans, scrapie in sheep and BSE in cattle are characterised by prolonged and variable incubation periods that are faithfully reproduced in mouse models. Incubation time is partly determined by genetic factors including polymorphisms in the prion protein gene. Quantitative trait loci studies in mice and human genome-wide association studies have confirmed that multiple genes are involved. Candidate gene approaches have also been used and identified App, Il1-r1 and Sod1 as affecting incubation times. In this study we looked for an association between App, Il1-r1 and Sod1 representative SNPs and prion disease incubation time in the Northport heterogeneous stock of mice inoculated with the Chandler/RML prion strain. No association was seen with App, however, significant associations were seen with Il1-r1 (P = 0.02) and Sod1 (P<0.0001) suggesting that polymorphisms at these loci contribute to the natural variation observed in incubation time. Furthermore, following challenge with Chandler/RML, ME7 and MRC2 prion strains, Sod1 deficient mice showed highly significant reductions in incubation time of 20, 13 and 24%, respectively. No differences were detected in Sod1 expression or activity. Our data confirm the protective role of endogenous Sod1 in prion disease.
C1 [Lloyd, Sarah E.] UCL, Inst Neurol, Med Res Council Prion Unit, London, England.
   UCL, Inst Neurol, Dept Neurodegenerat Dis, London, England.
RP Lloyd, SE (reprint author), UCL, Inst Neurol, Med Res Council Prion Unit, London, England.
EM s.lloyd@prion.ucl.ac.uk
RI Brandner, Sebastian/J-4562-2014
OI Brandner, Sebastian/0000-0002-9821-0342
FU UK Medical Research Council; Medical Research Council [MC_U123160652,
   MC_U123192748]
FX This work was funded by the UK Medical Research Council (www.mrc.ac.uk).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653
   Barry AE, 2011, J NEUROSCI, V31, P7259, DOI 10.1523/JNEUROSCI.6500-10.2011
   BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3
   CARLSON GA, 1993, GENETICS, V133, P979
   CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528
   Collinge J, 2005, J NEUROL NEUROSUR PS, V76, P906, DOI 10.1136/jnnp.2004.048660
   COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V
   Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519
   Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x
   Freir DB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1341
   Freixes M, 2006, NEUROBIOL AGING, V27, P1807, DOI 10.1016/j.neurobiolaging.2005.10.006
   Grizenkova J, 2012, P NATL ACAD SCI USA, V109, P13722, DOI 10.1073/pnas.1208917109
   Grizenkova J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015019
   HITZEMANN B, 1994, J PHARMACOL EXP THER, V271, P969
   Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715
   Joyce PI, 2011, MAMM GENOME, V22, P420, DOI 10.1007/s00335-011-9339-1
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761
   Lee DW, 1999, FREE RADICAL RES, V30, P499, DOI 10.1080/10715769900300541
   Lloyd SE, 2010, NEUROGENETICS, V11, P185, DOI 10.1007/s10048-009-0219-8
   Lloyd SE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000383
   Lloyd SE, 2005, CURR GENOMICS, V6, P1, DOI 10.2174/1389202053202166
   Lloyd SE, 2004, J GEN VIROL, V85, P2471, DOI 10.1099/vir.0.79889-0
   Lloyd SE, 2004, MAMM GENOME, V15, P383, DOI [10.1007/s00335-004-3041-5, 10.1077/s00335-004-3041-5]
   Lloyd SE, 2002, NEUROGENETICS, V4, P77, DOI 10.1007/s10048-002-0133-9
   Lloyd SE, 2001, P NATL ACAD SCI USA, V98, P6279, DOI 10.1073/pnas.101130398
   Manolakou K, 2001, P NATL ACAD SCI USA, V98, P7402, DOI 10.1073/pnas.121172098
   Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008
   Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320
   Mead S., 2011, HUM MOL GENET, V21, P1897
   Mead S, 2009, LANCET NEUROL, V8, P57, DOI 10.1016/S1474-4422(08)70265-5
   Moore RC, 1998, NAT GENET, V18, P118, DOI 10.1038/ng0298-118
   Moreno CR, 2003, GENETICS, V165, P2085
   Murakami K, 2011, J BIOL CHEM, V286, P44557, DOI 10.1074/jbc.M111.279208
   O'Shea M, 2008, SEMIN PERINATOL, V32, P1, DOI 10.1053/j.semperi.2007.12.002
   PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0
   Parkin ET, 2007, P NATL ACAD SCI USA, V104, P11062, DOI 10.1073/pnas.0609621104
   Schultz J, 2004, AM J PATHOL, V165, P671, DOI 10.1016/S0002-9440(10)63331-7
   Siskova Z, 2010, AM J PATHOL, V177, P1411, DOI 10.2353/ajpath.2010.091037
   Stephenson DA, 2000, GENOMICS, V69, P47, DOI 10.1006/geno.2000.6320
   Tamguney G, 2008, J GEN VIROL, V89, P1777, DOI 10.1099/vir.0.2008/001255-0
   Valdar W, 2006, NAT GENET, V38, P879, DOI 10.1038/ng1840
   Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4
   Wadsworth JDF, 2006, BRAIN, V129, P1557, DOI 10.1093/brain/awl076
   WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6
NR 45
TC 14
Z9 14
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2013
VL 8
IS 1
AR e54454
DI 10.1371/journal.pone.0054454
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 077HS
UT WOS:000314019100070
PM 23349894
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Feng, Q
   Zou, X
   Lu, L
   Li, Y
   Liu, YZ
   Zhou, JF
   Duan, CM
AF Feng, Qiang
   Zou, Xia
   Lu, Ling
   Li, Yun
   Liu, Yunzhang
   Zhou, Jianfeng
   Duan, Cunming
TI The Stress-Response Gene redd1 Regulates Dorsoventral Patterning by
   Antagonizing Wnt/beta-catenin Activity in Zebrafish
SO PLOS ONE
LA English
DT Article
ID WNT SIGNALING PATHWAY; BETA-CATENIN; HOMEOBOX GENE; IGF BINDING;
   ORGANIZER FORMATION; MAMMALIAN TARGET; SKELETAL-MUSCLE; AXIS FORMATION;
   ENERGY STRESS; CELL-GROWTH
AB REDD1/redd1 is a stress-response gene that is induced under various stressful conditions such as hypoxia, DNA damage, and energy stress. The increased REDD1 inhibits mTOR signaling and cell growth. Here we report an unexpected role of Redd1 in regulating dorsoventral patterning in zebrafish embryos and the underlying mechanisms. Zebrafish redd1 mRNA is maternally deposited. Although it is ubiquitously detected in many adult tissues, its expression is highly tissue-specific and dynamic during early development. Hypoxia and heat shock strongly induce redd1 expression in zebrafish embryos. Knockdown of Redd1 using two independent morpholinos results in dorsalized embryos and this effect can be rescued by injecting redd1 mRNA. Forced expression of Redd1 ventralizes embryos. Co-expression of Redd1 with Wnt3a or a constitutively active form of beta-catenin suggests that Redd1 alters dorsoventral patterning by antagonizing the Wnt/beta-catenin signaling pathway. These findings have unraveled a novel role of Redd1 in early development by antagonizing Wnt/beta-catenin signaling.
C1 [Feng, Qiang; Zou, Xia; Lu, Ling; Li, Yun; Liu, Yunzhang; Zhou, Jianfeng] Ocean Univ China, Sch Med & Pharm, Chinese Minist Educ, Key Lab Marine Drugs, Qingdao, Shandong, Peoples R China.
   [Duan, Cunming] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.
RP Zhou, JF (reprint author), Ocean Univ China, Sch Med & Pharm, Chinese Minist Educ, Key Lab Marine Drugs, Qingdao, Shandong, Peoples R China.
EM jfzhou@ouc.edu.cn; cduan@umich.edu
FU National Science Foundation of China [30972238, 40876064, 30970357,
   30928021]; Program for New Century Excellent Talents in University
   [NCET-10-0723]; Major Science Programs of China [2011CB943800]; US NSF
   [IOS-1051034]
FX This work was supported by grants from the National Science Foundation
   of China (Grant #30972238, #40876064, #30970357 and #30928021), Program
   for New Century Excellent Talents in University (NCET-10-0723) and Major
   Science Programs of China (#2011CB943800). C. D. was supported by US NSF
   Research Grant IOS-1051034. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Baker KD, 2010, DEV DYNAM, V239, P2828, DOI 10.1002/dvdy.22419
   Bellipanni G, 2006, DEVELOPMENT, V133, P1299, DOI 10.1242/dev.02295
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Dai W, 2010, FASEB J, V24, P2020, DOI 10.1096/fj.09-149435
   DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608
   Dorsky RI, 2003, DEVELOPMENT, V130, P1937, DOI 10.1242/dev.00402
   Ellisen LW, 2005, CELL CYCLE, V4, P1500, DOI 10.4161/cc.4.11.2139
   Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2
   Erter CE, 2001, DEVELOPMENT, V128, P3571
   Flowers GP, 2012, DEVELOPMENT, V139, P2416, DOI 10.1242/dev.063206
   Horndasch M, 2006, ONCOGENE, V25, P3397, DOI 10.1038/sj.onc.1209380
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jin HO, 2007, CELL SIGNAL, V19, P1393, DOI 10.1016/j.cellsig.2006.12.014
   Jin HO, 2009, FREE RADICAL BIO MED, V46, P1158, DOI [10.1016/j.freeradbiomed.2009.01.015, 10.1016/j.freeradbiomed.2009.01.075]
   JOLY JS, 1993, DEVELOPMENT, V119, P1261
   Katiyar S, 2009, EMBO REP, V10, P866, DOI 10.1038/embor.2009.93
   Kelly C, 2000, DEVELOPMENT, V127, P3899
   KELLY GM, 1995, DEVELOPMENT, V121, P1787
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Kishimoto Y, 1997, DEVELOPMENT, V124, P4457
   Langdon YG, 2011, ANNU REV GENET, V45, P357, DOI 10.1146/annurev-genet-110410-132517
   Lekven AC, 2001, DEV CELL, V1, P103, DOI 10.1016/S1534-5807(01)00007-7
   Leung TC, 2003, DEV DYNAM, V228, P424, DOI 10.1002/dvdy.10408
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   McGhee NK, 2009, J NUTR, V139, P828, DOI 10.3945/jn.108.099846
   Miyazaki M, 2009, AM J PHYSIOL-CELL PH, V296, pC583, DOI 10.1152/ajpcell.00464.2008
   Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427
   Mullins MC, 1996, DEVELOPMENT, V123, P81
   Myers DC, 2002, DEV BIOL, V243, P81, DOI 10.1006/dbio.2001.0523
   Pelegri F, 1998, MECH DEVELOP, V77, P63, DOI 10.1016/S0925-4773(98)00132-4
   Ramel MC, 2005, DEV BIOL, V287, P237, DOI 10.1016/j.ydbio.2005.08.012
   Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704
   Ryu SL, 2001, DEV BIOL, V231, P397, DOI 10.1006/dbio.2000.0150
   Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752
   Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586
   Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1
   SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092
   Scuderi A, 2006, DEV BIOL, V291, P110, DOI 10.1016/j.ydbio.2005.12.014
   Shimizu T, 2002, MECH DEVELOP, V118, P125, DOI 10.1016/S0925-4773(02)00243-5
   Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002
   Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005
   SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67
   STACHEL SE, 1993, DEVELOPMENT, V117, P1261
   Sun ZH, 2006, BIOCHEM BIOPH RES CO, V345, P694, DOI 10.1016/j.bbrc.2006.04.148
   Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013
   Wang HM, 2006, J BIOL CHEM, V281, P39128, DOI 10.1074/jbc.M610023200
   Wang XL, 2009, AM J PHYSIOL-REG I, V296, pR1348, DOI 10.1152/ajpregu.90969.2008
   Whitney ML, 2009, BIOCHEM BIOPH RES CO, V379, P451, DOI 10.1016/j.bbrc.2008.12.079
   Xiong B, 2006, DEV CELL, V11, P225, DOI 10.1016/j.devcel.2006.06.012
   Yamanaka Y, 1998, GENE DEV, V12, P2345, DOI 10.1101/gad.12.15.2345
   Yoshida T, 2010, NAT MED, V16, P767, DOI 10.1038/nm.2157
   Zhong YB, 2011, J CELL SCI, V124, P1925, DOI 10.1242/jcs.082644
NR 57
TC 17
Z9 17
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2012
VL 7
IS 12
AR e52674
DI 10.1371/journal.pone.0052674
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 071TV
UT WOS:000313618800125
PM 23300740
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Franco, NH
   Correia-Neves, M
   Olsson, IAS
AF Franco, Nuno Henrique
   Correia-Neves, Margarida
   Olsson, I. Anna S.
TI Animal Welfare in Studies on Murine Tuberculosis: Assessing Progress
   over a 12-Year Period and the Need for Further Improvement
SO PLOS ONE
LA English
DT Article
ID VIRULENT MYCOBACTERIUM-TUBERCULOSIS; BIOMEDICAL-RESEARCH; CELL
   RESPONSES; INBRED STRAINS; MOUSE MODEL; MICE; INFECTION; LUNGS;
   SUSCEPTIBILITY; CHALLENGE
AB There is growing concern over the welfare of animals used in research, in particular when these animals develop pathology. The present study aims to identify the main sources of animal distress and to assess the possible implementation of refinement measures in experimental infection research, using mouse models of tuberculosis (TB) as a case study. This choice is based on the historical relevance of mouse studies in understanding the disease and the present and long-standing impact of TB on a global scale. Literature published between 1997 and 2009 was analysed, focusing on the welfare impact on the animals used and the implementation of refinement measures to reduce this impact. In this 12-year period, we observed a rise in reports of ethical approval of experiments. The proportion of studies classified into the most severe category did however not change significantly over the studied period. Information on important research parameters, such as method for euthanasia or sex of the animals, were absent in a substantial number of papers. Overall, this study shows that progress has been made in the application of humane endpoints in TB research, but that a considerable potential for improvement remains.
C1 [Franco, Nuno Henrique; Olsson, I. Anna S.] Univ Porto, Lab Anim Sci Grp, Inst Mol & Cell Biol, P-4100 Oporto, Portugal.
   [Correia-Neves, Margarida] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Correia-Neves, Margarida] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
RP Franco, NH (reprint author), Univ Porto, Lab Anim Sci Grp, Inst Mol & Cell Biol, Rua Campo Alegre 823, P-4100 Oporto, Portugal.
EM nfranco@ibmc.up.pt
RI Correia-Neves, Margarida/C-9122-2009; Franco, Nuno Henrique/K-4691-2012;
   Olsson, Anna/C-1792-2008
OI Correia-Neves, Margarida/0000-0002-2202-5431; Franco, Nuno
   Henrique/0000-0003-4015-0532; Olsson, Anna/0000-0002-4369-8723
FU Fundacao para a Ciencia e Tecnologia [SFRH/BD/38337/2007]; FEDER funds
   through the Operational Competitiveness Programme - COMPETE; FCT -
   Fundacao para a Ciencia e a Tecnologia [FCOMP-01-0124-FEDER-022718
   (PEst-C/SAU/LA0002/2011]
FX Nuno H. Franco is funded by Fundacao para a Ciencia e Tecnologia
   (SFRH/BD/38337/2007). The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. This work is funded by FEDER funds through the Operational
   Competitiveness Programme - COMPETE and by national funds through FCT -
   Fundacao para a Ciencia e a Tecnologia under the project
   FCOMP-01-0124-FEDER-022718 (PEst-C/SAU/LA0002/2011.
CR Abebe F, 2006, CLIN EXP IMMUNOL, V143, P180, DOI 10.1111/j.1365-2249.2005.02976.x
   Actor JK, 1999, J INTERF CYTOK RES, V19, P1183, DOI 10.1089/107999099313136
   Apt A, 2009, TUBERCULOSIS, V89, P195, DOI 10.1016/j.tube.2009.02.002
   Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002
   Canadian Council on Animal Welfare, 1991, CCAC POL STAT CAT IN
   Chackerian AA, 2003, TUBERCULOSIS, V83, P279, DOI 10.1016/S1472-9792(03)00017-9
   Commission E, 2010, OFFICIAL J EUROPEAN, P33
   Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703
   Das RG, 2007, LAB ANIM-UK, V41, P312
   de Meijer VE, 2010, PHYSIOL BEHAV, V100, P387, DOI 10.1016/j.physbeh.2010.04.001
   Dormans J, 2004, CLIN EXP IMMUNOL, V137, P460, DOI 10.1111/j.1365-2249.2004.02551.x
   Dunn PL, 1996, J MED MICROBIOL, V45, P103, DOI 10.1099/00222615-45-2-103
   Editor, 2010, NATURE, V468, P731
   Eruslanov EB, 2004, CLIN EXP IMMUNOL, V135, P19, DOI 10.1046/j.1365-2249.2004.02328.x
   Flynn JL, 2001, INFECT IMMUN, V69, P4195, DOI 10.1128/IAI.69.7.4195-4201.2001
   Flynn JL, 2006, MICROBES INFECT, V8, P1179, DOI 10.1016/j.micinf.2005.10.033
   Franco NH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002399
   Gupta UD, 2005, TUBERCULOSIS, V85, P277, DOI 10.1016/j.tube.2005.08.008
   Hagelin J, 2003, LAB ANIM-UK, V37, P10, DOI 10.1258/002367703762226656
   Harries AD, 2010, LANCET, V375, P1906, DOI 10.1016/S0140-6736(10)60409-6
   Hendriksen C, 2011, HDB LAB ANIMAL SCI, VI, P467
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   Kamala T, 2007, J IMMUNOL METHODS, V328, P204, DOI 10.1016/j.jim.2007.08.004
   Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Kondratieva E, 2010, PLOS ONE, V5
   Koul A, 2011, NATURE, V469, P483, DOI 10.1038/nature09657
   Lavebratt C, 1999, J INFECT DIS, V180, P150, DOI 10.1086/314843
   Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3
   MacCallum CJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000413
   Markova N, 2003, INT IMMUNOPHARMACOL, V3, P1557, DOI 10.1016/S1567-5769(03)00178-4
   McClelland EE, 2011, ARCH IMMUNOL THER EX, V59, P203, DOI 10.1007/s00005-011-0124-3
   Medina E, 1998, IMMUNOLOGY, V93, P270
   Mitsos LM, 2003, P NATL ACAD SCI USA, V100, P6610, DOI 10.1073/pnas.1031727100
   Morton DB, 2001, LAB ANIM-UK, V35, P1, DOI 10.1258/0023677011911345
   Morton DB, 1999, HUMANE ENDPOINTS ANI, P5
   Mustafa T, 1999, SCAND J IMMUNOL, V50, P127
   Neyrolles O, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000199
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635
   O'Connor JC, 2009, J NEUROSCI, V29, P4200, DOI 10.1523/JNEUROSCI.5032-08.2009
   OECD, 2000, GUID DOC REC ASS US
   Olsson IAS, 2007, SCIENCE, V317, P1680, DOI 10.1126/science.317.5845.1680
   Orme Ian M., 1994, P113
   Palomino JC, 2009, CURR MED CHEM, V16, P1898, DOI 10.2174/092986709788186066
   Quenelle DC, 2001, ANTIMICROB AGENTS CH, V45, P1637, DOI 10.1128/AAC.45.6.1637-1644.2001
   Rhoades ER, 1997, TUBERCLE LUNG DIS, V78, P57, DOI 10.1016/S0962-8479(97)90016-2
   Russell W. M. S., 1959, PRINCIPLES HUMANE EX
   Rylance J, 2010, LANCET INFECT DIS, V10, P886, DOI 10.1016/S1473-3099(10)70201-2
   Sanchez F, 2003, INFECT IMMUN, V71, P126, DOI 10.1128/IAI.71.1.126-131.2003
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   Smith JA, 2007, LAB ANIM-UK, V41, P143, DOI 10.1258/002367707780378212
   Smith JA, 1997, LAB ANIM, V31, P312, DOI 10.1258/002367797780596176
   STEVENSON MM, 1995, CLIN EXP IMMUNOL, V99, P98, DOI 10.1111/j.1365-2249.1995.tb03478.x
   Urdahl KB, 2003, J IMMUNOL, V170, P1987, DOI 10.4049/jimmunol.170.4.1987
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Veziris N, 2009, AM J RESP CRIT CARE, V179, P75, DOI 10.1164/rccm.200711-1736OC
   Wald C, 2010, SCIENCE, V327, P1571, DOI 10.1126/science.327.5973.1571
   World Health Organization, 2011, GLOB TUB CONTR WHO R
   Yuan R, 2009, AGING CELL, V8, P277, DOI 10.1111/j.1474-9726.2009.00478.x
NR 60
TC 13
Z9 13
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 26
PY 2012
VL 7
IS 10
AR e47723
DI 10.1371/journal.pone.0047723
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026GL
UT WOS:000310262500018
PM 23110093
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Moller, KA
   Kinert, S
   Storkson, R
   Berge, OG
AF Moller, Kristina Angeby
   Kinert, Susanne
   Storkson, Rolf
   Berge, Odd-Geir
TI Gait Analysis in Rats with Single Joint Inflammation: Influence of
   Experimental Factors
SO PLOS ONE
LA English
DT Article
ID RESTRAINT STRESS; WEIGHT-BEARING; INDUCED MONOARTHRITIS; ANALGESIC
   ACTIVITY; OBJECTIVE-MEASURE; ARTHRITIC RATS; ANIMAL-MODELS; CHRONIC
   PAIN; OSTEOARTHRITIS; EFFICACY
AB Disability and movement-related pain are major symptoms of joint disease, motivating the development of methods to quantify motor behaviour in rodent joint pain models. We used observational scoring and automated methods to compare weight bearing during locomotion and during standing after single joint inflammation induced by Freund's complete adjuvant (0.12-8.0 mg/mL) or carrageenan (0.47-30 mg/mL). Automated gait analysis was based on video capture of prints generated by light projected into the long edge of the floor of a walkway, producing an illuminated image of the contact area of each paw with light intensity reflecting the contact pressure. Weight bearing was calculated as an area-integrated paw pressure, that is, the light intensity of all pixels activated during the contact phase of a paw placement. Automated static weight bearing was measured with the Incapacitance tester. Pharmacological sensitivity of weight-bearing during locomotion was tested in carrageenan-induced monoarthritis by administration of the commonly used analgesics diclofenac, ibuprofen, and naproxen, as well as oxycodone and paracetamol. Observational scoring and automated quantification yielded similar results. We found that the window between control rats and monoarthritic rats was greater during locomotion. The response was more pronounced for inflammation in the ankle as compared to the knee, suggesting a methodological advantage of using this injection site. The effects of both Freund's complete adjuvant and carrageenan were concentration related, but Freund's incomplete adjuvant was found to be as effective as lower, commonly used concentrations of the complete adjuvant. The results show that gait analysis can be an effective method to quantify behavioural effects of single joint inflammation in the rat, sensitive to analgesic treatment.
C1 [Moller, Kristina Angeby; Berge, Odd-Geir] AstraZeneca R&D Sodertalje, CNSP IMed Sci, Sodertalje, Sweden.
   [Kinert, Susanne] AstraZeneca R&D Sodertalje, Regulatory Affairs, Sodertalje, Sweden.
   [Storkson, Rolf] Haukeland Hosp, Dept Immunol & Transfus Med, N-5021 Bergen, Norway.
   [Berge, Odd-Geir] Univ Uppsala Hosp, Ctr Multidisciplinary Pain, Uppsala, Sweden.
RP Moller, KA (reprint author), AstraZeneca R&D Sodertalje, CNSP IMed Sci, Sodertalje, Sweden.
EM tinna.angeby-moller@hotmail.com
FU AstraZeneca RD Sodertalje
FX This work was funded in full by AstraZeneca R&D Sodertalje. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Angeby-Moller K, 2000, 3 INT C METH BEH RES
   BELANGER PM, 1987, J PHARMACOKINET BIOP, V15, P133, DOI 10.1007/BF01062340
   Berge OG, 2011, BRIT J PHARMACOL, V164, P1195, DOI 10.1111/j.1476-5381.2011.01300.x
   Betts R. P., 1978, Engineering in Medicine, V7, P223
   Boettger MK, 2009, PAIN, V145, P142, DOI 10.1016/j.pain.2009.06.006
   Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063-4584(03)0163-8
   BUTLER SH, 1992, PAIN, V48, P73, DOI 10.1016/0304-3959(92)90133-V
   CALCAGNETTI DJ, 1992, PHARMACOL BIOCHEM BE, V41, P449, DOI 10.1016/0091-3057(92)90125-Y
   CALCAGNETTI DJ, 1992, BRAIN RES, V592, P305, DOI 10.1016/0006-8993(92)91689-C
   Carrive P, 2011, PAIN, V152, P676, DOI 10.1016/j.pain.2010.12.019
   Clarke KA, 1997, PHYSIOL BEHAV, V62, P951, DOI 10.1016/S0031-9384(97)00022-X
   CLARKE KA, 1995, PHYSIOL BEHAV, V58, P415, DOI 10.1016/0031-9384(95)00072-Q
   Clayton N, 2002, PAIN, V96, P253, DOI 10.1016/S0304-3959(01)00454-7
   Clayton N, 1997, BR J PHARM, V120, p75P
   CODERRE TJ, 1987, PAIN, V28, P379, DOI 10.1016/0304-3959(87)90072-8
   Conrozier T, 2006, JOINT BONE SPINE, V73, P705, DOI 10.1016/j.jbspin.2006.02.008
   Coulthard P, 2002, J NEUROSCI METH, V116, P197, DOI 10.1016/S0165-0270(02)00042-0
   Coulthard P, 2003, J NEUROSCI METH, V128, P95, DOI 10.1016/S0165-0270(03)00154-7
   Creamer P, 1998, OSTEOARTHR CARTILAGE, V6, P318, DOI 10.1053/joca.1998.0130
   Danziger N, 1999, J NEUROSCI, V19, P2394
   Dieppe P. A., 2000, RHEUMATOLOGY, P831
   DONALDSON LF, 1993, J NEUROSCI METH, V49, P5, DOI 10.1016/0165-0270(93)90103-X
   Eisenach JC, 2004, ANESTHESIOLOGY, V100, P765, DOI 10.1097/00000542-200404000-00003
   Ferland CE, 2011, PHARMACOL BIOCHEM BE, V97, P603, DOI 10.1016/j.pbb.2010.11.003
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   Ferreira-Gomes J, 2008, J PAIN, V9, P945, DOI 10.1016/j.jpain.2008.05.012
   Finn A, 2010, INFLAMM RES, V59, P315, DOI 10.1007/s00011-009-0107-6
   Gabriel AF, 2007, J NEUROSCI METH, V163, P9, DOI 10.1016/j.jneumeth.2007.02.003
   Gamaro GD, 1998, PHYSIOL BEHAV, V63, P693, DOI 10.1016/S0031-9384(97)00520-9
   GRUBB BD, 1988, AGENTS ACTIONS, V25, P216, DOI 10.1007/BF01965015
   GRUBB BD, 1991, EXP BRAIN RES, V84, P383
   Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   Hoffmann MH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2950
   Holmdahl R, 2001, IMMUNOL REV, V184, P184, DOI 10.1034/j.1600-065x.2001.1840117.x
   Hong SK, 2002, NEUROSCI LETT, V322, P21, DOI 10.1016/S0304-3940(02)00070-8
   Huntjens DRH, 2009, EUR J PAIN, V13, P448, DOI 10.1016/j.ejpain.2008.06.011
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   King CD, 2003, BRAIN RES, V987, P214, DOI 10.1016/S0006-8993(03)03339-0
   KLEINAU S, 1991, J AUTOIMMUN, V4, P871, DOI 10.1016/0896-8411(91)90050-M
   Koopmans GC, 2007, PHYSIOL BEHAV, V92, P993, DOI 10.1016/j.physbeh.2007.07.018
   Kuptniratsaikul V, 2009, J ALTERN COMPLEM MED, V15, P891, DOI 10.1089/acm.2008.0186
   Laird JMA, 1997, INFLAMM RES, V46, P203, DOI 10.1007/s000110050174
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   Lee C, 2004, ARTHRIT RHEUM-ARTHR, V51, P746, DOI 10.1002/art.20698
   Lindner MD, 2007, PHARMACOL THERAPEUT, V115, P148, DOI 10.1016/j.pharmthera.2007.05.002
   Lindner MD, 2003, J PAIN, V4, P64, DOI 10.1054/jpai.2003.6
   LOPEZMUNOZ FJ, 1993, DRUG DEVELOP RES, V28, P169, DOI 10.1002/ddr.430280207
   Marchand F, 2007, SOC NEUR ABSTR, V2007, P18119
   Masocha W, 2009, LIFE SCI, V85, P462, DOI 10.1016/j.lfs.2009.07.015
   McCarthy C J, 2004, Health Technol Assess, V8, piii
   McCarthy CJ, 2004, RHEUMATOLOGY, V43, P514, DOI 10.1093/rheumatology/keh081
   MCDOUGALL JJ, 1995, EXP PHYSIOL, V80, P349, DOI 10.1113/expphysiol.1995.sp003852
   Moller KA, 2008, J NEUROSCI METH, V174, P1, DOI 10.1016/j.jneumeth.2008.06.017
   Orito K, 2007, J PHARMACOL SCI, V103, P113, DOI 10.1254/jphs.SC0060156
   Piesla MJ, 2009, BRAIN RES, V1295, P89, DOI 10.1016/j.brainres.2009.07.091
   Pini LA, 1997, J PHARMACOL EXP THER, V280, P934
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Rejeski WJ, 1996, J GERONTOL B-PSYCHOL, V51, pP24, DOI 10.1093/geronb/51B.1.P24
   Rice ASC, 2008, PAIN, V139, P243, DOI 10.1016/j.pain.2008.08.017
   SCHOTT E, 1994, J PHARMACOL TOXICOL, V31, P79, DOI 10.1016/1056-8719(94)90046-9
   Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009
   Simjee SU, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2290
   Simjee SU, 2004, PAIN, V109, P453, DOI 10.1016/j.pain.2004.02.022
   Sun S, 2008, BRAIN RES BULL, V75, P83, DOI 10.1016/j.brainresbull.2007.07.027
   van Baar ME, 1998, J RHEUMATOL, V25, P125
   Vermeirsch H, 2007, PHARMACOL BIOCHEM BE, V87, P349, DOI 10.1016/j.pbb.2007.05.010
   Wilson AW, 2006, EUR J PAIN, V10, P537, DOI 10.1016/j.ejpain.2005.08.003
   Yu YC, 2002, J NEUROSCI METH, V115, P107, DOI 10.1016/S0165-0270(02)00011-0
NR 70
TC 11
Z9 11
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 5
PY 2012
VL 7
IS 10
AR e46129
DI 10.1371/journal.pone.0046129
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 020QD
UT WOS:000309827300016
PM 23071540
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ruscher, K
   Inacio, AR
   Valind, K
   Ravan, AR
   Kuric, E
   Wieloch, T
AF Ruscher, Karsten
   Inacio, Ana R.
   Valind, Kristian
   Ravan, Arman Rowshan
   Kuric, Enida
   Wieloch, Tadeusz
TI Effects of the Sigma-1 Receptor Agonist
   1-(3,4-Dimethoxyphenethyl)-4-(3-Phenylpropyl)-Piperazine
   Dihydro-Chloride on Inflammation after Stroke
SO PLOS ONE
LA English
DT Article
ID CEREBRAL-ARTERY OCCLUSION; ENRICHED ENVIRONMENT; RAT-BRAIN; IBA1;
   MICROGLIA; ACTIVATION; PROTEIN; CELLS; MECHANISMS; LIGAND
AB Activation of the sigma-1 receptor (Sig-1R) improves functional recovery in models of experimental stroke and is known to modulate microglia function. The present study was conducted to investigate if Sig-1R activation after experimental stroke affects mediators of the inflammatory response in the ischemic hemisphere. Male Wistar rats were subjected to transient occlusion of the middle cerebral artery (MCAO) and injected with the specific Sig-1R agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride (SA4503) or saline for 5 days starting on day 2 after MCAO. Treatment did not affect the increased levels of the pro-inflammatory cytokines interleukin 1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), interleukin 4 (IL-4), interleukin 5 (IL-5), and interleukin 13 (IL-13) in the infarct core and peri-infarct area after MCAO. In addition, treatment with SA4503 did not affect elevated levels of nitrite, TNF-alpha and IL-1 beta observed in primary cultures of microglia exposed to combined Hypoxia/Aglycemia, while the unspecific sigma receptor ligand 1,3-di-o-tolylguanidine (DTG) significantly decreased the production of nitrite and levels of TNF-alpha. Analysis of the ischemic hemisphere also revealed increased levels of ionized calcium binding adaptor molecule 1 (Iba1) levels in the infarct core of SA4503 treated animals. However, no difference in Iba1 immunoreactivity was detected in the infarct core. Also, levels of the proliferation marker proliferating cell nuclear antigen (PCNA) and OX-42 were not increased in the infarct core in rats treated with SA4503. Together, our results suggest that sigma-1 receptor activation affects Iba1 expression in microglia/macrophages of the ischemic hemisphere after experimental stroke but does not affect post-stroke inflammatory mediators.
C1 [Ruscher, Karsten; Inacio, Ana R.; Valind, Kristian; Ravan, Arman Rowshan; Kuric, Enida; Wieloch, Tadeusz] Lund Univ, Expt Brain Res Lab, Wallenberg Neurosci Ctr, Dept Clin Sci,Div Neurosurg, S-22101 Lund, Sweden.
RP Ruscher, K (reprint author), Lund Univ, Expt Brain Res Lab, Wallenberg Neurosci Ctr, Dept Clin Sci,Div Neurosurg, S-22101 Lund, Sweden.
EM karsten.ruscher@med.lu.se
RI Inacio, Ana/M-6905-2016
OI Wieloch, Tadeusz/0000-0002-7669-2520
FU Swedish Research Council [2011-2684, 2011-2652]; EU through the European
   Stroke Network [201024]; Pia Stahls Foundation; The Swedish Brain Fund;
   Greta och Johan Kocks Stiftelser; Thorsten och Elsa Segerfalk stiftelse;
   Kungliga Fysiografiska Sallskapet i Lund; Anna-Lisa Rosenbergs fond
FX This study was supported by the Swedish Research Council (grant
   2011-2684 (KR) and grant 2011-2652 (TW)), the EU 7th workprogram through
   the European Stroke Network (grant No 201024), the Pia Stahls Foundation
   (TW), The Swedish Brain Fund (TW), the Greta och Johan Kocks Stiftelser
   (KR), the Thorsten och Elsa Segerfalk stiftelse (KR), the Kungliga
   Fysiografiska Sallskapet i Lund (KR) and the Anna-Lisa Rosenbergs fond
   (KR). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143
   Ajmo CT, 2006, CURR NEUROVASC RES, V3, P89, DOI 10.2174/156720206776875849
   Allahtavakoli M, 2011, BRAIN RES BULL, V85, P219, DOI 10.1016/j.brainresbull.2011.03.019
   Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106
   Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001
   BEJANIAN M, 1991, J PHARMACOL EXP THER, V258, P88
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Bourrie B, 2002, EUR J PHARMACOL, V456, P123, DOI 10.1016/S0014-2999(02)02646-8
   Chapman KZ, 2009, J CEREBR BLOOD F MET, V29, P1764, DOI 10.1038/jcbfm.2009.113
   Farber K, 2006, PFLUG ARCH EUR J PHY, V452, P615, DOI 10.1007/s00424-006-0064-7
   Gannon C J, 2001, Surg Infect (Larchmt), V2, P267, DOI 10.1089/10962960152813304
   Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503
   Hall AA, 2009, GLIA, V57, P744, DOI 10.1002/glia.20802
   Hayashi T, 2003, J PHARMACOL EXP THER, V306, P718, DOI 10.1124/jpet.103.051284
   Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036
   Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399
   Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112
   Inacio AR, 2011, J CEREBR BLOOD F MET, V31, P1093, DOI 10.1038/jcbfm.2010.194
   Ishizaki T, 2010, J CEREBR BLOOD F MET, V30, P1756, DOI 10.1038/jcbfm.2010.39
   Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208
   Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0
   Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Leonardo CC, 2010, TRANSL STROKE RES, V1, P135, DOI 10.1007/s12975-009-0005-9
   Lever JR, 2006, SYNAPSE, V59, P350, DOI 10.1002/syn.20253
   Matsumoto H, 2008, J CEREBR BLOOD F MET, V28, P149, DOI 10.1038/sj.jcbfm.9600519
   Maurice T, 2009, PHARMACOL THERAPEUT, V124, P195, DOI 10.1016/j.pharmthera.2009.07.001
   Mitsios N, 2006, PATHOBIOLOGY, V73, P159, DOI 10.1159/000096017
   Morgan SC, 2004, J NEUROCHEM, V90, P89, DOI 10.1111/j.1471-4159.2004.02461.x
   Ohsawa K, 2000, J CELL SCI, V113, P3073
   Rickhag M, 2008, J CEREBR BLOOD F MET, V28, P551, DOI 10.1038/sj.jcbfm.9600552
   Ruscher K, 2011, BRAIN, V134, P732, DOI 10.1093/brain/awq367
   Ruscher K, 2009, J CEREBR BLOOD F MET, V29, P1796, DOI 10.1038/jcbfm.2009.96
   Schroeter M, 1999, NEUROSCIENCE, V89, P1367, DOI 10.1016/S0306-4522(98)00398-4
   Smirkin A, 2010, J CEREBR BLOOD F MET, V30, P603, DOI 10.1038/jcbfm.2009.233
   Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154
   TAKASAKI Y, 1981, J EXP MED, V154, P1899, DOI 10.1084/jem.154.6.1899
NR 37
TC 31
Z9 31
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2012
VL 7
IS 9
AR e45118
DI 10.1371/journal.pone.0045118
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 040HS
UT WOS:000311313900080
PM 23028794
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bohmann, F
   Mirceska, A
   Pfeilschifter, J
   Lindhoff-Last, E
   Steinmetz, H
   Foerch, C
   Pfeilschifter, W
AF Bohmann, Ferdinand
   Mirceska, Ana
   Pfeilschifter, Josef
   Lindhoff-Last, Edelgard
   Steinmetz, Helmuth
   Foerch, Christian
   Pfeilschifter, Waltraud
TI No Influence of Dabigatran Anticoagulation on Hemorrhagic Transformation
   in an Experimental Model of Ischemic Stroke
SO PLOS ONE
LA English
DT Article
ID DIRECT THROMBIN INHIBITOR; NONVALVULAR ATRIAL-FIBRILLATION; RE-LY TRIAL;
   TISSUE-PLASMINOGEN ACTIVATOR; INTRACEREBRAL HEMORRHAGE; ETEXILATE;
   WARFARIN; THERAPY; PHARMACOKINETICS; PHARMACODYNAMICS
AB Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after experimental stroke under DE treatment as we have shown for warfarin.
   Methods: 44 male C57BL/6 mice were pretreated orally with 37.5 mg/kg DE, 75 mg/kg DE or saline and diluted thrombin time (dTT) and DE plasma concentrations were monitored. Ischemic stroke was induced by transient middle cerebral artery occlusion (tMCAO) for 1 h or 3 h. We assessed functional outcome and HT blood volume 24 h and 72 h after tMCAO.
   Results: After 1 h tMCAO, HT blood volume did not differ significantly between mice pretreated with DE 37.5 mg/kg and controls (1.5 +/- 0.5 mu l vs. 1.8 +/- 0.5 mu l, p > 0.05). After 3 h tMCAO, DE-anticoagulated mice did also not show an increase in HT, neither at the dose of 37.5 mg/kg equivalent to anticoagulant treatment in the therapeutic range (1.3 +/- 0.9 mu l vs. control 2.3 +/- 0.5 mu l, p > 0.05) nor at 75 mg/kg, clearly representing supratherapeutic anticoagulation (1.8 +/- 0.8 mu l, p>0.05). Furthermore, no significant increase in HT under continued anticoagulation with DE 75 mg/kg could be found at 72 h after tMCAO for 1 h (1.7 +/- 0.9 mu l vs. control 1.6 +/- 0.4 mu l, p>0.05).
   Conclusion: Our experimental data suggest that DE does not significantly increase hemorrhagic transformation after transient focal cerebral ischemia in mice. From a translational viewpoint, this indicates that a continuation of DE anticoagulation in case of an ischemic stroke might be safe, but clearly, clinical data on this question are warranted.
C1 [Bohmann, Ferdinand; Steinmetz, Helmuth; Foerch, Christian; Pfeilschifter, Waltraud] Goethe Univ Frankfurt, Dept Neurol, Univ Hosp, Frankfurt, Germany.
   [Mirceska, Ana; Pfeilschifter, Josef] Goethe Univ Frankfurt, Dept Gen Pharmacol & Toxicol, Univ Hosp, Frankfurt, Germany.
   [Lindhoff-Last, Edelgard] Goethe Univ Frankfurt, Dept Internal Med, Div Vasc Med, Univ Hosp, Frankfurt, Germany.
RP Bohmann, F (reprint author), Goethe Univ Frankfurt, Dept Neurol, Univ Hosp, Frankfurt, Germany.
EM w.pfeilschifter@med.uni-frankfurt.de
RI Pfeilschifter, Waltraud/K-6134-2012
OI Pfeilschifter, Waltraud/0000-0001-6935-8842
CR Brouns R, 2009, CLIN NEUROL NEUROSUR, V111, P483, DOI 10.1016/j.clineuro.2009.04.001
   Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Demchuk AM, 1999, STROKE, V30, P34, DOI 10.1161/01.STR.30.1.34
   Di Nisio M, 2005, NEW ENGL J MED, V353, P1028, DOI 10.1056/NEJMra044440
   Dirnagl Ulrich Group Members of the MCAO-SOP, 2009, STANDARD OPERATING P
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Ezekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034
   Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kleinschnitz C, 2007, CIRCULATION, V115, P2323, DOI 10.1161/CIRCULATIONAHA.107.691279
   Lauer A, 2011, CIRCULATION, V124, P1654, DOI 10.1161/CIRCULATIONAHA.111.035972
   Lee CJ, 2011, BRIT J CLIN PHARMACO, V72, P581, DOI 10.1111/j.1365-2125.2011.03916.x
   Liesenfeld KH, 2011, J THROMB HAEMOST, V9, P2168, DOI 10.1111/j.1538-7836.2011.04498.x
   Mosesson MW, 2004, BIOPHYS CHEM, V110, P93, DOI 10.1016/j.bpc.2004.01.007
   Nielsen VG, 2005, ACTA ANAESTH SCAND, V49, P222, DOI 10.1111/j.1399-6576.2004.00602.x
   Oldgren J, 2011, ANN INTERN MED, V155, P660, DOI 10.7326/0003-4819-155-10-201111150-00004
   Pfeilschifter W, 2011, STROKE, V42, P1116, DOI 10.1161/STROKEAHA.110.604652
   Seifert J, 2007, RQUBE VERSION 1 00 8
   Selim M, 2002, STROKE, V33, P2047, DOI 10.1161/01.STR.0000023577.65990.4E
   Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001
   Stangier J, 2007, BRIT J CLIN PHARMACO, V64, P292, DOI 10.1111/j.1365-2125.2007.02899.x
   Tsakiris DA, 1999, THROMB HAEMOSTASIS, V81, P177
   van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758
   Wienen W, 2007, THROMB HAEMOSTASIS, V98, P333, DOI 10.1160/TH07-02-0113
   WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983
NR 26
TC 23
Z9 23
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2012
VL 7
IS 7
AR e40804
DI 10.1371/journal.pone.0040804
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 978NX
UT WOS:000306751300015
PM 22911709
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Liang, ZX
   Zhan, WQ
   Zhu, AZ
   Yoon, Y
   Lin, SB
   Sasaki, M
   Klapproth, JMA
   Yang, H
   Grossniklaus, HE
   Xu, JG
   Rojas, M
   Voll, RJ
   Goodman, MM
   Arrendale, RF
   Liu, J
   Yun, CC
   Snyder, JP
   Liotta, DC
   Shim, H
AF Liang, Zhongxing
   Zhan, Weiqiang
   Zhu, Aizhi
   Yoon, Younghyoun
   Lin, Songbai
   Sasaki, Maiko
   Klapproth, Jan-Michael A.
   Yang, Hua
   Grossniklaus, Hans E.
   Xu, Jianguo
   Rojas, Mauricio
   Voll, Ronald J.
   Goodman, Mark M.
   Arrendale, Richard F.
   Liu, Jin
   Yun, C. Chris
   Snyder, James P.
   Liotta, Dennis C.
   Shim, Hyunsuk
TI Development of a Unique Small Molecule Modulator of CXCR4
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER METASTASIS; CHEMOKINE RECEPTOR CXCR4; EXPERIMENTAL
   COLITIS; HEPATIC MICROMETASTASES; ACCURATE DOCKING; MELANOMA MODEL;
   NECK-CANCER; STEM-CELLS; HIV-1; AXIS
AB Background: Metastasis, the spread and growth of tumor cells to distant organ sites, represents the most devastating attribute and plays a major role in the morbidity and mortality of cancer. Inflammation is crucial for malignant tumor transformation and survival. Thus, blocking inflammation is expected to serve as an effective cancer treatment. Among anti-inflammation therapies, chemokine modulation is now beginning to emerge from the pipeline. CXC chemokine receptor-4 (CXCR4) and its ligand stromal cell-derived factor-1 (CXCL12) interaction and the resulting cell signaling cascade have emerged as highly relevant targets since they play pleiotropic roles in metastatic progression. The unique function of CXCR4 is to promote the homing of tumor cells to their microenvironment at the distant organ sites.
   Methodology/Principal Findings: We describe the actions of N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine (designated MSX-122), a novel small molecule and partial CXCR4 antagonist with properties quite unlike that of any other reported CXCR4 antagonists, which was prepared in a single chemical step using a reductive amination reaction. Its specificity toward CXCR4 was tested in a binding affinity assay and a ligand competition assay using F-18-labeled MSX-122. The potency of the compound was determined in two functional assays, Matrigel invasion assay and cAMP modulation. The therapeutic potential of MSX-122 was evaluated in three different murine models for inflammation including an experimental colitis, carrageenan induced paw edema, and bleomycin induced lung fibrosis and three different animal models for metastasis including breast cancer micrometastasis in lung, head and neck cancer metastasis in lung, and uveal melanoma micrometastasis in liver in which CXCR4 was reported to play crucial roles.
   Conclusions/Significance: We developed a novel small molecule, MSX-122, that is a partial CXCR4 antagonist without mobilizing stem cells, which can be safer for long-term blockade of metastasis than other reported CXCR4 antagonists.
C1 [Liang, Zhongxing; Zhu, Aizhi; Yoon, Younghyoun; Voll, Ronald J.; Goodman, Mark M.; Shim, Hyunsuk] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA.
   [Zhan, Weiqiang; Liu, Jin; Snyder, James P.; Liotta, Dennis C.] Emory Univ, Dept Chem, Atlanta, GA 30322 USA.
   [Lin, Songbai; Sasaki, Maiko; Klapproth, Jan-Michael A.; Xu, Jianguo; Rojas, Mauricio; Yun, C. Chris] Emory Univ, Dept Med, Atlanta, GA 30322 USA.
   [Yang, Hua; Grossniklaus, Hans E.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Goodman, Mark M.; Liotta, Dennis C.; Shim, Hyunsuk] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Arrendale, Richard F.; Snyder, James P.; Liotta, Dennis C.] Emory Univ, Emory Inst Drug Discovery, Atlanta, GA 30322 USA.
RP Liang, ZX (reprint author), Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA.
EM jsnyder@emory.edu; dliotta@emory.edu; hshim@emory.edu
FU United States National Institutes of Health
FX All the studies were funded by the United States National Institutes of
   Health. The NIH had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR AbdelMagid AF, 1996, J ORG CHEM, V61, P3849, DOI 10.1021/jo960057x
   Andres PG, 2000, J IMMUNOL, V164, P6303, DOI 10.4049/jimmunol.164.12.6303
   Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003
   Boudeau J, 1999, INFECT IMMUN, V67, P4499
   Calandra G, 2010, CURR TOP MICROBIOL, V341, P173, DOI 10.1007/82_2010_26
   Castaneda FE, 2005, GASTROENTEROLOGY, V129, P1991, DOI 10.1053/j.gastro.2005.09.017
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fricker SP, 2006, BIOCHEM PHARMACOL, V72, P588, DOI 10.1016/j.bcp.2006.05.010
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x
   Gao C, 2007, TRANSPLANT P, V39, P268, DOI 10.1016/j.transproceed.2006.10.020
   Graves AP, 2008, J MOL BIOL, V377, P914, DOI 10.1016/j.jmb.2008.01.049
   Guimaraes CRW, 2008, J CHEM INF MODEL, V48, P958, DOI 10.1021/ci800004w
   Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102
   Kajiyama H, 2007, CELL TISSUE RES, V330, P221, DOI 10.1007/s00441-007-0455-x
   Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kofuku Y, 2009, J BIOL CHEM, V284, P35240, DOI 10.1074/jbc.M109.024851
   Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342
   Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003
   Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958
   Lin SB, 2010, GASTROENTEROLOGY, V138, P649, DOI 10.1053/j.gastro.2009.09.055
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Mikami S, 2008, J PHARMACOL EXP THER, V327, P383, DOI 10.1124/jpet.108.141085
   Moyer RA, 2007, LAB INVEST, V87, P807, DOI 10.1038/labinvest.3700595
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Porta C, 2010, CANC LETT
   Sanchez X, 1997, J BIOL CHEM, V272, P27529, DOI 10.1074/jbc.272.44.27529
   Sasaki T, 2007, BIOL PHARM BULL, V30, P1599, DOI 10.1248/bpb.30.1599
   Schiffer D, 2012, ANTICANCER RES, V30, P1977
   Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c
   Shim H, 2009, SEMIN CANCER BIOL, V19, P123, DOI 10.1016/j.semcancer.2008.11.004
   Strieter RM, 2009, J LEUKOCYTE BIOL, V86, P1111, DOI 10.1189/jlb.0309132
   Thelen M, 2008, J NEUROIMMUNOL, V198, P9, DOI 10.1016/j.jneuroim.2008.04.020
   Wang J, 2005, ONCOGENE, V24, P5897, DOI 10.1038/sj.onc.1208740
   Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200
   Weinberg R A, 2007, BIOL CANC
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Xia XM, 2010, WORLD J GASTROENTERO, V16, P2873, DOI 10.3748/wjg.v16.i23.2873
   Xui J, 2007, AM J RESP CELL MOL B
   Yang H, 2008, MELANOMA RES, V18, P95, DOI 10.1097/CMR.0b013e3282f628df
   Yang H, 2006, CURR EYE RES, V31, P557, DOI 10.1080/02713680600718962
   Yoon Y, 2007, CANCER RES, V67, P7518, DOI 10.1158/0008-5472.CAN-06-2263
   Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369
   Zhan WQ, 2007, J MED CHEM, V50, P5655, DOI 10.1021/jm070679i
   Zhu AZ, 2010, J MED CHEM, V53, P8556, DOI 10.1021/jm100786g
   Zlotnik A, 2006, CONTRIB MICROBIOL, V13, P191
NR 55
TC 60
Z9 61
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2012
VL 7
IS 4
AR e34038
DI 10.1371/journal.pone.0034038
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 952GU
UT WOS:000304780500032
PM 22485156
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wever, KE
   Menting, TP
   Rovers, M
   van der Vliet, JA
   Rongen, GA
   Masereeuw, R
   Ritskes-Hoitinga, M
   Hooijmans, CR
   Warle, M
AF Wever, Kimberley E.
   Menting, Theo P.
   Rovers, Maroeska
   van der Vliet, J. Adam
   Rongen, Gerard A.
   Masereeuw, Rosalinde
   Ritskes-Hoitinga, Merel
   Hooijmans, Carlijn R.
   Warle, Michiel
TI Ischemic Preconditioning in the Animal Kidney, a Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID DELAYED GRAFT FUNCTION; ACUTE-RENAL-FAILURE; REPERFUSION INJURY;
   CARDIAC-SURGERY; SEARCH FILTER; TRANSPLANTATION; HYPOTHERMIA;
   MYOCARDIUM; MECHANISMS; PROTECTS
AB Ischemic preconditioning (IPC) is a potent renoprotective strategy which has not yet been translated successfully into clinical practice, in spite of promising results in animal studies. We performed a unique systematic review and meta-analysis of animal studies to identify factors modifying IPC efficacy in renal ischemia/reperfusion injury (IRI), in order to enhance the design of future (clinical) studies. An electronic literature search for animal studies on IPC in renal IRI yielded fifty-eight studies which met our inclusion criteria. We extracted data for serum creatinine, blood urea nitrogen and histological renal damage, as well as study quality indicators. Meta-analysis showed that IPC reduces serum creatinine (SMD 1.54 [95% CI 1.16, 1.93]), blood urea nitrogen (SMD 1.42 [95% CI 0.97, 1.87]) and histological renal damage (SMD 1.12 [95% CI 0.89, 1.35]) after IRI as compared to controls. Factors influencing IPC efficacy were the window of protection (<24 h = early vs. >= 24 h = late) and animal species (rat vs. mouse). No difference in efficacy between local and remote IPC was observed. In conclusion, our findings show that IPC effectively reduces renal damage after IRI, with higher efficacy in the late window of protection. However, there is a large gap in study data concerning the optimal window of protection, and IPC efficacy may differ per animal species. Moreover, current clinical trials on RIPC may not be optimally designed, and our findings identify a need for further standardization of animal experiments.
C1 [Wever, Kimberley E.; Rongen, Gerard A.; Masereeuw, Rosalinde] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, NL-6525 ED Nijmegen, Netherlands.
   [Wever, Kimberley E.; Menting, Theo P.; van der Vliet, J. Adam; Warle, Michiel] Radboud Univ Nijmegen, Med Ctr, Dept Surg, NL-6525 ED Nijmegen, Netherlands.
   [Rovers, Maroeska] Radboud Univ Nijmegen, Med Ctr, Dept Operating Rooms & Epidemiol Biostat & HTA, NL-6525 ED Nijmegen, Netherlands.
   [Rovers, Maroeska; Ritskes-Hoitinga, Merel; Hooijmans, Carlijn R.] Radboud Univ Nijmegen, Med Ctr, Cent Anim Lab, NL-6525 ED Nijmegen, Netherlands.
   [Rovers, Maroeska; Ritskes-Hoitinga, Merel; Hooijmans, Carlijn R.] Radboud Univ Nijmegen, Med Ctr, Res Ctr 3R, NL-6525 ED Nijmegen, Netherlands.
RP Wever, KE (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, NL-6525 ED Nijmegen, Netherlands.
EM k.wever@chir.umcn.nl
RI Masereeuw, Roos/N-3582-2014; Wever, Kimberley/D-9705-2016; Hooijmans,
   C.R./L-4390-2015; Ritskes-Hoitinga, J./H-8083-2014; Warle,
   M.C./L-4743-2015; Rovers, Maroeska/F-2969-2014
OI Wever, Kimberley/0000-0003-3635-3660; Hooijmans,
   C.R./0000-0001-6435-5714; Rovers, Maroeska/0000-0002-3095-170X;
   Masereeuw, Rosalinde/0000-0002-1560-1074
FU Netherlands Heart Foundation [2006T035]
FX This work was partially funded by the Netherlands Heart Foundation
   (grant #2006T035). No additional external funding was received for this
   study. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ali ZA, 2007, CIRCULATION, V116, pI98, DOI 10.1161/circulationaha.106.679167
   Chen X, 2009, AM J NEPHROL, V30, P287, DOI 10.1159/000225928
   Choi YS, 2011, J THORAC CARDIOV SUR, V142, P148, DOI 10.1016/j.jtcvs.2010.11.018
   Cochrane J, 1999, RENAL FAILURE, V21, P135, DOI 10.3109/08860229909066978
   de Vries RBM, 2011, LAB ANIM-UK, V45, P268, DOI 10.1258/la.2011.011056
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eisner C, 2010, KIDNEY INT, V77, P519, DOI 10.1038/ki.2009.501
   Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141
   Hausenloy DJ, 2011, NAT REV CARDIOL, V8, P619, DOI 10.1038/nrcardio.2011.85
   Hausenloy DJ, 2009, ATHEROSCLEROSIS, V204, P334, DOI 10.1016/j.atherosclerosis.2008.10.029
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Hooijmans CR, 2010, ATLA-ALTERN LAB ANIM, V38, P167, DOI 10.1177/026119291003800208
   JABLONSKI P, 1983, TRANSPLANTATION, V35, P198, DOI 10.1097/00007890-198303000-00002
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124
   Nigwekar SU, 2009, AM J KIDNEY DIS, V54, P413, DOI 10.1053/j.ajkd.2009.01.267
   Obal D, 2006, EUR J ANAESTH, V23, P319, DOI 10.1017/S0265021505002000
   Ojo AO, 1997, TRANSPLANTATION, V63, P968, DOI 10.1097/00007890-199704150-00011
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Park KM, 2003, J BIOL CHEM, V278, P27256, DOI 10.1074/jbc.M301778200
   Perico N, 2004, LANCET, V364, P1814, DOI 10.1016/S0140-6736(04)17406-0
   Pitcher JM, 2005, J SURG RES, V129, P202, DOI 10.1016/j.jss.2005.04.015
   Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514
   PRZYKLENK K, 1993, CIRCULATION, V87, P893, DOI 10.1161/01.CIR.87.3.893
   Przyklenk K, 2011, DRUG AGING, V28, P331, DOI 10.2165/11587190-000000000-00000
   Safian RD, 2001, NEW ENGL J MED, V344, P431, DOI 10.1056/NEJM200102083440607
   Schrier RW, 2004, NEW ENGL J MED, V351, P159, DOI 10.1056/NEJMra032401
   van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083
   van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44
   Walsh SR, 2010, VASC ENDOVASC SURG, V44, P334, DOI 10.1177/1538574410370788
   Walsh SR, 2008, EUR J CARDIO-THORAC, V34, P985, DOI 10.1016/j.ejcts.2008.07.062
   Waring WS, 2011, CLIN TOXICOL, V49, P720, DOI 10.3109/15563650.2011.615319
   Wever KE, 2011, NEPHROL DIAL TRANSPL, V26, P3108, DOI 10.1093/ndt/gfr103
   Yin DP, 1998, TRANSPLANTATION, V66, P152, DOI 10.1097/00007890-199807270-00002
   Zimmerman RF, 2011, KIDNEY INT, V80, P861, DOI 10.1038/ki.2011.156
NR 35
TC 96
Z9 105
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2012
VL 7
IS 2
AR e32296
DI 10.1371/journal.pone.0032296
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 928RC
UT WOS:000302999600031
PM 22389693
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ekser, B
   Klein, E
   He, J
   Stolz, DB
   Echeverri, GJ
   Long, C
   Lin, CC
   Ezzelarab, M
   Hara, H
   Veroux, M
   Ayares, D
   Cooper, DKC
   Gridelli, B
AF Ekser, Burcin
   Klein, Edwin
   He, Jing
   Stolz, Donna B.
   Echeverri, Gabriel J.
   Long, Cassandra
   Lin, Chih Che
   Ezzelarab, Mohamed
   Hara, Hidetaka
   Veroux, Massimiliano
   Ayares, David
   Cooper, David K. C.
   Gridelli, Bruno
TI Genetically-Engineered Pig-to-Baboon Liver Xenotransplantation:
   Histopathology of Xenografts and Native Organs
SO PLOS ONE
LA English
DT Article
ID GENE-KNOCKOUT PIGS; HYPERACUTE REJECTION; TRANSGENIC PIG;
   TRANSPLANTATION; DONORS; CELLS; TRANSFERASE; COAGULATION; COMPLEMENT;
   ACTIVATION
AB Orthotopic liver transplantation was carried out in baboons using wild-type (WT, n = 1) or genetically-engineered pigs (alpha 1,3-galactosyltransferase gene-knockout, GTKO), n = 1; GTKO pigs transgenic for human CD46, n = 7) and a clinically-acceptable immunosuppressive regimen. Biopsies were obtained from the WT pig liver pre-Tx and at 30 min, 1, 2, 3, 4 and 5 h post-transplantation. Biopsies of genetically-engineered livers were obtained pre-Tx, 2 h after reperfusion and at necropsy (4-7 days after transplantation). Tissues were examined by light, confocal, and electron microscopy. All major native organs were also examined. The WT pig liver underwent hyperacute rejection. After genetically-engineered pig liver transplantation, hyperacute rejection did not occur. Survival was limited to 4-7 days due to repeated spontaneous bleeding in the liver and native organs (as a result of profound thrombocytopenia) which necessitated euthanasia. At 2 h, graft histology was largely normal. At necropsy, genetically-engineered pig livers showed hemorrhagic necrosis, platelet aggregation, platelet-fibrin thrombi, monocyte/macrophage margination mainly in liver sinusoids, and vascular endothelial cell hypertrophy, confirmed by confocal and electron microscopy. Immunohistochemistry showed minimal deposition of IgM, and almost absence of IgG, C3, C4d, C5b-9, and of a cellular infiltrate, suggesting that neither antibody-nor cell-mediated rejection played a major role.
C1 [Ekser, Burcin; Echeverri, Gabriel J.; Long, Cassandra; Lin, Chih Che; Ezzelarab, Mohamed; Hara, Hidetaka; Cooper, David K. C.; Gridelli, Bruno] Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA.
   [Ekser, Burcin; Veroux, Massimiliano] Univ Hosp Catania, Dept Surg Transplantat & Adv Technol, Vasc Surg & Organ Transplant Unit, Catania, Italy.
   [Klein, Edwin] Univ Pittsburgh, Div Lab Anim Resources, Pittsburgh, PA USA.
   [He, Jing] Childrens Hosp Pittsburgh, Dept Pediat, Div Immunogenet, Pittsburgh, PA 15213 USA.
   [Stolz, Donna B.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA.
   [Ayares, David] Revivicor Inc, Blacksburg, VA USA.
   [Echeverri, Gabriel J.; Gridelli, Bruno] Mediterranean Inst Transplantat & Adv Specialized, Palermo, Italy.
RP Ekser, B (reprint author), Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA.
EM cooperdk@upmc.edu
RI Ekser, Burcin/I-3288-2019
OI Ekser, Burcin/0000-0003-0741-8007; Veroux,
   Massimiliano/0000-0002-2780-6421; Ezzelarab,
   Mohamed/0000-0002-3919-5250; ECHEVERRI, GABRIEL/0000-0001-6432-0327
FU American Society of Transplantation/European Society for Organ
   Transplantation; American Transplant Congress; International
   Xenotransplantation Association Congress; NIH NIAID [T32 AI 074490]; NIH
   [U19 AI090959-01, U01 AI068642, R21 A1074844, RR012317-09]; University
   of Pittsburgh; Revivicor, Inc., Blacksburg, VA
FX Burcin Ekser, MD, is a recipient of an American Society of
   Transplantation/European Society for Organ Transplantation Exchange
   Grant, a Young Investigator Award from the American Transplant Congress,
   2009, a Travel Award from the International Xenotransplantation
   Association Congress, 2009, and an NIH NIAID T32 AI 074490 Training
   Grant. Work on xenotransplantation in the Thomas E. Starzl
   Transplantation Institute of the University of Pittsburgh is supported
   in part by NIH grants #U19 AI090959-01, #U01 AI068642 and # R21
   A1074844, and by Sponsored Research Agreements between the University of
   Pittsburgh and Revivicor, Inc., Blacksburg, VA. The baboons were
   provided by the Oklahoma University Health Sciences Center, Division of
   Animal Resources, which is supported in part by NIH P40 sponsored grant
   RR012317-09. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Balamurugan AN, 2005, AM J TRANSPLANT, V5, P2671, DOI 10.1111/j.1600-6143.2005.01078.x
   Burlak C, 2010, XENOTRANSPLANTATION, V17, P350, DOI 10.1111/j.1399-3089.2010.00605.x
   CALNE RY, 1968, LANCET, V1, P1176
   COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964
   DONATO MF, 1993, TRANSPLANT P, V25, P850
   Ekser B, 2010, AM J TRANSPLANT, V10, P273, DOI 10.1111/j.1600-6143.2009.02945.x
   Ekser B, 2011, XENOTRANSPLANTATION, V18, P158, DOI 10.1111/j.1399-3089.2011.00642.x
   Ekser B, 2009, TRANSPLANTATION, V88, P1041, DOI 10.1097/TP.0b013e3181ba0555
   Elvevold K, 2008, AM J PHYSIOL-GASTR L, V294, pG391, DOI 10.1152/ajpgi.00167.2007
   Ezzelarab M, 2009, TRANSPLANTATION, V87, P805, DOI 10.1097/TP.0b013e318199c34f
   Hara H, 2008, TRANSPL INT, V21, P1163, DOI 10.1111/j.1432-2277.2008.00736.x
   Hara H, 2008, LIVER TRANSPLANT, V14, P425, DOI 10.1002/lt.21476
   Hara H, 2010, XENOTRANSPLANTATION, V17, P370, DOI 10.1111/j.1399-3089.2010.00602.x
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kuwaki K, 2005, NAT MED, V11, P29, DOI 10.1038/nm1171
   Loveland BE, 2004, XENOTRANSPLANTATION, V11, P171, DOI 10.1046/j.1399-3089.2003.00103.x
   Luo T, 1998, XENOTRANSPLANTATION, V5, P197
   Mohiuddin MM, 2010, TRANSPLANTATION S, V90, P325
   Peng Q, 2011, XENOTRANSPLANTATION, V18, P287
   Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942
   POWELSON J, 1994, TRANSPLANT P, V26, P1353
   Ramirez P, 2000, TRANSPLANTATION, V70, P989, DOI 10.1097/00007890-200010150-00001
   Ramirez P, 2005, TRANSPLANT P, V37, P4103, DOI 10.1016/j.transproceed.2005.09.186
   Rumjantseva V, 2009, NAT MED, V15, P1273, DOI 10.1038/nm.2030
   Shimizu A, 2008, AM J PATHOL, V172, P1471, DOI 10.2353/ajpath.2008.070672
   SHIRATORI Y, 1993, SEMIN LIVER DIS, V13, P39, DOI 10.1055/s-2007-1007336
   Wack KE, 2001, HEPATOLOGY, V33, P363, DOI 10.1053/jhep.2001.21998
   Weatherall D, USE NONHUMAN PRIMATE, P1
   Wight DGD, 1991, XENOTRANSPLANTATION, P253
   Yamada K, 2005, NAT MED, V11, P32, DOI 10.1038/nm1172
   Yang YG, 2010, XENOTRANSPLANTATION, V17, P267, DOI 10.1111/j.1399-3089.2010.00601.x
NR 31
TC 22
Z9 23
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 11
PY 2012
VL 7
IS 1
AR e29720
DI 10.1371/journal.pone.0029720
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 906ON
UT WOS:000301355700040
PM 22247784
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kulesskaya, N
   Rauvala, H
   Voikar, V
AF Kulesskaya, Natalia
   Rauvala, Heikki
   Voikar, Vootele
TI Evaluation of Social and Physical Enrichment in Modulation of
   Behavioural Phenotype in C57BL/6J Female Mice
SO PLOS ONE
LA English
DT Article
ID REPEATED MATERNAL SEPARATION; ENVIRONMENTAL ENRICHMENT; ANIMAL-MODELS;
   LABORATORY MICE; KNOCKOUT MICE; PREPULSE INHIBITION; GENDER-DIFFERENCES;
   NESTING MATERIAL; NEUROPSYCHIATRIC DISORDERS; TEST BATTERIES
AB Housing conditions represent an important environmental variable playing a critical role in the assessment of mouse behaviour. In the present study the effects of isolation and nesting material on the behaviour of female C57BL/6J mice were evaluated. The mice were subjected to different rearing conditions from weaning (at the age of 3 weeks). The study groups were group- and single-housed mice, divided further into groups with or without nesting material (species-specific enrichment). After 8 weeks spent in respective conditions the behavioural testing began. Both factors (social conditions and nesting material) appeared to have a significant impact on the behavioural phenotype. However, it is important to stress that the interaction between the factors was virtually absent. We established that isolation increased locomotor activity and reduced anxiety-like behaviour in several tests of exploration. In contrast, absence of nesting material increased anxiety-like behaviour. Neither factor affected rota-rod performance, nociception and prepulse inhibition. Contextual fear memory was significantly reduced in single-housed mice, and interestingly, in mice with nesting material. Cued fear memory was reduced by single-housing, but not affected by enrichment. Mice from enriched cages displayed faster and better learning and spatial search strategy in the water maze. In contrast, isolation caused significant impairment in the water maze. In conclusion, both isolation and species-specific enrichment have profound effects on mouse behaviour and should be considered in design of the experiments and in assessment of animal welfare issues.
C1 [Kulesskaya, Natalia] Univ Helsinki, Dept Biosci, Helsinki, Finland.
   Univ Helsinki, Ctr Neurosci, Helsinki, Finland.
RP Kulesskaya, N (reprint author), Univ Helsinki, Dept Biosci, Helsinki, Finland.
EM vootele.voikar@gmail.com
RI ; Voikar, Vootele/F-6871-2017
OI Rauvala, Heikki/0000-0001-7809-9811; Voikar,
   Vootele/0000-0003-4201-8666; Kulesskaya, Natalia/0000-0001-5517-8525
FU Biocenter Finland
FX This work was supported by a Biocenter Finland technology platform
   grant. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abramov U, 2004, BEHAV BRAIN RES, V155, P1, DOI 10.1016/j.bbr.2004.03.027
   Anna I, 2002, LAB ANIM-UK, V36, P243, DOI 10.1258/002367702320162379
   Arndt SS, 2009, PHYSIOL BEHAV, V97, P385, DOI 10.1016/j.physbeh.2009.03.008
   Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921
   Auwerx J, 2004, NAT GENET, V36, P925, DOI 10.1038/ng0904-925
   Bailey KR, 2006, ILAR J, V47, P124, DOI 10.1093/ilar.47.2.124
   Bartolomucci A, 2003, PSYCHONEUROENDOCRINO, V28, P540, DOI 10.1016/S0306-4530(02)00039-2
   Bartolomucci A, 2007, FRONT NEUROENDOCRIN, V28, P28, DOI 10.1016/j.yfrne.2007.02.001
   Baumans V, 2005, ILAR J, V46, P162, DOI 10.1093/ilar.46.2.162
   BAUMANS V, 2011, COST MANUAL LAB ANIM, P75
   Beckers J, 2009, NAT REV GENET, V10, P371, DOI 10.1038/nrg2578
   Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002
   Bernberg E, 2008, STRESS, V11, P381, DOI 10.1080/10253890701824051
   Blanchard RJ, 2001, PHYSIOL BEHAV, V73, P261, DOI 10.1016/S0031-9384(01)00449-8
   Bowers SL, 2008, BRAIN BEHAV IMMUN, V22, P105, DOI 10.1016/j.bbi.2007.07.012
   BRAIN P, 1975, LIFE SCI, V16, P187, DOI 10.1016/0024-3205(75)90017-X
   BROWN KJ, 1995, PHYSIOL BEHAV, V58, P1085, DOI 10.1016/0031-9384(95)02043-8
   BURROWS EL, 2011, PROG NEUROP IN PRESS, DOI DOI 10.1016/J.PNPBP.2010.1012.1011
   Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670
   Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382
   Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825
   Fone KCF, 2008, NEUROSCI BIOBEHAV R, V32, P1087, DOI 10.1016/j.neubiorev.2008.03.003
   Fox C, 2006, BEHAV BRAIN RES, V175, P1, DOI 10.1016/j.bbr.2006.08.016
   Gerlai R, 2002, TRENDS NEUROSCI, V25, P506, DOI 10.1016/S0166-2236(02)02250-6
   Geyer MA, 1999, PSYCHOPHARMACOLOGY, V147, P11, DOI 10.1007/s002130051130
   Green ECJ, 2005, BIOINFORMATICS, V21, P2930, DOI 10.1093/bioinformatics/bti441
   HILAKIVI LA, 1989, PHARMACOL BIOCHEM BE, V33, P371, DOI 10.1016/0091-3057(89)90516-9
   Holmes A, 2005, NEUROSCI BIOBEHAV R, V29, P1335, DOI 10.1016/j.neubiorev.2005.04.012
   House JS, 2001, PSYCHOSOM MED, V63, P273, DOI 10.1097/00006842-200103000-00011
   Hurst JL, 2010, NAT METHODS, V7, P825, DOI [10.1038/NMETH.1500, 10.1038/nmeth.1500]
   Jordan EG, 2006, SCIENCE, V314, P253, DOI 10.1126/science.314.5797.253
   Karolewicz B, 2001, EUR J PHARMACOL, V415, P197, DOI 10.1016/S0014-2999(01)00830-5
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824
   Kim JW, 1996, BIOL PSYCHIAT, V40, P918, DOI 10.1016/0006-3223(95)00546-3
   King LA, 2003, ILAR J, V44, P211, DOI 10.1093/ilar.44.3.211
   Koike H, 2009, BEHAV BRAIN RES, V202, P114, DOI 10.1016/j.bbr.2009.03.028
   Koolhaas JM, 2011, NEUROSCI BIOBEHAV R, V35, P1291, DOI 10.1016/j.neubiorev.2011.02.003
   Krohn TC, 2006, ANIM WELFARE, V15, P343
   Lambert TJ, 2005, NEUROBIOL LEARN MEM, V83, P206, DOI 10.1016/j.nlm.2004.12.001
   Laviola G, 2008, NEUROBIOL DIS, V31, P159, DOI 10.1016/j.nbd.2008.05.001
   LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S
   LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180
   Loo P. L. P. van, 2001, Journal of Applied Animal Welfare Science, V4, P91, DOI 10.1207/S15327604JAWS0402_1
   Mandillo S, 2008, PHYSIOL GENOMICS, V34, P243, DOI 10.1152/physiolgenomics.90207.2008
   Marques JM, 2009, COMPARATIVE MED, V59, P129
   Marris E, 2009, NATURE, V458, P394, DOI 10.1038/458394a
   Martin AL, 2010, BEHAV BRAIN RES, V207, P196, DOI 10.1016/j.bbr.2009.10.006
   McIlwain KL, 2001, PHYSIOL BEHAV, V73, P705, DOI 10.1016/S0031-9384(01)00528-5
   McLean CP, 2009, CLIN PSYCHOL REV, V29, P496, DOI 10.1016/j.cpr.2009.05.003
   Miller G, 2006, SCIENCE, V312, P1860
   Millstein RA, 2006, GENES BRAIN BEHAV, V5, P346, DOI 10.1111/j.1601-183X.2005.00172.x
   Millstein RA, 2007, NEUROSCI BIOBEHAV R, V31, P3, DOI 10.1016/j.neubiorev.2006.05.003
   Mohammed AH, 2002, PROG BRAIN RES, V138, P109, DOI 10.1016/S0079-6123(02)38074-9
   Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970
   *NUFF COUNC, 2005, ETH RES INV AN
   Olsson IAS, 2007, SCIENCE, V317, P1680, DOI 10.1126/science.317.5845.1680
   Palanza P, 2001, NEUROSCI BIOBEHAV R, V25, P219, DOI 10.1016/S0149-7634(01)00010-0
   Palanza P, 2001, PHYSIOL BEHAV, V73, P411, DOI 10.1016/S0031-9384(01)00494-2
   Palermo-Neto J, 2008, PHYSIOL BEHAV, V95, P435, DOI 10.1016/j.physbeh.2008.07.006
   Parker G, 2010, INT REV PSYCHIATR, V22, P429, DOI 10.3109/09540261.2010.492391
   Paylor R, 2006, PHYSIOL BEHAV, V87, P95, DOI 10.1016/j.physbeh.2005.09.002
   Pietropaolo S, 2008, PSYCHOPHARMACOLOGY, V197, P613, DOI 10.1007/s00213-008-1081-3
   Ponder CA, 2007, GENES BRAIN BEHAV, V6, P736, DOI 10.1111/j.1601-183X.2007.00306.x
   Poole T, 1997, LAB ANIM-UK, V31, P116, DOI 10.1258/002367797780600198
   PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327
   Rampon C, 2000, NAT NEUROSCI, V3, P238
   Richter SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016461
   Richter SH, 2009, NAT METHODS, V6, P257, DOI [10.1038/nmeth.1312, 10.1038/NMETH.1312]
   RODGERS RJ, 1993, PHYSIOL BEHAV, V54, P729, DOI 10.1016/0031-9384(93)90084-S
   Schmidt MV, 2011, PSYCHOPHARMACOLOGY, V214, P131, DOI 10.1007/s00213-010-2096-0
   Schmidt MV, 2010, NEUROSCI BIOBEHAV R, V34, P845, DOI 10.1016/j.neubiorev.2009.05.002
   Schneider I, 2006, J NEUROSCI METH, V157, P82, DOI 10.1016/j.jneumeth.2006.04.002
   Smith AL, 2005, ILAR J, V46, P140, DOI 10.1093/ilar.46.2.140
   Swerdlow NR, 1998, SCHIZOPHRENIA BULL, V24, P285, DOI 10.1093/oxfordjournals.schbul.a033326
   Tucci V, 2006, MAMM GENOME, V17, P1113, DOI 10.1007/s00335-006-0075-x
   VALZELLI L, 1973, PSYCHOPHARMACOLOGIA, V31, P305, DOI 10.1007/BF00421275
   Van Bogaert MJV, 2006, GENES BRAIN BEHAV, V5, P139, DOI 10.1111/j.1601-183X.2005.00143.x
   Van de Weerd HA, 1998, ANIM WELFARE, V7, P11
   Van de Weerd HA, 1998, APPL ANIM BEHAV SCI, V55, P369, DOI 10.1016/S0168-1591(97)00043-9
   van Dellen A, 2000, NATURE, V404, P721, DOI 10.1038/35008142
   van der Staay FJ, 2002, GENES BRAIN BEHAV, V1, P9, DOI 10.1046/j.1601-1848.2001.00007.x
   van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558
   VandeWeerd HA, 1997, PHYSIOL BEHAV, V62, P1019, DOI 10.1016/S0031-9384(97)00232-1
   VandeWeerd HA, 1997, LAB ANIM, V31, P133, DOI 10.1258/002367797780600152
   Varga O, 2010, EMBO REP, V11, P500, DOI 10.1038/embor.2010.91
   Varty GB, 2006, BEHAV BRAIN RES, V169, P162, DOI 10.1016/j.bbr.2005.11.025
   Voikar V, 2004, GENES BRAIN BEHAV, V3, P27, DOI 10.1046/j.1601-183X.2003.0044.x
   Voikar V, 2005, GENES BRAIN BEHAV, V4, P240, DOI 10.1111/j.1601-183X.2004.00103.x
   Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4
   Wahlsten D, 2003, J NEUROBIOL, V54, P283, DOI 10.1002/neu.10173
   Wahlsten D, 2003, TRENDS NEUROSCI, V26, P132, DOI 10.1016/S0166-2236(03)00033-X
   Weiss IC, 2001, PSYCHOPHARMACOLOGY, V156, P305, DOI 10.1007/s002130100800
   Willner P, 2002, BEHAV PHARMACOL, V13, P169, DOI 10.1097/00008877-200205000-00001
   Wolfer DP, 2002, TRENDS NEUROSCI, V25, P336, DOI 10.1016/S0166-2236(02)02192-6
   Wurbel H, 2007, NATURE, V446, P257, DOI 10.1038/446257a
   Wurbel H, 2000, NAT GENET, V26, P263, DOI 10.1038/81541
   Wurbel H, 2002, GENES BRAIN BEHAV, V1, P3, DOI 10.1046/j.1601-1848.2001.00006.x
   Wurbel H, 2001, TRENDS NEUROSCI, V24, P207, DOI 10.1016/S0166-2236(00)01718-5
NR 99
TC 44
Z9 45
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 8
PY 2011
VL 6
IS 9
AR e24755
DI 10.1371/journal.pone.0024755
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 819CK
UT WOS:000294802800089
PM 21931844
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Mead, RJ
   Bennett, EJ
   Kennerley, AJ
   Sharp, P
   Sunyach, C
   Kasher, P
   Berwick, J
   Pettmann, B
   Battaglia, G
   Azzouz, M
   Grierson, A
   Shaw, PJ
AF Mead, Richard J.
   Bennett, Ellen J.
   Kennerley, Aneurin J.
   Sharp, Paul
   Sunyach, Claire
   Kasher, Paul
   Berwick, Jason
   Pettmann, Brigitte
   Battaglia, Guiseppe
   Azzouz, Mimoun
   Grierson, Andrew
   Shaw, Pamela J.
TI Optimised and Rapid Pre-clinical Screening in the SOD1(G93A) Transgenic
   Mouse Model of Amyotrophic Lateral Sclerosis (ALS)
SO PLOS ONE
LA English
DT Article
ID CU,ZN SUPEROXIDE-DISMUTASE; LINKED SOD1 MUTANTS; SPINAL-CORD;
   MOTOR-NEURONS; FALS MICE; AXONAL-TRANSPORT; OXIDATIVE DAMAGE; GAIT
   ANALYSIS; RAT MODEL; DEGENERATION
AB The human SOD1(G93A) transgenic mouse has been used extensively since its development in 1994 as a model for amyotrophic lateral sclerosis (ALS). In that time, a great many insights into the toxicity of mutant SOD1 have been gained using this and other mutant SOD transgenic mouse models. They all demonstrate a selective toxicity towards motor neurons and in some cases features of the pathology seen in the human disease. These models have two major drawbacks. Firstly the generation of robust preclinical data in these models has been highlighted as an area for concern. Secondly, the amount of time required for a single preclinical experiment in these models (3-4 months) is a hurdle to the development of new therapies. We have developed an inbred C57BL/6 mouse line from the original mixed background (SJLxC57BL/6) SOD1(G93A) transgenic line and show here that the disease course is remarkably consistent and much less prone to background noise, enabling reduced numbers of mice for testing of therapeutics. Secondly we have identified very early readouts showing a large decline in motor function compared to normal mice. This loss of motor function has allowed us to develop an early, sensitive and rapid screening protocol for the initial phases of denervation of muscle fibers, observed in this model. We describe multiple, quantitative readouts of motor function that can be used to interrogate this early mechanism. Such an approach will increase throughput for reduced costs, whilst reducing the severity of the experimental procedures involved.
C1 [Mead, Richard J.; Bennett, Ellen J.; Sharp, Paul; Kasher, Paul; Azzouz, Mimoun; Grierson, Andrew; Shaw, Pamela J.] Univ Sheffield, Sch Med & Biomed Sci, Dept Neurosci, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England.
   [Kennerley, Aneurin J.; Berwick, Jason] Univ Sheffield, Dept Psychol, Fac Sci, Sheffield S10 2TN, S Yorkshire, England.
   [Sunyach, Claire; Pettmann, Brigitte] Mediterranean Inst Neurobiol, Inserm Avenir Team, Marseille, France.
   [Sunyach, Claire; Pettmann, Brigitte] Aix Marseille Univ, Fac Sci, Marseille, France.
   [Sharp, Paul; Battaglia, Guiseppe] Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England.
RP Mead, RJ (reprint author), Univ Sheffield, Sch Med & Biomed Sci, Dept Neurosci, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England.
EM Pamela.Shaw@sheffield.ac.uk
RI Battaglia, Giuseppe/I-2142-2013; Battaglia, Giuseppe/A-2253-2012; Mead,
   Richard/B-4779-2009; Grierson, Andy/A-5067-2009; Berwick,
   Jason/P-6950-2017; Azzouz, Mimoun/B-3979-2009
OI Battaglia, Giuseppe/0000-0003-3349-6770; Mead,
   Richard/0000-0002-3207-0068; Grierson, Andy/0000-0001-7039-6731; Shaw,
   Pamela/0000-0002-8925-2567; Bennett, Ellen/0000-0002-9818-827X; Berwick,
   Jason/0000-0003-4026-0088; Kasher, Paul/0000-0002-9213-502X; Azzouz,
   Mimoun/0000-0001-6564-5967
FU Wellcome Trust; EPSRC/BBSRC [EP/G062137/1]; European Union
   [HEALTH-F2-2008-223388]; Engineering and Physical Sciences Research
   Council [EP/G062137/1]; National Centre for the Replacement, Refinement
   and Reduction of Animals in Research (NC3Rs) [G0700628/1]
FX This work was funded by a program grant to Dr. Shaw from the Wellcome
   Trust (http://www.wellcome.ac.uk/), an NC3Rs project grant
   (http://www.nc3rs.org.uk/) to Dr. Grierson, Dr. Mead, Dr. Azzouz and Dr.
   Sharp, an EPSRC/BBSRC collaborative project grant (EP/G062137/1,
   http://www.epsrc.ac.uk/) to Dr. Battaglia, Dr. Mead, Dr. Azzouz and Dr.
   Shaw, and by the European Union under the 7th Framework Program for RTD
   (http://cordis.europa.eu/fp7/home_en.html) -Project MitoTarget - Grant
   Agreement HEALTH-F2-2008-223388 awarded to Dr. Shaw, Dr. Grierson, Dr.
   Sunyach and Dr. Pettmann and the Moody Trust (Dr. Kasher). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alexander GM, 2004, MOL BRAIN RES, V130, P7, DOI 10.1016/j.molbrainres.2004.07.002
   Alves CJ, 2011, BRAIN RES, V1394, P90, DOI 10.1016/j.brainres.2011.02.060
   Amendola J, 2004, EUR J NEUROSCI, V20, P2822, DOI 10.1111/j.1460-9568.2004.03745.x
   Andrus PK, 1998, J NEUROCHEM, V71, P2041
   Barneoud P, 1997, NEUROREPORT, V8, P2861, DOI 10.1097/00001756-199709080-00012
   Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015
   Bendotti C, 2001, J NEUROCHEM, V79, P737, DOI 10.1046/j.1471-4159.2001.00572.x
   Bendotti C, 2001, J NEUROL SCI, V191, P25, DOI 10.1016/S0022-510X(01)00627-X
   Bittner RE, 1999, NAT GENET, V23, P141, DOI 10.1038/13770
   Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511
   Bories C, 2007, EUR J NEUROSCI, V25, P451, DOI 10.1111/j.1460-9568.2007.05306.x
   Brooks KJ, 2004, NMR BIOMED, V17, P28, DOI 10.1002/nbm.861
   Chia R, 2005, NAT GENET, V37, P1181, DOI 10.1038/ng1665
   De Bono JP, 2006, AM J PHYSIOL-REG I, V290, pR926, DOI 10.1152/ajpregue.00694.2005
   De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226
   Dupuis L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005390
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309
   Festing MFW, 2002, DESIGN ANIMAL EXPT
   Festing MFW, 2010, METHODS MOL BIOL, V602, P1, DOI 10.1007/978-1-60761-058-8_1
   Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004
   Frey D, 2000, J NEUROSCI, V20, P2534
   Garbuzova-Davis S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001205
   GOODRICK CL, 1975, J GERONTOL, V30, P257, DOI 10.1093/geronj/30.3.257
   Graber DJ, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-8
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Hayworth CR, 2009, NEUROSCIENCE, V164, P975, DOI 10.1016/j.neuroscience.2009.08.031
   Heiman-Patterson TD, 2005, J NEUROL SCI, V236, P1, DOI 10.1016/j.jns.2005.02.006
   Henkel JS, 2006, MOL CELL NEUROSCI, V31, P427, DOI 10.1016/j.mcn.2005.10.016
   Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299
   Kennel PF, 1996, NEUROREPORT, V7, P1427, DOI 10.1097/00001756-199605310-00021
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim K, 2006, EUR J PHARMACOL, V542, P100, DOI 10.1016/j.ejphar.2006.05.025
   Knippenberg S, 2010, BEHAV BRAIN RES, V213, P82, DOI 10.1016/j.bbr.2010.04.042
   Kong JM, 1998, J NEUROSCI, V18, P3241
   Ludolph Albert C, 2007, Amyotroph Lateral Scler, V8, P217, DOI 10.1080/17482960701292837
   Ludolph AC, 2010, AMYOTROPH LATERAL SC, V11, P38, DOI 10.3109/17482960903545334
   Miana-Mena FJ, 2005, AMYOTROPH LATERAL SC, V6, P55, DOI 10.1080/14660820510026162
   Morrison BM, 1996, J COMP NEUROL, V373, P619, DOI 10.1002/(SICI)1096-9861(19960930)373:4<619::AID-CNE9>3.0.CO;2-4
   Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472
   Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653
   Reinholz MM, 1999, EXP NEUROL, V159, P204, DOI 10.1006/exnr.1999.7142
   Russell W. M. S., 1959, PRINCIPLES HUMANE EX
   Schnabel J, 2008, NATURE, V454, P682, DOI 10.1038/454682a
   Scott S, 2008, AMYOTROPH LATERAL SC, V9, P4, DOI 10.1080/17482960701856300
   Taft RA, 2006, TRENDS GENET, V22, P649, DOI 10.1016/j.tig.2006.09.010
   Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155
   van Zundert B, 2008, J NEUROSCI, V28, P10864, DOI 10.1523/JNEUROSCI.1340-08.2008
   Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2
   Williamson TL, 1999, NAT NEUROSCI, V2, P50
   WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7
   Wooley CM, 2005, MUSCLE NERVE, V32, P43, DOI 10.1002/mus.20228
   Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307
NR 53
TC 40
Z9 41
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2011
VL 6
IS 8
AR e23244
DI 10.1371/journal.pone.0023244
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 810LN
UT WOS:000294126900011
PM 21876739
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

EF